<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004293.pub3" GROUP_ID="RENAL" ID="927203040414031220" MERGED_FROM="" MODIFIED="2014-11-19 16:52:34 +1100" MODIFIED_BY="Narelle Willis" REVIEW_NO="015" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2014-11-19 16:23:29 +1100" MODIFIED_BY="Narelle Willis">
<TITLE MODIFIED="2012-03-23 21:02:10 +1100" MODIFIED_BY="[Empty name]">Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome</TITLE>
<CONTACT>
<PERSON ID="6329" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Annalisa</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Perna</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>perna@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Renal Medicine, Laboratory of Biostatistics, Clinical Research Center for Rare Diseases "Aldo e Cele Daccò"</DEPARTMENT>
<ORGANISATION>Mario Negri Institute for Pharmacological Research</ORGANISATION>
<ADDRESS_1>Via Camozzi</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ranica (Bergamo)</CITY>
<ZIP>24020</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 035 511111</PHONE_1>
<PHONE_2/>
<FAX_1>+39 035 4535371</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-11-19 15:46:56 +1100" MODIFIED_BY="Narelle Willis">
<PERSON ID="399ECB6682E26AA2017F61BBC29478EB" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Yizhi</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chen</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Beijing</CITY>
<ZIP>100853</ZIP>
<REGION/>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16147" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Arrigo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schieppati</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>aschieppati@hpg23.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Unit of Nephrology</DEPARTMENT>
<ORGANISATION>Azienda Ospedaliera "Ospedali Riuniti di Bergamo"</ORGANISATION>
<ADDRESS_1>Mario Negri Institute for Pharmacological Research</ADDRESS_1>
<ADDRESS_2>Via Gavazzeni, 11</ADDRESS_2>
<CITY>Bergamo</CITY>
<ZIP>24125</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 035 319888</PHONE_1>
<PHONE_2/>
<FAX_1>+39 035 319331</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="63882854628184122512110208224254" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Xiangmei</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chen</LAST_NAME>
<SUFFIX/>
<POSITION>Professor and Director</POSITION>
<EMAIL_1>xmchen301@126.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Beijing</CITY>
<ZIP>100853</ZIP>
<REGION/>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="51176850043215379255120618014345" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Guangyan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cai</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>caiguangyan@sina.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Beijing</CITY>
<ZIP>100853</ZIP>
<REGION/>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16160" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Javier</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zamora</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Researcher</POSITION>
<EMAIL_1>javier.zamora@hrc.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Biostatistics Unit</DEPARTMENT>
<ORGANISATION>Ramon y Cajal Institute for Health Research (IRYCIS), CIBER Epidemiology and Public Health (CIBERESP) and Cochrane Collaborating Centre</ORGANISATION>
<ADDRESS_1>Ctra. Colmenar km 9,100</ADDRESS_1>
<ADDRESS_2/>
<CITY>Madrid</CITY>
<ZIP>28034</ZIP>
<REGION>Madrid</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34913368103</PHONE_1>
<PHONE_2/>
<FAX_1>+34913369016</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16105" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Giuliano</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>giovanniantonio.giuliano@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Renal Medicine, Laboratory of Biostatistics, Clinical Research Center for Rare Diseases "Aldo e Cele Daccò"</DEPARTMENT>
<ORGANISATION>Mario Negri Institute for Pharmacological Research</ORGANISATION>
<ADDRESS_1>Via Gavazzeni, 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ranica (Bergamo)</CITY>
<ZIP>24125</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5863" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Norbert</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Braun</LAST_NAME>
<SUFFIX/>
<POSITION>Head</POSITION>
<EMAIL_1>norbert.braun@mueritz-klinikum.de</EMAIL_1>
<EMAIL_2>norbert.richard.braun@t-online.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>MediClin Müritz-Klinikum Waren</ORGANISATION>
<ADDRESS_1>Weinbergstrasse 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Waren/Müritz</CITY>
<ZIP>17192</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 3991772100</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6329" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Annalisa</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Perna</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>perna@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Renal Medicine, Laboratory of Biostatistics, Clinical Research Center for Rare Diseases "Aldo e Cele Daccò"</DEPARTMENT>
<ORGANISATION>Mario Negri Institute for Pharmacological Research</ORGANISATION>
<ADDRESS_1>Via Camozzi</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ranica (Bergamo)</CITY>
<ZIP>24020</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 035 511111</PHONE_1>
<PHONE_2/>
<FAX_1>+39 035 4535371</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-10-16 08:02:05 +1100" MODIFIED_BY="Narelle Willis">
<UP_TO_DATE>
<DATE DAY="30" MONTH="6" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="12" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-11-19 16:23:29 +1100" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-11-19 16:23:29 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="19" MONTH="11" YEAR="2014"/>
<DESCRIPTION>
<P>Minor edit to study names and number of reports of studies excluded and awaiting classification</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-11-19 16:11:53 +1100" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-11-19 16:11:49 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="30" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>The conclusion has been changed in this update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-19 16:11:53 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="30" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>New search undertaken, new studies identified and included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-06-18 10:39:09 +1000" MODIFIED_BY="Narelle S Willis">
<DATE DAY="9" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="30" MONTH="4" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-01-28 13:56:08 +1100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-01-28 13:56:08 +1100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-01-28 13:56:08 +1100" MODIFIED_BY="[Empty name]">
<NAME>Division of Nephrology, State Key Discipline and State Key Laboratory of Kidney Diseases (2011DAV00088), Chinese People's Liberation Army (PLA) General Hospital (301 Hospital), Chinese PLA Medical Academy, Fuxing Road 28, Haidian District, Beijing 100853</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-19 16:47:05 +1100" MODIFIED_BY="Narelle Willis">
<SUMMARY MODIFIED="2014-04-22 16:08:33 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-04-10 17:34:07 +1000" MODIFIED_BY="Narelle S Willis">Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2014-04-22 16:08:33 +1000" MODIFIED_BY="[Empty name]">
<P>Idiopathic membranous nephropathy (IMN) is a disease in which glomerular basement membrane becomes thickening by light microscopy on renal biopsy and it represents a major cause of primary nephrotic syndrome in adults. A combined alkylating agent and corticosteroid regimen had short- and long-term benefits on adult IMN with nephrotic syndrome. Among alkylating agents, cyclophosphamide was safer than chlorambucil. It should be emphasised that the number of included randomised studies with high-quality design was relatively small and most of the included studies did not have adequate follow-up and enough power to assess the prespecified outcomes. Meanwhile, this regimen was significantly associated with more withdrawals or hospitalisations. Although a six-month course of alternating monthly cycles of corticosteroids and cyclophosphamide was recommended by the KDIGO Clinical Practice Guideline 2012 as the initial therapy for adult IMN with nephrotic syndrome, clinicians should inform their patients of the lack of high-quality evidence for these benefits as well as the well-recognised adverse effects of this therapy. Whether this combined therapy should be indicated in all adult patients at high risk of progression to ESKD or only restricted to those with deteriorating kidney function still remained unclear.</P>
<P>Cyclosporine or tacrolimus was recommended by the KDIGO Clinical Practice Guideline 2012 as the alternative regimen for adult IMN with nephrotic syndrome; however, there was no evidence that calcineurin inhibitors could alter the definite endpoints such as all-cause mortality or risk of ESKD. There was no clear evidence to support the use of either corticosteroid or alkylating agent monotherapy. The numbers of corresponding studies related to tacrolimus, mycophenolate mofetil, adrenocorticotropic hormone, azathioprine, mizoribine, and Tripterygium wilfordii are still too sparse to draw final conclusions.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-10-13 16:08:01 +1100" MODIFIED_BY="Narelle Willis">
<ABS_BACKGROUND MODIFIED="2014-04-10 17:37:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Idiopathic membranous nephropathy (IMN) is the most common form of nephrotic syndrome in adults. The disease shows a benign or indolent course in the majority of patients, with a rate of spontaneous complete or partial remission of nephrotic syndrome as high as 30% or more. Despite this, 30% to 40% of patients progress toward end-stage kidney disease (ESKD) within five to 15 years. The efficacy and safety of immunosuppression for IMN with nephrotic syndrome are still controversial. This is an update of a Cochrane review first published in 2004.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-04-22 16:08:16 +1000" MODIFIED_BY="[Empty name]">
<P>The aim of this review was to evaluate the safety and efficacy of immunosuppressive treatments for adult patients with IMN and nephrotic syndrome. Moreover it was attempted to identify the best therapeutic regimen, when to start immunosuppression and whether the above therapies should be given to all adult patients at high risk of progression to ESKD or only restricted to those with impaired kidney function.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-10-13 16:08:01 +1100" MODIFIED_BY="Narelle Willis">
<P>We searched Cochrane Renal Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Chinese databases, reference lists of articles, and clinical trial registries to June 2014. We also contacted principal investigators of some of the studies for additional information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-04-27 17:32:57 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) investigating the effects of immunosuppression in adults with IMN and nephrotic syndrome.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-04-27 17:32:32 +1000" MODIFIED_BY="[Empty name]">
<P>Study selection, data extraction, quality assessment, and data synthesis were performed using the Cochrane-recommended methods. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-10-09 11:06:11 +1100" MODIFIED_BY="[Empty name]">
<P>Thirty nine studies with 1825 patients were included, 36 of these could be included in our meta-analyses. The data from two studies could not be extracted and one study was terminated due to poor accrual. Immunosuppression significantly reduced all-cause mortality or risk of ESKD ((15 studies, 791 patients): RR 0.58 (95% CI 0.36 to 0.95, P = 0.03) and risk of ESKD ((15 studies, 791 patients): RR 0.55, 95% CI 0.31 to 0.95, P = 0.03), increased complete or partial remission ((16 studies, 864 patients): RR 1.31, 95% CI 1.01 to 1.70, P = 0.04), and decreased proteinuria ((9 studies,(393 patients): MD -0.95 g/24 h, 95% CI -1.81 to -0.09, P = 0.03) at the end of follow-up (range 6 to 120 months). However this regimen was associated with more discontinuations or hospitalisations ((16 studies, 880 studies): RR 5.35, 95% CI 2.19 to 13.02), P = 0.0002). Combined corticosteroids and alkylating agents significantly reduced death or risk of ESKD ((8 studies, 448 patients): RR 0.44, 95% CI 0.26 to 0.75, P = 0.002) and ESKD ((8 studies, 448 patients): RR 0.45, 95% CI 0.25 to 0.81, P = 0.008), increased complete or partial remission ((7 studies, 422 patients): RR 1.46, 95% CI 1.13 to 1.89, P = 0.004) and complete remission ((7 studies, 422 patients): RR 2.32, 95% CI 1.61 to 3.32, P &lt; 0.00001), and decreased proteinuria ((6 studies, 279 patients): MD -1.25 g/24 h, 95% CI -1.93 to -0.57, P = 0.0003) at the end of follow-up (range 9 to 120 months). In a population with an assumed risk of death or ESKD of 181/1000 patients, this regimen would be expected to reduce the number of patients experiencing death or ESKD to 80/1000 patients (range 47 to 136). In a population with an assumed complete or partial remission of 408/1000 patients, this regimen would be expected to increase the number of patients experiencing complete or partial remission to 596/1000 patients (range 462 to 772). However this combined regimen was associated with a significantly higher risk of discontinuation or hospitalisation due to adverse effects ((4 studies, 303 patients): RR 4.20, 95% CI 1.15 to 15.32, P = 0.03). Whether this combined therapy should be indicated in all adult patients at high risk of progression to ESKD or only restricted to those with deteriorating kidney function still remained unclear. Cyclophosphamide was safer than chlorambucil ((3 studies, 147 patients): RR 0.48, 95% CI 0.26 to 0.90, P = 0.02). There was no clear evidence to support the use of either corticosteroid or alkylating agent monotherapy. Cyclosporine and mycophenolate mofetil failed to show superiority over alkylating agents. Tacrolimus and adrenocorticotropic hormone significantly reduced proteinuria. The numbers of corresponding studies related to tacrolimus, mycophenolate mofetil, adrenocorticotropic hormone, azathioprine, mizoribine, and Tripterygium wilfordii are still too sparse to draw final conclusions.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-04-22 13:34:19 +1000" MODIFIED_BY="[Empty name]">
<P>In this update, a combined alkylating agent and corticosteroid regimen had short- and long-term benefits on adult IMN with nephrotic syndrome. Among alkylating agents, cyclophosphamide was safer than chlorambucil. This regimen was significantly associated with more withdrawals or hospitalisations. It should be emphasised that the number of included studies with high-quality design was relatively small and most of included studies did not have adequate follow-up and enough power to assess the prespecified definite endpoints. Although a six-month course of alternating monthly cycles of corticosteroids and cyclophosphamide was recommended by the KDIGO Clinical Practice Guideline 2012 as the initial therapy for adult IMN with nephrotic syndrome, clinicians should inform their patients of the lack of high-quality evidence for these benefits as well as the well-recognised adverse effects of this therapy. Cyclosporine or tacrolimus was recommended by the KDIGO Clinical Practice Guideline 2012 as the alternative regimen for adult IMN with nephrotic syndrome; however, there was no evidence that calcineurin inhibitors could alter the combined outcome of death or ESKD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-11-19 16:47:05 +1100" MODIFIED_BY="Narelle Willis">
<BACKGROUND MODIFIED="2014-11-19 16:14:58 +1100" MODIFIED_BY="Narelle Willis">
<P>This is an update of a Cochrane review investigating the effects of immunosuppressive treatments in adult patients with idiopathic membranous nephropathy (IMN) and nephrotic syndrome (<LINK REF="REF-Schieppati-2004" TYPE="REFERENCE">Schieppati 2004</LINK>).</P>
<CONDITION MODIFIED="2014-04-22 16:08:36 +1000" MODIFIED_BY="[Empty name]">
<P>IMN is the most common form of primary nephrotic syndrome in adults (<LINK REF="REF-Hofstra-2012" TYPE="REFERENCE">Hofstra 2012</LINK>). The disease shows a benign or indolent course in about one third of patients, with a high rate of spontaneous remission. Approximate another one third continues to have nephrotic syndrome but maintains normal kidney function. Despite this, 10% to 30% of patients progresses toward end-stage kidney disease (ESKD) within 10 years (<LINK REF="REF-Waldman-2009" TYPE="REFERENCE">Waldman 2009</LINK>). If follow-up is extended to 10 to 20 years, progression to ESKD may occur in 50% to 60% of patients without treatment (<LINK REF="REF-Ponticelli-2010" TYPE="REFERENCE">Ponticelli 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-11-19 16:14:58 +1100" MODIFIED_BY="Narelle Willis">
<P>Several immunosuppressive treatments have been used (<LINK REF="REF-Hofstra-2010a" TYPE="REFERENCE">Hofstra 2010a</LINK>; <LINK REF="REF-Hofstra-2012" TYPE="REFERENCE">Hofstra 2012</LINK>; <LINK REF="REF-Ponticelli-2010" TYPE="REFERENCE">Ponticelli 2010</LINK>; <LINK REF="REF-Ruggenenti-2009" TYPE="REFERENCE">Ruggenenti 2009</LINK>; <LINK REF="REF-Waldman-2009" TYPE="REFERENCE">Waldman 2009</LINK>), including corticosteroids (<LINK REF="STD-Coggins-1979" TYPE="STUDY">Coggins 1979</LINK>), alkylating agents (chlorambucil and cyclophosphamide) (<LINK REF="STD-Donadio-1974a" TYPE="STUDY">Donadio 1974a</LINK>; <LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK>), azathioprine (<LINK REF="STD-Silverberg-1976" TYPE="STUDY">Silverberg 1976</LINK>), and mizoribine (<LINK REF="STD-Shibasaki-2004" TYPE="STUDY">Shibasaki 2004</LINK>). More recently, calcineurin inhibitors (cyclosporine and tacrolimus) (<LINK REF="STD-Cattran-1995" TYPE="STUDY">Cattran 1995</LINK>; <LINK REF="STD-Praga-2007" TYPE="STUDY">Praga 2007</LINK>), mycophenolate mofetil (<LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK>), adrenocorticotropic hormone (<LINK REF="STD-Arnadottir-2006" TYPE="STUDY">Arnadottir 2006</LINK>), Tripterygium wilfordii (a traditional Chinese immunosuppressive medicine) (<LINK REF="STD-Liu-2009b" TYPE="STUDY">Liu 2009b</LINK>), and newer therapeutic approaches such as biologics (rituximab and eculizumab) (<LINK REF="STD-Appel-2002" TYPE="STUDY">Appel 2002</LINK>; <LINK REF="REF-Remuzzi-2002" TYPE="REFERENCE">Remuzzi 2002</LINK>) and high-dose gamma-globulin (<LINK REF="STD-JPRN_x002d_UMIN000006939" TYPE="STUDY">JPRN-UMIN000006939</LINK>) have been proposed. However due to the uncertain risk-benefit profile of these regimens and the lack of definite evidence on altering the long-term course of the disease, the most appropriate therapy still cannot be easily identified.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-11-19 15:48:26 +1100" MODIFIED_BY="Narelle Willis">
<P>Four meta-analyses have been performed in this field (<LINK REF="REF-Couchoud-1994" TYPE="REFERENCE">Couchoud 1994</LINK>; <LINK REF="REF-Hogan-1995" TYPE="REFERENCE">Hogan 1995</LINK>; <LINK REF="REF-Imperiale-1995" TYPE="REFERENCE">Imperiale 1995</LINK>; <LINK REF="REF-Schieppati-2004" TYPE="REFERENCE">Schieppati 2004</LINK>). Meta-analysis of data from eight randomised controlled trials (RCTs) enrolling 526 patients showed that there was a tendency in favour of immunosuppressive treatments (corticosteroids, alkylating agents and azathioprine) in two surrogate outcomes (improvement in proteinuria and impairment of kidney function). However, there was no statistically significant difference in complete remission and renal survival rate (<LINK REF="REF-Couchoud-1994" TYPE="REFERENCE">Couchoud 1994</LINK>). <LINK REF="REF-Imperiale-1995" TYPE="REFERENCE">Imperiale 1995</LINK> included five prospective studies, four RCTs and one non-RCT, in which alkylating agents were compared with corticosteroids, placebo or symptomatic treatments. They found a beneficial effect of alkylating agents on complete or partial remission in 228 patients, of whom 202 were included in RCTs. However there was not enough evidence related to the long-term effects of alkylating agents on the definite endpoints. <LINK REF="REF-Hogan-1995" TYPE="REFERENCE">Hogan 1995</LINK> performed a pooled analysis of 35 retrospective and prospective studies in 1815 patients, of whom 475 were included in RCTs. Complete remission was more frequently with the use of alkylating agents compared with no treatment or corticosteroids. However, there was still no evidence that corticosteroids or alkylating therapy could improve renal survival in the long run.</P>
<P>In 2004, a Cochrane systematic review (<LINK REF="REF-Schieppati-2004" TYPE="REFERENCE">Schieppati 2004</LINK>) was published with the aim to assess the role of available immunosuppressive treatments. A total of 18 RCTs with 1025 patients were selected and analysed. Immunosuppressive treatments, especially alkylating agents (chlorambucil and cyclophosphamide) and cyclosporine, could increase complete or partial remission. However, the long-term effects of immunosuppressive treatments on definite endpoints such as all-cause mortality or renal survival rate could not be demonstrated. As expected, immunosuppressive treatments led to a significantly higher risk of severe adverse effects.</P>
<P>During the latest decade some RCTs evaluating newer immunosuppressive therapies have been published. These alternative agents were expected to be more effective and less toxic. However <LINK REF="STD-Dussol-2008" TYPE="STUDY">Dussol 2008</LINK> failed to demonstrate the effect of mycophenolate mofetil on complete or partial remission. <LINK REF="STD-Chen-2010a" TYPE="STUDY">Chen 2010a</LINK> reported that tacrolimus was associated with high risk for relapse. There was no evidence related to the favourable impact of adrenocorticotropic hormone on all-cause mortality or risk of ESKD (<LINK REF="STD-Arnadottir-2006" TYPE="STUDY">Arnadottir 2006</LINK>; <LINK REF="STD-Ponticelli-2006" TYPE="STUDY">Ponticelli 2006</LINK>). More studies that evaluated the effects of corticosteroids, alkylating agents, and cyclosporine have also been published (<LINK REF="STD-Jha-2007" TYPE="STUDY">Jha 2007</LINK>; <LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK>; <LINK REF="STD-Naumovic-2011" TYPE="STUDY">Naumovic 2011</LINK>). Thus there is need to update the previously published Cochrane systematic review in order to explore whether adding novel agents could modify previous findings.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-04-22 13:47:03 +1000" MODIFIED_BY="[Empty name]">
<P>The aim of this review was to evaluate the safety and efficacy of immunosuppressive treatments for adult patients with IMN and nephrotic syndrome. Moreover it was attempted to identify the best therapeutic regimen, when to start immunosuppression and whether the above therapies should be given to all adult patients at high risk of progression to ESKD or only restricted to those with impaired kidney function.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-11-19 16:14:58 +1100" MODIFIED_BY="Narelle Willis">
<SELECTION_CRITERIA MODIFIED="2014-11-19 16:14:58 +1100" MODIFIED_BY="Narelle Willis">
<CRIT_STUDIES MODIFIED="2014-10-09 08:32:45 +1100" MODIFIED_BY="[Empty name]">
<P>All RCTs aimed to assess the effects of immunosuppressive treatments in adult patients with IMN and nephrotic syndrome were included. All the included RCTs had a follow-up of at least six months. Quasi-RCTS (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-04-22 16:11:51 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<UL>
<LI>Adults</LI>
<LI>Histologically proven diagnosis of IMN</LI>
<LI>Diagnosis of nephrotic syndrome as defined by the authors in each single study. In studies that included a minority of non-nephrotic patients analyses were restricted to nephrotic patients only. In absence of an explicit definition of nephrotic syndrome, the cut-off value of proteinuria above 3.5 g/24 h was used</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Secondary forms of membranous nephropathy were excluded. We also excluded studies where it was impossible to identify how many adult IMN patients had nephrotic syndrome, unless it was assessed that the majority of adult patients had IMN and nephrotic syndrome and/or this information could be inferred by baseline characteristics.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-11-19 16:14:58 +1100" MODIFIED_BY="Narelle Willis">
<P>The widely recognised immunosuppressive treatments included corticosteroids, alkylating agents (chlorambucil and cyclophosphamide), calcineurin inhibitors (cyclosporine and tacrolimus), sirolimus, mycophenolate mofetil, and synthetic adrenocorticotropic hormone (<LINK REF="REF-Hofstra-2012" TYPE="REFERENCE">Hofstra 2012</LINK>; <LINK REF="REF-Ponticelli-2010" TYPE="REFERENCE">Ponticelli 2010</LINK>; <LINK REF="REF-Waldman-2009" TYPE="REFERENCE">Waldman 2009</LINK>). Other seldom studied immunosuppressive regiments such as Tripterygium wilfordii (a traditional Chinese immunosuppressive medicine) (<LINK REF="REF-Cameron-2011" TYPE="REFERENCE">Cameron 2011</LINK>; <LINK REF="REF-Chen-2010a" TYPE="REFERENCE">Chen 2010a</LINK>; <LINK REF="REF-Goldbach_x002d_Mansky-2009" TYPE="REFERENCE">Goldbach-Mansky 2009</LINK>; <LINK REF="REF-Tao-2002" TYPE="REFERENCE">Tao 2002</LINK>; <LINK REF="REF-Xu-2009" TYPE="REFERENCE">Xu 2009</LINK>), leflunomide (<LINK REF="REF-Chen-2010b" TYPE="REFERENCE">Chen 2010b</LINK>; <LINK REF="REF-Tam-2006" TYPE="REFERENCE">Tam 2006</LINK>), azathioprine (<LINK REF="REF-Ahuja-1999" TYPE="REFERENCE">Ahuja 1999</LINK>), mizoribine (<LINK REF="REF-Yoshioka-2000" TYPE="REFERENCE">Yoshioka 2000</LINK>), methotrexate (<LINK REF="REF-Lehman-2004" TYPE="REFERENCE">Lehman 2004</LINK>), and levamisole (<LINK REF="REF-Srivastava-1991" TYPE="REFERENCE">Srivastava 1991</LINK>) were also investigated. Furthermore, biologics (eculizumab and rituximab) and high-dose gamma-globulin were considered to be potentially eligible for this review (<LINK REF="STD-Appel-2002" TYPE="STUDY">Appel 2002</LINK>; <LINK REF="REF-Remuzzi-2002" TYPE="REFERENCE">Remuzzi 2002</LINK>; <LINK REF="REF-Ruggenenti-2009" TYPE="REFERENCE">Ruggenenti 2009</LINK>; <LINK REF="STD-JPRN_x002d_UMIN000006939" TYPE="STUDY">JPRN-UMIN000006939</LINK>).</P>
<P>The following interventions, nonimmunological in nature, were excluded: drugs aimed to reduce proteinuria through the inhibition of renin-angiotensin system (e.g. angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) or aliskiren); drugs aimed to correct dyslipidaemia (e.g. statins); anti-aldosterone drugs (e.g. spironolactone); nonsteroidal anti-inflammatory drugs (e.g. indomethacin).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-10-09 08:33:03 +1100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-04-22 14:02:23 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Composite definite endpoints (death or ESKD), death alone (all causes), and risk of ESKD (need renal replacement therapy) alone at the last follow-up</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-10-09 08:33:03 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>100% or 50% serum creatinine (SCr) increase from baseline at different time points and at the last follow-up</LI>
<LI>SCr (&#956;mol/L) or glomerular filtration rate (GFR) (mL/min/1.73 m²) at different time points and at the last follow-up</LI>
<LI>Complete or partial remission, complete remission alone, and partial remission alone at different time points and at the last follow-up.</LI>
<UL>
<LI>Complete and partial remission of nephrotic syndrome was assessed according to the definition provided in each single study.</LI>
<LI>In the absence of an explicit definition, complete remission was defined as proteinuria less than 0.3 g/24 h and with a normal or stable SCr (within 50% of baseline value).</LI>
<LI>In the absence of an explicit definition, partial remission was defined as proteinuria reduced by at least 50% and remained between 0.3 - 3.5 g/24 h with a normal or stable SCr (within 50% of baseline value).</LI>
</UL>
<LI>Proteinuria (g/24 h) at different time points and at the last follow-up.</LI>
<LI>Severe adverse events (defined as those leading to patient temporary or permanent withdrawal or hospitalisation).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-10-09 10:12:07 +1100" MODIFIED_BY="[Empty name]">
<P>For this update we searched the Cochrane Renal Group's Specialised Register (June 2014) through contact with the Trials' Search Co-ordinator using search terms relevant to this review. The Cochrane Renal Group&#8217;s specialised register contains studies identified from the following sources.</P>
<UL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of renal-related journals and the proceedings of major renal conferences</LI>
<LI>Searching the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected renal journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</UL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
<P>We also searched the following databases in order to further identify potentially eligible RCTs (all accessed in June 2012).</P>
<UL>
<LI>United States National Institutes of Health Clinical Trial Registry (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>)</LI>
<LI>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>)</LI>
<LI>Chinese Clinical Trial Registry (ChiCTR) (<A HREF="http://www.chictr.org/en/">http://www.chictr.org/en/</A>)</LI>
<LI>China Biomedicine Database (CBM) (<A HREF="http://sinomed.imicams.ac.cn/">http://sinomed.imicams.ac.cn/</A>)</LI>
<LI>China National Knowledge Infrastructure (CNKI) (<A HREF="http://www.cnki.net/">http://www.cnki.net/</A>)</LI>
<LI>China Wei Pu Database (<A HREF="http://www.cqvip.com/">http://www.cqvip.com/</A>)</LI>
<LI>China Wang Fang Database (<A HREF="http://www.wanfangdata.com.cn/">http://www.wanfangdata.com.cn/</A>)</LI>
<LI>The University of Hong Kong (HKU) Clinical Trial Register (<A HREF="http://www.hkclinicaltrials.com/">http://www.hkclinicaltrials.com/</A>)</LI>
</UL>
<P>Please refer to our review published in 2004 for the original search strategies used (<LINK REF="REF-Schieppati-2004" TYPE="REFERENCE">Schieppati 2004</LINK>).</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-10-13 16:08:28 +1100" MODIFIED_BY="Narelle Willis">
<STUDY_SELECTION MODIFIED="2014-04-22 16:12:06 +1000" MODIFIED_BY="[Empty name]">
<P>The initial 2004 version of this review was undertaken by six authors. The search strategy was initially performed independently by two authors in December 2003. Two authors independently inspected all articles identified in abstract form. For studies that could possibly be RCTs, or in the case of disagreement between the two authors, the full articles were obtained. In turn, the same authors compiled an 'ad hoc' questionnaire and they revised these articles independently. The questionnaires were then cross-checked and discrepancies were resolved by discussion with a third author. One author provided unpublished material, handsearched abstract books in German language and helped preparing the manuscript.</P>
<P>In this update, selection of studies was done by four authors. The titles and abstracts of retrieved citations, and where necessary the full-text articles, were independently evaluated by two authors. A third author helped search for studies published in Chinese. Disagreements were resolved by consulting a fourth author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-04-22 14:59:22 +1000" MODIFIED_BY="[Empty name]">
<P>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non-English language journals, were translated before assessment. In case of duplicates, reports were grouped together and the publication with the most complete data was included. When relevant outcomes were only published in earlier versions these data were used. Any differences between published versions were highlighted. A third author addressed the resolved these discrepancies. If needed, further details were requested by written correspondence to principal investigators and any relevant information obtained in this manner was included in this review. We also contacted principal investigators for missing data whenever necessary. Disagreements were resolved by consultation with a third author.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-04-22 13:41:35 +1000" MODIFIED_BY="[Empty name]">
<P>The following items were independently assessed by two authors using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). </P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?</LI>
<UL>
<LI>Participants and personnel</LI>
<LI>Outcome assessors</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-04-22 14:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Data were quantitatively combined by two independent authors. Dichotomous outcomes were expressed as risk ratio (RR) with 95% confidence intervals (CI). When a continuous scale of measurement was used, the mean difference (MD) was chosen or the standardised mean difference (SMD) was considered if a different scale was adopted.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-04-22 15:00:09 +1000" MODIFIED_BY="[Empty name]">
<P>Studies with multiple intervention arms were analysed by entering each pair-wise comparison separately. For dichotomous outcomes, both the number of events and the total number of patients were halved. For continuous outcomes, only the total numbers of participants were halved, while the means and standard deviations were left unchanged (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-06-13 06:52:34 +1000" MODIFIED_BY="[Empty name]">
<P>Missing data were assessed for each included study. For missing participants due to drop-out, intention-to-treat analysis (ITT) was performed and compared with per-protocol analysis (PP) for the dichotomous data; while the continuous data remained unchanged due to the difficulty of application of ITT for this type of data (<LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>). For missing statistics such as standard deviations, these studies were not considered in the meta-analysis unless the missing data could be appropriately imputed using methods recommended by the Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We also contacted principal investigators to request the missing data if possible.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-11-29 10:59:28 +1100" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was assessed by using Q test and quantified by using I² statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The threshold P value of heterogeneity was 0.10. The I² statistic of 25%, 50%, and 75% was interpreted as indicating low, medium, and high levels of heterogeneity, respectively.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-06-01 02:35:21 +1000" MODIFIED_BY="[Empty name]">
<P>Reporting biases such as publication bias were firstly addressed by using funnel plots and then further quantified by using Harbord test if there was adequate number of identified RCTs (i.e. at least 10 studies) (<LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>; <LINK REF="REF-Harbord-2009" TYPE="REFERENCE">Harbord 2009,</LINK> <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Harbord test was performed by using STATA software (version 11.2).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-05-29 19:57:40 +1000" MODIFIED_BY="[Empty name]">
<P>A random-effects model was used for analyses of both dichotomous and continuous data. Robustness of study findings was also confirmed by using the fixed-effect model when appropriate. The quality of evidence was assessed by using GRADE Profiler software (version 3.6).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-04-22 16:12:14 +1000" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was used to explore possible sources of heterogeneity (e.g. participants and interventions). Heterogeneity among participants could be related to age, renal pathology, and disease severity. Heterogeneity in treatments could be related to the route, dose and duration of therapies during the studies and whether relative agents were previously used before entry to studies. Subgroup analysis was also performed to explore the following covariates, i.e. language of publication, source of funding, sample size calculation.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-10-13 16:08:28 +1100" MODIFIED_BY="Narelle Willis">
<P>We performed sensitivity analysis in order to explore the influence of following factors.</P>
<UL>
<LI>Repeating the analysis excluding unpublished studies or low quality studies based on the assessment of risk of bias;</LI>
<LI>Repeating the analysis excluding any very long or very large study to determine the extent to which they unduly influenced the results.</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-11-19 16:47:05 +1100" MODIFIED_BY="Narelle Willis">
<STUDY_DESCRIPTION MODIFIED="2014-11-19 16:47:05 +1100" MODIFIED_BY="Narelle Willis">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2014-11-19 15:48:26 +1100" MODIFIED_BY="Narelle Willis">
<P>in our 2004 original review (<LINK REF="REF-Schieppati-2004" TYPE="REFERENCE">Schieppati 2004</LINK>) after screening 943 records, 18 studies (19 records) were identified (<LINK REF="STD-Ahmed-1994" TYPE="STUDY">Ahmed 1994</LINK>; <LINK REF="STD-Branten-1998" TYPE="STUDY">Branten 1998</LINK>; <LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>; <LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>; <LINK REF="STD-Cattran-1989" TYPE="STUDY">Cattran 1989</LINK>; <LINK REF="STD-Cattran-1995" TYPE="STUDY">Cattran 1995</LINK>; <LINK REF="STD-Cattran-2001" TYPE="STUDY">Cattran 2001</LINK>; <LINK REF="STD-Coggins-1979" TYPE="STUDY">Coggins 1979</LINK>; <LINK REF="STD-CYCLOMEN-Study-1994" TYPE="STUDY">CYCLOMEN Study 1994</LINK>; <LINK REF="STD-Donadio-1974a" TYPE="STUDY">Donadio 1974a</LINK>; <LINK REF="STD-Falk-1992" TYPE="STUDY">Falk 1992</LINK>; <LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK>; <LINK REF="STD-Murphy-1992" TYPE="STUDY">Murphy 1992</LINK>; <LINK REF="STD-Pahari-1993" TYPE="STUDY">Pahari 1993</LINK>; <LINK REF="STD-Ponticelli-1992" TYPE="STUDY">Ponticelli 1992</LINK>; <LINK REF="STD-Ponticelli-1998" TYPE="STUDY">Ponticelli 1998</LINK>; <LINK REF="STD-Reichert-1994" TYPE="STUDY">Reichert 1994</LINK>; <LINK REF="STD-Silverberg-1976" TYPE="STUDY">Silverberg 1976</LINK>).</P>
<P>In this update the Cochrane Renal Group's Specialised Register was searched and 17 new studies (<LINK REF="STD-Arnadottir-2006" TYPE="STUDY">Arnadottir 2006</LINK>; <LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK>; <LINK REF="STD-Chen-2010a" TYPE="STUDY">Chen 2010a</LINK>; <LINK REF="STD-Dussol-2008" TYPE="STUDY">Dussol 2008</LINK>; <LINK REF="STD-Dyadyk-2001" TYPE="STUDY">Dyadyk 2001</LINK>; <LINK REF="STD-Hofstra-2010" TYPE="STUDY">Hofstra 2010</LINK>; <LINK REF="STD-Jha-2007" TYPE="STUDY">Jha 2007</LINK>; <LINK REF="STD-Jurubita-2012" TYPE="STUDY">Jurubita 2012</LINK>; <LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK>; <LINK REF="STD-Naumovic-2011" TYPE="STUDY">Naumovic 2011</LINK>; <LINK REF="STD-Ponticelli-2006" TYPE="STUDY">Ponticelli 2006</LINK>; <LINK REF="STD-Praga-2007" TYPE="STUDY">Praga 2007</LINK>; <LINK REF="STD-Saito-2009" TYPE="STUDY">Saito 2009</LINK>; <LINK REF="STD-Senthil-Nayagam-2008" TYPE="STUDY">Senthil Nayagam 2008</LINK>; <LINK REF="STD-Shibasaki-2004" TYPE="STUDY">Shibasaki 2004</LINK>; <LINK REF="STD-Tiller-1981" TYPE="STUDY">Tiller 1981</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>) were identified. One Japanese study (<LINK REF="STD-Koshisawa-1993" TYPE="STUDY">Koshisawa 1993</LINK>) was identified in the list of references of <LINK REF="STD-Shibasaki-2004" TYPE="STUDY">Shibasaki 2004</LINK> and one Chinese study (<LINK REF="STD-Liu-2009b" TYPE="STUDY">Liu 2009b</LINK>) was identified by searching the Chinese databases. Two studies previously identified as awaiting assessment on 2004 have been added to the included studies (<LINK REF="STD-Austin-1996a" TYPE="STUDY">Austin 1996a</LINK>; <LINK REF="STD-Stegeman-1994" TYPE="STUDY">Stegeman 1994</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-11-19 16:14:58 +1100" MODIFIED_BY="Narelle Willis">
<P>A total of 39 studies (1825 patients) were included in this updated review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The median sample size was 31 (range 9 to 120). The median follow-up was 24 months (range 6 to 120). Eight studies were only published as abstracts (<LINK REF="STD-Arnadottir-2006" TYPE="STUDY">Arnadottir 2006</LINK>; <LINK REF="STD-Austin-1996a" TYPE="STUDY">Austin 1996a</LINK>; <LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>; <LINK REF="STD-Dyadyk-2001" TYPE="STUDY">Dyadyk 2001</LINK>; <LINK REF="STD-Jurubita-2012" TYPE="STUDY">Jurubita 2012</LINK>; <LINK REF="STD-CYCLOMEN-Study-1994" TYPE="STUDY">CYCLOMEN Study 1994</LINK>; <LINK REF="STD-Saito-2009" TYPE="STUDY">Saito 2009</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>) and unpublished data were provided by the authors of two studies (<LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>; <LINK REF="STD-CYCLOMEN-Study-1994" TYPE="STUDY">CYCLOMEN Study 1994</LINK>). Two studies (<LINK REF="STD-Austin-1996a" TYPE="STUDY">Austin 1996a</LINK>; <LINK REF="STD-Dyadyk-2001" TYPE="STUDY">Dyadyk 2001</LINK>) could not be included in the meta-analyses as we were unable to extract the necessary data and one study was prematurely terminated due to low accrual rate (<LINK REF="STD-Stegeman-1994" TYPE="STUDY">Stegeman 1994</LINK>).Three studies were included in more than one comparison category (<LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>; <LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK>; <LINK REF="STD-Naumovic-2011" TYPE="STUDY">Naumovic 2011</LINK>).</P>
<P>Six studies included patients with declining kidney function (baseline SCr 203 to 260 &#956;mol/L or GFR 43 to 51 mL/min/1.73 m²) (<LINK REF="STD-Austin-1996a" TYPE="STUDY">Austin 1996a</LINK>; <LINK REF="STD-Branten-1998" TYPE="STUDY">Branten 1998</LINK>; <LINK REF="STD-Cattran-1995" TYPE="STUDY">Cattran 1995</LINK>; <LINK REF="STD-CYCLOMEN-Study-1994" TYPE="STUDY">CYCLOMEN Study 1994</LINK>; <LINK REF="STD-Falk-1992" TYPE="STUDY">Falk 1992</LINK>; <LINK REF="STD-Reichert-1994" TYPE="STUDY">Reichert 1994</LINK>). Five studies involved patients who were resistant to corticosteroids monotherapy (<LINK REF="STD-Koshisawa-1993" TYPE="STUDY">Koshisawa 1993</LINK>; <LINK REF="STD-Saito-2009" TYPE="STUDY">Saito 2009</LINK>; <LINK REF="STD-Shibasaki-2004" TYPE="STUDY">Shibasaki 2004</LINK>) or corticosteroids plus alkylating agents (<LINK REF="STD-Cattran-2001" TYPE="STUDY">Cattran 2001</LINK>; <LINK REF="STD-Naumovic-2011" TYPE="STUDY">Naumovic 2011</LINK>). Subgroup analysis was performed to investigate the impact of baseline characteristics.</P>
<P>The 39 included studies were divided into three categories according to financial ties. Eight studies had industrial support (<LINK REF="STD-Dussol-2008" TYPE="STUDY">Dussol 2008</LINK>; <LINK REF="STD-Praga-2007" TYPE="STUDY">Praga 2007</LINK>; <LINK REF="STD-Senthil-Nayagam-2008" TYPE="STUDY">Senthil Nayagam 2008</LINK>) or both industrial support and non-profit support (<LINK REF="STD-Cattran-1995" TYPE="STUDY">Cattran 1995</LINK>; <LINK REF="STD-Cattran-2001" TYPE="STUDY">Cattran 2001</LINK>; <LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK>; <LINK REF="STD-Saito-2009" TYPE="STUDY">Saito 2009</LINK>; <LINK REF="STD-Silverberg-1976" TYPE="STUDY">Silverberg 1976</LINK>); 16 studies declared non-profit support (<LINK REF="STD-Cattran-1989" TYPE="STUDY">Cattran 1989</LINK>; <LINK REF="STD-Coggins-1979" TYPE="STUDY">Coggins 1979</LINK>; <LINK REF="STD-Donadio-1974a" TYPE="STUDY">Donadio 1974a</LINK>; <LINK REF="STD-Falk-1992" TYPE="STUDY">Falk 1992</LINK>; <LINK REF="STD-Hofstra-2010" TYPE="STUDY">Hofstra 2010</LINK>; <LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK>; <LINK REF="STD-Liu-2009b" TYPE="STUDY">Liu 2009b</LINK>; <LINK REF="STD-Naumovic-2011" TYPE="STUDY">Naumovic 2011</LINK>; <LINK REF="STD-Ponticelli-1998" TYPE="STUDY">Ponticelli 1998</LINK>; <LINK REF="STD-Ponticelli-2006" TYPE="STUDY">Ponticelli 2006</LINK>; <LINK REF="STD-Reichert-1994" TYPE="STUDY">Reichert 1994</LINK>; <LINK REF="STD-Tiller-1981" TYPE="STUDY">Tiller 1981</LINK>) or had no support (<LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>; <LINK REF="STD-CYCLOMEN-Study-1994" TYPE="STUDY">CYCLOMEN Study 1994</LINK>; <LINK REF="STD-Jha-2007" TYPE="STUDY">Jha 2007</LINK>; <LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK>); 14 studies did not declare financial support (<LINK REF="STD-Ahmed-1994" TYPE="STUDY">Ahmed 1994</LINK>; <LINK REF="STD-Arnadottir-2006" TYPE="STUDY">Arnadottir 2006</LINK>; <LINK REF="STD-Austin-1996a" TYPE="STUDY">Austin 1996a</LINK>; <LINK REF="STD-Branten-1998" TYPE="STUDY">Branten 1998</LINK>; <LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>; <LINK REF="STD-Chen-2010a" TYPE="STUDY">Chen 2010a</LINK>; <LINK REF="STD-Dyadyk-2001" TYPE="STUDY">Dyadyk 2001</LINK>; <LINK REF="STD-Jurubita-2012" TYPE="STUDY">Jurubita 2012</LINK>; <LINK REF="STD-Koshisawa-1993" TYPE="STUDY">Koshisawa 1993</LINK>; <LINK REF="STD-Murphy-1992" TYPE="STUDY">Murphy 1992</LINK>; <LINK REF="STD-Pahari-1993" TYPE="STUDY">Pahari 1993</LINK>; <LINK REF="STD-Ponticelli-1992" TYPE="STUDY">Ponticelli 1992</LINK>; <LINK REF="STD-Shibasaki-2004" TYPE="STUDY">Shibasaki 2004</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>). Subgroup analysis was carried out to determine whether industrial support was associated with more favourable results.</P>
<P>Eight studies provided a priori sample size calculation (<LINK REF="STD-Cattran-1989" TYPE="STUDY">Cattran 1989</LINK>; <LINK REF="STD-Cattran-2001" TYPE="STUDY">Cattran 2001</LINK>; <LINK REF="STD-Dussol-2008" TYPE="STUDY">Dussol 2008</LINK>; <LINK REF="STD-Hofstra-2010" TYPE="STUDY">Hofstra 2010</LINK>; <LINK REF="STD-Ponticelli-1992" TYPE="STUDY">Ponticelli 1992</LINK>; <LINK REF="STD-Ponticelli-1998" TYPE="STUDY">Ponticelli 1998</LINK>; <LINK REF="STD-Praga-2007" TYPE="STUDY">Praga 2007</LINK>; <LINK REF="STD-Tiller-1981" TYPE="STUDY">Tiller 1981</LINK>). Subgroup analysis was conducted to inspect the influence of a priori sample size estimation.</P>
<P>The majority of studies were published in English. For the studies published in Chinese (<LINK REF="STD-Liu-2009b" TYPE="STUDY">Liu 2009b</LINK>) and Japanese (<LINK REF="STD-Koshisawa-1993" TYPE="STUDY">Koshisawa 1993</LINK>) there were not enough data to perform subgroup analyses based on language.</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting classification</HEADING>
<P>There are eight studies awaiting assessment (<LINK REF="STD-Berg-2007" TYPE="STUDY">Berg 2007</LINK>; <LINK REF="STD-Gaskin-2004" TYPE="STUDY">Gaskin 2004</LINK>; <LINK REF="STD-Hirayama-2006" TYPE="STUDY">Hirayama 2006</LINK>; <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>; <LINK REF="STD-Liu-2007" TYPE="STUDY">Liu 2007</LINK>; <LINK REF="STD-Howman-2012" TYPE="STUDY">Howman 2012</LINK>; <LINK REF="STD-Appel-2002" TYPE="STUDY">Appel 2002</LINK>; <LINK REF="STD-Saito-2006" TYPE="STUDY">Saito 2006</LINK>). All were due to be completed between 2005 and 2009 but as yet no full-text reports have been identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We have identified 14 ongoing studies (<LINK REF="STD-ChiCTR_x002d_TRC_x002d_08000098" TYPE="STUDY">ChiCTR-TRC-08000098</LINK>; <LINK REF="STD-ChiCTR_x002d_TRC_x002d_11001144" TYPE="STUDY">ChiCTR-TRC-11001144</LINK>; <LINK REF="STD-CTRI_x002f_2010_x002f_091_x002f_000231" TYPE="STUDY">CTRI/2010/091/000231</LINK>; <LINK REF="STD-EUCTR2007_x002d_005410_x002d_39_x002d_ES" TYPE="STUDY">EUCTR2007-005410-39-ES</LINK>; <LINK REF="STD-JPRN_x002d_UMIN000001099" TYPE="STUDY">JPRN-UMIN000001099</LINK>; <LINK REF="STD-JPRN_x002d_UMIN000006939" TYPE="STUDY">JPRN-UMIN000006939</LINK>; <LINK REF="STD-NCT00805753" TYPE="STUDY">NCT00805753</LINK>; <LINK REF="STD-NCT00843856" TYPE="STUDY">NCT00843856</LINK>; <LINK REF="STD-NCT01093157" TYPE="STUDY">NCT01093157</LINK>; <LINK REF="STD-NCT01161459" TYPE="STUDY">NCT01161459</LINK>; <LINK REF="STD-NCT01180036" TYPE="STUDY">NCT01180036</LINK>; <LINK REF="STD-NCT01282073" TYPE="STUDY">NCT01282073</LINK>; <LINK REF="STD-NCT01386554" TYPE="STUDY">NCT01386554</LINK>; <LINK REF="STD-NCT01508468" TYPE="STUDY">NCT01508468</LINK>) and these will be assessed and included or excluded in a future update.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-11-19 16:47:05 +1100" MODIFIED_BY="Narelle Willis">
<P>Twenty three studies (35 records) were excluded. Reasons for exclusion were: 10 were not randomised (<LINK REF="STD-Alexopoulos-2006" TYPE="STUDY">Alexopoulos 2006</LINK>; <LINK REF="STD-Austin-2008" TYPE="STUDY">Austin 2008</LINK>; <LINK REF="STD-Dominguez_x002d_Gil-1999" TYPE="STUDY">Dominguez-Gil 1999</LINK>; <LINK REF="STD-du-Buf_x002d_Vereijken-2004" TYPE="STUDY">du Buf-Vereijken 2004</LINK>; <LINK REF="STD-Goumenos-2007" TYPE="STUDY">Goumenos 2007</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>; <LINK REF="STD-Michail-2004" TYPE="STUDY">Michail 2004</LINK>; <LINK REF="STD-Polenakovic-1997" TYPE="STUDY">Polenakovic 1997</LINK>; <LINK REF="STD-Rashid-1995" TYPE="STUDY">Rashid 1995</LINK>; <LINK REF="STD-Yao-2001" TYPE="STUDY">Yao 2001</LINK>); the exact number of adult IMN patients with nephrotic syndrome was unavailable in each intervention group in 11 studies (<LINK REF="STD-Ambalavanan-1996" TYPE="STUDY">Ambalavanan 1996</LINK>; <LINK REF="STD-Black-1970" TYPE="STUDY">Black 1970</LINK>; <LINK REF="STD-Lagrue-1975" TYPE="STUDY">Lagrue 1975</LINK>; <LINK REF="STD-Majima-1990" TYPE="STUDY">Majima 1990</LINK>; <LINK REF="STD-MRCWP-1971" TYPE="STUDY">MRCWP 1971</LINK>; <LINK REF="STD-Nand-1997" TYPE="STUDY">Nand 1997</LINK>; <LINK REF="STD-Plavljanic-1998" TYPE="STUDY">Plavljanic 1998</LINK>; <LINK REF="STD-Edefonti-1988" TYPE="STUDY">Edefonti 1988</LINK>; <LINK REF="STD-Ponticelli-1993a" TYPE="STUDY">Ponticelli 1993a</LINK>; <LINK REF="STD-Sahay-2002" TYPE="STUDY">Sahay 2002</LINK>; <LINK REF="STD-Shilov-1998" TYPE="STUDY">Shilov 1998</LINK>); one study only enrolled children (<LINK REF="STD-Tejani-1991" TYPE="STUDY">Tejani 1991</LINK>); and one study did not complete the scheduled follow-up (<LINK REF="STD-Sun-2008" TYPE="STUDY">Sun 2008</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-04-27 17:39:11 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2014-04-27 17:38:34 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>Twenty-two studies (56%) specified appropriate methods for random sequence generation and were considered to be at low risk of bias. Appropriate methods of randomisation were not reported in the remaining 17 studies (44%). These studies were thus considered to have unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Fifteen studies (38%) reported appropriate allocation concealment methods and were considered to be at low risk of bias, while the remaining 24 studies (62%) did not provided details about allocation concealment and were considered to have unclear risk of bias.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2014-04-27 17:38:48 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants</HEADING>
<P>Appropriate procedure related to blinding of participants was confirmed in six studies (15%) and were considered to be at low risk of bias. Three studies (8%) were considered to have unclear risk of bias, and the remaining 30 studies (77%) did not perform adequate blinding of participants and were considered to be at high risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of personnel and outcome assessors</HEADING>
<P>Adequate blinding of personnel and outcome assessors was confirmed in four studies (10%) and were considered to be at low risk of bias. Three studies (8%) were considered to have unclear risk of bias, and the remaining 32 studies (82%) did not perform adequate blinding of personnel and outcome assessors and were considered to be at high risk of bias.</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-04-27 17:38:55 +1000" MODIFIED_BY="[Empty name]">
<P>Thirty-two studies (82%) were considered to be at low risk of bias; two studies (5%) were consider to have unclear risk of bias; and five studies (13%) were considered to be at high risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-04-27 17:39:00 +1000" MODIFIED_BY="[Empty name]">
<P>Thirty studies (83%) were considered to be at low risk of bias and, nine studies (17%) were considered to be at high risk of bias. Six studies did not provide any data related to primary outcomes - all-cause mortality or risk of ESKD. The reporting rates of secondary outcomes - increase of SCr, SCr, GFR, complete or partial remission, proteinuria, and severe adverse effects - were 59% (23/39), 38% (15/39), 33% (13/39), 82% (32/39), 56% (22/39), and 79% (31/39), respectively. Two studies did not provide data that could be extracted and meta-analysed, and one study was terminated due to poor accrual. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-04-27 17:39:11 +1000" MODIFIED_BY="[Empty name]">
<P>Fourteen studies (36%) were considered to be at low risk of bias; seven studies (18%) were considered to have unclear risk of bias. The remaining 18 studies (46%) were considered to be at high risk of bias. The underlying rationale has been detailed in the risk of bias tables in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Publication bias</HEADING>
<P>It has been recommended that tests for publication bias should be used only when at least 10 studies were included in the meta-analysis (<LINK REF="REF-Harbord-2009" TYPE="REFERENCE">Harbord 2009</LINK>). Thus, tests were restricted to the comparison of immunosuppressive treatments versus no treatment or ACEi (18 studies). There was no evidence of publication bias for composite definite endpoints (Z = 0.81, 95% CI -1.13 to 2.76, SE = 0.87, N = 12, P = 0.374) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>A; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>C) and complete or partial remission (Z = -1.19, 95% CI -3.50 to 1.12, SE = 1.08, N = 17, P = 0.290) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>B; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>D). Publication bias could be partially responsible for the significant heterogeneity in complete or partial remission when alkylating agents and corticosteroids were compared with no treatment in three studies. Beneficial intervention effects were reported in two published studies (<LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK>; <LINK REF="STD-Jha-2007" TYPE="STUDY">Jha 2007</LINK>), while neutral findings remained unpublished in one study (<LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>) (RR 2.04, 95% CI 1.46 to 2.86 versus RR 0.73, 95% CI 0.36 to 1.48; I² = 85%, subgroup differences P = 0.0010).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis</HEADING>
<P>Seventeen studies was classified to be totally or partially unpublished or have low quality design (<LINK REF="STD-Ahmed-1994" TYPE="STUDY">Ahmed 1994</LINK>; <LINK REF="STD-Arnadottir-2006" TYPE="STUDY">Arnadottir 2006</LINK>; <LINK REF="STD-Branten-1998" TYPE="STUDY">Branten 1998</LINK>; <LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>; <LINK REF="STD-Cattran-1989" TYPE="STUDY">Cattran 1989</LINK>; <LINK REF="STD-CYCLOMEN-Study-1994" TYPE="STUDY">CYCLOMEN Study 1994</LINK>; <LINK REF="STD-Jurubita-2012" TYPE="STUDY">Jurubita 2012</LINK>; <LINK REF="STD-Koshisawa-1993" TYPE="STUDY">Koshisawa 1993</LINK>; <LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK>; <LINK REF="STD-Liu-2009b" TYPE="STUDY">Liu 2009b</LINK>; <LINK REF="STD-Murphy-1992" TYPE="STUDY">Murphy 1992</LINK>; <LINK REF="STD-Naumovic-2011" TYPE="STUDY">Naumovic 2011</LINK>; <LINK REF="STD-Pahari-1993" TYPE="STUDY">Pahari 1993</LINK>; <LINK REF="STD-Saito-2009" TYPE="STUDY">Saito 2009</LINK>; <LINK REF="STD-Shibasaki-2004" TYPE="STUDY">Shibasaki 2004</LINK>; <LINK REF="STD-Tiller-1981" TYPE="STUDY">Tiller 1981</LINK>; <LINK REF="STD-Xu-2010" TYPE="STUDY">Xu 2010</LINK>). Sensitivity analysis, designed to exclude these studies, was performed to detect publication bias (<LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>; <LINK REF="REF-Harbord-2009" TYPE="REFERENCE">Harbord 2009</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>Since no studies were of long duration and most enrolled &lt; 100 patients, sensitivity analyses were not performed.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-04-27 17:40:41 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Immunosuppressive treatments versus no treatment or ACEi</HEADING>
<P>Immunosuppressive treatment significantly reduced the composite outcome of death or ESKD (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (15 studies, 791 patients): RR 0.58, 95% CI 0.36 to 0.95, P = 0.03; I² = 21%), and ESKD alone (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (15 studies, 791 patients): RR 0.55, 95% CI 0.31 to 0.95, P = 0.03; I² = 16%) at the end of follow-up (range 6 to 120 months) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). There was no significant difference in all-cause mortality (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (15 studies, 791 patients): RR 0.65, 95% CI 0.29 to 1.44, P = 0.29; I² = 0%).</P>
<P>Immunosuppressive treatment significantly reduced the risk of 100% increase in SCr (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (8 studies, 409 patients): RR 0.42, 95% CI 0.26 to 0.67, P = 0.0003; I² = 52%) and the risk of 50% increase in SCr (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (8 studies, 414 patients): RR 0.52, 95% CI 0.33 to 0.81, P = 0.004; I² = 12%) and increased GFR (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (8 studies, 287 patients): MD 9.77 mL/min/1.73 m², 95% CI 3.92 to 15.62, P = 0.001; I² = 0%), but significantly increased SCr (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> (5 studies, 198 patients): MD 25.43 &#956;mol/L, 95% CI 10.09 to 40.78, P = 0.001; I² = 0%) at the end of follow-up.</P>
<P>Immunosuppressive treatments significantly increased complete or partial remission (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK> (16 studies, 864 patients): RR 1.31, 95% CI 1.01 to 1.70, P = 0.04; I² = 53%) and reduced proteinuria (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK> (8 studies, 393 patients): MD -0.95 g/24 h, 95% CI -1.81 to -0.09, P = 0.03; I² = 59%) at the end of follow-up (range 6 to 120 months). Significant heterogeneity was found for complete or partial remission (I² = 53%, P = 0.004) and proteinuria (I² = 59%, P = 0.009). There were no significant differences in complete remission (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> (15 studies, 761 patients): RR 1.59, 95% CI 0.87 to 2.88, P = 0.13; I² = 46%) or partial remission (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> (15 studies, 761 patients): RR 1.16, 95% CI 0.86 to 1.57, P = 0.33; I² = 27%).</P>
<P>Immunosuppressive treatments resulted in a significantly higher risk of severe adverse effects (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK> (16 studies, 880 patients): RR 5.35, 95% CI 2.19 to 13.02, P = 0.0002; I² = 0%).</P>
<SUBSECTION>
<HEADING LEVEL="6">Sensitivity analysis</HEADING>
<P>Nine of 18 studies (<LINK REF="STD-Arnadottir-2006" TYPE="STUDY">Arnadottir 2006</LINK>; <LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>; <LINK REF="STD-Cattran-1989" TYPE="STUDY">Cattran 1989</LINK>; <LINK REF="STD-CYCLOMEN-Study-1994" TYPE="STUDY">CYCLOMEN Study 1994</LINK>; <LINK REF="STD-Koshisawa-1993" TYPE="STUDY">Koshisawa 1993</LINK>; <LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK>; <LINK REF="STD-Murphy-1992" TYPE="STUDY">Murphy 1992</LINK>; <LINK REF="STD-Shibasaki-2004" TYPE="STUDY">Shibasaki 2004</LINK>; <LINK REF="STD-Tiller-1981" TYPE="STUDY">Tiller 1981</LINK>), which provided unpublished data or had low quality design, were excluded for the sensitivity analysis. There were no significant changes to the outcomes (<LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>; <LINK REF="STD-Cattran-1995" TYPE="STUDY">Cattran 1995</LINK>; <LINK REF="STD-Coggins-1979" TYPE="STUDY">Coggins 1979</LINK>; <LINK REF="STD-Donadio-1974a" TYPE="STUDY">Donadio 1974a</LINK>; <LINK REF="STD-Dussol-2008" TYPE="STUDY">Dussol 2008</LINK>; <LINK REF="STD-Jha-2007" TYPE="STUDY">Jha 2007</LINK>; <LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK>; <LINK REF="STD-Praga-2007" TYPE="STUDY">Praga 2007</LINK>; <LINK REF="STD-Silverberg-1976" TYPE="STUDY">Silverberg 1976</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis</HEADING>
<P>According to the baseline characteristics, two studies involved patients with significantly declining kidney function (baseline GFR: 46 to 51 mL/min/1.73 m²) (<LINK REF="STD-Cattran-1995" TYPE="STUDY">Cattran 1995</LINK>; <LINK REF="STD-CYCLOMEN-Study-1994" TYPE="STUDY">CYCLOMEN Study 1994</LINK>). There were no statistically significant subgroup differences in the outcomes. Four studies were partially or totally supported by drug companies (<LINK REF="STD-Cattran-1995" TYPE="STUDY">Cattran 1995</LINK>; <LINK REF="STD-Dussol-2008" TYPE="STUDY">Dussol 2008</LINK>; <LINK REF="STD-Praga-2007" TYPE="STUDY">Praga 2007</LINK>; <LINK REF="STD-Silverberg-1976" TYPE="STUDY">Silverberg 1976</LINK>). Industrial support was not associated with more favourable results. Four studies estimated sample size in advance (<LINK REF="STD-Cattran-1989" TYPE="STUDY">Cattran 1989</LINK>; <LINK REF="STD-Dussol-2008" TYPE="STUDY">Dussol 2008</LINK>; <LINK REF="STD-Praga-2007" TYPE="STUDY">Praga 2007</LINK>; <LINK REF="STD-Tiller-1981" TYPE="STUDY">Tiller 1981</LINK>). A priori sample size calculation was associated with more conservative results in complete remission (RR 0.50, 95% CI 0.24 to 1.02 versus RR 2.42, 95% CI 1.40 to 4.17; I² = 91.5%, subgroup differences P = 0.0006).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Corticosteroid monotherapy versus no treatment</HEADING>
<P>There were no significant differences in any of the considered outcomes at the end of follow-up (range 24 to 48 months) (<LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>; <LINK REF="STD-Cattran-1989" TYPE="STUDY">Cattran 1989</LINK>; <LINK REF="STD-Coggins-1979" TYPE="STUDY">Coggins 1979</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Alkylating agent monotherapy versus no treatment</HEADING>
<P>Alkylating agents significantly increased the risk of temporary or permanent discontinuation or hospitalisation due to adverse events (<LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK> (3 studies, 102 patients): RR 7.18, 95% CI 1.33 to 38.70, P = 0.02; I² = 0%) at the end of follow-up (range 12 to 36 months) (<LINK REF="STD-Donadio-1974a" TYPE="STUDY">Donadio 1974a</LINK>; <LINK REF="STD-Murphy-1992" TYPE="STUDY">Murphy 1992</LINK>; <LINK REF="STD-Tiller-1981" TYPE="STUDY">Tiller 1981</LINK>).</P>
<P>There were no significant differences in any of the other outcomes at the end of follow-up (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>; <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>; <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>; <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Alkylating agents plus corticosteroids versus no treatment, ACEi or ARB, or corticosteroids</HEADING>
<P>Alkylating agents plus corticosteroids significantly reduced the composite outcome of death or ESKD (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> (8 studies, 448 patients): RR 0.44, 95% CI 0.26 to 0.75, P = 0.002; I² = 0%) and ESKD alone (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK> (8 studies, with 448 patients): RR 0.45, 95% CI 0.25 to 0.81, P = 0.008; I² = 0%) at the end of follow-up (range 9 to 120 months) (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). There was no significant difference in all-cause mortality (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK> (8 studies, 448 patients): RR 0.57, 95% CI 0.16 to 1.98, P = 0.38; I² = 0%).</P>
<P>Alkylating agents plus corticosteroids significantly increased GFR (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>.1 (2 studies, 102 patients): MD 11.70 mL/min/1.73 m², 95% CI 1.50 to 21.91, P = 0.02; I² = 15%) at the end of follow-up (range 9 to 120 months).</P>
<P>Alkylating agents plus corticosteroids significantly increased complete or partial remission (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.1 (7 studies, 442 patients): RR 1.46, 95% CI 1.13 to 1.89, P = 0.004; I² = 53%) and complete remission (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>.1 (7 studies, 442 patients): RR 2.32, 95% CI 1.61 to 3.32, P &lt; 0.00001; I² = 11%) and decreased proteinuria (<LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>.1 (6 studies, 279 patients): MD -1.25 g/24 h, 95% CI -1.93 to -0.57, P = 0.0003; I² = 50%) at the end of follow-up (range 9 to 120 months). Significant heterogeneity was found for complete or partial remission (I² = 53%, P = 0.05) and proteinuria (I² = 50%, P = 0.08). There was no significant difference in partial remission (<LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>.1 (7 studies, 442 patients): RR 0.94, 95% CI 0.56 to 1.57, P = 0.82; I² = 0%).</P>
<SUBSECTION>
<HEADING LEVEL="6">Sensitivity analysis</HEADING>
<P>Four unpublished or low quality studies (<LINK REF="STD-Ahmed-1994" TYPE="STUDY">Ahmed 1994</LINK>; <LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>; <LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK>; <LINK REF="STD-Pahari-1993" TYPE="STUDY">Pahari 1993</LINK>) were excluded. This did not affect efficacy outcomes, while the risk of severe adverse effects significantly increased (<LINK REF="CMP-004.12" TYPE="ANALYSIS">Analysis 4.12</LINK> (8 studies, 448 patients): RR 2.11 95% CI 0.77 to 5.79, P = 0.15 versus 4 studies, 303 patients: RR 4.20, 95% CI 1.15 to 15.32, P = 0.03) (<LINK REF="STD-Falk-1992" TYPE="STUDY">Falk 1992</LINK>; <LINK REF="STD-Jha-2007" TYPE="STUDY">Jha 2007</LINK>; <LINK REF="STD-Ponticelli-1992" TYPE="STUDY">Ponticelli 1992</LINK>; <LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis</HEADING>
<P>One study involved patients with established renal insufficiency (baseline SCr: 203-239 &#956;mol/L) (<LINK REF="STD-Falk-1992" TYPE="STUDY">Falk 1992</LINK>) and there were no statistically significant subgroup differences in the outcomes. No study declared to receive financial support from drug companies, and the planned subgroup analysis was not conducted. One study estimated the sample size in advance (<LINK REF="STD-Ponticelli-1992" TYPE="STUDY">Ponticelli 1992</LINK>) and there were no statistically significant subgroup differences in the outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Alkylating agents plus corticosteroids versus no treatment</HEADING>
<P>Alkylating agents plus corticosteroids significantly reduced the composite outcome of death or ESKD (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.1 (3 studies, 211 patients): RR 0.33, 95% CI 0.17 to 0.64, P = 0.001; I² = 0%) and ESKD alone (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>.1 (3 studies, 211 patients): RR 0.31, 95% CI 0.15 to 0.65, P = 0.002; I² = 0%) at the end of follow-up (range 60 to 120 months). There was no significant difference in all-cause mortality (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.1 (3 studies, 211 patients): RR 0.48, 95% CI 0.12 to 1.97, P = 0.31; I² = 0%).</P>
<P>Alkylating agents plus corticosteroids significantly reduced the risk of 100% increase in SCr (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>.2 (3 studies, 211 patients): RR 0.39, 95% CI 0.17 to 0.89, P = 0.02; I² = 52%). <LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK> reported a significantly reduced risk of 50% increase of SCr (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>.2 (1 study, 81 patients): RR 0.33, 95% CI 0.15 to 0.68, P = 0.003), and <LINK REF="STD-Jha-2007" TYPE="STUDY">Jha 2007</LINK> reported a significant increase in GFR (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>.2 (1 study, 93 patients): MD 14.00 mL/min/1.73 m², 95% CI 5.82 to 22.18, P = 0.0008) at the end of follow-up (60 to 120 months). However <LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK> reported this combined treatment significantly increased SCr (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>.2 (1 study, 56 patients): MD 26.86 &#956;mol/L, 95% CI 10.14 to 43.58, P = 0.002) at the end of follow-up (120 months).</P>
<P>Alkylating agents plus corticosteroids significantly increased complete remission (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>.2 (3 studies, 211 patients): RR 3.18, 95% CI 1.23 to 8.21, P = 0.02; I² = 39%) and decreased proteinuria (<LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>.2 (2 studies, 174 patients): MD -2.06 g/24 h, 95% CI -3.69 to -0.44, P = 0.01; I² = 77%) at the end of follow-up (range 60-120 months). There was no significant difference in complete or partial remission (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.2 (3 studies, 211 patients): RR 1.52, 95% CI 0.85 to 2.73, P = 0.16; I² = 71%) or partial remission (<LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>.2 (3 studies, 211 patients): RR 1.00, 95% CI 0.50 to 2.02, P = 0.99; I² = 56%) at the end of follow-up (range 60-120 months). Significant heterogeneity was found for complete or partial remission (I² = 71%, P = 0.03) and proteinuria (I² = 77%, P = 0.04)</P>
<P>Alkylating agents plus corticosteroids led to a significantly higher risk of severe adverse effects (<LINK REF="CMP-004.12" TYPE="ANALYSIS">Analysis 4.12</LINK>.1 (3 studies, 211 patients): RR 9.79, 95% CI 1.28 to 75.01, P = 0.03; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Alkylating agents plus corticosteroids versus ACEi</HEADING>
<P>
<LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK> (9 patients) reported no significant differences in any of the considered outcomes at the end of follow-up (9 months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Alkylating agents plus corticosteroids versus corticosteroids (same dose)</HEADING>
<P>Alkylating agents and corticosteroids significantly increased complete or partial remission (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.15 (2 studies, 112 patients): RR 1.52, 95% CI 1.07 to 2.15, P = 0.02; I² = 0%) at the end of follow-up (range 12 to 54 months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Alkylating agents + corticosteroids versus corticosteroids (low dose)</HEADING>
<P>
<LINK REF="STD-Pahari-1993" TYPE="STUDY">Pahari 1993</LINK> reported alkylating agents and corticosteroids significantly increased complete or partial remission (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.20 (90 patients): RR 1.71, 95% CI 1.21 to 2.42, P = 0.002) and complete remission (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>.20 (90 patients(: RR 2.51, 95% CI 1.61 to 3.94, P &lt; 0.0001) at the end of follow-up (46 months).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cyclophosphamide plus corticosteroids versus chlorambucil plus corticosteroids</HEADING>
<P>Cyclophosphamide plus corticosteroids led to a significantly lower risk of severe adverse effects (<LINK REF="CMP-005.11" TYPE="ANALYSIS">Analysis 5.11</LINK> (3 studies, 147 patients): RR 0.48, 95% CI 0.26 to 0.90, P = 0.02; I² = 0%) at the end of follow-up (15 to 39 months).</P>
<P>There were no significant differences in any of the other outcomes at the end of follow-up (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>; <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>; <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>; <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>; <LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>; <LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>; <LINK REF="CMP-005.10" TYPE="ANALYSIS">Analysis 5.10</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cyclosporine with or without corticosteroids versus no treatment, ACEi, or corticosteroids with or without alkylating agents/azathioprine</HEADING>
<P>There were no significant differences in any of the considered outcomes at the end of follow-up (range 12 to 21 months) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>; <LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>; <LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>; <LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>; <LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>; <LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>; <LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>; <LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>; <LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Cyclosporine versus placebo or no treatment</HEADING>
<P>There were no significant differences in any of the considered outcomes at the end of follow-up (range 12 to 21 months) (2 studies, 38 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cyclosporine plus corticosteroids versus no treatment</HEADING>
<P>
<LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (60 months) (33 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cyclosporine plus corticosteroids versus ACEi</HEADING>
<P>
<LINK REF="STD-Kosmadakis-2010" TYPE="STUDY">Kosmadakis 2010</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (9 months) (10 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cyclosporine plus corticosteroids versus placebo of cyclosporine plus corticosteroids</HEADING>
<P>
<LINK REF="STD-Cattran-2001" TYPE="STUDY">Cattran 2001</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (18 months) (51 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cyclosporine plus corticosteroids versus alkylating agents plus corticosteroids</HEADING>
<P>There were no significant differences in any of the considered outcomes at the end of follow-up (range 9 to 60 months) (2 studies, 47 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cyclosporine plus corticosteroids versus azathioprine plus corticosteroids</HEADING>
<P>
<LINK REF="STD-Naumovic-2011" TYPE="STUDY">Naumovic 2011</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (36 months) (23 patients).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cyclosporine (1.5 mg/kg twice/d) plus corticosteroids versus cyclosporine (3.0 mg/kg once/d) plus corticosteroids</HEADING>
<P>
<LINK REF="STD-Saito-2009" TYPE="STUDY">Saito 2009</LINK> reported cyclosporine (1.5 mg/kg twice/d) significantly reduced proteinuria (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK> (33 patients): MD -0.70, 95% CI -0.96 to -0.44, P &lt; 0.00001) at the end of follow-up (12 months) (33 patients). There was no significant difference reported for complete remission at 12 months (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK> (33 patients): RR 1.06, 95% CI 0.66 to 1.72).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tacrolimus with or without corticosteroids versus no treatment or corticosteroids plus alkylating agents</HEADING>
<P>Tacrolimus with or without corticosteroids significantly decreased proteinuria (<LINK REF="CMP-008.09" TYPE="ANALYSIS">Analysis 8.9</LINK>.1 (2 studies, 145 patients): MD -1.06 g/24 h, 95% CI -1.66 to -0.47, P = 0.0004; I² = 0%) at the end of follow-up (range 9 to 30 months).</P>
<SUBSECTION>
<HEADING LEVEL="5">Tacrolimus versus no treatment</HEADING>
<P>
<LINK REF="STD-Praga-2007" TYPE="STUDY">Praga 2007</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (30 months) (48 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tacrolimus plus corticosteroids versus alkylating agents plus corticosteroids</HEADING>
<P>Tacrolimus plus corticosteroids significantly reduced proteinuria (<LINK REF="CMP-008.09" TYPE="ANALYSIS">Analysis 8.9</LINK>.5 (2 studies, 84 patients): MD -1.03 g/24 h, 95% CI -1.69 to -0.37, P = 0.002; I² = 7%) at the end of follow-up (9 to 12 months).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mycophenolate mofetil with or without corticosteroids versus no treatment or corticosteroids with alkylating agents</HEADING>
<P>There were no significant differences in any of the considered outcomes at the end of follow-up (range 12-24 months) (3 studies, 77 patients).</P>
<SUBSECTION>
<HEADING LEVEL="5">Mycophenolate mofetil versus no treatment</HEADING>
<P>
<LINK REF="STD-Dussol-2008" TYPE="STUDY">Dussol 2008</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (12 months) (36 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mycophenolate mofetil plus corticosteroids versus alkylating agents plus corticosteroids</HEADING>
<P>There were no significant differences in any of the considered outcomes at the end of follow-up (range 15 to 24 months) (2 studies, 41 patients).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mycophenolate mofetil plus cyclosporine (2 mg/kg/d) plus corticosteroids versus cyclosporine (5 mg/kg/d) plus corticosteroids</HEADING>
<P>
<LINK REF="STD-Jurubita-2012" TYPE="STUDY">Jurubita 2012</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (12 months) (18 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adrenocorticotropic hormone versus no treatment or corticosteroids plus alkylating agents</HEADING>
<P>
<LINK REF="STD-Ponticelli-2006" TYPE="STUDY">Ponticelli 2006</LINK> reported ACTH significantly reduced proteinuria (<LINK REF="CMP-011.10" TYPE="ANALYSIS">Analysis 11.10</LINK>.1 (32 patients): MD -1.80 g/24 h, 95% CI -3.19 to -0.41, P = 0.01) at the end of follow-up (22 months).</P>
<SUBSECTION>
<HEADING LEVEL="5">Adrenocorticotropic hormone versus no treatment</HEADING>
<P>
<LINK REF="STD-Arnadottir-2006" TYPE="STUDY">Arnadottir 2006</LINK> reported ACTH significantly increased complete or partial remission (<LINK REF="CMP-011.07" TYPE="ANALYSIS">Analysis 11.7</LINK>.2 (30 patients): RR 7.00, 95% CI 1.91 to 25.62, P = 0.003) and complete remission (<LINK REF="CMP-011.08" TYPE="ANALYSIS">Analysis 11.8</LINK>.2 (30 patients): RR 11.00, 95% CI 1.62 to 74.88, P = 0.01) at the end of follow-up (21 months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adrenocorticotropic hormone versus alkylating agents plus corticosteroids</HEADING>
<P>
<LINK REF="STD-Ponticelli-2006" TYPE="STUDY">Ponticelli 2006</LINK> reported ACTH significantly reduced proteinuria (<LINK REF="CMP-011.10" TYPE="ANALYSIS">Analysis 11.10</LINK>.2 (32 patients): MD -1.80 g/24 h, 95% CI -3.19 to -0.41, P = 0.01) at the end of follow-up (22 months).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Azathioprine with or without corticosteroids versus placebo or cyclosporine plus corticosteroids</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Azathioprine versus placebo or no treatment at 12 months</HEADING>
<P>
<LINK REF="STD-Silverberg-1976" TYPE="STUDY">Silverberg 1976</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (12 months) (9 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Azathioprine plus corticosteroids versus cyclosporine plus corticosteroids at 36 months</HEADING>
<P>
<LINK REF="STD-Naumovic-2011" TYPE="STUDY">Naumovic 2011</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (36 months) (23 patients).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mizoribine versus no treatment</HEADING>
<P>Mizoribine significantly increased complete or partial remission (<LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>.1 (2 studies, 114 patients): RR 2.24, 95% CI 1.14 to 4.38, P = 0.02; I² = 0%) at the end of follow-up (range 6 to 24 months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tripterygium wilfordii plus corticosteroids versus Tripterygium wilfordii</HEADING>
<P>
<LINK REF="STD-Liu-2009b" TYPE="STUDY">Liu 2009b</LINK> reported Tripterygium wilfordii and corticosteroids significantly increased complete or partial remission (<LINK REF="CMP-014.06" TYPE="ANALYSIS">Analysis 14.6</LINK>.1 (84 patients): RR 2.03, 95% CI 1.31 to 3.16, P = 0.002) and complete remission (<LINK REF="CMP-014.07" TYPE="ANALYSIS">Analysis 14.7</LINK>.1 (84 patients): RR 7.63, 95% CI 1.87 to 31.13, P = 0.005) at the end of follow-up (12 months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Early versus late immunosuppressive treatments</HEADING>
<P>
<LINK REF="STD-Hofstra-2010" TYPE="STUDY">Hofstra 2010</LINK> reported no significant differences in any of the considered outcomes at the end of follow-up (72 months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other results</HEADING>
<P>The reported results of the three studies which could not be included in our meta-analyses can be found in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-04-22 15:09:40 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-04-22 15:08:07 +1000" MODIFIED_BY="[Empty name]">
<P>Immunosuppressive treatments significantly reduced the composite definite endpoints and risk of ESKD. In a population with an assumed risk of ESKD of 125/1000 patients, immunosuppressive treatments would be expected to reduce the number of patients experiencing ESKD to 69/1000 patients (95% CI 39 to 119) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). However, there was no significant difference in the all-cause mortality. Immunosuppressive treatments significantly reduced the risks of 100% and 50% increase of SCr and increased GFR but were also associated with a significantly increased SCr at the end of follow-up. It should be noted that these three outcomes - increase of SCr, GFR, and SCr - were reported in 8, 8, and 5 of 18 studies, respectively. Thus, the inconsistent results could be attributed to the selective reporting bias. Immunosuppressive treatments significantly increased complete or partial remission but not complete remission alone or partial remission alone. In a population with an assumed complete or partial remission of 296/1000 patients, this regimen would be expected to increase the number of patients experiencing complete or partial remission to 388/1000 patients (95% CI 299 to 504) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Moreover, the prespecified subgroup analysis indicated that a priori sample size calculation resulted in more conservative estimate in complete remission. Immunosuppressive treatments resulted in more temporary or permanent discontinuations or hospitalisations due to adverse effects. The type of adverse effects was not assessed because different immunosuppressive treatments have different safety profiles. The proportion of patients experiencing mild adverse effects was also not considered because they were quite common for immunosuppressive treatments and very likely under-reported, particularly in the control group of non-double-blind studies. Conversely, permanent or temporary discontinuation or hospitalisation due to adverse effects was more likely reported in sufficient detail.</P>
<P>It should be noted that not all immunosuppressive treatments are equal. Which treatments could be confidently discarded or recommended? The role of corticosteroids monotherapy or alkylating agents monotherapy remained very uncertain not only for definite but also for surrogate endpoints. Furthermore, safety concerns with the use of alkylating agent monotherapy could be raised. So far, only three studies compared corticosteroids plus alkylating agents with no treatment: two published studies with positive results (<LINK REF="STD-Imbasciati-1980" TYPE="STUDY">Imbasciati 1980</LINK>; <LINK REF="STD-Jha-2007" TYPE="STUDY">Jha 2007</LINK>) and one unpublished study with neutral results (<LINK REF="STD-Braun-1995" TYPE="STUDY">Braun 1995</LINK>). Meta-analysis of these three studies (211 patients) showed that this regimen significantly reduced the composite outcome of death or ESKD, increased complete remission and decreased proteinuria, but significantly increased the risk of adverse effects leading to withdrawals or hospitalisations. When compared with no treatment or ACEi or corticosteroids monotherapy in eight studies (448 patients), combined corticosteroids and alkylating agents significantly reduced the composite outcome of death or ESKD, increased complete or partial remission and complete remission, and decreased proteinuria. In a population with an assumed risk of all-cause mortality or ESKD of 181/1000 patients, this regimen would be expected to reduce the number of patients experiencing death or ESKD to 80/1000 patients (95% CI 47 to 136). In a population with an assumed complete or partial remission of 408/1000 patients, this regimen would be expected to increase the number of patients experiencing complete or partial remission to 596/1000 patients (95% CI 462 to 772) (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). However, it should be noted that four of these eight studies were classified as unpublished or having low quality design. The number of included high quality studies was relatively small. Furthermore, most of included studies did not have adequate follow-up to appropriately assess definite endpoints. Among alkylating agents, cyclophosphamide was safer than chlorambucil.</P>
<P>The superiority of cyclosporine or mycophenolate mofetil plus corticosteroids over alkylating agents plus corticosteroids was not identified, but this conclusion was based on four small studies totalling &lt; 150 participants. In contrast, tacrolimus and adrenocorticotropic hormone significantly reduced proteinuria. Two studies demonstrated a significant benefit of mizoribine monotherapy on complete or partial remission in Japanese patients (<LINK REF="STD-Koshisawa-1993" TYPE="STUDY">Koshisawa 1993</LINK>; <LINK REF="STD-Shibasaki-2004" TYPE="STUDY">Shibasaki 2004</LINK>). Tripterygium wilfordii might have beneficial effects on "complete or partial remission" and complete remission for Chinese patients (<LINK REF="STD-Liu-2009b" TYPE="STUDY">Liu 2009b</LINK>). There was no clear evidence to support the use of corticosteroid monotherapy, alkylating agent monotherapy, or azathioprine. A better understanding of genetic susceptibility and pathogenic mechanisms of IMN may allow the discovery of newer drugs. The recent identification of M-type phospholipase A2 receptor and the utilization of rituximab represent major milestones in understanding the pathogenesis and searching for new therapeutic strategies for IMN (<LINK REF="REF-Beck-2009" TYPE="REFERENCE">Beck 2009</LINK>; <LINK REF="REF-Beck-2011" TYPE="REFERENCE">Beck 2011</LINK>; <LINK REF="REF-Herrmann-2012" TYPE="REFERENCE">Herrmann 2012</LINK>; <LINK REF="REF-Stanescu-2011" TYPE="REFERENCE">Stanescu 2011</LINK>; <LINK REF="REF-Waldman-2012" TYPE="REFERENCE">Waldman 2012</LINK>). Numerous non-randomised studies have demonstrated that rituximab is a promising new immunosuppressive drug, but these pioneering studies are still ongoing (<LINK REF="STD-NCT01508468" TYPE="STUDY">NCT01508468</LINK>; <LINK REF="STD-NCT01180036" TYPE="STUDY">NCT01180036</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-04-22 15:08:37 +1000" MODIFIED_BY="[Empty name]">
<P>One major limitation was the relatively small numbers of included studies in some immunosuppressive regimens, especially for the newer immunosuppressive drugs, such as tacrolimus, mycophenolate mofetil, and adrenocorticotropic hormone. This issue is common in systematic reviews carried out in the field of glomerulonephritis. Another major concern relied in the relatively short follow-up in most of the included studies (median follow-up 24 months). It has been recognised that for definite endpoints such as ESKD a follow-up of at least seven to 10 years should be considered. For surrogate outcomes such as complete or partial remission an adequate follow-up should be of at least two to three years (<LINK REF="REF-du-Buf_x002d_Vereijken-2005" TYPE="REFERENCE">du Buf-Vereijken 2005</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-04-20 16:16:51 +1000" MODIFIED_BY="[Empty name]">
<P>Due to the paucity of studies, subgroup analysis allowing for variations in interventions (different doses, routes and duration of therapies used and previously-used relative agents before entry to the studies) and in populations (age, race, and renal pathology) could not be properly carried out. Language bias was not addressed by subgroup analysis. Sensitivity analysis could not be performed to explore the effect of dominating studies with very long follow-up or very large same size. However, we performed sensitivity analysis to investigate the impact of unpublished or low quality studies and subgroup analysis to investigate covariate effects of clinical baseline characteristics, industrial support, and a priori sample size estimation. Heterogeneity was found to be statistically significant in certain comparisons when complete or partial remission and proteinuria were assessed. Differences in immunosuppressive therapeutic approaches, in the choices of the control arm, in adequacy of sample size, and more generally in study quality could at least partially account for heterogeneity. There was no clear evidence of publication bias in the comparison of immunosuppressive treatments versus no treatment or ACEi. However, publication bias cannot be completely excluded in other comparisons with insufficient number of studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-04-22 15:09:40 +1000" MODIFIED_BY="[Empty name]">
<P>The Cochrane Renal Group's Trial Search Co-ordinator implemented comprehensive search strategies for this update. We also searched clinical trials registries such as ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform. The major difference in the review process between this update and 2004 initial version was the addition of studies published in Chinese language, which contributed to reduce the impact of language bias. However, the authenticity of randomised studies published in Chinese language constituted a non-negligible issue (<LINK REF="REF-Wu-2009" TYPE="REFERENCE">Wu 2009</LINK>). Finally, only one study related to Tripterygium wilfordii (a traditional Chinese immunosuppressive medicine) was included (<LINK REF="STD-Liu-2009b" TYPE="STUDY">Liu 2009b</LINK>). This study was not combined with other studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-04-20 16:19:56 +1000" MODIFIED_BY="[Empty name]">
<P>Three systematic reviews were published before 1995 (<LINK REF="REF-Couchoud-1994" TYPE="REFERENCE">Couchoud 1994</LINK>; <LINK REF="REF-Hogan-1995" TYPE="REFERENCE">Hogan 1995</LINK>; <LINK REF="REF-Imperiale-1995" TYPE="REFERENCE">Imperiale 1995</LINK>). During the past few years there was no published systematic review or meta-analysis of RCTs related to immunosuppressive treatments for adult patients with IMN and nephrotic syndrome. In 2004, we published the first version of this systematic review. The present update of systematic review (39 studies, 1825 patients) seemed to be more powerful than the 2004 original version (18 studies, 1025 patients). However, after careful scrutiny there was no improvement neither in median sample size/study (42 patients/study in the 2004 version versus 31 patients/study in this update) nor in the proportion of studies without potential methodological problems (61% in the 2004 version versus 53% in this update).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-04-27 17:42:19 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-04-27 17:40:59 +1000" MODIFIED_BY="[Empty name]">
<P>In this update, a combined alkylating agent and corticosteroid regimen had short- and long-term benefits on adult IMN with nephrotic syndrome. Among alkylating agents, cyclophosphamide was safer than chlorambucil. It should be emphasised that the number of included studies with high-quality design was relatively small and most of the included studies did not have adequate follow-up and enough power to assess the prespecified definite endpoints. This regimen was significantly associated with more withdrawals or hospitalisations. Although a six-month course of alternating monthly cycles of corticosteroids and cyclophosphamide was recommended by the KDIGO Clinical Practice Guideline 2012 as the initial therapy for adult IMN with nephrotic syndrome (<LINK REF="REF-KDIGO-2012" TYPE="REFERENCE">KDIGO 2012</LINK>), clinicians should inform their patients of the lack of high-quality evidence for these benefits as well as the well-recognised adverse effects of this therapy. Whether this combined therapy should be indicated in all adult patients at high risk of progression to ESKD or only restricted to those with deteriorating kidney function still remained unclear.</P>
<P>Cyclosporine or tacrolimus was recommended by the KDIGO Clinical Practice Guideline 2012 as the alternative regimen for adult IMN with nephrotic syndrome (<LINK REF="REF-KDIGO-2012" TYPE="REFERENCE">KDIGO 2012</LINK>); however, there was no evidence that calcineurin inhibitors could alter the combined outcome of death or ESKD. There was no clear evidence to support the use of corticosteroid monotherapy or alkylating agent monotherapy. The numbers of corresponding studies related to tacrolimus, mycophenolate mofetil, adrenocorticotropic hormone, azathioprine, mizoribine, and Tripterygium wilfordii are still too sparse to draw final conclusions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-04-27 17:42:19 +1000" MODIFIED_BY="[Empty name]">
<P>There is need for more methodologically sound studies with an emphasis on adequate sample size and follow-up. Furthermore, priority should be given to the choice of definite rather than surrogate endpoints. Any immunosuppressive treatments (including calcineurin inhibitors (cyclosporine and tacrolimus), sirolimus, mycophenolate mofetil, synthetic adrenocorticotropic hormone, Tripterygium wilfordii (a traditional Chinese immunosuppressive medicine), leflunomide, azathioprine, mizoribine, methotrexate, levamisole, and even biologics (eculizumab and rituximab) and high-dose gamma-globulin), should be further directly compared with alkylating agents and corticosteroids after the superiority over placebo or no treatment or non-immunosuppressive treatments are clearly established. More studies are needed to assess whether immunosuppressive treatments should be given to all adult patients at high risk of progression to ESKD or only restricted to those with established renal insufficiency. Ideally, optimal doses, routes, and durations of therapies that are most beneficial and least harmful to patients of different races, ages, and clinical and pathological severity still remain to be clarified.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-10-09 11:06:11 +1100" MODIFIED_BY="[Empty name]">
<P>The authors thank Professor Giuseppe Remuzzi, who had the idea and revised the manuscript for the original review and the review update.</P>
<P>The authors are also indebted to Dr Antonietta Chianca, who provided statistical advice for the review update, Dr Lisa A Tjosvold, who helped perform the electronic search for the original review, Dr Luciana Tammuzzo, who hand-searched the Journal of Nephrology for the original review, and principal investigators of the completed and ongoing studies considered in the review, who provided additional information or clarification for the original review (Professor Daniel C Cattran, Professor Peter Mathieson, Dr Roberto Pisoni, and Professor Teut Risler).</P>
<P>The authors also thank Ms Ruth Mitchell, the Cochrane Trials Search Coordinator, who provided us with the Cochrane Library search strategy and relevant information, and Ms Narelle Willis, the Cochrane Renal Group Coordinator, for her help and support.</P>
<P>The review update was partially supported by the Key Science and Technology Planning of Science and Technology Commission Foundation of Beijing (D131100004713003, D131100005313006), the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2011BAI10B08), and the National Basic Research Program Project of China (2011CB944004). The sponsors had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-04-22 16:12:40 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Protocol: AS, AP, GR</LI>
<LI>Search strategy: AP,GAG</LI>
<LI>Study selection: AP, JZ</LI>
<LI>Quality assessment: AP, JZ</LI>
<LI>Data extraction and data entry: AP, GAG</LI>
<LI>Resolution of disagreements: AS</LI>
<LI>Final manuscript: AS, AP</LI>
<LI>Final manuscript review: GR, AS, NB</LI>
<LI>Update: YC, AP, GC, XC</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2014-04-15 20:38:27 +1000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-11-19 16:15:00 +1100" MODIFIED_BY="Narelle Willis">
<STUDIES MODIFIED="2014-11-19 16:15:00 +1100" MODIFIED_BY="Narelle Willis">
<INCLUDED_STUDIES MODIFIED="2014-11-19 15:48:26 +1100" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmed-1994" MODIFIED="2014-04-27 18:00:28 +1000" MODIFIED_BY="[Empty name]" NAME="Ahmed 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-04-27 18:00:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed S, Rahman M, Alam MR, Islam S, Chowdhury MN, Chowdhury SM, et al</AU>
<TI>Methyl prednisolone plus chlorambucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy - a preliminary study</TI>
<SO>Bangladesh Renal Journal</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>2</NO>
<PG>51-4</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:11:52 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:11:52 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1995085509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 18:00:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rahman M, Ahmed S, Alam MR, Selim SI, Chowdhury MN, Chowdhury SM, et al</AU>
<TI>Methyl prednisolone plus chlorambucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy - a preliminary study [abstract]</TI>
<SO>10th Asian Colloquium in Nephrology; 1994, Dec 2-6; Karachi, Pakistan</SO>
<YR>1994</YR>
<PG>66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnadottir-2006" MODIFIED="2014-04-03 15:17:47 +1100" MODIFIED_BY="Narelle S Willis" NAME="Arnadottir 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-03 15:17:47 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnadottir M, Stefansson B, Berg A</AU>
<TI>A randomized study on treatment with adrenocorticotropic hormone in idiopathic membranous nephropathy [abstract no: F-PO1112]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>571A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:17:47 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:17:47 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00782355"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Austin-1996a" MODIFIED="2014-04-27 17:50:55 +1000" MODIFIED_BY="[Empty name]" NAME="Austin 1996a" YEAR="1996">
<REFERENCE MODIFIED="2014-04-16 16:38:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Austin HA, Vaughan EM, Boumpas DT, Balow JE</AU>
<TI>Randomized trial of pulse cyclophosphamide and prednisone vs. prednisone alone in idiopathic membranous nephropathy [abstract no: A0410]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1327</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00583858"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branten-1998" MODIFIED="2014-04-03 15:20:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="Branten 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-04-03 15:20:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branten AJ, Reichert LJ, Koene RA, Wetzels JF</AU>
<TI>Cyclophosphamide is superior to chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency [abstract no: A0395]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Programs &amp; Abstracts</NO>
<PG>82A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:20:19 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:20:19 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00444527"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:18:45 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Branten AJ, Reichert LJ, Koene RA, Wetzels JF</AU>
<TI>Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency</TI>
<SO>Qjm</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>5</NO>
<PG>359-66</PG>
<IDENTIFIERS MODIFIED="2012-07-05 16:54:02 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-05 16:54:02 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9709470"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Braun-1995" MODIFIED="2014-04-03 15:22:56 +1100" MODIFIED_BY="Narelle S Willis" NAME="Braun 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-04-03 15:22:06 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Braun N, Dietz K, Vonthein R, Erley C, Risler T</AU>
<TI>Remission and relapses in idiopathic membranous nephropathy. Description by a longitudinal multi-state Markov-model [abstract]</TI>
<SO>41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal</SO>
<YR>2004</YR>
<PG>34-5</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:22:06 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:22:06 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00509101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 13:06:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun N, Erley CM, Benda N, Zauner I, Kanis R, Grupp C et al</AU>
<TI>Therapy of membranous glomerulonephritis with nephrotic syndrome. 5 years follow-up of a prospective, randomized multi-centre study [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>6</NO>
<PG>967</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:22:56 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Braun N, Erley CM, Benda N, Zauner I, Kanis R, Grupp C, et al</AU>
<TI>Therapy of membranous glomerulonephritis with nephrotic syndrome. 5 years follow-up of a prospective, randomized multi-center study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>413</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:22:56 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:22:56 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00261096"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cameron-1990" MODIFIED="2014-04-27 18:00:35 +1000" MODIFIED_BY="[Empty name]" NAME="Cameron 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-04-27 18:00:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cameron JS, Healy MJ, Adu D</AU>
<TI>The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1990</YR>
<VL>74</VL>
<NO>2</NO>
<PG>133-56</PG>
<IDENTIFIERS MODIFIED="2014-04-08 10:35:22 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-04-08 10:35:22 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2189149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:26:13 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cameron JS, Working Party of the MRC Glomerulonephritis Registry</AU>
<TI>The MRC trial of prednisolone in membranous nephropathy. The Working Party of the MRC Glomerulonephritis Registry [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>6</NO>
<PG>844</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:25:16 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:25:16 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00260412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:25:55 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cameron JS, Working party of the UK MRC Glomerulonephritis Registry</AU>
<TI>The MRC trial of prednisolone in membranous nephropathy. The Working Party of the UK MRC Glomerulonephritis Registry [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>4</NO>
<PG>507-8</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:25:55 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:25:55 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00260389"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cattran-1989" MODIFIED="2014-04-27 18:00:54 +1000" MODIFIED_BY="[Empty name]" NAME="Cattran 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-04-27 18:00:49 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cattran D, Cardella C, Charron R, Roscoe J, Cole E, Bear R, et al</AU>
<TI>Results of a controlled trial of alternate day prednisone (ADS) in idiopathic membranous glomerulonephritis (IMGN) [abstract]</TI>
<SO>Kidney International</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>3</NO>
<PG>600</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:27:01 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:27:01 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550495"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:27:50 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cattran D, Cardella C, Charron R, Roscoe J, Rance P, Cusimano M, et al</AU>
<TI>Preliminary results of controlled trial of alternate-day prednisone in idiopathic membranous glomerulonephritis [abstract]</TI>
<SO>Kidney International</SO>
<YR>1981</YR>
<VL>19</VL>
<NO>2</NO>
<PG>388-9</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:27:50 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:27:50 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644365"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:28:37 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cattran DC, Cole E, Cardella C, Charron R, Roscoe J, Delmore T, et al</AU>
<TI>Results of a controlled trial of alternate day prednisone (P) in membranous nephropathy (IMGN) [abstract]</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>1</NO>
<PG>208</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:28:34 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:28:34 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644367"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 18:00:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, et al</AU>
<TI>A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<NO>4</NO>
<PG>210-5</PG>
<IDENTIFIERS MODIFIED="2014-04-08 10:53:04 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-04-08 10:53:04 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2643046"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cattran-1995" MODIFIED="2014-04-27 18:01:03 +1000" MODIFIED_BY="[Empty name]" NAME="Cattran 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-04-27 18:00:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cattran D, Greenwood CM, Ritchie S, Bernstein K, Churchill DN, Clarke WF, et al</AU>
<TI>A controlled trial of cyclosporine in patients with progressive membranous nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>Program &amp; Abstracts</NO>
<PG>271</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:29:51 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:29:51 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00483446"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 18:01:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, et al</AU>
<TI>A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group</TI>
<SO>Kidney International</SO>
<YR>1995</YR>
<VL>47</VL>
<NO>4</NO>
<PG>1130-5</PG>
<IDENTIFIERS MODIFIED="2014-04-08 11:12:01 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-04-08 11:12:01 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7783410"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:30:53 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cattran DC</AU>
<TI>Cyclosporine in the treatment of membranous nephropathy (MGN) [abstract]</TI>
<SO>12th International Congress of Nephrology; 1993, Jun 13-18; Jerusalem, Israel</SO>
<YR>1993</YR>
<PG>535</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:30:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:30:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00602121"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cattran-2001" MODIFIED="2014-04-27 18:01:16 +1000" MODIFIED_BY="[Empty name]" NAME="Cattran 2001" YEAR="1998">
<REFERENCE MODIFIED="2014-04-27 18:01:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al</AU>
<TI>Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial</TI>
<SO>Kidney International</SO>
<YR>2001</YR>
<VL>59</VL>
<NO>4</NO>
<PG>1484-90</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:07:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:07:24 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11260412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 18:01:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cattran DC, Pohl M, Maxwell D, Appel G, Hunsicker GP, Kunis C, et al</AU>
<TI>Randomized controlled trial of cyclosporine (D) vs placebo (P) in steroid resistant, nephrotic patients (NS) with membranous nephropathy (SR-MGN) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>85A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:32:34 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:32:34 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00444711"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 17:51:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cattran DC, Wald R, Brenchley PE, Coupes B, for the North American Nephrotic Syndrome Group and the Genes Gender and Glomerulonephritis Group</AU>
<TI>Clinical correlates of serial urinary membrane attack complex estimates in patients with idiopathic membranous nephropathy</TI>
<SO>Clinical Nephrology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>7-12</PG>
<IDENTIFIERS MODIFIED="2013-10-30 15:40:00 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="12872852"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2007" MODIFIED="2012-07-09 10:25:42 +1000" MODIFIED_BY="[Empty name]" NAME="Chan 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-09 10:25:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan TM, Lin AW, Tang SC, Qian JQ, Lam MF, Ho YW, et al</AU>
<TI>Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome</TI>
<SO>Nephrology</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>6</NO>
<PG>576-81</PG>
<IDENTIFIERS MODIFIED="2012-07-09 10:25:42 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 10:25:42 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17995584"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2010a" MODIFIED="2014-11-19 15:48:26 +1100" MODIFIED_BY="Narelle Willis" NAME="Chen 2010a" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 15:33:49 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen M, Chen J, Li X, Lu F, Xu FF, Qian JQ, et al</AU>
<TI>A randomized controlled study comparing prednisone plus tacrolimus versus prednisone plus cyclophosphamide in patients with membranous nephropathy and nephrotic syndrome [abstract no: SA-PO1086]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>802A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:33:49 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:33:49 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00782317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-08 13:56:02 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF, et al</AU>
<TI>Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>2010</YR>
<VL>339</VL>
<NO>3</NO>
<PG>233-8</PG>
<IDENTIFIERS MODIFIED="2012-07-09 10:27:46 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 10:27:46 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20220333"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coggins-1979" MODIFIED="2014-04-27 18:01:42 +1000" MODIFIED_BY="[Empty name]" NAME="Coggins 1979" YEAR="1979">
<REFERENCE MODIFIED="2014-04-27 18:01:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coggins CH, Pinn V, Glassock RR, Blades JM, Cotran R, Cohen J, et al</AU>
<TI>A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1979</YR>
<VL>301</VL>
<NO>24</NO>
<PG>1301-6</PG>
<IDENTIFIERS MODIFIED="2012-07-09 10:29:20 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 10:29:19 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="388220"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 18:01:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coggins CH, The Collaborative Study of the Adult Nephrotic Syndrome</AU>
<TI>The effect of short-term prednisone treatment in adult nephrotics with minimal change (MC) and membranous (M) histology [abstract]</TI>
<SO>Kidney International</SO>
<YR>1977</YR>
<VL>12</VL>
<NO>6</NO>
<PG>463</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:34:45 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:34:45 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00784389"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-CYCLOMEN-Study-1994" MODIFIED="2014-04-27 18:01:51 +1000" MODIFIED_BY="[Empty name]" NAME="CYCLOMEN Study 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-04-27 17:55:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurens W, Ruggenenti P, Perna A, Vanrenterghem Y, Remuzzi G</AU>
<TI>A randomised and controlled study to assess the effect of cyclosporin in nephrotic patients with membranous nephropathy and reduced renal function (CYCLOMEN)</TI>
<SO>Journal of Nephrology</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>4</NO>
<PG>237-47</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:25:31 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:25:01 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1994281713"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 18:01:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pisoni R, Grinyo JM, Salvadori M, Laurens W, Garini G, Oliver YA, et al</AU>
<TI>Cyclosporine versus conservative therapy in patients with idiopathic membranous nephropathy (IMN) and deteriorating renal function: Results of the CYCLOMEN trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>95A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:18:02 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:18:02 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583866"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donadio-1974a" MODIFIED="2014-04-27 18:01:56 +1000" MODIFIED_BY="[Empty name]" NAME="Donadio 1974a" YEAR="1974">
<REFERENCE MODIFIED="2014-04-27 18:01:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Holley KE, Anderson CF, Taylor WF</AU>
<TI>Controlled trial of cyclophosphamide in idiopathic membranous nephropathy</TI>
<SO>Kidney International</SO>
<YR>1974</YR>
<VL>6</VL>
<NO>6</NO>
<PG>431-9</PG>
<IDENTIFIERS MODIFIED="2012-07-09 10:39:51 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 10:39:51 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="4613934"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dussol-2008" MODIFIED="2014-04-03 15:36:17 +1100" MODIFIED_BY="Narelle S Willis" NAME="Dussol 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-07-09 10:43:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, et al</AU>
<TI>Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2008</YR>
<VL>52</VL>
<NO>4</NO>
<PG>699-705</PG>
<IDENTIFIERS MODIFIED="2012-07-09 10:43:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 10:43:21 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18585835"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:36:17 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dussol B, Sichez H, Burtey S, Cassuto E, Kaaraslan H, Villar E, et al</AU>
<TI>Mycophenolate mofetil (MMF) in patients with idiopathic membranous nephropathy with nephrotic syndrome: a multicenter randomized trial [abstract no: TH-F-DS1092]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>566A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:36:17 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:36:17 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00653744"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dyadyk-2001" MODIFIED="2014-04-16 16:38:22 +1000" MODIFIED_BY="[Empty name]" NAME="Dyadyk 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-04-16 16:38:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyadyk AI, Bagriy AE, Yarovaya NF, Dyadyk IA</AU>
<TI>Results of long-term randomised study of immunosuppressive treatment of patients with idiopathic membranous glomerulonephritis [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>6</NO>
<PG>A64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE=" CN-00487685"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falk-1992" MODIFIED="2014-04-27 18:02:07 +1000" MODIFIED_BY="[Empty name]" NAME="Falk 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-04-27 18:02:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falk RJ, Hogan SL, Muller KE, Jennette JC</AU>
<TI>Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>116</VL>
<NO>6</NO>
<PG>438-45</PG>
<IDENTIFIERS MODIFIED="2012-07-09 10:45:28 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 10:45:28 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1371211"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofstra-2010" MODIFIED="2014-04-27 18:02:15 +1000" MODIFIED_BY="[Empty name]" NAME="Hofstra 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-27 18:02:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branten AJ, Du Buf-Vereijken PW, Wetzels JF</AU>
<TI>Early versus late start of immunosuppressive therapy in patients with membranous nephropathy; a randomized study. [abstract no: SA-PO188]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>341A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:37:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:37:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE=" CN-00583772"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:38:46 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branten AJ, du Buf-Vereijken PW, Wetzels JF</AU>
<TI>Defining the optimal time of treatment start in patients with membranous nephropathy: a randomized study [abstract no: SU-PO969]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>September, Program &amp; Abstracts</NO>
<PG>668A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:38:46 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:38:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00444526"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:39:39 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofstra JM, Branten AJ, Wetzels FM</AU>
<TI>No benefit of early start of immunosuppressive therapy in idiopathic membranous nephropathy [abstract no: F-FC264]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>60A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:39:39 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:39:39 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00747283"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 10:59:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF</AU>
<TI>Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>1</NO>
<PG>129-36</PG>
<IDENTIFIERS MODIFIED="2012-07-09 10:59:48 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 10:59:48 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19666912"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imbasciati-1980" MODIFIED="2014-04-27 17:56:32 +1000" MODIFIED_BY="[Empty name]" NAME="Imbasciati 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-04-27 17:56:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imbasciati E, Cagnoli L, Case N, Pasquali S, Di Filippo G, Limido D, et al</AU>
<TI>Controlled study of treatment of steroids and chlorambucil, in alternate months, for membranous nephropathy and focal glomerulosclerosis. Preliminary evaluation of the results</TI>
<TO>Studio controllato di un trattamento a mesi alterni di steroidi e clorambucil nella nefropatia membranosa e nella glomerulosclerosi focale. Valutazione preliminare dei risultati</TO>
<SO>Minerva Nefrologica</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>4</NO>
<PG>571-5</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:21:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:21:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7019771"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:22:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Grassi C, et al</AU>
<TI>Controlled trial of monthly alternated courses of steroid and chlorambucil for idiopathic membranous nephropathy</TI>
<SO>Proceedings of the European Dialysis &amp; Transplant Association</SO>
<YR>1983</YR>
<VL>19</VL>
<PG>717-23</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:22:14 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:22:14 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6348763"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 11:36:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, et al</AU>
<TI>Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>310</VL>
<NO>15</NO>
<PG>946-50</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:36:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:36:47 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6366560"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:23:18 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Zucchelli P, Locatelli F, Grassi G, Limido D, Volpini T, et al</AU>
<TI>Controlled trial of monthly alternated courses of steroid and chlorambucil in idiopathic membranous nephropathy [abstract]</TI>
<SO>Kidney International</SO>
<YR>1983</YR>
<VL>23</VL>
<NO>3</NO>
<PG>554</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:23:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:23:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644373"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 17:56:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, et al</AU>
<TI>A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<NO>1</NO>
<PG>8-13</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:38:54 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:38:54 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2642605"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 11:39:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, et al</AU>
<TI>A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy</TI>
<SO>Kidney International</SO>
<YR>1995</YR>
<VL>48</VL>
<NO>5</NO>
<PG>1600-4</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:39:50 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:39:50 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8544420"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:24:29 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ponticelli C</AU>
<TI>Treatment of membranous nephropathy (MN) [abstract]</TI>
<SO>9th Asian Colloquium in Nephrology; 1992, May 17-21; Seoul, Korea</SO>
<YR>1992</YR>
<PG>22-4</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:24:29 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:24:29 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00461530"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:25:07 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ponticelli C</AU>
<TI>Treatment of membranous nephropathy [abstract]</TI>
<SO>12th International Congress of Nephrology; 1993, Jun 13-18; Jerusalem, Israel</SO>
<YR>1993</YR>
<PG>565</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 11:42:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zucchelli P, Cagnoli L, Pasquali S, Casanova S, Donini U</AU>
<TI>Clinical and morphologic evolution of idiopathic membranous nephropathy</TI>
<SO>Clinical Nephrology</SO>
<YR>1986</YR>
<VL>25</VL>
<NO>6</NO>
<PG>282-8</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:42:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="3524923"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 11:42:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zucchelli P, Ponticelli C, Cagnoli L, Aroldi A, Beltrandi E</AU>
<TI>Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy</TI>
<SO>American Journal of Nephrology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>1</NO>
<PG>15-20</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:42:26 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="2967032"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jha-2007" MODIFIED="2014-04-03 15:43:31 +1100" MODIFIED_BY="Narelle S Willis" NAME="Jha 2007" YEAR="2001">
<REFERENCE MODIFIED="2012-07-09 11:02:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al</AU>
<TI>A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1899-904</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:02:00 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:02:00 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17494881"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:41:26 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jha V, Kohli HS, Sud K, Gupta KL, Sakhuja V</AU>
<TI>A randomized controlled trial of steroids and cyclophosphamide in adults with idiopathic membranous nephropathy [abstract no: FC3-02]</TI>
<SO>Nephrology</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>Suppl</NO>
<PG>A16</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:25:03 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:42:55 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jha V, Kohli HS, Sud K, Krishan L, Joshi K, Sakhuja V</AU>
<TI>Randomized controlled trial of steroids and cyclophosphamide in adults with idiopathic membranous nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>213A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:42:55 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 15:42:55 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00445921"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:43:31 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jha V, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, et al</AU>
<TI>A randomized controlled trial of steroids and cyclophosphamide in adults with idiopathic membranous nephropathy [abstract]</TI>
<SO>35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998, Jun 6-9; Rimini, Italy</SO>
<YR>1998</YR>
<PG>114</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:05:34 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jurubita-2012" MODIFIED="2014-04-03 15:44:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="Jurubita 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-03 15:44:05 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jurubita R, Ismail G, Bobeica G, Rusu E, Zilisteanu D, Andronesi A, et al</AU>
<TI>Efficacy and safety of triple therapy with MMF, cyclosporine and prednisolone versus cyclosporine and prednisolone in adult patients with idiopathic membranous nephropathy and persistent heavy proteinuria [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>Suppl 2</NO>
<PG>FP347</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koshisawa-1993" MODIFIED="2014-04-22 15:46:42 +1000" MODIFIED_BY="[Empty name]" NAME="Koshisawa 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-04-22 15:46:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koshisawa S, Sato M, Narita M, Sakai O, Nakajima M</AU>
<TI>Clinical evaluation of an immunosuppressive drug, mizoribine (HE-69) on steroid-resistant nephrotic syndrome. A multicenter double-blind comparison study with placebo</TI>
<SO>Jin ToTohseki [Kidney &amp; Dialysis]</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>4</NO>
<PG>631-50</PG>
<IDENTIFIERS MODIFIED="2011-12-31 09:33:37 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosmadakis-2010" MODIFIED="2014-04-27 18:02:44 +1000" MODIFIED_BY="[Empty name]" NAME="Kosmadakis 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-27 18:02:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosmadakis G, Filiopoulos V, Smirloglou D, Skarlas P, Georgoulias C, Michail S</AU>
<TI>Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy</TI>
<SO>Renal Failure</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>5</NO>
<PG>566-71</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:17:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:17:39 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20486839"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2009b" MODIFIED="2014-04-27 17:57:07 +1000" MODIFIED_BY="[Empty name]" NAME="Liu 2009b" YEAR="2009">
<REFERENCE MODIFIED="2014-04-22 15:47:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu ZH, Li SJ, Wu Y, Zuo K, Wang B, Zeng CH, et al</AU>
<TI>Treatment of membranous nephropathy with Tripterygium wilfordii and steroid: a prospective randomized control trial</TI>
<SO>Shenzangbing Yu Touxi Shenyizhi Zazhi [Chinese Journal of Nephrology Dialysis &amp; Transplantation]</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>4</NO>
<PG>303-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1992" MODIFIED="2014-04-27 18:02:51 +1000" MODIFIED_BY="[Empty name]" NAME="Murphy 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-04-27 18:02:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS</AU>
<TI>Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis</TI>
<SO>Clinical Nephrology</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>5</NO>
<PG>229-34</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:19:44 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:19:44 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1606772"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naumovic-2011" MODIFIED="2014-04-27 18:02:56 +1000" MODIFIED_BY="[Empty name]" NAME="Naumovic 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-27 18:02:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naumovic R, Jovanovic D, Pavlovic S, Stosovic M, Marinkovic J, Basta-Jovanovic G</AU>
<TI>Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study</TI>
<SO>Biomedicine &amp; Pharmacotherapy</SO>
<YR>2011</YR>
<VL>65</VL>
<NO>2</NO>
<PG>105-10</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:16:40 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:16:40 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21109389"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pahari-1993" MODIFIED="2014-04-27 18:03:03 +1000" MODIFIED_BY="[Empty name]" NAME="Pahari 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-04-27 18:03:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pahari DK, Das S, Dutta BN, Banerjee D</AU>
<TI>Prognosis and management of membraneous nephropathy</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1993</YR>
<VL>41</VL>
<NO>6</NO>
<PG>350-1</PG>
<IDENTIFIERS MODIFIED="2014-04-22 15:49:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-22 15:49:18 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8005970"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponticelli-1992" MODIFIED="2014-04-27 18:03:11 +1000" MODIFIED_BY="[Empty name]" NAME="Ponticelli 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-04-27 18:03:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Zucchelli P, Passerini P, Cesana B</AU>
<TI>Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<NO>9</NO>
<PG>599-603</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:30:51 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:30:51 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1640953"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:26:14 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ponticelli C</AU>
<TI>Treatment of idiopathic membranous nephropathy (IMN) [abstract]</TI>
<SO>Pakistan Society of Nephrology &amp; Urology. 10th Asian Colloquium in Nephrology; 1994, Dec 2-6; Karachi, Pakistan</SO>
<YR>1994</YR>
<PG>38</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:30:59 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponticelli-1998" MODIFIED="2014-04-27 18:03:15 +1000" MODIFIED_BY="[Empty name]" NAME="Ponticelli 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-04-27 18:03:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al</AU>
<TI>A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>3</NO>
<PG>444-50</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:09:20 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:09:20 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9513907"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponticelli-2006" MODIFIED="2012-07-09 11:45:41 +1000" MODIFIED_BY="[Empty name]" NAME="Ponticelli 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-09 11:45:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, et al</AU>
<TI>A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>2</NO>
<PG>233-40</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:45:40 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:45:40 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16431252"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Praga-2007" MODIFIED="2014-04-03 16:27:13 +1100" MODIFIED_BY="Narelle S Willis" NAME="Praga 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-03 16:27:13 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Praga M, Barrio V, Juárez GF, Luño J, Grupo Español de Estudio de la Nefropatía Membranosa</AU>
<TI>Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial</TI>
<SO>Kidney International</SO>
<YR>2007</YR>
<VL>71</VL>
<NO>9</NO>
<PG>924-30</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:27:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:27:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17377504"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichert-1994" MODIFIED="2014-04-27 18:03:18 +1000" MODIFIED_BY="[Empty name]" NAME="Reichert 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-04-27 18:03:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reichert LJ, Huysmans FT, Assmann K, Koene RA, Wetzels JF</AU>
<TI>Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<NO>5</NO>
<PG>328-33</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:48:59 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 11:48:59 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8042821"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:27:34 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reichert LJ, Koene RA, Wetzels JF</AU>
<TI>Chlorambucil but not pulse cyclophosphamide reverses the deterioration of renal function in patients with membranous glomerulonephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>Program &amp; Abstracts</NO>
<PG>285</PG>
<IDENTIFIERS MODIFIED="2012-07-09 11:49:35 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-2009" MODIFIED="2014-04-03 16:29:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="Saito 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-03 16:29:02 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Saito T, Watanabe M, Ogahara S, Shuto H, Kataoka Y</AU>
<TI>Significance of blood concentration of cyclosporine at 2 hours after administration for the treatment of idiopathic membranous nephropathy with steroid resistant nephrotic syndrome [abstract no: SA285]</TI>
<SO>World Congress of Nephrology; 2009 May, 22-26; Milan, Italy</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Senthil-Nayagam-2008" MODIFIED="2014-04-08 14:13:32 +1000" MODIFIED_BY="Narelle Willis" NAME="Senthil Nayagam 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-03 16:29:38 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, et al</AU>
<TI>Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>6</NO>
<PG>1926-30</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:29:38 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:29:38 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17989103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shibasaki-2004" MODIFIED="2014-04-22 15:51:22 +1000" MODIFIED_BY="[Empty name]" NAME="Shibasaki 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-04-22 15:51:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, et al</AU>
<TI>A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)</TI>
<SO>Clinical &amp; Experimental Nephrology</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>2</NO>
<PG>117-26</PG>
<IDENTIFIERS MODIFIED="2014-04-22 15:51:22 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-22 15:51:22 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15235928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silverberg-1976" MODIFIED="2014-04-27 18:03:27 +1000" MODIFIED_BY="[Empty name]" NAME="Silverberg 1976" YEAR="1976">
<REFERENCE MODIFIED="2014-04-27 18:03:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Western Canadian Glomerulonephritis Study Group</AU>
<TI>Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1976</YR>
<VL>115</VL>
<NO>12</NO>
<PG>1209-10</PG>
<IDENTIFIERS MODIFIED="2012-07-09 12:08:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 12:08:27 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="793706"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stegeman-1994" MODIFIED="2014-04-27 17:59:50 +1000" MODIFIED_BY="[Empty name]" NAME="Stegeman 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-04-16 17:53:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>De Jong PE</AU>
<TI>ACE inhibition versus corticosteroids in membranous nephropathy (ACIMEN)</TI>
<SO>European Union biomedical and health research: the BIOMED 1 programme</SO>
<YR>1995</YR>
<VL>1</VL>
<PG>606-607</PG>
<PB>IOS Press</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN 0929-6743"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 17:59:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegeman CA, De Zeeuw D, De Jong PE</AU>
<TI>ACE inhibition versus corticosteroids in membranous nephropathy (ACIMEN)</TI>
<SO>Journal of Nephrology</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>5</NO>
<PG>294-300</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="1994344069"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiller-1981" MODIFIED="2014-04-03 16:31:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="Tiller 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-04-03 16:30:07 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mathew TH</AU>
<TI>The treatment of idiopathic glomerulonephritis</TI>
<SO>Proceedings of the Second Asian Pacific Congress of Nephrology</SO>
<YR>1983</YR>
<PG>164-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:31:00 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tiller D</AU>
<TI>Australian glomerulonephritis trial: membranous glomerulonephritis, mesangiocapillary glomerulonephritis [abstract]</TI>
<SO>Australian &amp; New Zealand Journal of Medicine</SO>
<YR>1981</YR>
<VL>11</VL>
<NO>4</NO>
<PG>603</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:31:00 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:31:00 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583749"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:31:41 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Tiller DJ, Clarkson AR, Mathew T, Thompson N, Row G, Lauer C, et al</AU>
<TI>A prospective randomised trial of cyclophosphamide, dipyridamole and warfarin in membranous and mesangiocapillary glomerulonephritis</TI>
<SO>Advances in Basic and Clinical Nephrology. 8th International Congress of Nephrology; 1981 June 7-12; Athens, Greece</SO>
<YR>1981</YR>
<PG>345-51</PG>
<ED>Zurukzoglu W, Papadimitriou M, Pyrpasopoulos M, Sion M, Zamboulis C</ED>
<PB>Karger</PB>
<CY>Basel</CY>
<IDENTIFIERS MODIFIED="2012-07-09 12:10:28 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2010" MODIFIED="2014-04-03 16:33:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="Xu 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 16:33:05 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu J, Zhang W, Xu YW, Chen N</AU>
<TI>A double-blinded prospective randomised study on the efficacy of corticosteroid plus cyclophosphamide or FK506 in idiopathic membranous nephropathy patients with nephrotic syndrome [abstract]</TI>
<SO>NDT Plus</SO>
<YR>2010</YR>
<VL>3</VL>
<NO>Suppl 3</NO>
<PG>iii431</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:33:05 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:33:05 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="70484584"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-11-19 16:07:23 +1100" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Alexopoulos-2006" MODIFIED="2014-04-27 18:07:40 +1000" MODIFIED_BY="[Empty name]" NAME="Alexopoulos 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-27 18:07:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D</AU>
<TI>Induction and long-term treatment with Cyclosporin A in membranous glomerulonephritis with the nephrotic syndrome [abstract no: SA-PO1020]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>Nov</NO>
<PG>780A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:37:05 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:37:05 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644271"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 13:12:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D</AU>
<TI>Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>11</NO>
<PG>3127-32</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:12:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:12:56 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16968719"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ambalavanan-1996" MODIFIED="2014-04-27 18:07:52 +1000" MODIFIED_BY="[Empty name]" NAME="Ambalavanan 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-04-27 18:07:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ambalavanan S, Fauvel J-P, Sibley RK, Myers BD</AU>
<TI>Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>2</NO>
<PG>290-8</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:38:10 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:38:10 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8785399"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Austin-2008" MODIFIED="2014-04-03 16:40:57 +1100" MODIFIED_BY="Narelle S Willis" NAME="Austin 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-03 16:40:57 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Austin HA, Braun MJ, Howard LV, Kopp JB, Balow JE</AU>
<TI>Sirolimus therapy in idiopathic and lupus membranous nephropathy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>561A</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:16:19 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-1970" MODIFIED="2014-04-03 16:41:33 +1100" MODIFIED_BY="Narelle S Willis" NAME="Black 1970" YEAR="1970">
<REFERENCE MODIFIED="2014-04-03 16:41:33 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black DA, Rose G, Brewer DB</AU>
<TI>Controlled trial of prednisone in adult patients with the nephrotic syndrome</TI>
<SO>British Medical Journal</SO>
<YR>1970</YR>
<VL>3</VL>
<NO>5270</NO>
<PG>412-6</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:41:33 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:41:33 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="4916790"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominguez_x002d_Gil-1999" MODIFIED="2014-04-03 16:43:29 +1100" MODIFIED_BY="Narelle S Willis" NAME="Dominguez-Gil 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-04-03 16:42:18 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dominguez-Gil B, Hernandez E, Segura J, Carreno A, Morales E, Herrero JC, Praga M</AU>
<TI>Immunosuppressive treatment in idiopathic membranous glomerulonephritis (MGN) with progressive renal function worsening [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A155</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:42:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:42:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="CN-00583436"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:43:29 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torres A, Dominguez-Gil B, Carreno A, Segura J, Gonzalez E, Ortiz M, et al</AU>
<TI>Immunosuppressive treatment in idiopathic membranous glomerulonephritis (MGN) with progressive renal function worsening [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>99A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:43:29 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:43:29 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00783416"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 13:29:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torres A, Domínguez-Gil B, Carreño A, Hernández E, Morales E, Segura J, et al</AU>
<TI>Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>1</NO>
<PG>219-27</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:29:53 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:29:53 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11786104"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-du-Buf_x002d_Vereijken-2004" MODIFIED="2014-04-03 16:44:23 +1100" MODIFIED_BY="Narelle S Willis" NAME="du Buf-Vereijken 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-04-03 16:44:23 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study Group</AU>
<TI>Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>5</NO>
<PG>1142-8</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:44:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:44:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14993502"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edefonti-1988" MODIFIED="2014-11-19 16:07:23 +1100" MODIFIED_BY="Narelle Willis" NAME="Edefonti 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-11-19 15:54:32 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edefonti A, Ghio L, Bettinelli A, Paterlini G, Giani M, Nebbia G, et al</AU>
<TI>Unconjugated hyperbilirubinemia due to ciclosporin administration in children with nephrotic syndrome</TI>
<SO>Contributions to Nephrology</SO>
<YR>1988</YR>
<VL>67</VL>
<PG>121-4</PG>
<IDENTIFIERS MODIFIED="2014-11-19 15:54:10 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="3208520"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-19 15:56:32 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edefonti A, Ghio L, Bettinelli A, Paterlini G</AU>
<TI>Unconjugated hyperbilirubinemia due to cyclosporin a (CyA) administration in children with nephrotic syndrome (NS) [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1987</YR>
<VL>1</VL>
<NO>4</NO>
<PG>C8</PG>
<IDENTIFIERS MODIFIED="2014-11-19 15:56:32 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-11-19 15:56:32 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00465774"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-19 15:59:24 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, et al</AU>
<TI>Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing/steroid dependant nephrotic syndrome (FR/SDNS): long term study [abstract]</TI>
<SO>9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 - Sept 4; Jerusalem, Israel</SO>
<YR>1992</YR>
<PG>C70</PG>
<IDENTIFIERS MODIFIED="2014-11-19 15:59:24 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-11-19 15:59:24 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00483820"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-19 15:58:31 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, et al</AU>
<TI>Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing/steroid dependent nephrotic syndrome (FR/SDNS): long term study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>3</NO>
<PG>310</PG>
<IDENTIFIERS MODIFIED="2014-11-19 15:58:31 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-11-19 15:58:31 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00520331"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-09 13:43:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, et al</AU>
<TI>Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>12</NO>
<PG>1326-32</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:43:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:43:12 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8159300"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-19 15:54:32 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Rivolta E</AU>
<TI>Ciclosporin in minimal-change glomerulopathy and in focal segmental glomerular sclerosis. [Review] [39 refs]</TI>
<SO>American Journal of Nephrology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>105-9</PG>
<IDENTIFIERS MODIFIED="2014-11-19 15:54:10 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="2256469"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:51:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C</AU>
<TI>A multicenter controlled prospective trial with cyclosporine vs cyclophosphamide in frequent relapsers and steroid dependent patients with idiopathic nephrotic syndrome</TI>
<SO>Journal of Nephrology</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>2</NO>
<PG>147-51</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:51:19 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:51:19 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1991014828"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-27 18:08:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ponticelli C</AU>
<TI>Ciclosporin in the treatment of idiopathic nephrotic syndrome [abstract]</TI>
<SO>10th Asian Colloquium in Nephrology; 1994, Dec 2-6; Karachi, Pakistan</SO>
<YR>1994</YR>
<PG>116</PG>
<IDENTIFIERS MODIFIED="2013-10-30 16:16:17 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goumenos-2007" MODIFIED="2012-07-09 13:33:09 +1000" MODIFIED_BY="[Empty name]" NAME="Goumenos 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-09 13:33:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, et al</AU>
<TI>Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs</TI>
<SO>American Journal of Nephrology</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>3</NO>
<PG>226-31</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:33:09 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:33:09 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17389782"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lagrue-1975" MODIFIED="2014-04-27 18:08:02 +1000" MODIFIED_BY="[Empty name]" NAME="Lagrue 1975" YEAR="1975">
<REFERENCE MODIFIED="2014-04-27 18:08:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lagrue G, Bernard D, Bariety J, Druet P, Guenel J</AU>
<TI>Treatment with chlorambucil and azathioprine in primary glomerulonephritis. Results of a "controlled" study</TI>
<TO>Traitement par le chlorambucil et l'azathioprine dans les glomérulonéphrites primitives: Résultats d'une étude "controlée"</TO>
<SO>Journal d Urologie et de Nephrologie</SO>
<YR>1975</YR>
<VL>81</VL>
<NO>9</NO>
<PG>655-72</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:34:51 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:34:50 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="765492"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008" MODIFIED="2012-07-09 13:35:50 +1000" MODIFIED_BY="[Empty name]" NAME="Li 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-07-09 13:35:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X, Lv R, He Q, Li H, Du X, Lin W, et al</AU>
<TI>Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria</TI>
<SO>Journal of Nephrology</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>4</NO>
<PG>584-91</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:35:50 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:35:50 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18651550"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Majima-1990" MODIFIED="2014-04-03 16:47:06 +1100" MODIFIED_BY="Narelle S Willis" NAME="Majima 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-04-03 16:47:06 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Majima K, Hori Y, Inoue T, Ishizaki K, Kinoshita E, Nomura G</AU>
<TI>The effects of treatment with prednisolone in patients with idiopathic membranous nephropathy [abstract]</TI>
<SO>11th International Congress of Nephrology; 1990, Jul 15-20; Tokyo, Japan</SO>
<YR>1990</YR>
<PG>117A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:47:06 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:47:06 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00784437"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michail-2004" MODIFIED="2014-04-03 16:47:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Michail 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-04-03 16:47:53 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Michail S, Filiopoulos V, Kosmadakis G, Tentolouris N, Georgoulias C, Gobou A, et al</AU>
<TI>Comparison of three regimens in patients with idiopathic membranous nephropathy (IMN) associated with nephrotic syndrome (NS) [abstract no: SP053]</TI>
<SO>41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004, May 15-18; Lisbon, Portugal</SO>
<YR>2004</YR>
<PG>34</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:47:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:47:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00509354"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRCWP-1971" MODIFIED="2014-04-27 18:08:12 +1000" MODIFIED_BY="[Empty name]" NAME="MRCWP 1971" YEAR="1971">
<REFERENCE MODIFIED="2014-04-27 18:08:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party</TI>
<SO>British Medical Journal</SO>
<YR>1971</YR>
<VL>2</VL>
<NO>5756</NO>
<PG>239-41</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:48:37 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:48:37 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="4929367"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nand-1997" MODIFIED="2014-04-27 18:08:16 +1000" MODIFIED_BY="[Empty name]" NAME="Nand 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-27 18:08:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nand N, Das R, Jaswal TS</AU>
<TI>Evaluation of efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis</TI>
<SO>Journal of the Indian Medical Association</SO>
<YR>1997</YR>
<VL>95</VL>
<NO>6</NO>
<PG>163-5, 174</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:41:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:41:27 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9420390"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plavljanic-1998" MODIFIED="2014-04-03 16:49:29 +1100" MODIFIED_BY="Narelle S Willis" NAME="Plavljanic 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-04-03 16:49:29 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Plavljanic D, Spoljar-Scukanec M, Milutinovic S</AU>
<TI>Tubular damage in patients with membranous nephropathy. The response to treatment [abstract]</TI>
<SO>35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998, Jun 6-9; Rimini, Italy</SO>
<YR>1998</YR>
<PG>193</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:49:29 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:49:29 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00485443"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polenakovic-1997" MODIFIED="2014-04-03 16:50:22 +1100" MODIFIED_BY="Narelle S Willis" NAME="Polenakovic 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-03 16:50:22 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polenakovic M, Grcevska L, Polenakovic H</AU>
<TI>Long-term follow-up of patients with stage II idiopathic membranous nephropathy (IMN)- good response to steroid and chlorambucil treatment [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>9</NO>
<PG>A76</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:50:22 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:50:22 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00520378"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponticelli-1993a" MODIFIED="2014-04-27 18:07:05 +1000" MODIFIED_BY="[Empty name]" NAME="Ponticelli 1993a" YEAR="1993">
<REFERENCE MODIFIED="2012-07-09 13:47:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al</AU>
<TI>A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome</TI>
<SO>Kidney International</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1377-84</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:47:06 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 13:47:06 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8315953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rashid-1995" MODIFIED="2014-04-03 16:51:33 +1100" MODIFIED_BY="Narelle S Willis" NAME="Rashid 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-04-03 16:51:33 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rashid HU, Khanam A, Islam KM</AU>
<TI>Treatment of membranous nephropathy with prednisolone and ACE-inhibitor [abstract]</TI>
<SO>ISN XIII International Congress of Nephrology; 1995, Jul 2-6; Madrid, Spain</SO>
<YR>1995</YR>
<PG>269</PG>
<IDENTIFIERS MODIFIED="2012-07-09 13:52:16 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahay-2002" MODIFIED="2014-04-03 16:54:13 +1100" MODIFIED_BY="Narelle S Willis" NAME="Sahay 2002" YEAR="2003">
<REFERENCE MODIFIED="2014-04-03 16:53:07 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gopal KA, Sahay M, Raman A, Narayen G</AU>
<TI>Ponticelli regime for membranous nephropathy - do Indians respond differently? [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>615</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:53:07 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:53:07 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE=" CN-00445523"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 16:54:13 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahay M, Anuradha, Narayen G</AU>
<TI>Ponticelli regimen for membranous nephropathy - do Indians respond differently? [abstract]</TI>
<SO>Indian Journal of Nephrology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>4</NO>
<PG>180</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:54:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:54:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE=" CN-00461642"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shilov-1998" MODIFIED="2014-04-03 16:55:16 +1100" MODIFIED_BY="Narelle S Willis" NAME="Shilov 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-04-03 16:55:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Shilov EM, Krasnova TN, Ivanov AA, Ivanova LV, Shnyakina OV, Tareyeva IE</AU>
<TI>Oral cyclophosphamide versus cyclophosphamide (CPA) pulses in membranous and mesangial GN [abstract]</TI>
<SO>35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998, Jun 6-9; Rimini, Italy</SO>
<YR>1998</YR>
<PG>116</PG>
<IDENTIFIERS MODIFIED="2014-04-03 16:55:16 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 16:55:16 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00485850"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2008" MODIFIED="2014-04-03 17:00:25 +1100" MODIFIED_BY="Narelle S Willis" NAME="Sun 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-03 17:00:25 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun GD, Xu ZG, Luo P, Miao LN</AU>
<TI>The effect of tacrolimus combined with small dose of hormone on idiopathic membranous nephropathy</TI>
<SO>Zhongguo Shiyong Neike Zazhi [Chinese Journal of Practical Internal Medicine]</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>7</NO>
<PG>542-545</PG>
<IDENTIFIERS MODIFIED="2012-07-09 15:03:10 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 15:03:10 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ChiCTR-TRC-09000539"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tejani-1991" MODIFIED="2014-10-09 10:55:31 +1100" MODIFIED_BY="[Empty name]" NAME="Tejani 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-10-09 10:55:31 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tejani A, Suthanthiran M, Pomrantz A</AU>
<TI>A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children</TI>
<SO>Nephron</SO>
<YR>1991</YR>
<VL>59</VL>
<NO>1</NO>
<PG>96-9</PG>
<IDENTIFIERS MODIFIED="2014-10-09 10:55:26 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-09 10:55:26 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1944755"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yao-2001" MODIFIED="2014-04-27 18:08:55 +1000" MODIFIED_BY="[Empty name]" NAME="Yao 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-04-27 18:08:55 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yao X, Chen H, Wang Q, Tang Z, Hu W, Yin G, et al</AU>
<TI>Cyclosporin A treatment for idiopathic membranous nephropathy</TI>
<SO>Chinese Medical Journal</SO>
<YR>2001</YR>
<VL>114</VL>
<NO>12</NO>
<PG>1305-8</PG>
<IDENTIFIERS MODIFIED="2014-04-03 17:00:46 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 17:00:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11793859"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 17:00:51 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yao XD, Li L, Tang Z, Hu WX, Ying G, Chen HP</AU>
<TI>Prospective clinical trial of Cyclosporin A in idiopathic membranous nephropathy [abstract]</TI>
<SO>6th Asian Pacific Congress of Nephrology; 1995, Dec 5-9; Hong Kong</SO>
<YR>1995</YR>
<PG>52</PG>
<IDENTIFIERS MODIFIED="2011-12-08 14:12:03 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-08 14:12:03 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00462029"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-11-19 16:15:00 +1100" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Appel-2002" MODIFIED="2014-11-19 16:15:00 +1100" MODIFIED_BY="Narelle Willis" NAME="Appel 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-04-22 15:53:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appel G, Nachman P, Hogan S, Radhakrishnan J, Old C, Hebert L, et al</AU>
<TI>Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (IMN): preliminary baseline and pharmacokinetic (PK)/pharmacodynamic (PD) data [abstract no: SU-PO970]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>Program &amp; Abstracts</NO>
<PG>668A</PG>
<IDENTIFIERS MODIFIED="2012-07-09 15:16:20 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-03 18:03:00 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 18:03:00 +1100" MODIFIED_BY="Narelle S Willis" TYPE="OTHER" VALUE="00-DK-0126"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berg-2007" MODIFIED="2014-04-03 18:02:18 +1100" MODIFIED_BY="Narelle S Willis" NAME="Berg 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-03 18:01:58 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Berg AL</AU>
<TI>Treatment with adrenocorticotropic hormone in idiopathic membranous nephropathy</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2014-04-03 18:01:58 +1100" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-03 18:02:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 18:02:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="ISRCTN" VALUE="ISRCTN70791258"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaskin-2004" MODIFIED="2014-04-03 18:01:48 +1100" MODIFIED_BY="Narelle S Willis" NAME="Gaskin 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-04-03 18:01:48 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Gaskin G</AU>
<TI>A national, randomised controlled trial of immunosuppressive therapy in idiopathic membranous nephropathy with declining renal function. 2004</TI>
<SO>http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0016094239</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2014-04-03 18:01:48 +1100" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-03 18:01:39 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 18:01:39 +1100" MODIFIED_BY="Narelle S Willis" TYPE="OTHER" VALUE="N0016094239"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirayama-2006" MODIFIED="2014-04-03 18:01:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hirayama 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-03 18:00:55 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Hirayama K, Koyama A</AU>
<TI>CYPMEN (CYclosporine with/without Prednisolone in MEmbranous Nephropathy) study. 2006</TI>
<SO>http://www.anzctr.org.au/ACTRN12609000996268.aspx</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2014-04-03 18:00:55 +1100" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-03 18:01:05 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 18:01:05 +1100" MODIFIED_BY="Narelle S Willis" TYPE="OTHER" VALUE="ACTRN12609000996268"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howman-2012" MODIFIED="2014-11-19 16:13:44 +1100" MODIFIED_BY="Narelle Willis" NAME="Howman 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-27 18:09:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, et al</AU>
<TI>Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2013</YR>
<VL>381</VL>
<NO>9868</NO>
<PG>744-51</PG>
<IDENTIFIERS MODIFIED="2014-04-03 17:17:57 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="23312808"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 17:19:43 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mathieson PW</AU>
<TI>The UK randomized controlled trial of Immunosuppression for progressive membranous nephropathy [abstract no: THOR048]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2011</YR>
<VL>22</VL>
<PG>11A</PG>
<IDENTIFIERS MODIFIED="2014-04-03 17:19:43 +1100" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-03 17:58:42 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 17:58:42 +1100" MODIFIED_BY="Narelle S Willis" TYPE="ISRCTN" VALUE="ISRCTN99959692"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2014-04-03 18:00:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-03 18:00:02 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Liu Z</AU>
<TI>Tacrolimus treatment of patients with idiopathic membranous nephropathy</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00302523</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2014-04-03 18:00:02 +1100" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-03 17:59:43 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 17:59:43 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CTG" VALUE="NCT00302523"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2007" MODIFIED="2014-04-03 18:00:42 +1100" MODIFIED_BY="Narelle S Willis" NAME="Liu 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-03 17:59:49 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Liu Z</AU>
<TI>To compare the efficacy and safety of Tripterygium wilfordii (TW) versus valsartan in the membranous nephropathy (MN)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00518219</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2014-04-03 17:59:49 +1100" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-03 18:00:42 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-03 18:00:42 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CTG" VALUE="NCT00518219"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-2006" MODIFIED="2014-04-03 17:59:11 +1100" MODIFIED_BY="Narelle S Willis" NAME="Saito 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-03 17:34:57 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Saito T</AU>
<TI>Combined therapy of prednisolone and mizoribine in membranous nephropathy with refractory nephrotic syndrome</TI>
<SO>www.who.int/trialsearch/trial.aspx?trialid=JPRN-C000000368&#8206;</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2014-04-03 17:34:57 +1100" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-04-03 17:59:11 +1100" MODIFIED_BY="Narelle S Willis"/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2014-04-22 15:56:18 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ChiCTR_x002d_TRC_x002d_08000098" MODIFIED="2014-04-03 17:40:20 +1100" MODIFIED_BY="Narelle S Willis" NAME="ChiCTR-TRC-08000098" YEAR="2008">
<REFERENCE MODIFIED="2014-04-03 17:40:20 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>ChiCTR-TRC-08000098</AU>
<TI>Research on integrated therapy of traditional Chinese medicine for membranous nephropathy</TI>
<SO>http://www.chictr.org/en/proj/show.aspx?proj=1290</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:15:32 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ChiCTR_x002d_TRC_x002d_11001144" MODIFIED="2014-04-03 17:41:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="ChiCTR-TRC-11001144" YEAR="2011">
<REFERENCE MODIFIED="2014-04-03 17:41:41 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>ChiCTR-TRC-11001144</AU>
<TI>A prospective randomized study on the efficacy of steroid combined with CTX or tacrolimus in IMN patients with NS</TI>
<SO>http://www.chictr.org/en/proj/show.aspx?proj=261</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:15:26 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CTRI_x002f_2010_x002f_091_x002f_000231" MODIFIED="2014-04-03 17:45:39 +1100" MODIFIED_BY="Narelle S Willis" NAME="CTRI/2010/091/000231" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 17:45:39 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>CTRI/2010/091/000231</AU>
<TI>Comparison of efficacy of tacrolimus versus cyclophosphamide in idiopathic membranous nephropathy</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=CTRI/2010/091/000231</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:15:16 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EUCTR2007_x002d_005410_x002d_39_x002d_ES" MODIFIED="2014-04-03 17:49:06 +1100" MODIFIED_BY="Narelle S Willis" NAME="EUCTR2007-005410-39-ES" YEAR="2008">
<REFERENCE MODIFIED="2014-04-03 17:49:06 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>EUCTR2007-005410-39-ES</AU>
<TI>Randomized pilot study comparing tacrolimus vs. cyclophosphamide-prednisone in idiopathic membranous nephropathy - MEMTAC</TI>
<TO>Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática - MEMTAC</TO>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2007-005410-39-ES</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:15:00 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JPRN_x002d_UMIN000001099" MODIFIED="2014-04-03 17:49:52 +1100" MODIFIED_BY="Narelle S Willis" NAME="JPRN-UMIN000001099" YEAR="2008">
<REFERENCE MODIFIED="2014-04-03 17:49:52 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>JPRN-UMIN000001099</AU>
<TI>Optimal use of ciclosporin in membranous nephropathy (OCIM-NS study)</TI>
<SO>http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000001321&amp;language=E</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:14:44 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JPRN_x002d_UMIN000006939" MODIFIED="2014-04-03 17:50:32 +1100" MODIFIED_BY="Narelle S Willis" NAME="JPRN-UMIN000006939" YEAR="2012">
<REFERENCE MODIFIED="2014-04-03 17:50:32 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>JPRN-UMIN000006939</AU>
<TI>High-dose gamma-globulin therapy for nephrotic membranous nephropathy patients</TI>
<SO>http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000007975&amp;language=E</SO>
<YR>(accessed 93 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:14:38 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00805753" MODIFIED="2014-04-22 15:56:18 +1000" MODIFIED_BY="[Empty name]" NAME="NCT00805753" YEAR="2008">
<REFERENCE MODIFIED="2014-04-22 15:56:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00805753</AU>
<TI>Dose-finding pilot study of ACTH in patients with idiopathic membranous nephropathy (MN)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00805753</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:14:29 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-05 22:47:55 +1100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00843856" MODIFIED="2014-04-03 17:52:45 +1100" MODIFIED_BY="Narelle S Willis" NAME="NCT00843856" YEAR="2009">
<REFERENCE MODIFIED="2014-04-03 17:52:45 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00843856</AU>
<TI>Mycophenylate mofetil and tacrolimus versus tacrolimus for the treatment of idiopathic membranous glomerulonephritis (IMG) (MTAC)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00843856</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:14:22 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01093157" MODIFIED="2014-04-03 17:53:25 +1100" MODIFIED_BY="Narelle S Willis" NAME="NCT01093157" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 17:53:25 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01093157</AU>
<TI>A dose escalation study of long-acting ACTH gel in membranous nephropathy</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01093157</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:14:16 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01161459" MODIFIED="2014-04-03 17:54:08 +1100" MODIFIED_BY="Narelle S Willis" NAME="NCT01161459" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 17:54:08 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01161459</AU>
<TI>Treatment of idiopathic membranous nephropathy with Tripterygium wilfordii plus steroid vs tacrolimus plus steroid</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01161459</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:14:12 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01180036" MODIFIED="2014-04-03 17:55:20 +1100" MODIFIED_BY="Narelle S Willis" NAME="NCT01180036" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 17:55:20 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01180036</AU>
<TI>A randomized controlled trial of rituximab versus cyclosporine in the treatment of membranous nephropathy (IMN)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01180036</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:14:07 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01282073" MODIFIED="2014-04-03 17:56:28 +1100" MODIFIED_BY="Narelle S Willis" NAME="NCT01282073" YEAR="2011">
<REFERENCE MODIFIED="2014-04-03 17:56:28 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01282073</AU>
<TI>Mycophenolate mofetil in patients with progressive idiopathic membranous nephropathy (MMFPRIMER)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01282073?</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:14:02 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01386554" MODIFIED="2014-04-03 17:57:21 +1100" MODIFIED_BY="Narelle S Willis" NAME="NCT01386554" YEAR="2011">
<REFERENCE MODIFIED="2014-04-03 17:57:21 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01386554</AU>
<TI>Acthar for treatment of proteinuria in membranous nephropathy patients (CHART)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01386554?</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:13:58 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01508468" MODIFIED="2014-04-03 17:58:09 +1100" MODIFIED_BY="Narelle S Willis" NAME="NCT01508468" YEAR="2012">
<REFERENCE MODIFIED="2014-04-03 17:58:09 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01508468</AU>
<TI>Evaluate rituximab treatment for idiopathic membranous nephropathy (GEMRITUX)</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT01508468</SO>
<YR>(accessed 3 April 2014)</YR>
<IDENTIFIERS MODIFIED="2012-07-09 16:13:51 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-10-09 11:06:11 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-04-22 15:57:54 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ahuja-1999" MODIFIED="2012-07-09 16:19:09 +1000" MODIFIED_BY="[Empty name]" NAME="Ahuja 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ahuja M, Goumenos D, Shortland JR, Gerakis A, Brown CB</AU>
<TI>Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy?</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>3</NO>
<PG>521-9</PG>
<IDENTIFIERS MODIFIED="2012-07-09 16:18:53 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 16:18:53 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10469864"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Beck-2009" MODIFIED="2014-04-04 16:33:04 +1100" MODIFIED_BY="Narelle S Willis" NAME="Beck 2009" TYPE="JOURNAL_ARTICLE">
<AU>Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al</AU>
<TI>M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>361</VL>
<NO>1</NO>
<PG>11-21</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:33:04 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:33:04 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19571279"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Beck-2011" MODIFIED="2014-04-04 16:38:14 +1100" MODIFIED_BY="Narelle S Willis" NAME="Beck 2011" TYPE="JOURNAL_ARTICLE">
<AU>Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al</AU>
<TI>Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>8</NO>
<PG>1543-50</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:38:14 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:38:14 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21784898"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cameron-2011" MODIFIED="2012-07-09 16:23:50 +1000" MODIFIED_BY="[Empty name]" NAME="Cameron 2011" TYPE="JOURNAL_ARTICLE">
<AU>Cameron M, Gagnier JJ, Chrubasik S</AU>
<TI>Herbal therapy for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<VL>2</VL>
<PG>CD002948</PG>
<IDENTIFIERS MODIFIED="2012-07-09 16:23:50 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 16:23:50 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002948.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chen-2010a" MODIFIED="2014-04-22 15:57:54 +1000" MODIFIED_BY="[Empty name]" NAME="Chen 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Chen YZ, Gao Q, Zhao XZ, Chen XM, Zhang F, Chen J, et al</AU>
<TI>Meta-analysis of tTripterygium wilfordii hook F in the immunosuppressive treatment of IgA nephropathy</TI>
<SO>Internal Medicine</SO>
<YR>2010</YR>
<VL>49</VL>
<NO>19</NO>
<PG>2049-55</PG>
<IDENTIFIERS MODIFIED="2012-07-09 16:24:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 16:24:56 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20930429"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chen-2010b" MODIFIED="2012-07-09 16:25:07 +1000" MODIFIED_BY="[Empty name]" NAME="Chen 2010b" TYPE="JOURNAL_ARTICLE">
<AU>Chen YZ, Zhao XZ, Wu J, Mei CL</AU>
<TI>Combination regimen of leflunomide plus methylprednisolone in a female patient with reactive arthritis and concomitant IgA nephropathy</TI>
<SO>Chinese Medical Journal</SO>
<YR>2010</YR>
<VL>123</VL>
<NO>3</NO>
<PG>375-8</PG>
<IDENTIFIERS MODIFIED="2012-07-09 16:25:07 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 16:25:07 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20193265"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Couchoud-1994" MODIFIED="2012-07-09 16:25:22 +1000" MODIFIED_BY="[Empty name]" NAME="Couchoud 1994" TYPE="JOURNAL_ARTICLE">
<AU>Couchoud C, Laville M, Boissel JP</AU>
<TI>Treatment of membranous nephropathy: a meta-analysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>5</NO>
<PG>469-70</PG>
<IDENTIFIERS MODIFIED="2012-07-09 16:25:22 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-09 16:25:22 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8090324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-du-Buf_x002d_Vereijken-2005" MODIFIED="2014-04-04 16:38:40 +1100" MODIFIED_BY="Narelle S Willis" NAME="du Buf-Vereijken 2005" TYPE="JOURNAL_ARTICLE">
<AU>du Buf-Vereijken PW, Branten AJ, Wetzels JF</AU>
<TI>Idiopathic membranous nephropathy: outline and rationale of a treatment strategy</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>6</NO>
<PG>1012-29</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:38:39 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:38:39 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16310567"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldbach_x002d_Mansky-2009" MODIFIED="2014-04-04 16:39:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="Goldbach-Mansky 2009" TYPE="JOURNAL_ARTICLE">
<AU>Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al</AU>
<TI>Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2009</YR>
<VL>151</VL>
<NO>4</NO>
<PG>229-40, W49-51</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:39:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:39:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19687490"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2014-04-04 16:40:14 +1100" MODIFIED_BY="Narelle S Willis" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:40:14 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:40:14 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16345038"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2009" MODIFIED="2012-07-09 16:27:39 +1000" MODIFIED_BY="[Empty name]" NAME="Harbord 2009" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Harris RJ, Sterne JAC</AU>
<TI>Updated tests for small-study effects in meta-analyses</TI>
<SO>The Stata Journal</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>2</NO>
<PG>197-210</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herrmann-2012" MODIFIED="2014-04-04 16:44:52 +1100" MODIFIED_BY="Narelle S Willis" NAME="Herrmann 2012" TYPE="JOURNAL_ARTICLE">
<AU>Herrmann SM, Sethi S, Fervenza FC</AU>
<TI>Membranous nephropathy: the start of a paradigm shift</TI>
<SO>Current Opinion in Nephrology &amp; Hypertension</SO>
<YR>2012</YR>
<VL>21</VL>
<NO>2</NO>
<PG>203-10</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:44:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:44:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="22240444"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-07-09 16:29:34 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofstra-2010a" MODIFIED="2014-04-22 14:37:35 +1000" MODIFIED_BY="[Empty name]" NAME="Hofstra 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Hofstra JM, Wetzels JF</AU>
<TI>Alkylating agents in membranous nephropathy: efficacy proven beyond doubt</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1760-6</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:45:34 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:45:34 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20133280"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofstra-2012" MODIFIED="2014-04-04 16:46:22 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hofstra 2012" TYPE="JOURNAL_ARTICLE">
<AU>Hofstra JM, Wetzels JF</AU>
<TI>Management of patients with membranous nephropathy</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>1</NO>
<PG>6-9</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:46:22 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:46:22 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21737514"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hogan-1995" MODIFIED="2014-04-04 16:46:56 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hogan 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hogan SL, Muller KE, Jennette JC, Falk RJ</AU>
<TI>A review of therapeutic studies of idiopathic membranous glomerulopathy</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>6</NO>
<PG>862-75</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:46:56 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:46:56 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7771482"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Imperiale-1995" MODIFIED="2014-04-04 16:47:31 +1100" MODIFIED_BY="Narelle S Willis" NAME="Imperiale 1995" TYPE="JOURNAL_ARTICLE">
<AU>Imperiale TF, Goldfarb S, Berns JS</AU>
<TI>Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>8</NO>
<PG>1553-8</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:47:31 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:47:31 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7756587"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDIGO-2012" MODIFIED="2014-04-04 16:49:52 +1100" MODIFIED_BY="Narelle S Willis" NAME="KDIGO 2012" TYPE="JOURNAL_ARTICLE">
<AU>KDIGO</AU>
<TI>Idiopathic membranous nephropathy</TI>
<SO>Kidney International - Supplement</SO>
<YR>2012</YR>
<VL>2</VL>
<PG>186-97</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:49:52 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:49:52 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1038/kisup.2012.20"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lehman-2004" MODIFIED="2014-04-04 16:51:23 +1100" MODIFIED_BY="Narelle S Willis" NAME="Lehman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lehman TJ, Edelheit BS, Onel KB</AU>
<TI>Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>3</NO>
<PG>321-3</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:51:23 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:51:23 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14962970"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2010" MODIFIED="2014-04-04 16:52:29 +1100" MODIFIED_BY="Narelle S Willis" NAME="Moher 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c869</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:52:29 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:52:29 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20332511"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ponticelli-2010" MODIFIED="2014-04-04 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="Ponticelli 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ponticelli C, Passerini P</AU>
<TI>Management of idiopathic membranous nephropathy</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>13</NO>
<PG>2163-75</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:53:02 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20707756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Remuzzi-2002" MODIFIED="2014-04-04 16:54:18 +1100" MODIFIED_BY="Narelle S Willis" NAME="Remuzzi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P</AU>
<TI>Rituximab for idiopathic membranous nephropathy</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9337</NO>
<PG>923-4</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:54:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:54:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12354476"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ruggenenti-2009" MODIFIED="2014-04-04 16:54:48 +1100" MODIFIED_BY="Narelle S Willis" NAME="Ruggenenti 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ruggenenti P, Cravedi P, Remuzzi G</AU>
<TI>Rituximab for membranous nephropathy and immune disease: less might be enough</TI>
<SO>Nature Clinical Practice Nephrology</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>2</NO>
<PG>76-7</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:54:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:54:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19048001"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Srivastava-1991" MODIFIED="2014-04-04 16:55:24 +1100" MODIFIED_BY="Narelle S Willis" NAME="Srivastava 1991" TYPE="JOURNAL_ARTICLE">
<AU>Srivastava RN, Vasudev AS, Bagga A</AU>
<TI>Levamisole in nephrotic syndrome</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<NO>8777</NO>
<PG>1275</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:55:24 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:55:24 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1682671"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stanescu-2011" MODIFIED="2014-04-04 16:56:48 +1100" MODIFIED_BY="Narelle S Willis" NAME="Stanescu 2011" TYPE="JOURNAL_ARTICLE">
<AU>Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al</AU>
<TI>Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>364</VL>
<NO>7</NO>
<PG>616-26</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:56:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:56:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21323541"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tam-2006" MODIFIED="2014-04-04 16:57:32 +1100" MODIFIED_BY="Narelle S Willis" NAME="Tam 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC</AU>
<TI>Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>3</NO>
<PG>417-8</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:57:32 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:57:32 +1100" MODIFIED_BY="Narelle S Willis" TYPE="PUBMED" VALUE="16474039"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tao-2002" MODIFIED="2014-04-04 16:58:09 +1100" MODIFIED_BY="Narelle S Willis" NAME="Tao 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tao X, Younger J, Fan FZ, Wang B, Lipsky PE</AU>
<TI>Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>7</NO>
<PG>1735-43</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:58:09 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:58:09 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12124856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Waldman-2009" MODIFIED="2014-04-04 16:58:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="Waldman 2009" TYPE="JOURNAL_ARTICLE">
<AU>Waldman M, Austin HA 3rd</AU>
<TI>Controversies in the treatment of idiopathic membranous nephropathy</TI>
<SO>Nature Reviews Nephrology</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>8</NO>
<PG>469-79</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:58:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:58:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19581908"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Waldman-2012" MODIFIED="2014-04-04 16:59:33 +1100" MODIFIED_BY="Narelle S Willis" NAME="Waldman 2012" TYPE="JOURNAL_ARTICLE">
<AU>Waldman M, Austin HA 3rd</AU>
<TI>Treatment of idiopathic membranous nephropathy</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>10</NO>
<PG>1617-30</PG>
<IDENTIFIERS MODIFIED="2014-04-04 16:59:33 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 16:59:33 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="22859855"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wu-2009" MODIFIED="2014-04-04 17:00:55 +1100" MODIFIED_BY="Narelle S Willis" NAME="Wu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wu T, Li Y, Bian Z, Liu G, Moher D</AU>
<TI>Randomized trials published in some Chinese journals: how many are randomized?</TI>
<SO>Trials [Electronic Resource]</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>46</PG>
<IDENTIFIERS MODIFIED="2014-04-04 17:00:55 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 17:00:55 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19573242"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xu-2009" MODIFIED="2014-04-04 17:01:32 +1100" MODIFIED_BY="Narelle S Willis" NAME="Xu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xu G, Tu W, Jiang D, Xu C</AU>
<TI>Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis</TI>
<SO>Nephron Clinical Practice</SO>
<YR>2009</YR>
<VL>111</VL>
<NO>4</NO>
<PG>c223-8</PG>
<IDENTIFIERS MODIFIED="2014-04-04 17:01:32 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 17:01:32 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19287181"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yoshioka-2000" MODIFIED="2014-04-04 17:02:29 +1100" MODIFIED_BY="Narelle S Willis" NAME="Yoshioka 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al</AU>
<TI>A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome</TI>
<SO>Kidney International</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>1</NO>
<PG>317-24</PG>
<IDENTIFIERS MODIFIED="2014-04-04 17:02:29 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 17:02:29 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10886577"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-10-09 11:06:11 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chen-2013" MODIFIED="2014-10-09 11:06:11 +1100" MODIFIED_BY="[Empty name]" NAME="Chen 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, et al</AU>
<TI>Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>5</NO>
<PG>787-96</PG>
<IDENTIFIERS MODIFIED="2014-04-04 17:07:28 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 17:07:28 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="23449768"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Perna-2004" MODIFIED="2014-04-04 17:02:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Perna 2004" TYPE="JOURNAL_ARTICLE">
<AU>Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G</AU>
<TI>Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>3</NO>
<PG>385-401</PG>
<IDENTIFIERS MODIFIED="2014-04-04 17:02:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-04-04 17:02:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15332211"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schieppati-2004" MODIFIED="2012-02-01 00:36:18 +1100" MODIFIED_BY="[Empty name]" NAME="Schieppati 2004" TYPE="COCHRANE_REVIEW">
<AU>Schieppati A, Perna A, Zamora J, Giuliano GA, Braun N, Remuzzi G</AU>
<TI>Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-02-01 00:36:18 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-01 00:36:18 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004293.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-01-14 17:34:58 +1100" MODIFIED_BY="Narelle S Willis"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-10-09 11:12:08 +1100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-04-22 16:19:16 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-04-22 15:11:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmed-1994">
<CHAR_METHODS MODIFIED="2014-04-08 10:48:53 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: prior to 1994</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-08 11:07:08 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Bangladesh</LI>
<LI>Setting: single centre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome; SCr &lt; 1.7 mg/dL</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (6.11 ± 1.86); treatment group 2 (7.61 ± 1.99)</LI>
<LI>Hypertension: treatment group 1 (0/10); treatment group 2 (2/10)</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (mg/dL): treatment group 1 (1.35 ± 0.13); treatment group 2 (1.22 ± 0.16)</LI>
<LI>GFR: NS</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive treatment: none</LI>
</UL>
<LI>Number: treatment group 1 (10); treatment group 2 (10)</LI>
<LI>Mean age ± SD (years): treatment group 1 (32 ± 7); treatment group 2 (38 ± 14)</LI>
<LI>Sex (M/F): treatment group 1 (8/2); treatment group 2 (8/2)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-03 14:21:03 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Methylprednisolone: 1 g/d IV for 3 consecutive days</LI>
<LI>Prednisolone: 0.5 mg/kg/d for 27 days</LI>
<LI>Chlorambucil: 0.2 mg/kg/d for 1 month for 3 cycles (6 months)</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Prednisolone: 1.0 to 1.5 mg/kg/d for 8 weeks and then in tapering dose and finally withdrawal after 8 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-03 14:22:05 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:11:58 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: NS</LI>
<LI>Follow-up period (months): treatment group 1 (14.6 ± 1.15); treatment group 2 (15.6 ± 2)</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: one patient in the treatment group 1 developed hypertension at the end of follow-up</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnadottir-2006">
<CHAR_METHODS MODIFIED="2014-04-03 14:48:41 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: before 2006</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:26 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Countries: Iceland; Sweden</LI>
<LI>Setting: international multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria: NS</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (&#956;mol/L): treatment group (107); control group (104)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: NS</LI>
<LI>Use of ACEi or ARB during follow-up: yes</LI>
<LI>Previous immunosuppressive use: NS</LI>
</UL>
<LI>Number: treatment group (15); control group (15)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-17 17:23:36 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>ACTH: SC 1.0 mg once/wk, 0.75 mg twice/wk or 1.0 mg twice/wk for 9 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No specific treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-17 17:31:49 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Partial or complete remission</LI>
<LI>Proteinuria</LI>
<LI>GFR</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:01 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline characteristics: comparable</LI>
<LI>Follow-up period: at least 21 months in each patient</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
<LI>Only abstract was available and unpublished data were not used</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Austin-1996a">
<CHAR_METHODS MODIFIED="2014-04-17 17:25:38 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Study duration: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:31 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: USA</LI>
<LI>Setting: NS</LI>
<LI>Patients with IMN</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria: NS</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (&#956;mol/L): NS</LI>
<LI>GFR: 24 to 156 mL/min</LI>
<LI>Baseline declining kidney function: NS</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive use: NS</LI>
</UL>
<LI>Number: treatment group 1 (17); treatment group 2 (14)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-17 17:30:47 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>IV CPA: (0.5.0 g/m² every other month)</LI>
<LI>Prednisone: 40 mg/m² every other day for 2 months tapered to 10 mg/m²</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Prednisone: 40 mg/m² every other day for 2 months tapered to 10 mg/m²</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-17 17:51:41 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Partial or complete remission</LI>
<LI>GFR</LI>
<LI>Proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:02 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline characteristics: comparable</LI>
<LI>Follow-up period: 1 year</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
<LI>Only abstract was available and data could not used</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Branten-1998">
<CHAR_METHODS MODIFIED="2014-04-08 10:49:00 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: 1989 to 1996</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:52 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: NS</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome and deteriorating kidney function</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (9 ± 2.6); treatment group 2 (11 ± 5.3)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group 1 (22 ± 5.6); treatment group 2 (22 ± 6.0)</LI>
<LI>SCr (&#956;mol/L): treatment group 1 (219 ± 73); treatment group 2 (274 ± 126)</LI>
<LI>GFR (mL/min): treatment group 1 (46 ± 17); treatment group 2 (43 ± 23)</LI>
<LI>Baseline declining kidney function: yes</LI>
<LI>Use of ACEi or ARB during follow-up: treatment group 1 (7/15), treatment group 2 (9/17) received ACEi before, no confounding effect was found during follow-up</LI>
<LI>Previous immunosuppressive status: treatment group 1 (prednisone (6)); Treatment group 2 (prednisone (4); prednisone and chlorambucil (4))</LI>
</UL>
<LI>Number: treatment group 1 (15); treatment group 2 (17)</LI>
<LI>Mean age ± SD (years): treatment group 1 (51 ± 12); treatment group 2 (53 ± 14)</LI>
<LI>Sex (M/F): treatment group 1 (15/0); treatment group 2 (15/2)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 16:09:53 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Monthly cycles of steroids and chlorambucil</LI>
<UL>
<LI>Steroids: 1g IV methylprednisolone on 3 consecutive days, followed by oral prednisone 0.5 mg/kg/d, months 1, 3 and 5</LI>
<LI>Chlorambucil: 0.15 mg/kg/d months 2, 4 and 6</LI>
<LI>The cumulative dosage was 9.8 ± 4.1 mg/kg.</LI>
<LI>Because of deteriorating kidney function, 5 patients received a second course of therapy consisting of oral CPA and prednisone (four patients) or AZA and prednisone (one patient).</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CPA and steroids</LI>
<UL>
<LI>Oral CPA: 1.5&#8211;2.0 mg/kg/d for 1 year</LI>
<LI>Steroids in a comparable dose</LI>
<LI>The median daily dose was 1.56 mg/kg</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-04 18:42:30 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:13:08 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period (months): mean (32 ± 18); treatment group 1 (median 38, range 8-71); treatment group 2 (median 26, range 5-68)</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
<LI>This study was not fully randomised. Furthermore, this study partially overlapped with <LINK REF="STD-Reichert-1994" TYPE="STUDY">Reichert 1994</LINK>
</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Braun-1995">
<CHAR_METHODS MODIFIED="2014-04-08 10:49:23 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: 1986 to 1996</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:54 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Germany</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II/III/IV): treatment group 1 (2/18/4/4); treatment group 2 (1/23/4/9); control group (1/11/2/4)</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (9.3 ± 6.3); treatment group 2 (7.2 ± 3.9); control group (6.5 ± 5.4)</LI>
<LI>Hypertension: treatment group 1 (13/31); treatment group 2 (33/44); control group (9/22)</LI>
<LI>Serum albumin (% of total protein): treatment group 1 (53 ± 12); treatment group 2 (52 ± 9); control group 3 (52 ± 9)</LI>
<LI>SCr (mg/dL): treatment group 1 (1.0 ± 0.3); treatment group 2 (1.2 ± 0.4); control group (1.0 ± 0.4)</LI>
<LI>GFR (mL/min): treatment group 1 (103 ± 31); treatment group 2 (102 ± 43); control group (107 ± 33)</LI>
<LI>Baseline declining kidney function: no</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect</LI>
<LI>Previous immunosuppressive status: no</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (31); treatment group 2 (44); control group (22)</LI>
<LI>Mean age ± SD (years): treatment group 1 (42.5 ± 13.9); treatment group 2 (43.0 ± 15.7); control group (46.9 ± 16.1)</LI>
<LI>Sex (M/F): treatment group 1 (25/6); treatment group 2 (21/23); control group (13/9)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 16:39:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Monthly cycles of steroids and chlorambucil</LI>
<UL>
<LI>Steroids: IV methylprednisolone 1g over 20 to 30 min for 3 consecutive days, followed by oral prednisone 0.5 mg/kg/d or methylprednisolone 0.4 mg/kg/d, months 1, 3 and 5</LI>
<LI>Chlorambucil: 0.2 mg/kg/d, months 2, 4 and 6; the dose was lowered if the leukocyte count fell below 5000/mm³</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CSA + steroids</LI>
<UL>
<LI>Oral CSA and prednisone for 6 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Symptomatic treatments as the above two groups</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-04 18:56:09 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:03 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: more patients in the two treatment groups had more severe nephrotic syndrome and aggressive IMN than the control group</LI>
<LI>Follow-up period: 68/97 patients completed the 5-year follow-up</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
<LI>Only abstract was available and unpublished data were included</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cameron-1990">
<CHAR_METHODS MODIFIED="2014-04-08 10:31:51 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: November 1981 to February 1985</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:54 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: UK</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: 89/103 biopsies were reviewed by a central panel after the local judgement was made in each working party. Of these 89, 70 were graded (4 as I, 32 as II, 26 as III, and 8 as IV)</LI>
<LI>Proteinuria (g/24 h): treatment group (10.8 ± 5.9); control group (10.4 ± 5.3)</LI>
<LI>Hypertension: treatment group (9/52); control group (16/51)</LI>
<LI>Serum albumin (g/L): treatment group (26 ± 6); group (25 ± 5)</LI>
<LI>SCr (&#956;mol/L): treatment group (114 ± 42); control group (115 ± 43)</LI>
<LI>GFR (mL/min): treatment group (87 ± 30); control group (89 ± 34)</LI>
<LI>Baseline declining kidney function: 13/103 patients with an initial SCr &#8805; 150 &#956;mol/L</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: no</LI>
</UL>
<LI>Number: treatment group (52); control group (51)</LI>
<LI>Mean age ± SD (years): treatment group (45 ± 11.6); control group (44 ± 12.1)</LI>
<LI>Sex (M/F): treatment group (43/9); control group (43/8)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-08 10:45:51 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Prednisolone: 125 mg was given every alternate day for 8 weeks. Patients who weighted more than 80 kg received 150 mg on alternative days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo: identical tablets as prednisolone for 8 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 15:14:10 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:04 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: mean 49 (36-72) months</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: At the last follow-up (49 months) a higher proportion of females were in remission or had stable function than corresponding males (P = 0.012)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cattran-1989">
<CHAR_METHODS MODIFIED="2014-04-08 10:49:46 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: 1977 to 1985</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:55 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Canada</LI>
<LI>Setting: single centre</LI>
<LI>Patients with biopsy-proven IMN; 120/158 patients with IMN had nephrotic-range proteinuria (64 in prednisone group and 56 in control group), while the remaining 38 patients did not have the diagnosis of nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II/III/IV): treatment group (6/33/33/9); control group (7/35/28/7)</LI>
<LI>Proteinuria (g/24 h): treatment group (6.9 ± 0.8); control group (5.2 ± 0.9)</LI>
<LI>Hypertension: treatment group (28/81); control group (24/77)</LI>
<LI>Serum albumin (g/L): treatment group (27 ± 1.3); control group (30 ± 1)</LI>
<LI>SCr (&#956;mol/L): treatment group (120 ± 10); control group (103 ± 9)</LI>
<LI>GFR (mL/sec/1.73 m²): treatment group (1.3 ± 0.08); control group (1.5 ± 0.08).</LI>
<LI>Baseline declining kidney function: a portion had</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: the use of any immunosuppressive agent other than prednisone was not allowed in the 6 months before entry</LI>
</UL>
<LI>Number: treatment group (81); control group (77)</LI>
<LI>Median age, range (years): treatment group (46, 18-77); control group (45, 16-83)</LI>
<LI>Sex (M/F): treatment group (61/20); control group (44/33)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 15:15:31 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Prednisone: 45 mg/m² in a single dose on alternate days for 6 months. The cumulative dose was 0.6 ± 0.05 mg/kg/d</LI>
</UL>
<P>Control group 2</P>
<UL>
<LI>No specific treatment for 6 months</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 11:15:13 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:04 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 48 ± 3.2 months. 72% of the 158 patients were followed for 3 years or more</LI>
<LI>Funding information: supported by grants from the Kidney Foundation of Canada</LI>
<LI>Sample size calculation: the estimated total sample size was 150 patients; enrolled 158</LI>
<LI>Confounding factors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cattran-1995">
<CHAR_METHODS MODIFIED="2014-04-08 11:13:11 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: before 1994</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:57 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Canada</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic-range proteinuria and progressive decline of kidney function (the decline of CrCl was &#8805; 8 mL/min 8-12 months before entry to the study)</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group (11.5, 9-18); control group (12.8, 4-21)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group (29 ± 6.6); control group (30 ± 9.2)</LI>
<LI>SCr (&#956;mol/L): treatment group (186 ± 65); control group (204 ± 81)</LI>
<LI>GFR (mL/min): treatment group (51 ± 20); control group (46 ± 16)</LI>
<LI>Baseline declining kidney function: yes</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. No ACEi were allowed unless the patient had been on such therapy a minimum of 3 months prior to entry</LI>
<LI>Previous immunosuppressive status: No corticosteroids, immunosuppressive drugs or nonsteroidal anti-inflammatory agents were allowed 8-12 months before entry to the study</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group (9); control group (8)</LI>
<LI>Median age, range (years): treatment group (44, 22-59); control group (40, 20-61)</LI>
<LI>Sex (M/F): treatment group (8/1); control group (6/2)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 16:39:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>CSA: 100 mg/mL, was initiated at 3.5 mg/kg/d taken in 2 divided doses, and periodic adjustments were made as necessary to achieve a 12-hour trough level of between 110 and 170 ng/mL. The mean dose of CSA was 3.8 mg/kg with a range between 2.5 and 4.9</LI>
</UL>
<P>Group 2</P>
<UL>
<LI>Placebo: made of the identical carrier except CSA was excluded. It was initially prescribed at 0.035 mL/kg/d, taken in 2 divided quantities with periodic arbitrary adjustments in dose to match the CSA group</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 11:35:16 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death.</LI>
<LI>ESKD</LI>
<LI>Final GFR</LI>
<LI>Final proteinuria</LI>
<LI> Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:05 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: total observation was 21 months</LI>
<UL>
<LI>Treatment group: 10.1 (4-13) months for the study and 20 (0-41) months for the extension observation</LI>
<LI>Control group: 8.9 (4-13) months for the study and 22 (6-56) months for the extension observation</LI>
</UL>
<LI>Funding information: grant support was in part by the Ontario Ministry of Health, Kidney Foundation of Canada, Metropolitan Toronto Community Foundation and Sandoz Canada Limited</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
<LI>An automatic dose reduction was reached because of a 30% rise in SCr in 10 patients (6 in CSA group, 4 in placebo group). With medication adjustment this reversed in 5 in CS group but none in placebo group</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cattran-2001">
<CHAR_METHODS MODIFIED="2014-04-08 12:39:41 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: before 2001</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:58 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Countries: Canada, USA</LI>
<LI>Setting: multicentre (11)</LI>
<LI>Patients with biopsy-proven steroid-resistant IMN and nephrotic-range proteinuria. All patients must have failed to achieve remission of their proteinuria after a minimum of 8 weeks of prednisone treatment at &#8805; 1 mg/kg/d</LI>
<UL>
<LI>Pathology stage (I-IV): treatment group 1 (2.2, 1-4); treatment group 2 (2.4, 1-4)</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (9.7 ± 5.3); treatment group 2 (8.8 ± 4.7)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group 1 (28 ± 6); treatment group 2 (27 ± 6)</LI>
<LI>SCr (mg/dL): treatment group 1 (1.3 ± 0.5); treatment group 2 (1.1 ± 0.3)</LI>
<LI>GFR (mL/min/1.73 m²): treatment group 1 (95 ± 37); treatment group 2 (90 ± 27)</LI>
<LI>Baseline declining kidney function: CrCl was &#8805; 42 mL/min/1.73 m² in all included patients</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect</LI>
<LI>Previous immunosuppressive status: no immunosuppressive agents, plasma exchange therapy, or antilymphocyte products were allowed in the 6 months prior to entry to the study. The average per patient prednisone dose given prior to the 6-month run-in period was not different in the 2 groups. In the placebo group, the mean total dose was 92 mg/kg (range 65 to 120), and in the CSA group, it was 108 mg/kg (range 60 to 140). The mean duration of treatment was also similar at 12 weeks in the placebo patients (range 8 to 22) and 14 weeks in the CSA patients (range 8 to 28). In addition, in the prestudy period, 18 patients (placebo (10), CSA (8)) had failed a course of a cytotoxic agents (CPA (9),</LI>
<LI>chlorambucil (5), AZA (4)) for an average of 4 months (range 2 to 12).</LI>
</UL>
<LI>Number: treatment group 1 (28); treatment group 2 (23)</LI>
<LI>Mean age ± SD (years): treatment group 1 (47 ± 11); treatment group 2 (49 ± 14)</LI>
<LI>Sex (M/F): treatment group 1 (26/2); treatment group 2 (16/7)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 15:19:07 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>CSA + prednisone</LI>
<UL>
<LI>CSA: started at a dose of 3.5 mg/kg/d in 2 equal doses at 12-hour intervals. Adjustments in dosages were made to achieve a whole-blood 12-hour trough level measured by monoclonal assay between 125 and 225 mg/L. It was continued for 26 weeks and then tapered to zero over 4 weeks</LI>
<LI>Prednisone: 0.15 mg/kg/d up to a maximum dose of 15 mg. This was reduced after 26 weeks by thirds at 4-week intervals and was stopped after 8 weeks</LI>
</UL>
<LI>Early stop points included a confirmed &#8805; 30% rise in baseline creatinine. Confirmed meant that the creatinine was not improved by two 25% reductions in the dose of the test medication spaced out over a four-week period. Other premature stop points included doubling of baseline liver enzymes and intolerable side effects. The test medication was also stopped if a complete remission of proteinuria was achieved and persisted for 1 month or more. The mean CSA dose was 3.7 ± 2.0 mg/kg. The mean trough level at 26 weeks was 148 ± 29 ng/L. All patients completed the 6 months of the test medications except 1 case of complete remission, where the CSA was stopped at week 20 after 4 week with no proteinuria</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Placebo + prednisone</LI>
<UL>
<LI>Placebo: started at a dose of 0.035 mL/kg/d. A comparable number of adjustments were made in the placebo patient's medication volume to ensure that masking was maintained. It was continued for 26 weeks and then tapered to zero over 4 weeks</LI>
<LI>Prednisone: 0.15 mg/kg/d up to a maximum dose of 15 mg. This was reduced after 26 weeks by thirds at 4-week intervals and was stopped after 8 weeks</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 14:25:44 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:05 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 18 months</LI>
<LI>Funding information: supported by the Kidney Foundation of Canada and Novartis Canada</LI>
<LI>Sample size calculation: the estimated total sample size was 50 patients. The number of finally included patients was similar to the estimate (51).</LI>
<LI>Confounding factors: no. At randomisation, 53% (27) of the patients were hypertensive (CSA (16), placebo (11)). Nineteen were on ACEi (CSA (11), placebo (8)), and 8 were on other antihypertensive medications. During the CS period, there was an increase in the number of patients in both groups that required antihypertensive medication, but more in the CSA than in the placebo group (8 versus 5). Despite this, no significant differences in supine, sitting, or mean arterial pressure measurements were noted during the active medication period or during the post-CSA period. Since ACEi could not be introduced in this period, these additional cases resulted in a decreased percentage of the hypertensive patients within each group on this class of CSA. In the CSA group, this fell from 69% to 46% and in the placebo group from 73% to 50%. During the post-test medication period, neither the percentage of patients with hypertension nor the use of ACEi changed significantly. There was no difference in the CSA group between those on ACEi compared with those not on an ACEi in either baseline proteinuria or in the amount of protein reduction by week 26. The number as well as the severity of hypertension was greater in the CSA compared with the placebo group in the active treatment period. A new antihypertensive agent (8) or an increase in the dose of the antihypertensive drugs (2) was required in the CSA group versus a new agent (5) in the placebo group</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:09:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chan-2007">
<CHAR_METHODS MODIFIED="2014-04-08 14:31:21 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: before 2007</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:09:59 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: China</LI>
<LI>Setting: NS</LI>
<LI>Patients with biopsy-proven IMN with proteinuria of &#8805; 3 g/d</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): 5.7 ± 2.7</LI>
<LI>Hypertension: 14/20</LI>
<LI>Serum albumin (g/L): 26.5 ± 7.5</LI>
<LI>SCr (&#956;mol/L): treatment group 1 (103.3 ± 48.7); treatment group 2 (85.7 ± 31.8)</LI>
<LI>GFR (mL/min): treatment group 1 (87.1 ± 38.5); treatment group 2 (101.8 ± 40.6)</LI>
<LI>Baseline declining kidney function: initial creatinine was &lt; 300 &#956;mol/L in all included patients 3/20 patients (2 in the MMF group and 2 in the control group) had abnormal SCr at baseline.</LI>
<LI>Use of ACEi or ARB during follow-up: in view of their confounding effects on proteinuria and kidney function, ACEi and ARB were not started during the study, and if a patient was already on either medication at the start of the study, the dose was kept unchanged. Only 1 patient was receiving ACEi prior to the study, and the dose was kept unchanged</LI>
<LI>Previous immunosuppressive status: those who had received cytotoxic or CSA treatment within the previous 12 months, or who had received prednisolone at &#8805; 20 mg/d for 4 weeks or more within the past 6 months, were excluded</LI>
</UL>
<LI>Number: treatment group 1 (11); treatment group 2 (9)</LI>
<LI>Mean age ± SD (years): 49.5 ± 13.5</LI>
<LI>Sex (M/F): 13/7</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-08 14:45:17 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1 </P>
<UL>
<LI>MMF + prednisolone</LI>
<UL>
<LI>MMF: 1 g twice/d was given for 6 months. </LI>
<LI>Oral prednisolone: started at 0.8 mg/kg/d, then tapered by 5 mg/d every fortnight until reaching 10 mg/d at around 4 months, then tapered by 2.5 mg/d every fortnight, till total withdrawal at around 6 months from baseline. The cumulative dose of prednisolone was 3.80 ± 0.28 g</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Modified Ponticelli regimen</LI>
<LI>IV methylprednisolone 1 g/d for 3 days, followed by oral prednisolone 0.4 mg/kg/d. for 3 weeks, then 0.2 mg/kg/d till the end of the month, alternating with chlorambucil 0.2 mg/kg/d for 1 month, for a total duration of 6 months. The cumulative dose of prednisolone was 9.93 ± 0.25 g</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 14:45:58 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:06 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 15-24 months</LI>
<LI>Funding information: the study received partial funding support from the Wai Hung Charity Foundation and Roche Pharmaceuticals (Hong Kong). The donors had no role in the study design and execution, data analysis and interpretation, or writing of the report</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:17:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2010a">
<CHAR_METHODS MODIFIED="2014-04-08 14:48:45 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: July 2004 to August 2008</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:00 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: China</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN and nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II/III): treatment group 1 (16/21/2); treatment group 2 (16/17/1)</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (7.71 ± 3.93); treatment group 2 (7.28 ± 3.91)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group 1 (23.1 ± 4.25); treatment group 2 (23.1 ± 4.81)</LI>
<LI>SCr (&#956;mol/L): treatment group 1 (75.7 ± 22.4); treatment group 2 (85.0 ± 37.5)</LI>
<LI>GFR (mL/min/1.73m²): treatment group 1 (105.5 ± 28.7); treatment group 2 (97.0 ± 34.3)</LI>
<LI>Baseline declining kidney function: initial creatinine was l&lt; 221 &#956;mol/Lin all included patients</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. To exclude the interference of ACEi or ARB on the level of proteinuria, patients who were taking ACEi or ARB before initiation of immunosuppressive therapy were instructed to maintain the dose of ACEi or ARB; those not taking ACEi or ARB before initiation of immunosuppressive therapy were instructed not to take ACEi or ARB; and other antihypertensive drugs were prescribed in those patients who did not reach the above target values. There were no significant differences in both systolic and diastolic BP between the two groups during follow-up. 12/39 patients in tacrolimus group received ACEi or ARB; while 7/34 patients in CPA group received ACEi or ARB (P = 0.32). Five new patients in tacrolimus group were diagnosed as hypertension and none in CPA were diagnosed (P = 0.09)</LI>
<LI>Previous immunosuppressive status: No immunosuppressive treatment was allowed within previous 3 months before entry</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (39); treatment group 2 (34)</LI>
<LI>Mean age ± SD (years): treatment group 1 (47.2 ± 11.9); treatment group 2 (48.6 ± 11.6)</LI>
<LI>Sex (M/F): treatment group 1 (23/16); treatment group 2 (18/16)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 15:19:41 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Tacrolimus + steroids</LI>
<UL>
<LI>Tacrolimus: started at a dose of 0.1 mg/kg/d, divided into 2 daily doses at a 12-hour interval. Later doses for the first 6 months were adjusted to achieve a whole blood 12 hours trough level between 5 and 10 ng/mL. Treatment was tapered for the next 3 months with a target trough level between 2 and 5 ng/mL. Doses were reduced by 25% every 2 weeks in the presence of a 50% Scr increase. If increasing of SCr persisted 50% of baseline values for 2 to 4 weeks after 75% reduction of tacrolimus doses, definition of end point was established. The daily dose was 4.43 ± 2.42 mg/d during the first 6 months</LI>
<LI>Oral prednisone: 1 mg/kg/d for 4 weeks, tapered gradually, and discontinued by 8 months</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CPA + steroids</LI>
<UL>
<LI>Oral CPA: 100 mg/d for 4 months (accumulated dosage was 12 g). The dosage was reduced by 50 mg/d if the total white blood cell count fell below 4000/L (when it returns to the normal range, the dosage can be increased with careful monitoring).</LI>
<LI>Oral prednisone: 1 mg/kg/d for 4 weeks, tapered gradually, and discontinued by 8 months</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 15:00:17 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 16:17:59 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: No</LI>
<LI>Glucose intolerance was only noted in 11 patients in the tacrolimus group (including 3 patients developed diabetes mellitus) (P = 0.00). Infection and hypertension tended to be more common in the tacrolimus group than in the CPA group although the P value did not reach statistical significance (8 versus 1 with P = 0.55 for infection; 5 versus 1 with P = 0.09 for hypertension)</LI>
<LI>Relapse occurred in 11 patients, 6 in the tacrolimus group and 5 in the CPA group. All the patients experiencing relapse had partial remission to the initial treatment. All the relapses in the tacrolimus group took place within 3 months after withdrawal of tacrolimus. There was no significant difference of relapse rate between the 2 groups. For the 6 patients experiencing relapse in the tacrolimus group, 2 were retreated with tacrolimus; 2 were retreated with CPA, and the other 2 received conservative therapies (ACEi and/or ARB). For the 5 patients experiencing relapse in the CPA group, 2 received MMF, 1 received CSA, and the other 2 received conservative therapies (ACEi and/or ARB)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coggins-1979">
<CHAR_METHODS MODIFIED="2014-04-08 15:11:02 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: before 1979</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:01 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (Interhospital Group)</LI>
<LI>Patients with biopsy-proven IMN and nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II/III-IV/Indeterminate): treatment group (5/18/9/2); control group (9/20/8/1)</LI>
<LI>Proteinuria (g/24 h): treatment group (9.4 ± 6); control group (8.3 ± 4)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (mg/dL): treatment group (1.1 ± 0.2); control group (1.0 ± 0.2)</LI>
<LI>GFR (L/d/1.73 m²): &gt; 60</LI>
<LI>Baseline declining kidney function: no</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: no patient received before</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group (34); control group (38)</LI>
<LI>Mean age, range (years): 39, 16-65</LI>
<LI>Sex (M/F): treatment group (22/12); control group (20/18)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-08 15:22:18 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Prednisone</LI>
<UL>
<LI>Weight 45 to 80 kg: 125 mg, given as a single dose every other morning</LI>
<LI>Weight &lt; 45 kg: 100 mg every other day</LI>
<LI>Weight &gt; 80 kg: 150 mg, every other day</LI>
</UL>
<LI>If no response at the end of 8 weeks, prednisone was tapered within an additional 4-week period. If a partial or complete response occurred, the drug was reduced by 25 mg/dose each week until a dosage of 25 mg was reached, and tapered 5 mg/dose/wk thereafter. If a patient relapsed after a complete or partial remission, the dosage was returned to the original level, maintained at that level for 1 month, and tapered as before</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo: identical placebo control tablets (supplied by Upjohn Company)</LI>
<LI>If no response at the end of 8 weeks, placebo was tapered within an additional 4-week period. If a partial or complete response occurred, the drug was reduced by 25 mg/dose each week until a dosage of 25 mg was reached, and tapered 5 mg/dose/wk thereafter. If a patient relapsed after a complete or partial remission, the dosage was returned to the original level, maintained at that level for 1 month, and tapered as before</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 15:22:51 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:07 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 23 ± 4.4 (4-52) months. Only 31/72 patients were followed for 24 months, and 21/72 were still under observation at 3 years</LI>
<LI>Funding information: The Collaborative Study, its members, and their institutions were supported by the following grants from the National Institutes of Health: AM15646, USPHS 5-M01-RR-00058, USPHS HL-05949, NIH 5 T32 AM 07241-02, 5K0 HL 4418, and USPHS RR-109</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CYCLOMEN-Study-1994">
<CHAR_METHODS MODIFIED="2014-04-09 16:28:37 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:03 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Europe</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome and worsening kidney function</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group (6.8 ± 0.9); control group (4.0 ± 0.5)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr: NS</LI>
<LI>GFR (mL/min/1.73 m²): treatment group (49.3 ± 6.5); control group (47.8 ± 7.3)</LI>
<LI>Baseline declining kidney function: yes</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect</LI>
<LI>Previous immunosuppressive status: NS</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group (10); control group (11)</LI>
<LI>Age: 49 years</LI>
<LI>Sex (M/F): treatment group (9/1); control group (8/3)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-09 16:49:15 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>CSA: 5 mg/kg/d for 6 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Conservative therapy for 6 months</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-09 16:49:36 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>Final SCr</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 14:52:17 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: the baseline proteinuria was not balanced (P &lt; 0.05)</LI>
<LI>Follow-up period: 12 (6-25) months</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: The estimated total sample size was 186 patients. This study was prematurely stopped and the number of finally included patients was far from the estimate (21)</LI>
<LI>Confounding factors: NS</LI>
<LI>Only abstract was available and unpublished data were included</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donadio-1974a">
<CHAR_METHODS MODIFIED="2014-04-08 15:25:28 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: May 1971 to June 1973</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:04 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: USA</LI>
<LI>Setting: single centre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II/III): treatment group (3/7/1); control group (2/8/1)</LI>
<LI>Proteinuria (g/24 h): treatment group (7.8, 2-16.6); control group (7.6, 2-12.1)</LI>
<LI>Hypertension: treatment group (2/11); control group (2/11)</LI>
<LI>Serum albumin (g/L): treatment group (27, 19-34); control group (23, 16-37).</LI>
<LI>SCr (mg/dL): treatment group (1.2, 0.8-1.9); control group (1.1, 0.8-2.2)</LI>
<LI>GFR (mL/min/1.73 m²): treatment group (75, 44-117); control group (80.6, 33-112)</LI>
<LI>Baseline declining kidney function: no</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: no patients had received prior cytotoxic drug treatment. 3 patients in treatment group (27%) and 4 in control group (36%) had received or were currently receiving prednisone treatment; such treatment was tapered off and then stopped within 30 days.</LI>
</UL>
<LI>Number: treatment group (11); control group (11)</LI>
<LI>Mean age, range (years): treatment group (males: 41, 25-74; females: 48.5, 40-59); control group (males: 47.6, 34-69; females: 41, 26/65)</LI>
<LI>Sex (M/F): treatment group (9/2); control group (8/3)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-08 15:35:00 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Oral CPA: 1.5 to 2.5mg/kg/d (mean: 1.8) for 1 year. If the leukocyte count was &lt; 3000/mmm³ or if the platelet count was &lt; 80000/mm³ the drug was stopped for a minimum of 7 days. When the counts increased to above these limits, treatment was started again at one-half the previous dose and then increased to the initial dose level if possible. The cumulative dose was 538 ± 120 (310-665) mg/kg in the 9 patients who completed the 12 month treatment</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 15:35:32 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:07 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 19/22 patients were followed at least 12 months (treatment group (9); control group (10)). 17/22 patients were followed for an average of 1 year beyond the 1 year of treatment (treatment group (7); control group (8))</LI>
<LI>Funding information: supported by a grant from the Mayo Foundation and by Public Health Service grant RR-585 from the National Institutes of Health Clinical Research Center</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
<LI>Nine patients in each group had the nephrotic syndrome on initial evaluation. Two in each group presented with non-nephrotic proteinuria, but all had previously been documented to have the nephrotic syndrome</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dussol-2008">
<CHAR_METHODS MODIFIED="2014-04-08 15:41:09 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: January 2004 to January 2008</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:08 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: France</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN and nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II): treatment group (8/9); control group (13/6)</LI>
<LI>Proteinuria (g/24 h): treatment group (6.2 ± 3.5); control group (9.5 ± 5.8)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group (23.2 ± 7.3); control group (20.2 ± 6.0)</LI>
<LI>SCr (mg/dL): treatment group (1.01 ± 0.34); control group (1.09 ± 0.39)</LI>
<LI>GFR (mL/min/1.73 m²): treatment group (92.1 ± 29.8); control group (80.7 ± 25.4)</LI>
<LI>Baseline declining kidney function: initial creatinine was &lt; 200 &#956;mol/L in all included patients.</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. In the control group, 14 patients received ACEi, 1 received ARB, and 2 received a combination of ACEi and ARB In the MMF group, 17 patients received ACEi, 1 received ARB, and 1 received a combination of ACEi and ARB</LI>
<LI>Previous immunosuppressive status: no patient received previous immunosuppressive treatment before entry</LI>
</UL>
<LI>Number: treatment group (19); control group (17)</LI>
<LI>Mean age ± SD (years): treatment group (47.8 ± 15.2); control group (55.9 ± 15.2)</LI>
<LI>Sex (M/F): treatment group (17/2); control group (15/2)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-17 17:42:33 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>MMF + conservative treatment</LI>
<UL>
<LI>MMF: 250 mg/d, progressively increased by 250 mg every other day to 2 g/d for 12 months. MMF therapy was then progressively stopped in 15 days. Mean dose of MMF was 1,850 mg. Sixteen patients could achieve the target dose of 2 g/d. Two patients were maintained on 1.5 g/d, and 1 was maintained on 1 g/d because of gastrointestinal symptoms</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Conservative treatment</LI>
<UL>
<LI>Renin-angiotensin blockers, statins, low-salt and low-protein diet, and diuretics in case of oedema</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 15:52:15 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:08 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Funding information: partial support for this study was provided by Roche through technical assistance and financing for the clinical research assistant. Roche did not intervene in the design or conduct of the study, analysis and interpretation of the data, or preparation of the article</LI>
<LI>Sample size calculation: estimated total sample size was 34 patients. The number of finally included patients was similar to the estimate (35)</LI>
<LI>Confounding factors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dyadyk-2001">
<CHAR_METHODS MODIFIED="2014-04-17 17:37:09 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Study duration: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:10 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Ukraine</LI>
<LI>Setting: NS</LI>
<LI>Patients with IMN</LI>
<UL>
<LI>Pathology stage (I/II): NS</LI>
<LI>Proteinuria (g/24 h): NS</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): NS</LI>
<LI>SCr (mg/dL): NS</LI>
<LI>GFR (mL/min/1.73 m²): NS</LI>
<LI>Baseline declining kidney function: NS</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: NS</LI>
</UL>
<LI>Number: treatment group 1 (16); treatment group 2 (16)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): treatment group 19/13</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-17 17:44:21 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>CPA</LI>
<UL>
<LI>Initial dose:1.5 to 3.5 mg/kg/d</LI>
<LI>Mean treatment duration: 5.8 months</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Azathioprine</LI>
<UL>
<LI>Initial dose: 1.4 to 2.0 mg/kg/d</LI>
<LI>Mean treatment duration: 6.6 months</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-17 17:47:45 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Proteinuria</LI>
<LI>Creatinine</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:09 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 12-48 months</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
<LI>Only abstract was available and data could not used</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Falk-1992">
<CHAR_METHODS MODIFIED="2014-04-08 15:54:56 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: March 1986 to November 1990</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:12 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (Glomerular Disease Collaborative Network)</LI>
<LI>Patients with biopsy-proven progressive IMN with either deteriorating kidney function or persistent proteinuria associated with morbid complications</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (12.4 ± 9.9); treatment group 2 (11.1 ± 6.7)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (mg/dL): treatment group 1 (2.3 ± 1.0); treatment group 2 (2.7 ± 1.6)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: yes</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect.</LI>
<LI>Previous immunosuppressive status: all patient had received a course of corticosteroids therapy. All patients had received initial therapy with prednisone at a dose of 2.0 mg/kg body weight every other day (not exceeding a maximum single dose of 120 mg) for 8 weeks; the drug was then tapered by 25%/dose/wk over 4 weeks. Patients were not eligible if they had previously been treated with CPA or chlorambucil</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (13); treatment group 2 (13)</LI>
<LI>Mean age ± SD (years): treatment group 1 (43.3 ± 14.8); treatment group 2 (46.0 ± 13.7)</LI>
<LI>Sex (M/F): treatment group (9/4); control group (7/6)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-08 16:03:37 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>CPA + steroids: IV CPA in conjunction with a 3-day course of pulse methylprednisolone and alternate-day corticosteroids</LI>
<UL>
<LI>Steroids: IV pulse methylprednisolone at a dose of 7 mg/kg (not exceeding a single maximum dose of 1000 mg) given on 3 consecutive days. Forty-eight hours after completing therapy with pulse methylprednisolone, patients began treatment with oral corticosteroids (prednisone, 1mg/kg every other day, not exceeding 80mg per single dose) for 2 months; drug was tapered 25%/dose/wk over the next 4 weeks. </LI>
<LI>CPA: monthly IV CPA was given at an initial dose of 0.5g/m². Leukocyte counts were monitored to maintain counts at levels no lower than 3x10<SUP>6</SUP>/L If leukocyte nadir counts remained above 5x10<SUP>6</SUP>/L after each treatment, the subsequent cyclophosphamide dose was raised by 250mg/m². The maximum single dose did not exceed 1000 mg/m². CPA was administered monthly for 6 months</LI>
</UL>
</UL>
<P>Treatment group 2 </P>
<UL>
<LI>Prednisone: oral 2.0 mg/kg prednisone on alternate days for 8 weeks, and then tapered by 25%/dose/wk over 4 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-08 16:04:01 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 16:10:14 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable except the racial distribution (P = 0.003). The numbers of Whites/Blacks/Others were 11/1/1 and 6/7/0 in treatment group 1 and treatment group 2, respectively</LI>
<LI>Follow-up period: 29.2 ± 17.1 months</LI>
<LI>Funding information: in part by the Jessie Bell DuPont Religious, Charitable and Educational Fund, the Telephone Pioneers of North Carolina (Chapter 35, and the National Institutes of Health General Clinical Research Center) (grant RR00046)</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
<LI>To be included in the study, patients had to have either deteriorating kidney function or persistent proteinuria associated with morbid complications. Deterioration in kidney function was defined by a sustained doubling of the SCr over, at most, 2 years of follow-up or by a 50% fall in the GFR during the same interval. Additionally, patients were accepted into the protocol if they had a sustained SCr &gt; 2.0 mg/dL (reciprocal value, 0.5) (two successive measurements at least 2 weeks apart). Patients were also eligible if they had an entry SCr &lt; 2.0 mg/dL (reciprocal value, 0.5) but had persistent proteinuria with morbid complications</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hofstra-2010">
<CHAR_METHODS MODIFIED="2014-04-09 14:31:00 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: May 1998 to May 2005</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:17 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome and high risk for ESKD. The high risk for ESKD was defined as urinary B<SUB>2</SUB> microglobulin &gt; 0.5 &#956;g/min and urinary IgG &gt; 125 mg/24 h</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/10 mmol Cr): treatment group 1 (9.6, 5.9-14.4); treatment group 2 (12.0, 5.6-17.2)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group 1 (22.6 ± 4.8); treatment group 2 (22.3 ± 3.8)</LI>
<LI>SCr (mg/dL): treatment group 1 (94, 68-122); treatment group 2 (101, 75-126)</LI>
<LI>GFR (mL/min/1.73 m²): treatment group 1 (81 ± 17); treatment group 2 (76 ± 13)</LI>
<LI>Baseline declining kidney function: no; SCr was &lt; 135 &#956;mol/L in all patients at randomisation</LI>
<LI>Use of ACEi or ARB during follow-up: all patients were aggressively treated to decrease BP (target value 130/80 mmHg), primarily by using ACEi and/or ARB</LI>
<LI>Previous immunosuppressive status: patients who had previously been treated with immunosuppressive drugs were excluded</LI>
</UL>
<LI>Number: treatment group 1 (14); treatment group 2 (12)</LI>
<LI>Mean age ± SD (years): treatment group 1 (48 ± 13); treatment group 2 (49 ± 10)</LI>
<LI>Sex (M/F): treatment group 1 (13/1); treatment group 2 (11/1)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 16:10:18 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Early treatment: started immunosuppressive therapy immediately after randomisation</LI>
<UL>
<LI>Oral CPA: 1.5 mg/kg BW/d for 12 months,</LI>
<LI>IV methylprednisolone: 1 g on days 1, 2, 3, 60, 61, 62, 120, 121 and 122</LI>
<LI>Oral prednisone: 0.5 mg/kg BW/d for 6 months, and subsequently tapered by decreasing the dose by 5 mg/week.</LI>
<LI>For prevention of gastric symptoms, famotidine 1 daily dose 20 mg was added.</LI>
<LI>From 1999 onwards, trimethoprim&#8211;sulfamethoxazole was added 480 mg/d in the first 4&#8211;6 months, to prevent pneumocystis jiroveci pneumonia. In young fertile patients, the treatment regimen was modified because of the infertility risk associated with the use of CPA; in these patients, after 3 months of treatment CPA was replaced by AZA 1.5 mg/kg BW/day for the remaining 9 months. Three patients were treated according to the modified treatment scheme with AZA</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Late treatment: started treatment when kidney function deteriorated, defined as an increase of SCr with &#8805; 25% reaching a level of &#8805; 135 &#956;mol/l or an increase of SCr with &#8805; 50%</LI>
<LI>Two patients received modified treatment with AZA after 3 months</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-09 14:51:47 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Final SCr</LI>
<LI>Final GFR</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:10 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 72 ± 22 months; treatment group 1 (73 ± 20); treatment group 2 (71 ± 26)</LI>
<LI>Funding information: supported by grants from the Dutch Kidney Foundation (NSN OW08 and NSN PC152).</LI>
<LI>Sample size calculation: the estimated total sample size was 30 patients. The number of finally included patients was similar to the estimate (26).</LI>
<LI>Confounding factors: NS</LI>
<LI>Relapse re-treatment</LI>
<UL>
<LI>Treatment group 1: 3 patients (23%) relapsed to nephrotic syndrome 36 months after treatment (range 25&#8211;106 months). One patient achieved a spontaneous complete remission, and another was retreated with CPA and steroids for 6 months, followed by a course of AZA. With this regimen, a partial remission was achieved. In the third patient, the relapse was only recently diagnosed.</LI>
<LI>Treatment group 2: 3 patients (27%) relapsed to nephrotic syndrome 38 months after treatment (range 13&#8211;76 months). Two were retreated. The first patient received 6 months of CPA and steroid therapy, followed by AZA for 1 year and achieved a complete remission. The second patient started re-treatment with 3 months of CPA and steroids, followed by MMF. At the end of the follow-up, the patient had just started this treatment and nephrotic proteinuria still persisted. The third patient has not been retreated yet, as the relapse was diagnosed shortly before the last follow-up date</LI>
</UL>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Imbasciati-1980">
<CHAR_METHODS MODIFIED="2014-04-09 15:00:18 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: 1976 to 1985</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:19 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II/III/IV): treatment group (11/21/8/2); control group (7/23/7/2)</LI>
<LI>Proteinuria (g/24 h): treatment group (6.18 ± 2.98); control group (5.30 ± 2.84)</LI>
<LI>Hypertension: treatment group (8/42); control group (12/39)</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (&#956;mol/L): treatment group (93.8 ± 21.5); control group (93.1 ± 25.3)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: no</LI>
<LI>Use of ACEi or ARB during follow-up: yes; 2 (1 per group) were recorded to receive captopril during the 5-year follow-up</LI>
<LI>Previous immunosuppressive status: patients who had previously received steroids or cytotoxic therapy were excluded</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group (42); control group (39)</LI>
<LI>Mean age, range (years): treatment group (43.5, 15-70); control group (42, 16-74)</LI>
<LI>Sex (M/F): treatment group (34/8); control group (29/10)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-09 15:14:25 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Chlorambucil + steroids</LI>
<OL>
<LI>IV methylprednisolone: 1g was given for 20 to 30 minutes on 3 consecutive days</LI>
<LI>Cycle A: on day 4, oral methylprednisolone (0.4 mg/kg/d) or prednisone (0.5 mg/kg/d) was given in a single morning dose for 27 days. At the end of the first month, the steroid was discontinued</LI>
<LI>Cycle B: chlorambucil (0.2 mg/kg/d) for 1 month; the dose was lowered if the leukocyte count fell below 5.0x10<SUP>9</SUP>/L. After one month the chlorambucil was discontinued</LI>
<LI>Cycle A</LI>
<LI>Cycle B</LI>
<LI>Cycle A</LI>
<LI>Cycle B</LI>
</OL>
<LI>The entire duration of the treatment period was six months. During the study it was decided that clinicians would be free to treat the patients again, but not until 2 years after the first 6 month course of therapy. No patient relapsed within the first 2 years</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No specific therapy</LI>
</UL>
<P>Both the treatment and control groups received low salt diets and were given diuretic and antihypertensive agents as needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-09 15:14:51 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 16:10:21 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: median 5 years (2-11) in the first report and 10 years in the second report</LI>
<LI>Funding information: supported in part by a grant (82.01308.04) from the Consiglio Nazionale delle Ricerche</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: absence of tubulointerstitial lesions reduced the risk of a deterioration of kidney function significantly (P = 0.0073) at the 5-year follow-up, this significance disappeared at the 10-year follow-up</LI>
<LI>The first report of the study analysed the data at 5-years follow-up; the second report analysed the data at 10-year follow-up</LI>
<LI>In the treatment group, 4 of relapsed patients were treated again. Three patients who had partial remissions after treatment were given new courses of therapy because of recurrence of the nephrotic syndrome at 24, 38, and 39 months, respectively. Another patient who had a recurrence of the nephrotic syndrome after having a complete remission with therapy was retreated 36 months later. Two controls, one still nephrotic and the other one with kidney function deterioration asked to be treated because of the deterioration of kidney function and then were lost to follow-up 22 and 29 months after randomisation with unchanged clinical conditions. Their data were analysed according to the intention-to-treat principle</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jha-2007">
<CHAR_METHODS MODIFIED="2014-04-09 15:34:56 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: March 1993 to February 1995</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:22 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: India</LI>
<LI>Setting:</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: the majority of the patients had stage II IMN with minimal interstitial scaring</LI>
<LI>Proteinuria (g/24 h): treatment group (6.11 ± 2.5); control group (5.91 ± 2.2)</LI>
<LI>Hypertension: treatment group (5/47); control group (7/46)</LI>
<LI>Serum albumin (g/L): treatment group (23.4 ± 5.8); control group (24.2 ± 8.1)</LI>
<LI>SCr (mg/dL): treatment group (1.21 ± 0.31); control group (1.17 ± 0.22)</LI>
<LI>GFR (mL/min): treatment group (89 ± 26); control group (84 ± 22)</LI>
<LI>Baseline declining kidney function: a portion had</LI>
<LI>Use of ACEi or ARB during follow-up: ACEi and ARB were withheld for at least 1 year after randomisation. During follow-up more control group patients developed hypertension that required drugs for control (16/47 versus 7/35 at the 10-year follow-up, P &lt; 0.01). Treatment group patients exhibited significantly lower prevalence of ACEi/ARB use at various time points (13/47 versus 32/46 at the 10-year follow-up, P &lt; 0.01). The actual mean BP values were not different between the two groups either at baseline or during follow-up</LI>
<LI>Previous immunosuppressive status: patients who had received steroids or immunosuppressive drugs for &#8805; 2 months were excluded</LI>
</UL>
<LI>Number: treatment group (47); control group (46)</LI>
<LI>Mean age ± SD (years): treatment group (38.0 ± 13.6); control group (37.2 ± 12.4)</LI>
<LI>Sex (M/F): treatment group (30/17); control group (27/19)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-09 15:43:20 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>CPA + steroids</LI>
<UL>
<LI>IV methylprednisolone 1 g/d for 3 consecutive days followed by oral prednisolone 0.5 mg/kg/d for 27 d in the first, third, and fifth months</LI>
<LI>Oral CPA 2 mg/kg/d in the second, fourth, and sixth months. It was withheld temporarily when the counts fell to 3500/mm³ until recovery to 4000/mm³. Treatment was halted when a patient exhibited any evidence of active ulcer disease, neoplasm, diabetes, and/or life-threatening infections</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Supportive therapy that consisted of dietary sodium restriction, diuretics, and antihypertensive agents</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-09 15:44:13 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:11 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: median 11 years (10.5 to 12)</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
<LI>Patients in control group were given the choice of opting for the immunosuppressive regimen 24 months after randomisation. Finally, 15 patients elected to receive the experimental protocol 24 to 54 months after randomisation. All of them had nephrotic-range proteinuria at the time of treatment. Data were analysed on an intention-to-treat basis</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jurubita-2012">
<CHAR_METHODS MODIFIED="2014-04-09 15:58:02 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: before 2012</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:23 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Romania</LI>
<LI>Setting: single centre</LI>
<LI>Patients with biopsy-proven IMN with persistent heavy proteinuria (&gt; 8 g/d, minimum 6 months)</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (10.4, 8.4-14.9); treatment group 2 (10.26, 8-14.1).</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr: NS</LI>
<LI>GFR (mL/min/1.73 m²): &gt; 60</LI>
<LI>Baseline declining kidney function: NS</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: NS</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (9); treatment group 2 (9)</LI>
<LI>Age: NS</LI>
<LI>Sex: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-09 16:03:48 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>MMF + CSA + steroids for 12 months</LI>
<UL>
<LI>MMF: 1 g/ d</LI>
<LI>CSA: 2 mg/kg/d, but not exceeding 150 mg/d</LI>
<LI>Prednisolone: 0.15 mg/kg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CSA + steroids</LI>
<UL>
<LI>CSA: 5 mg/kg/d, but not exceeding 150 mg/d</LI>
<LI>Prednisolone: 0.15 mg/kg/d</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-09 16:03:59 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Partial or complete remission</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:11 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: NS</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
<LI>Only abstract was available and unpublished data were not used</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koshisawa-1993">
<CHAR_METHODS MODIFIED="2014-04-09 16:05:40 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: April 1989 to June 1992</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:24 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: NS</LI>
<LI>Patients with biopsy-proven IMN with steroid-resistant nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria: NS</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr: NS</LI>
<LI>GFR (mL/min): &#8805; 50</LI>
<LI>Baseline declining kidney function: NS</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: receiving a daily maintenance dose of 20 mg prednisolone-equivalent a day (including zero dosage) before entry was allowed. Other immunosuppressant medication should be stopped at the start of the study</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group (48); control group (41)</LI>
<LI>Age: &gt; 15 years</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-09 16:09:41 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Mizoribine: 50 mg 3 times/d after meals for 24 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-09 16:10:04 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>50% or 100% creatinine increase</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 12:39:18 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: NS</LI>
<LI>Follow-up period: 24 weeks</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: the data were abstracted from a RCT aiming to investigate the effect of mizoribine on steroid-resistant primary nephrotic syndrome. This study included all different pathologic variants of nephrotic syndrome. The randomisation were not stratified according to the pathologic diagnosis</LI>
<LI>Published in Japanese</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosmadakis-2010">
<CHAR_METHODS MODIFIED="2014-04-09 16:14:40 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: before 2010</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:25 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Greece</LI>
<LI>Setting: single centre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (6.6 ± 1.0); treatment group 2 (7.0 ± 0.7); treatment group 3 (5.2 ± 0.8)</LI>
<LI>Hypertension: patients with prior history of essential hypertension were excluded</LI>
<LI>Serum albumin (g/L): treatment group 1 (27 ± 7); treatment group 2 (28 ± 2); treatment group 3 (22 ± 1.4)</LI>
<LI>SCr: NS</LI>
<LI>GFR (mL/min/1.73 m²): treatment group 1 (81.6 ± 8); treatment group 2 (51.5 ± 7); treatment group 3 (65.7 ± 5.6)</LI>
<LI>Baseline declining kidney function: a portion had</LI>
<LI>Use of ACEi or ARB during follow-up: used only in the ACEi group</LI>
<LI>Previous immunosuppressive status: NS</LI>
</UL>
<LI>Number: treatment group 1 (10); treatment group 2 (8); treatment group 3 (10)</LI>
<LI>Mean age ± SD (years): treatment group 1 (50.5 ± 4.9); treatment group 2 (55.4 ± 2.8); treatment group 3 (51.8 ± 5.4)</LI>
<LI>Sex (M/F): treatment group 1 (8/2); treatment group 2 (4/4); treatment group 3 (5/5)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 15:22:13 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>CSA + steroids for 9 months</LI>
<UL>
<LI>Oral CSA: 3&#8211;3.5 mg/kg/d</LI>
<LI>Oral methylprednisolone: 12.5 mg/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CPA + steroids for 9 months</LI>
<UL>
<LI>Oral CPA: 2 mg/kg/24 h</LI>
<LI>Oral methylprednisolone: 1.5 mg/kg/48 h</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>ACEi for 9 months</LI>
<UL>
<LI>: Lisinopril</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-09 16:26:02 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:12 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: GFR was worsen in CPA group than other 2 groups</LI>
<LI>Follow-up period: At least 9 months</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2009b">
<CHAR_METHODS MODIFIED="2014-04-09 16:52:34 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: January 2006 to December 2007</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:25 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: China</LI>
<LI>Setting: NS</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (6.04 ± 2.52); treatment group 2 (5.66 ± 2.28)</LI>
<LI>Hypertension: treatment group 1 (10/43);treatment group 2 (11/41)</LI>
<LI>Serum albumin (g/L): treatment group 1 (24.1 ± 3.66); treatment group 2 (27.3 ± 4.96)</LI>
<LI>SCr (mg/dL): treatment group 1 (0.79 ± 0.31); treatment group 2 (0.88 ± 0.38)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: 9/84 patients with an initial SCr of between 1.25 and 1.5 mg/dL (treatment group 1 (4); treatment group 2 (5)). No patients had SCr &gt; 1.5 mg/dL</LI>
<LI>Use of ACEi or ARB during follow-up: 15 in treatment group 1 and 14 in treatment group 2 received before the entry of study. 14 in treatment group 1 and 12 in treatment group 2 received during the follow-up</LI>
<LI>Previous immunosuppressive status: patients treated with steroids or immunosuppressive therapy within the 3-month period before screening were excluded. There were no differences in the number of patients that had been previously treated with steroids alone or in combination with cytotoxics. Previous treatment with steroids/steroids plus cytotoxics: treatment group 1 (13/4); treatment group 2 (14/3)</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (43); treatment group 2 (41)</LI>
<LI>Mean age ± SD (years): treatment group 1 (40.5 ± 12.0); treatment group 2 (48.6 ± 10.3)</LI>
<LI>Sex (M/F): treatment group 1 (31/12); treatment group 2 (30/11)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-09 17:18:53 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Tripterygium wilfordii + steroids</LI>
<UL>
<LI>Tripterygium wilfordii: 120 mg/d for 3 months. If the patients had complete remission, then gradually reduced to 60 mg/d for remaining 9 months. If the patients did not reach complete remission, then continued the 120 mg-dosage to a maximum of 6 months and then gradually reduced to 60 mg/d for the remission 6 months</LI>
<LI>Prednisone: 30 mg/d for 8 weeks, and gradually reduced by 5 mg every 2 weeks and then maintained at 10 mg every two days</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Tripterygium wilfordii: 120 mg/d for 3 months. If the patients had complete remission, then gradually reduced to 60 mg/d for remaining 9 months. If the patients did not reach complete remission, then continued the 120 mg-dosage to a maximum of 6 months and then gradually reduced to 60 mg/d for the remission 6 months</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-09 17:19:21 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 12:39:18 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: comparable except that the percentage of males and serum albumin was significantly higher in treatment group 2 at baseline.</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Funding information: supported by Chinese grants (06G040, BK2007718, and 06Z025)</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: baseline age was lower in patients with complete remission than patients with no-response (P &lt; 0.01)</LI>
<LI>Published in Chinese</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-1992">
<CHAR_METHODS MODIFIED="2014-04-10 10:37:40 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: 1978 to 1986</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:26 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Australia</LI>
<LI>Setting: multicentre (2)</LI>
<LI>Patients with biopsy-proven IMN</LI>
<UL>
<LI>Pathology stage (I/II/III): treatment group (4/14/1); control group (5/15/1)</LI>
<LI>Proteinuria (g/24 h): treatment group (5.0, 0.9-13); control group (3.9, 0.5-12)</LI>
<LI>Hypertension: treatment group 6/19); control group (6/21)</LI>
<LI>Serum albumin (g/L): treatment group (28, 16-42); control group (30, 19-41)</LI>
<LI>SCr (&#956;mol/L): treatment group (110, 50-280); control group (90, 50-200)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: 2 patients had the SCr &gt; 200 &#956;mol/L (one in each group)</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: patients who had received any immunosuppressive therapy within 12 months prior to consideration of study entry were excluded</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group (19); control group (21)</LI>
<LI>Mean age, range (years): treatment group (47, 26-66); control group (40, 18-65)</LI>
<LI>Sex (M/F): treatment group (12/7); control group (14/7)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 10:47:25 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>CPA + warfarin + dipyridamole</LI>
<UL>
<LI>Oral CPA: maximum dosage of l.5 mg/kg/d for 6 mouths</LI>
<LI>Dipyridamole and sodium warfarin therapy were continued for 2 years</LI>
</UL>
<LI>Symptomatic treatment</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Symptomatic treatment only</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 10:47:48 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:13 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: At least 24 months in all patients</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naumovic-2011">
<CHAR_METHODS MODIFIED="2014-04-10 10:50:00 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: 1995 to 2002</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:28 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Serbia</LI>
<LI>Setting: single centre</LI>
<LI>Patients with biopsy-proven high-risk IMN; all had nephrotic syndrome with average proteinuria of 9 g/d</LI>
<UL>
<LI>Pathology stage (I/II/III/IV): treatment group 1 (mean 2.2); treatment group 2 (mean 2.08)</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (11.6 ± 4.7); treatment group 2 (7.0 ± 2.7)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group 1 (22.9 ± 4.8); treatment group 2 (28.3 ± 6.4)</LI>
<LI>SCr (&#956;mol/L): treatment group 1 (124.5 ± 75.9); treatment group 2 (120.5 ± 46.5)</LI>
<LI>GFR (mL/min): treatment group 1 (80.7±27.5); treatment group 2 (76.2 ± 31.3)</LI>
<LI>Baseline declining kidney function: 22% of the patients exhibited elevated SCr values, and nearly 40% had lower CrCl</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. ACEi were also given to all patients either in doses needed for adequate regulation of arterial hypertension, or in normotensive patients in smaller amounts in order to achieve an antiproteinuric effect. During the 3-year follow-up newly diagnosed hypertension was recorded in two patients of CSA group that required an increased dose of ACEi or addition of another antihypertensive. Hypertension developed in three new patients of AZA was successfully regulated by ACEi and calcium channel antagonists</LI>
<LI>Previous immunosuppressive status: all the patients previously received the so-called Ponticelli protocol (chlorambucil and corticosteroids for six months). The lead-time between the end of the Ponticelli protocol and the beginning of the new treatment was at least 1 year: 17.9 ± 4.9 months in CSA group and 19.5 ± 8.1 months in AZA group</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (10); treatment group 2 (13)</LI>
<LI>Mean age ± SD (years): treatment group 1 (39.2 ± 13.1); treatment group 2 (47.5 ± 8.2)</LI>
<LI>Sex (M/F): treatment group 1 (9/1); treatment group 2 (10/3)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 11:23:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>CSA + steroids</LI>
<UL>
<LI>CSA: 3 mg/kg/d. During the follow-up, the CSA dose was adjusted to achieve 12-h trough levels of 80&#8211;100 ng/mL. </LI>
<LI>Prednisone: 0.5 mg/kg/d 8 weeks. The dose was gradually reduced to 5 to 10 mg/d, and remained unchanged until the end of the treatment. </LI>
<LI>CSA and prednisone, were slowly discontinued over 2 weeks at the end of the 24-month period</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>AZA + steroids</LI>
<UL>
<LI>AZA: 1.5-2 mg/kg for 6 months, and afterwards 50 mg/d. AZA was temporarily withdrawn or the dose was reduced if the white cell count fell below 4x10<SUP>9</SUP>/L</LI>
<LI>Prednisone: 0.5 mg/kg/d 8 weeks. The dose was gradually reduced to 5 to 10 mg/d, and remained unchanged until the end of the treatment. </LI>
<LI>AZA and prednisone, were slowly discontinued over 2 weeks at the end of the 24-month period</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 11:23:27 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 11:24:26 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: average proteinuria was significantly greater in the CSA group (P = 0.003). In addition, patients in the CSA group had significantly higher serum triglyceride and lower total protein and albumin concentrations</LI>
<LI>Follow-up period: at least 36 months</LI>
<LI>Funding information: funded by the Ministry of Science and Technology of the Republic of Serbia (project number 145043)</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pahari-1993">
<CHAR_METHODS MODIFIED="2014-04-10 11:25:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: before 1993</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:29 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: India</LI>
<LI>Setting: NS</LI>
<LI>Patients with biopsy-proven IMN and &gt; 2.0 g/24 h proteinuria</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): &#8805; 2</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (mg/dL): &#8804; 2</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: no</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: NS</LI>
</UL>
<LI>Number: treatment group 1 (36); treatment group 2 (35)</LI>
<LI>Mean age ± SD (years): treatment group 1 (35 ± 16); treatment group 2 (32 ± 20)</LI>
<LI>Sex (M/F): treatment group 1 (25/11); treatment group 2 (24/11)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 11:32:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>CPA + steroids</LI>
<UL>
<LI>Oral prednisolone: 4 mg/kg/d from 1 to 3 days followed by oral prednisolone 0.5 mg/kg/d from 4 to 30 days (Injection dexamethasone 1 mg/kg/d from 1 to 3 days in cases who are intolerant to high dose oral prednisolone)</LI>
<LI>Oral CPA: 2 mg/kg/d from 1 to 30 days of next months (oral chlorambucil was used in patients intolerant to oral CPA). The treatment was continued for 1 year.</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Oral prednisolone: 60 mg/d was given for 12 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 11:32:22 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:22:24 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: NS</LI>
<LI>Follow-up period: 46 ± 10.2 months</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Drop-out rate: treatment group 1 (2/42); treatment group 2 (8/48)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ponticelli-1992">
<CHAR_METHODS MODIFIED="2014-04-10 11:49:43 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: before December 1989</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:29 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: multicentre (Italian Idiopathic Membranous Nephropathy Treatment Study Group)</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I-II/III-IV): treatment group 1 (27/18); treatment group 2 (29/18)</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (7.6 ± 4.2); treatment group 2 (7.0 ± 4.1)</LI>
<LI>Hypertension: treatment group 1 (15/45); treatment group 2 (14/47)</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (mg/dL): treatment group 1 (1.0 ± 0.3); treatment group 2 (1.0 ± 0.3)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: no. Patients with SCr &gt;1.7 mg/dL (150 &#956;mol/L) were excluded</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: patients with previous treatment with corticosteroids or cytotoxic agents were excluded</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (45); treatment group 2 (47)</LI>
<LI>Mean age, range (years): treatment group 1 (46, 14-65); treatment group 2 (47, 14-64)</LI>
<LI>Sex (M/F): treatment group 1 (32/13); treatment group 2 (27/20)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 12:00:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Chlorambucil + steroids (3 cycles of each for 6 months)</LI>
<UL>
<LI>Methylprednisolone: 3 cycles of IV 1 g on 3 consecutive days and then 0.4 mg/kg/d given orally for 27 days, in a single morning dose</LI>
<LI>Oral chlorambucil: 0.2 mg/kg/d</LI>
</UL>
</UL>
<P>Treatment group 2 </P>
<UL>
<LI>IV methylprednisolone: 1 g on 3 consecutive days at the beginning of treatment and again 2 and 4 months</LI>
<LI>Oral methylprednisolone: 0.4 mg/kg every other day, except during the period of IV administration, for six months</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 12:19:27 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 12:39:18 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: treatment group 1 (54 ± 16 months); treatment group 2 (54 ± 17 months). 63/92 (68%) patients completed the 48-month follow-up and were analysed for the outcomes of partial or complete remission (treatment group 1 (32/45, 71%), treatment group 2 (31/47, 66%). 50/92 (54%) patients had data for final proteinuria at 48 months (treatment group 1 (26/45, 58%); treatment group 2 24/47 (51%))</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: the estimated total sample size was unclear and this study was prematurely stopped. The number of finally included patients (N = 92) gave the study a power of 0.80 to demonstrate an increase of 0.30 in clinical response in the intervention group, assuming a 0.50 response in the control group, at the 5% level of significance with a two-tailed test</LI>
<LI>Confounding factors: several factors influenced remission of nephrotic syndrome: baseline proteinuria and SCr, presence of mesangial sclerosis. The more severe the disease, the poorer the response to therapy</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:19:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ponticelli-1998">
<CHAR_METHODS MODIFIED="2014-04-10 12:25:36 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:30 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I-II/III-IV): treatment group 1 (32/18); treatment group 2 (27/18)</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (7.96 ± 5.19); treatment group 2 (6.85 ± 3.51)</LI>
<LI>Hypertension: treatment group 1 (15/50); treatment group 2 (14/45)</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (mg/dL): treatment group 1 (1.06 ± 0.27); treatment group 2 (1.04 ± 0.27)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: patients with SCr &gt; 1.7 mg/dL were excluded</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. The use of ACEi was discouraged but not prohibited</LI>
<LI>Previous immunosuppressive status: patients who had previously received corticosteroids, immunosuppressive drugs, or CSA were excluded</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (50); control group 2 (45)</LI>
<LI>Mean age, range (years): treatment group 1 (50, 18-65); control group 2 (48, 17-55)</LI>
<LI>Sex (M/F): treatment group 1 (37/13); control group 2 (29/16)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 16:19:16 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Chlorambucil + steroids (3 cycles of each for 6 months)</LI>
<UL>
<LI>Methylprednisolone: 1 g IV on 3 consecutive days and then 0.4 mg/kg/d given orally for 27 d, in a single morning dose</LI>
<LI>Chlorambucil: 0.2 mg/kg/d, orally for 1 month. The total duration of treatment, therefore, was 6 mo for both groups; 3 mo with the same doses of methylprednisolone and 3 mo with either of the two cytotoxic drugs. Steroids were completely stopped at the end of the study period. Two relapse patients were retreated with steroids and chlorambucil. One did not respond, and the other attained partial remission</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CPA + steroids (3 cycles of each for 6 months)</LI>
<UL>
<LI>Methylprednisolone: 1 g IV on 3 consecutive days and then 0.4 mg/kg/d given orally for 27 d, in a single morning dose</LI>
<LI>Oral CPA: 2.5 mg/kg/d. Two relapse patients were retreated. One patient was retreated with steroids and cyclophosphamide and had complete remission. Another patient was treated with steroids and chlorambucil and had partial remission.</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 12:38:52 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 12:41:58 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: treatment group 1 (36, 12-78 months); treatment group 2 (42, 12-72 months)</LI>
<LI>Funding information: supported in part by a grant from Ospedale Maggiore di Milano</LI>
<LI>Sample size calculation: The estimated total sample size was 100 patients. The number of finally included patients was similar to the estimate (95)</LI>
<LI>Confounding factors: NS</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ponticelli-2006">
<CHAR_METHODS MODIFIED="2014-04-10 13:08:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: September 2001 to December 2003</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:31 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I-II/III-IV): treatment group 1 (12/4); treatment group 2 (14/2)</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (5.5 ± 2.0); treatment group 2 (6.7 ± 2.8)</LI>
<LI>Hypertension: treatment group 1 (9/16); treatment group 2 (9/16)</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (mg/dL): treatment group 1 (0.9 ± 0.17); treatment group 2 (1.0 ± 0.36)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: no; patients with SCr concentrations &gt; 1.9 mg/dL (168 mol/L) were excluded</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. Eleven patients in treatment group 2 and 12 patients in treatment group 1 were treated with ACEi and/or ARB during the study. There was no significant difference between the 2 groups in the probability of remission between patients administered ACEi and/or ARB or statins and those not administered either of these drugs</LI>
<LI>Previous immunosuppressive status: patients who previously received treatment with corticosteroids or cytotoxic agents were excluded</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (16); control group 2 (16)</LI>
<LI>Mean age ± SD (years): treatment group 1 (51.4 ± 9.5); control group 2 (48 ± 12.9)</LI>
<LI>Sex (M/F): treatment group 1 (7/9); control group 2 (12/4)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 15:26:10 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>CPA/chlorambucil + steroids (3 cycles of each for 6 months)</LI>
<UL>
<LI>Methylprednisolone: 1 g, administered IV on 3 consecutive days, and then 0.4 mg/kg/d 27 days, administered orally in a single morning dose.</LI>
<LI>Oral chlorambucil (0.2 mg/kg/d orally) or oral CPA (2.5 mg/kg/d) for 1 month</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Synthetic ACTH (tetracosactide): IM 1 mg between 7:00 and 9:00 AM. Administration of ACTH was increased from 1 injection every other week to 2 injections/wk for a total treatment period of 1 year</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 13:17:59 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:22:32 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period (months): treatment group 1 (21.8 ± 7.5); treatment group 2 (21.8 ± 7.6)</LI>
<LI>Funding information: spontaneous clinical study sponsored by the grant "Project Glomerulonephritis" in memory of Pippo Neglia. The corresponding author was an external consultant to Novartis, which produces tetracosactide used in this study</LI>
<LI>Sample size calculation: estimated total sample size was too large to validate the study assumption. The author decided to perform a pilot study with a limited number of patients (32)</LI>
<LI>Confounding factors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Praga-2007">
<CHAR_METHODS MODIFIED="2014-04-10 13:21:04 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: January 2003 to September 2006</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:32 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Spain</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II/III/IV): treatment group (4/15/3/0); control group (4/18/1/0)</LI>
<LI>Proteinuria (g/24 h): treatment group (7.2 ± 3.3); control group (8.4 ± 5.4)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group (27 ± 8); control group (29 ± 8)</LI>
<LI>SCr (mg/dL): treatment group (0.98 ± 0.2); control group (1.1 ± 0.3)</LI>
<LI>GFR (mL/min/1.73 m²): treatment group (104 ± 26); control group (107 ± 63)</LI>
<LI>Baseline declining kidney function: no; GFR by Cockroft-Gault formula was &#8805; 50 mL/min/1.73 m² in all included patients.</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. Included patients who also had to be treated with an ACEi or an ARB at their maximal tolerated doses for at least 2 months before screening. All the patients were instructed to maintain the same doses of ACEi or ARB that they were taking at randomisation until the end of the study</LI>
<LI>Previous immunosuppressive status: patients treated with steroids or immunosuppressive therapy within the 6-month period before screening were excluded. There were no differences in the number of patients that had been previously treated with steroids alone or in combination with cytotoxics (previous treatment with steroids/steroids plus cytotoxics: treatment group (5/4); control group (6/4)</LI>
</UL>
<LI>Number: treatment group (25); control group (23)</LI>
<LI>Mean age ± SD (years): treatment group (3.7 ± 12.1); control group (50.1 ± 12.2)</LI>
<LI>Sex (M/F): treatment group (20/5); control group (20/3)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 13:26:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Tacrolimus: 0.05 mg/kg/d, divided into two daily doses at 12-h interval. Later doses were adjusted to achieve a whole blood 12-h trough level between 3 and 5 ng/mL. When a remission was not obtained after the first 2 months of treatment, doses were increased to achieve levels between 5 and 8 ng/mL. Tacrolimus treatment was continued for 12 months and then gradually tapered off for the next 6 months; a 25% tacrolimus dose reduction was indicated at months 12, 14, and 16 and treatment was withdrawn by month 18. Tacrolimus doses were reduced by 25% every 2 weeks in the presence of a 50% SCr increase. If SCr persisted &gt; 50% of baseline values 2&#8211;4 weeks after &gt; 75% reduction of tacrolimus doses, definition of end point was established</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No specific immunosuppressive treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 13:27:11 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 13:28:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: comparable except that diastolic BP was significantly higher in control group than in tacrolimus group at baseline</LI>
<LI>Follow-up period: 30 months</LI>
<LI>Funding information: partially supported by Astellas. Astellas did not intervene in the design or conduct of the study, analysis, and interpretation of the data or preparation of this paper</LI>
<LI>Sample size calculation: estimated total sample size was 48. The number of finally included patients was 48.</LI>
<LI>Confounding factors: by multivariate analysis, baseline eGFR (OR 1.06, 95% CI: 1.02 to 1.09, P = 0.004) and the treatment group (OR 16.1, 95% CI: 2.7 to 96.1, P = 0.002) were the only factors statistically significantly correlated with the achievement of a partial remission or complete remission</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reichert-1994">
<CHAR_METHODS MODIFIED="2014-04-10 13:37:39 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: June 1989 to November 1992</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:33 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: university hospital and teaching hospitals</LI>
<LI>Patients with</LI>
<UL>
<LI>Pathology stage (I-II/III/unavailable): treatment group 1 (6/2/1); treatment group 2 (6/3/0)</LI>
<LI>Proteinuria (g/10 mmol of creatinine): treatment group 1 (8.5 ± 2.5); treatment group 2 (9.8 ± 4.8)</LI>
<LI>Hypertension: treatment group 1 (7/9); treatment group 2 (5/9)</LI>
<LI>Serum albumin (g/L): treatment group 1 (22.9 ± 6.4); treatment group 2 (25.9 ± 9.7)</LI>
<LI>SCr (&#956;mol/L): treatment group 1 (260 ± 112); treatment group 2 (218 ± 85)</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: yes</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. Three patients in the treatment group 1 and 5 patients in the treatment group 2 received ACEi.</LI>
<LI>Previous immunosuppressive status: six patients in the treatment group 1 and 5 patients in treatment group 2 had been treated previously with short-term, high-dose prednisone according to <LINK REF="STD-Coggins-1979" TYPE="STUDY">Coggins 1979</LINK>
</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (9); treatment group 2 (9)</LI>
<LI>Mean age, range (years): treatment group 1 (45, 31-65); treatment group 2 (49, 24-65)</LI>
<LI>Sex (M/F): treatment group 1 (9/0); treatment group 2 (8/1)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 13:47:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Chlorambucil + steroids</LI>
<UL>
<LI>Oral chlorambucil: 0.15 mg/kg/d in months 2, 4, and 6</LI>
<LI>Prednisone; 3 IV pulses of 1 g of methylprednisolone followed by oral prednisone at 0.5 mg/kg/d in months 1, 3, and 5)</LI>
</UL>
<LI>Three patients were retreated with new immunosuppressive therapy</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CPA + steroids</LI>
<UL>
<LI>IV CPA: 750 mg/m² body surface area once every month for 6 months</LI>
<LI>Methylprednisolone: (3 IV 1 g pulses in months 1, 3, and 5)</LI>
</UL>
<LI>One patient were retreated with new immunosuppressive therapy</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 13:48:09 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:27:25 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: Mean 15 (6-36) months: treatment group 1 (26 ± 12 months); treatment group 2 (13 ± 5.8 months)</LI>
<LI>Funding information: NWO grant 900/716-111 from the Netherlands Foundation of Scientific Research</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saito-2009">
<CHAR_METHODS MODIFIED="2014-04-10 14:03:50 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:34 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: NS</LI>
<LI>Patients with biopsy-proven IMN with steroid-resistant nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group 1 (3.5 ± 0.3); treatment group 2 (3.7 ± 0.5)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr: NS</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: NS</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: steroids</LI>
</UL>
<LI>Number: treatment group 1 (16); treatment group 2 (17)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 14:09:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>CSA + steroids continued for 48 weeks</LI>
<UL>
<LI>CSA: 1.5 mg/kg twice a day</LI>
<LI>Prednisolone: initially prescribed at 40 mg/d and tapered</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CSA + steroids continued for 48 weeks</LI>
<UL>
<LI>CSA: 3 mg/kg once a day before breakfast</LI>
<LI>Prednisolone: initially prescribed at 40 mg/d and tapered</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 14:09:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Complete remission</LI>
<LI>Final proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 15:12:14 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Baseline comparison: NS</LI>
<LI>Follow-up period: 48 weeks</LI>
<LI>Funding information: Kidney Foundation, Japan, and Novartis Pharma, Japan</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
<LI>Only abstract was available and unpublished data were not used</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Senthil-Nayagam-2008">
<CHAR_METHODS MODIFIED="2014-04-10 14:11:00 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: before 2008</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:35 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: India</LI>
<LI>Setting: single centre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria: NS</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): treatment group 1 (27 ± 7); treatment group 2 (27 ± 4)</LI>
<LI>SCr: NS</LI>
<LI>GFR (mL/min): treatment group 1 (85 ± 10.8); treatment group 2 (80 ± 13.4)</LI>
<LI>Baseline declining kidney function: a small number of patients</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. All patients with GFR of &gt; 60 mL/min were started on escalating doses of ACEi and/or ARB before entry and during study.</LI>
<LI>Previous immunosuppressive status: patients who had received steroids or immunosuppressive drugs previously were excluded</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group 1 (11); treatment group 2 (10)</LI>
<LI>Mean age ± SD (years): adults</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 14:21:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>MMF + steroids</LI>
<UL>
<LI>MMF: 2 g/day in 2 divided doses for 6 months. MMF dose was decreased by 25&#8211;33% for persistent gastrointestinal symptoms, discontinued temporarily if the white blood cell count decreased to &lt; 4000 &#956;L, platelets below 100,000 &#956;L or if the patient developed severe infections or unacceptable gastrointestinal symptoms. It was permanently discontinued if there was any evidence of development of malignancy.</LI>
<LI>Prednisolone: 0.5 mg/kg/d for 8&#8211;12 wk. The cumulative dose was 1.8 ± 0.3 g</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CPA + steroids (3 cycles for 6 months)</LI>
<UL>
<LI>Methylprednisolone: IV 1 g/d for 3 consecutive days followed by oral prednisolone 0.5 mg/kg/d for 27 days. The cumulative prednisolone dose was 2 ± 0.4 g</LI>
<LI>Oral CPA: 2 mg/kg/d for 30 days</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 14:21:47 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 14:22:37 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: NS</LI>
<LI>Follow-up period: treatment group 1 (18.2 (14.6-20.8) months); treatment group 2 (16.1 (13.1-18.8) months)</LI>
<LI>Funding information: supported by a grant from M/s Panacea Biotec Ltd, New Delhi, India</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shibasaki-2004">
<CHAR_METHODS MODIFIED="2014-04-10 14:24:10 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: open, parallel RCT</LI>
<LI>Study duration: April 1996 to June 2001</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:35 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with steroid-resistant nephrotic syndrome. Steroids resistance was defined as absence of a satisfactory response to corticosteroid therapy for 3 months</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria: NS</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr (mg/dL): &lt; 2.0</LI>
<LI>GFR (mL/min): &#8805; 40</LI>
<LI>Baseline declining kidney function: NS</LI>
<LI>Use of ACEi or ARB during follow-up: yes, no confounding effect. Concomitant use of ACEi, antiplatelet agents, and anticoagulants was allowed, and the same method of administration of these drugs was followed during the study period as is usual for these drugs.</LI>
<LI>Previous immunosuppressive status: receiving a daily maintenance dose of 20 mg prednisolone-equivalent a day (including zero dosage) before entry was allowed. Other immunosuppressant medication should be stopped at the start of the study</LI>
</UL>
</UL>
<UL>
<LI>Number: treatment group (14); control group (11)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 14:27:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Mizoribine: 50 mg, 3 times/d. after meals</LI>
<LI>No particular restriction was placed on the use of corticosteroids during the study period</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Conservative therapy</LI>
<LI>No particular restriction was placed on the use of corticosteroids during the study period</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 14:27:09 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Partial or complete remission</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 14:27:29 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: NS</LI>
<LI>Follow-up period: 2 years</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: The data were abstracted from a RCT aiming to investigate the effect of mizoribine on steroid-resistant nephrotic syndrome. This study included all different pathologic variants of nephrotic syndrome. The randomisation were not stratified according to the pathologic diagnosis</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silverberg-1976">
<CHAR_METHODS MODIFIED="2014-04-17 17:56:35 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: before 1976</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:36 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Canada</LI>
<LI>Setting: multicentre (4) (Western Canadian Glomerulonephritis Study Group)</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage (I/II/III): treatment group (0/4/1); control group (1/3/0)</LI>
<LI>Proteinuria (g/24 h): treatment group (12.2 ± 4.9); control group (9.1 ± 5.9)</LI>
<LI>Hypertension: treatment group (2/5); control group (1/4)</LI>
<LI>Serum albumin (g/L): treatment group (24 ± 5); control group (25 ± 3)</LI>
<LI>SCr (mg/dL): treatment group (1.1 ± 0.4); control group (1.5 ± 0.5)</LI>
<LI>GFR (mL/min/1.73 m²): treatment group (95 ± 37); control group (74 ± 22)</LI>
<LI>Baseline declining kidney function: CrCl &gt; 50 mL/min/1.73 m² in all included patients</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: patients were required to have received no AZA, CPA or nitrogen mustard for at least 1 year before entry into the study, and no steroids for at least 4 months</LI>
</UL>
<LI>Number: treatment group (5); control group (4)</LI>
<LI>Mean age ± SD (years): treatment group (41 ± 15); control group (45 ± 18)</LI>
<LI>Sex (M/F): treatment group (3/2); control group (3/1)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 14:35:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>AZA: 2.5 mg/kg/d (in 50 mg tablets) once-a-day for 1 year</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo: similar number of placebo tablets as AZA</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 14:36:06 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>50% or 100% creatinine increase</LI>
<LI>Final SCr</LI>
<LI>Final GFR</LI>
<LI>Partial or complete remission</LI>
<LI>Final proteinuria</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 14:36:29 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Funding information: supported by the Medical Research Council of Canada, grant MA 4718, and by Burroughs-Wellcome Ltd</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stegeman-1994">
<CHAR_METHODS MODIFIED="2014-04-22 15:29:12 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: January 1994 to January 1996</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:37 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Countries: Europe</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN with nephrotic syndrome</LI>
<UL>
<LI>Pathology stage: stages: 1-IV</LI>
<LI>Proteinuria: &#8805; 3 g/d</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin (g/L): NS</LI>
<LI>SCr (mg/dL): NS</LI>
<LI>CrCl: &gt; 60 mL/min/1.73 m²</LI>
<LI>Baseline declining kidney function: NS</LI>
<LI>Use of ACEi or ARB during follow-up: no</LI>
<LI>Previous immunosuppressive status: no previous antiproteinuric treatments with cytotoxic drugs and/or steroids</LI>
</UL>
<LI>Number: treatment group 1 (50); treatment group 2 (50); control group (50)</LI>
<LI>Age range: 18 to 65 years</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-17 18:17:37 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>ACEi</LI>
<UL>
<LI>Dose: 10 mg/d for study period</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Steroids</LI>
<UL>
<LI>Prednisolone: 6 month treatment, dose adjusted for body weight at the start of the study and tapered from 8 weeks</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No specific treatment</LI>
<UL>
<LI>Continuation of salt restriction and diuretics as needed</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-17 18:19:14 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Partial or complete remission</LI>
<LI>Relapse after complete or partial remission</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-17 18:27:21 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Follow-up: 60 months</LI>
<LI>This study was terminated due to poor accrual rate</LI>
<LI>Data presented here is from the published study protocol</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tiller-1981">
<CHAR_METHODS MODIFIED="2014-04-10 14:39:43 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: May 1974 to November 1980</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:37 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Australia</LI>
<LI>Setting: multicentre</LI>
<LI>Patients with biopsy-proven IMN</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): treatment group (5.0); control group (4.2)</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr: patients with SCr &gt; 350 &#956;mol/L were excluded</LI>
<LI>GFR: patients with GFR &lt; 0.33 mL/sec/1.73 m²(20 mL/min/1.73 m²) were excluded</LI>
<LI>Baseline declining kidney function: no.</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: previous treatment did not preclude patients from the study, provided that they had been on no "specific" treatment for a period of 6 months before entering the study</LI>
</UL>
<LI>Number: treatment group (27); control group (27)</LI>
<LI>Mean age ± SD (years): patients were not excluded on account of age</LI>
<LI>Sex (M/F): NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 14:43:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>CPA + warfarin + dipyridamole</LI>
<UL>
<LI>CPA was given at a dosage of l.5 mg/kg/d for 6 mouths</LI>
<LI>Dipyridamole and sodium warfarin therapy were prescribed</LI>
<LI>Symptomatic treatment</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Symptomatic treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 14:43:36 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>ESKD</LI>
<LI>Side effects leading to patient withdrawal or hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 14:53:10 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 36 months</LI>
<LI>Funding information: supported by a grant from the National Health and Medical Research Council of Australia</LI>
<LI>Sample size calculation: sample size calculation not reported, however It was proposed to enter a minimum of 50 patients into study protocol. The number of finally included patients was similar to the estimate (54)</LI>
<LI>Confounding factors: NS</LI>
<LI>The full text was published at a conference</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 16:10:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2010">
<CHAR_METHODS MODIFIED="2014-04-10 14:46:37 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: November 2006 to January 2008</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:40 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: China</LI>
<LI>Setting: NS</LI>
<LI>Patients with biopsy-proven IMN with severe NS (urinary protein excretion &gt; 5 g/24 h or albumin &lt; 25 g/L) or kidney dysfunction</LI>
<UL>
<LI>Pathology stage: NS</LI>
<LI>Proteinuria (g/24 h): &gt; 5.0</LI>
<LI>Hypertension: NS</LI>
<LI>Serum albumin: NS</LI>
<LI>SCr: NS</LI>
<LI>GFR: NS</LI>
<LI>Baseline declining kidney function: some patients had kidney dysfunction</LI>
<LI>Use of ACEi or ARB during follow-up: NS</LI>
<LI>Previous immunosuppressive status: NS</LI>
</UL>
<LI>Number: treatment group 1 (11); treatment group 2 (12)</LI>
<LI>Mean age ± SD (years): treatment group 1 (55.0 ± 13.5); treatment group 2 (54.6 ± 13.5)</LI>
<LI>Sex (M/F): treatment group 1 (6/5); treatment group 2 (9/4)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-15 21:30:44 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>FK506 + steroids</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>CPA +steroids</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 14:50:05 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Final proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 14:50:21 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Baseline comparison: comparable</LI>
<LI>Follow-up period: 9 months</LI>
<LI>Funding information: NS</LI>
<LI>Sample size calculation: NS</LI>
<LI>Confounding factors: NS</LI>
<LI>Only abstract was available and unpublished data were not used</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AZA - azathioprine, BP - blood pressure; ACEi - angiotensin converting enzyme inhibitors; ACTH - adrenocorticotropic hormone; ARB - angiotensin receptor blockers; CPA - cyclophosphamide; CSA - cyclosporine; GFR - glomerular filtration rate; IMN - idiopathic membranous nephropathy; IV - intravenous; NS - not stated; RCT - randomised controlled trial; SC - subcutaneous; SCr - serum creatinine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-10-09 10:56:57 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-10-09 08:30:38 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alexopoulos-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 08:30:38 +1100" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-22 15:30:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ambalavanan-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-22 15:30:22 +1000" MODIFIED_BY="[Empty name]">
<P>This RCT with cross-over design compared the efficacy of CSA versus ACEi in the treatment of adult IMN and secondary membranous nephropathy. We could not determine the number of patients with IMN in each intervention group. The first period of the cross-over was only 3 months (&lt; 6 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-22 16:12:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Austin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-22 16:12:57 +1000" MODIFIED_BY="[Empty name]">
<P>A pilot uncontrolled trial to investigate the effects of sirolimus on adult IMN patients with nephrotic syndrome. This study was prematurely terminated owing to the unfavourable risk-benefit ratio</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-22 13:51:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-22 13:51:50 +1000" MODIFIED_BY="[Empty name]">
<P>A RCT compared prednisone and supportive treatment in patients with nephrotic syndrome; we could not determine the number of patients diagnosed with IMN and nephrotic syndrome in each intervention group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-08 10:52:12 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dominguez_x002d_Gil-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-08 10:52:12 +1100" MODIFIED_BY="[Empty name]">
<P>A retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-28 12:12:32 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-du-Buf_x002d_Vereijken-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-13 13:58:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>A controlled clinical trial of one treatment group versus one historical control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:33 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edefonti-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:33 +1100" MODIFIED_BY="[Empty name]">
<P>RCT compared CSA to CPA in patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome; only 35/66 patients received renal biopsy and all patients were diagnosed with minimal change nephropathy and focal segmental glomerulosclerosis. No IMN were included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:46 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goumenos-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:46 +1100" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:49 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lagrue-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:49 +1100" MODIFIED_BY="[Empty name]">
<P>RCT compared chlorambucil, AZA and placebo; we could not determine the number of patients diagnosed with IMN and nephrotic syndrome in each intervention group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-08 12:11:38 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-08 12:11:38 +1100" MODIFIED_BY="[Empty name]">
<P>A prospective non-randomised cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:42 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Majima-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:42 +1100" MODIFIED_BY="[Empty name]">
<P>RCT compared prednisone with non-prednisone in the treatment of IMN; we could not determine whether all included patients had the diagnosis of nephrotic syndrome. The age of included patients were not available for us to make sure they were all adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-22 13:48:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Michail-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-22 13:48:02 +1000" MODIFIED_BY="[Empty name]">
<P>It was unclear whether randomisation was used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:52 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MRCWP-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:52 +1100" MODIFIED_BY="[Empty name]">
<P>RCT compared AZA with prednisone in CKD; we could not determine the number of patients with IMN and nephrotic syndrome in each intervention group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nand-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:39 +1100" MODIFIED_BY="[Empty name]">
<P>RCT evaluated the efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis; we could not determine the number of patients with IMN and nephrotic syndrome in each intervention group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:36 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plavljanic-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:36 +1100" MODIFIED_BY="[Empty name]">
<P>RCT compared methylprednisolone plus CPA to no treatment in patients with MN; it was uncertain that MN were idiopathic or secondary. The clinical diagnosis of nephrotic syndrome was also unclear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 08:30:34 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Polenakovic-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 08:30:34 +1100" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:57 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ponticelli-1993a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:57 +1100" MODIFIED_BY="[Empty name]">
<P>RCT compared the efficacy and safety of CSA with those of supportive therapy in patients with steroid-resistant idiopathic nephrotic syndrome; all patients were diagnosed with minimal change nephropathy and focal segmental glomerulosclerosis. No IMN were included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 08:30:29 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rashid-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 08:30:29 +1100" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:26 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sahay-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:26 +1100" MODIFIED_BY="[Empty name]">
<P>RCT compared the Ponticelli regimen, ACEi and non-specific treatment; the number of patients in each comparison group was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:28 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shilov-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:28 +1100" MODIFIED_BY="[Empty name]">
<P>RCT included 12 membranous nephropathy, 16 mesangial proliferative glomerulonephropathy, 3 mesangiocapillary glomerulonephropathy. We could not determine the number of patients with IMN and nephrotic syndrome in each intervention group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:30 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:30 +1100" MODIFIED_BY="[Empty name]">
<P>RCT compared 24-month tacrolimus plus steroids with 6-month tacrolimus plus steroids in 20 adults diagnosed as IMN and nephrotic syndrome. The recruiting of patients was from March 2004 to August 2007; the publication of this study was submitted to that journal on Februray 2008. Thus, we concluded that some of randomised patients did not complete the 24-month treatment of tacrolimus plus steroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 10:56:16 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tejani-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 10:56:16 +1100" MODIFIED_BY="[Empty name]">
<P>Participants were children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-09 08:30:26 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yao-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-09 08:30:26 +1100" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ACEi - angiotensin-converting enzyme inhibitors; ARB - angiotensin receptor blockers; AZA - azathioprine; CPA - cyclophosphamide; CKD - chronic kidney disease; CSA - cyclosporine; IMN - idiopathic membranous nephropathy; RCT - randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-10-09 11:12:08 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-04-22 15:33:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Appel-2002">
<CHAR_METHODS MODIFIED="2014-04-10 16:47:09 +1000" MODIFIED_BY="Narelle S Willis">
<P>Phase II double-blind, placebo-controlled RCT of the effect of h5G1.1-mAb on the reduction of proteinuria</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:47:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>Adults (18 years of age and older) IMN</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 15:33:13 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: infusion of h5G1.1-mAb every 2 weeks</P>
<P>Group 2: alternating infusions of h5G1.1-mAb and placebo every 2 weeks</P>
<P>Group 3: infusion of placebo every 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-09 03:57:36 +1100" MODIFIED_BY="[Empty name]">
<P>Not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 16:47:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>End data: 01/06/2005. A preliminary analysis results were available in a published abstract in 2002; no data were available to be included in this meta-analysis</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-10-09 11:11:46 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berg-2007">
<CHAR_METHODS MODIFIED="2014-04-10 16:45:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>Open-label RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 15:03:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>IMN</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 15:03:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Depot preparation of a synthetic fragment of ACTH versus no specific treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-09 11:11:46 +1100" MODIFIED_BY="[Empty name]">
<P>The primary outcomes were complete remissions and the combination of complete and partial remissions at the end of the treatment period (nine months after study start) and at the end of the follow-up period (21 months after study start)<BR/>
</P>
<P>The secondary outcomes were the changes at the end of the treatment period and the end of the follow-up period, as compared to baseline, in the serum concentrations of albumin, creatinine, apolipoprotein A1, apolipoprotein B and lipoprotein(a), the urinary excretion/24 h of albumin, immunoglobulin G and protein HC, glomerular filtration rate and mean arterial pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 15:03:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>Anticipated completion before 31/01/2005</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-04-22 16:10:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaskin-2004">
<CHAR_METHODS MODIFIED="2014-04-10 16:44:54 +1000" MODIFIED_BY="Narelle S Willis">
<P>National RCT (All UK renal units were invited to participate)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:10:48 +1000" MODIFIED_BY="[Empty name]">
<P>IMN with declining kidney function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-06 05:52:36 +1100" MODIFIED_BY="[Empty name]">
<P>Immunosuppressive therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 16:10:53 +1000" MODIFIED_BY="[Empty name]">
<P>Kidney function (GFR); proteinuria; adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 16:35:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>End date: 01/06/2005</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-10-09 11:11:55 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hirayama-2006">
<CHAR_METHODS MODIFIED="2014-04-10 16:35:00 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:35:09 +1000" MODIFIED_BY="Narelle S Willis">
<P>IMN in adults with nephrotic syndrome</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 16:37:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>CSA with/without low-dose prednisolone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-09 11:11:55 +1100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: rates of patients with complete remission or partial remission, and rates of patients with relapse or recurrence by urinary examinations at the follow-up clinic visiting until 24 months after the initiation of the treatment<BR/>Secondary outcome: excretion of urinary protein (g/d), serum levels of protein and albumin (mg/dL), CrCl (mL/min), SCr level (mg/dL), adverse effects until 24 months after the initiation of the treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 16:34:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Completed before 18/11/2009</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-10-09 08:31:43 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Howman-2012">
<CHAR_METHODS MODIFIED="2014-04-10 16:45:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre open label RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:04:17 +1000" MODIFIED_BY="[Empty name]">
<P>120 patients aged between 18 and 75 years, with IMN</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-09 08:31:43 +1100" MODIFIED_BY="[Empty name]">
<P>120 (40 in each group), interim follow-up at 2 years, final follow-up at 5 years</P>
<P>Randomisation will be between three groups</P>
<P>Group 1: Supportive treatment only</P>
<P>Grou 2: 12 months treatment with CSA</P>
<P>Grou 3: 6 months treatment with a combination of prednisolone and chlorambucil</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 16:46:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>Change in GFR with a further decline of 20% being an end-point. Secondary outcome measures include proteinuria and adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 16:46:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Completed in 31/03/2009. Added 23/09/09: Closed to recruitment, 108 recruited, in follow-up</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-04-22 16:19:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2006">
<CHAR_METHODS MODIFIED="2014-04-10 16:35:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:44:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>Biopsy-proven IMN. Nephrotic syndrome with proteinuria (&gt; 4 g/d) and serum albumin &lt; 30 g/dL. Age 18-60 years with informed consent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 16:19:26 +1000" MODIFIED_BY="[Empty name]">
<P>Tacrolimus versus IV CPA pulse</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 16:10:57 +1000" MODIFIED_BY="[Empty name]">
<P>Proteinuria, kidney function, and adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 16:44:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary completion date: December 2008 (final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-10-09 11:12:08 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2007">
<CHAR_METHODS MODIFIED="2014-04-10 16:44:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-09 11:12:06 +1100" MODIFIED_BY="[Empty name]">
<P>Biopsy-proven IMN nephrotic syndrome with proteinuria (&gt; 4 g/d) and serum albumin &lt; 30 g/dL. Age over 18 with informed consent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-09 08:31:08 +1100" MODIFIED_BY="[Empty name]">
<P>Tripterygium Wilfordii (TW) versus valsartan</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 15:32:49 +1000" MODIFIED_BY="[Empty name]">
<P>Not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-09 11:12:08 +1100" MODIFIED_BY="[Empty name]">
<P>Primary completion date: March 2009 (Final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-10-09 11:08:55 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saito-2006">
<CHAR_METHODS MODIFIED="2014-04-10 16:47:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Parallel, open-label RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-06 01:56:50 +1100" MODIFIED_BY="[Empty name]">
<P>Membranous nephropathy with primary steroid resistant nephrotic syndrome</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-09 11:08:55 +1100" MODIFIED_BY="[Empty name]">
<P>Group 1: oral mizoribine once a day administration (150 mg) after breakfast for 2 years<BR/>Group 2: oral mizoribine 3 times a day administration (50 mg each) after meals for 2 years<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 16:10:58 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: urine protein excretion (g/d), remission status of nephrotic syndrome<BR/>Key secondary outcomes: kidney function (CrCl), serum total protein and albumin levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-10 16:48:25 +1000" MODIFIED_BY="Narelle S Willis">
<P>Last follow-up date was 2009/12</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>ACTH - adrenocorticotropic hormone; CPA - cyclophosphamide; CrCl - creatinine clearance; CSA - cyclosporine; GFR - glomerular filtration rate; IMN - idiopathic membranous nephropathy; RCT - randomised controlled trial; SCr - serum creatinine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-10-09 11:07:39 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-04-22 16:11:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ChiCTR_x002d_TRC_x002d_08000098">
<CHAR_STUDY_NAME MODIFIED="2014-04-22 15:34:34 +1000" MODIFIED_BY="[Empty name]">
<P>Research on integrated therapy of traditional Chinese medicine for membranous nephropathy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 16:48:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:51:55 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Diagnosed with IMN by renal biopsy</LI>
<LI>Age 18 to 75 years, without gender or nation restrict</LI>
<LI>CKD &#8804; phase 3 (GFR &gt; 30 mL/min), 24 h urinary albumin &#8805; 3.5 g </LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 16:51:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: integrated therapy of TCM</P>
<P>Group 2: prednisone and CPA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 16:11:04 +1000" MODIFIED_BY="[Empty name]">
<P>Kidney function and TCM symptoms and signs, blood, stool and urine routine, liver function and ECG, Serum lipid, GFR, and renal biopsy, 24 h urinary albumin, creatinine and serum albumin</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-06 04:59:13 +1100" MODIFIED_BY="[Empty name]">
<P>2007/12/01</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-04-10 16:53:25 +1000" MODIFIED_BY="Narelle S Willis">
<P>Yueyi Deng, Yiping Chen, Tel: +86 021 28333352, +86 0 13661791159, Fax: +86 021 64871762, +86 021 54363399, dengyueyi@medmail.com.cn, chenyplonghua@medmail.com.cn, No.725, Wanping South Road, Shanghai, 200032, Longhua Hospital Affiliated to Shanghai University of TCM</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-22 15:34:52 +1000" MODIFIED_BY="[Empty name]">
<P>Recruiting in December 2011</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:02:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ChiCTR_x002d_TRC_x002d_11001144">
<CHAR_STUDY_NAME MODIFIED="2014-04-10 16:53:48 +1000" MODIFIED_BY="Narelle S Willis">
<P>A prospective randomized study on the efficacy of steroid combined with CTX or tacrolimus in IMN patients with NS</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 16:53:55 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:55:45 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>IMN patients proven by biopsy within 24 weeks</LI>
<LI>24 h urinary protein excretion at admission &#8805; 5 g or serum albumin &lt; 25 g/L</LI>
<LI>The patient had renal insufficiency defined as CKD 2-3 stage with moderate proteinuria or severe NS with pleural effusion, ascites, renal venous thrombosis</LI>
<LI>Nephrotic syndrome patients without severe oedema, follow-up 3 months, 24 h urinary protein excretion &gt; 5 g or serum albumin &lt; 25 g/L</LI>
<LI>Written informed consent</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 16:55:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: CPA + prednisone</P>
<P>Group 2: Tacrolimus + prednisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 16:56:04 +1000" MODIFIED_BY="Narelle S Willis">
<P>24 h urinary protein excretion, SCr, and serum albumin</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-06 05:11:31 +1100" MODIFIED_BY="[Empty name]">
<P>2008/01/01</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-04-22 16:02:44 +1000" MODIFIED_BY="[Empty name]">
<P>Chen Nan, Zhang Wen, Tel: +86 021 64370045, Fax: +86 021 64456419, chen-nan@medmail.com.cn, zhangwen255@163.com, nephrology department, Shanghai Jiaotong university affiliated Ruijin hospital, No.197, Ruijin NO.2 Road, Luwan District, Shanghai, 200025, China</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-22 15:35:10 +1000" MODIFIED_BY="[Empty name]">
<P>Recruiting in December 2011</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 15:36:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CTRI_x002f_2010_x002f_091_x002f_000231">
<CHAR_STUDY_NAME MODIFIED="2014-04-10 16:56:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Comparison of efficacy of tacrolimus versus cyclophosphamide in idiopathic membranous nephropathy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 16:56:31 +1000" MODIFIED_BY="Narelle S Willis">
<P>Clinical controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:57:52 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Adults (age &gt; 18 y)</LI>
<LI>Nephrotic range proteinuria (urine P/Cr ratio &gt; 3 g/d)</LI>
<LI>Biopsy-proven primary membranous glomerulonephritis (IMN)</LI>
<LI>GFR &gt; 30 mL/min (MDRD)</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 16:58:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: Tacrolimus + prednisolone: tacrolimus (0.1 mg/kg/d); prednisolone (0.5 mg/kg/d)</P>
<P>Group 2: CPA + prednisolone: CPA (2 mg/Kg/d); prednisolone (0.5 mg/kg/d)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 16:58:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not specified</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-06 02:10:21 +1100" MODIFIED_BY="[Empty name]">
<P>04/05/2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-04-22 15:36:14 +1000" MODIFIED_BY="[Empty name]">
<P>Dr SK Agarwal and Dr PM Dogra, Dept of Nephrology, 4th Floor, AIIMS, Ansari Nagar 110029 New Delhi, DELHI India, Telephone: 01126594911, Email: skagarwal58@yahoo.co.in and dodgemanu@gmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-12-06 02:12:49 +1100" MODIFIED_BY="[Empty name]">
<P>Open to Recruitment in December 2011</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:16:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2007_x002d_005410_x002d_39_x002d_ES">
<CHAR_STUDY_NAME MODIFIED="2012-05-30 23:59:01 +1000" MODIFIED_BY="[Empty name]">
<P>Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática - MEMTAC</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-05-30 23:59:11 +1000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:43:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>IMN</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 16:16:57 +1000" MODIFIED_BY="[Empty name]">
<P>tacrolimus versus CPA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 16:59:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Efficacy and safety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-05-31 00:00:50 +1000" MODIFIED_BY="[Empty name]">
<P>11/06/2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-05-31 00:42:58 +1000" MODIFIED_BY="[Empty name]">
<P>Spain</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-05-31 00:01:32 +1000" MODIFIED_BY="[Empty name]">
<P>None</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:11:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-JPRN_x002d_UMIN000001099">
<CHAR_STUDY_NAME MODIFIED="2011-12-06 01:15:36 +1100" MODIFIED_BY="[Empty name]">
<P>Optimal use of cyclosporine in idiopathic membranous nephropathy associated with nephrotic syndrome</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 16:59:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Parallel open RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:43:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>IMN associated with nephrotic syndrome</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 16:59:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: Steroid + CSA</P>
<P>Group 2: Steroid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 16:11:12 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: quantity of urinary protein, frequency of relapse, kidney function (SCr, eGFR), time to remission, total dose of steroid (until remission)<BR/>Key secondary outcomes: adverse effects of steroid and CSA, total dose of steroid (in all treatment period), duration of hospitalisation, serum albumin, serum total protein, serum total cholesterol, degree of oedema</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-06 01:19:20 +1100" MODIFIED_BY="[Empty name]">
<P>2007/07</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-12-06 01:17:21 +1100" MODIFIED_BY="[Empty name]">
<P>Masaaki Izumi, Hyogo College of Medicine, Division of Kidney and Dialysis, Department of Internal Medicine, 1-1, Mukogawa, NIshinomiya, Hyogo, Japan, TEL +81-798-45-6521, Email izumi@hyo-med.ac.jp</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-12-06 01:19:33 +1100" MODIFIED_BY="[Empty name]">
<P>Last follow-up date: 2010/07</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:11:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-JPRN_x002d_UMIN000006939">
<CHAR_STUDY_NAME MODIFIED="2012-05-31 00:41:43 +1000" MODIFIED_BY="[Empty name]">
<P>High-dose gamma-globulin therapy for nephrotic membranous nephropathy patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:00:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>Parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 23:29:03 +1000" MODIFIED_BY="[Empty name]">
<P>Nephrotic membranous nephropathy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 17:01:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Immunoglobulin versus ARB or ACEi with or without statin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 16:11:13 +1000" MODIFIED_BY="[Empty name]">
<P>Remission rate, alteration of proteinuria or kidney function, complication of infectious diseases or cardiovascular diseases</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-05-30 23:30:38 +1000" MODIFIED_BY="[Empty name]">
<P>2012/02/01</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-05-30 23:32:04 +1000" MODIFIED_BY="[Empty name]">
<P>Hitoshi Yokoyama, Kanazawa Medical University Hospital Nephrology, 1-1 Daigaku, Uchinada, Ishikawa, Japan, Telephone: 076-286-2211(3401), Email: h-yoko@kanazawa-med.ac.jp</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-05-30 23:31:09 +1000" MODIFIED_BY="[Empty name]">
<P>Not yet recruiting in May 2012</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-10 17:06:57 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-NCT00805753">
<CHAR_STUDY_NAME MODIFIED="2014-04-10 17:05:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>A dose-finding pilot study of ACTH on the serum lipoprotein profile and proteinuria in patients with idiopathic membranous nephropathy (MN)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:05:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 17:05:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>IMN with diagnostic biopsy performed &lt; 36 months from the time of dose randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 17:06:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: ACTH 40 units subcutaneously for up to 12 weeks. If at day 91 no response has been shown, you will have the option to increase the dose of ACTH to 80 units for up to an additional 120 days</P>
<P>Group 2: ACTH 80 units subcutaneously for up to 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 17:06:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcome measures: change in proteinuria, change in LDL cholesterol, HDL cholesterol, and triglycerides, and side effects/toxicity<BR/>Secondary outcome measures: complete or partial remission, and the effect of maximizing angiotensin II blockade on proteinuria<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-05 22:53:00 +1100" MODIFIED_BY="[Empty name]">
<P>January 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-04-10 17:06:48 +1000" MODIFIED_BY="Narelle S Willis">
<P>Lori Riess 507-266-1047 riess.lori@mayo.edu; Shirley Jennison 507-255-0231 jennison.shirley@mayo.edu; Fernando C. Fervenza, M.D., Ph.D</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-10 17:06:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Estimated primary completion date: December 2011 (final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:11:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00843856">
<CHAR_STUDY_NAME MODIFIED="2014-04-22 15:37:35 +1000" MODIFIED_BY="[Empty name]">
<P>Mycophenolate mofetil and tacrolimus vs tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:07:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-05 22:40:54 +1100" MODIFIED_BY="[Empty name]">
<P>Idiopathic membranous glomerulonephritis on renal biopsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 17:07:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: tacrolimus</P>
<P>Group 2: tacrolimus and MMF</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 16:11:16 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures: efficacy of MMF in preventing relapse of nephrotic syndrome secondary to membranous glomerulonephritis on withdrawal of tacrolimus therapy. This will be initially measured at 6 months post withdrawal of tacrolimus therapy<BR/>Secondary outcome measures: the time to obtaining remission from proteinuria. The degree of remission of proteinuria obtained (complete or partial). The rate of decline of kidney function measured by the MDRD equation for GFR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-05 22:41:17 +1100" MODIFIED_BY="[Empty name]">
<P>February 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-12-06 01:15:57 +1100" MODIFIED_BY="[Empty name]">
<P>Megan E Griffith, MB ChB (hons) PhD 02083835272 megan.griffith@imperial.nhs.uk; Tom D Cairns 02083835272 tom.cairns@nhs.net</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-10 17:08:04 +1000" MODIFIED_BY="Narelle S Willis">
<P>Estimated primary completion date: February 2014 (final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:16:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01093157">
<CHAR_STUDY_NAME MODIFIED="2014-04-10 17:25:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>A dose-finding pilot study of ACTH (adrenocorticotropic hormone) on the proteinuria and serum lipoprotein profile in patients with idiopathic membranous nephropathy (MN)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:09:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 17:09:09 +1000" MODIFIED_BY="Narelle S Willis">
<P>IMN with diagnostic biopsy performed less than 36 months from the time of dose randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 16:16:21 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: ACTH (HP Acthar gel) 40 units</P>
<P>Group 2: ACTH (HP Acthar gel) 80 units</P>
<P>Note: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice/wk over a total of three months exposed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 17:10:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcome measures: change in proteinuria from baseline to value at 3 months.<BR/>Secondary outcome measures: complete remission or partial remission at 3 months and adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-05 22:33:19 +1100" MODIFIED_BY="[Empty name]">
<P>February 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-12-05 22:34:14 +1100" MODIFIED_BY="[Empty name]">
<P>Daniel Cattran, MD 416-340-4187; Paul Ling 416-340-3514</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-22 16:15:40 +1000" MODIFIED_BY="[Empty name]">
<P>Estimated primary completion date: August 2011 (Final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-10 17:12:02 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-NCT01161459">
<CHAR_STUDY_NAME MODIFIED="2014-04-10 17:10:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment of idiopathic membranous nephropathy with Tripterygium wilfordii plus steroid vs tacrolimus plus steroid</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:10:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:43:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>Biopsy-proven IMN</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 17:10:54 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: Tripterygium wilfordii plus steroid</P>
<P>Group 2: tacrolimus plus steroid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 17:11:47 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcome measures: the number of complete remission and partial remission<BR/>Secondary outcome measures: number of participants with adverse events as a measure of safety and tolerability steroid</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-05 22:25:57 +1100" MODIFIED_BY="[Empty name]">
<P>June 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-12-05 22:27:06 +1100" MODIFIED_BY="[Empty name]">
<P>Ke Zuo, Master 00862580860734 ext 210002 alexzuo_3000@yahoo.com.cn</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-10 17:12:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>Estimated primary completion date: November 2011 (final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:15:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01180036">
<CHAR_STUDY_NAME MODIFIED="2014-04-10 17:12:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>A randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (IMN)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:12:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 17:12:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>IMN with diagnostic biopsy performed within the past 36 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 17:12:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: rituximab</P>
<P>Group 2: CSA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 17:14:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcome measures: remission status<BR/>Secondary outcome measures: remission status</P>
<P>Note: complete remission or partial remission, and complete remission alone at 6, 12, 18, 24, and 27 months. Frequency of and time to relapse rate of change in urinary protein at 6 and 12 months and beyond time to complete remission or partial remission and to complete remission alone. Toxicity quality of life as measured by SF-36 frequency of PRA2 antibodies and its relation to therapy and proteinuria response</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-05 22:19:17 +1100" MODIFIED_BY="[Empty name]">
<P>May 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-12-05 22:20:07 +1100" MODIFIED_BY="[Empty name]">
<P>Fernando C Fervenza, M.D., Ph.D. 507-266-7083 fervenza.fernando@mayo.edu; Shirley A Jennison 507-255-0231 jennison.shirley@mayo.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-22 16:15:41 +1000" MODIFIED_BY="[Empty name]">
<P>Estimated primary completion date: January 2015 (Final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:14:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01282073">
<CHAR_STUDY_NAME MODIFIED="2014-04-10 17:14:48 +1000" MODIFIED_BY="Narelle S Willis">
<P>A randomized controlled multi-center trial of mycophenolate mofetil for the patient with high risk membranous nephropathy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:14:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:43:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Patients with IMN</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 17:15:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: MMF + low dose steroid</P>
<P>Group 2: CSA + low dose steroid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 17:15:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcome measures: percentage of complete and partial remission<BR/>Secondary outcome measures: eGFR, relapse, proteinuria, and side effects</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-05 22:11:42 +1100" MODIFIED_BY="[Empty name]">
<P>March 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-12-05 22:11:57 +1100" MODIFIED_BY="[Empty name]">
<P>Se-Hee Yoon, MD +82-11-9403-9623 sehei@hanmail.net</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-22 16:14:52 +1000" MODIFIED_BY="[Empty name]">
<P>Estimated primary completion date: March 2013 (Final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-10-09 11:07:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01386554">
<CHAR_STUDY_NAME MODIFIED="2014-10-09 11:07:39 +1100" MODIFIED_BY="[Empty name]">
<P>A randomized, placebo-controlled, parallel-group, double-blind study of H.P. Acthar gel (Acthar) in treatment-resistant subjects with persistent proteinuria and nephrotic syndrome due to idiopathic membranous nephropathy (IMN)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:16:55 +1000" MODIFIED_BY="Narelle S Willis">
<P>Parallel, placebo-controlled RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-22 16:11:17 +1000" MODIFIED_BY="[Empty name]">
<P>A history of nephrotic syndrome due to IMN as confirmed by documented results from a kidney biopsy performed within 4 years prior to screening</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-10 17:17:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>Group 1: 0.5 mL acthar</P>
<P>Group 2: 0.5 mL placebo</P>
<P>Group 3: 1.0 mL acthar</P>
<P>Group 4: 1.0 mL placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 17:17:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcome measures: complete or partial remission in proteinuria<BR/>Secondary outcome measures: proportion of subjects that have sustained complete or partial remission<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-05 22:01:38 +1100" MODIFIED_BY="[Empty name]">
<P>August 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-12-05 22:20:20 +1100" MODIFIED_BY="[Empty name]">
<P>Jay Elliott, PhD (513) 579-9911 ext 2032 j.elliott@medpace.com; Mary Nyberg, MBA (410) 480-7500 ext 315 mnyberg@questcor.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-10 17:17:47 +1000" MODIFIED_BY="Narelle S Willis">
<P>Estimated primary completion date: March 2013 (final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-04-22 16:14:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01508468">
<CHAR_STUDY_NAME MODIFIED="2014-04-10 17:18:01 +1000" MODIFIED_BY="Narelle S Willis">
<P>Evaluate rituximab treatment for idiopathic membranous nephropathy (GEMRITUX)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-04-10 17:18:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre open-label RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-10 16:43:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>IMN proved by renal biopsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 23:13:01 +1000" MODIFIED_BY="[Empty name]">
<P>Rituximab and symptomatic treatment versus symptomatic treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-10 17:18:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcomes: rate of proteinuria<BR/>Secondary outcomes: progression of CKD, Percentage of proteinuria variation, percentage of nephrotic syndrome complication, rituximab tolerance in IMN at 3 and 6 months</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-05-30 23:14:28 +1000" MODIFIED_BY="[Empty name]">
<P>January 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-05-30 23:16:22 +1000" MODIFIED_BY="[Empty name]">
<P>Karine Dahan, MD, + 33 (0) 1 56 01 66 39, karine.dahan@tnn.aphp.fr, department of Nephrology, Tenon hospital Paris, France</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-22 16:14:41 +1000" MODIFIED_BY="[Empty name]">
<P>Estimated primary completion date: July 2014 (Final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>ACEi - angiotensin converting enzyme inhibitors; ACTH - adrenocorticotropic hormone; ARB - angiotensin receptor blockers; CKD - chronic kidney disease; CPA - cyclophosphamide; CrCl - creatinine clearance; CSA - cyclosporine; ECG - electrocardiogram, eGFR - estimated glomerular filtration rate; GFR - glomerular filtration rate; IMN - idiopathic membranous nephropathy; P/Cr - protein/creatinine; RCT - randomised controlled trial; SCr - serum creatinine; TCM - traditional Chinese medicine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-04-22 16:10:31 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-04-22 16:10:16 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:26:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:59:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:48:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:44:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 15:13:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>The patients were randomised into one of the two treatment groups (1986 to 1990) using sealed envelopes that contained the treatment protocol and that were numbered according to a table of randomisation. The study group decided to change the randomisation protocol in 1990 by adding a control group to the two treatment arms. Patients were then randomised into one of the two treatment groups or the control group (1991 to 1996) using a computer based-randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:51:04 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 10:47:49 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Randomization was performed centrally, and coded tablets given locally from bottles supplied from the coordinator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:57:39 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Patients were assigned by the study coordinator in Toronto Glomerulonephritis Registry according to a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:55:12 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>The patients were randomly assigned to either CSA or placebo in blocks stratified by centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:29:00 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Randomization was performed by the clinical coordinating centre from a table of random numbers and was stratified by centre in blocks of two to ensure a balance between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:46:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>No information provided. However, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:02:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Randomization was performed by a clinical coordinating centre using a table of random numbers and was stratified by centres<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:23:53 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Immediately after admission to the study, patients were randomly allocated to prednisone or placebo. Randomization was stratified according to initial histologic diagnosis with the light microscope (before review by the Central Pathology Board) in the participating hospital. No further information was provided, however, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:38:44 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Only after a patient was deemed eligible was the treatment ascertained by referral to a list created from a table of random numbers (by WFT). The table was maintained by the renal pathologist (KEH) and was not seen by the clinicians (JVD. and CFA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:53:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>Randomization was performed by each centre through a centralized Internet on-line application provided by the sponsor (minimization method). Randomization was stratified according to sex and centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:52:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 16:10:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>All patients were randomised under the same computer generated randomisation table through the central Glomerular Disease Collaborative Network office. Patients were stratified on the basis of whether they had deterioration in kidney function or persistent proteinuria with morbid complications</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 14:55:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>No information provided. However, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:16:42 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>For all patients, the indications for therapy were contained in sealed, completely opaque envelopes numbered in sequence according to a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:44:46 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:04:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:10:56 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:26:40 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 17:20:39 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 10:48:11 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement. However, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:24:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:33:26 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:24:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>The coordinating centre assigned the patients consecutively to one of the two treatment regimens in random order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:42:11 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>At the coordinating centre, patients were assigned consecutively to one of the two treatment regimens, according to a centre-stratified random order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:19:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>The coordinating centre assigned patients consecutively by telephone to 1 of the 2 treatment regimens in a centralized randomised order, with assignation produced by a table from a statistical textbook</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:28:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Randomization was performed by the clinical coordinating centre using a table of random numbers and was stratified by centres</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:01:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>No information was provided, however, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:09:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:22:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Treatment allocation was on the basis of minimization, using the following parameters: (MN or FSGS), sex and GFR. Minimization is a valid alternative to randomisation, and ensures uniformity between the two groups with respect to the characteristics used in the allocation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:27:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:36:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement. However, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 18:24:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Patients stratified centrally according to the clinical characteristics during the pre-treatment phase</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:45:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:59:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:26:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:59:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:48:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:44:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:57:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Randomisation method described could usually not allow investigators/participants to know or influence intervention group before eligible participant entered in the study. But the authors failed to clarify the randomisation was centrally performed and it was possible for investigators to open the sealed envelopes in advance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:51:05 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Central Randomisation method described could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:57:38 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Randomisation method described could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:08:53 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Central Randomisation method described could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:55:00 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:29:06 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Central randomisation method described could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:46:49 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Patients who satisfied the selection criteria were randomised by drawing envelope into either one of two treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:02:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Allocation concealment was performed by enclosing assignments in sequentially numbered, opaque-closed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:23:54 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:38:45 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Neither patient nor clinician knew what treatment was going to be given before the patient agreed to enter study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:53:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>Central randomisation method described could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:52:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 16:06:07 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Central randomisation method described could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 14:55:39 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:16:44 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Randomisation method described could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:44:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:04:23 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:10:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:26:42 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 17:20:40 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 10:48:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>After consent was obtained from patient, randomisation was performed by opening sealed envelops</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:24:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:33:27 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:24:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Central Randomisation method described could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:42:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Central Randomisation method described above could not allow investigators/participants to know or influence intervention group before eligible participant entered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:19:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>The sequence was concealed until intervention was assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:28:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Allocation concealment was performed by enclosing assignments in sequentially numbered, opaque-closed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:01:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:10:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:22:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:27:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:36:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Closed-envelope technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 18:23:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Central trial coordinator will randomly allocate eligible patients after stratification</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:45:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:59:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>No sufficient detail about concealment of the random allocation sequence before or during enrolment of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of participants (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:26:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:32:27 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:48:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:44:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:57:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:51:06 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 10:47:52 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Identical tablets contained either 5mg of prednisolone or placebo. It could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:08:55 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:55:01 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>The patients were masked in regards to their assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:29:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>The patients were masked in regards to CSA versus placebo assignment. Novartis Canada Ltd. (Whitby, Ontario, Canada) provided CSA in a drink solution (100 mg/mL) and an identical placebo made from the same carrier</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:46:51 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:02:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:24:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Patients were assigned without the knowledge of either the patient or physician to prednisone therapy or identical placebo control tablets (supplied by the Upjohn Company)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:38:46 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>No placebo was used and no blinding was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:53:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:53:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 16:06:08 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 14:55:40 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:17:03 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:44:50 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:04:24 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:10:59 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:26:43 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 17:20:41 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 10:48:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:24:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:33:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>No information provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:24:51 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>No information provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:42:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:19:39 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:28:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:01:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:10:01 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:22:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:27:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:36:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Double-Blind. Only the pharmacist knew which tablets were AZA and which were placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 18:24:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:45:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:59:17 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>It was claimed that double-blind was performed, we still judged that it could not be done because it was only published in the conference abstract and there was no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:26:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:32:33 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:49:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:44:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:57:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:51:07 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 10:47:53 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Identical tablets contained either 5mg of prednisolone or placebo. It could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:08:55 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:55:02 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>The patients were masked in regards to their assignment, but for safety reasons the physician in charge was not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:29:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>The physicians were not masked in regards to CSA versus placebo assignment for safety reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:46:51 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:02:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:24:04 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Patients were assigned without the knowledge of either the patient or physician to prednisone therapy or identical placebo control tablets (kindly supplied by the Upjohn Company)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:38:47 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>No placebo was used and no blinding was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:53:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:53:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 16:06:09 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 14:55:41 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:17:04 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:44:50 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:04:25 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:11:00 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:26:44 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 17:20:42 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 10:48:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:24:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:33:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>No information provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:24:51 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>No information provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:42:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:19:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:28:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:01:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:10:02 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:22:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:27:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:36:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Double-Blind. Only the pharmacist knew which tablets were AZA and which were placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 18:25:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:45:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:59:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>It was claimed that double-blind was performed, we still judged that it could not be done because it was only published in the conference abstract and there was no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-03 14:26:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-17 17:32:37 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-17 17:49:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-04 18:44:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-04 18:57:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-09 16:51:07 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 10:47:54 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Identical tablets contained either 5mg of prednisolone or placebo. It could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 11:08:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 11:55:03 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>No information provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 14:29:30 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>The end points were objective and measured centrally by a lab blinded to patient designation. No further information was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 14:46:54 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 15:02:23 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 15:24:07 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>No further information was provided, however, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 15:38:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>No placebo was used and no blinding was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 15:53:24 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-17 17:53:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-08 16:06:10 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-09 14:55:42 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-09 15:17:05 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-09 15:44:51 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-09 16:04:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-09 16:11:01 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>No information provided. However, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-09 16:26:47 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-09 17:20:43 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 10:48:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 11:24:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 11:33:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>No information provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 12:24:52 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>No information provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 12:42:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 13:19:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 13:28:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 14:01:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 14:10:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 14:22:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 14:27:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 14:36:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>No information provided, however, it could be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-17 18:25:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 14:45:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>No information was provided, however, it could not be done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-10 14:59:19 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>It was claimed that double-blind was performed, we still judged that it could not be done because it was only published in the conference abstract and there was no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-04-22 16:10:31 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 11:57:33 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-17 17:34:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-17 17:49:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 11:57:35 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-04 18:57:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>A total of 97/124 (78%) randomised patients were entered to the final analysis. Furthermore, of these 97 patients 18 were lost to follow-up and 11 did not complete the five-year follow-up. Eventually only 68/124 (55%) completed the five-year follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-09 16:51:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>21/22 (95%) randomised completed the treatment and were finally analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 10:47:58 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>4 patients (8%) in the treatment group were lost at 4, 6, 21, and 24 months and 3 (6%) in the placebo group at 9, 18, and 21 months. Their data to the point of loss have been included in the analysis on an intention-to-treat basis. No patient lost was in remission or had a plasma creatinine of over 400&#956;mol/L when lost. Thus, missing outcome data balanced in numbers across intervention groups and have been imputed using appropriate methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 11:09:10 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>27/158 (17%) patients were lost during follow-up of 48 months: 10/81 (12%) in the prednisolone group and 17/77 (22%) in the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 11:57:39 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 14:29:32 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>All patients except 2 patients completed the study. The reasons were relocation outside of North America and noncompliance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 14:46:55 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 15:05:20 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>A total of 13/73 patients (18%) did not finish the 12-month follow-up. 6/39 patients (15%) withdrew in the tacrolimus group (infection (3); severe gastrointestinal complaint (1); elevated aminotransferase (1); patient's intention (1)). In the CPA group 7/34 patients (21%) did not finish the follow-up: 3 patients withdrew (severe gastrointestinal complaint (1); elevated aminotransferase (1); patient's intention(1)) and 4 patients were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 15:24:09 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 15:39:32 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>2/11 patients (18%) in the CPA group and 1/11 patients (9%) in the no-drug group did not complete the 12-month follow-up. In 2 patients in the CPA group, the drug was stopped after 8 months, on the advice of the clinicians, when data analysis to that point revealed no treatment benefit either to these patients or to the 19 patients who had completed the study. 1 patient in the no-drug group was dropped from the study because the patient was not considered to have purely IMN</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 15:53:25 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>No patients were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-17 17:53:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-08 16:06:13 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Two (one in each group) patients had less than 18 months of follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-09 14:55:59 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>During the first year of the study, 3 patients were excluded because of the following reasons: discovery of a malignancy and withdrawal from the study within 3 months; protocol violation (start of prednisone by a physician in another hospital) and loss to follow-up due to emigration 7 months after randomisation. Thus, the final analysis included 26 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-22 15:21:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Four patients in the treatment group did not complete the 6-month therapy, these patients were continued to be followed up because of side effects. They were considered to be treated patients in the data analysis, according to the intention-to-treat principle. In the case of patients who died, data obtained before the time of death were included. 3/81 patients (3%) were lost to 5-year follow-up: two controls and one treated patient were lost to follow-up 22, 28, and 24 months after randomisation, respectively. At the second analysis, 9/42 (21%) treated patients and 10/39 (26%) controls were lost to follow-up from 12 to 96 months after randomisation. These 3 patients were also considered in the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-09 15:45:15 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>11/104 (11%) patients were lost to follow-up, 4/51 (8%) in treatment group and 7/53 (13%) in control group, between 18 to 48 month of randomisation and excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-09 16:04:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>No patient was lost to follow-up, and an intention-to-treat analysis was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-09 16:11:08 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Only 2/48 patients in the treatment group did not complete 24-week follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-09 16:26:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-09 17:21:10 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Only 3/84 patients (all in treatment group 2) losses to 12-month follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-22 16:10:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>All except 1 patient completed the 2 years of follow-up. One treatment group patient died 8 months after study entry, 2 months after cessation of CPA. As this patient had a severe nephrotic syndrome and was the only patient with progressive deterioration in kidney function, his death and consequent removal from the remainder of the study could have biased data at time points subsequent to 6 months in favour of a benefit of therapy. Accordingly, it was decided to enter dummy values for SCr and proteinuria. These dummy values were chosen so as to be higher (900 &#956;mol/L for SCr and 30g/24 h for proteinuria) than all the other patients at that time point, in order to ensure that any bias introduced due to the death of this patient would be against an effect of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 11:24:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 14:52:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>90 patients were randomised, only 71/90 (79%) were finally analysed. The missing outcome data were not balanced in numbers across intervention groups: 6/42 (14%) in CPA group and 13/48 (27%) in prednisolone group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 12:24:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Patients who could not complete treatment were included in the analysis according to the intention-to-treat principle. For the two patients who died and the one who was lost to follow-up, data obtained at the last observation were considered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-22 16:10:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>A total of 8/95 (8%) patients did not complete the 6-month regimen and then excluded in some final analyses: treatment group 1 (6/50), treatment group 2 (2/45). Two patients did not present at the follow-up visit and a 51-yr-old woman died because of a deep-vein thrombosis with acute kidney failure and cardiac shock 3 mo after the diagnosis of membranous nephropathy, before treatment was started. Four patients in treatment group 1 and one in treatment group 2, who completed the treatment, did not present at the follow-up visit and were considered lost to follow-up after the sixth month</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 13:19:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-22 15:26:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>A total of 8/48 (17%) randomised patients did not complete the 18-month regimen. Two patients of the treated group (personal decision because lack of response after 6 months of treatment and a partial seizure in a patient with history of epilepsy) and one of the control group (severe oedema six months after randomisation and deafness attributed to high-dose diuretics) withdrew from the study. Five patients (three in the control group and two in the treatment group) were lost to follow-up between 3 and 18 months after randomisation. But they were all included in the final analyses according to the intention-to-treat basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 14:01:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>18/20 patients completed the study. 2 (1 from each treatment group) immediately withdrew after assignment: one had to receive regular dialysis before treatment with methylprednisolone and CPA had begun, and the other became psychotic 2 weeks after starting prednisone treatment. Because these 2 patients received neither chlorambucil nor CPA, their data are not used for analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 14:10:04 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 14:23:02 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>1/11 patients in MMF group was lost to follow-up after 1.5 months and was included in the non-responder category</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 14:28:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Approximate 32% (8/25) of patients were lost in the two-year follow-up: 21% (3/14) in the mizoribine group and 45% (5/11) in the control group. The proportion of loses in the follow-up could have an substantial influence on the results. The reason for missing data were not specified and the missing data were not imputed using appropriate methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 14:36:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>All patients completed the study and there were no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-17 18:25:31 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 14:53:17 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>29/54 patients (54%) completed the 36-month follow-up: 14/27 (52%) in the treatment group and 15/27 (56%) in the control group. The missing numbers of patients were balanced and the missing reason was specified in each patient. The rate of loss to follow-up was high (54%), intention to treat principle was used to deal with these data to avoid potential bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-10 14:59:20 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>22 of 24 randomised patients completed the study. Only 2 patients in FK506 group dropped out at 2 years</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:27:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:33:33 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Data was unable to be extracted from the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:49:29 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Data could not be extracted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:44:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:57:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:51:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>The study protocol was available and it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 10:47:59 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:09:13 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:55:05 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:29:34 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:47:08 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:05:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:24:10 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:39:34 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:53:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:53:40 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Data could not be extracted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 16:06:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 14:56:08 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:17:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:45:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:04:28 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Only remission data were provided in that abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:25:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>The primary outcome such as death and ESKD were NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:26:49 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 17:21:11 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 10:48:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:24:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:34:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:24:54 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:43:52 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:19:43 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:28:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:03:04 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:10:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Only remission and final proteinuria data were provided in that abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:23:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:28:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Only complete or partial remission were reported. The primary outcome such as death and ESKD were not stated; side effects leading to patient withdrawal were not recorded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:36:39 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 18:25:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:45:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>The primary outcomes and key adverse effects were detailed in the publication, although other outcomes were not available to be included in this meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:59:22 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Only final proteinuria data were provided in that abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Selective reporting (reporting bias)-Death</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-11.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-03 14:27:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-03 14:59:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-17 17:49:43 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-04 18:44:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-04 18:57:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-09 16:51:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 10:48:00 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 11:09:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 11:55:06 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 14:29:36 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 14:47:09 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 15:05:27 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 15:24:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 15:39:35 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 15:53:27 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-17 17:53:43 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-08 16:06:15 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-09 14:56:10 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-09 15:17:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-09 15:45:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-09 16:04:28 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-09 16:11:13 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-09 16:26:50 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-09 17:21:12 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 10:48:54 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 11:24:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 11:34:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 12:24:55 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 12:43:52 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 13:19:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 13:28:57 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 14:03:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 14:10:06 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 14:23:04 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 14:28:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 14:36:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-17 18:25:51 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 14:45:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2014-04-10 14:59:23 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Selective reporting (reporting bias)-ESKD</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-12.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-03 14:27:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-03 14:59:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-17 17:49:50 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-04 18:44:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-04 18:57:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-09 16:51:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 10:48:01 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 11:09:15 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2011-11-09 01:53:19 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>Reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 14:29:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 14:47:10 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 15:05:28 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 15:24:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 15:39:36 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 15:53:28 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-18 15:32:50 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-08 16:06:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-09 14:56:11 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-09 15:17:50 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-09 15:45:20 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-09 16:04:29 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-09 16:11:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-09 16:26:51 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-09 17:21:13 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 10:48:54 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 11:24:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 11:34:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 12:24:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 12:43:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 13:19:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 13:28:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 14:03:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 14:10:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 14:23:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 14:28:17 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 14:36:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-17 18:25:56 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 14:45:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2014-04-10 14:59:23 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-18" LEVEL="STUDY" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Selective reporting (reporting bias)-Creatinine increase</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:27:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:59:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:50:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Nor reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:44:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:57:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:51:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 10:48:02 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:09:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:55:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:29:39 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:47:13 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:05:28 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:24:20 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:39:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:53:29 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:54:17 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Data could not be extracted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 16:06:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 14:56:11 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:17:51 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:45:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:04:30 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:11:15 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:26:52 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 17:21:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 10:48:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:24:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:34:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:24:57 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:43:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:19:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:28:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-21 06:47:24 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:10:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:23:06 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:28:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:36:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 18:26:00 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:45:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:59:25 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="GROUP" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Selective reporting (reporting bias)-Creatinine</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-15.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-03 14:59:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-03 14:59:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-17 17:50:42 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-04 18:44:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-04 18:57:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-09 16:51:20 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 10:48:03 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 11:09:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 11:55:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 14:29:40 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 14:47:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 15:05:29 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 15:24:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 15:39:38 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 15:53:31 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>No reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-17 17:54:18 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Data could not be extracted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-08 16:06:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-09 14:56:12 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-09 15:17:52 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-09 15:45:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-09 16:04:31 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-09 16:11:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-09 16:26:54 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-09 17:21:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 10:48:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 11:24:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 11:34:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 12:24:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 12:43:54 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 13:19:47 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 13:28:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 14:03:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 14:10:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 14:23:06 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 14:28:20 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 14:36:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-17 18:26:04 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 14:45:43 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-15.01" MODIFIED="2014-04-10 14:59:25 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="GROUP" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Selective reporting (reporting bias)-GFR</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-16.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-03 14:27:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-17 17:34:14 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Data was unable to be extracted from the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-17 17:50:33 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Data could not be extracted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-04 18:44:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-04 18:57:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-09 16:51:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 10:48:05 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 11:09:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 11:55:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 14:29:40 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 14:47:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 15:05:31 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 15:24:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 15:39:38 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 15:53:32 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-17 17:54:44 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-08 16:06:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-09 14:56:13 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-09 15:17:53 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-09 15:45:24 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-09 16:04:33 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-09 16:11:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-09 16:26:55 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-09 17:21:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 10:48:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 11:24:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 11:34:11 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 12:24:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 12:43:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 13:19:47 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 13:29:01 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 14:03:11 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 14:10:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 14:23:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 14:28:26 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 14:36:43 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-17 18:26:08 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 14:45:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-16.01" MODIFIED="2014-04-10 14:59:26 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Selective reporting (reporting bias)-Remission</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-03 14:27:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-17 17:34:55 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Data was unable to be extracted from the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-17 17:52:02 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Data could not be extracted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-04 18:44:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-04 18:57:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-09 16:51:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 10:48:06 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 11:09:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 11:55:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 14:29:41 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 14:47:15 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 15:05:32 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 15:24:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 15:39:40 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 15:53:33 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-17 17:54:54 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-08 16:06:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-09 14:56:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-09 15:17:56 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-09 15:45:25 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-09 16:04:34 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-09 16:11:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-09 16:26:56 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-09 17:21:19 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 10:49:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 11:24:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 11:34:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 12:25:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 12:43:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 13:19:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 13:29:01 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 14:03:11 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 14:10:11 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 14:23:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 14:28:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 14:36:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-17 18:26:13 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 14:45:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2014-04-10 14:59:27 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="GROUP" MODIFIED="2014-04-22 15:27:58 +1000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Selective reporting (reporting bias)-Proteinuria</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-14.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-03 14:52:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-17 17:34:24 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Data was unable to be extracted from the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-17 17:51:04 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-04 18:44:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-04 18:57:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-09 16:51:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 10:48:06 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 11:09:20 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 11:55:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 14:29:42 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 14:47:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 15:05:33 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 15:24:23 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 15:39:41 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 15:53:34 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>No reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-17 17:55:10 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Data could not be extracted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-08 16:06:20 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-09 14:56:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-09 15:17:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-09 15:45:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-09 16:04:35 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-09 16:11:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-09 16:26:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-09 17:21:20 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 10:49:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 11:24:47 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 11:34:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 12:25:01 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 12:43:57 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 13:19:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 13:29:02 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 14:03:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-22 15:27:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 14:23:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 14:28:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 14:36:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-17 18:26:17 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 14:45:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-14.01" MODIFIED="2014-04-10 14:59:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="GROUP" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Selective reporting (reporting bias)-Side effects</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-17.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-03 14:52:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-17 17:34:27 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Data was unable to be extracted from the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-17 17:51:11 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-04 18:44:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-04 18:57:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2011-11-09 02:10:53 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 10:48:07 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 11:09:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 11:55:22 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 14:29:43 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 14:47:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 15:05:33 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 15:24:24 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 15:39:42 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 15:53:35 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-17 17:55:20 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-08 16:06:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-09 14:56:17 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-09 15:17:58 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-09 15:45:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-09 16:04:35 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2011-12-10 23:22:18 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>Reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-09 16:26:58 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-09 17:21:21 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 10:49:01 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 11:24:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 11:34:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 12:25:02 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 12:43:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 13:19:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 13:29:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 14:03:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 14:10:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 14:23:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 14:28:31 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 14:36:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-17 18:26:20 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 14:45:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>Reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2014-04-10 14:59:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-04-22 14:26:49 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:27:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-03 14:59:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Arnadottir-2006">
<DESCRIPTION>
<P>Only abstract was available and unpublished data were not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:51:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1996a">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:44:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Branten-1998">
<DESCRIPTION>
<P>This study was not fully randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 18:57:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Braun-1995">
<DESCRIPTION>
<P>Only abstract was available and unpublished data were included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-20 03:21:37 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CYCLOMEN-Study-1994">
<DESCRIPTION>
<P>Only abstract was available and unpublished data were included.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 10:49:36 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:51:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Cattran-1989">
<DESCRIPTION>
<P>158 patients were properly randomised, only 120 of them were diagnosed with nephrotic syndrome. The randomisation was not stratified according to nephrotic syndrome or non-nephrotic syndrome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 11:55:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-1995">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:29:45 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Cattran-2001">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 14:47:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:05:35 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2010a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:24:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Coggins-1979">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:39:43 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Donadio-1974a">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 15:53:36 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Dussol-2008">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 17:55:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dyadyk-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 16:06:23 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Falk-1992">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 14:56:18 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hofstra-2010">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:17:59 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Imbasciati-1980">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:45:28 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Jha-2007">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:04:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jurubita-2012">
<DESCRIPTION>
<P>Only abstract was available and unpublished data were not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:11:29 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Koshisawa-1993">
<DESCRIPTION>
<P>The data were abstracted from a RCT aiming to investigate the effect of mizoribine on steroid-resistant primary nephrotic syndrome. This study included all different pathologic variants of nephrotic syndrome. The randomisation were not stratified according to the pathologic diagnosis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 16:27:11 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Kosmadakis-2010">
<DESCRIPTION>
<P>There was a significant difference in the baseline GFR (P = 0.021). The sample size was also small for a 3-arm study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 17:21:28 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Liu-2009b">
<DESCRIPTION>
<P>Published in Chinese</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:52:24 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Murphy-1992">
<DESCRIPTION>
<P>40 patients were properly randomised, only 26 were diagnosed with nephrotic syndrome, 13 in each group. The randomisation was not stratified according to nephrotic syndrome or non-nephrotic syndrome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:24:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Naumovic-2011">
<DESCRIPTION>
<P>This study was not fully randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 11:34:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pahari-1993">
<DESCRIPTION>
<P>The inclusion criteria of proteinuria was rather 2 g/24 h than 3.5 g/24 h</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:25:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1992">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 12:43:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-1998">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:19:51 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ponticelli-2006">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 13:29:04 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Praga-2007">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:03:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Reichert-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:10:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Saito-2009">
<DESCRIPTION>
<P>Only abstract was available and unpublished data were not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:23:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Senthil-Nayagam-2008">
<DESCRIPTION>
<P>The study appeared to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:28:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shibasaki-2004">
<DESCRIPTION>
<P>The data were abstracted from a RCT aiming to investigate the effect of mizoribine on steroid-resistant nephrotic syndrome. This study included all different pathologic variants of nephrotic syndrome. The randomisation were not stratified according to the pathologic diagnosis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:36:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Silverberg-1976">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-17 18:26:25 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegeman-1994">
<DESCRIPTION>
<P>Study terminated due to poor accrual rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:45:47 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tiller-1981">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 14:59:30 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Xu-2010">
<DESCRIPTION>
<P>Only abstract was available and unpublished data were not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-17 03:47:46 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-11-17 03:47:46 +1100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-10-09 11:13:43 +1100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-10-09 11:13:36 +1100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-04-22 15:38:16 +1000" MODIFIED_BY="[Empty name]">Immunosuppressive treatments versus no treatment or angiotensin-converting enzyme inhibitors (ACEi)</TITLE>
<TABLE COLS="6" ROWS="24">
<TR>
<TD COLSPAN="6">
<P>
<B>Immunosuppressive treatments versus no treatment or angiotensin-converting enzyme inhibitor (ACEi) for adult IMN with nephrotic syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> adults with IMN and nephrotic syndrome<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> immunosuppressive treatments</P>
<P>
<B>Comparison: </B>no treatment or ACEi<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>No treatment or ACEi</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Immunosuppressive treatments</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death or ESKD (dialysis/transplantation)</B>
<BR/>Follow-up: 6 to 120 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.58 </B>
<BR/>(0.36 to 0.95)</P>
<P>
<B>P = 0.03</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>791 (15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>Moderate</B>
<SUP>1 </SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>97 per 1000</B>
<BR/>(60 to 159)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>91 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
<BR/>(33 to 86)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>ESKD (dialysis/transplantation)</B>
<BR/>Follow-up: 6 to 120 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.55 </B>
<BR/>(0.31 to 0.95)</P>
<P>
<B>P</B> <B>= 0.03</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>791 (15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;</P>
<P>
<B>Moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>125 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>69 per 1000</B>
<BR/>(39 to 119)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>39 per 1000</B>
<BR/>(22 to 67)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Complete or partial remission</B>
<BR/>Follow-up: 6 to 120 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.31 </B>
<BR/>(1.01 to 1.70)</P>
<P>
<B>P</B> <B>= 0.04</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>864 (16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>Moderate</B>
<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>296 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>388 per 1000</B>
<BR/>(299 to 504)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>306 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>401 per 1000</B>
<BR/>(309 to 520)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Temporary or permanent discontinuation or hospitalisation due to adverse effects</B>
<BR/>Follow-up: 6 to 120 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 5.35 </B>
<BR/>(2.19 to 13.02)</P>
<P>
<B>P = 0.0002</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>880 (16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>2 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 1000</B>
<BR/>(5 to 31)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<SUP>1</SUP>The relatively small number of included RCTs with high-quality design and adequate follow-up did not guarantee enough power to appropriately assess the definite endpoint.</P>
<P>
<SUP>2</SUP>Substantial heterogeneity (P = 0.004, I² = 53%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ESKD - end-stage kidney disease; IMN - idiopathic membranous nephropathy</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-10-09 11:13:43 +1100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-04-22 15:38:31 +1000" MODIFIED_BY="[Empty name]">Alkylating agents and corticosteroids versus no treatment or angiotensin-converting enzyme inhibitors (ACEi) or corticosteroids</TITLE>
<TABLE COLS="6" ROWS="24">
<TR>
<TD COLSPAN="6">
<P>
<B>Alkylating agents and corticosteroids versus no treatment or ACEi or corticosteroids monotherapy for adult IMN with nephrotic syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> adults with IMN and nephrotic syndrome<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> alkylating agents and corticosteroids<BR/>
<B>Comparison: </B>no treatment or ACEi or corticosteroids monotherapy</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No treatment or </B>ACEi or corticosteroids</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Alkylating agents and corticosteroids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death or ESKD (dialysis/transplantation)</B>
<BR/>Follow-up: 9 to 120 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.44 </B>
<BR/>(0.26 to 0.75)</P>
<P>
<B>P = 0.002</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>448 (8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>Moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>181 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>80 per 1000</B>
<BR/>(47 to 136)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>77 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
<BR/>(20 to 58)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>ESKD (dialysis/transplantation)</B>
<BR/>Follow-up: 9 to 120 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.45 </B>
<BR/>(0.25 to 0.81)</P>
<P>
<B>P</B> <B>= 0.008</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>448 (8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>Moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>68 per 1000</B>
<BR/>(38 to 122)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>30 per 1000</B>
<BR/>(17 to 54)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Complete or partial remission</B>
<BR/>Follow-up: 9 to 120 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.46 </B>
<BR/>(1.13 to 1.89)</P>
<P>
<B>P = 0.004</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>422 (7)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>Moderate</B>
<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>408 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>596 per 1000</B>
<BR/>(462 to 772)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>458 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>669 per 1000</B>
<BR/>(518 to 866)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Temporary or permanent discontinuation or hospitalisation due to adverse effects</B>
<BR/>Follow-up: 9 to 120 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.11 </B>
<BR/>(0.77 to 5.79)</P>
<P>
<B>P = 0.15</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>448 (8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8854;&#8854;<BR/>
<B>Low</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>31 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 1000</B>
<BR/>(24 to 179)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<SUP>1</SUP>The relatively small number of included RCTs with high-quality design and adequate follow-up did not guarantee enough power to appropriately assess the definite endpoint.</P>
<P>
<SUP>2</SUP>Moderate heterogeneity (P = 0.05, I² = 53%)</P>
<P>
<SUP>3</SUP>Sensitivity analysis revealed a statistically significant difference (P = 0.03, RR 4.20, 95% CI 1.15 to 15.32), whereby four low quality studies were excluded and only four high quality studies were analysed.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ESKD - end-stage kidney disease; IMN - idiopathic membranous nephropathy</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-10-09 11:10:37 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-10-09 11:10:37 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-04-16 18:10:23 +1000" MODIFIED_BY="[Empty name]">Studies not included in the meta-analyses</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Reported results</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Austin-1996a" TYPE="STUDY">Austin 1996a</LINK>
</P>
</TD>
<TD>
<P>Eleven of 15 patients with initial GFR &lt; 60 mL/min showed an average 86% (median 67%) increase in GFR at 1 year. Treatment group, gender, severity of initial urinary protein, and degree of glomerular sclerosis or interstitial fibrosis did not predict change in GFR for all patients or those with GFR &lt; 60 mL/min. Initial urinary protein averaged 12 g/d (median 10, range 2.1 to 36 g/d, 1 patient had initial urinary protein &lt; 3.5 g/d). Urinary protein decreased &gt; 50% in 14 patients, including 11/20 patients with initial urinary protein &gt; 8 g/d. Only 6 patients had urinary protein &lt; 2 g/d at 1 year. Treatment group, gender, initial GFR, glomerular sclerosis and interstitial fibrosis did not predict percent change in urinary protein or remission of urinary protein for all patients or those with initial urinary protein &gt; 8 g/d. After one-year follow-up there was no evidence that cyclophosphamide plus prednisone was more effective than prednisone alone</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dyadyk-2001" TYPE="STUDY">Dyadyk 2001</LINK>
</P>
</TD>
<TD>
<P>After 12 to 48 months, cyclophosphamide group had a higher rate of proteinuria reduction (43.8% versus 6.3%, P &lt; 0.001) and a lower level of SCr (186 &#956;mol/L versus 236 &#956;mol/L, P &lt; 0.05) than azathioprine group</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stegeman-1994" TYPE="STUDY">Stegeman 1994</LINK>
</P>
</TD>
<TD>
<P>The interim analysis of the study failed to demonstrate the superiority of ACEi over placebo. No appropriate detailed data could be identified</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ACEi - angiotensin-converting enzyme inhibitor; GFR - glomerular filtration rate; SCr - serum creatinine</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-04-22 16:17:46 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-04-22 16:17:46 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Immunosuppressive treatments versus placebo/no treatment/non-immunosuppressive treatments</NAME>
<DICH_OUTCOME CHI2="13.974714551598085" CI_END="0.9530377320398907" CI_START="0.3555666524717759" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5821240727376916" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="64" I2="21.286406535279895" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.020889904721250498" LOG_CI_START="-0.4490789769667666" LOG_EFFECT_SIZE="-0.23498444084400855" METHOD="IV" MODIFIED="2014-04-22 16:17:46 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23439583944172526" P_Q="0.5291186093568383" P_Z="0.03146009464787189" Q="4.142279539571522" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14952173945546227" TOTALS="YES" TOTAL_1="408" TOTAL_2="383" WEIGHT="100.0" Z="2.151204086392294">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6660941001635927" CI_END="1.633934934424152" CI_START="0.3444273578659249" DF="2" EFFECT_SIZE="0.7501812396938116" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="24.983893108751147" ID="CMP-001.01.01" LOG_CI_END="0.21323475832664507" LOG_CI_START="-0.46290235983648187" LOG_EFFECT_SIZE="-0.12483380075491839" MODIFIED="2014-03-31 17:52:58 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.2636727876910363" P_Z="0.46923261536965155" STUDIES="3" TAU2="0.12691608709230837" TOTAL_1="150" TOTAL_2="145" WEIGHT="37.880728642773605" Z="0.7237282112172381">
<NAME>Steroids versus placebo/no treatment at final follow-up (24-48 months)</NAME>
<DICH_DATA CI_END="1.9911624381802222" CI_START="0.3913019325390922" EFFECT_SIZE="0.8826923076923077" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.29910669103076776" LOG_CI_START="-0.4074880072258436" LOG_EFFECT_SIZE="-0.05419065809753793" MODIFIED="2012-02-05 02:09:08 +1100" MODIFIED_BY="[Empty name]" ORDER="893" O_E="0.0" SE="0.4150572234561001" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.17227249874308698" WEIGHT="19.659302234526326"/>
<DICH_DATA CI_END="3.254775439720698" CI_START="0.3387330463863303" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5125210301839611" LOG_CI_START="-0.47014243204408507" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2012-02-05 02:09:09 +1100" MODIFIED_BY="[Empty name]" ORDER="894" O_E="0.0" SE="0.5772213819753421" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.33318452380952385" WEIGHT="13.105796770243234"/>
<DICH_DATA CI_END="1.2322994129962144" CI_START="0.020686977281907746" EFFECT_SIZE="0.15966386554621848" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.09071624160569046" LOG_CI_START="-1.684302962485094" LOG_EFFECT_SIZE="-0.7967933604397018" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="850" O_E="0.0" SE="1.0426550669696937" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="1.0871295886775763" WEIGHT="5.1156296380040445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.956296023616371" CI_END="12.273363997540656" CI_START="0.03154326933441352" DF="1" EFFECT_SIZE="0.6222073819987346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="48.88299173908152" ID="CMP-001.01.02" LOG_CI_END="1.0889636145064048" LOG_CI_START="-1.5010932957784653" LOG_EFFECT_SIZE="-0.20606484063603017" MODIFIED="2014-04-10 18:27:47 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.16191030297723819" P_Z="0.7551398268187541" STUDIES="3" TAU2="2.2655108178530687" TOTAL_1="51" TOTAL_2="51" WEIGHT="5.042726324362034" Z="0.31186933732833216">
<NAME>CPA versus placebo/no treatment at final follow-up (12-36 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:53:32 +1100" MODIFIED_BY="[Empty name]" ORDER="899" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-12-17 05:53:37 +1100" MODIFIED_BY="[Empty name]" ORDER="901" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="2.3664295828224735"/>
<DICH_DATA CI_END="2.6395530143189947" CI_START="0.007731673944261138" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4215303890477133" LOG_CI_START="-2.111726469076227" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-12-19 06:26:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1886" O_E="0.0" SE="1.4880476182856899" STUDY_ID="STD-Tiller-1981" TOTAL_1="27" TOTAL_2="27" VAR="2.2142857142857144" WEIGHT="2.67629674153956"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9928899216951503" CI_END="0.64297014110834" CI_START="0.17404943872417486" DF="2" EFFECT_SIZE="0.3345274161803634" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="32" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-0.1918091948098045" LOG_CI_START="-0.759327372893262" LOG_EFFECT_SIZE="-0.4755682838515333" MODIFIED="2014-03-31 17:53:09 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.3691897023036991" P_Z="0.0010204859250040076" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="103" WEIGHT="35.63341547120178" Z="3.284817102022256">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="14.208863658145452" CI_START="0.15139219876164783" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1525593469823352" LOG_CI_START="-0.8198965034492852" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2012-01-17 01:31:21 +1100" MODIFIED_BY="[Empty name]" ORDER="2080" O_E="0.0" SE="1.1586303303574623" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="1.3424242424242425" WEIGHT="4.240267585361224"/>
<DICH_DATA CI_END="0.7613239573508241" CI_START="0.07078498660408751" EFFECT_SIZE="0.23214285714285715" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.11843050360803206" LOG_CI_START="-1.1500588457906953" LOG_EFFECT_SIZE="-0.6342446746993636" MODIFIED="2012-02-05 02:09:29 +1100" MODIFIED_BY="[Empty name]" ORDER="920" O_E="0.0" SE="0.605983594840749" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.36721611721611713" WEIGHT="12.242668317013164"/>
<DICH_DATA CI_END="0.7551995141250635" CI_START="0.14260835950041595" EFFECT_SIZE="0.3281733746130031" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.12193829812321799" LOG_CI_START="-0.8458550160094471" LOG_EFFECT_SIZE="-0.4838966570663326" MODIFIED="2012-02-05 02:09:29 +1100" MODIFIED_BY="[Empty name]" ORDER="921" O_E="0.0" SE="0.4252322635319177" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.18082247794847828" WEIGHT="19.15047956882739"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:53:13 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:57:47 +1100" MODIFIED_BY="[Empty name]" ORDER="922" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.426735749004852" CI_END="7.208724162191864" CI_START="0.1487026312110299" DF="1" EFFECT_SIZE="1.0353532008896562" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="58.792381889537126" ID="CMP-001.01.05" LOG_CI_END="0.8578584078054482" LOG_CI_START="-0.8276813468087718" LOG_EFFECT_SIZE="0.015088530498338151" MODIFIED="2014-04-22 16:17:46 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1192812660144501" P_Z="0.9720078037480093" STUDIES="2" TAU2="1.1815605779953056" TOTAL_1="19" TOTAL_2="19" WEIGHT="14.43263260516466" Z="0.0350902151971439">
<NAME>CSA versus placebo/no treatment at final follow-up (12-21 months)</NAME>
<DICH_DATA CI_END="1.8113826089229539" CI_START="0.10904977403696202" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.25801019376720685" LOG_CI_START="-0.9623752299899319" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2011-12-17 06:01:20 +1100" MODIFIED_BY="[Empty name]" ORDER="951" O_E="0.0" SE="0.7168604389202189" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" VAR="0.5138888888888888" WEIGHT="9.535949404161071"/>
<DICH_DATA CI_END="26.811079872984088" CI_START="0.4061753592764908" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4283143064645425" LOG_CI_START="-0.3912864267087673" LOG_EFFECT_SIZE="0.5185139398778874" MODIFIED="2011-12-17 06:01:20 +1100" MODIFIED_BY="[Empty name]" ORDER="952" O_E="0.0" SE="1.068842477834897" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="1.1424242424242423" WEIGHT="4.896683201003588"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.804356527890043" CI_START="0.1757214425495823" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.01.06" LOG_CI_END="1.1073577582508822" LOG_CI_START="-0.7551752401395198" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.7109313543846907" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="4.6983218867475225" Z="0.3706055420652529">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="12.804356527890043" CI_START="0.1757214425495823" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1073577582508822" LOG_CI_START="-0.7551752401395198" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2012-01-28 04:21:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1877" O_E="0.0" SE="1.0940611029415575" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="1.196969696969697" WEIGHT="4.6983218867475225"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:01:20 +1100" MODIFIED_BY="[Empty name]" ORDER="950" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.195817676132171" CI_START="0.01315688646851685" DF="0" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2014-04-10 18:27:53 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.4636374323790845" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="2.312175069750406" Z="0.7328704842081468">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="7.195817676132171" CI_START="0.01315688646851685" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2011-12-17 06:04:50 +1100" MODIFIED_BY="[Empty name]" ORDER="974" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="2.5865384615384617" WEIGHT="2.312175069750406"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:53:47 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:07:03 +1100" MODIFIED_BY="[Empty name]" ORDER="982" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:53:52 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:11:44 +1100" MODIFIED_BY="[Empty name]" ORDER="994" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.987967160316099" CI_END="1.4431688937093796" CI_START="0.29059749309129185" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6475965276460944" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.1593171594467866" LOG_CI_START="-0.5367081365669536" LOG_EFFECT_SIZE="-0.18869548856008347" METHOD="IV" MODIFIED="2014-04-10 18:28:17 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.7265804719447229" P_Q="0.9079585489163411" P_Z="0.2879137082834483" Q="1.5438179904412563" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="408" TOTAL_2="383" WEIGHT="100.00000000000003" Z="1.0627095415671577">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.754833787836008" CI_END="2.9743473079790452" CI_START="0.11239885937732105" DF="2" EFFECT_SIZE="0.5781982746505304" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="27.400338676292673" ID="CMP-001.02.01" LOG_CI_END="0.4733916787562798" LOG_CI_START="-0.9492380959613428" LOG_EFFECT_SIZE="-0.2379232086025314" MODIFIED="2014-03-31 17:54:00 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.2522294886124915" P_Z="0.5120970198537982" STUDIES="3" TAU2="0.5800687700929907" TOTAL_1="150" TOTAL_2="145" WEIGHT="33.78697428757326" Z="0.6555759316083932">
<NAME>Steroids versus placebo/no treatment at final follow-up (24-48 months)</NAME>
<DICH_DATA CI_END="2.119716513397403" CI_START="0.028361937726815344" EFFECT_SIZE="0.24519230769230768" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3262777831459583" LOG_CI_START="-1.5472641008756087" LOG_EFFECT_SIZE="-0.6104931588648252" MODIFIED="2011-12-17 05:51:52 +1100" MODIFIED_BY="[Empty name]" ORDER="895" O_E="0.0" SE="1.1005277768561663" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="1.211161387631976" WEIGHT="13.801402908103796"/>
<DICH_DATA CI_END="24.52408656473462" CI_START="0.28097376763906257" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3895928404237263" LOG_CI_START="-0.5513342249397749" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2011-12-17 05:51:52 +1100" MODIFIED_BY="[Empty name]" ORDER="896" O_E="0.0" SE="1.1401101659384458" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="1.2998511904761905" WEIGHT="12.859723035929449"/>
<DICH_DATA CI_END="4.484600709492909" CI_START="0.011074632802273455" EFFECT_SIZE="0.22285714285714286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6517237812968287" LOG_CI_START="-1.9556706646164193" LOG_EFFECT_SIZE="-0.6519734416597952" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="1.5315964043401074" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="2.345787545787546" WEIGHT="7.125848343540016"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.511327318208873" CI_END="10.606205490960889" CI_START="0.05263571873505015" DF="1" EFFECT_SIZE="0.747171499100683" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="33.832996469280054" ID="CMP-001.02.02" LOG_CI_END="1.0255600371447784" LOG_CI_START="-1.2787194424442145" LOG_EFFECT_SIZE="-0.12657970264971796" MODIFIED="2014-04-10 18:28:04 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.2189370561537931" P_Z="0.8295090888495863" STUDIES="3" TAU2="1.2405774696543843" TOTAL_1="51" TOTAL_2="51" WEIGHT="13.801745072310379" Z="0.21533122224521814">
<NAME>CPA versus placebo/no treatment at final follow-up (12-36 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:54:28 +1100" MODIFIED_BY="[Empty name]" ORDER="902" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-12-17 05:54:41 +1100" MODIFIED_BY="[Empty name]" ORDER="904" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="6.623212306535599"/>
<DICH_DATA CI_END="3.9804702774957645" CI_START="0.010049063857139322" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5999343853540574" LOG_CI_START="-1.9978743940260948" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-12-19 06:25:16 +1100" MODIFIED_BY="[Empty name]" ORDER="1885" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Tiller-1981" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="7.178532765774778"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1787084387941342" CI_END="1.974316240338338" CI_START="0.11902366221187707" DF="2" EFFECT_SIZE="0.48475803169153736" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.2954167179556183" LOG_CI_START="-0.9243666911579241" LOG_EFFECT_SIZE="-0.31447498660115286" MODIFIED="2014-03-31 17:54:12 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.5546855883159792" P_Z="0.31220550282856907" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="103" WEIGHT="32.56001553081718" Z="1.0106050683619399">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="50.541308142018366" CI_START="0.10016559100082345" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7036464784130976" LOG_CI_START="-0.9992814421903727" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2012-01-28 02:40:55 +1100" MODIFIED_BY="[Empty name]" ORDER="2082" O_E="0.0" SE="1.5877132402714706" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="2.520833333333333" WEIGHT="6.631031919648391"/>
<DICH_DATA CI_END="2.852188343933463" CI_START="0.033589993755463766" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4551782007135673" LOG_CI_START="-1.4737900768956944" LOG_EFFECT_SIZE="-0.5093059380910637" MODIFIED="2011-12-17 05:58:12 +1100" MODIFIED_BY="[Empty name]" ORDER="924" O_E="0.0" SE="1.1330855148146515" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="1.283882783882784" WEIGHT="13.019666987740445"/>
<DICH_DATA CI_END="3.222419432482004" CI_START="0.03723803962371684" EFFECT_SIZE="0.3464052287581699" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5081820678513844" LOG_CI_START="-1.429013190285004" LOG_EFFECT_SIZE="-0.46041556121680977" MODIFIED="2011-12-17 05:58:12 +1100" MODIFIED_BY="[Empty name]" ORDER="923" O_E="0.0" SE="1.137918083900496" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="1.2948575656677765" WEIGHT="12.909316623428342"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:54:19 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:58:12 +1100" MODIFIED_BY="[Empty name]" ORDER="925" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="58.239100526092926" CI_START="0.1251736365113307" DF="0" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="1.7652146588947637" LOG_CI_START="-0.9024871305767889" LOG_EFFECT_SIZE="0.43136376415898736" MODIFIED="2014-04-10 18:28:09 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.5261806542340917" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="6.807309351901488" Z="0.633847040418054">
<NAME>CSA versus placebo/no treatment at final follow-up (12-21 months)</NAME>
<DICH_DATA CI_END="58.239100526092926" CI_START="0.1251736365113307" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7652146588947637" LOG_CI_START="-0.9024871305767889" LOG_EFFECT_SIZE="0.43136376415898736" MODIFIED="2011-12-17 06:01:37 +1100" MODIFIED_BY="[Empty name]" ORDER="954" O_E="0.0" SE="1.567021236472421" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" VAR="2.4555555555555553" WEIGHT="6.807309351901488"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:01:37 +1100" MODIFIED_BY="[Empty name]" ORDER="953" O_E="0.0" SE="0.0" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2132534428550692E-33" CI_END="35.57361413555459" CI_START="0.06886861348150151" DF="0" EFFECT_SIZE="1.565217391304348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="100.0" ID="CMP-001.02.06" LOG_CI_END="1.5511279899930068" LOG_CI_START="-1.161978660493618" LOG_EFFECT_SIZE="0.1945746647496944" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Z="0.7786154986987281" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="6.581370125670997" Z="0.281123733300315">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="35.57361413555459" CI_START="0.06886861348150151" EFFECT_SIZE="1.565217391304348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5511279899930068" LOG_CI_START="-1.161978660493618" LOG_EFFECT_SIZE="0.1945746647496944" MODIFIED="2012-01-28 04:24:01 +1100" MODIFIED_BY="[Empty name]" ORDER="1876" O_E="0.0" SE="1.593692276590361" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="2.5398550724637676" WEIGHT="6.581370125670997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:01:37 +1100" MODIFIED_BY="[Empty name]" ORDER="955" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.195817676132171" CI_START="0.01315688646851685" DF="0" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.02.08" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2014-04-10 18:28:17 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.4636374323790845" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="6.462585631726714" Z="0.7328704842081468">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="7.195817676132171" CI_START="0.01315688646851685" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2011-12-17 06:05:01 +1100" MODIFIED_BY="[Empty name]" ORDER="975" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="2.5865384615384617" WEIGHT="6.462585631726714"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:54:49 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:07:38 +1100" MODIFIED_BY="[Empty name]" ORDER="983" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:46:21 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at the final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:11:56 +1100" MODIFIED_BY="[Empty name]" ORDER="995" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.705925036810859" CI_END="0.9500007189632431" CI_START="0.31280296276999825" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5451266270558895" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="48" I2="15.934401099814066" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.022276066035730104" LOG_CI_START="-0.5047291420937506" LOG_EFFECT_SIZE="-0.2635026040647404" METHOD="IV" MODIFIED="2014-04-10 18:28:46 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.29640617152137183" P_Q="0.5091133769871908" P_Z="0.032277516331118354" Q="3.2988581708485754" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.12505465561488088" TOTALS="YES" TOTAL_1="408" TOTAL_2="383" WEIGHT="100.0" Z="2.1409568699166055">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.414182732075807" CI_END="1.9268755894469405" CI_START="0.3363266729360384" DF="2" EFFECT_SIZE="0.805021525277652" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" I2="17.15622958332059" ID="CMP-001.03.01" LOG_CI_END="0.2848536749248239" LOG_CI_START="-0.47323868888641973" LOG_EFFECT_SIZE="-0.09419250698079795" MODIFIED="2014-03-31 17:55:01 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.29906595476198394" P_Z="0.6262238751392555" STUDIES="3" TAU2="0.11248324315561246" TOTAL_1="150" TOTAL_2="145" WEIGHT="39.48046882451003" Z="0.48704862391113185">
<NAME>Steroids versus placebo/no treatment at final follow-up (24-48 months)</NAME>
<DICH_DATA CI_END="3.503537862775098" CI_START="0.4880949596026692" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5445068152805551" LOG_CI_START="-0.3114956771376807" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2011-12-17 05:52:10 +1100" MODIFIED_BY="[Empty name]" ORDER="897" O_E="0.0" SE="0.5028201013271472" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.2528280542986425" WEIGHT="21.253396399891432"/>
<DICH_DATA CI_END="2.807061136898403" CI_START="0.15342168962370814" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4482518715330762" LOG_CI_START="-0.8141132387050496" LOG_EFFECT_SIZE="-0.18293068358598671" MODIFIED="2011-12-17 05:52:10 +1100" MODIFIED_BY="[Empty name]" ORDER="898" O_E="0.0" SE="0.7415195145619502" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.5498511904761904" WEIGHT="11.899868808327911"/>
<DICH_DATA CI_END="1.8191590769205934" CI_START="0.02746620598373126" EFFECT_SIZE="0.2235294117647059" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2598706777375301" LOG_CI_START="-1.5612013272604577" LOG_EFFECT_SIZE="-0.6506653247614638" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="856" O_E="0.0" SE="1.0697067101876259" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="1.1442724458204334" WEIGHT="6.327203616290687"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.836867951075732" CI_START="0.014177999655571498" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.8941425290950501" LOG_CI_START="-1.8483850385343752" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-04-10 18:28:28 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.49526728049818114" STUDIES="3" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="2.9523627646101698" Z="0.6819552055167947">
<NAME>CPA versus placebo/no treatment at final follow-up (12-36 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:55:03 +1100" MODIFIED_BY="[Empty name]" ORDER="905" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:55:07 +1100" MODIFIED_BY="[Empty name]" ORDER="907" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.836867951075732" CI_START="0.014177999655571498" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8941425290950501" LOG_CI_START="-1.8483850385343752" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-12-19 06:24:09 +1100" MODIFIED_BY="[Empty name]" ORDER="1884" O_E="0.0" SE="1.6109742689559308" STUDY_ID="STD-Tiller-1981" TOTAL_1="27" TOTAL_2="27" VAR="2.5952380952380953" WEIGHT="2.9523627646101698"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7066052309703073" CI_END="0.6529978738913564" CI_START="0.14502573848790692" DF="2" EFFECT_SIZE="0.30773608643142114" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="26" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-0.18508823275058459" LOG_CI_START="-0.8385549143767842" LOG_EFFECT_SIZE="-0.5118215735636844" MODIFIED="2014-03-31 17:55:16 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.7023647149609678" P_Z="0.002138822659374191" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="103" WEIGHT="38.78434409707166" Z="3.0702463611427677">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="10.487880939999085" CI_START="0.05127611391227567" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0206877485337722" LOG_CI_START="-1.2900848963286846" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2011-12-17 05:58:42 +1100" MODIFIED_BY="[Empty name]" ORDER="928" O_E="0.0" SE="1.357359290101277" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="1.8424242424242425" WEIGHT="4.0820214308075355"/>
<DICH_DATA CI_END="0.8964528004721072" CI_START="0.04749831216827371" EFFECT_SIZE="0.20634920634920634" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.04747257172827957" LOG_CI_START="-1.3233218225652104" LOG_EFFECT_SIZE="-0.685397197146745" MODIFIED="2011-12-17 05:58:42 +1100" MODIFIED_BY="[Empty name]" ORDER="926" O_E="0.0" SE="0.7494401654972608" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.5616605616605617" WEIGHT="11.69522798449351"/>
<DICH_DATA CI_END="0.8211823469290466" CI_START="0.12843158007714855" EFFECT_SIZE="0.3247549019607843" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.08556039528988758" LOG_CI_START="-0.891328174344219" LOG_EFFECT_SIZE="-0.48844428481705326" MODIFIED="2011-12-17 05:58:42 +1100" MODIFIED_BY="[Empty name]" ORDER="927" O_E="0.0" SE="0.47331198203134817" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.22402423233444324" WEIGHT="23.007094681770617"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:55:21 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:58:42 +1100" MODIFIED_BY="[Empty name]" ORDER="929" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3757635508388475" CI_END="11.759731352118113" CI_START="0.05945848121005324" DF="1" EFFECT_SIZE="0.8361912255191327" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="70.37707218115118" ID="CMP-001.03.05" LOG_CI_END="1.0703974005134749" LOG_CI_START="-1.2257861884798418" LOG_EFFECT_SIZE="-0.07769439398318335" MODIFIED="2014-04-10 18:28:39 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.06616200122310623" P_Z="0.8944813215688155" STUDIES="2" TAU2="2.5614450707844596" TOTAL_1="19" TOTAL_2="19" WEIGHT="13.387956659876348" Z="0.13263592226479246">
<NAME>CSA versus placebo/no treatment at final follow-up (12-21 months)</NAME>
<DICH_DATA CI_END="1.5991152606402737" CI_START="0.030881273704817407" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.20387976784630216" LOG_CI_START="-1.5103047953969895" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2011-12-17 06:02:05 +1100" MODIFIED_BY="[Empty name]" ORDER="957" O_E="0.0" SE="1.0069204977995476" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" VAR="1.0138888888888888" WEIGHT="7.051526886660987"/>
<DICH_DATA CI_END="26.811079872984088" CI_START="0.4061753592764908" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4283143064645425" LOG_CI_START="-0.3912864267087673" LOG_EFFECT_SIZE="0.5185139398778874" MODIFIED="2011-12-17 06:02:05 +1100" MODIFIED_BY="[Empty name]" ORDER="956" O_E="0.0" SE="1.068842477834897" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="1.1424242424242423" WEIGHT="6.33642977321536"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.862550818305001" CI_START="0.10139364738623087" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="0.9939892539921364" LOG_CI_START="-0.9939892539921364" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="5.394867653931796" Z="0.0">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="9.862550818305001" CI_START="0.10139364738623087" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9939892539921364" LOG_CI_START="-0.9939892539921364" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:02:05 +1100" MODIFIED_BY="[Empty name]" ORDER="958" O_E="0.0" SE="1.1677484162422844" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="1.3636363636363638" WEIGHT="5.394867653931796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:02:05 +1100" MODIFIED_BY="[Empty name]" ORDER="959" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:28:46 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:05:11 +1100" MODIFIED_BY="[Empty name]" ORDER="976" O_E="0.0" SE="0.0" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:55:50 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:07:56 +1100" MODIFIED_BY="[Empty name]" ORDER="984" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:56:06 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:12:09 +1100" MODIFIED_BY="[Empty name]" ORDER="996" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.568745860497266" CI_END="0.6686060830679792" CI_START="0.2630668167690196" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41939012142049314" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="63" I2="7.514400284803585" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.17482967645592642" LOG_CI_START="-0.579933930336905" LOG_EFFECT_SIZE="-0.3773818033964157" METHOD="IV" MODIFIED="2014-04-10 18:28:59 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.3721512783571155" P_Q="0.6522868124033322" P_Z="2.605344421499161E-4" Q="2.4573618862773867" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.037096259507503546" TOTALS="YES" TOTAL_1="212" TOTAL_2="197" WEIGHT="100.0" Z="3.6516760117511096">
<NAME>100% increase in serum creatinine (ITT analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8524086840551119" CI_START="0.048443567111511536" DF="0" EFFECT_SIZE="0.20320855614973266" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.06935213448809781" LOG_CI_START="-1.3147638853512797" LOG_EFFECT_SIZE="-0.6920580099196887" MODIFIED="2014-03-31 17:56:18 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.02938746509715693" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="9.89468368513329" Z="2.178249520634346">
<NAME>Steroids versus placebo/no treatment at final follow-up (24 months)</NAME>
<DICH_DATA CI_END="0.8524086840551119" CI_START="0.048443567111511536" EFFECT_SIZE="0.20320855614973263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.06935213448809781" LOG_CI_START="-1.3147638853512797" LOG_EFFECT_SIZE="-0.6920580099196888" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="859" O_E="0.0" SE="0.7315610273446258" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.5351815367295244" WEIGHT="9.89468368513329"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8356088574380856" CI_END="5.728417021995094" CI_START="0.14923496158688973" DF="1" EFFECT_SIZE="0.924597260557873" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.7580346265761315" LOG_CI_START="-0.8261294218661908" LOG_EFFECT_SIZE="-0.03404739764502959" MODIFIED="2014-04-10 18:28:59 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.3606557381812845" P_Z="0.9328589072540209" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="6.389249831737974" Z="0.08424843780186503">
<NAME>CPA versus placebo/no treatment at final follow-up (12-24 months)</NAME>
<DICH_DATA CI_END="4.745176453876752" CI_START="0.05268507977100682" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6762523667148672" LOG_CI_START="-1.2783123580428297" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-12-17 05:55:32 +1100" MODIFIED_BY="[Empty name]" ORDER="909" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="4.178115079854927"/>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-12-17 05:55:32 +1100" MODIFIED_BY="[Empty name]" ORDER="908" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="2.2111347518830464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.183152021173834" CI_END="0.8852341623092077" CI_START="0.1702766089616869" DF="2" EFFECT_SIZE="0.38824563267994583" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="46" I2="52.189162863873634" ID="CMP-001.04.03" LOG_CI_END="-0.05294183444643514" LOG_CI_START="-0.768845007331474" LOG_EFFECT_SIZE="-0.4108934208889546" MODIFIED="2014-03-31 17:56:48 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.12349240750493651" P_Z="0.024458658690231873" STUDIES="3" TAU2="0.27997407018916687" TOTAL_1="108" TOTAL_2="103" WEIGHT="68.45042293821726" Z="2.2498470098445322">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="3.512772582467454" CI_START="0.27216375676802224" EFFECT_SIZE="0.9777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.5456500343987793" LOG_CI_START="-0.5651697089770918" LOG_EFFECT_SIZE="-0.009759837289156262" MODIFIED="2011-12-17 05:59:12 +1100" MODIFIED_BY="[Empty name]" ORDER="932" O_E="0.0" SE="0.6525010159053974" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.42575757575757567" WEIGHT="12.233900515370259"/>
<DICH_DATA CI_END="0.5161674286075996" CI_START="0.05202171959962352" EFFECT_SIZE="0.1638655462184874" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.28720940394226185" LOG_CI_START="-1.2838152961177636" LOG_EFFECT_SIZE="-0.7855123500300127" MODIFIED="2011-12-17 05:59:12 +1100" MODIFIED_BY="[Empty name]" ORDER="931" O_E="0.0" SE="0.5854112343426189" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.3427063132945486" WEIGHT="14.909082189766455"/>
<DICH_DATA CI_END="0.7428254191177341" CI_START="0.21506905874037682" EFFECT_SIZE="0.3996983408748115" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.12911324333602195" LOG_CI_START="-0.6674220655999086" LOG_EFFECT_SIZE="-0.39826765446796525" MODIFIED="2011-12-17 05:59:12 +1100" MODIFIED_BY="[Empty name]" ORDER="930" O_E="0.0" SE="0.3162052668694525" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.09998577079598168" WEIGHT="41.30744023308055"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4716460442909356" CI_START="0.1798171892253878" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.3929862770892373" LOG_CI_START="-0.7451687952005998" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.5441979504152998" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="11.697802123908" Z="0.6064771561349387">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="2.4716460442909356" CI_START="0.1798171892253878" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.3929862770892373" LOG_CI_START="-0.7451687952005998" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-12-17 06:02:43 +1100" MODIFIED_BY="[Empty name]" ORDER="960" O_E="0.0" SE="0.6685579234215214" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.4469696969696969" WEIGHT="11.697802123908"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 17:57:33 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:08:40 +1100" MODIFIED_BY="[Empty name]" ORDER="985" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.97014179196706E-34" CI_END="9.179676193816485" CI_START="0.06971923480602833" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="100.0" ID="CMP-001.04.06" LOG_CI_END="0.962827362059746" LOG_CI_START="-1.1566473880758588" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-03-31 17:57:51 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Z="0.8577545854214135" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="3.567841421003476" Z="0.17923321353551983">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="9.179676193816485" CI_START="0.06971923480602833" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.962827362059746" LOG_CI_START="-1.1566473880758588" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-12-17 06:12:25 +1100" MODIFIED_BY="[Empty name]" ORDER="997" O_E="0.0" SE="1.2449899597988732" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="1.55" WEIGHT="3.567841421003476"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.809653216981966" CI_END="0.8070772729311673" CI_START="0.334397935775824" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5195045467363723" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="61" I2="11.889786325136884" I2_Q="17.875851411481737" ID="CMP-001.05" LOG_CI_END="-0.09308488212922304" LOG_CI_START="-0.4757364121060356" LOG_EFFECT_SIZE="-0.28441064711762937" METHOD="IV" MODIFIED="2014-04-10 18:29:18 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.3388099002465469" P_Q="0.2977174932916197" P_Z="0.0035735990548407936" Q="6.088343180338368" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04541355227089974" TOTALS="YES" TOTAL_1="215" TOTAL_2="199" WEIGHT="99.99999999999999" Z="2.913536633208093">
<NAME>50% increase in serum creatinine (ITT analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9372201296137322" CI_START="0.3416078793111174" DF="0" EFFECT_SIZE="0.5658284023668639" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.02815839219811815" LOG_CI_START="-0.46647212070588084" LOG_EFFECT_SIZE="-0.2473152564519995" MODIFIED="2014-03-31 17:58:29 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.02698116745284744" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="51" WEIGHT="45.22897142367283" Z="2.2117901582661545">
<NAME>Steroids versus placebo/no treatment at final follow-up (36 months)</NAME>
<DICH_DATA CI_END="0.9372201296137322" CI_START="0.3416078793111174" EFFECT_SIZE="0.5658284023668639" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="-0.02815839219811815" LOG_CI_START="-0.46647212070588084" LOG_EFFECT_SIZE="-0.2473152564519995" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.2574676538134082" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.066289592760181" WEIGHT="45.22897142367283"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7213100366435988" CI_END="4.914740778700723" CI_START="0.20052962593799795" DF="1" EFFECT_SIZE="0.9927492784863059" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.6915006165020888" LOG_CI_START="-0.6978214563060571" LOG_EFFECT_SIZE="-0.00316041990198407" MODIFIED="2014-04-10 18:29:12 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.3957145540578203" P_Z="0.992885338448601" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="7.3356670215803055" Z="0.008917024072599988">
<NAME>CPA versus placebo/no treatment at final follow-up (12-24 months)</NAME>
<DICH_DATA CI_END="4.745176453876752" CI_START="0.05268507977100682" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6762523667148672" LOG_CI_START="-1.2783123580428297" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-12-17 05:55:42 +1100" MODIFIED_BY="[Empty name]" ORDER="911" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="3.705071507296023"/>
<DICH_DATA CI_END="19.43689862203422" CI_START="0.20579414842785088" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.288626969500306" LOG_CI_START="-0.6865669781723437" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-12-17 05:55:42 +1100" MODIFIED_BY="[Empty name]" ORDER="910" O_E="0.0" SE="1.1602387022306428" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="1.3461538461538463" WEIGHT="3.6305955142842823"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.682692937091351" CI_START="0.15471816721880977" DF="0" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="-0.16577459018789992" LOG_CI_START="-0.8104586878543513" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2014-03-31 17:59:17 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.0029980535104139256" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="39" WEIGHT="26.75677606548602" Z="2.967937432299193">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (120 months)</NAME>
<DICH_DATA CI_END="0.682692937091351" CI_START="0.15471816721880977" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.16577459018789992" LOG_CI_START="-0.8104586878543513" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2011-12-17 05:59:30 +1100" MODIFIED_BY="[Empty name]" ORDER="933" O_E="0.0" SE="0.37869063020702454" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.1434065934065934" WEIGHT="26.75677606548602"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.179060171309071" CI_START="0.01994055238504708" DF="0" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2014-04-10 18:29:18 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.07159296555727772" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="4.476528078326019" Z="1.8016977927592697">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="1.179060171309071" CI_START="0.01994055238504708" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2011-12-17 06:05:32 +1100" MODIFIED_BY="[Empty name]" ORDER="977" O_E="0.0" SE="1.0407633764680142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="1.0831884057971015" WEIGHT="4.476528078326019"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-31 18:00:02 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:08:57 +1100" MODIFIED_BY="[Empty name]" ORDER="986" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.16470792875079" CI_START="0.25469354507112146" DF="0" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.05.06" LOG_CI_END="1.8335595781915652" LOG_CI_START="-0.5939820616147772" LOG_EFFECT_SIZE="0.619788758288394" MODIFIED="2014-03-31 18:00:26 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.31691483509560725" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="2.430415357219691" Z="1.0008179669082515">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="68.16470792875079" CI_START="0.25469354507112146" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8335595781915652" LOG_CI_START="-0.5939820616147772" LOG_EFFECT_SIZE="0.619788758288394" MODIFIED="2011-12-17 06:12:43 +1100" MODIFIED_BY="[Empty name]" ORDER="998" O_E="0.0" SE="1.4259499757471625" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="2.033333333333333" WEIGHT="2.430415357219691"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1625103052817094" CI_START="0.23429583095269915" DF="0" EFFECT_SIZE="0.7118055555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-001.05.07" LOG_CI_END="0.33495818573977293" LOG_CI_START="-0.630235439146726" LOG_EFFECT_SIZE="-0.14763862670347655" MODIFIED="2014-03-31 18:00:47 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.5487709961789005" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="41" WEIGHT="13.771642053715132" Z="0.5996027814622072">
<NAME>Mizoribine versus placebo/no treatment at final follow-up (6 months)</NAME>
<DICH_DATA CI_END="2.1625103052817094" CI_START="0.23429583095269915" EFFECT_SIZE="0.7118055555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.33495818573977293" LOG_CI_START="-0.630235439146726" LOG_EFFECT_SIZE="-0.14763862670347655" MODIFIED="2011-12-17 06:12:43 +1100" MODIFIED_BY="[Empty name]" ORDER="999" O_E="0.0" SE="0.5669595130438277" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="0.32144308943089434" WEIGHT="13.771642053715132"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.340807687420417" CI_END="40.78307096258761" CI_START="10.085709643313761" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="25.434390302950685" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2014-04-10 18:29:35 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.8544148967559099" P_Q="0.85441489675591" P_Z="0.001162731928053371" Q="1.3408076874204167" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="96" UNITS="&#956;mol/L" WEIGHT="100.0" Z="3.24786801341252">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.3570614627455478E-32" CI_END="138.70951421751056" CI_START="-42.70951421751058" DF="0" EFFECT_SIZE="47.99999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.06.01" MODIFIED="2014-03-31 18:01:25 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.29967162878095466" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="2.8630993506072326" Z="1.0371378578032526">
<NAME>Steroids versus placebo/no treatment at final follow-up (36 months)</NAME>
<CONT_DATA CI_END="138.70951421751056" CI_START="-42.70951421751057" EFFECT_SIZE="48.0" ESTIMABLE="YES" MEAN_1="251.0" MEAN_2="203.0" MODIFIED="2013-01-27 18:17:44 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3743" SD_1="257.0" SD_2="166.0" SE="46.28121482487211" STUDY_ID="STD-Cameron-1990" TOTAL_1="44" TOTAL_2="43" WEIGHT="2.8630993506072326"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="83.3382309555809" CI_START="-43.37823095558089" DF="0" EFFECT_SIZE="19.980000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" MODIFIED="2014-04-10 18:29:30 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5365265097990762" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="5.86862035184438" Z="0.6180740816227112">
<NAME>CPA versus placebo/no treatment at final follow-up (24 months)</NAME>
<CONT_DATA CI_END="83.3382309555809" CI_START="-43.37823095558089" EFFECT_SIZE="19.980000000000004" ESTIMABLE="YES" MEAN_1="127.67" MEAN_2="107.69" MODIFIED="2013-01-27 18:18:18 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="106" SD_1="104.95" SD_2="40.65" SE="32.326222040477546" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" WEIGHT="5.86862035184438"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.733625213131096E-31" CI_END="43.583635444320635" CI_START="10.136364555679346" DF="0" EFFECT_SIZE="26.85999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.06.03" MODIFIED="2014-03-31 18:02:23 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.001644378286571116" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="84.23269906810735" Z="3.1479179751328528">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (120 months)</NAME>
<CONT_DATA CI_END="43.583635444320635" CI_START="10.13636455567935" EFFECT_SIZE="26.859999999999992" ESTIMABLE="YES" MEAN_1="73.71" MEAN_2="46.85" MODIFIED="2013-01-27 18:19:14 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3806" SD_1="32.71" SD_2="30.94" SE="8.532623852394504" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="84.23269906810735"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="73.19307644491332" CI_START="-50.193076444913316" DF="0" EFFECT_SIZE="11.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.04" MODIFIED="2014-04-10 18:29:35 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.7148499141141942" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="6.189694940402903" Z="0.36535032974626513">
<NAME>CSA versus placebo/no treatment at final follow-up (12 months)</NAME>
<CONT_DATA CI_END="73.19307644491332" CI_START="-50.193076444913316" EFFECT_SIZE="11.5" ESTIMABLE="YES" MEAN_1="189.2" MEAN_2="177.7" MODIFIED="2013-01-27 18:30:05 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="372" SD_1="65.4" SD_2="78.7" SE="31.476637801276162" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="6.189694940402903"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="113.78413714560352" CI_START="-219.9841371456035" DF="0" EFFECT_SIZE="-53.099999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.05" MODIFIED="2014-03-31 18:02:59 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.5328700834452091" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.8458862890381357" Z="0.6236307977448692">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<CONT_DATA CI_END="113.78413714560355" CI_START="-219.98413714560354" EFFECT_SIZE="-53.099999999999994" ESTIMABLE="YES" MEAN_1="159.1" MEAN_2="212.2" MODIFIED="2013-01-27 18:36:54 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="598" SD_1="106.1" SD_2="141.4" SE="85.14653251894643" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.8458862890381357"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.563802534591026" CI_END="15.62298339848266" CI_START="3.923551042690285" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="9.773267220586472" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2014-04-10 18:29:48 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.6959614659720695" P_Q="0.7192682016896773" P_Z="0.0010582633292993678" Q="3.684608197382241" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="143" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="3.274560881434837">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.485355256889985" CI_START="-11.485355256889985" DF="0" EFFECT_SIZE="8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2014-03-31 18:03:22 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.4209973739363906" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="9.012658877445201" Z="0.8046921223453762">
<NAME>Steroids versus placebo/no treatment at final follow-up (36 months)</NAME>
<CONT_DATA CI_END="27.485355256889985" CI_START="-11.485355256889985" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="75.0" MEAN_2="67.0" MODIFIED="2013-01-27 18:17:53 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3744" SD_1="49.0" SD_2="43.0" SE="9.941690465022816" STUDY_ID="STD-Cameron-1990" TOTAL_1="43" TOTAL_2="43" WEIGHT="9.012658877445201"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.799599677915403" CI_START="-26.4595996779154" DF="0" EFFECT_SIZE="-5.329999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" MODIFIED="2014-04-10 18:29:42 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.6210192393368754" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="7.664556891879466" Z="0.49440633977165466">
<NAME>CPA versus placebo/no treatment at final follow-up (12 months)</NAME>
<CONT_DATA CI_END="15.799599677915403" CI_START="-26.4595996779154" EFFECT_SIZE="-5.329999999999998" ESTIMABLE="YES" MEAN_1="76.67" MEAN_2="82.0" MODIFIED="2013-01-27 18:18:26 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="739" SD_1="18.76" SD_2="27.77" SE="10.78060609510327" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" WEIGHT="7.664556891879466"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1773145771370286" CI_END="21.908219687589828" CI_START="1.49792526618951" DF="1" EFFECT_SIZE="11.703072476889668" ESTIMABLE="YES" I2="15.060934484326088" ID="CMP-001.07.03" MODIFIED="2014-03-31 18:03:59 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.2779034279213536" P_Z="0.024598507643162567" STUDIES="2" TAU2="14.97132192414434" TOTAL_1="51" TOTAL_2="51" WEIGHT="57.031098776264884" Z="2.247650140618795">
<NAME>Alkylating agents+steroids versus placebo/no treatment/ACEi/ARB at final follow-up (9-120 months)</NAME>
<CONT_DATA CI_END="22.179264851104982" CI_START="5.820735148895018" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="64.0" MEAN_2="50.0" MODIFIED="2013-01-27 18:19:55 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3812" SD_1="18.0" SD_2="22.0" SE="4.173170994784587" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="51.149459366811634"/>
<CONT_DATA CI_END="24.020460636392638" CI_START="-24.22046063639264" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="62.1" MODIFIED="2013-01-27 18:19:55 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3813" SD_1="17.0" SD_2="19.9" SE="12.306583603908926" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" WEIGHT="5.881639409453253"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.21426487098626867" CI_END="20.032855144495837" CI_START="-18.33516002651871" DF="1" EFFECT_SIZE="0.8488475589885615" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.04" MODIFIED="2014-04-10 18:29:48 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.6434449966465906" P_Z="0.9308910328787479" STUDIES="2" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="9.298029402825751" Z="0.08672383163772227">
<NAME>CSA versus placebo/no treatment at final follow-up (12-24 months)</NAME>
<CONT_DATA CI_END="42.97818890947444" CI_START="-27.358188909474435" EFFECT_SIZE="7.810000000000002" ESTIMABLE="YES" MEAN_1="43.24" MEAN_2="35.43" MODIFIED="2013-01-27 18:31:17 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="364" SD_1="16.12" SD_2="28.46" SE="17.943283237282227" STUDY_ID="STD-Cattran-1995" TOTAL_1="5" TOTAL_2="3" WEIGHT="2.766747861546578"/>
<CONT_DATA CI_END="20.789462395231432" CI_START="-24.989462395231435" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="44.1" MEAN_2="46.2" MODIFIED="2013-01-27 18:31:33 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="733" SD_1="27.2" SD_2="26.2" SE="11.678511735817898" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="6.5312815412791725"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="37.41395216598051" CI_START="-19.01395216598052" DF="0" EFFECT_SIZE="9.199999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.05" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.5227548442998184" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="4.298745545027094" Z="0.6391046724574271">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<CONT_DATA CI_END="37.41395216598052" CI_START="-19.013952165980523" EFFECT_SIZE="9.199999999999996" ESTIMABLE="YES" MEAN_1="71.3" MEAN_2="62.1" MODIFIED="2013-01-27 18:31:59 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="770" SD_1="25.3" SD_2="19.9" SE="14.395138068111747" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" WEIGHT="4.298745545027094"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="29.672651201550224" CI_START="-4.932651201550243" DF="0" EFFECT_SIZE="12.36999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.06" MODIFIED="2014-03-31 18:04:53 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.16114944306368015" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="11.429948774321717" Z="1.4012161608267433">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<CONT_DATA CI_END="29.672651201550224" CI_START="-4.932651201550243" EFFECT_SIZE="12.36999999999999" ESTIMABLE="YES" MEAN_1="86.6" MEAN_2="74.23" MODIFIED="2013-01-27 18:35:50 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="558" SD_1="27.84" SD_2="21.13" SE="8.82804548350446" STUDY_ID="STD-Dussol-2008" TOTAL_1="15" TOTAL_2="17" WEIGHT="11.429948774321717"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="85.01110748227539" CI_START="-19.011107482275392" DF="0" EFFECT_SIZE="33.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.07" MODIFIED="2014-03-31 18:05:12 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.21366242853004946" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="1.2649617322358904" Z="1.2435576672129767">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<CONT_DATA CI_END="85.01110748227539" CI_START="-19.011107482275392" EFFECT_SIZE="33.0" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="54.0" MODIFIED="2013-01-27 18:37:17 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="599" SD_1="54.0" SD_2="22.0" SE="26.53676694701146" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" WEIGHT="1.2649617322358904"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="36.49460645557516" CI_END="1.6978178345738029" CI_START="1.008276442118905" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3083843952027623" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="123" I2="53.41777415604117" I2_Q="46.99666695635143" ID="CMP-001.08" LOG_CI_END="0.22989109127693724" LOG_CI_START="0.003579620231601674" LOG_EFFECT_SIZE="0.11673535575426952" METHOD="IV" MODIFIED="2014-04-10 18:30:10 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0039375288111401785" P_Q="0.03601768331886157" P_Z="0.0431798251558733" Q="20.75341184853683" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14516366416472104" TOTALS="YES" TOTAL_1="449" TOTAL_2="415" WEIGHT="99.99999999999997" Z="2.0219663806171386">
<NAME>Complete or partial remission (ITT analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.050280463589816" CI_END="2.159205583534534" CI_START="0.63945603637879" DF="2" EFFECT_SIZE="1.1750391670808022" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="33" I2="50.62070348018877" ID="CMP-001.08.01" LOG_CI_END="0.3342939946010271" LOG_CI_START="-0.19418930859646638" LOG_EFFECT_SIZE="0.07005234300228035" MODIFIED="2014-03-31 18:06:00 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.13197557309062002" P_Z="0.6033421175018192" STUDIES="3" TAU2="0.14688065528344965" TOTAL_1="150" TOTAL_2="145" WEIGHT="18.45153870529734" Z="0.5196004054864423">
<NAME>Steroids versus placebo/no treatment at final follow-up (24-48 months)</NAME>
<DICH_DATA CI_END="3.395807001782088" CI_START="0.5780888400401856" EFFECT_SIZE="1.401098901098901" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5309429994627041" LOG_CI_START="-0.23800541456494348" LOG_EFFECT_SIZE="0.14646879244888034" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="863" O_E="0.0" SE="0.4516841047558777" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.20401853048911872" WEIGHT="5.0609989704998535"/>
<DICH_DATA CI_END="1.290030191148355" CI_START="0.42087099341863726" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.11059987440444312" LOG_CI_START="-0.375851004953625" LOG_EFFECT_SIZE="-0.13262556527459096" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="864" O_E="0.0" SE="0.2857436545056173" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.08164943609022557" WEIGHT="7.7914843793129664"/>
<DICH_DATA CI_END="4.303529570941928" CI_START="0.8530038271826506" EFFECT_SIZE="1.915966386554622" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6338247914896153" LOG_CI_START="-0.06904902027376932" LOG_EFFECT_SIZE="0.28238788560792305" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="865" O_E="0.0" SE="0.4128715563112935" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.1704629220109096" WEIGHT="5.5990553554845235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06734836001433708" CI_END="4.62527833845853" CI_START="0.9883222008528062" DF="1" EFFECT_SIZE="2.138051745637169" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.6651378726900578" LOG_CI_START="-0.005101448893336062" LOG_EFFECT_SIZE="0.33001821189836084" MODIFIED="2014-04-10 18:30:05 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.7952374316719293" P_Z="0.05359099138330019" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="7.488347478217424" Z="1.9301279072526483">
<NAME>CPA versus placebo/no treatment at final follow-up (12-24 months)</NAME>
<DICH_DATA CI_END="10.248873583471138" CI_START="0.6098231136424284" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.010676136283019" LOG_CI_START="-0.2147961189389436" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-12-17 05:55:53 +1100" MODIFIED_BY="[Empty name]" ORDER="912" O_E="0.0" SE="0.7198484689028782" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.5181818181818181" WEIGHT="2.6640879823415324"/>
<DICH_DATA CI_END="5.027180990960556" CI_START="0.7956745554203151" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7013245211859962" LOG_CI_START="-0.09926452985803394" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-12-17 05:55:53 +1100" MODIFIED_BY="[Empty name]" ORDER="913" O_E="0.0" SE="0.4702699715629801" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.22115384615384615" WEIGHT="4.824259495875891"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.913610997537111" CI_END="2.7314823477685195" CI_START="0.850823954565576" DF="2" EFFECT_SIZE="1.5244706008823115" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="36" I2="71.07155724103546" ID="CMP-001.08.03" LOG_CI_END="0.4363983982273185" LOG_CI_START="-0.07016029123146887" LOG_EFFECT_SIZE="0.18311905349792482" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.03153035480540045" P_Z="0.15647147877824158" STUDIES="3" TAU2="0.18680162784403098" TOTAL_1="108" TOTAL_2="103" WEIGHT="23.736027807453503" Z="1.4170391593615965">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="1.479112799951296" CI_START="0.3635813156342677" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.17000129538187236" LOG_CI_START="-0.43939844317678484" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2011-12-17 05:59:55 +1100" MODIFIED_BY="[Empty name]" ORDER="934" O_E="0.0" SE="0.35796442300671183" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.12813852813852813" WEIGHT="6.4661417925953195"/>
<DICH_DATA CI_END="3.071946806928875" CI_START="1.122734151534607" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.48741369128874734" LOG_CI_START="0.05027693329641265" LOG_EFFECT_SIZE="0.26884531229257996" MODIFIED="2011-12-17 05:59:55 +1100" MODIFIED_BY="[Empty name]" ORDER="936" O_E="0.0" SE="0.2567762955065478" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.06593406593406595" WEIGHT="8.371528802479137"/>
<DICH_DATA CI_END="3.474003986473355" CI_START="1.4037796531321036" EFFECT_SIZE="2.2083333333333335" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" LOG_CI_END="0.540830312471007" LOG_CI_START="0.14729894330735907" LOG_EFFECT_SIZE="0.3440646278891831" MODIFIED="2011-12-17 05:59:55 +1100" MODIFIED_BY="[Empty name]" ORDER="935" O_E="0.0" SE="0.23116227425842129" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.053435997040325575" WEIGHT="8.898357212379048"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4606855634238305" CI_START="0.6846100386287185" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.16455673696984163" LOG_CI_START="-0.1645567369698416" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="9.681362355142502" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="1.4606855634238305" CI_START="0.6846100386287185" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.16455673696984163" LOG_CI_START="-0.1645567369698416" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:59:55 +1100" MODIFIED_BY="[Empty name]" ORDER="937" O_E="0.0" SE="0.19332288373014034" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.037373737373737365" WEIGHT="9.681362355142502"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.381367147137342" CI_START="0.12702787151642592" DF="0" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="0.37682635789272834" LOG_CI_START="-0.8961009789042407" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2014-04-10 18:30:10 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.4239758978383188" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="2.5093351108683546" Z="0.7995425393480902">
<NAME>CSA versus placebo/no treatment at final follow-up (21 months)</NAME>
<DICH_DATA CI_END="2.381367147137342" CI_START="0.12702787151642592" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37682635789272834" LOG_CI_START="-0.8961009789042407" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2011-12-17 06:03:21 +1100" MODIFIED_BY="[Empty name]" ORDER="961" O_E="0.0" SE="0.7477238187264794" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.5590909090909091" WEIGHT="2.5093351108683546"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4864315243170512" CI_START="0.5912860670819117" DF="0" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-001.08.06" LOG_CI_END="0.17214490728718904" LOG_CI_START="-0.22820235448767603" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.783747898715015" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="8.815482952676959" Z="0.27443818921383306">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="1.4864315243170512" CI_START="0.5912860670819117" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.17214490728718904" LOG_CI_START="-0.22820235448767603" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2011-12-17 06:03:21 +1100" MODIFIED_BY="[Empty name]" ORDER="962" O_E="0.0" SE="0.2351659633174628" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.05530303030303027" WEIGHT="8.815482952676959"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3047512408616342" CI_START="0.31037232615967697" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.08.07" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.2172726787339797" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="6.325862777757058" Z="1.2338128358563585">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="1.3047512408616342" CI_START="0.31037232615967697" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2011-12-20 03:35:51 +1100" MODIFIED_BY="[Empty name]" ORDER="963" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="6.325862777757058"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.874146434896417" CI_START="0.6009947571922385" DF="0" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-001.08.08" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.49361949744298717" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="5.802836910597699" Z="0.6845633627749433">
<NAME>Tacrolimus versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="2.874146434896417" CI_START="0.6009947571922385" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" MODIFIED="2011-12-17 06:05:54 +1100" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="0.3992228475270142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.15937888198757763" WEIGHT="5.802836910597699"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0277946620172553" CI_START="0.3947904744083435" DF="0" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-001.08.09" LOG_CI_END="0.3070239754799399" LOG_CI_START="-0.40363333462904993" LOG_EFFECT_SIZE="-0.04830467957455503" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.789896753727007" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="5.532512074750957" Z="0.26644468692330925">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="2.0277946620172553" CI_START="0.3947904744083435" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3070239754799399" LOG_CI_START="-0.40363333462904993" LOG_EFFECT_SIZE="-0.04830467957455503" MODIFIED="2011-12-17 06:09:15 +1100" MODIFIED_BY="[Empty name]" ORDER="987" O_E="0.0" SE="0.4174436217684402" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.17425917735515256" WEIGHT="5.532512074750957"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1254129761984543E-31" CI_END="25.615203722900386" CI_START="1.9129264217482393" DF="0" EFFECT_SIZE="7.000000000000001" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="100.0" ID="CMP-001.08.10" LOG_CI_END="1.4084978142580222" LOG_CI_START="0.2816982657704915" LOG_EFFECT_SIZE="0.8450980400142569" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Z="0.003282754521303212" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.029890706875683" Z="2.939940336427394">
<NAME>ACTH versus placebo/no treatment at final follow-up (21 months)</NAME>
<DICH_DATA CI_END="25.615203722900386" CI_START="1.912926421748239" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4084978142580222" LOG_CI_START="0.28169826577049145" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-12-17 06:10:38 +1100" MODIFIED_BY="[Empty name]" ORDER="991" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.4380952380952381" WEIGHT="3.029890706875683"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1436437641875323E-32" CI_END="5.427609016158131" CI_START="0.01421629553592598" DF="0" EFFECT_SIZE="0.27777777777777773" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="99.99999999999999" ID="CMP-001.08.11" LOG_CI_END="0.7346085552292557" LOG_CI_START="-1.8472135567638306" LOG_EFFECT_SIZE="-0.5563025007672874" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Z="0.39832150266566846" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.7227371948796113" Z="0.844622765409462">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="5.427609016158132" CI_START="0.014216295535925991" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7346085552292558" LOG_CI_START="-1.8472135567638301" LOG_EFFECT_SIZE="-0.5563025007672873" MODIFIED="2011-12-17 06:13:01 +1100" MODIFIED_BY="[Empty name]" ORDER="1000" O_E="0.0" SE="1.51657508881031" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="2.3" WEIGHT="0.7227371948796113"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6255052895046023" CI_END="4.3752179969095835" CI_START="1.1447892370836827" DF="1" EFFECT_SIZE="2.238013063580488" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" I2="0.0" ID="CMP-001.08.12" LOG_CI_END="0.6409996967860485" LOG_CI_START="0.05872553768294053" LOG_EFFECT_SIZE="0.3498626172344946" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.42900902594939216" P_Z="0.018507249551544317" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="7.9040659254829" Z="2.355310187121342">
<NAME>Mizoribine versus placebo/no treatment at final follow-up (6-24 months)</NAME>
<DICH_DATA CI_END="4.139431378393984" CI_START="0.9941954681460111" EFFECT_SIZE="2.0286458333333335" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6169406874526974" LOG_CI_START="-0.002528220842630064" LOG_EFFECT_SIZE="0.30720623330503366" MODIFIED="2011-12-17 06:13:01 +1100" MODIFIED_BY="[Empty name]" ORDER="1001" O_E="0.0" SE="0.36387910315322597" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="0.13240800171159606" WEIGHT="6.366682716266192"/>
<DICH_DATA CI_END="33.60917724158162" CI_START="0.6612625366033063" EFFECT_SIZE="4.714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5264578809962663" LOG_CI_START="-0.17962608126900487" LOG_EFFECT_SIZE="0.6734158998636307" MODIFIED="2011-12-17 06:13:01 +1100" MODIFIED_BY="[Empty name]" ORDER="1002" O_E="0.0" SE="1.0021621646864367" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="14" TOTAL_2="11" VAR="1.0043290043290045" WEIGHT="1.5373832092167086"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.84979001420316" CI_END="2.876467830107221" CI_START="0.8742961320207755" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5858387994197067" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="38" I2="45.84095270287416" I2_Q="45.48531349512908" ID="CMP-001.09" LOG_CI_END="0.45885952131822144" LOG_CI_START="-0.05834144297240969" LOG_EFFECT_SIZE="0.2002590391729059" METHOD="IV" MODIFIED="2014-04-10 18:30:33 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.027048305143418827" P_Q="0.04943570839088651" P_Z="0.12906805034538568" Q="18.343680650362895" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5629193681251058" TOTALS="YES" TOTAL_1="397" TOTAL_2="364" WEIGHT="99.99999999999999" Z="1.5177872102223435">
<NAME>Complete remission (ITT analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0832665706909363" CI_END="1.4201529279867173" CI_START="0.2899727747659677" DF="1" EFFECT_SIZE="0.6417208778903192" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="7.686618690524781" ID="CMP-001.09.01" LOG_CI_END="0.15233511354127302" LOG_CI_START="-0.5376427756319125" LOG_EFFECT_SIZE="-0.19265383104531975" MODIFIED="2014-04-01 15:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.2979683949207578" P_Z="0.273730465512372" STUDIES="2" TAU2="0.02782627491364865" TOTAL_1="98" TOTAL_2="94" WEIGHT="20.891604003473113" Z="1.0945120887423523">
<NAME>Steroids versus placebo/no treatment at final follow-up (24-48 months)</NAME>
<DICH_DATA CI_END="1.2070156228978242" CI_START="0.1887210503965696" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.08171289138517528" LOG_CI_START="-0.7241796548897116" LOG_EFFECT_SIZE="-0.3212333817522681" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="875" O_E="0.0" SE="0.47338527091431004" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.22409361471861472" WEIGHT="11.727675998940864"/>
<DICH_DATA CI_END="4.127266954971465" CI_START="0.3026542653346546" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6156625603049641" LOG_CI_START="-0.5190532011558541" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="874" O_E="0.0" SE="0.6665376552156925" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.44427244582043346" WEIGHT="9.163928004532247"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.43689862203422" CI_START="0.20579414842785088" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="1.288626969500306" LOG_CI_START="-0.6865669781723437" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-04-10 18:30:20 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5502285173068775" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.834719381486489" Z="0.5974177375977199">
<NAME>CPA versus placebo/no treatment at final follow-up (12-24 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 05:56:00 +1100" MODIFIED_BY="[Empty name]" ORDER="915" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="19.43689862203422" CI_START="0.20579414842785088" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.288626969500306" LOG_CI_START="-0.6865669781723437" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-12-17 05:56:00 +1100" MODIFIED_BY="[Empty name]" ORDER="914" O_E="0.0" SE="1.1602387022306428" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="1.3461538461538463" WEIGHT="4.834719381486489"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2897446585764896" CI_END="8.20655503331498" CI_START="1.2333101363598693" DF="2" EFFECT_SIZE="3.181387670055705" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="9" I2="39.20500806085592" ID="CMP-001.09.03" LOG_CI_END="0.9141608862300161" LOG_CI_START="0.09107230090491568" LOG_EFFECT_SIZE="0.5026165935674658" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.19303738714240637" P_Z="0.016679733299411314" STUDIES="3" TAU2="0.2804527659538315" TOTAL_1="108" TOTAL_2="103" WEIGHT="27.725872613355143" Z="2.393692341232856">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="5.50957941564827" CI_START="0.2196174895970038" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.741118447411729" LOG_CI_START="-0.6583330770952789" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2011-12-17 06:00:15 +1100" MODIFIED_BY="[Empty name]" ORDER="938" O_E="0.0" SE="0.8220447528921864" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.6757575757575757" WEIGHT="7.451364389507312"/>
<DICH_DATA CI_END="31.96980139235623" CI_START="1.9486262399004417" EFFECT_SIZE="7.892857142857143" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.5047399382900903" LOG_CI_START="0.28972854639569257" LOG_EFFECT_SIZE="0.8972342423428915" MODIFIED="2011-12-17 06:00:15 +1100" MODIFIED_BY="[Empty name]" ORDER="940" O_E="0.0" SE="0.7137037060021583" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.5093729799612152" WEIGHT="8.607571700220829"/>
<DICH_DATA CI_END="7.951338298608254" CI_START="1.2224009114405654" EFFECT_SIZE="3.1176470588235294" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.9004402313967758" LOG_CI_START="0.08721366504825456" LOG_EFFECT_SIZE="0.4938269482225151" MODIFIED="2011-12-17 06:00:15 +1100" MODIFIED_BY="[Empty name]" ORDER="939" O_E="0.0" SE="0.4776933106095478" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.2281908990011099" WEIGHT="11.666936523627001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="98.1571794174011" CI_START="0.36675870490241486" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="1.9919220702868148" LOG_CI_START="-0.43561956951952757" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.2089212210158906" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="3.555059669101672" Z="1.2565373959133574">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="98.1571794174011" CI_START="0.36675870490241486" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9919220702868148" LOG_CI_START="-0.43561956951952757" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2011-12-17 06:00:15 +1100" MODIFIED_BY="[Empty name]" ORDER="941" O_E="0.0" SE="1.4259499757471625" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="2.033333333333333" WEIGHT="3.555059669101672"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.025911702882953" CI_START="0.01647556188677972" DF="0" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.09.05" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2014-04-10 18:30:27 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.5216759098125796" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="3.0208822463970404" Z="0.6407641842385507">
<NAME>CSA versus placebo/no treatment at final follow-up (21 months)</NAME>
<DICH_DATA CI_END="8.025911702882953" CI_START="0.01647556188677972" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2011-12-17 06:03:43 +1100" MODIFIED_BY="[Empty name]" ORDER="964" O_E="0.0" SE="1.5787413475374117" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="2.492424242424242" WEIGHT="3.0208822463970404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.444471073244248" CI_START="0.2869883922569798" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.09.06" LOG_CI_END="0.7359556947200622" LOG_CI_START="-0.5421356687039494" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.766294996840361" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="8.192966410387438" Z="0.29722465963348416">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="5.444471073244248" CI_START="0.2869883922569798" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.7359556947200622" LOG_CI_START="-0.5421356687039494" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2011-12-17 06:03:43 +1100" MODIFIED_BY="[Empty name]" ORDER="965" O_E="0.0" SE="0.7507571935295483" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.5636363636363636" WEIGHT="8.192966410387438"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:03:43 +1100" MODIFIED_BY="[Empty name]" ORDER="966" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0551828882219874" CI_START="0.14826125779181165" DF="0" EFFECT_SIZE="0.552" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.09.08" LOG_CI_END="0.3128504752687488" LOG_CI_START="-0.8289723198103509" LOG_EFFECT_SIZE="-0.2580609222708011" MODIFIED="2014-04-10 18:30:33 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.37565282413187306" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="9.113414497688654" Z="0.8859345174185664">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="2.0551828882219874" CI_START="0.14826125779181165" EFFECT_SIZE="0.552" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3128504752687488" LOG_CI_START="-0.8289723198103509" LOG_EFFECT_SIZE="-0.2580609222708011" MODIFIED="2011-12-17 06:06:05 +1100" MODIFIED_BY="[Empty name]" ORDER="979" O_E="0.0" SE="0.670712361943455" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.4498550724637681" WEIGHT="9.113414497688654"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.876883792725292E-33" CI_END="4.504968170232591" CI_START="0.0444261749678004" DF="0" EFFECT_SIZE="0.44736842105263164" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="99.99999999999999" ID="CMP-001.09.09" LOG_CI_END="0.6536917268264735" LOG_CI_START="-1.3523610773035457" LOG_EFFECT_SIZE="-0.3493346752385362" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Z="0.4948485731953328" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="4.729696290137559" Z="0.6826175069857738">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="4.5049681702325906" CI_START="0.0444261749678004" EFFECT_SIZE="0.4473684210526316" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6536917268264734" LOG_CI_START="-1.3523610773035457" LOG_EFFECT_SIZE="-0.34933467523853623" MODIFIED="2011-12-17 06:09:29 +1100" MODIFIED_BY="[Empty name]" ORDER="988" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="1.388544891640867" WEIGHT="4.729696290137559"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="74.87602215221686" CI_START="1.6160046503808239" DF="0" EFFECT_SIZE="11.000000000000002" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" ID="CMP-001.09.10" LOG_CI_END="1.8743427641057142" LOG_CI_START="0.20844260621073604" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.01426827082034153" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.0702813930407835" Z="2.45043755713751">
<NAME>ACTH versus placebo/no treatment at final follow-up (22 months)</NAME>
<DICH_DATA CI_END="74.87602215221686" CI_START="1.6160046503808239" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.8743427641057142" LOG_CI_START="0.20844260621073604" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2011-12-17 06:10:50 +1100" MODIFIED_BY="[Empty name]" ORDER="992" O_E="0.0" SE="0.9785579990862869" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.9575757575757575" WEIGHT="6.0702813930407835"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1436437641875323E-32" CI_END="5.427609016158131" CI_START="0.01421629553592598" DF="0" EFFECT_SIZE="0.27777777777777773" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="99.99999999999999" ID="CMP-001.09.11" LOG_CI_END="0.7346085552292557" LOG_CI_START="-1.8472135567638306" LOG_EFFECT_SIZE="-0.5563025007672874" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Z="0.39832150266566846" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="3.2239235839169567" Z="0.844622765409462">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="5.427609016158132" CI_START="0.014216295535925991" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7346085552292558" LOG_CI_START="-1.8472135567638301" LOG_EFFECT_SIZE="-0.5563025007672873" MODIFIED="2011-12-17 06:13:17 +1100" MODIFIED_BY="[Empty name]" ORDER="1003" O_E="0.0" SE="1.51657508881031" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="2.3" WEIGHT="3.2239235839169567"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07308386647291532" CI_END="22.8059834363604" CI_START="0.7310389762848056" DF="1" EFFECT_SIZE="4.083143737916306" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.09.12" LOG_CI_END="1.3580488045653718" LOG_CI_START="-0.13605946745505226" LOG_EFFECT_SIZE="0.6109946685551598" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.7868984866702163" P_Z="0.1089347235126229" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="8.641579911015146" Z="1.60299968555121">
<NAME>Mizoribine versus placebo/no treatment at final follow-up (6-24 months)</NAME>
<DICH_DATA CI_END="29.369805407980195" CI_START="0.397469814625984" EFFECT_SIZE="3.4166666666666665" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.467901069079137" LOG_CI_START="-0.40069584773491573" LOG_EFFECT_SIZE="0.5336026106721107" MODIFIED="2011-12-17 06:13:17 +1100" MODIFIED_BY="[Empty name]" ORDER="1005" O_E="0.0" SE="1.0976230786404901" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="1.2047764227642277" WEIGHT="5.221392344385004"/>
<DICH_DATA CI_END="98.20668387837253" CI_START="0.31932653421877966" EFFECT_SIZE="5.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9921410465722078" LOG_CI_START="-0.49576499255980705" LOG_EFFECT_SIZE="0.7481880270062004" MODIFIED="2011-12-17 06:13:17 +1100" MODIFIED_BY="[Empty name]" ORDER="1004" O_E="0.0" SE="1.4614083227196584" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="14" TOTAL_2="11" VAR="2.1357142857142852" WEIGHT="3.420187566630143"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.474822885733065" CI_END="1.5662064684469013" CI_START="0.8603583859819561" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="1.16081818960054" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="78" I2="26.739293015071414" I2_Q="29.374485223733206" ID="CMP-001.10" LOG_CI_END="0.19484901327529217" LOG_CI_START="-0.06532060383486848" LOG_EFFECT_SIZE="0.06476420472021183" METHOD="IV" MODIFIED="2014-04-10 18:30:52 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.1544645411689093" P_Q="0.1658536997382768" P_Z="0.32916835036470693" Q="14.159188830947013" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09451149875283527" TOTALS="YES" TOTAL_1="397" TOTAL_2="364" WEIGHT="100.0" Z="0.9757904104939922">
<NAME>Partial remission (ITT analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6913843590795996" CI_END="4.2461139544315225" CI_START="0.621940592046259" DF="1" EFFECT_SIZE="1.625063268526805" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="40.87683295450539" ID="CMP-001.10.01" LOG_CI_END="0.6279916452978805" LOG_CI_START="-0.20625109726848945" LOG_EFFECT_SIZE="0.2108702740146955" MODIFIED="2014-04-01 15:53:12 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.1934186644487088" P_Z="0.3217665335321661" STUDIES="2" TAU2="0.20538389474749116" TOTAL_1="98" TOTAL_2="94" WEIGHT="12.86358377506268" Z="0.9908342533672442">
<NAME>Steroids versus placebo/no treatment at final follow-up (24-48 months)</NAME>
<DICH_DATA CI_END="2.5788572150415536" CI_START="0.46388340367294195" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.41142729699012415" LOG_CI_START="-0.3335911649293849" LOG_EFFECT_SIZE="0.03891806603036966" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="882" O_E="0.0" SE="0.43762753243238384" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.19151785714285716" WEIGHT="8.165405397116265"/>
<DICH_DATA CI_END="10.336445219758424" CI_START="0.8593609524200205" EFFECT_SIZE="2.980392156862745" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0143712073383206" LOG_CI_START="-0.06582438364464817" LOG_EFFECT_SIZE="0.4742734118468362" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="883" O_E="0.0" SE="0.6345122371978075" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.4026057791537667" WEIGHT="4.698178377946414"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05760845762553227" CI_END="5.340777403701973" CI_START="0.8955247880368726" DF="1" EFFECT_SIZE="2.1869610312948717" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.7276044775462797" LOG_CI_START="-0.04792238842060204" LOG_EFFECT_SIZE="0.3398410445628388" MODIFIED="2014-04-10 18:30:40 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.8103165996639681" P_Z="0.08584430942564027" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="9.1119764680227" Z="1.7177385775828944">
<NAME>CPA versus placebo/no treatment at final follow-up (12-24 months)</NAME>
<DICH_DATA CI_END="10.248873583471138" CI_START="0.6098231136424284" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.010676136283019" LOG_CI_START="-0.2147961189389436" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-12-17 05:56:08 +1100" MODIFIED_BY="[Empty name]" ORDER="917" O_E="0.0" SE="0.7198484689028782" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.5181818181818181" WEIGHT="3.811932628952558"/>
<DICH_DATA CI_END="6.336261118415285" CI_START="0.63128711478993" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8018330663008477" LOG_CI_START="-0.19977307497288524" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-12-17 05:56:08 +1100" MODIFIED_BY="[Empty name]" ORDER="916" O_E="0.0" SE="0.5883484054145521" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.34615384615384615" WEIGHT="5.300043839070143"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.531091480952724" CI_END="2.016231034290524" CI_START="0.5006464165612899" DF="2" EFFECT_SIZE="1.0046983837337522" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" I2="55.86052481157426" ID="CMP-001.10.03" LOG_CI_END="0.3045402952182405" LOG_CI_START="-0.3004688880040038" LOG_EFFECT_SIZE="0.0020357036071183138" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.10377351708422744" P_Z="0.9894765501478041" STUDIES="3" TAU2="0.2102152896278855" TOTAL_1="108" TOTAL_2="103" WEIGHT="27.19106278743533" Z="0.01318957088188378">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="1.6931265280713392" CI_START="0.2032794195067245" EFFECT_SIZE="0.5866666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.22868941433451248" LOG_CI_START="-0.6919065881455377" LOG_EFFECT_SIZE="-0.23160858690551261" MODIFIED="2011-12-17 06:00:33 +1100" MODIFIED_BY="[Empty name]" ORDER="942" O_E="0.0" SE="0.5407626488804885" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.2924242424242425" WEIGHT="6.036003909226711"/>
<DICH_DATA CI_END="1.6336005542104033" CI_START="0.35333316996160546" EFFECT_SIZE="0.7597402597402597" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.21314587208029778" LOG_CI_START="-0.4518155902609006" LOG_EFFECT_SIZE="-0.11933485909030143" MODIFIED="2011-12-17 06:00:33 +1100" MODIFIED_BY="[Empty name]" ORDER="944" O_E="0.0" SE="0.39060165459154494" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.15256965256965258" WEIGHT="9.452544776740355"/>
<DICH_DATA CI_END="3.3882282953244376" CI_START="0.9509562861984915" EFFECT_SIZE="1.7950089126559714" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5299726649583587" LOG_CI_START="-0.021839446363445574" LOG_EFFECT_SIZE="0.25406660929745656" MODIFIED="2011-12-17 06:00:33 +1100" MODIFIED_BY="[Empty name]" ORDER="943" O_E="0.0" SE="0.3241371657044322" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.10506490219090255" WEIGHT="11.702514101468266"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3538904701556491" CI_START="0.2197523859687265" DF="0" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="0.13158353131287054" LOG_CI_START="-0.6580664008620333" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.19129229053446825" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="7.5422169955556475" Z="1.3067657207942374">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="1.3538904701556491" CI_START="0.2197523859687265" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.13158353131287054" LOG_CI_START="-0.6580664008620333" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2011-12-17 06:00:33 +1100" MODIFIED_BY="[Empty name]" ORDER="945" O_E="0.0" SE="0.4638442789897436" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.21515151515151512" WEIGHT="7.5422169955556475"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.52818330812873" CI_START="0.15242342327814115" DF="0" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786977" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2014-04-10 18:30:45 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.6987847323689892" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="3.169266349646583" Z="0.3869614715102904">
<NAME>CSA versus placebo/no treatment at final follow-up (21 months)</NAME>
<DICH_DATA CI_END="3.52818330812873" CI_START="0.15242342327814115" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786977" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2011-12-17 06:04:04 +1100" MODIFIED_BY="[Empty name]" ORDER="967" O_E="0.0" SE="0.8015137194235931" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.6424242424242423" WEIGHT="3.169266349646583"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6907575092527263" CI_START="0.4107297709127858" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-001.10.06" LOG_CI_END="0.22808132495722366" LOG_CI_START="-0.3864438170524732" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.6135021673106729" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="10.388766491973486" Z="0.5050806871686963">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="1.6907575092527263" CI_START="0.4107297709127858" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.22808132495722366" LOG_CI_START="-0.3864438170524732" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2011-12-17 06:04:04 +1100" MODIFIED_BY="[Empty name]" ORDER="968" O_E="0.0" SE="0.3609751103650088" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.13030303030303028" WEIGHT="10.388766491973486"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.207498031553913" CI_START="0.1711071694104944" DF="0" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.10.07" LOG_CI_END="0.08188643144345012" LOG_CI_START="-0.7667317930878625" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.11371462832435121" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="6.80924349537148" Z="1.581715081058608">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="1.207498031553913" CI_START="0.1711071694104944" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.08188643144345012" LOG_CI_START="-0.7667317930878625" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2011-12-17 06:04:04 +1100" MODIFIED_BY="[Empty name]" ORDER="969" O_E="0.0" SE="0.498482545817653" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.2484848484848485" WEIGHT="6.80924349537148"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.947084488308839" CI_START="0.7434098509040599" DF="0" EFFECT_SIZE="3.22" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-001.10.08" LOG_CI_END="1.1444834317692567" LOG_CI_START="-0.12877168837759487" LOG_EFFECT_SIZE="0.5078558716958309" MODIFIED="2014-04-10 18:30:52 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.11793059543891246" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="3.571769390031082" Z="1.5635188928142236">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="13.947084488308839" CI_START="0.7434098509040599" EFFECT_SIZE="3.22" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1444834317692567" LOG_CI_START="-0.12877168837759487" LOG_EFFECT_SIZE="0.5078558716958309" MODIFIED="2011-12-17 06:06:19 +1100" MODIFIED_BY="[Empty name]" ORDER="980" O_E="0.0" SE="0.7479163602887542" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.5593788819875776" WEIGHT="3.571769390031082"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.889951427770075" CI_START="0.39889867104895677" DF="0" EFFECT_SIZE="1.0736842105263158" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.10.09" LOG_CI_END="0.46089054350786235" LOG_CI_START="-0.39913741056172275" LOG_EFFECT_SIZE="0.030876566473069796" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.8880812395306014" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="6.678271847432744" Z="0.1407325377439471">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="2.889951427770075" CI_START="0.39889867104895677" EFFECT_SIZE="1.0736842105263158" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.46089054350786235" LOG_CI_START="-0.39913741056172275" LOG_EFFECT_SIZE="0.030876566473069796" MODIFIED="2011-12-17 06:09:41 +1100" MODIFIED_BY="[Empty name]" ORDER="989" O_E="0.0" SE="0.5051846774275063" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.25521155830753356" WEIGHT="6.678271847432744"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.6782739076548" CI_START="0.3504908481140964" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.10.10" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.3159133624715845" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.8041907303368871" Z="1.0028912207598348">
<NAME>ACTH versus placebo/no treatment at final follow-up (22 months)</NAME>
<DICH_DATA CI_END="25.6782739076548" CI_START="0.3504908481140964" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-12-17 06:11:10 +1100" MODIFIED_BY="[Empty name]" ORDER="993" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="1.8041907303368871"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:13:38 +1100" MODIFIED_BY="[Empty name]" ORDER="1006" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0479131256948779" CI_END="3.973331320996746" CI_START="0.8973248452458816" DF="1" EFFECT_SIZE="1.8882184494183982" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="0.0" ID="CMP-001.10.12" LOG_CI_END="0.5991547807314771" LOG_CI_START="-0.04705030728099648" LOG_EFFECT_SIZE="0.2760522367252403" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.8267352149572635" P_Z="0.09402190207406458" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="10.869651669131395" Z="1.6745533325876645">
<NAME>Mizoribine versus placebo/no treatment at final follow-up (6-24 months)</NAME>
<DICH_DATA CI_END="4.050993762107117" CI_START="0.8270087457911954" EFFECT_SIZE="1.8303571428571428" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6075615744389465" LOG_CI_START="-0.08248989766780115" LOG_EFFECT_SIZE="0.26253583838557265" MODIFIED="2011-12-17 06:13:38 +1100" MODIFIED_BY="[Empty name]" ORDER="1008" O_E="0.0" SE="0.40533965052537996" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="0.16430023228803714" WEIGHT="9.024110448824821"/>
<DICH_DATA CI_END="19.655895228225052" CI_START="0.28266951896453085" EFFECT_SIZE="2.357142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2934928285592757" LOG_CI_START="-0.5487210201599768" LOG_EFFECT_SIZE="0.37238590419964945" MODIFIED="2011-12-17 06:13:38 +1100" MODIFIED_BY="[Empty name]" ORDER="1007" O_E="0.0" SE="1.0821255338433111" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="14" TOTAL_2="11" VAR="1.170995670995671" WEIGHT="1.8455412203065733"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="22.057849476979044" CI_END="-0.09225929869227012" CI_START="-1.8097808808591496" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9510200897757098" ESTIMABLE="YES" I2="59.19819831306327" I2_Q="20.720001602343398" ID="CMP-001.11" MODIFIED="2014-04-10 18:31:10 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.008697445419439509" P_Q="0.2714816548713491" P_Z="0.029966800914969748" Q="7.568113170114987" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.8200733191201993" TOTALS="YES" TOTAL_1="199" TOTAL_2="194" UNITS="g/24 h" WEIGHT="100.0" Z="2.1705289108306904">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9866745072190628" CI_START="-1.9866745072190628" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" MODIFIED="2014-04-01 15:53:20 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.3910687301658" Z="0.0">
<NAME>Steroids versus placebo/no treatment at final follow-up (36 months)</NAME>
<CONT_DATA CI_END="1.9866745072190628" CI_START="-1.9866745072190628" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="5.6" MODIFIED="2013-01-27 18:18:00 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3773" SD_1="4.7" SD_2="4.7" SE="1.0136280681123213" STUDY_ID="STD-Cameron-1990" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.3910687301658"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.619036695209595" CI_START="-3.5990366952095956" DF="0" EFFECT_SIZE="-0.4900000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" MODIFIED="2014-04-10 18:30:58 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.7573973728201391" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="5.754118481230798" Z="0.3089002950349169">
<NAME>CPA versus placebo/no treatment at final follow-up (12 months)</NAME>
<CONT_DATA CI_END="2.619036695209595" CI_START="-3.5990366952095956" EFFECT_SIZE="-0.4900000000000002" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.69" MODIFIED="2013-01-27 18:18:34 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="738" SD_1="3.15" SD_2="3.76" SE="1.5862723599684891" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" WEIGHT="5.754118481230798"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.798014051721769" CI_END="-0.7561756084396757" CI_START="-2.488000334903514" DF="2" EFFECT_SIZE="-1.6220879716715948" ESTIMABLE="YES" I2="58.31608706351539" ID="CMP-001.11.03" MODIFIED="2014-04-08 11:29:53 +1000" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.09080811952482215" P_Z="2.4109101807185865E-4" STUDIES="3" TAU2="0.3492465727308672" TOTAL_1="93" TOTAL_2="90" WEIGHT="52.06901224806878" Z="3.671542455365605">
<NAME>Alkylating agents+steroids versus placebo/no treatment/ACEi/ARB at final follow-up (9-120 months)</NAME>
<CONT_DATA CI_END="-1.5120981589833844" CI_START="-4.687901841016616" EFFECT_SIZE="-3.1" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="5.2" MODIFIED="2013-01-27 18:20:58 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3885" SD_1="2.4" SD_2="4.5" SE="0.8101688875621097" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" WEIGHT="13.002605525168134"/>
<CONT_DATA CI_END="-1.161849395868547" CI_START="-1.6381506041314529" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.5" MODIFIED="2013-01-27 18:20:58 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3889" SD_1="0.2" SD_2="0.8" SE="0.12150764300260336" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="22.995683474841947"/>
<CONT_DATA CI_END="0.19942750024749323" CI_START="-2.1994275002474932" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" MODIFIED="2013-01-27 18:20:58 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3890" SD_1="1.1" SD_2="0.6" SE="0.6119640512317697" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" WEIGHT="16.070723248058698"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.856345463510227" CI_END="9.133934541182912" CI_START="-9.287275396545043" DF="1" EFFECT_SIZE="-0.07667042768106551" ESTIMABLE="YES" I2="87.27143549574514" ID="CMP-001.11.04" MODIFIED="2014-04-10 18:31:04 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.005064282482538096" P_Z="0.9869830686149463" STUDIES="2" TAU2="38.556520202020195" TOTAL_1="19" TOTAL_2="19" WEIGHT="6.034206265509269" Z="0.01631502788819587">
<NAME>CSA versus placebo/no treatment at final follow-up (12-21 months)</NAME>
<CONT_DATA CI_END="-0.3602051960550483" CI_START="-9.03979480394495" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="9.2" MODIFIED="2013-01-27 18:33:38 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="844" SD_1="4.0" SD_2="5.0" SE="2.214221709264404" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" WEIGHT="3.3545617186338395"/>
<CONT_DATA CI_END="9.636690511419754" CI_START="-0.23669051141975483" EFFECT_SIZE="4.7" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="2.8" MODIFIED="2013-01-27 18:33:46 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="740" SD_1="7.6" SD_2="2.5" SE="2.518765931598611" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="2.679644546875429"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8978023739083103" CI_START="-1.0978023739083105" DF="0" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.05" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.6006792822874161" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="13.672831005096652" Z="0.5234239225902135">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<CONT_DATA CI_END="1.8978023739083103" CI_START="-1.0978023739083105" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.0" MODIFIED="2013-01-27 18:33:38 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="393" SD_1="1.6" SD_2="0.6" SE="0.7641989269817121" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" WEIGHT="13.672831005096652"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1542767241751446" CI_START="-3.754276724175145" DF="0" EFFECT_SIZE="-1.3000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.06" MODIFIED="2014-04-10 18:31:10 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.29919155500890793" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="8.038914571918724" Z="1.0381686607725173">
<NAME>TAC versus placebo/no treatment at final follow-up (18 months)</NAME>
<CONT_DATA CI_END="1.1542767241751446" CI_START="-3.754276724175145" EFFECT_SIZE="-1.3000000000000003" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="3.2" MODIFIED="2013-01-27 18:35:07 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="517" SD_1="4.0" SD_2="4.62" SE="1.2522050116911159" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" WEIGHT="8.038914571918724"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.98646575733909" CI_START="-2.7864657573390885" DF="0" EFFECT_SIZE="1.1000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.07" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.5790756180881118" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="4.0398486980099655" Z="0.5547354634278734">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<CONT_DATA CI_END="4.98646575733909" CI_START="-2.786465757339089" EFFECT_SIZE="1.1000000000000005" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="4.1" MODIFIED="2013-01-27 18:37:42 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="606" SD_1="2.9" SD_2="3.0" SE="1.98292712927127" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" WEIGHT="4.0398486980099655"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.073673933827453" CI_END="13.024947493246868" CI_START="2.194890712707357" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="5.346806176254056" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="1.1147759812276765" LOG_CI_START="0.34141290086527215" LOG_EFFECT_SIZE="0.7280944410464743" METHOD="IV" MODIFIED="2014-04-10 18:31:30 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.9439622502707534" P_Q="0.9133826433392255" P_Z="2.238349485757209E-4" Q="1.4972875806045214" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="456" TOTAL_2="424" WEIGHT="100.0" Z="3.690475839953957">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9887098294615504" CI_END="13.116317764186752" CI_START="0.37715457834135957" DF="2" EFFECT_SIZE="2.2241581094299794" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="1.1178119296168123" LOG_CI_START="-0.4234806159440063" LOG_EFFECT_SIZE="0.3471656568364031" MODIFIED="2014-04-01 15:53:29 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.36996213046598514" P_Z="0.37727026746717895" STUDIES="3" TAU2="0.0" TOTAL_1="150" TOTAL_2="145" WEIGHT="25.176578836757113" Z="0.882937098512934">
<NAME>Steroids versus placebo/no treatment</NAME>
<DICH_DATA CI_END="70.613833580842" CI_START="0.12268957662178398" EFFECT_SIZE="2.943396226415094" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8488897897104928" LOG_CI_START="-0.9111923322031477" LOG_EFFECT_SIZE="0.4688487287536725" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="891" O_E="0.0" SE="1.6212859010389238" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="2.6285679729075953" WEIGHT="7.8509617741899165"/>
<DICH_DATA CI_END="143.43796966328114" CI_START="0.4342540601786314" EFFECT_SIZE="7.892307692307693" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.156664129243237" LOG_CI_START="-0.3622561123053155" LOG_EFFECT_SIZE="0.8972040084689608" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="892" O_E="0.0" SE="1.4796262187419105" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="2.189293747188484" WEIGHT="9.426230126797467"/>
<DICH_DATA CI_END="8.824292041204897" CI_START="0.015634022880166597" EFFECT_SIZE="0.37142857142857144" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9456798727078586" LOG_CI_START="-1.8059292567947365" LOG_EFFECT_SIZE="-0.43012469204343884" MODIFIED="2011-12-17 05:50:27 +1100" MODIFIED_BY="[Empty name]" ORDER="890" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="2.6124542124542125" WEIGHT="7.89938693576973"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5653158496775045" CI_END="38.70187707810473" CI_START="1.3311580366280817" DF="2" EFFECT_SIZE="7.177625979745061" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="1.5877320292280475" LOG_CI_START="0.12422961848081585" LOG_EFFECT_SIZE="0.8559808238544316" MODIFIED="2014-04-10 18:31:17 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.7537776147003704" P_Z="0.021864841840596005" STUDIES="3" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="27.924151560705255" Z="2.2927076496649135">
<NAME>CPA versus placebo/no treatment</NAME>
<DICH_DATA CI_END="121.3913604556164" CI_START="0.4036531085580476" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0841877786670033" LOG_CI_START="-0.39399169863848965" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-12-17 05:56:18 +1100" MODIFIED_BY="[Empty name]" ORDER="918" O_E="0.0" SE="1.455694892155502" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="2.1190476190476186" WEIGHT="9.73870831908552"/>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-12-17 05:56:18 +1100" MODIFIED_BY="[Empty name]" ORDER="919" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="8.176840003760484"/>
<DICH_DATA CI_END="250.24188037027548" CI_START="0.8991300723407052" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.398359994772363" LOG_CI_START="-0.046177476661000354" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2011-12-19 06:28:36 +1100" MODIFIED_BY="[Empty name]" ORDER="1887" O_E="0.0" SE="1.435933411375598" STUDY_ID="STD-Tiller-1981" TOTAL_1="27" TOTAL_2="27" VAR="2.061904761904762" WEIGHT="10.00860323785925"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.02236067408387591" CI_END="75.01497612803543" CI_START="1.2776254104869469" DF="1" EFFECT_SIZE="9.789843699888667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="1.8751479753981348" LOG_CI_START="0.10640354082964365" LOG_EFFECT_SIZE="0.9907757581138894" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.8811316175907982" P_Z="0.028107857786927003" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="103" WEIGHT="19.117746480127185" Z="2.195777710681351">
<NAME>Alkylating agents+steroids versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:00:51 +1100" MODIFIED_BY="[Empty name]" ORDER="947" O_E="0.0" SE="0.0" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="150.61827011481574" CI_START="0.46536148328232585" EFFECT_SIZE="8.372093023255815" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.177877655322793" LOG_CI_START="-0.33220956494739146" LOG_EFFECT_SIZE="0.9228340451877007" MODIFIED="2011-12-17 06:00:51 +1100" MODIFIED_BY="[Empty name]" ORDER="946" O_E="0.0" SE="1.4744376583188366" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="2.173966408268734" WEIGHT="9.492688846370804"/>
<DICH_DATA CI_END="201.44979468534842" CI_START="0.6477379964290575" EFFECT_SIZE="11.423076923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3041668290981088" LOG_CI_START="-0.1886006264053199" LOG_EFFECT_SIZE="1.0577831013463943" MODIFIED="2011-12-17 06:00:51 +1100" MODIFIED_BY="[Empty name]" ORDER="948" O_E="0.0" SE="1.464263942760626" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="2.144068894068894" WEIGHT="9.62505763375638"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.12.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:00:51 +1100" MODIFIED_BY="[Empty name]" ORDER="949" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.54624195667168" CI_START="0.29299032187126384" DF="0" EFFECT_SIZE="5.454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.12.05" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254185" MODIFIED="2014-04-10 18:31:23 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.2554928994991701" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="9.27180340794002" Z="1.137108620704471">
<NAME>CSA versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:04:30 +1100" MODIFIED_BY="[Empty name]" ORDER="970" O_E="0.0" SE="0.0" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2011-12-17 06:04:30 +1100" MODIFIED_BY="[Empty name]" ORDER="971" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="9.27180340794002"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.12.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:04:30 +1100" MODIFIED_BY="[Empty name]" ORDER="972" O_E="0.0" SE="0.0" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.12.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:04:30 +1100" MODIFIED_BY="[Empty name]" ORDER="973" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.12.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:31:30 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>TAC versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:06:35 +1100" MODIFIED_BY="[Empty name]" ORDER="981" O_E="0.0" SE="0.0" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="140.24211218898935" CI_START="0.46783379810755" DF="0" EFFECT_SIZE="8.100000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.12.09" LOG_CI_END="2.146878444052046" LOG_CI_START="-0.32990840629474627" LOG_EFFECT_SIZE="0.9084850188786499" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.15048259320620055" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="9.749662996609796" Z="1.437828949428596">
<NAME>MMF versus placebo/no treatment</NAME>
<DICH_DATA CI_END="140.24211218898935" CI_START="0.46783379810755" EFFECT_SIZE="8.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.146878444052046" LOG_CI_START="-0.32990840629474627" LOG_EFFECT_SIZE="0.9084850188786497" MODIFIED="2011-12-17 06:09:56 +1100" MODIFIED_BY="[Empty name]" ORDER="990" O_E="0.0" SE="1.4548768561863465" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="2.116666666666667" WEIGHT="9.749662996609796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.12.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-17 06:13:54 +1100" MODIFIED_BY="[Empty name]" ORDER="1009" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="86.795025768913" CI_START="0.21161750660317297" DF="0" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.12.11" LOG_CI_END="1.9384948364320844" LOG_CI_START="-0.6744484070212731" LOG_EFFECT_SIZE="0.6320232147054056" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.34304856196848" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="41" WEIGHT="8.760056717860637" Z="0.9481589325137082">
<NAME>Mizoribine versus placebo/no treatment</NAME>
<DICH_DATA CI_END="86.795025768913" CI_START="0.21161750660317297" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9384948364320844" LOG_CI_START="-0.6744484070212731" LOG_EFFECT_SIZE="0.6320232147054056" MODIFIED="2011-12-17 06:13:54 +1100" MODIFIED_BY="[Empty name]" ORDER="1010" O_E="0.0" SE="1.5348557954821587" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="2.3557823129251703" WEIGHT="8.760056717860637"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-04-02 18:39:19 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Steroids versus placebo/no treatment/non-immunosuppressive treatments</NAME>
<DICH_OUTCOME CHI2="2.6660941001635927" CI_END="1.633934934424152" CI_START="0.3444273578659249" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7501812396938116" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="24.983893108751147" I2_Q="61.6342631938886" ID="CMP-002.01" LOG_CI_END="0.21323475832664507" LOG_CI_START="-0.46290235983648187" LOG_EFFECT_SIZE="-0.12483380075491839" METHOD="IV" MODIFIED="2014-04-01 17:03:27 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.2636727876910363" P_Q="0.10642697630440445" P_Z="0.46923261536965155" Q="2.6064923633649775" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.12691608709230837" TOTALS="YES" TOTAL_1="150" TOTAL_2="145" WEIGHT="100.00000000000001" Z="0.7237282112172381">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2322994129962144" CI_START="0.020686977281907746" DF="0" EFFECT_SIZE="0.15966386554621848" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.09071624160569046" LOG_CI_START="-1.684302962485094" LOG_EFFECT_SIZE="-0.7967933604397018" MODIFIED="2014-04-01 15:57:54 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.07847098809692821" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="12.993008844162075" Z="1.7596274857008072">
<NAME>At final follow-up (24 months)</NAME>
<DICH_DATA CI_END="1.2322994129962144" CI_START="0.020686977281907746" EFFECT_SIZE="0.15966386554621848" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.09071624160569046" LOG_CI_START="-1.684302962485094" LOG_EFFECT_SIZE="-0.7967933604397018" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3727" O_E="0.0" SE="1.0426550669696937" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="1.0871295886775763" WEIGHT="12.993008844162075"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05960173679861487" CI_END="1.81276440422981" CI_START="0.48379357831485426" DF="1" EFFECT_SIZE="0.9364847984693263" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.25834136471793745" LOG_CI_START="-0.3153399005895435" LOG_EFFECT_SIZE="-0.02849926793580301" MODIFIED="2014-04-01 15:58:01 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.8071265249942119" P_Z="0.8456014254256263" STUDIES="2" TAU2="0.0" TOTAL_1="116" TOTAL_2="107" WEIGHT="87.00699115583794" Z="0.1947337036010498">
<NAME>At final follow-up (48 months)</NAME>
<DICH_DATA CI_END="1.9911624381802222" CI_START="0.3913019325390922" EFFECT_SIZE="0.8826923076923077" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.29910669103076776" LOG_CI_START="-0.4074880072258436" LOG_EFFECT_SIZE="-0.05419065809753793" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3729" O_E="0.0" SE="0.4150572234561001" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.17227249874308698" WEIGHT="52.72295451529451"/>
<DICH_DATA CI_END="3.254775439720698" CI_START="0.3387330463863303" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5125210301839611" LOG_CI_START="-0.47014243204408507" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3728" O_E="0.0" SE="0.5772213819753421" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.33318452380952385" WEIGHT="34.284036640543434"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7548337878360085" CI_END="2.9743473079790457" CI_START="0.11239885937732105" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5781982746505304" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="27.400338676292684" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.47339167875627985" LOG_CI_START="-0.9492380959613428" LOG_EFFECT_SIZE="-0.2379232086025314" METHOD="IV" MODIFIED="2014-04-01 17:03:39 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.2522294886124914" P_Q="0.5145644874400617" P_Z="0.5120970198537982" Q="0.42477400776786023" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5800687700929911" TOTALS="YES" TOTAL_1="150" TOTAL_2="145" WEIGHT="100.0" Z="0.6555759316083932">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.484600709492909" CI_START="0.011074632802273455" DF="0" EFFECT_SIZE="0.2228571428571429" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.6517237812968287" LOG_CI_START="-1.9556706646164193" LOG_EFFECT_SIZE="-0.6519734416597952" MODIFIED="2014-04-01 15:58:18 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.3270023906190148" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="23.867448665018177" Z="0.9801696605840977">
<NAME>At final follow-up (24 months)</NAME>
<DICH_DATA CI_END="4.484600709492909" CI_START="0.011074632802273455" EFFECT_SIZE="0.22285714285714286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6517237812968287" LOG_CI_START="-1.9556706646164193" LOG_EFFECT_SIZE="-0.6519734416597952" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3730" O_E="0.0" SE="1.5315964043401074" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="2.345787545787546" WEIGHT="23.867448665018177"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.238404189733443" CI_END="8.036752511617182" CI_START="0.07714519593549986" DF="1" EFFECT_SIZE="0.7873987853647145" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="55.32531592879642" ID="CMP-002.02.02" LOG_CI_END="0.9050805946195324" LOG_CI_START="-1.112691113588705" LOG_EFFECT_SIZE="-0.10380525948458641" MODIFIED="2014-04-01 15:58:30 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.134619949140668" P_Z="0.8401804830346935" STUDIES="2" TAU2="1.554824248601264" TOTAL_1="116" TOTAL_2="107" WEIGHT="76.13255133498183" Z="0.20166262532869983">
<NAME>At final follow-up (48 months)</NAME>
<DICH_DATA CI_END="2.119716513397403" CI_START="0.028361937726815344" EFFECT_SIZE="0.24519230769230768" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3262777831459583" LOG_CI_START="-1.5472641008756087" LOG_EFFECT_SIZE="-0.6104931588648252" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3731" O_E="0.0" SE="1.1005277768561663" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="1.211161387631976" WEIGHT="38.985903134409114"/>
<DICH_DATA CI_END="24.52408656473462" CI_START="0.28097376763906257" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3895928404237263" LOG_CI_START="-0.5513342249397749" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3732" O_E="0.0" SE="1.1401101659384458" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="1.2998511904761905" WEIGHT="37.14664820057271"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4141827320758074" CI_END="1.9268755894469405" CI_START="0.33632667293603835" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8050215252776519" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" I2="17.15622958332061" I2_Q="45.11351777363222" ID="CMP-002.03" LOG_CI_END="0.2848536749248239" LOG_CI_START="-0.47323868888641984" LOG_EFFECT_SIZE="-0.09419250698079801" METHOD="IV" MODIFIED="2014-04-01 17:03:57 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.29906595476198383" P_Q="0.17708242136538344" P_Z="0.6262238751392553" Q="1.8219422331999886" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11248324315561259" TOTALS="YES" TOTAL_1="150" TOTAL_2="145" WEIGHT="100.00000000000001" Z="0.4870486239111321">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8191590769205934" CI_START="0.02746620598373126" DF="0" EFFECT_SIZE="0.2235294117647059" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.2598706777375301" LOG_CI_START="-1.5612013272604577" LOG_EFFECT_SIZE="-0.6506653247614638" MODIFIED="2014-04-01 15:58:40 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.16133901893291744" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="15.7786044219126" Z="1.4005822933101826">
<NAME>At final follow-up (24 months)</NAME>
<DICH_DATA CI_END="1.8191590769205934" CI_START="0.02746620598373126" EFFECT_SIZE="0.2235294117647059" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2598706777375301" LOG_CI_START="-1.5612013272604577" LOG_EFFECT_SIZE="-0.6506653247614638" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3733" O_E="0.0" SE="1.0697067101876259" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="1.1442724458204334" WEIGHT="15.7786044219126"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5922404988758189" CI_END="2.3791853128006424" CI_START="0.4655323841095545" DF="1" EFFECT_SIZE="1.052419978386252" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.37642827019716124" LOG_CI_START="-0.33205010254324024" LOG_EFFECT_SIZE="0.022189083826960485" MODIFIED="2014-04-01 15:58:48 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.4415541889656458" P_Z="0.9022895434916955" STUDIES="2" TAU2="0.0" TOTAL_1="116" TOTAL_2="107" WEIGHT="84.22139557808741" Z="0.12276960546463478">
<NAME>At final follow-up (48 months)</NAME>
<DICH_DATA CI_END="3.503537862775098" CI_START="0.4880949596026692" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5445068152805551" LOG_CI_START="-0.3114956771376807" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3735" O_E="0.0" SE="0.5028201013271472" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.2528280542986425" WEIGHT="54.28206302276864"/>
<DICH_DATA CI_END="2.807061136898403" CI_START="0.15342168962370814" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4482518715330762" LOG_CI_START="-0.8141132387050496" LOG_EFFECT_SIZE="-0.18293068358598671" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3734" O_E="0.0" SE="0.7415195145619502" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.5498511904761904" WEIGHT="29.93933255531877"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-01 17:04:21 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="68" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>100% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="11" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:59:06 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.8524086840551119" CI_START="0.048443567111511536" EFFECT_SIZE="0.20320855614973263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.06935213448809781" LOG_CI_START="-1.3147638853512797" LOG_EFFECT_SIZE="-0.6920580099196888" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3736" O_E="0.0" SE="0.7315610273446258" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.5351815367295244" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="11" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:59:14 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="0.8524086840551119" CI_START="0.048443567111511536" EFFECT_SIZE="0.20320855614973263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.06935213448809781" LOG_CI_START="-1.3147638853512797" LOG_EFFECT_SIZE="-0.6920580099196888" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3737" O_E="0.0" SE="0.7315610273446258" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.5351815367295244" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-01 17:04:40 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="104" TOTAL_2="102" WEIGHT="0.0" Z="0.0">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="26" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:59:24 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (36 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.9372201296137322" CI_START="0.3416078793111174" EFFECT_SIZE="0.5658284023668639" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="-0.02815839219811815" LOG_CI_START="-0.46647212070588084" LOG_EFFECT_SIZE="-0.2473152564519995" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3738" O_E="0.0" SE="0.2574676538134082" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.066289592760181" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="26" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:59:33 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>At 36 months</NAME>
<DICH_DATA CI_END="0.9372201296137322" CI_START="0.3416078793111174" EFFECT_SIZE="0.5658284023668639" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="-0.02815839219811815" LOG_CI_START="-0.46647212070588084" LOG_EFFECT_SIZE="-0.2473152564519995" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3739" O_E="0.0" SE="0.2574676538134082" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.066289592760181" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2014-04-01 17:05:10 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="220" TOTAL_2="215" UNITS="&#956;mol/L" WEIGHT="0.0" Z="0.0">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sterods</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.01" MODIFIED="2014-04-01 15:59:45 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (36 months)</NAME>
<CONT_DATA CI_END="138.70951421751056" CI_START="-42.70951421751057" EFFECT_SIZE="48.0" ESTIMABLE="YES" MEAN_1="251.0" MEAN_2="203.0" MODIFIED="2013-01-27 18:03:37 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3743" SD_1="257.0" SD_2="166.0" SE="46.28121482487211" STUDY_ID="STD-Cameron-1990" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.02" MODIFIED="2014-04-01 15:59:54 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="9.84956132209275" CI_START="-32.849561322092754" EFFECT_SIZE="-11.5" ESTIMABLE="YES" MEAN_1="138.5" MEAN_2="150.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3740" SD_1="51.1" SD_2="50.5" SE="10.892833485969826" STUDY_ID="STD-Cameron-1990" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.03" MODIFIED="2014-04-01 16:00:06 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="41.33593972980693" CI_START="0.8640602701930575" EFFECT_SIZE="21.099999999999994" ESTIMABLE="YES" MEAN_1="176.9" MEAN_2="155.8" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3741" SD_1="48.4" SD_2="47.9" SE="10.324648763663744" STUDY_ID="STD-Cameron-1990" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.04" MODIFIED="2014-04-01 16:00:13 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<CONT_DATA CI_END="80.37181959562265" CI_START="-76.57181959562264" EFFECT_SIZE="1.9000000000000057" ESTIMABLE="YES" MEAN_1="242.3" MEAN_2="240.4" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3742" SD_1="216.9" SD_2="151.5" SE="40.03737834705043" STUDY_ID="STD-Cameron-1990" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.05" MODIFIED="2014-04-01 16:00:21 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At 36 months</NAME>
<CONT_DATA CI_END="138.70951421751056" CI_START="-42.70951421751057" EFFECT_SIZE="48.0" ESTIMABLE="YES" MEAN_1="251.0" MEAN_2="203.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3743" SD_1="257.0" SD_2="166.0" SE="46.28121482487211" STUDY_ID="STD-Cameron-1990" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2014-04-01 17:05:44 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="86" TOTAL_2="86" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroids</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.01" MODIFIED="2014-04-01 16:00:31 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (36 months)</NAME>
<CONT_DATA CI_END="27.485355256889985" CI_START="-11.485355256889985" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="75.0" MEAN_2="67.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3744" SD_1="49.0" SD_2="43.0" SE="9.941690465022816" STUDY_ID="STD-Cameron-1990" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.02" MODIFIED="2014-04-01 16:00:41 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At 36 months</NAME>
<CONT_DATA CI_END="27.485355256889985" CI_START="-11.485355256889985" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="75.0" MEAN_2="67.0" MODIFIED="2013-01-27 18:04:08 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3744" SD_1="49.0" SD_2="43.0" SE="9.941690465022816" STUDY_ID="STD-Cameron-1990" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="16.674942086873045" CI_END="1.6649914248533217" CI_START="1.0416729389610992" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3169572927289586" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="107" I2="40.029776727846844" I2_Q="8.880063458641636" ID="CMP-002.08" LOG_CI_END="0.22141200111652845" LOG_CI_START="0.017731382014504953" LOG_EFFECT_SIZE="0.1195716915655167" METHOD="IV" MODIFIED="2014-04-01 17:06:43 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0818733787599426" P_Q="0.35934351419637156" P_Z="0.021379613980703045" Q="5.487273356177716" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07627354631156687" TOTALS="SUB" TOTAL_1="419" TOTAL_2="407" WEIGHT="600.0" Z="2.301212654126464">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.050280463589815" CI_END="2.159205583534534" CI_START="0.6394560363787901" DF="2" EFFECT_SIZE="1.1750391670808022" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="33" I2="50.620703480188766" ID="CMP-002.08.01" LOG_CI_END="0.3342939946010271" LOG_CI_START="-0.1941893085964663" LOG_EFFECT_SIZE="0.07005234300228035" MODIFIED="2014-04-01 16:00:52 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.13197557309062014" P_Z="0.6033421175018192" STUDIES="3" TAU2="0.14688065528344957" TOTAL_1="150" TOTAL_2="145" WEIGHT="99.99999999999999" Z="0.5196004054864423">
<NAME>At final follow-up (24-48 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="3.395807001782088" CI_START="0.5780888400401856" EFFECT_SIZE="1.401098901098901" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5309429994627041" LOG_CI_START="-0.23800541456494348" LOG_EFFECT_SIZE="0.14646879244888034" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3747" O_E="0.0" SE="0.4516841047558777" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="0.20401853048911872" WEIGHT="27.463468476579227"/>
<DICH_DATA CI_END="1.290030191148355" CI_START="0.42087099341863726" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.11059987440444312" LOG_CI_START="-0.375851004953625" LOG_EFFECT_SIZE="-0.13262556527459096" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3745" O_E="0.0" SE="0.2857436545056173" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.08164943609022557" WEIGHT="42.16910197250436"/>
<DICH_DATA CI_END="4.303529570941928" CI_START="0.8530038271826506" EFFECT_SIZE="1.915966386554622" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6338247914896153" LOG_CI_START="-0.06904902027376932" LOG_EFFECT_SIZE="0.28238788560792305" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3746" O_E="0.0" SE="0.4128715563112935" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.1704629220109096" WEIGHT="30.36742955091641"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.025078484717345" CI_START="0.3570262390054204" DF="0" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="0.7799627085510805" LOG_CI_START="-0.4472998650180305" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2014-04-01 16:00:59 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5952320295112654" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="100.0" Z="0.5312695150666098">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="6.025078484717345" CI_START="0.3570262390054204" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7799627085510805" LOG_CI_START="-0.4472998650180305" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3748" O_E="0.0" SE="0.720900110762212" STUDY_ID="STD-Coggins-1979" TOTAL_1="30" TOTAL_2="33" VAR="0.5196969696969697" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09818241063004256" CI_END="3.0731187225920515" CI_START="1.1689590357180881" DF="1" EFFECT_SIZE="1.8953495452312767" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="16" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="0.4875793385091061" LOG_CI_START="0.06779929227962747" LOG_EFFECT_SIZE="0.2776893153943668" MODIFIED="2014-04-01 16:01:05 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.7540218355141535" P_Z="0.009512138482997597" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="72" WEIGHT="100.0" Z="2.5930773125267375">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="3.0740965167817627" CI_START="1.1100766327467468" EFFECT_SIZE="1.8472906403940887" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.48771749883311427" LOG_CI_START="0.045352960795897616" LOG_EFFECT_SIZE="0.26653522981450595" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3750" O_E="0.0" SE="0.25984711938284" STUDY_ID="STD-Cattran-1989" TOTAL_1="58" TOTAL_2="50" VAR="0.06752052545155991" WEIGHT="90.04984565026021"/>
<DICH_DATA CI_END="11.066895231651381" CI_START="0.5167064803846225" EFFECT_SIZE="2.391304347826087" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0440257985765324" LOG_CI_START="-0.2867560916232304" LOG_EFFECT_SIZE="0.37863485347665093" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3749" O_E="0.0" SE="0.7817078697799386" STUDY_ID="STD-Coggins-1979" TOTAL_1="23" TOTAL_2="22" VAR="0.6110671936758894" WEIGHT="9.950154349739789"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.1681525359808065" CI_START="0.9338290462825094" DF="0" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" ID="CMP-002.08.04" LOG_CI_END="0.7901551051070439" LOG_CI_START="-0.029732621683832002" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2014-04-01 16:01:16 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.06909307104549071" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="1.817810697542189">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="6.168152535980807" CI_START="0.9338290462825093" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.790155105107044" LOG_CI_START="-0.029732621683832054" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3751" O_E="0.0" SE="0.481606109226663" STUDY_ID="STD-Coggins-1979" TOTAL_1="15" TOTAL_2="16" VAR="0.23194444444444445" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9164035445380807" CI_END="1.5554153029915443" CI_START="0.7578575638707554" DF="1" EFFECT_SIZE="1.0857178511622918" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="25" I2="0.0" ID="CMP-002.08.05" LOG_CI_END="0.1918463674570192" LOG_CI_START="-0.12041241051264369" LOG_EFFECT_SIZE="0.0357169784721877" MODIFIED="2014-04-01 16:01:28 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.33842119598940135" P_Z="0.6538850012883239" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="76" WEIGHT="100.00000000000001" Z="0.4483716480110069">
<NAME>At 36 months</NAME>
<DICH_DATA CI_END="5.785893753012836" CI_START="0.5880732283816703" EFFECT_SIZE="1.8445945945945945" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7623704543890638" LOG_CI_START="-0.23056859109746644" LOG_EFFECT_SIZE="0.26590093164579864" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3753" O_E="0.0" SE="0.5832573104463331" STUDY_ID="STD-Cameron-1990" TOTAL_1="37" TOTAL_2="39" VAR="0.34018909018909016" WEIGHT="9.889723139686689"/>
<DICH_DATA CI_END="1.4959878786581355" CI_START="0.7014228186307068" EFFECT_SIZE="1.0243632336655593" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.17492807464260576" LOG_CI_START="-0.15402010979155212" LOG_EFFECT_SIZE="0.010453982425526817" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3752" O_E="0.0" SE="0.19322579185639846" STUDY_ID="STD-Cattran-1989" TOTAL_1="43" TOTAL_2="37" VAR="0.037336206638532224" WEIGHT="90.11027686031332"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6110067411674422" CI_END="2.115318814349595" CI_START="0.48466853504679586" DF="1" EFFECT_SIZE="1.0125356640176895" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" I2="61.7005967762122" ID="CMP-002.08.06" LOG_CI_END="0.3253758321735555" LOG_CI_START="-0.3145551740034876" LOG_EFFECT_SIZE="0.005410329085033925" MODIFIED="2014-04-01 16:01:35 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.10612441874603262" P_Z="0.9735619644525433" STUDIES="2" TAU2="0.18525903669542354" TOTAL_1="63" TOTAL_2="65" WEIGHT="99.99999999999999" Z="0.03314122944135765">
<NAME>At 48 months</NAME>
<DICH_DATA CI_END="3.831490487190253" CI_START="0.7008217122620222" EFFECT_SIZE="1.638655462184874" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5833677516293855" LOG_CI_START="-0.154392451689411" LOG_EFFECT_SIZE="0.21448764996998723" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3754" O_E="0.0" SE="0.43336399540136566" STUDY_ID="STD-Cameron-1990" TOTAL_1="34" TOTAL_2="39" VAR="0.18780435251023486" WEIGHT="37.87554399522021"/>
<DICH_DATA CI_END="1.1292097961737841" CI_START="0.5047877725241362" EFFECT_SIZE="0.7549909255898367" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.0527746371030823" LOG_CI_START="-0.29689117355316685" LOG_EFFECT_SIZE="-0.12205826822504227" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3755" O_E="0.0" SE="0.20539542805315872" STUDY_ID="STD-Cattran-1989" TOTAL_1="29" TOTAL_2="26" VAR="0.0421872818651403" WEIGHT="62.12445600477977"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.637888514896192" CI_END="1.038942010557371" CI_START="0.4407631035129224" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6767032621047591" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" I2="30.538580236907507" I2_Q="16.04151375070863" ID="CMP-002.09" LOG_CI_END="0.016591307713311704" LOG_CI_START="-0.35579476763042406" LOG_EFFECT_SIZE="-0.16960172995855619" METHOD="IV" MODIFIED="2014-04-01 17:07:21 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.19499047691343252" P_Q="0.3123523794417885" P_Z="0.07421018545418918" Q="4.764259312778833" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13750047104946111" TOTALS="SUB" TOTAL_1="296" TOTAL_2="278" WEIGHT="500.0" Z="1.7853153189340916">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0832665706909363" CI_END="1.4201529279867173" CI_START="0.2899727747659677" DF="1" EFFECT_SIZE="0.6417208778903192" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="7.686618690524781" ID="CMP-002.09.01" LOG_CI_END="0.15233511354127302" LOG_CI_START="-0.5376427756319125" LOG_EFFECT_SIZE="-0.19265383104531975" MODIFIED="2014-04-01 16:01:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.2979683949207578" P_Z="0.273730465512372" STUDIES="2" TAU2="0.02782627491364865" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="1.0945120887423523">
<NAME>At final follow-up (24-48 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.2070156228978242" CI_START="0.1887210503965696" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.08171289138517528" LOG_CI_START="-0.7241796548897116" LOG_EFFECT_SIZE="-0.3212333817522681" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3756" O_E="0.0" SE="0.47338527091431004" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.22409361471861472" WEIGHT="65.20532952809118"/>
<DICH_DATA CI_END="4.127266954971465" CI_START="0.3026542653346546" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6156625603049641" LOG_CI_START="-0.5190532011558541" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3757" O_E="0.0" SE="0.6665376552156925" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.44427244582043346" WEIGHT="34.794670471908816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:01:58 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3758" O_E="0.0" SE="0.0" STUDY_ID="STD-Coggins-1979" TOTAL_1="30" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.968321412372743" CI_END="16.412331344944963" CI_START="0.08937721161623671" DF="1" EFFECT_SIZE="1.2111516881600506" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="66.31092590473062" ID="CMP-002.09.03" LOG_CI_END="1.2151702762590841" LOG_CI_START="-1.0487731985520488" LOG_EFFECT_SIZE="0.08319853885351759" MODIFIED="2014-04-01 16:02:05 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.08491009317253884" P_Z="0.8854570729518706" STUDIES="2" TAU2="2.4981226562150702" TOTAL_1="81" TOTAL_2="72" WEIGHT="100.0" Z="0.14405495678981511">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="1.3464953374506" CI_START="0.13798096447831773" EFFECT_SIZE="0.43103448275862066" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.12920485390573055" LOG_CI_START="-0.8601808236875299" LOG_EFFECT_SIZE="-0.3654879848908997" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3759" O_E="0.0" SE="0.5811700445563718" STUDY_ID="STD-Cattran-1989" TOTAL_1="58" TOTAL_2="50" VAR="0.3377586206896552" WEIGHT="62.36175338316687"/>
<DICH_DATA CI_END="122.83267639664737" CI_START="0.36636616111654974" EFFECT_SIZE="6.708333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.089313914777384" LOG_CI_START="-0.4360846461368964" LOG_EFFECT_SIZE="0.8266146343202436" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3760" O_E="0.0" SE="1.483431615605537" STUDY_ID="STD-Coggins-1979" TOTAL_1="23" TOTAL_2="22" VAR="2.2005693581780537" WEIGHT="37.63824661683313"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="40.53510046934117" CI_START="0.7017237928387148" DF="0" EFFECT_SIZE="5.333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-002.09.04" LOG_CI_END="1.607831253786659" LOG_CI_START="-0.15383379791413418" LOG_EFFECT_SIZE="0.7269987279362624" MODIFIED="2014-04-01 16:02:13 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.10573496553507901" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="1.617664291161196">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="40.53510046934117" CI_START="0.7017237928387148" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.607831253786659" LOG_CI_START="-0.15383379791413418" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3761" O_E="0.0" SE="1.0348107717516923" STUDY_ID="STD-Coggins-1979" TOTAL_1="15" TOTAL_2="16" VAR="1.0708333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3295453555327126" CI_START="0.3295161274945638" DF="0" EFFECT_SIZE="0.6618962432915921" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-002.09.05" LOG_CI_END="0.1237031572535944" LOG_CI_START="-0.482123324892451" LOG_EFFECT_SIZE="-0.1792100838194283" MODIFIED="2014-04-01 16:02:29 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.24622904719687566" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="37" WEIGHT="100.0" Z="1.1595574650624458">
<NAME>At 36 months</NAME>
<DICH_DATA CI_END="1.3295453555327126" CI_START="0.3295161274945638" EFFECT_SIZE="0.6618962432915921" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.1237031572535944" LOG_CI_START="-0.482123324892451" LOG_EFFECT_SIZE="-0.1792100838194283" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3762" O_E="0.0" SE="0.3558654745020392" STUDY_ID="STD-Cattran-1989" TOTAL_1="43" TOTAL_2="37" VAR="0.12664023594256152" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1352321715179519" CI_START="0.21066051445027256" DF="0" EFFECT_SIZE="0.4890282131661442" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-002.09.06" LOG_CI_END="0.05508469016148858" LOG_CI_START="-0.6764168595669275" LOG_EFFECT_SIZE="-0.31066608470271956" MODIFIED="2014-04-01 16:02:45 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.0959567852229308" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="26" WEIGHT="100.0" Z="1.6647793499862402">
<NAME>At 48 months</NAME>
<DICH_DATA CI_END="1.1352321715179519" CI_START="0.21066051445027256" EFFECT_SIZE="0.4890282131661442" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.05508469016148858" LOG_CI_START="-0.6764168595669275" LOG_EFFECT_SIZE="-0.31066608470271956" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3763" O_E="0.0" SE="0.4296876313015415" STUDY_ID="STD-Cattran-1989" TOTAL_1="29" TOTAL_2="26" VAR="0.18463146049352944" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.114103629838463" CI_END="2.2345260678936083" CI_START="1.0122622925766236" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5039702391697158" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="41" I2="1.6039073335941008" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.34918542548835046" LOG_CI_START="0.005293059400224571" LOG_EFFECT_SIZE="0.17723924244428754" METHOD="IV" MODIFIED="2014-04-01 17:07:56 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.4170971102869273" P_Q="0.9367510545449962" P_Z="0.04335248486524081" Q="1.2822151075742485" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.004187311889065584" TOTALS="SUB" TOTAL_1="296" TOTAL_2="278" WEIGHT="600.0" Z="2.020298012366731">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6913843590795996" CI_END="4.2461139544315225" CI_START="0.621940592046259" DF="1" EFFECT_SIZE="1.625063268526805" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="40.87683295450539" ID="CMP-002.10.01" LOG_CI_END="0.6279916452978805" LOG_CI_START="-0.20625109726848945" LOG_EFFECT_SIZE="0.2108702740146955" MODIFIED="2014-04-01 16:02:56 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.1934186644487088" P_Z="0.3217665335321661" STUDIES="2" TAU2="0.20538389474749116" TOTAL_1="98" TOTAL_2="94" WEIGHT="100.0" Z="0.9908342533672442">
<NAME>At final follow-up (24-48 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.5788572150415536" CI_START="0.46388340367294195" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.41142729699012415" LOG_CI_START="-0.3335911649293849" LOG_EFFECT_SIZE="0.03891806603036966" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3764" O_E="0.0" SE="0.43762753243238384" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="0.19151785714285716" WEIGHT="60.50302135101931"/>
<DICH_DATA CI_END="10.336445219758424" CI_START="0.8593609524200205" EFFECT_SIZE="2.980392156862745" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0143712073383206" LOG_CI_START="-0.06582438364464817" LOG_EFFECT_SIZE="0.4742734118468362" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3765" O_E="0.0" SE="0.6345122371978075" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="0.4026057791537667" WEIGHT="39.496978648980686"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.025078484717345" CI_START="0.3570262390054204" DF="0" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.7799627085510805" LOG_CI_START="-0.4472998650180305" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2014-04-01 16:03:08 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5952320295112654" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="100.0" Z="0.5312695150666098">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="6.025078484717345" CI_START="0.3570262390054204" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7799627085510805" LOG_CI_START="-0.4472998650180305" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3766" O_E="0.0" SE="0.720900110762212" STUDY_ID="STD-Coggins-1979" TOTAL_1="30" TOTAL_2="33" VAR="0.5196969696969697" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.720229764376555" CI_END="8.439163428421455" CI_START="0.7305834017590647" DF="1" EFFECT_SIZE="2.483045051048579" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="8" I2="41.86823058706814" ID="CMP-002.10.03" LOG_CI_END="0.9262993972859035" LOG_CI_START="-0.13633019881768646" LOG_EFFECT_SIZE="0.39498459923410856" MODIFIED="2014-04-01 16:03:17 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.1896635690333769" P_Z="0.1451008320252526" STUDIES="2" TAU2="0.38854739961656004" TOTAL_1="81" TOTAL_2="72" WEIGHT="99.99999999999999" Z="1.4570563285372142">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="8.339411136716718" CI_START="1.6733732855559578" EFFECT_SIZE="3.735632183908046" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="6" LOG_CI_END="0.9211353852776089" LOG_CI_START="0.22359283144290296" LOG_EFFECT_SIZE="0.5723641083602559" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3768" O_E="0.0" SE="0.40973994901383526" STUDY_ID="STD-Cattran-1989" TOTAL_1="58" TOTAL_2="50" VAR="0.1678868258178603" WEIGHT="70.02049623801929"/>
<DICH_DATA CI_END="6.211054714026899" CI_START="0.14730732211436595" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7931653550216421" LOG_CI_START="-0.8317756654124153" LOG_EFFECT_SIZE="-0.01930515519538663" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3767" O_E="0.0" SE="0.9544983989907418" STUDY_ID="STD-Coggins-1979" TOTAL_1="23" TOTAL_2="22" VAR="0.9110671936758894" WEIGHT="29.9795037619807"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.328540329064508" CI_START="0.37960040169909515" DF="0" EFFECT_SIZE="1.4222222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.10.04" LOG_CI_END="0.7266082570843606" LOG_CI_START="-0.42067333666727363" LOG_EFFECT_SIZE="0.15296746020854352" MODIFIED="2014-04-01 16:03:26 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.6012210560260636" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.5226453809564258">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="5.3285403290645075" CI_START="0.37960040169909526" EFFECT_SIZE="1.4222222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7266082570843605" LOG_CI_START="-0.4206733366672735" LOG_EFFECT_SIZE="0.15296746020854352" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3769" O_E="0.0" SE="0.6739188873051909" STUDY_ID="STD-Coggins-1979" TOTAL_1="15" TOTAL_2="16" VAR="0.4541666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.371282752413941" CI_START="0.7721006221392839" DF="0" EFFECT_SIZE="1.6133720930232558" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-002.10.05" LOG_CI_END="0.5277951787041211" LOG_CI_START="-0.11232609760182882" LOG_EFFECT_SIZE="0.20773454055114612" MODIFIED="2014-04-01 16:03:33 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.20333419786815066" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="37" WEIGHT="100.0" Z="1.2721096232727656">
<NAME>At 36 months</NAME>
<DICH_DATA CI_END="3.371282752413941" CI_START="0.7721006221392839" EFFECT_SIZE="1.6133720930232558" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5277951787041211" LOG_CI_START="-0.11232609760182882" LOG_EFFECT_SIZE="0.20773454055114612" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3770" O_E="0.0" SE="0.376010406353536" STUDY_ID="STD-Cattran-1989" TOTAL_1="43" TOTAL_2="37" VAR="0.14138382568615127" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4066094666707483" CI_START="0.5218733328377999" DF="0" EFFECT_SIZE="1.1206896551724137" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-002.10.06" LOG_CI_END="0.38140562071515405" LOG_CI_START="-0.28243489455531756" LOG_EFFECT_SIZE="0.04948536307991826" MODIFIED="2014-04-01 16:03:44 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.7701281145273724" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="26" WEIGHT="100.0" Z="0.29220732138956895">
<NAME>At 48 months</NAME>
<DICH_DATA CI_END="2.4066094666707483" CI_START="0.5218733328377999" EFFECT_SIZE="1.1206896551724137" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.38140562071515405" LOG_CI_START="-0.28243489455531756" LOG_EFFECT_SIZE="0.04948536307991826" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3771" O_E="0.0" SE="0.38994320473342253" STUDY_ID="STD-Cattran-1989" TOTAL_1="29" TOTAL_2="26" VAR="0.1520557029177719" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.11" MODIFIED="2014-04-02 18:39:19 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="129" TOTAL_2="136" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.11.01" MODIFIED="2014-04-01 16:03:53 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (36 months)</NAME>
<CONT_DATA CI_END="1.9866745072190628" CI_START="-1.9866745072190628" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="5.6" MODIFIED="2013-01-27 18:04:28 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3773" SD_1="4.7" SD_2="4.7" SE="1.0136280681123213" STUDY_ID="STD-Cameron-1990" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.11.02" MODIFIED="2014-04-01 16:04:01 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="2.011121120669798" CI_START="-3.011121120669798" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="9.4" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3772" SD_1="6.56" SD_2="5.66" SE="1.2812077877334485" STUDY_ID="STD-Cameron-1990" TOTAL_1="43" TOTAL_2="50" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.11.03" MODIFIED="2014-04-01 16:04:07 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>At 36 months</NAME>
<CONT_DATA CI_END="1.9866745072190628" CI_START="-1.9866745072190628" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="5.6" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3773" SD_1="4.7" SD_2="4.7" SE="1.0136280681123213" STUDY_ID="STD-Cameron-1990" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.9887098294615504" CI_END="13.116317764186752" CI_START="0.37715457834135957" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2241581094299794" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="1.1178119296168123" LOG_CI_START="-0.4234806159440063" LOG_EFFECT_SIZE="0.3471656568364031" METHOD="IV" MODIFIED="2014-04-01 17:09:16 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.36996213046598514" P_Q="1.0" P_Z="0.37727026746717895" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="145" WEIGHT="99.99999999999999" Z="0.882937098512934">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.613833580842" CI_START="0.12268957662178398" EFFECT_SIZE="2.943396226415094" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8488897897104928" LOG_CI_START="-0.9111923322031477" LOG_EFFECT_SIZE="0.4688487287536725" MODIFIED="2014-04-01 16:04:53 +1100" MODIFIED_BY="Narelle S Willis" ORDER="3774" O_E="0.0" SE="1.6212859010389238" STUDY_ID="STD-Cameron-1990" TOTAL_1="52" TOTAL_2="51" VAR="2.6285679729075953" WEIGHT="31.183592596495785"/>
<DICH_DATA CI_END="143.43796966328114" CI_START="0.4342540601786314" EFFECT_SIZE="7.892307692307693" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.156664129243237" LOG_CI_START="-0.3622561123053155" LOG_EFFECT_SIZE="0.8972040084689608" MODIFIED="2014-04-01 16:04:53 +1100" MODIFIED_BY="Narelle S Willis" ORDER="3775" O_E="0.0" SE="1.4796262187419105" STUDY_ID="STD-Cattran-1989" TOTAL_1="64" TOTAL_2="56" VAR="2.189293747188484" WEIGHT="37.440472702492166"/>
<DICH_DATA CI_END="8.824292041204897" CI_START="0.015634022880166597" EFFECT_SIZE="0.37142857142857144" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9456798727078586" LOG_CI_START="-1.8059292567947365" LOG_EFFECT_SIZE="-0.43012469204343884" MODIFIED="2014-04-01 16:04:53 +1100" MODIFIED_BY="Narelle S Willis" ORDER="3776" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Coggins-1979" TOTAL_1="34" TOTAL_2="38" VAR="2.6124542124542125" WEIGHT="31.375934701012046"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-04-01 17:17:39 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Cyclophosphamide (CPA) versus placebo/no treatment/non-immunosuppressive treatments</NAME>
<DICH_OUTCOME CHI2="1.956296023616371" CI_END="12.273363997540656" CI_START="0.03154326933441352" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6222073819987346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="48.88299173908152" I2_Q="48.88299173908152" ID="CMP-003.01" LOG_CI_END="1.0889636145064048" LOG_CI_START="-1.5010932957784653" LOG_EFFECT_SIZE="-0.20606484063603017" METHOD="IV" MODIFIED="2014-04-01 17:11:07 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.16191030297723819" P_Q="0.16191030297723819" P_Z="0.7551398268187541" Q="1.956296023616371" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.2655108178530687" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.31186933732833216">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:09:23 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-02 08:18:33 +1100" MODIFIED_BY="[Empty name]" ORDER="729" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6395530143189947" CI_START="0.007731673944261138" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.4215303890477133" LOG_CI_START="-2.111726469076227" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2014-04-01 16:09:31 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.19097730008968364" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="51.66965102359783" Z="1.307693467025676">
<NAME>At final follow-up (36 months)</NAME>
<DICH_DATA CI_END="2.6395530143189947" CI_START="0.007731673944261138" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4215303890477133" LOG_CI_START="-2.111726469076227" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-12-19 06:31:19 +1100" MODIFIED_BY="[Empty name]" ORDER="1889" O_E="0.0" SE="1.4880476182856899" STUDY_ID="STD-Tiller-1981" TOTAL_1="27" TOTAL_2="27" VAR="2.2142857142857144" WEIGHT="51.66965102359783"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.51227986921384" CI_START="0.13330908121359522" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 16:09:38 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.4892273981416261" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="48.33034897640216" Z="0.6915381840105491">
<NAME>At final follow-up (24 months)</NAME>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-16 03:25:50 +1100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="48.33034897640216"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.511327318208873" CI_END="10.606205490960889" CI_START="0.05263571873505015" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.747171499100683" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="33.832996469280054" I2_Q="33.832996469280054" ID="CMP-003.02" LOG_CI_END="1.0255600371447784" LOG_CI_START="-1.2787194424442145" LOG_EFFECT_SIZE="-0.12657970264971796" METHOD="IV" MODIFIED="2014-04-01 17:11:19 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.2189370561537931" P_Q="0.2189370561537931" P_Z="0.8295090888495863" Q="1.511327318208873" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.2405774696543843" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.21533122224521814">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:09:49 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-02 08:19:25 +1100" MODIFIED_BY="[Empty name]" ORDER="730" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.51227986921384" CI_START="0.13330908121359522" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 16:09:56 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.4892273981416261" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="48.66886793682066" Z="0.6915381840105491">
<NAME>At final follow-up (24 months)</NAME>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-16 03:26:00 +1100" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="48.66886793682066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9804702774957645" CI_START="0.010049063857139322" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.5999343853540574" LOG_CI_START="-1.9978743940260948" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2014-04-01 16:10:02 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.29156201254705527" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="51.331132063179346" Z="1.0547012125344186">
<NAME>At final follow-up (36 months)</NAME>
<DICH_DATA CI_END="3.9804702774957645" CI_START="0.010049063857139322" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5999343853540574" LOG_CI_START="-1.9978743940260948" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-12-19 06:31:47 +1100" MODIFIED_BY="[Empty name]" ORDER="1890" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Tiller-1981" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="51.331132063179346"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.836867951075732" CI_START="0.014177999655571498" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.8941425290950501" LOG_CI_START="-1.8483850385343752" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="IV" MODIFIED="2014-04-01 17:11:46 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.49526728049818114" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="99.99999999999999" Z="0.6819552055167947">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:10:12 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-02 08:20:15 +1100" MODIFIED_BY="[Empty name]" ORDER="731" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:10:23 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (24 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-16 03:26:09 +1100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.836867951075732" CI_START="0.014177999655571498" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.8941425290950501" LOG_CI_START="-1.8483850385343752" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-04-01 16:10:32 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.49526728049818114" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.6819552055167947">
<NAME>At final follow-up (36 months)</NAME>
<DICH_DATA CI_END="7.836867951075732" CI_START="0.014177999655571498" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8941425290950501" LOG_CI_START="-1.8483850385343752" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-12-19 06:32:13 +1100" MODIFIED_BY="[Empty name]" ORDER="1891" O_E="0.0" SE="1.6109742689559308" STUDY_ID="STD-Tiller-1981" TOTAL_1="27" TOTAL_2="27" VAR="2.5952380952380953" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.583665182881187" CI_END="3.445394054643535" CI_START="0.26376880032109973" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9533034440443267" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.5372388999650849" LOG_CI_START="-0.5787765759227785" LOG_EFFECT_SIZE="-0.0207688379788468" METHOD="IV" MODIFIED="2014-04-01 17:12:05 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.6630993225383169" P_Q="0.6879576834023873" P_Z="0.9418466044987037" Q="0.7480563254431016" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="86" WEIGHT="300.0" Z="0.07294912179762186">
<NAME>100% increase in serum creatinine</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8356088574380856" CI_END="5.728417021995094" CI_START="0.14923496158688973" DF="1" EFFECT_SIZE="0.924597260557873" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.7580346265761315" LOG_CI_START="-0.8261294218661908" LOG_EFFECT_SIZE="-0.03404739764502959" MODIFIED="2014-04-01 16:10:54 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.3606557381812845" P_Z="0.9328589072540209" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.08424843780186503">
<NAME>At final follow-up (12-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.745176453876752" CI_START="0.05268507977100682" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6762523667148672" LOG_CI_START="-1.2783123580428297" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-12-02 08:26:07 +1100" MODIFIED_BY="[Empty name]" ORDER="1613" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="65.69014084507042"/>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-17 09:02:53 +1100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="34.30985915492958"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.51227986921384" CI_START="0.13330908121359522" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 16:11:01 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.4892273981416261" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.6915381840105491">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-17 09:05:43 +1100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.141503769473175" CI_START="0.0600295145441986" DF="0" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.7110901585419324" LOG_CI_START="-1.2216351687485447" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2014-04-01 16:11:10 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.6046394635106067" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.5177403215874566">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="5.141503769473175" CI_START="0.0600295145441986" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7110901585419324" LOG_CI_START="-1.2216351687485447" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2011-12-02 08:26:58 +1100" MODIFIED_BY="[Empty name]" ORDER="1614" O_E="0.0" SE="1.1352924243950933" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" VAR="1.2888888888888888" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-02 09:09:02 +1100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:11:16 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-02 09:09:03 +1100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:11:25 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-02 09:09:06 +1100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9541703229547591" CI_END="3.199774893696991" CI_START="0.40704268931227816" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.141247115187737" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.505119426487411" LOG_CI_START="-0.3903600409946049" LOG_EFFECT_SIZE="0.05737969274640302" METHOD="IV" MODIFIED="2014-04-01 17:12:28 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.8554494527593643" P_Q="0.8726593395611756" P_Z="0.8016769068712576" Q="1.2328602863111604" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="86" WEIGHT="500.0" Z="0.2511774648349104">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7213100366435988" CI_END="4.914740778700723" CI_START="0.20052962593799795" DF="1" EFFECT_SIZE="0.9927492784863059" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.6915006165020888" LOG_CI_START="-0.6978214563060571" LOG_EFFECT_SIZE="-0.00316041990198407" MODIFIED="2014-04-01 16:11:41 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.3957145540578203" P_Z="0.992885338448601" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.008917024072599988">
<NAME>At final follow-up (12-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.745176453876752" CI_START="0.05268507977100682" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6762523667148672" LOG_CI_START="-1.2783123580428297" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-12-02 08:27:15 +1100" MODIFIED_BY="[Empty name]" ORDER="1615" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="50.5249343832021"/>
<DICH_DATA CI_END="19.43689862203422" CI_START="0.20579414842785088" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.288626969500306" LOG_CI_START="-0.6865669781723437" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-12-02 09:13:19 +1100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="1.1602387022306428" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="1.3461538461538463" WEIGHT="49.4750656167979"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.51227986921384" CI_START="0.13330908121359522" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 16:11:47 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.4892273981416261" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.6915381840105491">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-17 09:07:27 +1100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.141503769473175" CI_START="0.0600295145441986" DF="0" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="0.7110901585419324" LOG_CI_START="-1.2216351687485447" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2014-04-01 16:11:53 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.6046394635106067" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.5177403215874566">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="5.141503769473175" CI_START="0.0600295145441986" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7110901585419324" LOG_CI_START="-1.2216351687485447" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2011-12-02 08:27:21 +1100" MODIFIED_BY="[Empty name]" ORDER="1616" O_E="0.0" SE="1.1352924243950933" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" VAR="1.2888888888888888" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-02 09:14:34 +1100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.45938986445702" CI_START="0.14405130711161593" DF="0" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.05.04" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" MODIFIED="2014-04-01 16:12:00 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.4599122083836973" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.7389914278442653">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="72.45938986445702" CI_START="0.14405130711161593" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" MODIFIED="2011-12-02 09:14:38 +1100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.463493017511325" CI_START="0.07589560196923674" DF="0" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.05.05" LOG_CI_END="1.189307602575942" LOG_CI_START="-1.119783390057518" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2014-04-01 16:12:07 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.9529422483520236" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.05901237890768988">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="15.463493017511325" CI_START="0.07589560196923674" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.189307602575942" LOG_CI_START="-1.119783390057518" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2011-12-02 09:13:35 +1100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="1.3563714792576516" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="1.8397435897435899" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2014-04-01 17:13:43 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="61" TOTAL_2="65" UNITS="&#956;mol/L" WEIGHT="0.0" Z="0.0">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.01" MODIFIED="2014-04-01 16:12:19 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (24 months)</NAME>
<CONT_DATA CI_END="83.3382309555809" CI_START="-43.37823095558089" EFFECT_SIZE="19.980000000000004" ESTIMABLE="YES" MEAN_1="127.67" MEAN_2="107.69" MODIFIED="2013-01-27 18:04:58 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="106" SD_1="104.95" SD_2="40.65" SE="32.326222040477546" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.02" MODIFIED="2014-04-01 16:12:28 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="58.36014077453216" CI_START="-30.680140774532184" EFFECT_SIZE="13.83999999999999" ESTIMABLE="YES" MEAN_1="118.46" MEAN_2="104.62" MODIFIED="2011-11-16 03:43:21 +1100" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="66.81" SD_2="47.37" SE="22.714774927346298" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.03" MODIFIED="2014-04-01 16:15:24 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="67.77375963098976" CI_START="-36.733759630989766" EFFECT_SIZE="15.519999999999996" ESTIMABLE="YES" MEAN_1="121.67" MEAN_2="106.15" MODIFIED="2011-11-16 03:43:55 +1100" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="78.14" SD_2="51.24" SE="26.660571338637215" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.04" MODIFIED="2014-04-01 16:15:36 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months</NAME>
<CONT_DATA CI_END="101.12788973835214" CI_START="-29.92788973835215" EFFECT_SIZE="35.599999999999994" ESTIMABLE="YES" MEAN_1="131.75" MEAN_2="96.15" MODIFIED="2011-11-16 03:44:30 +1100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="111.24" SD_2="33.55" SE="33.4332111483822" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.05" MODIFIED="2014-04-01 16:15:44 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<CONT_DATA CI_END="83.3382309555809" CI_START="-43.37823095558089" EFFECT_SIZE="19.980000000000004" ESTIMABLE="YES" MEAN_1="127.67" MEAN_2="107.69" MODIFIED="2011-11-16 03:44:56 +1100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="104.95" SD_2="40.65" SE="32.326222040477546" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2014-04-01 17:14:38 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.01" MODIFIED="2014-04-01 16:16:03 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (12 months)</NAME>
<CONT_DATA CI_END="15.799599677915403" CI_START="-26.4595996779154" EFFECT_SIZE="-5.329999999999998" ESTIMABLE="YES" MEAN_1="76.67" MEAN_2="82.0" MODIFIED="2011-12-02 08:28:46 +1100" MODIFIED_BY="[Empty name]" ORDER="739" SD_1="18.76" SD_2="27.77" SE="10.78060609510327" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.02" MODIFIED="2014-04-01 16:16:10 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="15.799599677915403" CI_START="-26.4595996779154" EFFECT_SIZE="-5.329999999999998" ESTIMABLE="YES" MEAN_1="76.67" MEAN_2="82.0" MODIFIED="2013-01-27 18:05:26 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="739" SD_1="18.76" SD_2="27.77" SE="10.78060609510327" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.4464129796407208" CI_END="3.209975476737651" CI_START="1.387533183102934" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1104377486484056" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.5065017145362742" LOG_CI_START="0.14224337814871144" LOG_EFFECT_SIZE="0.32437254634249285" METHOD="IV" MODIFIED="2014-04-01 17:15:32 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.9939543065927033" P_Q="0.9681008697905882" P_Z="4.8175469260859486E-4" Q="0.25587961970268286" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="86" WEIGHT="400.0" Z="3.49070121337403">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.06734836001433708" CI_END="4.62527833845853" CI_START="0.9883222008528062" DF="1" EFFECT_SIZE="2.138051745637169" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.6651378726900578" LOG_CI_START="-0.005101448893336062" LOG_EFFECT_SIZE="0.33001821189836084" MODIFIED="2014-04-01 16:16:22 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.7952374316719293" P_Z="0.05359099138330019" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.9301279072526483">
<NAME>At final follow-up (12-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="10.248873583471138" CI_START="0.6098231136424284" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.010676136283019" LOG_CI_START="-0.2147961189389436" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-12-02 08:44:19 +1100" MODIFIED_BY="[Empty name]" ORDER="732" O_E="0.0" SE="0.7198484689028782" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.5181818181818181" WEIGHT="29.912508867344528"/>
<DICH_DATA CI_END="5.027180990960556" CI_START="0.7956745554203151" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7013245211859962" LOG_CI_START="-0.09926452985803394" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-11-16 03:27:28 +1100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.4702699715629801" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.22115384615384615" WEIGHT="70.08749113265547"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:16:30 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-16 03:34:40 +1100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12318499992370092" CI_END="4.068929911817223" CI_START="0.7941066437362082" DF="1" EFFECT_SIZE="1.7975439565893907" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="0.609480209102933" LOG_CI_START="-0.10012117052488456" LOG_EFFECT_SIZE="0.25467951928902427" MODIFIED="2014-04-01 16:16:36 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.7256055129688421" P_Z="0.1594623975240784" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.4068819473498484">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="9.367991071897338" CI_START="0.527143073369529" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9716464681629865" LOG_CI_START="-0.2780714957136739" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2011-11-15 21:27:02 +1100" MODIFIED_BY="[Empty name]" ORDER="733" O_E="0.0" SE="0.7340905181848413" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" VAR="0.5388888888888889" WEIGHT="32.2407307898979"/>
<DICH_DATA CI_END="4.384055277068699" CI_START="0.6023247502859033" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6418760213829199" LOG_CI_START="-0.2201692907531335" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2011-11-16 03:35:00 +1100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.2564102564102564" WEIGHT="67.7592692101021"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.867134644646194" CI_START="1.01265892294147" DF="0" EFFECT_SIZE="2.4375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" ID="CMP-003.08.04" LOG_CI_END="0.7684260549379747" LOG_CI_START="0.005463193803174106" LOG_EFFECT_SIZE="0.3869446243705744" MODIFIED="2014-04-01 16:16:42 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.04680808245443853" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.9880326196997196">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="5.867134644646193" CI_START="1.01265892294147" EFFECT_SIZE="2.4375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7684260549379747" LOG_CI_START="0.005463193803174106" LOG_EFFECT_SIZE="0.3869446243705744" MODIFIED="2011-11-16 03:35:31 +1100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.44816816135765475" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.20085470085470086" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.373318675860461" CI_START="0.8736582971589145" DF="0" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-003.08.05" LOG_CI_END="0.7302425980716918" LOG_CI_START="-0.05865839422530558" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2014-04-01 16:16:59 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.0952166259529393" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.6684994251209957">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="5.373318675860461" CI_START="0.8736582971589145" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7302425980716918" LOG_CI_START="-0.05865839422530558" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2011-11-16 03:35:53 +1100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.21474358974358976" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6027711233328108" CI_END="4.132781776438745" CI_START="0.3087810435415558" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1296568813840246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.6162424738056398" LOG_CI_START="-0.5103493694049578" LOG_EFFECT_SIZE="0.05294655220034104" METHOD="IV" MODIFIED="2014-04-01 17:16:08 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.6587617016971484" P_Q="0.6587617016971484" P_Z="0.8538367471448074" Q="1.6027711233328108" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="86" WEIGHT="400.0" Z="0.1842252561007398">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.43689862203422" CI_START="0.20579414842785088" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="1.288626969500306" LOG_CI_START="-0.6865669781723437" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-04-01 16:17:37 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.5502285173068775" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.00000000000001" Z="0.5974177375977199">
<NAME>At final follow-up (12-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-02 08:44:39 +1100" MODIFIED_BY="[Empty name]" ORDER="734" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="19.43689862203422" CI_START="0.20579414842785088" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.288626969500306" LOG_CI_START="-0.6865669781723437" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-11-16 03:36:30 +1100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="1.1602387022306428" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="1.3461538461538463" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:17:44 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-16 03:36:52 +1100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.051043318273" CI_START="0.01600570079017955" DF="0" EFFECT_SIZE="0.3589743589743589" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="0.9058521633503449" LOG_CI_START="-1.7957253060468672" LOG_EFFECT_SIZE="-0.44493657134826126" MODIFIED="2014-04-01 16:17:50 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.5185430219941782" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.6455929286691201">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-15 21:28:46 +1100" MODIFIED_BY="[Empty name]" ORDER="735" O_E="0.0" SE="0.0" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.051043318273" CI_START="0.01600570079017955" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9058521633503449" LOG_CI_START="-1.7957253060468672" LOG_EFFECT_SIZE="-0.4449365713482612" MODIFIED="2011-11-16 03:37:10 +1100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.051043318273" CI_START="0.01600570079017955" DF="0" EFFECT_SIZE="0.3589743589743589" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.09.04" LOG_CI_END="0.9058521633503449" LOG_CI_START="-1.7957253060468672" LOG_EFFECT_SIZE="-0.44493657134826126" MODIFIED="2014-04-01 16:17:59 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.5185430219941782" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.6455929286691201">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="8.051043318273" CI_START="0.01600570079017955" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9058521633503449" LOG_CI_START="-1.7957253060468672" LOG_EFFECT_SIZE="-0.4449365713482612" MODIFIED="2011-11-16 03:37:40 +1100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.942804971075702" CI_START="0.22415547730726543" DF="0" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.09.05" LOG_CI_END="1.3210348483971615" LOG_CI_START="-0.6494506445507751" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2014-04-01 16:18:08 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.504134716733027" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.6679982455266427">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="20.942804971075702" CI_START="0.22415547730726543" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3210348483971615" LOG_CI_START="-0.6494506445507751" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2011-11-16 03:37:54 +1100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="1.3397435897435899" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.49428602115311104" CI_END="3.8822109646011977" CI_START="1.4606226542707739" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3812696788803454" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.5890791318438777" LOG_CI_START="0.16453803226906927" LOG_EFFECT_SIZE="0.3768085820564735" METHOD="IV" MODIFIED="2014-04-01 17:16:41 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.9923310234740498" P_Q="0.9327203617163708" P_Z="5.029170553906445E-4" Q="0.43594803051267467" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="86" WEIGHT="400.0" Z="3.479197894554646">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05760845762553227" CI_END="5.340777403701973" CI_START="0.8955247880368726" DF="1" EFFECT_SIZE="2.1869610312948717" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="0.7276044775462797" LOG_CI_START="-0.04792238842060204" LOG_EFFECT_SIZE="0.3398410445628388" MODIFIED="2014-04-01 16:18:19 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8103165996639681" P_Z="0.08584430942564027" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.7177385775828944">
<NAME>At final follow-up (12-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="10.248873583471138" CI_START="0.6098231136424284" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.010676136283019" LOG_CI_START="-0.2147961189389436" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-12-02 08:45:00 +1100" MODIFIED_BY="[Empty name]" ORDER="736" O_E="0.0" SE="0.7198484689028782" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="0.5181818181818181" WEIGHT="40.0485436893204"/>
<DICH_DATA CI_END="6.336261118415285" CI_START="0.63128711478993" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8018330663008477" LOG_CI_START="-0.19977307497288524" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-11-16 03:39:21 +1100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.5883484054145521" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.34615384615384615" WEIGHT="59.95145631067961"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:18:25 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-16 03:39:43 +1100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.295330149040565E-4" CI_END="5.353035030782371" CI_START="0.8943084992747574" DF="1" EFFECT_SIZE="2.1879818840530163" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-003.10.03" LOG_CI_END="0.7286000854581001" LOG_CI_START="-0.04851264180659394" LOG_EFFECT_SIZE="0.3400437218257531" MODIFIED="2014-04-01 16:18:33 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.9784518634702634" P_Z="0.08629838954317659" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.715255521018957">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="9.367991071897338" CI_START="0.527143073369529" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9716464681629865" LOG_CI_START="-0.2780714957136739" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2011-11-15 21:27:55 +1100" MODIFIED_BY="[Empty name]" ORDER="737" O_E="0.0" SE="0.7340905181848413" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" VAR="0.5388888888888889" WEIGHT="38.66731517509728"/>
<DICH_DATA CI_END="6.79104233881076" CI_START="0.6912700893669484" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8319364380877975" LOG_CI_START="-0.1603522342414112" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2011-11-16 03:39:59 +1100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.5828752780343234" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.33974358974358976" WEIGHT="61.33268482490272"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.239593304455946" CI_START="1.143178022230271" DF="0" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-003.10.04" LOG_CI_END="0.9656528554714302" LOG_CI_START="0.05811386648631864" LOG_EFFECT_SIZE="0.5118833609788743" MODIFIED="2014-04-01 16:18:40 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.027037576912432863" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="2.2109748759683727">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="9.239593304455946" CI_START="1.143178022230271" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9656528554714302" LOG_CI_START="0.05811386648631864" LOG_EFFECT_SIZE="0.5118833609788743" MODIFIED="2011-11-16 03:40:22 +1100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.5330928945203023" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.2841880341880342" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.79104233881076" CI_START="0.6912700893669484" DF="0" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-003.10.05" LOG_CI_END="0.8319364380877975" LOG_CI_START="-0.1603522342414112" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2014-04-01 16:18:52 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.18467082321861245" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.326510005435419">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="6.79104233881076" CI_START="0.6912700893669484" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8319364380877975" LOG_CI_START="-0.1603522342414112" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2011-11-16 03:40:38 +1100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.5828752780343234" STUDY_ID="STD-Murphy-1992" TOTAL_1="12" TOTAL_2="13" VAR="0.33974358974358976" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2014-04-01 17:17:22 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="20" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.11.01" MODIFIED="2014-04-01 16:19:05 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (12 months)</NAME>
<CONT_DATA CI_END="2.619036695209595" CI_START="-3.5990366952095956" EFFECT_SIZE="-0.4900000000000002" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.69" MODIFIED="2011-12-02 08:46:13 +1100" MODIFIED_BY="[Empty name]" ORDER="738" SD_1="3.15" SD_2="3.76" SE="1.5862723599684891" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.11.02" MODIFIED="2014-04-01 16:19:12 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="2.619036695209595" CI_START="-3.5990366952095956" EFFECT_SIZE="-0.4900000000000002" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.69" MODIFIED="2013-01-27 18:05:49 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="738" SD_1="3.15" SD_2="3.76" SE="1.5862723599684891" STUDY_ID="STD-Donadio-1974a" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5653158496775045" CI_END="38.70187707810471" CI_START="1.331158036628082" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="7.177625979745061" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="1.5877320292280472" LOG_CI_START="0.12422961848081593" LOG_EFFECT_SIZE="0.8559808238544316" METHOD="IV" MODIFIED="2014-04-01 17:17:39 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.7537776147003704" P_Q="1.0" P_Z="0.021864841840595974" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="99.99999999999997" Z="2.292707649664914">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="121.3913604556164" CI_START="0.4036531085580476" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0841877786670033" LOG_CI_START="-0.39399169863848965" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-04-01 16:19:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="740" O_E="0.0" SE="1.455694892155502" STUDY_ID="STD-Donadio-1974a" TOTAL_1="11" TOTAL_2="11" VAR="2.1190476190476186" WEIGHT="34.87557463622203"/>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 16:19:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="107" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Murphy-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="29.282322100224157"/>
<DICH_DATA CI_END="250.24188037027548" CI_START="0.8991300723407052" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.398359994772363" LOG_CI_START="-0.046177476661000354" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2014-04-01 16:19:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="1892" O_E="0.0" SE="1.435933411375598" STUDY_ID="STD-Tiller-1981" TOTAL_1="27" TOTAL_2="27" VAR="2.061904761904762" WEIGHT="35.8421032635538"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-04-22 16:05:43 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Alkylating agents+steroids versus placebo/no treatment/non-immunosuppressive treatments/steroids</NAME>
<DICH_OUTCOME CHI2="4.704615327559697" CI_END="0.7469447525420551" CI_START="0.25547713290088386" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.436837846133785" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="41" I2="0.0" I2_Q="1.5371722043747995" ID="CMP-004.01" LOG_CI_END="-0.12671151940741723" LOG_CI_START="-0.5926479663684135" LOG_EFFECT_SIZE="-0.3596797428879154" METHOD="IV" MODIFIED="2014-04-01 17:20:11 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.45298172053894836" P_Q="0.3621809440520305" P_Z="0.002478211058013131" Q="2.031223401537186" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="222" TOTAL_2="226" WEIGHT="99.99999999999999" Z="3.0259892593804896">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylating</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9928899216951506" CI_END="0.64297014110834" CI_START="0.17404943872417486" DF="2" EFFECT_SIZE="0.3345274161803634" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="32" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-0.1918091948098045" LOG_CI_START="-0.759327372893262" LOG_EFFECT_SIZE="-0.4755682838515333" MODIFIED="2014-04-01 16:21:28 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.36918970230369896" P_Z="0.0010204859250040076" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="103" WEIGHT="67.40526390833317" Z="3.284817102022256">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="14.208863658145452" CI_START="0.15139219876164783" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1525593469823352" LOG_CI_START="-0.8198965034492852" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2012-01-28 04:03:57 +1100" MODIFIED_BY="[Empty name]" ORDER="1871" O_E="0.0" SE="1.1586303303574623" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="1.3424242424242425" WEIGHT="5.580058922712886"/>
<DICH_DATA CI_END="0.7613239573508241" CI_START="0.07078498660408751" EFFECT_SIZE="0.23214285714285715" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.11843050360803206" LOG_CI_START="-1.1500588457906953" LOG_EFFECT_SIZE="-0.6342446746993636" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3777" O_E="0.0" SE="0.605983594840749" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.36721611721611713" WEIGHT="20.398904135236872"/>
<DICH_DATA CI_END="0.7551995141250635" CI_START="0.14260835950041595" EFFECT_SIZE="0.3281733746130031" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.12193829812321799" LOG_CI_START="-0.8458550160094471" LOG_EFFECT_SIZE="-0.4838966570663326" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3778" O_E="0.0" SE="0.4252322635319177" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.18082247794847828" WEIGHT="41.42630085038341"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:21:25 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:46:43 +1100" MODIFIED_BY="[Empty name]" ORDER="3779" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6805020043273604" CI_END="2.2269959860401927" CI_START="0.2873207924503755" DF="1" EFFECT_SIZE="0.7999139025500641" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.3477194342580319" LOG_CI_START="-0.5416329444232345" LOG_EFFECT_SIZE="-0.09695675508260129" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.4094142747912445" P_Z="0.6691254387415607" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="70" WEIGHT="27.447678952620116" Z="0.4273486023651251">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (15-54 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:46:44 +1100" MODIFIED_BY="[Empty name]" ORDER="745" O_E="0.0" SE="0.0" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.168130559207642" CI_START="0.315643557394965" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5008030706368665" LOG_CI_START="-0.5008030706368665" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-04 22:20:45 +1100" MODIFIED_BY="[Empty name]" ORDER="816" O_E="0.0" SE="0.5883484054145521" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.34615384615384615" WEIGHT="21.640107296904723"/>
<DICH_DATA CI_END="3.2246396258991723" CI_START="0.03758780735853143" EFFECT_SIZE="0.34814814814814815" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5084811864973342" LOG_CI_START="-1.4249530076159114" LOG_EFFECT_SIZE="-0.45823591055928864" MODIFIED="2011-12-04 22:20:49 +1100" MODIFIED_BY="[Empty name]" ORDER="817" O_E="0.0" SE="1.1357088162757347" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="1.2898345153664303" WEIGHT="5.8075716557153925"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.079054470933905" CI_START="0.053714046124468125" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.7838360348665983" LOG_CI_START="-1.269912132239187" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.6427340922815046" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="5.14705713904671" Z="0.46387948622670017">
<NAME>Alkylating agents+steroids versus steroids (low dose) at final follow-up (46 months)</NAME>
<DICH_DATA CI_END="6.079054470933905" CI_START="0.053714046124468125" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7838360348665983" LOG_CI_START="-1.269912132239187" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2011-12-05 04:46:45 +1100" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="1.206381839575324" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="1.455357142857143" WEIGHT="5.14705713904671"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.417260294330382" CI_END="1.984424790032261" CI_START="0.16292877978244238" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5686122664962353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.2976346437355296" LOG_CI_START="-0.7880021950239918" LOG_EFFECT_SIZE="-0.24518377564423113" METHOD="IV" MODIFIED="2014-04-01 17:19:57 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.7014940953155817" P_Q="0.625254029098157" P_Z="0.3760005979089367" Q="0.23855185553624791" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="222" TOTAL_2="226" WEIGHT="100.0" Z="0.8852893577291153">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylating</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1787084387941342" CI_END="1.974316240338338" CI_START="0.11902366221187707" DF="2" EFFECT_SIZE="0.48475803169153736" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.2954167179556183" LOG_CI_START="-0.9243666911579241" LOG_EFFECT_SIZE="-0.31447498660115286" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.5546855883159792" P_Z="0.31220550282856907" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="103" WEIGHT="79.21432019261763" Z="1.0106050683619399">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="50.541308142018366" CI_START="0.10016559100082345" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7036464784130976" LOG_CI_START="-0.9992814421903727" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2012-03-21 02:45:06 +1100" MODIFIED_BY="[Empty name]" ORDER="1870" O_E="0.0" SE="1.5877132402714706" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="2.520833333333333" WEIGHT="16.132445796696235"/>
<DICH_DATA CI_END="2.852188343933463" CI_START="0.033589993755463766" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4551782007135673" LOG_CI_START="-1.4737900768956944" LOG_EFFECT_SIZE="-0.5093059380910637" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3780" O_E="0.0" SE="1.1330855148146515" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="1.283882783882784" WEIGHT="31.675171303035338"/>
<DICH_DATA CI_END="3.222419432482004" CI_START="0.03723803962371684" EFFECT_SIZE="0.3464052287581699" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5081820678513844" LOG_CI_START="-1.429013190285004" LOG_EFFECT_SIZE="-0.46041556121680977" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3781" O_E="0.0" SE="1.137918083900496" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="1.2948575656677765" WEIGHT="31.406703092886065"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:47:57 +1100" MODIFIED_BY="[Empty name]" ORDER="3782" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.19956627537916" CI_START="0.06733909902197872" DF="0" EFFECT_SIZE="1.0444444444444445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="1.2095033869666376" LOG_CI_START="-1.17173269864589" LOG_EFFECT_SIZE="0.018885344160373813" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.9751989171228248" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="70" WEIGHT="20.78567980738237" Z="0.031088554901061147">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (15-54 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:47:58 +1100" MODIFIED_BY="[Empty name]" ORDER="749" O_E="0.0" SE="0.0" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-04 22:26:21 +1100" MODIFIED_BY="[Empty name]" ORDER="818" O_E="0.0" SE="0.0" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.19956627537916" CI_START="0.06733909902197872" EFFECT_SIZE="1.0444444444444445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2095033869666376" LOG_CI_START="-1.17173269864589" LOG_EFFECT_SIZE="0.018885344160373813" MODIFIED="2011-12-04 22:26:24 +1100" MODIFIED_BY="[Empty name]" ORDER="819" O_E="0.0" SE="1.3987498639975258" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="1.956501182033097" WEIGHT="20.78567980738237"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus steroids (low dose) at final follow-up (46 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:47:59 +1100" MODIFIED_BY="[Empty name]" ORDER="752" O_E="0.0" SE="0.0" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5830928534175652" CI_END="0.8110524632180889" CI_START="0.2494066660595379" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4497575912095309" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="34" I2="0.0" I2_Q="24.309935994732648" ID="CMP-004.03" LOG_CI_END="-0.09095105238663473" LOG_CI_START="-0.6030919430219338" LOG_EFFECT_SIZE="-0.3470214977042843" METHOD="IV" MODIFIED="2014-04-22 16:05:43 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6108537643582042" P_Q="0.26682112950895476" P_Z="0.007904932011829867" Q="2.6423547479901957" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="222" TOTAL_2="226" WEIGHT="100.00000000000001" Z="2.6561036222584615">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylating</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7066052309703073" CI_END="0.6529978738913564" CI_START="0.14502573848790692" DF="2" EFFECT_SIZE="0.30773608643142114" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="26" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="-0.18508823275058459" LOG_CI_START="-0.8385549143767842" LOG_EFFECT_SIZE="-0.5118215735636844" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.7023647149609678" P_Z="0.002138822659374191" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="103" WEIGHT="61.42313894134403" Z="3.0702463611427677">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<DICH_DATA CI_END="10.487880939999085" CI_START="0.05127611391227567" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0206877485337722" LOG_CI_START="-1.2900848963286846" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2011-12-05 04:49:00 +1100" MODIFIED_BY="[Empty name]" ORDER="3783" O_E="0.0" SE="1.357359290101277" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="1.8424242424242425" WEIGHT="4.9120691210998375"/>
<DICH_DATA CI_END="0.8964528004721072" CI_START="0.04749831216827371" EFFECT_SIZE="0.20634920634920634" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.04747257172827957" LOG_CI_START="-1.3233218225652104" LOG_EFFECT_SIZE="-0.685397197146745" MODIFIED="2011-12-04 22:31:55 +1100" MODIFIED_BY="[Empty name]" ORDER="823" O_E="0.0" SE="0.7494401654972608" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.5616605616605617" WEIGHT="16.113139940644967"/>
<DICH_DATA CI_END="0.8211823469290466" CI_START="0.12843158007714855" EFFECT_SIZE="0.3247549019607843" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.08556039528988758" LOG_CI_START="-0.891328174344219" LOG_EFFECT_SIZE="-0.48844428481705326" MODIFIED="2011-12-04 22:31:55 +1100" MODIFIED_BY="[Empty name]" ORDER="822" O_E="0.0" SE="0.47331198203134817" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.22402423233444324" WEIGHT="40.39792987959922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:48:55 +1100" MODIFIED_BY="[Empty name]" ORDER="3786" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23413287445706235" CI_END="2.488745498032789" CI_START="0.3130849327873777" DF="1" EFFECT_SIZE="0.8827166685729259" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.39598048742771674" LOG_CI_START="-0.5043378323024478" LOG_EFFECT_SIZE="-0.05417867243736548" MODIFIED="2014-04-22 16:05:43 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.628476177720851" P_Z="0.8135176793051851" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="70" WEIGHT="32.3583769748037" Z="0.2358904498116957">
<NAME>Alkylating agents+steroids versus steroids (same-dose) at final follow-up (15-54 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:48:56 +1100" MODIFIED_BY="[Empty name]" ORDER="753" O_E="0.0" SE="0.0" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.168130559207642" CI_START="0.315643557394965" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5008030706368665" LOG_CI_START="-0.5008030706368665" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-04 22:27:30 +1100" MODIFIED_BY="[Empty name]" ORDER="820" O_E="0.0" SE="0.5883484054145521" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.34615384615384615" WEIGHT="26.144777328736104"/>
<DICH_DATA CI_END="5.5607447385134" CI_START="0.04904308005614795" EFFECT_SIZE="0.5222222222222223" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7451329595977649" LOG_CI_START="-1.3094222626049794" LOG_EFFECT_SIZE="-0.2821446515036074" MODIFIED="2011-12-05 03:02:34 +1100" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="1.206855907734265" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="1.456501182033097" WEIGHT="6.213599646067593"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.079054470933905" CI_START="0.053714046124468125" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.03.04" LOG_CI_END="0.7838360348665983" LOG_CI_START="-1.269912132239187" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.6427340922815046" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="6.218484083852286" Z="0.46387948622670017">
<NAME>Alkylating agents+steroids versus steroids (low dose) at final follow-up (46 months)</NAME>
<DICH_DATA CI_END="6.079054470933905" CI_START="0.053714046124468125" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7838360348665983" LOG_CI_START="-1.269912132239187" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2011-12-05 04:48:57 +1100" MODIFIED_BY="[Empty name]" ORDER="756" O_E="0.0" SE="1.206381839575324" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="1.455357142857143" WEIGHT="6.218484083852286"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="26.48395439360883" CI_END="0.7513367241576921" CI_START="0.3932195872599291" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5435442176737003" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="163" I2="39.58606119688397" I2_Q="12.52675449476331" ID="CMP-004.04" LOG_CI_END="-0.12416538301003814" LOG_CI_START="-0.40536485699699576" LOG_EFFECT_SIZE="-0.264765120003517" METHOD="IV" MODIFIED="2014-04-01 17:20:56 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.04758770016266545" P_Q="0.33237830330012574" P_Z="2.2352116702556923E-4" Q="8.00244687340535" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1882684888410064" TOTALS="SUB" TOTAL_1="415" TOTAL_2="397" WEIGHT="800.0" Z="3.6908326478120466">
<NAME>100% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylating</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.989075769104348" CI_END="1.0397382657997778" CI_START="0.25126530522851503" DF="4" EFFECT_SIZE="0.5111263568961671" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="52" I2="49.931630195961475" ID="CMP-004.04.01" LOG_CI_END="0.016924027736502343" LOG_CI_START="-0.5998674747501935" LOG_EFFECT_SIZE="-0.29147172350684564" MODIFIED="2014-04-01 16:20:25 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.09197923416248188" P_Z="0.06396757200898213" STUDIES="5" TAU2="0.30872589685457485" TOTAL_1="131" TOTAL_2="126" WEIGHT="100.0" Z="1.8524058074148202">
<NAME>Alkylating agents+steroids versus placebo/no treatment/steroids at final follow-up (15-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.671852101612958" CI_START="0.05351196796527171" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6694890857160593" LOG_CI_START="-1.2715490770440216" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-12-05 04:49:50 +1100" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="8.159619640449066"/>
<DICH_DATA CI_END="3.512772582467454" CI_START="0.27216375676802224" EFFECT_SIZE="0.9777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.5456500343987793" LOG_CI_START="-0.5651697089770918" LOG_EFFECT_SIZE="-0.009759837289156262" MODIFIED="2011-12-05 04:49:51 +1100" MODIFIED_BY="[Empty name]" ORDER="824" O_E="0.0" SE="0.6525010159053974" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.42575757575757567" WEIGHT="17.871867664209812"/>
<DICH_DATA CI_END="3.6319014368426354" CI_START="0.43021541943559644" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.560134054051639" LOG_CI_START="-0.3663140280355262" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2011-12-04 23:05:07 +1100" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.5442001894099691" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.29615384615384616" WEIGHT="21.701158909351804"/>
<DICH_DATA CI_END="0.5161674286075996" CI_START="0.05202171959962352" EFFECT_SIZE="0.1638655462184874" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.28720940394226185" LOG_CI_START="-1.2838152961177636" LOG_EFFECT_SIZE="-0.7855123500300127" MODIFIED="2011-12-04 23:04:59 +1100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.5854112343426189" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.3427063132945486" WEIGHT="20.1503567363805"/>
<DICH_DATA CI_END="0.7428254191177341" CI_START="0.21506905874037682" EFFECT_SIZE="0.3996983408748115" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.12911324333602195" LOG_CI_START="-0.6674220655999086" LOG_EFFECT_SIZE="-0.39826765446796525" MODIFIED="2011-12-04 23:04:59 +1100" MODIFIED_BY="[Empty name]" ORDER="825" O_E="0.0" SE="0.3162052668694525" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.09998577079598168" WEIGHT="32.11699704960882"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.183152021173834" CI_END="0.8852341623092079" CI_START="0.17027660896168695" DF="2" EFFECT_SIZE="0.38824563267994594" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="46" I2="52.189162863873634" ID="CMP-004.04.02" LOG_CI_END="-0.05294183444643503" LOG_CI_START="-0.7688450073314739" LOG_EFFECT_SIZE="-0.4108934208889545" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.12349240750493651" P_Z="0.024458658690231897" STUDIES="3" TAU2="0.2799740701891669" TOTAL_1="108" TOTAL_2="103" WEIGHT="99.99999999999997" Z="2.249847009844532">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="3.512772582467454" CI_START="0.27216375676802224" EFFECT_SIZE="0.9777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.5456500343987793" LOG_CI_START="-0.5651697089770918" LOG_EFFECT_SIZE="-0.009759837289156262" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3788" O_E="0.0" SE="0.6525010159053974" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.42575757575757567" WEIGHT="25.057871988200848"/>
<DICH_DATA CI_END="0.5161674286075996" CI_START="0.05202171959962352" EFFECT_SIZE="0.1638655462184874" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.28720940394226185" LOG_CI_START="-1.2838152961177636" LOG_EFFECT_SIZE="-0.7855123500300127" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3789" O_E="0.0" SE="0.5854112343426189" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.3427063132945486" WEIGHT="28.400016623645953"/>
<DICH_DATA CI_END="0.7428254191177341" CI_START="0.21506905874037682" EFFECT_SIZE="0.3996983408748115" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.12911324333602195" LOG_CI_START="-0.6674220655999086" LOG_EFFECT_SIZE="-0.39826765446796525" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3787" O_E="0.0" SE="0.3162052668694525" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.09998577079598168" WEIGHT="46.54211138815318"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.151970842752906" CI_END="2.2502642823664925" CI_START="0.06796756519416002" DF="1" EFFECT_SIZE="0.39108181281649274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="75.91505244442024" ID="CMP-004.04.03" LOG_CI_END="0.35223352683723386" LOG_CI_START="-1.1676982875542816" LOG_EFFECT_SIZE="-0.4077323803585239" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.04158621550655894" P_Z="0.2930069001448272" STUDIES="2" TAU2="1.2110878860003995" TOTAL_1="57" TOTAL_2="50" WEIGHT="100.0" Z="1.0515481987636648">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="3.512772582467454" CI_START="0.27216375676802224" EFFECT_SIZE="0.9777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.5456500343987793" LOG_CI_START="-0.5651697089770918" LOG_EFFECT_SIZE="-0.009759837289156262" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3790" O_E="0.0" SE="0.6525010159053974" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.42575757575757567" WEIGHT="48.69851704852782"/>
<DICH_DATA CI_END="0.5161674286075996" CI_START="0.05202171959962352" EFFECT_SIZE="0.1638655462184874" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.28720940394226185" LOG_CI_START="-1.2838152961177636" LOG_EFFECT_SIZE="-0.7855123500300127" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3791" O_E="0.0" SE="0.5854112343426189" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.3427063132945486" WEIGHT="51.30148295147218"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2914083236727985E-31" CI_END="0.6896987397115354" CI_START="0.20545363012852683" DF="0" EFFECT_SIZE="0.3764320785597382" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" I2="100.0" ID="CMP-004.04.04" LOG_CI_END="-0.16134056759787288" LOG_CI_START="-0.6872861808520497" LOG_EFFECT_SIZE="-0.4243133742249613" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0015644641567058861" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="3.1624522029720947">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 120 months</NAME>
<DICH_DATA CI_END="0.6896987397115353" CI_START="0.20545363012852683" EFFECT_SIZE="0.37643207855973815" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.16134056759787294" LOG_CI_START="-0.6872861808520497" LOG_EFFECT_SIZE="-0.42431337422496135" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3792" O_E="0.0" SE="0.3089430566982773" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.09544581228207501" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5260073816453097" CI_END="2.7613574709822952" CI_START="0.40274308257337593" DF="1" EFFECT_SIZE="1.0545698743802758" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-004.04.05" LOG_CI_END="0.44112263178444217" LOG_CI_START="-0.3949719101912059" LOG_EFFECT_SIZE="0.023075360796618077" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.46829036522123935" P_Z="0.913848123539052" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.10818603356689833">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (15-24months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.671852101612958" CI_START="0.05351196796527171" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6694890857160593" LOG_CI_START="-1.2715490770440216" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-12-04 22:11:59 +1100" MODIFIED_BY="[Empty name]" ORDER="757" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="18.554216867469883"/>
<DICH_DATA CI_END="3.6319014368426354" CI_START="0.43021541943559644" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.560134054051639" LOG_CI_START="-0.3663140280355262" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2011-12-04 22:11:59 +1100" MODIFIED_BY="[Empty name]" ORDER="758" O_E="0.0" SE="0.5442001894099691" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.29615384615384616" WEIGHT="81.44578313253012"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5172910525660526" CI_START="0.008107192549110534" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-004.04.06" LOG_CI_END="0.40093343216166594" LOG_CI_START="-2.0911295121901796" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.18374581554595315" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="1.3293096994900602">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 6 months</NAME>
<DICH_DATA CI_END="2.5172910525660526" CI_START="0.008107192549110534" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40093343216166594" LOG_CI_START="-2.0911295121901796" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-12-04 22:11:59 +1100" MODIFIED_BY="[Empty name]" ORDER="759" O_E="0.0" SE="1.4638501094227996" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="2.1428571428571423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29186398041759903" CI_END="2.4084842501262798" CI_START="0.31020928255226166" DF="1" EFFECT_SIZE="0.8643692331811071" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-004.04.07" LOG_CI_END="0.38174381066473057" LOG_CI_START="-0.5083452107103301" LOG_EFFECT_SIZE="-0.06330070002279979" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.5890285941351607" P_Z="0.7804178313663528" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.27877457032150654">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 12-15 months</NAME>
<DICH_DATA CI_END="4.671852101612958" CI_START="0.05351196796527171" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6694890857160593" LOG_CI_START="-1.2715490770440216" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-12-04 22:11:59 +1100" MODIFIED_BY="[Empty name]" ORDER="760" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="21.028037383177573"/>
<DICH_DATA CI_END="3.168130559207642" CI_START="0.315643557394965" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5008030706368665" LOG_CI_START="-0.5008030706368665" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-04 22:11:59 +1100" MODIFIED_BY="[Empty name]" ORDER="761" O_E="0.0" SE="0.5883484054145521" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.34615384615384615" WEIGHT="78.97196261682242"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6319014368426354" CI_START="0.43021541943559644" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-004.04.08" LOG_CI_END="0.560134054051639" LOG_CI_START="-0.3663140280355262" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.6817770030658967" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.4100394591118128">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 24 months</NAME>
<DICH_DATA CI_END="3.6319014368426354" CI_START="0.43021541943559644" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.560134054051639" LOG_CI_START="-0.3663140280355262" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2011-12-04 22:11:59 +1100" MODIFIED_BY="[Empty name]" ORDER="762" O_E="0.0" SE="0.5442001894099691" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.29615384615384616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.958248069342183" CI_END="0.6873347037305076" CI_START="0.400389322777317" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5245964892638968" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="150" I2="36.24263668126322" I2_Q="35.18496594033872" ID="CMP-004.05" LOG_CI_END="-0.16283172788176095" LOG_CI_START="-0.39751751241330135" LOG_EFFECT_SIZE="-0.28017462014753114" METHOD="IV" MODIFIED="2014-04-01 17:21:16 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0794764036260237" P_Q="0.1172023043186321" P_Z="2.8726355897086736E-6" Q="15.428519239525738" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.14013923401589135" TOTALS="SUB" TOTAL_1="488" TOTAL_2="493" WEIGHT="1100.0" Z="4.679722429438849">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylating</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.642611661034424" CI_END="1.109848737090731" CI_START="0.28471718817802044" DF="3" EFFECT_SIZE="0.5621325570783106" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="41" I2="46.83313011390138" ID="CMP-004.05.01" LOG_CI_END="0.04526379218910584" LOG_CI_START="-0.5455863140067385" LOG_EFFECT_SIZE="-0.2501612609088163" MODIFIED="2014-04-01 16:20:25 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.1303534939433154" P_Z="0.09698156369658797" STUDIES="4" TAU2="0.2161629359327404" TOTAL_1="142" TOTAL_2="147" WEIGHT="100.0" Z="1.659666492624407">
<NAME>Alkylating agents+steroids versus placebo/no treatment/steroids at final follow-up (24-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.9638865365289027" CI_START="0.4858485580512227" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.47186157396903633" LOG_CI_START="-0.3134990818737867" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2011-12-04 23:07:54 +1100" MODIFIED_BY="[Empty name]" ORDER="835" O_E="0.0" SE="0.46132473684001907" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.21282051282051284" WEIGHT="28.079495687603725"/>
<DICH_DATA CI_END="0.682692937091351" CI_START="0.15471816721880977" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.16577459018789992" LOG_CI_START="-0.8104586878543513" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2011-12-04 23:07:47 +1100" MODIFIED_BY="[Empty name]" ORDER="834" O_E="0.0" SE="0.37869063020702454" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.1434065934065934" WEIGHT="33.50016593856763"/>
<DICH_DATA CI_END="1.8791331270349632" CI_START="0.02780265921958365" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.27395754874801437" LOG_CI_START="-1.5559136634646784" LOG_EFFECT_SIZE="-0.640978057358332" MODIFIED="2011-12-05 04:50:45 +1100" MODIFIED_BY="[Empty name]" ORDER="837" O_E="0.0" SE="1.074875408062322" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="1.155357142857143" WEIGHT="8.782692346690563"/>
<DICH_DATA CI_END="1.5627224866572142" CI_START="0.28268289906801847" EFFECT_SIZE="0.6646464646464646" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.19388186143941533" LOG_CI_START="-0.5487004634066043" LOG_EFFECT_SIZE="-0.17740930098359445" MODIFIED="2011-12-04 23:07:54 +1100" MODIFIED_BY="[Empty name]" ORDER="836" O_E="0.0" SE="0.4361965334563431" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.19026741579933068" WEIGHT="29.637646027138075"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.682692937091351" CI_START="0.15471816721880977" DF="0" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="-0.16577459018789992" LOG_CI_START="-0.8104586878543513" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.0029980535104139256" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="39" WEIGHT="100.0" Z="2.967937432299193">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.682692937091351" CI_START="0.15471816721880977" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.16577459018789992" LOG_CI_START="-0.8104586878543513" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3793" O_E="0.0" SE="0.37869063020702454" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.1434065934065934" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5911748877107204" CI_START="0.1010060673964368" DF="0" EFFECT_SIZE="0.24436090225563906" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" I2="0.0" ID="CMP-004.05.03" LOG_CI_END="-0.22828402244864582" LOG_CI_START="-0.9956525375277772" LOG_EFFECT_SIZE="-0.6119682799882115" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.0017714062806971102" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="39" WEIGHT="99.99999999999999" Z="3.1261011232240414">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="0.5911748877107204" CI_START="0.1010060673964368" EFFECT_SIZE="0.24436090225563908" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.22828402244864582" LOG_CI_START="-0.9956525375277772" LOG_EFFECT_SIZE="-0.6119682799882115" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3794" O_E="0.0" SE="0.45075606429289333" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.203181029496819" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.682692937091351" CI_START="0.15471816721880977" DF="0" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" ID="CMP-004.05.04" LOG_CI_END="-0.16577459018789992" LOG_CI_START="-0.8104586878543513" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.0029980535104139256" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="39" WEIGHT="100.0" Z="2.967937432299193">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 120 months</NAME>
<DICH_DATA CI_END="0.682692937091351" CI_START="0.15471816721880977" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.16577459018789992" LOG_CI_START="-0.8104586878543513" LOG_EFFECT_SIZE="-0.4881166390211256" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3795" O_E="0.0" SE="0.37869063020702454" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.1434065934065934" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.865990026332329" CI_END="1.6349144072457422" CI_START="0.47197660781081985" DF="1" EFFECT_SIZE="0.878431190243654" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-004.05.05" LOG_CI_END="0.21349502095110984" LOG_CI_START="-0.3260795254134333" LOG_EFFECT_SIZE="-0.056292252231161743" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.3520679276047861" P_Z="0.6825728694897868" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="60" WEIGHT="100.0" Z="0.4089547504606738">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (24-54 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.9638865365289027" CI_START="0.4858485580512227" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.47186157396903633" LOG_CI_START="-0.3134990818737867" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2011-12-04 22:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="764" O_E="0.0" SE="0.46132473684001907" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.21282051282051284" WEIGHT="47.202459386664955"/>
<DICH_DATA CI_END="1.5627224866572142" CI_START="0.28268289906801847" EFFECT_SIZE="0.6646464646464646" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.19388186143941533" LOG_CI_START="-0.5487004634066043" LOG_EFFECT_SIZE="-0.17740930098359445" MODIFIED="2011-12-04 22:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="763" O_E="0.0" SE="0.4361965334563431" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.19026741579933068" WEIGHT="52.79754061333504"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9459227897152802" CI_START="0.03211843775628156" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-004.05.06" LOG_CI_END="0.2891256043466023" LOG_CI_START="-1.4932455870025272" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.18547093395514574" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="1.3240966923866346">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 6 months</NAME>
<DICH_DATA CI_END="1.9459227897152802" CI_START="0.03211843775628156" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2891256043466023" LOG_CI_START="-1.4932455870025272" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2011-12-04 22:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="765" O_E="0.0" SE="1.0469736606781692" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="1.0961538461538463" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.168130559207642" CI_START="0.315643557394965" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-004.05.07" LOG_CI_END="0.5008030706368665" LOG_CI_START="-0.5008030706368665" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="99.99999999999999" Z="0.0">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 12 months</NAME>
<DICH_DATA CI_END="3.168130559207642" CI_START="0.315643557394965" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5008030706368665" LOG_CI_START="-0.5008030706368665" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-04 22:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="766" O_E="0.0" SE="0.5883484054145521" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.34615384615384615" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9638865365289027" CI_START="0.4858485580512227" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-004.05.08" LOG_CI_END="0.47186157396903633" LOG_CI_START="-0.3134990818737867" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.6926856626204092" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.39521305109892935">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 24 months</NAME>
<DICH_DATA CI_END="2.9638865365289027" CI_START="0.4858485580512227" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.47186157396903633" LOG_CI_START="-0.3134990818737867" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2011-12-04 22:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="767" O_E="0.0" SE="0.46132473684001907" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="0.21282051282051284" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5627224866572142" CI_START="0.28268289906801847" DF="0" EFFECT_SIZE="0.6646464646464646" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-004.05.09" LOG_CI_END="0.19388186143941533" LOG_CI_START="-0.5487004634066043" LOG_EFFECT_SIZE="-0.17740930098359445" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.3490135134399479" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="47" WEIGHT="99.99999999999999" Z="0.9365044893099851">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 54 months</NAME>
<DICH_DATA CI_END="1.5627224866572142" CI_START="0.28268289906801847" EFFECT_SIZE="0.6646464646464646" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.19388186143941533" LOG_CI_START="-0.5487004634066043" LOG_EFFECT_SIZE="-0.17740930098359445" MODIFIED="2011-12-04 22:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="768" O_E="0.0" SE="0.4361965334563431" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.19026741579933068" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.2674082971770343E-32" CI_END="1.8791331270349636" CI_START="0.027802659219583664" DF="0" EFFECT_SIZE="0.22857142857142862" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="100.0" ID="CMP-004.05.10" LOG_CI_END="0.2739575487480145" LOG_CI_START="-1.5559136634646782" LOG_EFFECT_SIZE="-0.6409780573583319" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Z="0.16972267894046003" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="100.0" Z="1.3730954385403555">
<NAME>Alkylating agents+steroids versus steroids (low dose) at final follow-up (46 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.8791331270349632" CI_START="0.02780265921958365" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.27395754874801437" LOG_CI_START="-1.5559136634646784" LOG_EFFECT_SIZE="-0.640978057358332" MODIFIED="2011-12-04 22:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="769" O_E="0.0" SE="1.074875408062322" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="1.155357142857143" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5815545407744207" CI_START="0.023905999445833423" DF="0" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-004.05.11" LOG_CI_END="0.19908417339302495" LOG_CI_START="-1.621493094899086" LOG_EFFECT_SIZE="-0.7112044607530305" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.12569251291686714" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.5313111428968078">
<NAME>Alkylating agents+steroids versus steroids (low dose) at 46 months</NAME>
<DICH_DATA CI_END="1.5815545407744207" CI_START="0.023905999445833423" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.19908417339302495" LOG_CI_START="-1.621493094899086" LOG_EFFECT_SIZE="-0.7112044607530305" MODIFIED="2011-12-04 22:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="770" O_E="0.0" SE="1.0694160993976076" STUDY_ID="STD-Pahari-1993" TOTAL_1="36" TOTAL_2="35" VAR="1.1436507936507938" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="52.05682204381817" CI_END="24.92280801232318" CI_START="16.98085278133332" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="MD" EFFECT_SIZE="20.95183039682825" ESTIMABLE="YES" I2="50.05457694264389" I2_Q="46.28525302566615" ID="CMP-004.06" MODIFIED="2014-04-01 17:22:36 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0017715519315070205" P_Q="0.014467276428965059" P_Z="4.585645554891978E-25" Q="33.51035053483695" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="104.03641190110964" TOTALS="SUB" TOTAL_1="706" TOTAL_2="616" UNITS="&#956;mol/L" WEIGHT="1900.0" Z="10.341240108666977">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylating</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.3802402748868765" CI_END="42.994828442194176" CI_START="-85.95784162282376" DF="3" EFFECT_SIZE="-21.481506590314797" ESTIMABLE="YES" I2="59.35091693141408" ID="CMP-004.06.01" MODIFIED="2014-04-01 16:20:25 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.060716801928935915" P_Z="0.5137569577286007" STUDIES="4" TAU2="2237.5171346513393" TOTAL_1="80" TOTAL_2="70" WEIGHT="99.99999999999999" Z="0.6529989527079743">
<NAME>Alkylating agents+steroids versus placebo/no treatment/steroids at final follow-up (12-120 months)</NAME>
<CONT_DATA CI_END="44.17300990660809" CI_START="-208.59300990660805" EFFECT_SIZE="-82.20999999999998" ESTIMABLE="YES" MEAN_1="128.18" MEAN_2="210.39" MODIFIED="2013-01-27 18:10:53 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="774" SD_1="30.94" SD_2="201.55" SE="64.48231238099328" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="16.921192624117328"/>
<CONT_DATA CI_END="153.05150011044282" CI_START="-327.5115001104428" EFFECT_SIZE="-87.22999999999999" ESTIMABLE="YES" MEAN_1="217.17" MEAN_2="304.4" MODIFIED="2013-01-27 18:10:53 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="776" SD_1="158.48" SD_2="213.93" SE="122.59485480639063" STUDY_ID="STD-Falk-1992" TOTAL_1="7" TOTAL_2="4" WEIGHT="6.2673972717626345"/>
<CONT_DATA CI_END="43.583635444320635" CI_START="10.13636455567935" EFFECT_SIZE="26.859999999999992" ESTIMABLE="YES" MEAN_1="73.71" MEAN_2="46.85" MODIFIED="2013-01-27 18:10:22 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3806" SD_1="32.71" SD_2="30.94" SE="8.532623852394504" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="46.84161278295468"/>
<CONT_DATA CI_END="23.635810742535867" CI_START="-121.63581074253587" EFFECT_SIZE="-49.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="155.0" MODIFIED="2013-01-27 18:09:31 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="778" SD_1="59.0" SD_2="198.0" SE="37.05976809547413" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="32" TOTAL_2="31" WEIGHT="29.96979732116536"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.733625213131096E-31" CI_END="43.583635444320635" CI_START="10.136364555679346" DF="0" EFFECT_SIZE="26.85999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-004.06.02" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.001644378286571116" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="3.1479179751328528">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (120 months)</NAME>
<CONT_DATA CI_END="43.583635444320635" CI_START="10.13636455567935" EFFECT_SIZE="26.859999999999992" ESTIMABLE="YES" MEAN_1="73.71" MEAN_2="46.85" MODIFIED="2013-02-14 01:38:18 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3806" SD_1="32.71" SD_2="30.94" SE="8.532623852394504" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.99870386332951" CI_START="0.2212961366704871" DF="0" EFFECT_SIZE="10.61" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.03" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.04531545931068289" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="2.001714376455933">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 6 months</NAME>
<CONT_DATA CI_END="20.99870386332951" CI_START="0.2212961366704871" EFFECT_SIZE="10.61" ESTIMABLE="YES" MEAN_1="91.94" MEAN_2="81.33" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3796" SD_1="17.68" SD_2="21.22" SE="5.300456511075858" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="26.88730914201092" CI_START="1.4126908579890927" DF="0" EFFECT_SIZE="14.150000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.04" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.029454988158774828" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.00000000000001" Z="2.1773429593358626">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="26.88730914201092" CI_START="1.4126908579890927" EFFECT_SIZE="14.150000000000006" ESTIMABLE="YES" MEAN_1="90.17" MEAN_2="76.02" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3797" SD_1="19.45" SD_2="27.4" SE="6.498746529263386" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="37.56204579390932" CI_START="15.47795420609067" DF="0" EFFECT_SIZE="26.519999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.05" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="2.510168269395765E-6" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="4.707302056170866">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 24 months</NAME>
<CONT_DATA CI_END="37.56204579390932" CI_START="15.47795420609067" EFFECT_SIZE="26.519999999999996" ESTIMABLE="YES" MEAN_1="91.94" MEAN_2="65.42" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3798" SD_1="19.45" SD_2="22.1" SE="5.633800356030812" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="36.76632162679299" CI_START="9.193678373207007" DF="0" EFFECT_SIZE="22.979999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.06" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.0010869202026979846" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.00000000000001" Z="3.267004323850796">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 36 months</NAME>
<CONT_DATA CI_END="36.76632162679299" CI_START="9.193678373207007" EFFECT_SIZE="22.979999999999997" ESTIMABLE="YES" MEAN_1="86.63" MEAN_2="63.65" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3799" SD_1="20.33" SD_2="30.06" SE="7.03396681548117" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="38.098825911222235" CI_START="9.641174088777774" DF="0" EFFECT_SIZE="23.870000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.07" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.0010090282902781242" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="3.2879972390464376">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 48 months</NAME>
<CONT_DATA CI_END="38.098825911222235" CI_START="9.641174088777774" EFFECT_SIZE="23.870000000000005" ESTIMABLE="YES" MEAN_1="83.98" MEAN_2="60.11" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3800" SD_1="19.45" SD_2="31.82" SE="7.259738456143783" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="40.03070313459981" CI_START="11.249296865400176" DF="0" EFFECT_SIZE="25.639999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.08" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="4.7927592963294656E-4" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="99.99999999999999" Z="3.4920793024200236">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 60 months</NAME>
<CONT_DATA CI_END="40.03070313459981" CI_START="11.249296865400176" EFFECT_SIZE="25.639999999999993" ESTIMABLE="YES" MEAN_1="83.1" MEAN_2="57.46" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3801" SD_1="18.56" SD_2="32.71" SE="7.342330393880626" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="44.16762152255997" CI_START="14.172378477440036" DF="0" EFFECT_SIZE="29.17" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.09" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="1.3780164852098478E-4" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="3.812081091860664">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 72 months</NAME>
<CONT_DATA CI_END="44.16762152255997" CI_START="14.172378477440036" EFFECT_SIZE="29.17" ESTIMABLE="YES" MEAN_1="81.33" MEAN_2="52.16" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3802" SD_1="22.1" SD_2="32.71" SE="7.651988322672911" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="45.491874540529714" CI_START="12.848125459470289" DF="0" EFFECT_SIZE="29.17" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.10" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="4.604069449815006E-4" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="3.502793094449182">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 84 months</NAME>
<CONT_DATA CI_END="45.491874540529714" CI_START="12.848125459470289" EFFECT_SIZE="29.17" ESTIMABLE="YES" MEAN_1="79.56" MEAN_2="50.39" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3803" SD_1="27.4" SD_2="33.59" SE="8.32764003281416" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="43.908951328680814" CI_START="10.891048671319183" DF="0" EFFECT_SIZE="27.4" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.11" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.0011420823738956907" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="3.2529633231821236">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 96 months</NAME>
<CONT_DATA CI_END="43.908951328680814" CI_START="10.891048671319183" EFFECT_SIZE="27.4" ESTIMABLE="YES" MEAN_1="76.02" MEAN_2="48.62" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3804" SD_1="28.29" SD_2="33.59" SE="8.423089127607097" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7682356745162458E-31" CI_END="42.1991570464688" CI_START="9.08084295353121" DF="0" EFFECT_SIZE="25.640000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-004.06.12" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.0" P_Z="0.0024070744611155146" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="3.0347847068896208">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 108 months</NAME>
<CONT_DATA CI_END="42.1991570464688" CI_START="9.080842953531214" EFFECT_SIZE="25.640000000000008" ESTIMABLE="YES" MEAN_1="74.26" MEAN_2="48.62" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3805" SD_1="30.94" SD_2="31.82" SE="8.448704760437085" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.733625213131096E-31" CI_END="43.583635444320635" CI_START="10.136364555679346" DF="0" EFFECT_SIZE="26.85999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-004.06.13" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="0.0" P_Z="0.001644378286571116" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0" Z="3.1479179751328528">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 120 months</NAME>
<CONT_DATA CI_END="43.583635444320635" CI_START="10.13636455567935" EFFECT_SIZE="26.859999999999992" ESTIMABLE="YES" MEAN_1="73.71" MEAN_2="46.85" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3806" SD_1="32.71" SD_2="30.94" SE="8.532623852394504" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="31" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2553635701268664" CI_END="1.7450825479994947" CI_START="-120.09150588193029" DF="2" EFFECT_SIZE="-59.1732116669654" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.14" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="0.880133411578589" P_Z="0.05693385151810529" STUDIES="3" TAU2="0.0" TOTAL_1="49" TOTAL_2="45" WEIGHT="100.00000000000001" Z="1.9038183063295144">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (24-54 months)</NAME>
<CONT_DATA CI_END="44.17300990660809" CI_START="-208.59300990660805" EFFECT_SIZE="-82.20999999999998" ESTIMABLE="YES" MEAN_1="128.18" MEAN_2="210.39" MODIFIED="2013-02-14 01:38:24 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="774" SD_1="30.94" SD_2="201.55" SE="64.48231238099328" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="23.233684079691876"/>
<CONT_DATA CI_END="153.05150011044282" CI_START="-327.5115001104428" EFFECT_SIZE="-87.22999999999999" ESTIMABLE="YES" MEAN_1="217.17" MEAN_2="304.4" MODIFIED="2013-02-14 01:38:24 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="776" SD_1="158.48" SD_2="213.93" SE="122.59485480639063" STUDY_ID="STD-Falk-1992" TOTAL_1="7" TOTAL_2="4" WEIGHT="6.427688161390893"/>
<CONT_DATA CI_END="23.635810742535867" CI_START="-121.63581074253587" EFFECT_SIZE="-49.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="155.0" MODIFIED="2013-02-14 01:38:24 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="778" SD_1="59.0" SD_2="198.0" SE="37.05976809547413" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="32" TOTAL_2="31" WEIGHT="70.33862775891724"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.989487366456172E-33" CI_END="87.12276238973558" CI_START="-206.64276238973557" DF="0" EFFECT_SIZE="-59.76" ESTIMABLE="YES" I2="100.0" ID="CMP-004.06.15" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="0.0" P_Z="0.42520638269247346" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.797421329844888">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 6 months</NAME>
<CONT_DATA CI_END="87.12276238973558" CI_START="-206.64276238973557" EFFECT_SIZE="-59.75999999999999" ESTIMABLE="YES" MEAN_1="178.28" MEAN_2="238.04" MODIFIED="2011-12-04 22:13:01 +1100" MODIFIED_BY="[Empty name]" ORDER="771" SD_1="75.37" SD_2="227.58" SE="74.94156196150952" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="10" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.8255805202553175" CI_END="44.127599937261685" CI_START="-54.85862255790072" DF="2" EFFECT_SIZE="-5.365511310319519" ESTIMABLE="YES" I2="29.218085074451132" ID="CMP-004.06.16" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="0.24346331839767577" P_Z="0.8317339561541417" STUDIES="3" TAU2="811.2773193799849" TOTAL_1="68" TOTAL_2="66" WEIGHT="100.00000000000001" Z="0.21247823508736305">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 12-15 months</NAME>
<CONT_DATA CI_END="44.17300990660809" CI_START="-208.59300990660805" EFFECT_SIZE="-82.20999999999998" ESTIMABLE="YES" MEAN_1="128.18" MEAN_2="210.39" MODIFIED="2011-12-05 08:28:53 +1100" MODIFIED_BY="[Empty name]" ORDER="774" SD_1="30.94" SD_2="201.55" SE="64.48231238099328" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.832250770868427"/>
<CONT_DATA CI_END="181.9927545462885" CI_START="-51.55275454628844" EFFECT_SIZE="65.22000000000003" ESTIMABLE="YES" MEAN_1="267.22" MEAN_2="202.0" MODIFIED="2011-12-04 22:13:01 +1100" MODIFIED_BY="[Empty name]" ORDER="773" SD_1="169.25" SD_2="110.07" SE="59.57903077167593" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="9" WEIGHT="14.622222693287423"/>
<CONT_DATA CI_END="10.12779626767416" CI_START="-22.12779626767416" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="91.0" MEAN_2="97.0" MODIFIED="2011-12-04 22:13:01 +1100" MODIFIED_BY="[Empty name]" ORDER="772" SD_1="29.0" SD_2="48.0" SE="8.228618686306564" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" WEIGHT="72.54552653584416"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.22666943115388233" CI_END="11.150550056472067" CI_START="-70.57668686137087" DF="1" EFFECT_SIZE="-29.713068402449405" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.17" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="0.634004487729981" P_Z="0.15411555686746656" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="1.425144080119061">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 24 months</NAME>
<CONT_DATA CI_END="153.05150011044282" CI_START="-327.5115001104428" EFFECT_SIZE="-87.22999999999999" ESTIMABLE="YES" MEAN_1="217.17" MEAN_2="304.4" MODIFIED="2011-12-05 02:58:55 +1100" MODIFIED_BY="[Empty name]" ORDER="776" SD_1="158.48" SD_2="213.93" SE="122.59485480639063" STUDY_ID="STD-Falk-1992" TOTAL_1="7" TOTAL_2="4" WEIGHT="2.8922309681739113"/>
<CONT_DATA CI_END="13.4676889549743" CI_START="-69.4676889549743" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="125.0" MODIFIED="2011-12-05 02:58:57 +1100" MODIFIED_BY="[Empty name]" ORDER="775" SD_1="56.0" SD_2="133.0" SE="21.157372932393727" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="44" TOTAL_2="47" WEIGHT="97.1077690318261"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.489199773223383" CI_START="-81.48919977322339" DF="0" EFFECT_SIZE="-27.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.18" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="18" P_CHI2="1.0" P_Z="0.33145677658055506" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="0.9711837906011326">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 36 months</NAME>
<CONT_DATA CI_END="27.489199773223383" CI_START="-81.48919977322339" EFFECT_SIZE="-27.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="133.0" MODIFIED="2011-12-05 03:10:02 +1100" MODIFIED_BY="[Empty name]" ORDER="777" SD_1="59.0" SD_2="172.0" SE="27.80112298135437" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.675995853808618E-32" CI_END="23.635810742535874" CI_START="-121.63581074253585" DF="0" EFFECT_SIZE="-48.99999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-004.06.19" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="19" P_CHI2="0.0" P_Z="0.1861053822439118" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.00000000000001" Z="1.322188521896985">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 48 months</NAME>
<CONT_DATA CI_END="23.635810742535867" CI_START="-121.63581074253587" EFFECT_SIZE="-49.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="155.0" MODIFIED="2011-12-04 22:13:01 +1100" MODIFIED_BY="[Empty name]" ORDER="778" SD_1="59.0" SD_2="198.0" SE="37.05976809547413" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="22.285922736934573" CI_END="11.730292184130349" CI_START="6.733818997632323" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="9.232055590881336" ESTIMABLE="YES" I2="55.128624836220276" I2_Q="56.4239724113529" ID="CMP-004.07" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="7" P_CHI2="0.013712478760788849" P_Q="0.014280770911994978" P_Z="4.391665760710807E-13" Q="20.65355769681213" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="21.947612381818608" TOTALS="SUB" TOTAL_1="388" TOTAL_2="383" UNITS="" WEIGHT="1000.0" Z="7.242907461325257">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alkylating</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1773145771370286" CI_END="21.908219687589828" CI_START="1.49792526618951" DF="1" EFFECT_SIZE="11.703072476889668" ESTIMABLE="YES" I2="15.060934484326088" ID="CMP-004.07.01" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.2779034279213536" P_Z="0.024598507643162567" STUDIES="2" TAU2="14.97132192414434" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="2.247650140618795">
<NAME>Alkylating agents+steroids versus placebo/no treatment/ACEi/ARB at final follow-up (9-120 months)</NAME>
<CONT_DATA CI_END="22.179264851104982" CI_START="5.820735148895018" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="64.0" MEAN_2="50.0" MODIFIED="2013-02-14 14:34:15 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3812" SD_1="18.0" SD_2="22.0" SE="4.173170994784587" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="83.70973387865011"/>
<CONT_DATA CI_END="24.020460636392638" CI_START="-24.22046063639264" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="62.1" MODIFIED="2013-02-14 14:34:15 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3813" SD_1="17.0" SD_2="19.9" SE="12.306583603908926" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" WEIGHT="16.290266121349887"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="22.179264851104982" CI_START="5.820735148895018" DF="0" EFFECT_SIZE="14.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.02" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="7.943298167492807E-4" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="3.354763084833206">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (120 months)</NAME>
<CONT_DATA CI_END="22.179264851104982" CI_START="5.820735148895018" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="64.0" MEAN_2="50.0" MODIFIED="2013-01-27 18:12:21 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3812" SD_1="18.0" SD_2="22.0" SE="4.173170994784587" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.11541119229647" CI_START="-6.11541119229647" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.03" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="0.0">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="6.11541119229647" CI_START="-6.11541119229647" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="90.0" MEAN_2="90.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3807" SD_1="14.0" SD_2="16.0" SE="3.1201650849373013" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.370731330267684" CI_START="-4.370731330267685" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.04" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.4250241699267433" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="0.7977352165143456">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 24 months</NAME>
<CONT_DATA CI_END="10.370731330267684" CI_START="-4.370731330267685" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="85.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3808" SD_1="16.0" SD_2="20.0" SE="3.7606463120787286" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.708162082556996" CI_START="1.2918379174430035" DF="0" EFFECT_SIZE="8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.05" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.019417978323306932" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.00000000000001" Z="2.337408023740489">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 48 months</NAME>
<CONT_DATA CI_END="14.708162082556996" CI_START="1.2918379174430035" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="76.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3809" SD_1="17.0" SD_2="16.0" SE="3.422594565752291" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="22.729844646089834" CI_START="7.270155353910167" DF="0" EFFECT_SIZE="15.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.06" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="1.427408749683927E-4" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="3.803370069406586">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 72 months</NAME>
<CONT_DATA CI_END="22.729844646089834" CI_START="7.270155353910167" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="64.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3810" SD_1="20.0" SD_2="18.0" SE="3.9438707583720216" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.489342973552596" CI_START="8.510657026447404" DF="0" EFFECT_SIZE="14.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.07" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="5.772264236703798E-7" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="4.998684891026668">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 96 months</NAME>
<CONT_DATA CI_END="19.489342973552596" CI_START="8.510657026447404" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="57.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3811" SD_1="14.0" SD_2="13.0" SE="2.800736654781329" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="22.179264851104982" CI_START="5.820735148895018" DF="0" EFFECT_SIZE="14.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.08" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="7.943298167492807E-4" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="3.354763084833206">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 120 months</NAME>
<CONT_DATA CI_END="22.179264851104982" CI_START="5.820735148895018" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="64.0" MEAN_2="50.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3812" SD_1="18.0" SD_2="22.0" SE="4.173170994784587" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="24.020460636392638" CI_START="-24.22046063639264" DF="0" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.09" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.9935166752507123" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="0.0081257319836708">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<CONT_DATA CI_END="24.020460636392638" CI_START="-24.22046063639264" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="62.1" MODIFIED="2013-02-14 14:33:09 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3813" SD_1="17.0" SD_2="19.9" SE="12.306583603908926" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="24.020460636392638" CI_START="-24.22046063639264" DF="0" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.10" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.9935166752507123" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="0.0081257319836708">
<NAME>Alkylating agents+steroids versus ACEi/ARB at 9 months</NAME>
<CONT_DATA CI_END="24.020460636392638" CI_START="-24.22046063639264" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="62.1" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3813" SD_1="17.0" SD_2="19.9" SE="12.306583603908926" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="84.99353927929936" CI_END="1.8734064581030654" CI_START="1.5667118900478698" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="RR" EFFECT_SIZE="1.713209903310899" ESTIMABLE="YES" EVENTS_1="889" EVENTS_2="444" I2="56.46727937942037" I2_Q="57.43559352896075" ID="CMP-004.08" LOG_CI_END="0.27263201301888834" LOG_CI_START="0.19498913937442555" LOG_EFFECT_SIZE="0.23381057619665702" METHOD="IV" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="8" P_CHI2="1.2139622184492715E-5" P_Q="5.889209028895337E-4" P_Z="3.7081649423313377E-32" Q="46.98761631648257" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07789242149583829" TOTALS="SUB" TOTAL_1="1340" TOTAL_2="1315" WEIGHT="2100.0" Z="11.804310866917211">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alkylating</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.73225412231399" CI_END="1.8909278346847072" CI_START="1.1332079641809272" DF="6" EFFECT_SIZE="1.4638355378785235" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="87" I2="52.87558713201723" ID="CMP-004.08.01" LOG_CI_END="0.27667495475923465" LOG_CI_START="0.05430961807896375" LOG_EFFECT_SIZE="0.16549228641909924" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.04749045636101068" P_Z="0.003530177335125695" STUDIES="7" TAU2="0.06110958805237032" TOTAL_1="209" TOTAL_2="213" WEIGHT="100.00000000000001" Z="2.917351471619002">
<NAME>Alkylating agents+steroids versus placebo/no treatment/ACEi/ARB/steroids at final follow-up (9-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.4135305587586395" CI_START="0.7365880540962153" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3826528019805788" LOG_CI_START="-0.132775328763979" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-12-05 04:54:27 +1100" MODIFIED_BY="[Empty name]" ORDER="761" O_E="0.0" SE="0.3027650354097491" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.09166666666666662" WEIGHT="11.167437270248422"/>
<DICH_DATA CI_END="1.479112799951296" CI_START="0.3635813156342677" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.17000129538187236" LOG_CI_START="-0.43939844317678484" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2011-12-05 04:54:28 +1100" MODIFIED_BY="[Empty name]" ORDER="757" O_E="0.0" SE="0.35796442300671183" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.12813852813852813" WEIGHT="9.015250853209773"/>
<DICH_DATA CI_END="3.071946806928875" CI_START="1.122734151534607" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.48741369128874734" LOG_CI_START="0.05027693329641265" LOG_EFFECT_SIZE="0.26884531229257996" MODIFIED="2011-12-04 23:12:40 +1100" MODIFIED_BY="[Empty name]" ORDER="759" O_E="0.0" SE="0.2567762955065478" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.06593406593406595" WEIGHT="13.42939365661265"/>
<DICH_DATA CI_END="3.474003986473355" CI_START="1.4037796531321036" EFFECT_SIZE="2.2083333333333335" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" LOG_CI_END="0.540830312471007" LOG_CI_START="0.14729894330735907" LOG_EFFECT_SIZE="0.3440646278891831" MODIFIED="2011-12-04 23:12:40 +1100" MODIFIED_BY="[Empty name]" ORDER="758" O_E="0.0" SE="0.23116227425842129" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.053435997040325575" WEIGHT="14.894674810711074"/>
<DICH_DATA CI_END="1.4606855634238305" CI_START="0.6846100386287185" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.16455673696984163" LOG_CI_START="-0.1645567369698416" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:54:28 +1100" MODIFIED_BY="[Empty name]" ORDER="760" O_E="0.0" SE="0.19332288373014034" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.037373737373737365" WEIGHT="17.32394020588232"/>
<DICH_DATA CI_END="2.4223101577779858" CI_START="1.213211900535419" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="0.38422975036256785" LOG_CI_START="0.08393666170416797" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2011-12-05 04:54:29 +1100" MODIFIED_BY="[Empty name]" ORDER="763" O_E="0.0" SE="0.17639364675270655" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="0.03111471861471862" WEIGHT="18.49967001776532"/>
<DICH_DATA CI_END="2.4935291215380655" CI_START="1.0585888033310542" EFFECT_SIZE="1.6246913580246913" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="18" LOG_CI_END="0.3968144446415818" LOG_CI_START="0.024727296156992075" LOG_EFFECT_SIZE="0.21077087039928694" MODIFIED="2011-12-04 23:12:56 +1100" MODIFIED_BY="[Empty name]" ORDER="762" O_E="0.0" SE="0.21856583288093814" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.047771023302938184" WEIGHT="15.669633185570438"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.913610997537112" CI_END="2.7314823477685195" CI_START="0.850823954565576" DF="2" EFFECT_SIZE="1.5244706008823115" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="36" I2="71.07155724103548" ID="CMP-004.08.02" LOG_CI_END="0.4363983982273185" LOG_CI_START="-0.07016029123146887" LOG_EFFECT_SIZE="0.18311905349792482" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.03153035480540034" P_Z="0.15647147877824158" STUDIES="3" TAU2="0.186801627844031" TOTAL_1="108" TOTAL_2="103" WEIGHT="99.99999999999999" Z="1.4170391593615965">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.479112799951296" CI_START="0.3635813156342677" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.17000129538187236" LOG_CI_START="-0.43939844317678484" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2012-01-03 00:29:02 +1100" MODIFIED_BY="[Empty name]" ORDER="3814" O_E="0.0" SE="0.35796442300671183" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.12813852813852813" WEIGHT="28.112968435455077"/>
<DICH_DATA CI_END="3.071946806928875" CI_START="1.122734151534607" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.48741369128874734" LOG_CI_START="0.05027693329641265" LOG_EFFECT_SIZE="0.26884531229257996" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3815" O_E="0.0" SE="0.2567762955065478" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.06593406593406595" WEIGHT="35.032260508358384"/>
<DICH_DATA CI_END="3.474003986473355" CI_START="1.4037796531321036" EFFECT_SIZE="2.2083333333333335" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" LOG_CI_END="0.540830312471007" LOG_CI_START="0.14729894330735907" LOG_EFFECT_SIZE="0.3440646278891831" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3816" O_E="0.0" SE="0.23116227425842129" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.053435997040325575" WEIGHT="36.854771056186536"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8033378001611244" CI_END="12.082963595577803" CI_START="1.7423311612773555" DF="1" EFFECT_SIZE="4.58830295350635" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="8" I2="44.5472722908236" ID="CMP-004.08.03" LOG_CI_END="1.0821734670129712" LOG_CI_START="0.2411307039704852" LOG_EFFECT_SIZE="0.6616520854917283" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.17930964078943956" P_Z="0.002043579148565665" STUDIES="2" TAU2="0.21969401162373045" TOTAL_1="88" TOTAL_2="85" WEIGHT="100.0" Z="3.0838247823888465">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="24.159602547849406" CI_START="2.600813573990472" EFFECT_SIZE="7.926829268292683" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="3" LOG_CI_END="1.3830897853838773" LOG_CI_START="0.4151092231344005" LOG_EFFECT_SIZE="0.8990995042591389" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3818" O_E="0.0" SE="0.5685965738464035" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="41" TOTAL_2="39" VAR="0.3233020637898686" WEIGHT="44.94844478117449"/>
<DICH_DATA CI_END="7.418725722570504" CI_START="1.16207228043295" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822404" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3817" O_E="0.0" SE="0.4729174774600778" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.2236509404872032" WEIGHT="55.05155521882551"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.002393876024238863" CI_END="6.7737671527067205" CI_START="2.383050224335979" DF="1" EFFECT_SIZE="4.017739082227395" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="13" I2="0.0" ID="CMP-004.08.04" LOG_CI_END="0.8308302637534529" LOG_CI_START="0.3771331954820493" LOG_EFFECT_SIZE="0.6039817296177511" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.9609772855184796" P_Z="1.804923519909608E-7" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="84" WEIGHT="100.00000000000001" Z="5.218382573558343">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 24 months</NAME>
<DICH_DATA CI_END="7.953361914584869" CI_START="1.9837875662028035" EFFECT_SIZE="3.9721254355400695" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="7" LOG_CI_END="0.900550745300854" LOG_CI_START="0.29749516390410646" LOG_EFFECT_SIZE="0.5990229546024802" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3819" O_E="0.0" SE="0.3542378336857216" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="41" TOTAL_2="38" VAR="0.12548444281435295" WEIGHT="56.60010844003901"/>
<DICH_DATA CI_END="9.011395404666795" CI_START="1.8454633207563016" EFFECT_SIZE="4.078014184397163" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="6" LOG_CI_END="0.9547920462092395" LOG_CI_START="0.2661054178592616" LOG_EFFECT_SIZE="0.6104487320342505" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3820" O_E="0.0" SE="0.40453793454656783" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.1636509404872032" WEIGHT="43.399891559961006"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.46592181755969964" CI_END="5.097352042738617" CI_START="2.026219138989781" DF="1" EFFECT_SIZE="3.2137753915240626" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="16" I2="0.0" ID="CMP-004.08.05" LOG_CI_END="0.7073446286719062" LOG_CI_START="0.3066864132391691" LOG_EFFECT_SIZE="0.5070155209555376" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.49486936396658077" P_Z="7.031264463339482E-7" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="79" WEIGHT="100.00000000000003" Z="4.960498112349306">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 36 months</NAME>
<DICH_DATA CI_END="5.229262894929748" CI_START="1.4461885263662189" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="8" LOG_CI_END="0.718440476013493" LOG_CI_START="0.16022491164703226" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3822" O_E="0.0" SE="0.32789858572046715" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="39" TOTAL_2="33" VAR="0.10751748251748253" WEIGHT="51.51624757660813"/>
<DICH_DATA CI_END="7.355898192541871" CI_START="1.9553641627149625" EFFECT_SIZE="3.7925531914893615" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.8666357098641299" LOG_CI_START="0.2912276513122415" LOG_EFFECT_SIZE="0.5789316805881857" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3821" O_E="0.0" SE="0.33799754190920617" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.11424233833666557" WEIGHT="48.48375242339189"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7275243923631027" CI_END="3.858884675971411" CI_START="1.4134338523490122" DF="1" EFFECT_SIZE="2.3354396231392585" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="21" I2="42.1136972409352" ID="CMP-004.08.06" LOG_CI_END="0.5864617997329316" LOG_CI_START="0.1502754886429996" LOG_EFFECT_SIZE="0.3683686441879656" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.1887274652855938" P_Z="9.314183589323164E-4" STUDIES="2" TAU2="0.05529870038450589" TOTAL_1="80" TOTAL_2="72" WEIGHT="100.0" Z="3.3104627875101027">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 48 months</NAME>
<DICH_DATA CI_END="3.096371190629844" CI_START="1.0605263662693118" EFFECT_SIZE="1.812121212121212" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.49085301802482795" LOG_CI_START="0.025521470196218803" LOG_EFFECT_SIZE="0.25818724411052335" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3824" O_E="0.0" SE="0.27333805462283595" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="33" TOTAL_2="26" VAR="0.07471369210499645" WEIGHT="50.49338866192719"/>
<DICH_DATA CI_END="5.216900819826401" CI_START="1.7542029255836291" EFFECT_SIZE="3.025145067698259" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="11" LOG_CI_END="0.7174125802892627" LOG_CI_START="0.2440798309705108" LOG_EFFECT_SIZE="0.4807462056298867" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3823" O_E="0.0" SE="0.27803799998473194" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.07730512943550981" WEIGHT="49.50661133807281"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.513398192449316" CI_END="2.8766631156020637" CI_START="0.8207203470160092" DF="2" EFFECT_SIZE="1.5365337453128323" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="31" I2="73.38088640091077" ID="CMP-004.08.07" LOG_CI_END="0.45888900488591317" LOG_CI_START="-0.08580479956415694" LOG_EFFECT_SIZE="0.1865421026608781" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.023360825462703905" P_Z="0.1794457250586159" STUDIES="3" TAU2="0.2235390452349679" TOTAL_1="91" TOTAL_2="82" WEIGHT="100.00000000000001" Z="1.3424636000213916">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="1.479112799951296" CI_START="0.3635813156342677" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.17000129538187236" LOG_CI_START="-0.43939844317678484" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2012-01-03 00:28:25 +1100" MODIFIED_BY="[Empty name]" ORDER="3825" O_E="0.0" SE="0.35796442300671183" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.12813852813852813" WEIGHT="29.109543908616256"/>
<DICH_DATA CI_END="3.075798515548664" CI_START="1.0655276599558134" EFFECT_SIZE="1.8103448275862069" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.4879578829982608" LOG_CI_START="0.027564728015740673" LOG_EFFECT_SIZE="0.25776130550700077" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3827" O_E="0.0" SE="0.2704372182196045" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="29" TOTAL_2="25" VAR="0.07313628899835797" WEIGHT="34.50631913922504"/>
<DICH_DATA CI_END="3.808001817369651" CI_START="1.4836264361287874" EFFECT_SIZE="2.3768996960486324" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="14" LOG_CI_END="0.580697146979617" LOG_CI_START="0.1713245632401304" LOG_EFFECT_SIZE="0.37601085510987375" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3826" O_E="0.0" SE="0.24046748211554578" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.05782460995499032" WEIGHT="36.384136952158705"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.484374537483129" CI_START="1.412441378493614" DF="0" EFFECT_SIZE="2.218439716312057" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" I2="0.0" ID="CMP-004.08.08" LOG_CI_END="0.5421248314159038" LOG_CI_START="0.14997043204895727" LOG_EFFECT_SIZE="0.3460476317324305" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="5.420836727619624E-4" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="3.4590502935875556">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 72 months</NAME>
<DICH_DATA CI_END="3.484374537483129" CI_START="1.412441378493614" EFFECT_SIZE="2.218439716312057" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" LOG_CI_END="0.5421248314159038" LOG_CI_START="0.14997043204895727" LOG_EFFECT_SIZE="0.3460476317324305" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3828" O_E="0.0" SE="0.23035343538372843" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.05306270519308555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.484374537483129" CI_START="1.412441378493614" DF="0" EFFECT_SIZE="2.218439716312057" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" I2="0.0" ID="CMP-004.08.09" LOG_CI_END="0.5421248314159038" LOG_CI_START="0.14997043204895727" LOG_EFFECT_SIZE="0.3460476317324305" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="5.420836727619624E-4" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="3.4590502935875556">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 84 months</NAME>
<DICH_DATA CI_END="3.484374537483129" CI_START="1.412441378493614" EFFECT_SIZE="2.218439716312057" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" LOG_CI_END="0.5421248314159038" LOG_CI_START="0.14997043204895727" LOG_EFFECT_SIZE="0.3460476317324305" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3829" O_E="0.0" SE="0.23035343538372843" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.05306270519308555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2080447094879485" CI_START="1.348333745503438" DF="0" EFFECT_SIZE="2.0797872340425534" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" I2="0.0" ID="CMP-004.08.10" LOG_CI_END="0.5062404122769012" LOG_CI_START="0.12979740398747275" LOG_EFFECT_SIZE="0.318018908132187" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="9.277945264697772E-4" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="3.3115536355644553">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 96 months</NAME>
<DICH_DATA CI_END="3.2080447094879485" CI_START="1.348333745503438" EFFECT_SIZE="2.0797872340425534" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" LOG_CI_END="0.5062404122769012" LOG_CI_START="0.12979740398747275" LOG_EFFECT_SIZE="0.318018908132187" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3830" O_E="0.0" SE="0.22112448649215422" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.0488960385264189" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2080447094879485" CI_START="1.348333745503438" DF="0" EFFECT_SIZE="2.0797872340425534" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" I2="0.0" ID="CMP-004.08.11" LOG_CI_END="0.5062404122769012" LOG_CI_START="0.12979740398747275" LOG_EFFECT_SIZE="0.318018908132187" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="9.277945264697772E-4" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="3.3115536355644553">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 108 months</NAME>
<DICH_DATA CI_END="3.2080447094879485" CI_START="1.348333745503438" EFFECT_SIZE="2.0797872340425534" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" LOG_CI_END="0.5062404122769012" LOG_CI_START="0.12979740398747275" LOG_EFFECT_SIZE="0.318018908132187" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3831" O_E="0.0" SE="0.22112448649215422" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.0488960385264189" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11164507051019078" CI_END="2.752361075867234" CI_START="1.4271019274751826" DF="1" EFFECT_SIZE="1.9818929831042333" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="29" I2="0.0" ID="CMP-004.08.12" LOG_CI_END="0.43970540738696734" LOG_CI_START="0.15445499270761862" LOG_EFFECT_SIZE="0.29708020004729296" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.7382790053746697" P_Z="4.4555044190664836E-5" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="85" WEIGHT="100.0" Z="4.082493575107873">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 120 months</NAME>
<DICH_DATA CI_END="3.071946806928875" CI_START="1.122734151534607" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.48741369128874734" LOG_CI_START="0.05027693329641265" LOG_EFFECT_SIZE="0.26884531229257996" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3832" O_E="0.0" SE="0.2567762955065478" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.06593406593406595" WEIGHT="42.5812018165018"/>
<DICH_DATA CI_END="3.2080447094879485" CI_START="1.348333745503438" EFFECT_SIZE="2.0797872340425534" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" LOG_CI_END="0.5062404122769012" LOG_CI_START="0.12979740398747275" LOG_EFFECT_SIZE="0.318018908132187" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3833" O_E="0.0" SE="0.22112448649215422" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.0488960385264189" WEIGHT="57.41879818349819"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4606855634238305" CI_START="0.6846100386287185" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-004.08.13" LOG_CI_END="0.16455673696984163" LOG_CI_START="-0.1645567369698416" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.4606855634238305" CI_START="0.6846100386287185" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.16455673696984163" LOG_CI_START="-0.1645567369698416" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3834" O_E="0.0" SE="0.19332288373014034" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.037373737373737365" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4606855634238305" CI_START="0.6846100386287185" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-004.08.14" LOG_CI_END="0.16455673696984163" LOG_CI_START="-0.1645567369698416" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB at 9 months</NAME>
<DICH_DATA CI_END="1.4606855634238305" CI_START="0.6846100386287185" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.16455673696984163" LOG_CI_START="-0.1645567369698416" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3835" O_E="0.0" SE="0.19332288373014034" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.037373737373737365" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.28012444982330326" CI_END="2.148868157653141" CI_START="1.0728035393251403" DF="1" EFFECT_SIZE="1.5183258428523776" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" I2="0.0" ID="CMP-004.08.15" LOG_CI_END="0.3322097704657517" LOG_CI_START="0.0305201976426127" LOG_EFFECT_SIZE="0.18136498405418214" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="0.5966197217735802" P_Z="0.018447047671898552" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="57" WEIGHT="100.0" Z="2.356520535174522">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (12-54 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.4135305587586395" CI_START="0.7365880540962153" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3826528019805788" LOG_CI_START="-0.132775328763979" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="780" O_E="0.0" SE="0.3027650354097491" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.09166666666666662" WEIGHT="34.25976385104451"/>
<DICH_DATA CI_END="2.4935291215380655" CI_START="1.0585888033310542" EFFECT_SIZE="1.6246913580246913" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="18" LOG_CI_END="0.3968144446415818" LOG_CI_START="0.024727296156992075" LOG_EFFECT_SIZE="0.21077087039928694" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="779" O_E="0.0" SE="0.21856583288093814" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.047771023302938184" WEIGHT="65.74023614895549"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6464405651128242" CI_END="2.95242771671513" CI_START="1.048127128512112" DF="1" EFFECT_SIZE="1.7591246643885705" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" I2="39.26291533448256" ID="CMP-004.08.16" LOG_CI_END="0.47017927373143475" LOG_CI_START="0.020413961906155055" LOG_EFFECT_SIZE="0.24529661781879492" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="0.1994441485690781" P_Z="0.03252633801894004" STUDIES="2" TAU2="0.054935398542332516" TOTAL_1="55" TOTAL_2="57" WEIGHT="100.0" Z="2.1378817966339287">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 12-15 months</NAME>
<DICH_DATA CI_END="2.4135305587586395" CI_START="0.7365880540962153" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3826528019805788" LOG_CI_START="-0.132775328763979" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="781" O_E="0.0" SE="0.3027650354097491" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.09166666666666662" WEIGHT="47.61097009494067"/>
<DICH_DATA CI_END="3.9161185218519674" CI_START="1.3076727231739516" EFFECT_SIZE="2.262962962962963" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" LOG_CI_END="0.5928558273107126" LOG_CI_START="0.11649906485642123" LOG_EFFECT_SIZE="0.35467744608356694" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="782" O_E="0.0" SE="0.27981432026965436" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.07829605382796871" WEIGHT="52.38902990505933"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8096846107218125" CI_START="1.0396155228208273" DF="0" EFFECT_SIZE="1.709090909090909" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" I2="0.0" ID="CMP-004.08.17" LOG_CI_END="0.4486575727483264" LOG_CI_START="0.01687275546258318" LOG_EFFECT_SIZE="0.23276516410545478" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="1.0" P_Z="0.034588606946475975" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="47" WEIGHT="100.0" Z="2.113142103374787">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 24 months</NAME>
<DICH_DATA CI_END="2.8096846107218125" CI_START="1.0396155228208273" EFFECT_SIZE="1.709090909090909" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" LOG_CI_END="0.4486575727483264" LOG_CI_START="0.01687275546258318" LOG_EFFECT_SIZE="0.23276516410545478" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="783" O_E="0.0" SE="0.2536325390429622" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="44" TOTAL_2="47" VAR="0.06432946486137975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5615603630707895" CI_START="1.083164178153156" DF="0" EFFECT_SIZE="1.66571018651363" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" I2="0.0" ID="CMP-004.08.18" LOG_CI_END="0.4085045944655984" LOG_CI_START="0.03469428881553047" LOG_EFFECT_SIZE="0.22159944164056444" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="18" P_CHI2="1.0" P_Z="0.020137153757241347" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="2.3237825070359346">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 36 months</NAME>
<DICH_DATA CI_END="2.5615603630707895" CI_START="1.083164178153156" EFFECT_SIZE="1.66571018651363" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" LOG_CI_END="0.4085045944655984" LOG_CI_START="0.03469428881553047" LOG_EFFECT_SIZE="0.22159944164056444" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="784" O_E="0.0" SE="0.21957802392970555" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="41" TOTAL_2="43" VAR="0.048214508592874336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4414666970514016" CI_START="0.9097999593677779" DF="0" EFFECT_SIZE="1.4903846153846154" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" ID="CMP-004.08.19" LOG_CI_END="0.3876508046449424" LOG_CI_START="-0.04105408690192011" LOG_EFFECT_SIZE="0.17329835887151113" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="19" P_CHI2="1.0" P_Z="0.11306185199636623" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.5845797361560103">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 48 months</NAME>
<DICH_DATA CI_END="2.4414666970514016" CI_START="0.9097999593677779" EFFECT_SIZE="1.4903846153846154" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.3876508046449424" LOG_CI_START="-0.04105408690192011" LOG_EFFECT_SIZE="0.17329835887151113" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="0.2518233754180654" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="32" TOTAL_2="31" VAR="0.06341501240694788" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4223101577779858" CI_START="1.213211900535419" DF="0" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="0.0" ID="CMP-004.08.20" LOG_CI_END="0.38422975036256785" LOG_CI_START="0.08393666170416797" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="20" P_CHI2="1.0" P_Z="0.002245764059225495" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="100.0" Z="3.0556457710085674">
<NAME>Alkylating agents+steroids versus steroids (low dose) at final follow-up (46 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.4223101577779858" CI_START="1.213211900535419" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="0.38422975036256785" LOG_CI_START="0.08393666170416797" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="786" O_E="0.0" SE="0.17639364675270655" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="0.03111471861471862" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9162008554072292" CI_START="1.109871183446027" DF="0" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="0.0" ID="CMP-004.08.21" LOG_CI_END="0.28244102970240703" LOG_CI_START="0.04527257557493217" LOG_EFFECT_SIZE="0.16385680263866959" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="21" P_CHI2="1.0" P_Z="0.006764300529836767" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="2.708230594791199">
<NAME>Alkylating agents+steroids versus steroids (low dose) at 46 months</NAME>
<DICH_DATA CI_END="1.9162008554072292" CI_START="1.109871183446027" EFFECT_SIZE="1.4583333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="0.28244102970240703" LOG_CI_START="0.04527257557493217" LOG_EFFECT_SIZE="0.16385680263866959" MODIFIED="2011-12-04 22:13:53 +1100" MODIFIED_BY="[Empty name]" ORDER="787" O_E="0.0" SE="0.1393139239572607" STUDY_ID="STD-Pahari-1993" TOTAL_1="36" TOTAL_2="35" VAR="0.019408369408369413" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="39.456925867611666" CI_END="2.969587346558835" CI_START="2.155031698024295" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5297341484602973" ESTIMABLE="YES" EVENTS_1="485" EVENTS_2="158" I2="6.226855776487243" I2_Q="15.989194203269856" ID="CMP-004.09" LOG_CI_END="0.47269610400961165" LOG_CI_START="0.3334536625133606" LOG_EFFECT_SIZE="0.4030748832614861" METHOD="IV" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="9" P_CHI2="0.36065716577438867" P_Q="0.25094873321131017" P_Z="7.649608192172629E-30" Q="23.806461335927857" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.016056902675366094" TOTALS="SUB" TOTAL_1="1340" TOTAL_2="1315" WEIGHT="2100.0" Z="11.347291038220838">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alkylating</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.711332200537953" CI_END="3.323464602341301" CI_START="1.6147647815649535" DF="6" EFFECT_SIZE="2.316595258701551" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="37" I2="10.598971698658211" ID="CMP-004.09.01" LOG_CI_END="0.5215910575378073" LOG_CI_START="0.20810926876726082" LOG_EFFECT_SIZE="0.36485016315253405" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.3483699315578842" P_Z="5.060520717445272E-6" STUDIES="7" TAU2="0.02715471166307285" TOTAL_1="209" TOTAL_2="213" WEIGHT="99.99999999999999" Z="4.562262977617135">
<NAME>Alkylating agents+steroids versus placebo/no treatment/ACEi/ARB/steroids at final follow-up (9-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="5.1676154704644395" CI_START="0.5375356958454429" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7132901897260784" LOG_CI_START="-0.26959269049336554" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2011-12-05 04:55:10 +1100" MODIFIED_BY="[Empty name]" ORDER="772" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.33333333333333337" WEIGHT="9.406086535314717"/>
<DICH_DATA CI_END="5.50957941564827" CI_START="0.2196174895970038" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.741118447411729" LOG_CI_START="-0.6583330770952789" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2011-12-05 04:55:11 +1100" MODIFIED_BY="[Empty name]" ORDER="775" O_E="0.0" SE="0.8220447528921864" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.6757575757575757" WEIGHT="4.8239044996996245"/>
<DICH_DATA CI_END="31.96980139235623" CI_START="1.9486262399004417" EFFECT_SIZE="7.892857142857143" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.5047399382900903" LOG_CI_START="0.28972854639569257" LOG_EFFECT_SIZE="0.8972342423428915" MODIFIED="2011-12-04 23:19:26 +1100" MODIFIED_BY="[Empty name]" ORDER="776" O_E="0.0" SE="0.7137037060021583" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.5093729799612152" WEIGHT="6.319863446222773"/>
<DICH_DATA CI_END="7.951338298608254" CI_START="1.2224009114405654" EFFECT_SIZE="3.1176470588235294" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.9004402313967758" LOG_CI_START="0.08721366504825456" LOG_EFFECT_SIZE="0.4938269482225151" MODIFIED="2011-12-04 23:19:26 +1100" MODIFIED_BY="[Empty name]" ORDER="777" O_E="0.0" SE="0.4776933106095478" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.2281908990011099" WEIGHT="13.279185560945482"/>
<DICH_DATA CI_END="98.1571794174011" CI_START="0.36675870490241486" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9919220702868148" LOG_CI_START="-0.43561956951952757" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2011-12-05 04:55:12 +1100" MODIFIED_BY="[Empty name]" ORDER="774" O_E="0.0" SE="1.4259499757471625" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="2.033333333333333" WEIGHT="1.6456206840979448"/>
<DICH_DATA CI_END="3.9366562778106533" CI_START="1.6058381039497207" EFFECT_SIZE="2.5142857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="15" LOG_CI_END="0.5951274967900099" LOG_CI_START="0.2057017588097761" LOG_EFFECT_SIZE="0.400414627799893" MODIFIED="2011-12-05 04:55:13 +1100" MODIFIED_BY="[Empty name]" ORDER="771" O_E="0.0" SE="0.2287506061780817" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="0.05232683982683983" WEIGHT="42.661242547749715"/>
<DICH_DATA CI_END="2.947575417407111" CI_START="0.7253737477025464" EFFECT_SIZE="1.4622222222222223" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4694649258772968" LOG_CI_START="-0.13943816620007324" LOG_EFFECT_SIZE="0.16501337983861183" MODIFIED="2011-12-04 23:19:12 +1100" MODIFIED_BY="[Empty name]" ORDER="773" O_E="0.0" SE="0.3576726904051641" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.12792975346166835" WEIGHT="21.86409672596974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.28974465857649" CI_END="8.206555033314977" CI_START="1.2333101363598689" DF="2" EFFECT_SIZE="3.1813876700557047" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="9" I2="39.20500806085592" ID="CMP-004.09.02" LOG_CI_END="0.9141608862300159" LOG_CI_START="0.09107230090491553" LOG_EFFECT_SIZE="0.5026165935674658" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.19303738714240637" P_Z="0.01667973329941134" STUDIES="3" TAU2="0.2804527659538316" TOTAL_1="108" TOTAL_2="103" WEIGHT="100.0" Z="2.3936923412328555">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="5.50957941564827" CI_START="0.2196174895970038" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.741118447411729" LOG_CI_START="-0.6583330770952789" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2011-12-03 07:38:48 +1100" MODIFIED_BY="[Empty name]" ORDER="3836" O_E="0.0" SE="0.8220447528921864" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.6757575757575757" WEIGHT="24.44640066681142"/>
<DICH_DATA CI_END="31.96980139235623" CI_START="1.9486262399004417" EFFECT_SIZE="7.892857142857143" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.5047399382900903" LOG_CI_START="0.28972854639569257" LOG_EFFECT_SIZE="0.8972342423428915" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3837" O_E="0.0" SE="0.7137037060021583" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.5093729799612152" WEIGHT="29.596276464935624"/>
<DICH_DATA CI_END="7.951338298608254" CI_START="1.2224009114405654" EFFECT_SIZE="3.1176470588235294" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.9004402313967758" LOG_CI_START="0.08721366504825456" LOG_EFFECT_SIZE="0.4938269482225151" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3838" O_E="0.0" SE="0.4776933106095478" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.2281908990011099" WEIGHT="45.95732286825295"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0064617670264555" CI_END="42.555681441489654" CI_START="1.3875113701597557" DF="1" EFFECT_SIZE="7.68417151454621" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" I2="0.6420280668531008" ID="CMP-004.09.03" LOG_CI_END="1.6289575492378383" LOG_CI_START="0.14223655069734997" LOG_EFFECT_SIZE="0.8855970499675941" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.315752250190405" P_Z="0.019544014085328566" STUDIES="2" TAU2="0.010462165412760991" TOTAL_1="88" TOTAL_2="85" WEIGHT="100.0" Z="2.334988642059102">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="388.9392622845821" CI_START="1.4575371504188546" EFFECT_SIZE="23.80952380952381" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.5898817861221777" LOG_CI_START="0.16361963308202165" LOG_EFFECT_SIZE="1.3767507096020994" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3840" O_E="0.0" SE="1.425198398887143" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="41" TOTAL_2="39" VAR="2.0311904761904764" WEIGHT="37.355306145550124"/>
<DICH_DATA CI_END="33.718956083332934" CI_START="0.45453340829165445" EFFECT_SIZE="3.9148936170212765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5278741206897755" LOG_CI_START="-0.3424341905421374" LOG_EFFECT_SIZE="0.592719965073819" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3839" O_E="0.0" SE="1.0986283601930802" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="1.2069842738205365" WEIGHT="62.644693854449876"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5541302340930376" CI_END="71.2077017788804" CI_START="2.6980909159018065" DF="1" EFFECT_SIZE="13.860910984197325" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="1" I2="0.0" ID="CMP-004.09.04" LOG_CI_END="1.852526969187056" LOG_CI_START="0.4310565797351537" LOG_EFFECT_SIZE="1.1417917744611048" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.45663507650726565" P_Z="0.0016401515983579563" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="84" WEIGHT="100.0" Z="3.1486702394845323">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 24 months</NAME>
<DICH_DATA CI_END="522.3683664230476" CI_START="2.0220405137331396" EFFECT_SIZE="32.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="2.7179768690635595" LOG_CI_START="0.30578985289418925" LOG_EFFECT_SIZE="1.5118833609788744" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3841" O_E="0.0" SE="1.4169305938161925" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="41" TOTAL_2="38" VAR="2.0076923076923077" WEIGHT="34.72591386892687"/>
<DICH_DATA CI_END="66.7741263933234" CI_START="1.1619749123781098" EFFECT_SIZE="8.808510638297872" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.8246082148507918" LOG_CI_START="0.06519675151957105" LOG_EFFECT_SIZE="0.9449024831851814" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3842" O_E="0.0" SE="1.0334870027879632" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="1.0680953849316477" WEIGHT="65.27408613107313"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2838724484179195" CI_END="81.68794046264738" CI_START="3.187944343999047" DF="1" EFFECT_SIZE="16.137428784376635" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="1" I2="0.0" ID="CMP-004.09.05" LOG_CI_END="1.9121579466535439" LOG_CI_START="0.5035107307588645" LOG_EFFECT_SIZE="1.2078343387062043" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.5941743041816969" P_Z="7.762883214399187E-4" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="79" WEIGHT="100.0" Z="3.3611138068396404">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 36 months</NAME>
<DICH_DATA CI_END="476.5290329261537" CI_START="1.8573107593575648" EFFECT_SIZE="29.75" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="2.6780893655315587" LOG_CI_START="0.26888457459757825" LOG_EFFECT_SIZE="1.4734869700645683" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3843" O_E="0.0" SE="1.4151788199506714" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="39" TOTAL_2="33" VAR="2.002731092436975" WEIGHT="34.18668939783141"/>
<DICH_DATA CI_END="86.70265853539442" CI_START="1.59092616793331" EFFECT_SIZE="11.74468085106383" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9380324143106993" LOG_CI_START="0.20165002527626338" LOG_EFFECT_SIZE="1.0698412197934815" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3844" O_E="0.0" SE="1.0199596105502755" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="1.0403176071538698" WEIGHT="65.81331060216858"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5560210277661388" CI_END="11.692597071831491" CI_START="1.9848762013335923" DF="1" EFFECT_SIZE="4.817505335716938" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="5" I2="0.0" ID="CMP-004.09.06" LOG_CI_END="1.0679109841042336" LOG_CI_START="0.2977334245730164" LOG_EFFECT_SIZE="0.682822204338625" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.45586799061821326" P_Z="5.10243351468935E-4" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="72" WEIGHT="100.0" Z="3.4753204940495537">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 48 months</NAME>
<DICH_DATA CI_END="11.45163568071975" CI_START="1.1804969111691055" EFFECT_SIZE="3.676767676767677" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="1.0588675230406324" LOG_CI_START="0.07206485506237983" LOG_EFFECT_SIZE="0.5654661890515061" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3846" O_E="0.0" SE="0.5796527719224123" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="33" TOTAL_2="26" VAR="0.33599733599733606" WEIGHT="60.91455712894936"/>
<DICH_DATA CI_END="30.316734664369136" CI_START="1.7772971788058254" EFFECT_SIZE="7.340425531914893" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.4816824227642988" LOG_CI_START="0.24976005151081435" LOG_EFFECT_SIZE="0.8657212371375567" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3845" O_E="0.0" SE="0.7236372989883836" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.5236509404872032" WEIGHT="39.085442871050645"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3541391014080553" CI_END="4.902361543120261" CI_START="1.4262748295502572" DF="2" EFFECT_SIZE="2.644260742496395" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="11" I2="0.0" ID="CMP-004.09.07" LOG_CI_END="0.690405336779805" LOG_CI_START="0.1542032179821361" LOG_EFFECT_SIZE="0.42230427738097054" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.508103830084024" P_Z="0.0020200195624797595" STUDIES="3" TAU2="0.0" TOTAL_1="91" TOTAL_2="82" WEIGHT="99.99999999999999" Z="3.0872730456189825">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="5.50957941564827" CI_START="0.2196174895970038" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.741118447411729" LOG_CI_START="-0.6583330770952789" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2011-12-03 07:38:46 +1100" MODIFIED_BY="[Empty name]" ORDER="3847" O_E="0.0" SE="0.8220447528921864" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.6757575757575757" WEIGHT="14.680516394768787"/>
<DICH_DATA CI_END="8.481411806217757" CI_START="1.2321920617015447" EFFECT_SIZE="3.2327586206896552" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.9284681504425382" LOG_CI_START="0.09067840655906251" LOG_EFFECT_SIZE="0.5095732785008004" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3849" O_E="0.0" SE="0.4921218426832698" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="29" TOTAL_2="25" VAR="0.24218390804597698" WEIGHT="40.96254887387054"/>
<DICH_DATA CI_END="7.418725722570504" CI_START="1.16207228043295" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822404" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3848" O_E="0.0" SE="0.4729174774600778" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.2236509404872032" WEIGHT="44.35693473136066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.418725722570504" CI_START="1.1620722804329497" DF="0" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-004.09.08" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822396" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.02275177777211773" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="2.277577240815914">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 72 months</NAME>
<DICH_DATA CI_END="7.418725722570504" CI_START="1.16207228043295" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822404" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3850" O_E="0.0" SE="0.4729174774600778" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.2236509404872032" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.418725722570504" CI_START="1.1620722804329497" DF="0" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-004.09.09" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822396" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.02275177777211773" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="2.277577240815914">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 84 months</NAME>
<DICH_DATA CI_END="7.418725722570504" CI_START="1.16207228043295" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822404" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3851" O_E="0.0" SE="0.4729174774600778" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.2236509404872032" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.418725722570504" CI_START="1.1620722804329497" DF="0" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-004.09.10" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822396" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.02275177777211773" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="2.277577240815914">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 96 months</NAME>
<DICH_DATA CI_END="7.418725722570504" CI_START="1.16207228043295" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822404" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3852" O_E="0.0" SE="0.4729174774600778" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.2236509404872032" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.418725722570504" CI_START="1.1620722804329497" DF="0" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-004.09.11" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822396" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.02275177777211773" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="2.277577240815914">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 108 months</NAME>
<DICH_DATA CI_END="7.418725722570504" CI_START="1.16207228043295" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822404" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3853" O_E="0.0" SE="0.4729174774600778" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.2236509404872032" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3339653236568418" CI_END="10.525757162051171" CI_START="1.6492090542571458" DF="1" EFFECT_SIZE="4.166434208596938" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="7" I2="25.035532613496425" ID="CMP-004.09.12" LOG_CI_END="1.0222533462628922" LOG_CI_START="0.217275710438757" LOG_EFFECT_SIZE="0.6197645283508246" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.24810115382242137" P_Z="0.0025443867869498135" STUDIES="2" TAU2="0.12240228542038159" TOTAL_1="89" TOTAL_2="85" WEIGHT="100.0" Z="3.0180121792314005">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 120 months</NAME>
<DICH_DATA CI_END="31.96980139235623" CI_START="1.9486262399004417" EFFECT_SIZE="7.892857142857143" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.5047399382900903" LOG_CI_START="0.28972854639569257" LOG_EFFECT_SIZE="0.8972342423428915" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3855" O_E="0.0" SE="0.7137037060021583" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.5093729799612152" WEIGHT="35.38997165559615"/>
<DICH_DATA CI_END="7.418725722570504" CI_START="1.16207228043295" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8703293150928142" LOG_CI_START="0.06523314183822404" LOG_EFFECT_SIZE="0.46778122846551906" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3854" O_E="0.0" SE="0.4729174774600778" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.2236509404872032" WEIGHT="64.61002834440386"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="98.1571794174011" CI_START="0.36675870490241486" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.09.13" LOG_CI_END="1.9919220702868148" LOG_CI_START="-0.43561956951952757" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="1.0" P_Z="0.2089212210158906" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="1.2565373959133574">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="98.1571794174011" CI_START="0.36675870490241486" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9919220702868148" LOG_CI_START="-0.43561956951952757" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3856" O_E="0.0" SE="1.4259499757471625" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="2.033333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="98.1571794174011" CI_START="0.36675870490241486" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.09.14" LOG_CI_END="1.9919220702868148" LOG_CI_START="-0.43561956951952757" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="1.0" P_Z="0.2089212210158906" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="1.2565373959133574">
<NAME>Alkylating agents+steroids versus ACEi/ARB at 9 months</NAME>
<DICH_DATA CI_END="98.1571794174011" CI_START="0.36675870490241486" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9919220702868148" LOG_CI_START="-0.43561956951952757" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3857" O_E="0.0" SE="1.4259499757471625" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="2.033333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03712958167570279" CI_END="2.7516155819793484" CI_START="0.8355360521989084" DF="1" EFFECT_SIZE="1.5162697716884113" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" I2="0.0" ID="CMP-004.09.15" LOG_CI_END="0.43958776012793704" LOG_CI_START="-0.07803480617364554" LOG_EFFECT_SIZE="0.1807764769771458" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="0.8472015335551433" P_Z="0.1709959686486906" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="57" WEIGHT="100.0" Z="1.3690105771810772">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (12-54 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="5.1676154704644395" CI_START="0.5375356958454429" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7132901897260784" LOG_CI_START="-0.26959269049336554" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="789" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.33333333333333337" WEIGHT="27.734661004539458"/>
<DICH_DATA CI_END="2.947575417407111" CI_START="0.7253737477025464" EFFECT_SIZE="1.4622222222222223" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4694649258772968" LOG_CI_START="-0.13943816620007324" LOG_EFFECT_SIZE="0.16501337983861183" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="788" O_E="0.0" SE="0.3576726904051641" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.12792975346166835" WEIGHT="72.26533899546054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0241407461034536" CI_END="3.7915196810824847" CI_START="0.8373633505739448" DF="1" EFFECT_SIZE="1.781819189457304" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" ID="CMP-004.09.16" LOG_CI_END="0.5788133146713449" LOG_CI_START="-0.07708605107771481" LOG_EFFECT_SIZE="0.25086363179681503" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="0.8765273434031501" P_Z="0.13380473860018324" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="57" WEIGHT="100.0" Z="1.499265616124373">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 12-15 months</NAME>
<DICH_DATA CI_END="5.1676154704644395" CI_START="0.5375356958454429" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7132901897260784" LOG_CI_START="-0.26959269049336554" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="790" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.33333333333333337" WEIGHT="44.531864673485444"/>
<DICH_DATA CI_END="5.181972519847465" CI_START="0.682056878237563" EFFECT_SIZE="1.88" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7144951055795141" LOG_CI_START="-0.16617940705215448" LOG_EFFECT_SIZE="0.2741578492636798" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="791" O_E="0.0" SE="0.5173125681289873" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.2676122931442081" WEIGHT="55.468135326514556"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.546517187309997" CI_START="1.0096400745337921" DF="0" EFFECT_SIZE="2.9375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-004.09.17" LOG_CI_END="0.9317891703438722" LOG_CI_START="0.004166580215713132" LOG_EFFECT_SIZE="0.4679778752797927" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="1.0" P_Z="0.047977119973963415" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="47" WEIGHT="100.0" Z="1.977571031303257">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 24 months</NAME>
<DICH_DATA CI_END="8.546517187309997" CI_START="1.0096400745337921" EFFECT_SIZE="2.9375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9317891703438722" LOG_CI_START="0.004166580215713132" LOG_EFFECT_SIZE="0.4679778752797927" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="792" O_E="0.0" SE="0.5448901012471574" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="44" TOTAL_2="47" VAR="0.2969052224371374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8008384075716811E-31" CI_END="10.236165613163937" CI_START="1.316339709253503" DF="0" EFFECT_SIZE="3.670731707317074" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="100.0" ID="CMP-004.09.18" LOG_CI_END="1.0101373038174712" LOG_CI_START="0.11936798260278242" LOG_EFFECT_SIZE="0.5647526432101267" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="18" P_CHI2="0.0" P_Z="0.012945834886682163" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="2.48525586704365">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 36 months</NAME>
<DICH_DATA CI_END="10.236165613163937" CI_START="1.3163397092535025" EFFECT_SIZE="3.6707317073170733" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="1.0101373038174712" LOG_CI_START="0.11936798260278228" LOG_EFFECT_SIZE="0.5647526432101266" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="793" O_E="0.0" SE="0.5232423086607618" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="41" TOTAL_2="43" VAR="0.273782513572644" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.685277687394787" CI_START="0.4564761819146037" DF="0" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-004.09.19" LOG_CI_END="0.4289892032078078" LOG_CI_START="-0.34058187822370084" LOG_EFFECT_SIZE="0.044203662492053486" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="19" P_CHI2="1.0" P_Z="0.8218562735159002" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="99.99999999999999" Z="0.22515811355081328">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 48 months</NAME>
<DICH_DATA CI_END="2.685277687394787" CI_START="0.4564761819146037" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4289892032078078" LOG_CI_START="-0.34058187822370084" LOG_EFFECT_SIZE="0.044203662492053486" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="794" O_E="0.0" SE="0.4520498626711591" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="32" TOTAL_2="31" VAR="0.20434907834101382" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.355569662694593E-31" CI_END="3.936656277810654" CI_START="1.6058381039497207" DF="0" EFFECT_SIZE="2.5142857142857147" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="15" I2="100.0" ID="CMP-004.09.20" LOG_CI_END="0.59512749679001" LOG_CI_START="0.2057017588097761" LOG_EFFECT_SIZE="0.40041462779989306" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="20" P_CHI2="0.0" P_Z="5.564856263360874E-5" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="100.0" Z="4.030541244865717">
<NAME>Alkylating agents+steroids versus steroids (low dose) at final follow-up (46 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="3.9366562778106533" CI_START="1.6058381039497207" EFFECT_SIZE="2.5142857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="15" LOG_CI_END="0.5951274967900099" LOG_CI_START="0.2057017588097761" LOG_EFFECT_SIZE="0.400414627799893" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="795" O_E="0.0" SE="0.2287506061780817" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="0.05232683982683983" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.175000939908352" CI_START="1.4408958502999374" DF="0" EFFECT_SIZE="2.138888888888889" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="15" I2="0.0" ID="CMP-004.09.21" LOG_CI_END="0.501743858193963" LOG_CI_START="0.1586325906164261" LOG_EFFECT_SIZE="0.3301882244051946" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="21" P_CHI2="1.0" P_Z="1.6175826274331112E-4" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="3.7722866551280774">
<NAME>Alkylating agents+steroids versus steroids (low dose) at 46 months</NAME>
<DICH_DATA CI_END="3.175000939908352" CI_START="1.4408958502999374" EFFECT_SIZE="2.138888888888889" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="15" LOG_CI_END="0.501743858193963" LOG_CI_START="0.1586325906164261" LOG_EFFECT_SIZE="0.3301882244051946" MODIFIED="2011-12-04 22:14:09 +1100" MODIFIED_BY="[Empty name]" ORDER="796" O_E="0.0" SE="0.20154525700321163" STUDY_ID="STD-Pahari-1993" TOTAL_1="36" TOTAL_2="35" VAR="0.040620490620490626" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="64.47998591179876" CI_END="1.625569060497212" CI_START="1.1786002040500585" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3841589599462467" ESTIMABLE="YES" EVENTS_1="404" EVENTS_2="286" I2="42.617853467567805" I2_Q="36.608640111304425" ID="CMP-004.10" LOG_CI_END="0.21100542474309386" LOG_CI_START="0.07136651194817396" LOG_EFFECT_SIZE="0.14118596834563388" METHOD="IV" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="10" P_CHI2="0.0034057507061241443" P_Q="0.048335255984909065" P_Z="7.39032194239877E-5" Q="31.55004094424949" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13174922251368487" TOTALS="SUB" TOTAL_1="1340" TOTAL_2="1315" WEIGHT="2100.0" Z="3.9633567397686256">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alkylating</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.888675415199407" CI_END="1.5735717785494439" CI_START="0.5642464199284337" DF="6" EFFECT_SIZE="0.9422750355108331" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="50" I2="49.531804087029464" ID="CMP-004.10.01" LOG_CI_END="0.19688655806395286" LOG_CI_START="-0.24853118778455316" LOG_EFFECT_SIZE="-0.025822314860300132" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.06449898552913902" P_Z="0.820228597099029" STUDIES="7" TAU2="0.21922735053394526" TOTAL_1="209" TOTAL_2="213" WEIGHT="100.00000000000001" Z="0.22725096876070713">
<NAME>Alkylating agents+steroids versus placebo/no treatment/ACEi/ARB/steroids at final follow-up (9-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:56:01 +1100" MODIFIED_BY="[Empty name]" ORDER="786" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="9.98052118439405"/>
<DICH_DATA CI_END="1.6931265280713392" CI_START="0.2032794195067245" EFFECT_SIZE="0.5866666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.22868941433451248" LOG_CI_START="-0.6919065881455377" LOG_EFFECT_SIZE="-0.23160858690551261" MODIFIED="2011-12-05 04:56:02 +1100" MODIFIED_BY="[Empty name]" ORDER="789" O_E="0.0" SE="0.5407626488804885" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.2924242424242425" WEIGHT="13.379377418413053"/>
<DICH_DATA CI_END="1.6336005542104033" CI_START="0.35333316996160546" EFFECT_SIZE="0.7597402597402597" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.21314587208029778" LOG_CI_START="-0.4518155902609006" LOG_EFFECT_SIZE="-0.11933485909030143" MODIFIED="2011-12-04 23:25:34 +1100" MODIFIED_BY="[Empty name]" ORDER="790" O_E="0.0" SE="0.39060165459154494" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.15256965256965258" WEIGHT="18.4121434863002"/>
<DICH_DATA CI_END="3.3882282953244376" CI_START="0.9509562861984915" EFFECT_SIZE="1.7950089126559714" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5299726649583587" LOG_CI_START="-0.021839446363445574" LOG_EFFECT_SIZE="0.25406660929745656" MODIFIED="2011-12-04 23:25:34 +1100" MODIFIED_BY="[Empty name]" ORDER="791" O_E="0.0" SE="0.3241371657044322" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.10506490219090255" WEIGHT="21.109291731147557"/>
<DICH_DATA CI_END="1.3538904701556491" CI_START="0.2197523859687265" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.13158353131287054" LOG_CI_START="-0.6580664008620333" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2011-12-05 04:56:03 +1100" MODIFIED_BY="[Empty name]" ORDER="788" O_E="0.0" SE="0.4638442789897436" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.21515151515151512" WEIGHT="15.759467850990756"/>
<DICH_DATA CI_END="1.2915368972796055" CI_START="0.0044685427070200665" EFFECT_SIZE="0.07596899224806201" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.11110681783108033" LOG_CI_START="-2.3498340870445884" LOG_EFFECT_SIZE="-1.1193636346067541" MODIFIED="2011-12-05 04:56:04 +1100" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="1.4455688693779134" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="2.089669356114539" WEIGHT="2.9648705155184936"/>
<DICH_DATA CI_END="3.9336549295916545" CI_START="0.8492792745511795" EFFECT_SIZE="1.8277777777777777" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.5947962598163709" LOG_CI_START="-0.0709494741230345" LOG_EFFECT_SIZE="0.2619233928466682" MODIFIED="2011-12-04 23:25:21 +1100" MODIFIED_BY="[Empty name]" ORDER="787" O_E="0.0" SE="0.39106233961053877" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.15292975346166834" WEIGHT="18.394327813235908"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.531091480952724" CI_END="2.016231034290524" CI_START="0.5006464165612899" DF="2" EFFECT_SIZE="1.0046983837337522" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" I2="55.86052481157426" ID="CMP-004.10.02" LOG_CI_END="0.3045402952182405" LOG_CI_START="-0.3004688880040038" LOG_EFFECT_SIZE="0.0020357036071183138" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.10377351708422744" P_Z="0.9894765501478041" STUDIES="3" TAU2="0.2102152896278855" TOTAL_1="108" TOTAL_2="103" WEIGHT="100.0" Z="0.01318957088188378">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.6931265280713392" CI_START="0.2032794195067245" EFFECT_SIZE="0.5866666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.22868941433451248" LOG_CI_START="-0.6919065881455377" LOG_EFFECT_SIZE="-0.23160858690551261" MODIFIED="2011-12-03 07:35:38 +1100" MODIFIED_BY="[Empty name]" ORDER="3858" O_E="0.0" SE="0.5407626488804885" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.2924242424242425" WEIGHT="25.127107342260015"/>
<DICH_DATA CI_END="1.6336005542104033" CI_START="0.35333316996160546" EFFECT_SIZE="0.7597402597402597" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.21314587208029778" LOG_CI_START="-0.4518155902609006" LOG_EFFECT_SIZE="-0.11933485909030143" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3859" O_E="0.0" SE="0.39060165459154494" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.15256965256965258" WEIGHT="34.81367611299627"/>
<DICH_DATA CI_END="3.3882282953244376" CI_START="0.9509562861984915" EFFECT_SIZE="1.7950089126559714" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5299726649583587" LOG_CI_START="-0.021839446363445574" LOG_EFFECT_SIZE="0.25406660929745656" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3860" O_E="0.0" SE="0.3241371657044322" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="0.10506490219090255" WEIGHT="40.05921654474371"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2760500831919212" CI_END="7.202713003285992" CI_START="1.4793373893379005" DF="1" EFFECT_SIZE="3.264236917019236" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="7" I2="0.0" ID="CMP-004.10.03" LOG_CI_END="0.8574961103795793" LOG_CI_START="0.17006723391403816" LOG_EFFECT_SIZE="0.5137816721468087" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.59930195477825" P_Z="0.0033924688393248176" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="85" WEIGHT="100.0" Z="2.9297389382361474">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="13.365445796358117" CI_START="1.2712244780243491" EFFECT_SIZE="4.121951219512195" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.1259834489638263" LOG_CI_START="0.10422224682405" LOG_EFFECT_SIZE="0.6151028478939381" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3861" O_E="0.0" SE="0.6001875879364263" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="41" TOTAL_2="39" VAR="0.36022514071294554" WEIGHT="45.264395738165646"/>
<DICH_DATA CI_END="7.844678257839369" CI_START="0.9234432243179016" EFFECT_SIZE="2.6914893617021276" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8945751361051882" LOG_CI_START="-0.034589800952949806" LOG_EFFECT_SIZE="0.42999266757611926" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3862" O_E="0.0" SE="0.5457960834685676" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.2978933647296275" WEIGHT="54.73560426183435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9221560843311696" CI_END="4.092775033337115" CI_START="1.2187377953609617" DF="1" EFFECT_SIZE="2.2333874766904334" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" I2="0.0" ID="CMP-004.10.04" LOG_CI_END="0.6120178735322889" LOG_CI_START="0.08591027963260149" LOG_EFFECT_SIZE="0.3489640765824451" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.33690963392537276" P_Z="0.009320605099550825" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="84" WEIGHT="100.0" Z="2.600065195524547">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 24 months</NAME>
<DICH_DATA CI_END="3.853430041658089" CI_START="0.768851782426818" EFFECT_SIZE="1.721254355400697" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5858474788539729" LOG_CI_START="-0.11415737447466362" LOG_EFFECT_SIZE="0.23584505218965462" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3864" O_E="0.0" SE="0.41118631592514915" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="41" TOTAL_2="38" VAR="0.16907418640409655" WEIGHT="56.48680862427972"/>
<DICH_DATA CI_END="7.844958114722064" CI_START="1.2503433106229698" EFFECT_SIZE="3.1319148936170214" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.8945906291729693" LOG_CI_START="0.09702927495855582" LOG_EFFECT_SIZE="0.4958099520657626" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3863" O_E="0.0" SE="0.46849148745792224" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.21948427382053654" WEIGHT="43.513191375720275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1664217900783735" CI_END="4.405129521174377" CI_START="0.5897635710890918" DF="1" EFFECT_SIZE="1.6118265779908776" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" I2="68.41861046012923" ID="CMP-004.10.05" LOG_CI_END="0.6439586822155735" LOG_CI_START="-0.229322056747931" LOG_EFFECT_SIZE="0.20731831273382134" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.07516700189419045" P_Z="0.35206183098022725" STUDIES="2" TAU2="0.36031932714439435" TOTAL_1="86" TOTAL_2="79" WEIGHT="100.0" Z="0.930597477224063">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 36 months</NAME>
<DICH_DATA CI_END="2.1872762029052817" CI_START="0.41428583330037655" EFFECT_SIZE="0.9519230769230769" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.33990362795014134" LOG_CI_START="-0.3826999173526022" LOG_EFFECT_SIZE="-0.021398144701230463" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3865" O_E="0.0" SE="0.4244608994560691" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="39" TOTAL_2="33" VAR="0.18016705516705517" WEIGHT="48.68534038481864"/>
<DICH_DATA CI_END="5.710720848052183" CI_START="1.2357770851984187" EFFECT_SIZE="2.6565349544072947" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.7566909314633901" LOG_CI_START="0.09194013790546746" LOG_EFFECT_SIZE="0.42431553468442873" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3866" O_E="0.0" SE="0.39047790670542143" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.1524729956250478" WEIGHT="51.314659615181355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6608034294651466" CI_END="3.026545379750275" CI_START="0.757027817196078" DF="1" EFFECT_SIZE="1.5136641115112777" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" I2="39.78817828416666" ID="CMP-004.10.06" LOG_CI_END="0.48094719006994285" LOG_CI_START="-0.12088816193612431" LOG_EFFECT_SIZE="0.18002951406690929" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.19749495275326" P_Z="0.24096254057850253" STUDIES="2" TAU2="0.10108001104617366" TOTAL_1="80" TOTAL_2="72" WEIGHT="100.0" Z="1.1725843706231207">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 48 months</NAME>
<DICH_DATA CI_END="2.3546209080548754" CI_START="0.4357995314532542" EFFECT_SIZE="1.0129870129870129" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.3719209960541117" LOG_CI_START="-0.36071324101811475" LOG_EFFECT_SIZE="0.0056038775179984845" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3868" O_E="0.0" SE="0.4303529774541884" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="33" TOTAL_2="26" VAR="0.1852036852036852" WEIGHT="43.6549985088729"/>
<DICH_DATA CI_END="4.082514455378345" CI_START="1.0457175563258543" EFFECT_SIZE="2.066193853427896" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6109277311625171" LOG_CI_START="0.019414399356204426" LOG_EFFECT_SIZE="0.3151710652593607" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3867" O_E="0.0" SE="0.3474578591412433" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.12072696387901606" WEIGHT="56.34500149112711"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.580934072732006" CI_END="2.430997487786885" CI_START="0.50273306607929" DF="2" EFFECT_SIZE="1.105505685496982" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="20" I2="56.34078185265767" ID="CMP-004.10.07" LOG_CI_END="0.3857845100400215" LOG_CI_START="-0.29866254913933615" LOG_EFFECT_SIZE="0.043560980450342665" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.10121932736860817" P_Z="0.8029894495973466" STUDIES="3" TAU2="0.2731633375782121" TOTAL_1="91" TOTAL_2="82" WEIGHT="100.0" Z="0.2494800778786074">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="1.6931265280713392" CI_START="0.2032794195067245" EFFECT_SIZE="0.5866666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.22868941433451248" LOG_CI_START="-0.6919065881455377" LOG_EFFECT_SIZE="-0.23160858690551261" MODIFIED="2011-12-03 07:36:28 +1100" MODIFIED_BY="[Empty name]" ORDER="3869" O_E="0.0" SE="0.5407626488804885" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.2924242424242425" WEIGHT="28.57952876728948"/>
<DICH_DATA CI_END="2.336742638072738" CI_START="0.31803369750675703" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.3686108831155079" LOG_CI_START="-0.49752686156934495" LOG_EFFECT_SIZE="-0.0644579892269185" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3871" O_E="0.0" SE="0.5087735986788658" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="29" TOTAL_2="25" VAR="0.25885057471264367" WEIGHT="30.383089877290075"/>
<DICH_DATA CI_END="4.082514455378345" CI_START="1.0457175563258543" EFFECT_SIZE="2.066193853427896" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6109277311625171" LOG_CI_START="0.019414399356204426" LOG_EFFECT_SIZE="0.3151710652593607" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3870" O_E="0.0" SE="0.3474578591412433" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.12072696387901606" WEIGHT="41.03738135542044"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.558211889656288" CI_START="0.9718412814049809" DF="0" EFFECT_SIZE="1.8595744680851063" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" I2="0.0" ID="CMP-004.10.08" LOG_CI_END="0.5512318065271355" LOG_CI_START="-0.012404657129764464" LOG_EFFECT_SIZE="0.26941357469868554" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.060972724339728" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.00000000000001" Z="1.8736931955383471">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 72 months</NAME>
<DICH_DATA CI_END="3.558211889656288" CI_START="0.9718412814049809" EFFECT_SIZE="1.8595744680851063" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.5512318065271355" LOG_CI_START="-0.012404657129764464" LOG_EFFECT_SIZE="0.26941357469868554" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3872" O_E="0.0" SE="0.33108284879755545" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.10961585276790496" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.558211889656288" CI_START="0.9718412814049809" DF="0" EFFECT_SIZE="1.8595744680851063" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" I2="0.0" ID="CMP-004.10.09" LOG_CI_END="0.5512318065271355" LOG_CI_START="-0.012404657129764464" LOG_EFFECT_SIZE="0.26941357469868554" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.060972724339728" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.00000000000001" Z="1.8736931955383471">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 84 months</NAME>
<DICH_DATA CI_END="3.558211889656288" CI_START="0.9718412814049809" EFFECT_SIZE="1.8595744680851063" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.5512318065271355" LOG_CI_START="-0.012404657129764464" LOG_EFFECT_SIZE="0.26941357469868554" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3873" O_E="0.0" SE="0.33108284879755545" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.10961585276790496" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.14702383371052" CI_START="0.9081168772469477" DF="0" EFFECT_SIZE="1.690522243713733" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" ID="CMP-004.10.10" LOG_CI_END="0.4979000320170546" LOG_CI_START="-0.04185825293613339" LOG_EFFECT_SIZE="0.22802088954046051" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.09772716816894425" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="1.655973585512813">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 96 months</NAME>
<DICH_DATA CI_END="3.14702383371052" CI_START="0.9081168772469477" EFFECT_SIZE="1.690522243713733" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.4979000320170546" LOG_CI_START="-0.04185825293613339" LOG_EFFECT_SIZE="0.22802088954046051" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3874" O_E="0.0" SE="0.3170566884281041" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.10052494367699587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.14702383371052" CI_START="0.9081168772469477" DF="0" EFFECT_SIZE="1.690522243713733" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" ID="CMP-004.10.11" LOG_CI_END="0.4979000320170546" LOG_CI_START="-0.04185825293613339" LOG_EFFECT_SIZE="0.22802088954046051" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.09772716816894425" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="1.655973585512813">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 108 months</NAME>
<DICH_DATA CI_END="3.14702383371052" CI_START="0.9081168772469477" EFFECT_SIZE="1.690522243713733" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.4979000320170546" LOG_CI_START="-0.04185825293613339" LOG_EFFECT_SIZE="0.22802088954046051" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3875" O_E="0.0" SE="0.3170566884281041" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.10052494367699587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5275367917823015" CI_END="2.557095303965911" CI_START="0.5360422506432219" DF="1" EFFECT_SIZE="1.1707737278599568" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" I2="60.435788580753105" ID="CMP-004.10.12" LOG_CI_END="0.40774691465722257" LOG_CI_START="-0.2708009780347489" LOG_EFFECT_SIZE="0.0684729683112368" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.11187504615927935" P_Z="0.6924267164588422" STUDIES="2" TAU2="0.19330565378402112" TOTAL_1="89" TOTAL_2="85" WEIGHT="100.0" Z="0.3955639778709006">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 120 months</NAME>
<DICH_DATA CI_END="1.6336005542104033" CI_START="0.35333316996160546" EFFECT_SIZE="0.7597402597402597" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.21314587208029778" LOG_CI_START="-0.4518155902609006" LOG_EFFECT_SIZE="-0.11933485909030143" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3877" O_E="0.0" SE="0.39060165459154494" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="0.15256965256965258" WEIGHT="45.93213783222072"/>
<DICH_DATA CI_END="3.14702383371052" CI_START="0.9081168772469477" EFFECT_SIZE="1.690522243713733" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.4979000320170546" LOG_CI_START="-0.04185825293613339" LOG_EFFECT_SIZE="0.22802088954046051" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3876" O_E="0.0" SE="0.3170566884281041" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" VAR="0.10052494367699587" WEIGHT="54.06786216777929"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3538904701556491" CI_START="0.2197523859687265" DF="0" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-004.10.13" LOG_CI_END="0.13158353131287054" LOG_CI_START="-0.6580664008620333" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="1.0" P_Z="0.19129229053446825" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="1.3067657207942374">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.3538904701556491" CI_START="0.2197523859687265" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.13158353131287054" LOG_CI_START="-0.6580664008620333" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3878" O_E="0.0" SE="0.4638442789897436" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.21515151515151512" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3538904701556491" CI_START="0.2197523859687265" DF="0" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-004.10.14" LOG_CI_END="0.13158353131287054" LOG_CI_START="-0.6580664008620333" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="1.0" P_Z="0.19129229053446825" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="1.3067657207942374">
<NAME>Alkylating agents+steroids versus ACEi/ARB at 9 months</NAME>
<DICH_DATA CI_END="1.3538904701556491" CI_START="0.2197523859687265" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.13158353131287054" LOG_CI_START="-0.6580664008620333" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3879" O_E="0.0" SE="0.4638442789897436" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.21515151515151512" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5870445399844163" CI_END="3.0631030858819646" CI_START="0.8098199907492216" DF="1" EFFECT_SIZE="1.5749800356426251" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-004.10.15" LOG_CI_END="0.48616161282888765" LOG_CI_START="-0.09161150669218267" LOG_EFFECT_SIZE="0.1972750530683525" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="0.4435644014402166" P_Z="0.1807590556423371" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="57" WEIGHT="100.00000000000001" Z="1.3384215568308324">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (12-54 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-04 22:14:25 +1100" MODIFIED_BY="[Empty name]" ORDER="797" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="24.682155753900663"/>
<DICH_DATA CI_END="3.9336549295916545" CI_START="0.8492792745511795" EFFECT_SIZE="1.8277777777777777" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.5947962598163709" LOG_CI_START="-0.0709494741230345" LOG_EFFECT_SIZE="0.2619233928466682" MODIFIED="2011-12-04 22:14:25 +1100" MODIFIED_BY="[Empty name]" ORDER="798" O_E="0.0" SE="0.39106233961053877" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.15292975346166834" WEIGHT="75.31784424609936"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3865230424076878" CI_END="4.408256038897103" CI_START="0.8015021078034257" DF="1" EFFECT_SIZE="1.8796878748646564" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" I2="27.877145246464362" ID="CMP-004.10.16" LOG_CI_END="0.6442668111275011" LOG_CI_START="-0.09609533119356309" LOG_EFFECT_SIZE="0.274085739966969" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="0.23899335389902054" P_Z="0.14673063778507464" STUDIES="2" TAU2="0.12075917568437734" TOTAL_1="55" TOTAL_2="57" WEIGHT="100.0" Z="1.451176791204187">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 12-15 months</NAME>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-03 00:33:32 +1100" MODIFIED_BY="[Empty name]" ORDER="799" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="32.1966408103543"/>
<DICH_DATA CI_END="5.530658017781328" CI_START="1.1633104942092862" EFFECT_SIZE="2.5365079365079364" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.7427768051727995" LOG_CI_START="0.06569564587598209" LOG_EFFECT_SIZE="0.40423622552439087" MODIFIED="2011-12-04 22:14:25 +1100" MODIFIED_BY="[Empty name]" ORDER="800" O_E="0.0" SE="0.3977208245767431" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.1581818543020045" WEIGHT="67.80335918964569"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.516096239806986" CI_START="0.6333801499130649" DF="0" EFFECT_SIZE="1.262396694214876" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="0.0" ID="CMP-004.10.17" LOG_CI_END="0.40072724870397614" LOG_CI_START="-0.19833555150769253" LOG_EFFECT_SIZE="0.10119584859814179" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="1.0" P_Z="0.5078633276922224" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="47" WEIGHT="100.0" Z="0.662168368883015">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 24 months</NAME>
<DICH_DATA CI_END="2.516096239806986" CI_START="0.6333801499130649" EFFECT_SIZE="1.262396694214876" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.40072724870397614" LOG_CI_START="-0.19833555150769253" LOG_EFFECT_SIZE="0.10119584859814179" MODIFIED="2011-12-04 22:14:25 +1100" MODIFIED_BY="[Empty name]" ORDER="801" O_E="0.0" SE="0.3518924542530207" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="44" TOTAL_2="47" VAR="0.12382829936021425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9864479492481835" CI_START="0.5537222921026124" DF="0" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" ID="CMP-004.10.18" LOG_CI_END="0.29807718975359987" LOG_CI_START="-0.2567079920338978" LOG_EFFECT_SIZE="0.02068459885985105" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="18" P_CHI2="1.0" P_Z="0.8838025728010732" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="0.14615051061509782">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 36 months</NAME>
<DICH_DATA CI_END="1.9864479492481835" CI_START="0.5537222921026124" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.29807718975359987" LOG_CI_START="-0.2567079920338978" LOG_EFFECT_SIZE="0.02068459885985105" MODIFIED="2011-12-04 22:14:25 +1100" MODIFIED_BY="[Empty name]" ORDER="802" O_E="0.0" SE="0.3258835620129166" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="41" TOTAL_2="43" VAR="0.10620009599022646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.516797772021163" CI_START="0.8310990306568926" DF="0" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" ID="CMP-004.10.19" LOG_CI_END="0.6548306465805732" LOG_CI_START="-0.0803472242238773" LOG_EFFECT_SIZE="0.2872417111783479" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="19" P_CHI2="1.0" P_Z="0.1256317893420693" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.5315570044326479">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 48 months</NAME>
<DICH_DATA CI_END="4.516797772021163" CI_START="0.8310990306568926" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.6548306465805732" LOG_CI_START="-0.0803472242238773" LOG_EFFECT_SIZE="0.2872417111783479" MODIFIED="2011-12-04 22:14:25 +1100" MODIFIED_BY="[Empty name]" ORDER="803" O_E="0.0" SE="0.43184712049968677" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="32" TOTAL_2="31" VAR="0.18649193548387097" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2915368972796055" CI_START="0.0044685427070200665" DF="0" EFFECT_SIZE="0.075968992248062" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-004.10.20" LOG_CI_END="0.11110681783108033" LOG_CI_START="-2.3498340870445884" LOG_EFFECT_SIZE="-1.1193636346067541" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="20" P_CHI2="1.0" P_Z="0.07458847392607314" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="100.0" Z="1.7829866658613907">
<NAME>Alkylating agents+steroids versus steroids (low dose) at final follow-up (46 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.2915368972796055" CI_START="0.0044685427070200665" EFFECT_SIZE="0.07596899224806201" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.11110681783108033" LOG_CI_START="-2.3498340870445884" LOG_EFFECT_SIZE="-1.1193636346067541" MODIFIED="2011-12-04 22:14:25 +1100" MODIFIED_BY="[Empty name]" ORDER="804" O_E="0.0" SE="1.4455688693779134" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="2.089669356114539" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0944490080815443" CI_START="0.003844355162158176" DF="0" EFFECT_SIZE="0.06486486486486487" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-004.10.21" LOG_CI_END="0.03919553198463195" LOG_CI_START="-2.41517649669541" LOG_EFFECT_SIZE="-1.1879904823553888" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="21" P_CHI2="1.0" P_Z="0.05777991411790613" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.8973639955024666">
<NAME>Alkylating agents+steroids versus steroids (low dose) at 46 months</NAME>
<DICH_DATA CI_END="1.0944490080815443" CI_START="0.003844355162158176" EFFECT_SIZE="0.06486486486486487" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.03919553198463195" LOG_CI_START="-2.41517649669541" LOG_EFFECT_SIZE="-1.1879904823553888" MODIFIED="2011-12-04 22:14:25 +1100" MODIFIED_BY="[Empty name]" ORDER="805" O_E="0.0" SE="1.4417102789841405" STUDY_ID="STD-Pahari-1993" TOTAL_1="36" TOTAL_2="35" VAR="2.0785285285285284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="54.1989956127973" CI_END="-1.3811982021577454" CI_START="-1.6647227190700382" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5229604606138918" ESTIMABLE="YES" I2="48.33852604938545" I2_Q="49.693210572584164" ID="CMP-004.11" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="11" P_CHI2="0.0021197786919574524" P_Q="0.010600948556954481" P_Z="0.0" Q="31.8048521523825" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.09151129457111018" TOTALS="SUB" TOTAL_1="865" TOTAL_2="830" UNITS="g/24 h" WEIGHT="1700.0" Z="21.056010853587967">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylating</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="10.004564804302724" CI_END="-0.5661985685623735" CI_START="-1.926134434422285" DF="5" EFFECT_SIZE="-1.2461665014923293" ESTIMABLE="YES" I2="50.02281360754824" ID="CMP-004.11.01" MODIFIED="2014-04-08 11:30:12 +1000" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.07510604665577336" P_Z="3.281560616086194E-4" STUDIES="6" TAU2="0.29842615408743417" TOTAL_1="142" TOTAL_2="137" WEIGHT="100.0" Z="3.591995068268673">
<NAME>Alkylating agents+steroids versus placebo/no treatment/ACEi/ARB/steroids at final follow-up (9-120 months)</NAME>
<CONT_DATA CI_END="1.5762977103190454" CI_START="-3.1762977103190453" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.6" MODIFIED="2013-01-27 18:15:00 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="807" SD_1="3.14" SD_2="2.2" SE="1.21241906946402" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.806182281818863"/>
<CONT_DATA CI_END="6.4735008813001444" CI_START="-2.2735008813001434" EFFECT_SIZE="2.1000000000000005" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="6.8" MODIFIED="2013-01-27 18:15:00 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="809" SD_1="6.8" SD_2="4.3" SE="2.2314190035111667" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" WEIGHT="2.2805496234863956"/>
<CONT_DATA CI_END="-1.5120981589833844" CI_START="-4.687901841016616" EFFECT_SIZE="-3.1" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="5.2" MODIFIED="2013-01-27 18:14:36 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3885" SD_1="2.4" SD_2="4.5" SE="0.8101688875621097" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" WEIGHT="12.605740759127201"/>
<CONT_DATA CI_END="-1.161849395868547" CI_START="-1.6381506041314529" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.5" MODIFIED="2013-01-27 18:14:36 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3889" SD_1="0.2" SD_2="0.8" SE="0.12150764300260336" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="38.43018124425408"/>
<CONT_DATA CI_END="0.19942750024749323" CI_START="-2.1994275002474932" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" MODIFIED="2013-01-27 18:14:43 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3890" SD_1="1.1" SD_2="0.6" SE="0.6119640512317697" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" WEIGHT="17.886001957652915"/>
<CONT_DATA CI_END="0.3777808427087668" CI_START="-1.5777808427087665" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.9" MODIFIED="2013-01-27 18:14:02 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="811" SD_1="1.6" SD_2="1.9" SE="0.4988769438731411" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="26" TOTAL_2="24" WEIGHT="21.991344133660554"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.306120569538336" CI_END="-0.4368972968049707" CI_START="-3.6856853390388062" DF="1" EFFECT_SIZE="-2.0612913179218886" ESTIMABLE="YES" I2="76.777241049077" ID="CMP-004.11.02" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.03797565396215563" P_Z="0.012878331392857418" STUDIES="2" TAU2="1.1094311331591609" TOTAL_1="89" TOTAL_2="85" WEIGHT="100.00000000000001" Z="2.487116236733068">
<NAME>Alkylating agents+steroids versus placebo/no treatment at final follow-up (60-120 months)</NAME>
<CONT_DATA CI_END="-1.5120981589833844" CI_START="-4.687901841016616" EFFECT_SIZE="-3.1" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="5.2" MODIFIED="2013-02-14 01:48:46 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3885" SD_1="2.4" SD_2="4.5" SE="0.8101688875621097" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" WEIGHT="38.899489289522855"/>
<CONT_DATA CI_END="-1.161849395868547" CI_START="-1.6381506041314529" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.5" MODIFIED="2013-02-14 01:48:46 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3889" SD_1="0.2" SD_2="0.8" SE="0.12150764300260336" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="61.10051071047716"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9267950157403024" CI_START="-3.673204984259698" DF="0" EFFECT_SIZE="-2.3000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.03" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.0010279222002210723" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="39" WEIGHT="100.0" Z="3.282770756088078">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 6 months</NAME>
<CONT_DATA CI_END="-0.9267950157403024" CI_START="-3.673204984259698" EFFECT_SIZE="-2.3000000000000003" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="5.2" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3880" SD_1="3.4" SD_2="2.9" SE="0.7006276620853054" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4689960382119363" CI_END="-1.2421144355983094" CI_START="-3.098571089176022" DF="1" EFFECT_SIZE="-2.1703427623871656" ESTIMABLE="YES" I2="31.926297009132767" ID="CMP-004.11.04" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.22550447928471873" P_Z="4.5900632925290065E-6" STUDIES="2" TAU2="0.19315409690525323" TOTAL_1="89" TOTAL_2="85" WEIGHT="99.99999999999999" Z="4.582701826286353">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="-1.3375289429199964" CI_START="-4.662471057080005" EFFECT_SIZE="-3.0000000000000004" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="5.4" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3882" SD_1="2.9" SD_2="4.5" SE="0.8482151050699726" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" WEIGHT="24.576614762469607"/>
<CONT_DATA CI_END="-1.2672534956308334" CI_START="-2.5327465043691673" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="5.2" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3881" SD_1="1.1" SD_2="1.9" SE="0.32283578135118335" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="75.42338523753038"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.5109022995135073" CI_START="-4.689097700486492" DF="0" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.05" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="1.3157956396176056E-4" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="39" WEIGHT="100.0" Z="3.823483194402756">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 18 months</NAME>
<CONT_DATA CI_END="-1.5109022995135073" CI_START="-4.689097700486492" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="5.1" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3883" SD_1="2.6" SD_2="4.4" SE="0.8107790311562315" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9433836460765347" CI_END="-1.7711307834580123" CI_START="-2.9718994639847427" DF="1" EFFECT_SIZE="-2.3715151237213776" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.06" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.3314093388908973" P_Z="9.798217988338601E-15" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="85" WEIGHT="100.0" Z="7.741847879055301">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 24 months</NAME>
<CONT_DATA CI_END="-1.5120981589833844" CI_START="-4.687901841016616" EFFECT_SIZE="-3.1" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="5.2" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3885" SD_1="2.4" SD_2="4.5" SE="0.8101688875621097" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" WEIGHT="14.29589690839742"/>
<CONT_DATA CI_END="-1.6014722724239023" CI_START="-2.8985277275760977" EFFECT_SIZE="-2.25" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="4.75" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3884" SD_1="0.8" SD_2="2.1" SE="0.3308875737980909" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="85.70410309160258"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0885404492216129" CI_START="-2.211459550778387" DF="0" EFFECT_SIZE="-1.65" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.07" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="8.417292383451846E-9" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="5.759881669138358">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 48 months</NAME>
<CONT_DATA CI_END="-1.0885404492216129" CI_START="-2.211459550778387" EFFECT_SIZE="-1.65" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.65" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3886" SD_1="0.6" SD_2="1.85" SE="0.28646421832600416" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.4435673829402664" CI_START="-2.3564326170597334" DF="0" EFFECT_SIZE="-1.9" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.08" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="3.384360746679916E-16" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="99.99999999999999" Z="8.158776194863284">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 72 months</NAME>
<CONT_DATA CI_END="-1.4435673829402664" CI_START="-2.3564326170597334" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="3.5" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3887" SD_1="0.5" SD_2="1.5" SE="0.2328780634032134" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.2078013265836827" CI_START="-1.792198673416317" DF="0" EFFECT_SIZE="-1.4999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.09" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="8.177445335666216E-24" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="10.06146243730998">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 96 months</NAME>
<CONT_DATA CI_END="-1.2078013265836827" CI_START="-1.792198673416317" EFFECT_SIZE="-1.4999999999999998" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="2.8" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3888" SD_1="0.35" SD_2="0.95" SE="0.14908369527253712" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.161849395868547" CI_START="-1.6381506041314529" DF="0" EFFECT_SIZE="-1.4" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.10" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="1.0231869796022699E-30" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="11.521908954895983">
<NAME>Alkylating agents+steroids versus placebo/no treatment at 120 months</NAME>
<CONT_DATA CI_END="-1.161849395868547" CI_START="-1.6381506041314529" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.5" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3889" SD_1="0.2" SD_2="0.8" SE="0.12150764300260336" STUDY_ID="STD-Jha-2007" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19942750024749323" CI_START="-2.1994275002474932" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.11" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.1022414419840063" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="99.99999999999999" Z="1.6340829138365012">
<NAME>Alkylating agents+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<CONT_DATA CI_END="0.19942750024749323" CI_START="-2.1994275002474932" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" MODIFIED="2013-02-14 01:53:54 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="3890" SD_1="1.1" SD_2="0.6" SE="0.6119640512317697" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19942750024749323" CI_START="-2.1994275002474932" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.12" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="1.0" P_Z="0.1022414419840063" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="99.99999999999999" Z="1.6340829138365012">
<NAME>Alkylating agents+steroids versus ACEi/ARB at 9 months</NAME>
<CONT_DATA CI_END="0.19942750024749323" CI_START="-2.1994275002474932" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3890" SD_1="1.1" SD_2="0.6" SE="0.6119640512317697" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4576151755449982" CI_END="0.36840898168826275" CI_START="-1.4025867724697352" DF="2" EFFECT_SIZE="-0.5170888953907362" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.13" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="0.48248405014923157" P_Z="0.2524054551684557" STUDIES="3" TAU2="0.0" TOTAL_1="49" TOTAL_2="47" WEIGHT="99.99999999999999" Z="1.1445263032302293">
<NAME>Alkylating agents+steroids versus steroids (same dose) at final follow-up (9-120 months)</NAME>
<CONT_DATA CI_END="1.5762977103190454" CI_START="-3.1762977103190453" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.6" MODIFIED="2013-02-14 01:48:47 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="807" SD_1="3.14" SD_2="2.2" SE="1.21241906946402" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.88587813791801"/>
<CONT_DATA CI_END="6.4735008813001444" CI_START="-2.2735008813001434" EFFECT_SIZE="2.1000000000000005" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="6.8" MODIFIED="2013-02-14 01:48:47 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="809" SD_1="6.8" SD_2="4.3" SE="2.2314190035111667" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" WEIGHT="4.099365217966653"/>
<CONT_DATA CI_END="0.3777808427087668" CI_START="-1.5777808427087665" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.9" MODIFIED="2013-02-14 01:48:47 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="811" SD_1="1.6" SD_2="1.9" SE="0.4988769438731411" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="26" TOTAL_2="24" WEIGHT="82.01475664411532"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.016007438944190436" CI_END="0.8424545692994102" CI_START="-2.207151619795389" DF="1" EFFECT_SIZE="-0.6823485252479894" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.14" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="0.899319920371444" P_Z="0.38044168743275464" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="34" WEIGHT="100.0" Z="0.8770827782108136">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 12-15 months</NAME>
<CONT_DATA CI_END="1.5762977103190454" CI_START="-3.1762977103190453" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.6" MODIFIED="2011-12-04 22:14:45 +1100" MODIFIED_BY="[Empty name]" ORDER="807" SD_1="3.14" SD_2="2.2" SE="1.21241906946402" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="41.1742626239948"/>
<CONT_DATA CI_END="1.3880626892806187" CI_START="-2.5880626892806182" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="3.3" MODIFIED="2011-12-04 22:14:45 +1100" MODIFIED_BY="[Empty name]" ORDER="806" SD_1="4.2" SD_2="2.9" SE="1.0143363372807883" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="26" TOTAL_2="24" WEIGHT="58.8257373760052"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5403925067951936" CI_END="2.275482491940679" CI_START="-2.5267976997214032" DF="1" EFFECT_SIZE="-0.1256576038903619" ESTIMABLE="YES" I2="35.081481142717784" ID="CMP-004.11.15" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="0.21455984934858674" P_Z="0.9183044394119539" STUDIES="2" TAU2="1.4751762820512846" TOTAL_1="39" TOTAL_2="37" WEIGHT="99.99999999999999" Z="0.10256976610249385">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 24-29 months</NAME>
<CONT_DATA CI_END="6.4735008813001444" CI_START="-2.2735008813001434" EFFECT_SIZE="2.1000000000000005" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="6.8" MODIFIED="2011-12-04 22:14:45 +1100" MODIFIED_BY="[Empty name]" ORDER="809" SD_1="6.8" SD_2="4.3" SE="2.2314190035111667" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" WEIGHT="23.25318607274613"/>
<CONT_DATA CI_END="0.5584921206157718" CI_START="-2.1584921206157714" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.9" MODIFIED="2011-12-04 22:14:45 +1100" MODIFIED_BY="[Empty name]" ORDER="808" SD_1="2.6" SD_2="2.3" SE="0.6931209610642767" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="26" TOTAL_2="24" WEIGHT="76.74681392725385"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.37383117369025E-31" CI_END="-0.4258552701457028" CI_START="-2.7741447298542967" DF="0" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-004.11.16" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="0.0" P_Z="0.007566368634725194" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0" Z="2.6708311978313226">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 36 months</NAME>
<CONT_DATA CI_END="-0.425855270145703" CI_START="-2.7741447298542967" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.8" MODIFIED="2011-12-04 22:14:45 +1100" MODIFIED_BY="[Empty name]" ORDER="810" SD_1="1.6" SD_2="2.5" SE="0.5990644415488247" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.37778084270876666" CI_START="-1.5777808427087665" DF="0" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.17" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="1.0" P_Z="0.22909191300576148" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0" Z="1.2027014023573985">
<NAME>Alkylating agents+steroids versus steroids (same dose) at 48 months</NAME>
<CONT_DATA CI_END="0.3777808427087668" CI_START="-1.5777808427087665" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.9" MODIFIED="2011-12-04 22:14:45 +1100" MODIFIED_BY="[Empty name]" ORDER="811" SD_1="1.6" SD_2="1.9" SE="0.4988769438731411" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.570008080072985" CI_END="5.78756425568206" CI_START="0.7714355608145392" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.112991452261999" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" I2="12.472802456486725" I2_Q="48.42673313451993" ID="CMP-004.12" LOG_CI_END="0.7624958257509752" LOG_CI_START="-0.11270034536424257" LOG_EFFECT_SIZE="0.3248977401933663" METHOD="IV" MODIFIED="2014-04-02 17:17:58 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.33432699990032677" P_Q="0.14384944657731502" P_Z="0.14561697762970174" Q="3.877978110668563" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17865934007046522" TOTALS="YES" TOTAL_1="222" TOTAL_2="226" WEIGHT="100.0" Z="1.4551888832557924">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>Alkylating agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylating</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.02236067408387591" CI_END="75.01497612803543" CI_START="1.2776254104869469" DF="1" EFFECT_SIZE="9.789843699888667" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-004.12.01" LOG_CI_END="1.8751479753981348" LOG_CI_START="0.10640354082964365" LOG_EFFECT_SIZE="0.9907757581138894" MODIFIED="2014-04-01 15:48:22 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8811316175907982" P_Z="0.028107857786927003" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="103" WEIGHT="22.612536196980848" Z="2.195777710681351">
<NAME>Alkylating agents+steroids versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:56:58 +1100" MODIFIED_BY="[Empty name]" ORDER="3893" O_E="0.0" SE="0.0" STUDY_ID="STD-Braun-1995" TOTAL_1="15" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="150.61827011481574" CI_START="0.46536148328232585" EFFECT_SIZE="8.372093023255815" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.177877655322793" LOG_CI_START="-0.33220956494739146" LOG_EFFECT_SIZE="0.9228340451877007" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3891" O_E="0.0" SE="1.4744376583188366" STUDY_ID="STD-Imbasciati-1980" TOTAL_1="42" TOTAL_2="39" VAR="2.173966408268734" WEIGHT="11.233967837956436"/>
<DICH_DATA CI_END="201.44979468534842" CI_START="0.6477379964290575" EFFECT_SIZE="11.423076923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3041668290981088" LOG_CI_START="-0.1886006264053199" LOG_EFFECT_SIZE="1.0577831013463943" MODIFIED="2011-12-03 07:04:27 +1100" MODIFIED_BY="[Empty name]" ORDER="3892" O_E="0.0" SE="1.464263942760626" STUDY_ID="STD-Jha-2007" TOTAL_1="51" TOTAL_2="53" VAR="2.144068894068894" WEIGHT="11.378568359024412"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:04 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Alkylating agents+steroids versus ACEi/ARB</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-05 04:56:59 +1100" MODIFIED_BY="[Empty name]" ORDER="3894" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="4" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6696692953205461" CI_END="12.665559452623235" CI_START="0.44507551891153563" DF="1" EFFECT_SIZE="2.374264190371659" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-004.12.03" LOG_CI_END="1.1026243778471356" LOG_CI_START="-0.3515662931450867" LOG_EFFECT_SIZE="0.3755290423510244" MODIFIED="2014-04-01 16:24:45 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.41316725575172253" P_Z="0.31140464779094756" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="70" WEIGHT="32.13305273040082" Z="1.01227908119452">
<NAME>Alkylating agents+steroids versus steroids (same dose)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-20 03:37:02 +1100" MODIFIED_BY="[Empty name]" ORDER="814" O_E="0.0" SE="0.0" STUDY_ID="STD-Ahmed-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.340198090726881" CI_START="0.0697340436773082" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.156555150572744" LOG_CI_START="-1.156555150572744" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-04 22:14:57 +1100" MODIFIED_BY="[Empty name]" ORDER="812" O_E="0.0" SE="1.3587324409735149" STUDY_ID="STD-Falk-1992" TOTAL_1="13" TOTAL_2="13" VAR="1.8461538461538463" WEIGHT="13.052721194923551"/>
<DICH_DATA CI_END="35.96767174829369" CI_START="0.4852643029729008" EFFECT_SIZE="4.177777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5559123260699845" LOG_CI_START="-0.3140216550933121" LOG_EFFECT_SIZE="0.6209453354883362" MODIFIED="2011-12-04 22:14:57 +1100" MODIFIED_BY="[Empty name]" ORDER="813" O_E="0.0" SE="1.0984084768578113" STUDY_ID="STD-Ponticelli-1992" TOTAL_1="45" TOTAL_2="47" VAR="1.206501182033097" WEIGHT="19.080331535477267"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.184359353423261" CI_START="0.26250754848013835" DF="0" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-004.12.04" LOG_CI_END="0.5030220717548595" LOG_CI_START="-0.5808582038155988" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2014-04-01 16:25:02 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.8880675411014689" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="48" WEIGHT="45.254411072618325" Z="0.1407498770606012">
<NAME>Alkylating agents+steroids versus steroids (low dose)</NAME>
<DICH_DATA CI_END="3.184359353423261" CI_START="0.26250754848013835" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5030220717548595" LOG_CI_START="-0.5808582038155988" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2012-03-20 03:37:06 +1100" MODIFIED_BY="[Empty name]" ORDER="815" O_E="0.0" SE="0.6366766391639817" STUDY_ID="STD-Pahari-1993" TOTAL_1="42" TOTAL_2="48" VAR="0.4053571428571429" WEIGHT="45.254411072618325"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-04-02 18:24:05 +1100" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Cyclophosphamide (CPA)+steroids versus chlorambucil+steroids</NAME>
<DICH_OUTCOME CHI2="5.228015340778827" CI_END="9.356220658441238" CI_START="0.14738813114810975" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1743065517389362" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="61.74456520049047" I2_Q="77.16848748182865" ID="CMP-005.01" LOG_CI_END="0.9711004557208439" LOG_CI_START="-0.8315374878773774" LOG_EFFECT_SIZE="0.06978148392173324" METHOD="IV" MODIFIED="2014-04-02 18:22:41 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.07324055274481978" P_Q="0.03636492304650585" P_Z="0.8793893340482524" Q="4.379911314259671" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.065301400125442" TOTALS="YES" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="0.1517433889151972">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlormbucil</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="41.21410435165619" CI_START="0.8734873792921172" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="1.615045866369217" LOG_CI_START="-0.05874336560192981" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2014-04-01 16:28:28 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.06839582248770927" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="36.980058822091905" Z="1.8223900550258079">
<NAME>At final follow-up (15 months)</NAME>
<DICH_DATA CI_END="41.21410435165619" CI_START="0.8734873792921172" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.615045866369217" LOG_CI_START="-0.05874336560192981" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2012-05-15 18:56:43 +1000" MODIFIED_BY="[Empty name]" ORDER="307" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.9666666666666667" WEIGHT="36.980058822091905"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.848104026519157" CI_END="2.0851530459886685" CI_START="0.07592334546725299" DF="1" EFFECT_SIZE="0.39788414779014825" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.31913793681050734" LOG_CI_START="-1.1196246635160063" LOG_EFFECT_SIZE="-0.4002433633527495" MODIFIED="2014-04-01 16:28:36 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.357089332109924" P_Z="0.27550688162073333" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="65" WEIGHT="63.019941177908095" Z="1.0904684025627873">
<NAME>At final follow-up (32-39 months)</NAME>
<DICH_DATA CI_END="1.7628737207288077" CI_START="0.027602186689842042" EFFECT_SIZE="0.22058823529411764" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24622120375997836" LOG_CI_START="-1.5590565110610886" LOG_EFFECT_SIZE="-0.656417653650555" MODIFIED="2012-05-15 18:57:05 +1000" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="1.0604290659547053" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="1.1245098039215686" WEIGHT="35.15015475349244"/>
<DICH_DATA CI_END="17.2489992255272" CI_START="0.07157330608534679" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2367639026881678" LOG_CI_START="-1.1452489215668176" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2012-05-15 18:57:10 +1000" MODIFIED_BY="[Empty name]" ORDER="795" O_E="0.0" SE="1.3992061241210239" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="1.9577777777777778" WEIGHT="27.869786424415654"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="65.90289327402995" CI_START="0.13656456572516806" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="IV" MODIFIED="2014-04-02 18:22:48 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.48584124712227683" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="0.6969385642065118">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorambucil</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="65.90289327402995" CI_START="0.13656456572516806" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 16:28:48 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.48584124712227683" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6969385642065118">
<NAME>At final follow-up (15 months)</NAME>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-05-15 18:57:30 +1000" MODIFIED_BY="[Empty name]" ORDER="308" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:28:53 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (32-39 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-15 18:57:35 +1000" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.0" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-15 18:57:38 +1000" MODIFIED_BY="[Empty name]" ORDER="796" O_E="0.0" SE="0.0" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.585076284771123" CI_END="7.716378798327804" CI_START="0.15521804197573802" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0944044993600583" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="56.38022410569695" I2_Q="73.2403686489295" ID="CMP-005.03" LOG_CI_END="0.8874135390840218" LOG_CI_START="-0.8090577993465072" LOG_EFFECT_SIZE="0.039177869868757244" METHOD="IV" MODIFIED="2014-04-02 18:22:58 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.1010099102747326" P_Q="0.0532210600822709" P_Z="0.9278693913874307" Q="3.7369722582519667" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.672971084151431" TOTALS="YES" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="0.09052580163812253">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloambucil</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="35.49535692115668" CI_START="0.7043174704660874" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-04-01 16:29:05 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.10752062089937621" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="37.15129842688955" Z="1.6094379124341005">
<NAME>At final follow-up (15 months)</NAME>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2012-05-15 18:57:47 +1000" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="37.15129842688955"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.848104026519157" CI_END="2.0851530459886685" CI_START="0.07592334546725299" DF="1" EFFECT_SIZE="0.39788414779014825" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.31913793681050734" LOG_CI_START="-1.1196246635160063" LOG_EFFECT_SIZE="-0.4002433633527495" MODIFIED="2014-04-01 16:29:12 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.357089332109924" P_Z="0.27550688162073333" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="65" WEIGHT="62.84870157311046" Z="1.0904684025627873">
<NAME>At final follow-up (32-39 months)</NAME>
<DICH_DATA CI_END="1.7628737207288077" CI_START="0.027602186689842042" EFFECT_SIZE="0.22058823529411764" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24622120375997836" LOG_CI_START="-1.5590565110610886" LOG_EFFECT_SIZE="-0.656417653650555" MODIFIED="2012-05-15 18:58:03 +1000" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="1.0604290659547053" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="1.1245098039215686" WEIGHT="35.49777475054013"/>
<DICH_DATA CI_END="17.2489992255272" CI_START="0.07157330608534679" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2367639026881678" LOG_CI_START="-1.1452489215668176" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2012-05-15 18:58:08 +1000" MODIFIED_BY="[Empty name]" ORDER="797" O_E="0.0" SE="1.3992061241210239" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="1.9577777777777778" WEIGHT="27.350926822570333"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.326215040828195" CI_END="3.328457782018171" CI_START="0.23869298975873438" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8913358173413896" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="76.91359601289584" I2_Q="67.39397907016676" ID="CMP-005.04" LOG_CI_END="0.5222430527544688" LOG_CI_START="-0.6221603357222172" LOG_EFFECT_SIZE="-0.049958641483874196" METHOD="IV" MODIFIED="2014-04-02 18:23:06 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0016702362011380423" P_Q="0.026737502638247035" P_Z="0.8641266837099191" Q="9.200754690233044" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="4.2810728725466864" TOTALS="SUB" TOTAL_1="61" TOTAL_2="58" WEIGHT="400.0" Z="0.17112346749563456">
<NAME>100% increase in serum creatinine</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorambucil</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.122834694229748" CI_END="41.01931871221747" CI_START="0.01626613231452096" DF="1" EFFECT_SIZE="0.8168388247533505" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="87.68902682815428" ID="CMP-005.04.01" LOG_CI_END="1.6129884429172414" LOG_CI_START="-1.7887156993153117" LOG_EFFECT_SIZE="-0.0878636281990352" MODIFIED="2014-04-01 16:29:21 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.00437114519266768" P_Z="0.9193528116183851" STUDIES="2" TAU2="7.002374989842043" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="0.10124898557938965">
<NAME>At final follow-up (15-32 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.7826097253504534" CI_START="0.015543880932601301" EFFECT_SIZE="0.11029411764705882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.10645475950230393" LOG_CI_START="-1.8084405391267686" LOG_EFFECT_SIZE="-0.9574476493145363" MODIFIED="2012-05-15 18:58:53 +1000" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.9997548719168957" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.9995098039215686" WEIGHT="49.897178359198"/>
<DICH_DATA CI_END="41.21410435165619" CI_START="0.8734873792921172" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.615045866369217" LOG_CI_START="-0.05874336560192981" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2012-05-15 18:58:57 +1000" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.9666666666666667" WEIGHT="50.102821640802006"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="91.51787421498676" CI_START="0.2731706807488985" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="1.9615059237367205" LOG_CI_START="-0.5635659150646829" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-04-01 16:29:28 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.2778849927268555" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="1.085082819206198">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="91.51787421498676" CI_START="0.2731706807488985" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9615059237367205" LOG_CI_START="-0.5635659150646829" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2012-05-15 18:59:04 +1000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="1.4832396974191324" STUDY_ID="STD-Reichert-1994" TOTAL_1="9" TOTAL_2="9" VAR="2.1999999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="191.46211780479598" CI_START="0.7802207442502274" DF="0" EFFECT_SIZE="12.222222222222218" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-005.04.03" LOG_CI_END="2.282082858430961" LOG_CI_START="-0.10778250699316073" LOG_EFFECT_SIZE="1.0871501757189" MODIFIED="2014-04-01 16:29:33 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.07455767039746222" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="9" WEIGHT="100.0" Z="1.783175923650656">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="191.4621178047958" CI_START="0.7802207442502276" EFFECT_SIZE="12.222222222222221" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2820828584309605" LOG_CI_START="-0.10778250699316061" LOG_EFFECT_SIZE="1.0871501757189002" MODIFIED="2012-05-15 18:59:13 +1000" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="1.40381874567448" STUDY_ID="STD-Reichert-1994" TOTAL_1="8" TOTAL_2="9" VAR="1.9707070707070704" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7826097253504534" CI_START="0.015543880932601301" DF="0" EFFECT_SIZE="0.11029411764705883" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-005.04.04" LOG_CI_END="-0.10645475950230393" LOG_CI_START="-1.8084405391267686" LOG_EFFECT_SIZE="-0.9574476493145362" MODIFIED="2014-04-01 16:29:39 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.02744390522837314" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="2.205145227656464">
<NAME>At 32 months</NAME>
<DICH_DATA CI_END="0.7826097253504534" CI_START="0.015543880932601301" EFFECT_SIZE="0.11029411764705882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.10645475950230393" LOG_CI_START="-1.8084405391267686" LOG_EFFECT_SIZE="-0.9574476493145363" MODIFIED="2012-05-15 18:59:22 +1000" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.9997548719168957" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.9995098039215686" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.734273274436703" CI_END="7.1906876227393415" CI_START="0.7882627851468974" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="2.380787989851645" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" I2="67.97313719029005" I2_Q="36.918779455700516" ID="CMP-005.05" LOG_CI_END="0.8567704225779194" LOG_CI_START="-0.10332897652840106" LOG_EFFECT_SIZE="0.3767207230247591" METHOD="IV" MODIFIED="2014-04-02 18:23:14 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.004636759066179774" P_Q="0.19057945173597146" P_Z="0.12402691272413939" Q="4.755773547363778" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.7693660628749563" TOTALS="SUB" TOTAL_1="151" TOTAL_2="158" WEIGHT="400.0" Z="1.5380887646543604">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorambucil</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.32889596073154" CI_END="5.38628148185545" CI_START="0.13267911595843535" DF="2" EFFECT_SIZE="0.8453680058506309" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="72.71076011017124" ID="CMP-005.05.01" LOG_CI_END="0.7312890454776998" LOG_CI_START="-0.877197430849061" LOG_EFFECT_SIZE="-0.07295419268568061" MODIFIED="2014-04-01 16:29:57 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.02561837937474787" P_Z="0.8588867440835749" STUDIES="3" TAU2="1.9101443162481575" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="0.17779147327575265">
<NAME>At final follow-up (15-39 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.7826097253504534" CI_START="0.015543880932601301" EFFECT_SIZE="0.11029411764705882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.10645475950230393" LOG_CI_START="-1.8084405391267686" LOG_EFFECT_SIZE="-0.9574476493145363" MODIFIED="2012-05-15 19:00:28 +1000" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.9997548719168957" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.9995098039215686" WEIGHT="30.680940300541256"/>
<DICH_DATA CI_END="23.687279982684956" CI_START="0.20847778252919183" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.374515193422982" LOG_CI_START="-0.6809402209736692" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2012-05-15 19:00:35 +1000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="1.207384685084989" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="1.4577777777777778" WEIGHT="26.506231992272387"/>
<DICH_DATA CI_END="4.540598993367774" CI_START="0.8809410401232524" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.6571131485299748" LOG_CI_START="-0.055053157202012544" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-05-15 19:00:41 +1000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.17500000000000002" WEIGHT="42.81282770718636"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="173.65577419373983" CI_START="0.6967807466338887" DF="0" EFFECT_SIZE="11.000000000000002" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="2.239689228526635" LOG_CI_START="-0.15690385821018507" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2014-04-01 16:30:04 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.08850668754652732" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="1.703328085163355">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="173.65577419373983" CI_START="0.6967807466338887" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.239689228526635" LOG_CI_START="-0.15690385821018507" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2012-05-15 19:00:47 +1000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="1.4077706424763168" STUDY_ID="STD-Reichert-1994" TOTAL_1="9" TOTAL_2="9" VAR="1.9818181818181815" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="44.711368132181974" CI_START="1.019036140099802" DF="0" EFFECT_SIZE="6.750000000000001" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-005.05.03" LOG_CI_END="1.6504179591359014" LOG_CI_START="0.008189586526148478" LOG_EFFECT_SIZE="0.829303772831025" MODIFIED="2014-04-01 16:30:11 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.047758370501636574" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="9" WEIGHT="100.0" Z="1.979512172730248">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="44.711368132181974" CI_START="1.019036140099802" EFFECT_SIZE="6.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6504179591359014" LOG_CI_START="0.008189586526148478" LOG_EFFECT_SIZE="0.829303772831025" MODIFIED="2012-05-15 19:00:52 +1000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.9646530752325188" STUDY_ID="STD-Reichert-1994" TOTAL_1="8" TOTAL_2="9" VAR="0.9305555555555556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6701784679949188" CI_END="8.669810111428987" CI_START="0.0242693375549028" DF="1" EFFECT_SIZE="0.4587052955124669" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="72.75336856993994" ID="CMP-005.05.04" LOG_CI_END="0.9380095855429145" LOG_CI_START="-1.6149420778162589" LOG_EFFECT_SIZE="-0.3384662461366721" MODIFIED="2014-04-01 16:30:17 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.05539446542531079" P_Z="0.6032742384757961" STUDIES="2" TAU2="3.2806981951624494" TOTAL_1="62" TOTAL_2="65" WEIGHT="100.0" Z="0.5196977772289422">
<NAME>At 32-39 months</NAME>
<DICH_DATA CI_END="0.7826097253504534" CI_START="0.015543880932601301" EFFECT_SIZE="0.11029411764705882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.10645475950230393" LOG_CI_START="-1.8084405391267686" LOG_EFFECT_SIZE="-0.9574476493145363" MODIFIED="2012-05-15 19:01:00 +1000" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="0.9997548719168957" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.9995098039215686" WEIGHT="52.540658788342874"/>
<DICH_DATA CI_END="23.687279982684956" CI_START="0.20847778252919183" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.374515193422982" LOG_CI_START="-0.6809402209736692" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2012-05-15 19:01:06 +1000" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="1.207384685084989" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="1.4577777777777778" WEIGHT="47.45934121165712"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="19.233297893900918" CI_END="61.14843354983141" CI_START="-68.75316483922153" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.8023656446950547" ESTIMABLE="YES" I2="58.40546928492755" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2014-04-02 18:23:22 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.013660558576504389" P_Q="0.7074303441193195" P_Z="0.9086506584689968" Q="1.391918633787915" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2297.674697471661" TOTALS="SUB" TOTAL_1="166" TOTAL_2="165" UNITS="&#956;mol/L" WEIGHT="400.0" Z="0.114740693141198">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorambucil</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.7033010638017805" CI_END="97.59713272151714" CI_START="-134.94193931180368" DF="2" EFFECT_SIZE="-18.67240329514327" ESTIMABLE="YES" I2="70.16395383462459" ID="CMP-005.06.01" MODIFIED="2014-04-01 16:30:32 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.03502659660033225" P_Z="0.7529423253537084" STUDIES="3" TAU2="6778.170880309176" TOTAL_1="64" TOTAL_2="64" WEIGHT="100.0" Z="0.314762053905881">
<NAME>At final follow-up (12-39 months)</NAME>
<CONT_DATA CI_END="-22.138201446765137" CI_START="-218.70179855323488" EFFECT_SIZE="-120.42000000000002" ESTIMABLE="YES" MEAN_1="159.94" MEAN_2="280.36" MODIFIED="2013-01-27 18:06:31 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="353" SD_1="69.95" SD_2="155.87" SE="50.14469619261842" STUDY_ID="STD-Branten-1998" TOTAL_1="16" TOTAL_2="11" WEIGHT="37.870024153684895"/>
<CONT_DATA CI_END="64.03064806813333" CI_START="-51.63064806813333" EFFECT_SIZE="6.200000000000003" ESTIMABLE="YES" MEAN_1="116.7" MEAN_2="110.5" MODIFIED="2013-01-27 18:06:31 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="348" SD_1="152.0" SD_2="121.1" SE="29.505974867035366" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="43" TOTAL_2="44" WEIGHT="46.00911716494283"/>
<CONT_DATA CI_END="389.81744460849706" CI_START="-91.09744460849703" EFFECT_SIZE="149.36" ESTIMABLE="YES" MEAN_1="371.8" MEAN_2="222.44" MODIFIED="2013-01-27 18:07:26 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="344" SD_1="265.73" SD_2="91.44" SE="122.68462405696975" STUDY_ID="STD-Reichert-1994" TOTAL_1="5" TOTAL_2="9" WEIGHT="16.120858681372276"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.509478014379409" CI_END="174.93035803896828" CI_START="-74.59612140579858" DF="1" EFFECT_SIZE="50.167118316584855" ESTIMABLE="YES" I2="71.50573401791682" ID="CMP-005.06.02" MODIFIED="2014-04-01 16:30:38 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.061018808699021876" P_Z="0.4306389914889307" STUDIES="2" TAU2="6075.745543750001" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.788098684576124">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="46.78454899881957" CI_START="-48.78454899881957" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="165.0" MEAN_2="166.0" MODIFIED="2012-05-15 19:03:00 +1000" MODIFIED_BY="[Empty name]" ORDER="318" SD_1="80.0" SD_2="54.0" SE="24.380319932273242" STUDY_ID="STD-Branten-1998" TOTAL_1="16" TOTAL_2="15" WEIGHT="60.74937226404968"/>
<CONT_DATA CI_END="257.1015230953794" CI_START="1.6184769046206497" EFFECT_SIZE="129.36" ESTIMABLE="YES" MEAN_1="317.25" MEAN_2="187.89" MODIFIED="2012-05-15 19:03:18 +1000" MODIFIED_BY="[Empty name]" ORDER="345" SD_1="168.33" SD_2="79.71" SE="65.17544409131402" STUDY_ID="STD-Reichert-1994" TOTAL_1="8" TOTAL_2="9" WEIGHT="39.250627735950324"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.254841360962558" CI_END="191.02905242794543" CI_START="-156.11377689756029" DF="1" EFFECT_SIZE="17.45763776519257" ESTIMABLE="YES" I2="55.65098204633274" ID="CMP-005.06.03" MODIFIED="2014-04-01 16:30:43 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.1331972109380395" P_Z="0.8437248684197882" STUDIES="2" TAU2="10189.319057252738" TOTAL_1="19" TOTAL_2="22" WEIGHT="100.0" Z="0.19713120009654636">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="25.568873762098278" CI_START="-109.56887376209828" EFFECT_SIZE="-42.0" ESTIMABLE="YES" MEAN_1="174.0" MEAN_2="216.0" MODIFIED="2012-05-15 19:03:35 +1000" MODIFIED_BY="[Empty name]" ORDER="319" SD_1="78.0" SD_2="99.0" SE="34.474548662665704" STUDY_ID="STD-Branten-1998" TOTAL_1="14" TOTAL_2="13" WEIGHT="68.92891003073132"/>
<CONT_DATA CI_END="389.81744460849706" CI_START="-91.09744460849703" EFFECT_SIZE="149.36" ESTIMABLE="YES" MEAN_1="371.8" MEAN_2="222.44" MODIFIED="2012-05-15 19:03:57 +1000" MODIFIED_BY="[Empty name]" ORDER="344" SD_1="265.73" SD_2="91.44" SE="122.68462405696975" STUDY_ID="STD-Reichert-1994" TOTAL_1="5" TOTAL_2="9" WEIGHT="31.071089969268687"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.736243253363007" CI_END="72.81275227723467" CI_START="-174.04990593861615" DF="1" EFFECT_SIZE="-50.61857683069075" ESTIMABLE="YES" I2="78.88621959419119" ID="CMP-005.06.04" MODIFIED="2014-04-01 16:30:50 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.029533583900418603" P_Z="0.42152894545254593" STUDIES="2" TAU2="6323.765645447941" TOTAL_1="59" TOTAL_2="55" WEIGHT="100.0" Z="0.8037715242463292">
<NAME>At 32-39 months</NAME>
<CONT_DATA CI_END="-22.138201446765137" CI_START="-218.70179855323488" EFFECT_SIZE="-120.42000000000002" ESTIMABLE="YES" MEAN_1="159.94" MEAN_2="280.36" MODIFIED="2012-05-15 19:04:20 +1000" MODIFIED_BY="[Empty name]" ORDER="353" SD_1="69.95" SD_2="155.87" SE="50.14469619261842" STUDY_ID="STD-Branten-1998" TOTAL_1="16" TOTAL_2="11" WEIGHT="44.873303451817044"/>
<CONT_DATA CI_END="64.03064806813333" CI_START="-51.63064806813333" EFFECT_SIZE="6.200000000000003" ESTIMABLE="YES" MEAN_1="116.7" MEAN_2="110.5" MODIFIED="2012-05-15 19:04:37 +1000" MODIFIED_BY="[Empty name]" ORDER="348" SD_1="152.0" SD_2="121.1" SE="29.505974867035366" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="43" TOTAL_2="44" WEIGHT="55.12669654818296"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.810927056836686" CI_END="2.5652492162046254" CI_START="0.7494601702234727" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3865612551352893" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="83" I2="53.75049730968199" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="0.40912956358616775" LOG_CI_START="-0.12525144261796592" LOG_EFFECT_SIZE="0.14193906048410096" METHOD="IV" MODIFIED="2014-04-02 18:23:31 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.05526035790307127" P_Q="0.46667722263226485" P_Z="0.29778849080455727" Q="1.5242353819208128" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04499555445000568" TOTALS="SUB" TOTAL_1="141" TOTAL_2="143" WEIGHT="300.0" Z="1.041187629494524">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlorambucil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.64948375256348" CI_END="3.756363973380752" CI_START="0.7194591487092734" DF="2" EFFECT_SIZE="1.643943559411545" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="41" I2="56.984471686833935" ID="CMP-005.07.01" LOG_CI_END="0.5747676666538143" LOG_CI_START="-0.1429938605096102" LOG_EFFECT_SIZE="0.2158869030721021" MODIFIED="2014-04-01 16:31:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.09780886596933092" P_Z="0.23838695214812455" STUDIES="3" TAU2="0.31652578864219166" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="1.1790282391629738">
<NAME>At final follow-up (15-39 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="19.941210173101197" CI_START="1.4055155839391504" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.2997515108237805" LOG_CI_START="0.14783566529832134" LOG_EFFECT_SIZE="0.723793588061051" MODIFIED="2012-05-15 19:06:11 +1000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.676641069737052" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.457843137254902" WEIGHT="22.955546623520142"/>
<DICH_DATA CI_END="1.5099675922481666" CI_START="1.0093977583250189" EFFECT_SIZE="1.2345679012345678" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="36" LOG_CI_END="0.17896762632705787" LOG_CI_START="0.004062335915642543" LOG_EFFECT_SIZE="0.09151498112135023" MODIFIED="2012-05-15 19:06:19 +1000" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.10274023338281627" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="0.010555555555555554" WEIGHT="54.347526380131534"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-21 07:06:48 +1100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="22.696926996348317"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4353968035666176" CI_START="0.2309685219165204" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-005.07.02" LOG_CI_END="0.3865697316942399" LOG_CI_START="-0.6364472049108397" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-04-01 16:31:11 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.632129366162406" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="0.4787319061184504">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="2.4353968035666176" CI_START="0.2309685219165204" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3865697316942399" LOG_CI_START="-0.6364472049108397" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2012-05-15 19:06:27 +1000" MODIFIED_BY="[Empty name]" ORDER="312" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Reichert-1994" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.092572131824141" CI_END="9.306139915273365" CI_START="0.4824149983938458" DF="1" EFFECT_SIZE="2.118825493588253" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="38" I2="80.36355746930178" ID="CMP-005.07.03" LOG_CI_END="0.9687695777453214" LOG_CI_START="-0.3165791983421442" LOG_EFFECT_SIZE="0.32609518970158863" MODIFIED="2014-04-01 16:31:17 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.02402856247605678" P_Z="0.31998319199932834" STUDIES="2" TAU2="0.9507819138521703" TOTAL_1="60" TOTAL_2="59" WEIGHT="100.0" Z="0.994492450978735">
<NAME>At 32-39 months</NAME>
<DICH_DATA CI_END="19.941210173101197" CI_START="1.4055155839391504" EFFECT_SIZE="5.294117647058823" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.2997515108237805" LOG_CI_START="0.14783566529832134" LOG_EFFECT_SIZE="0.723793588061051" MODIFIED="2012-05-15 19:06:33 +1000" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.676641069737052" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.457843137254902" WEIGHT="40.46893477985206"/>
<DICH_DATA CI_END="1.3363068154470676" CI_START="0.9673357525809381" EFFECT_SIZE="1.1369509043927648" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="36" LOG_CI_END="0.12590618340717907" LOG_CI_START="-0.014422760472627036" LOG_EFFECT_SIZE="0.05574171146727601" MODIFIED="2012-05-15 19:06:40 +1000" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.0824299162744733" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="43" TOTAL_2="44" VAR="0.006794691097016678" WEIGHT="59.53106522014793"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.772229865307707" CI_END="5.298600971684797" CI_START="0.9524583248516165" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2464853895692376" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="0.7241612147925797" LOG_CI_START="-0.02115401794414361" LOG_EFFECT_SIZE="0.351503598424218" METHOD="IV" MODIFIED="2014-04-02 18:23:40 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.44430529865270185" P_Q="0.9873786846035719" P_Z="0.06450026831209696" Q="0.025403283750563124" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="141" TOTAL_2="143" WEIGHT="300.0" Z="1.8487060590939461">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlorambucil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.510707880088018" CI_END="6.473251094919219" CI_START="0.7642531114158803" DF="2" EFFECT_SIZE="2.2242307187583457" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" I2="20.341190790786627" ID="CMP-005.08.01" LOG_CI_END="0.8111224534605128" LOG_CI_START="-0.11676278450505045" LOG_EFFECT_SIZE="0.3471798344777312" MODIFIED="2014-04-01 16:31:26 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.28497506351166935" P_Z="0.1424604209031961" STUDIES="3" TAU2="0.2904511153034543" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="1.4666899394301702">
<NAME>At final follow-up (15-39 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="189.3628772696573" CI_START="0.7051586146284613" EFFECT_SIZE="11.555555555555555" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.2772948438481584" LOG_CI_START="-0.15171318412924717" LOG_EFFECT_SIZE="1.0627908298594555" MODIFIED="2012-05-15 19:07:53 +1000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="1.4268113394175834" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="2.0357905982905984" WEIGHT="12.770529239954893"/>
<DICH_DATA CI_END="2.784112414584529" CI_START="0.7883257042622296" EFFECT_SIZE="1.4814814814814814" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.444686766875344" LOG_CI_START="-0.10329431253739381" LOG_EFFECT_SIZE="0.17069622716897506" MODIFIED="2012-05-15 19:08:02 +1000" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.3218867985971327" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="0.10361111111111108" WEIGHT="75.38742825708599"/>
<DICH_DATA CI_END="92.62160011346378" CI_START="0.2699154405600246" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9667122795130358" LOG_CI_START="-0.5687722708409984" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2012-05-15 19:08:06 +1000" MODIFIED_BY="[Empty name]" ORDER="313" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="11.842042502959123"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.332356199323183" CI_START="0.21819344750390995" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.08.02" LOG_CI_END="1.2632182870354172" LOG_CI_START="-0.6611582957074547" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-04-01 16:31:32 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5397481693511708" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="0.6131938572300601">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="18.332356199323183" CI_START="0.21819344750390995" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2632182870354172" LOG_CI_START="-0.6611582957074547" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-05-15 19:08:11 +1000" MODIFIED_BY="[Empty name]" ORDER="314" O_E="0.0" SE="1.130388330520878" STUDY_ID="STD-Reichert-1994" TOTAL_1="9" TOTAL_2="9" VAR="1.2777777777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.137348958720654" CI_END="16.809528605924186" CI_START="0.37899311729128243" DF="1" EFFECT_SIZE="2.524023701662921" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" I2="53.21306818337391" ID="CMP-005.08.03" LOG_CI_END="1.22555553457472" LOG_CI_START="-0.4213686769700765" LOG_EFFECT_SIZE="0.4020934288023218" MODIFIED="2014-04-01 16:31:38 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.1437501811148435" P_Z="0.3385455668041938" STUDIES="2" TAU2="1.2144844455987078" TOTAL_1="60" TOTAL_2="59" WEIGHT="100.0" Z="0.9570429936585276">
<NAME>At 32-39 months</NAME>
<DICH_DATA CI_END="189.3628772696573" CI_START="0.7051586146284613" EFFECT_SIZE="11.555555555555555" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.2772948438481584" LOG_CI_START="-0.15171318412924717" LOG_EFFECT_SIZE="1.0627908298594555" MODIFIED="2012-05-15 19:08:18 +1000" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="1.4268113394175834" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="2.0357905982905984" WEIGHT="28.7940211371183"/>
<DICH_DATA CI_END="2.5345151773207717" CI_START="0.7344310318658362" EFFECT_SIZE="1.3643410852713178" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4038948962328968" LOG_CI_START="-0.13404898120309514" LOG_EFFECT_SIZE="0.13492295751490085" MODIFIED="2012-05-15 19:08:25 +1000" MODIFIED_BY="[Empty name]" ORDER="798" O_E="0.0" SE="0.3159908964710411" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="43" TOTAL_2="44" VAR="0.09985024665257222" WEIGHT="71.20597886288171"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.5271338624548765" CI_END="1.8399396311117935" CI_START="0.6776969486408739" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1166563812059096" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="58" I2="9.53720093583458" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.2648035739306617" LOG_CI_START="-0.1689644697848146" LOG_EFFECT_SIZE="0.047919552072923546" METHOD="IV" MODIFIED="2014-04-02 18:23:49 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.3549798289457765" P_Q="0.49080391368622545" P_Z="0.6649818953564535" Q="1.4234214620297196" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.015830340931276884" TOTALS="SUB" TOTAL_1="141" TOTAL_2="143" WEIGHT="300.0" Z="0.4330452534665173">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlorambucil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.660647875571859" CI_END="2.309392346904482" CI_START="0.5813725719969591" DF="2" EFFECT_SIZE="1.158713669751916" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" I2="24.83033856668705" ID="CMP-005.09.01" LOG_CI_END="0.36349772227209437" LOG_CI_START="-0.23554546123321077" LOG_EFFECT_SIZE="0.06397613051944182" MODIFIED="2014-04-01 16:31:48 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.2643917728477406" P_Z="0.6754812233258771" STUDIES="3" TAU2="0.13134515696046145" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="0.4186373040908802">
<NAME>At final follow-up (15-39 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="11.193023924985532" CI_START="0.6260078118464282" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.048947432061938" LOG_CI_START="-0.2034202472677987" LOG_EFFECT_SIZE="0.42276359239706973" MODIFIED="2012-05-15 19:09:57 +1000" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.7356469741582815" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.5411764705882353" WEIGHT="18.411332028934396"/>
<DICH_DATA CI_END="1.6532786305949043" CI_START="0.7467391632530385" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.21834605232065335" LOG_CI_START="-0.12683107119930304" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2012-05-15 19:10:07 +1000" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.20275875100994062" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="0.0411111111111111" WEIGHT="71.79802230383206"/>
<DICH_DATA CI_END="2.685665908545172" CI_START="0.04137190361525649" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42905198632986163" LOG_CI_START="-1.3832944957691864" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-05-15 19:10:14 +1000" MODIFIED_BY="[Empty name]" ORDER="315" O_E="0.0" SE="1.064581294844754" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="1.133333333333333" WEIGHT="9.790645667233552"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6310188124774583" CI_START="0.0422312111886745" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-005.09.02" LOG_CI_END="0.4201239534167336" LOG_CI_START="-1.3743664628560583" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-04-01 16:31:54 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.29730269483142824" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="1.0422351292924856">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="2.6310188124774583" CI_START="0.0422312111886745" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4201239534167336" LOG_CI_START="-1.3743664628560583" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-05-15 19:10:23 +1000" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="1.0540925533894596" STUDY_ID="STD-Reichert-1994" TOTAL_1="9" TOTAL_2="9" VAR="1.111111111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5615069737760714" CI_END="2.7354471932372983" CI_START="0.5827813569386325" DF="1" EFFECT_SIZE="1.2626035114432426" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" I2="35.95929977938059" ID="CMP-005.09.03" LOG_CI_END="0.4370283353054054" LOG_CI_START="-0.23449434967517765" LOG_EFFECT_SIZE="0.10126699281511387" MODIFIED="2014-04-01 16:32:00 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.21144474826689874" P_Z="0.5544312155018225" STUDIES="2" TAU2="0.16242339312324527" TOTAL_1="60" TOTAL_2="59" WEIGHT="100.0" Z="0.5911331461454311">
<NAME>At 32-39 months</NAME>
<DICH_DATA CI_END="11.193023924985532" CI_START="0.6260078118464282" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.048947432061938" LOG_CI_START="-0.2034202472677987" LOG_EFFECT_SIZE="0.42276359239706973" MODIFIED="2012-05-15 19:10:30 +1000" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="0.7356469741582815" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.5411764705882353" WEIGHT="22.11417968366685"/>
<DICH_DATA CI_END="1.4944769973719576" CI_START="0.700614638185038" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.1744892348712454" LOG_CI_START="-0.15452079305804356" LOG_EFFECT_SIZE="0.009984220906600923" MODIFIED="2012-05-15 19:10:36 +1000" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.1932621190315687" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="43" TOTAL_2="44" VAR="0.03735024665257223" WEIGHT="77.88582031633315"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="27.85968783477595" CI_END="-2.158036680290107" CI_START="-5.333492969170227" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.745764824730167" ESTIMABLE="YES" I2="82.05292166354164" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2014-04-02 18:23:57 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="3.877124840245827E-5" P_Q="0.8306273545766822" P_Z="3.7651369995278496E-6" Q="0.878440474044212" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.9772760049755926" TOTALS="SUB" TOTAL_1="150" TOTAL_2="144" UNITS="g/24 h" WEIGHT="400.0" Z="4.623942818382959">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorambucil</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.968844588778037" CI_END="2.2252826904726337" CI_START="-7.71324232177632" DF="1" EFFECT_SIZE="-2.7439798156518433" ESTIMABLE="YES" I2="88.85029180624653" ID="CMP-005.10.01" MODIFIED="2014-04-01 16:32:10 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0027462514701246388" P_Z="0.27913099045732537" STUDIES="2" TAU2="11.509711225727076" TOTAL_1="60" TOTAL_2="58" WEIGHT="100.0" Z="1.082273598215854">
<NAME>At final follow-up (32-39 months)</NAME>
<CONT_DATA CI_END="-2.3683473771939685" CI_START="-8.651652622806033" EFFECT_SIZE="-5.510000000000001" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="8.05" MODIFIED="2013-01-27 18:08:09 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="354" SD_1="4.28" SD_2="4.57" SE="1.6029134451382714" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="14" WEIGHT="45.65775669257059"/>
<CONT_DATA CI_END="0.6875895659577616" CI_START="-1.5275895659577614" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.11" MODIFIED="2013-01-27 18:08:09 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="349" SD_1="2.36" SD_2="2.89" SE="0.5651071013009864" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="43" TOTAL_2="44" WEIGHT="54.342243307429406"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.2272656189567952" CI_START="-5.772734381043205" DF="0" EFFECT_SIZE="-3.5" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.02" MODIFIED="2014-04-01 16:32:16 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.0025416768731383868" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="3.018335095868726">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="-1.2272656189567952" CI_START="-5.772734381043205" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="6.5" MODIFIED="2012-05-15 19:12:19 +1000" MODIFIED_BY="[Empty name]" ORDER="316" SD_1="2.3" SD_2="3.9" SE="1.159579665223567" STUDY_ID="STD-Branten-1998" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.9381251046935275" CI_START="-7.661874895306472" DF="0" EFFECT_SIZE="-4.8" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.03" MODIFIED="2014-04-01 16:32:23 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.0010115479616088986" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="3.2872950320858787">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-1.9381251046935275" CI_START="-7.661874895306472" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="6.8" MODIFIED="2012-05-15 19:12:35 +1000" MODIFIED_BY="[Empty name]" ORDER="317" SD_1="3.0" SD_2="4.4" SE="1.4601670836201972" STUDY_ID="STD-Branten-1998" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.968844588778037" CI_END="2.2252826904726337" CI_START="-7.71324232177632" DF="1" EFFECT_SIZE="-2.7439798156518433" ESTIMABLE="YES" I2="88.85029180624653" ID="CMP-005.10.04" MODIFIED="2014-04-01 16:32:32 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0027462514701246388" P_Z="0.27913099045732537" STUDIES="2" TAU2="11.509711225727076" TOTAL_1="60" TOTAL_2="58" WEIGHT="100.0" Z="1.082273598215854">
<NAME>At 32-39 months</NAME>
<CONT_DATA CI_END="-2.3683473771939685" CI_START="-8.651652622806033" EFFECT_SIZE="-5.510000000000001" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="8.05" MODIFIED="2012-05-15 19:12:51 +1000" MODIFIED_BY="[Empty name]" ORDER="354" SD_1="4.28" SD_2="4.57" SE="1.6029134451382714" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="14" WEIGHT="45.65775669257059"/>
<CONT_DATA CI_END="0.6875895659577616" CI_START="-1.5275895659577614" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.11" MODIFIED="2012-05-15 19:13:05 +1000" MODIFIED_BY="[Empty name]" ORDER="349" SD_1="2.36" SD_2="2.89" SE="0.5651071013009864" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="43" TOTAL_2="44" WEIGHT="54.342243307429406"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.40698064845815346" CI_END="0.9009979939787703" CI_START="0.25638792098845953" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48062979775601666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="-0.04527617595203632" LOG_CI_START="-0.5911024392609767" LOG_EFFECT_SIZE="-0.31818930760650654" METHOD="IV" MODIFIED="2014-04-02 18:24:05 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.8158781813892028" P_Q="1.0" P_Z="0.022305721983831035" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="2.2851212009983715">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Chlorambucil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chlorambucil</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.981201027247093" CI_START="0.23607163700652775" EFFECT_SIZE="0.48128342245989303" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="-0.008242005790243706" LOG_CI_START="-0.6269561884041045" LOG_EFFECT_SIZE="-0.3175990970971741" MODIFIED="2012-05-15 19:14:00 +1000" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.36343577355198015" STUDY_ID="STD-Branten-1998" TOTAL_1="17" TOTAL_2="15" VAR="0.1320855614973262" WEIGHT="77.82671767094016"/>
<DICH_DATA CI_END="1.7428940758141063" CI_START="0.0787048468130292" EFFECT_SIZE="0.37037037037037035" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.24127099371510083" LOG_CI_START="-1.1039985220330755" LOG_EFFECT_SIZE="-0.43136376415898736" MODIFIED="2012-05-15 19:14:06 +1000" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.7902179727419798" STUDY_ID="STD-Ponticelli-1998" TOTAL_1="45" TOTAL_2="50" VAR="0.6244444444444444" WEIGHT="16.462290271804285"/>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-21 08:15:06 +1100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Reichert-1994" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="5.71099205725556"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-04-10 18:26:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6">
<NAME>Cyclosporine (CSA) versus other treatments</NAME>
<DICH_OUTCOME CHI2="3.8282543438681973" CI_END="2.1489660798001182" CI_START="0.4667283727788914" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0014906098322354" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.33222956045566104" LOG_CI_START="-0.3309357972147692" LOG_EFFECT_SIZE="6.468816204459771E-4" METHOD="IV" MODIFIED="2014-04-10 17:57:34 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.5743987381070306" P_Q="0.8727566829594118" P_Z="0.9969491555148234" Q="1.2322752204639176" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="111" TOTAL_2="91" WEIGHT="100.0" Z="0.0038236758409357203">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.426735749004852" CI_END="7.208724162191864" CI_START="0.1487026312110299" DF="1" EFFECT_SIZE="1.0353532008896562" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="58.792381889537126" ID="CMP-006.01.01" LOG_CI_END="0.8578584078054482" LOG_CI_START="-0.8276813468087718" LOG_EFFECT_SIZE="0.015088530498338151" MODIFIED="2014-04-10 17:57:03 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.1192812660144501" P_Z="0.9720078037480093" STUDIES="2" TAU2="1.1815605779953056" TOTAL_1="19" TOTAL_2="19" WEIGHT="42.81191693234403" Z="0.0350902151971439">
<NAME>CSA versus placebo/no treatment at final follow-up (12-21 months)</NAME>
<DICH_DATA CI_END="1.8113826089229539" CI_START="0.10904977403696202" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.25801019376720685" LOG_CI_START="-0.9623752299899319" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2011-11-22 01:05:57 +1100" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.7168604389202189" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" VAR="0.5138888888888888" WEIGHT="29.529061168154353"/>
<DICH_DATA CI_END="26.811079872984088" CI_START="0.4061753592764908" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4283143064645425" LOG_CI_START="-0.3912864267087673" LOG_EFFECT_SIZE="0.5185139398778874" MODIFIED="2011-12-20 10:22:33 +1100" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="1.068842477834897" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="1.1424242424242423" WEIGHT="13.282855764189678"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.804356527890043" CI_START="0.1757214425495823" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="1.1073577582508822" LOG_CI_START="-0.7551752401395198" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-04-10 17:57:09 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.7109313543846907" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="12.677561071137996" Z="0.3706055420652529">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="12.804356527890043" CI_START="0.1757214425495823" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1073577582508822" LOG_CI_START="-0.7551752401395198" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2012-01-28 04:07:48 +1100" MODIFIED_BY="[Empty name]" ORDER="1873" O_E="0.0" SE="1.0940611029415575" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="1.196969696969697" WEIGHT="12.677561071137996"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:57:14 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 00:02:10 +1100" MODIFIED_BY="[Empty name]" ORDER="767" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="82.10513056584122" CI_START="0.20854328015963403" DF="0" EFFECT_SIZE="4.137931034482759" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="1.9143702960575109" LOG_CI_START="-0.6808037997601732" LOG_EFFECT_SIZE="0.6167832481486688" MODIFIED="2014-04-10 17:57:20 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.35152701525281704" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="6.5299622096017504" Z="0.9316314882976141">
<NAME>CSA+steroids versus steroids at final follow-up (18 months)</NAME>
<DICH_DATA CI_END="82.10513056584122" CI_START="0.20854328015963403" EFFECT_SIZE="4.137931034482759" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9143702960575109" LOG_CI_START="-0.6808037997601732" LOG_EFFECT_SIZE="0.6167832481486688" MODIFIED="2011-11-22 07:21:09 +1100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="1.5244181102022647" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="2.323850574712644" WEIGHT="6.5299622096017504"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5320991300708683E-35" CI_END="3.7455886630793525" CI_START="0.25104524218268776" DF="0" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="100.0" ID="CMP-006.01.05" LOG_CI_END="0.5735200818583346" LOG_CI_START="-0.6002480049742975" LOG_EFFECT_SIZE="-0.01336396155798149" MODIFIED="2014-04-10 17:57:28 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.9644018924450831" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="20" WEIGHT="31.92118962931958" Z="0.04463042340008066">
<NAME>CSA+steroids versus alkylating agents+steroids at final follow-up (9-60 months)</NAME>
<DICH_DATA CI_END="3.7455886630793533" CI_START="0.2510452421826877" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.5735200818583347" LOG_CI_START="-0.6002480049742976" LOG_EFFECT_SIZE="-0.01336396155798149" MODIFIED="2012-01-28 04:09:36 +1100" MODIFIED_BY="[Empty name]" ORDER="1875" O_E="0.0" SE="0.6894771844512245" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.47537878787878785" WEIGHT="31.92118962931958"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 07:20:33 +1100" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.432930996661408" CI_START="0.01908013899293761" DF="0" EFFECT_SIZE="0.42424242424242425" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.01.06" LOG_CI_END="0.9746466575195244" LOG_CI_START="-1.719418465918823" LOG_EFFECT_SIZE="-0.37238590419964945" MODIFIED="2014-04-10 17:57:34 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.587935467611872" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="6.05937015759664" Z="0.5418302284023451">
<NAME>CSA+steroids versus azathioprine+steroids at final follow-up (36 months)</NAME>
<DICH_DATA CI_END="9.432930996661408" CI_START="0.01908013899293761" EFFECT_SIZE="0.42424242424242425" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9746466575195244" LOG_CI_START="-1.719418465918823" LOG_EFFECT_SIZE="-0.37238590419964945" MODIFIED="2011-12-20 10:22:31 +1100" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="1.582507189345124" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="2.504329004329004" WEIGHT="6.05937015759664"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.77048300058385" CI_END="4.660968818762264" CI_START="0.3530964277493957" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.282876237115754" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.6684761975721942" LOG_CI_START="-0.45210667614002703" LOG_EFFECT_SIZE="0.10818476071608367" METHOD="IV" MODIFIED="2014-04-10 17:58:54 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.8565133284371153" P_Q="0.8565133284371153" P_Z="0.7051017130226023" Q="0.77048300058385" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="111" TOTAL_2="91" WEIGHT="100.0" Z="0.37844275448753917">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="58.239100526092926" CI_START="0.1251736365113307" DF="0" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="1.7652146588947637" LOG_CI_START="-0.9024871305767889" LOG_EFFECT_SIZE="0.43136376415898736" MODIFIED="2014-04-10 17:57:39 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.5261806542340917" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="17.644664345076464" Z="0.633847040418054">
<NAME>CSA versus placebo/no treatment at final follow-up (12-21 months)</NAME>
<DICH_DATA CI_END="58.239100526092926" CI_START="0.1251736365113307" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7652146588947637" LOG_CI_START="-0.9024871305767889" LOG_EFFECT_SIZE="0.43136376415898736" MODIFIED="2011-11-22 01:06:24 +1100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="1.567021236472421" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" VAR="2.4555555555555553" WEIGHT="17.644664345076464"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-20 10:22:39 +1100" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.0" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2132534428550692E-33" CI_END="35.57361413555459" CI_START="0.06886861348150151" DF="0" EFFECT_SIZE="1.565217391304348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="100.0" ID="CMP-006.02.02" LOG_CI_END="1.5511279899930068" LOG_CI_START="-1.161978660493618" LOG_EFFECT_SIZE="0.1945746647496944" MODIFIED="2014-04-10 17:57:48 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.7786154986987281" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="17.059025937427233" Z="0.281123733300315">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="35.57361413555459" CI_START="0.06886861348150151" EFFECT_SIZE="1.565217391304348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5511279899930068" LOG_CI_START="-1.161978660493618" LOG_EFFECT_SIZE="0.1945746647496944" MODIFIED="2012-01-28 04:07:27 +1100" MODIFIED_BY="[Empty name]" ORDER="1872" O_E="0.0" SE="1.593692276590361" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="2.5398550724637676" WEIGHT="17.059025937427233"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:58:39 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 00:02:22 +1100" MODIFIED_BY="[Empty name]" ORDER="768" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="58.20369009613711" CI_START="0.10590549084477896" DF="0" EFFECT_SIZE="2.4827586206896552" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.02.04" LOG_CI_END="1.764950519659977" LOG_CI_START="-0.9750815225953523" LOG_EFFECT_SIZE="0.3949344985323124" MODIFIED="2014-04-10 17:58:44 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.5720745902699301" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="16.72540636533112" Z="0.5649987893853898">
<NAME>CSA+steroids versus steroids at final follow-up (18 months)</NAME>
<DICH_DATA CI_END="58.20369009613711" CI_START="0.10590549084477896" EFFECT_SIZE="2.4827586206896552" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.764950519659977" LOG_CI_START="-0.9750815225953523" LOG_EFFECT_SIZE="0.3949344985323124" MODIFIED="2011-11-22 07:22:00 +1100" MODIFIED_BY="[Empty name]" ORDER="417" O_E="0.0" SE="1.6095083849981369" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="2.5905172413793105" WEIGHT="16.72540636533112"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.630644916938722" CI_START="0.11422288457055328" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-006.02.05" LOG_CI_END="0.6656414800812392" LOG_CI_START="-0.942246876413802" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2014-04-10 17:58:49 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.7359864556109499" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="20" WEIGHT="48.57090335216518" Z="0.33717304597131886">
<NAME>CSA+steroids versus alkylating agents+steroids at final follow-up (9-60 months)</NAME>
<DICH_DATA CI_END="4.630644916938722" CI_START="0.11422288457055328" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6656414800812392" LOG_CI_START="-0.942246876413802" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2012-01-28 04:09:13 +1100" MODIFIED_BY="[Empty name]" ORDER="1874" O_E="0.0" SE="0.9444815797809158" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.8920454545454546" WEIGHT="48.57090335216518"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 04:19:44 +1100" MODIFIED_BY="[Empty name]" ORDER="405" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:58:54 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus azathioprine+steroids at final follow-up (36 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 10:09:27 +1100" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.0" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.186369104541495" CI_END="2.531816128468858" CI_START="0.365206366859388" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9615796222019855" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.40343216213087396" LOG_CI_START="-0.4374616597582305" LOG_EFFECT_SIZE="-0.017014748813678295" METHOD="IV" MODIFIED="2014-04-10 18:17:34 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.5229075386395908" P_Q="0.9488785415257787" P_Z="0.9367810386754316" Q="0.7196915290876639" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="111" TOTAL_2="91" WEIGHT="100.0" Z="0.07931630370618405">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3757635508388475" CI_END="11.759731352118113" CI_START="0.05945848121005324" DF="1" EFFECT_SIZE="0.8361912255191327" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="70.37707218115118" ID="CMP-006.03.01" LOG_CI_END="1.0703974005134749" LOG_CI_START="-1.2257861884798418" LOG_EFFECT_SIZE="-0.07769439398318335" MODIFIED="2014-04-10 17:58:59 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.06616200122310623" P_Z="0.8944813215688155" STUDIES="2" TAU2="2.5614450707844596" TOTAL_1="19" TOTAL_2="19" WEIGHT="45.420465519383455" Z="0.13263592226479246">
<NAME>CSA versus placebo/no treatment at final follow-up (12-21 months)</NAME>
<DICH_DATA CI_END="1.5991152606402737" CI_START="0.030881273704817407" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.20387976784630216" LOG_CI_START="-1.5103047953969895" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2011-11-22 01:07:30 +1100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="1.0069204977995476" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" VAR="1.0138888888888888" WEIGHT="24.063963697118016"/>
<DICH_DATA CI_END="26.811079872984088" CI_START="0.4061753592764908" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4283143064645425" LOG_CI_START="-0.3912864267087673" LOG_EFFECT_SIZE="0.5185139398778874" MODIFIED="2011-12-20 10:23:10 +1100" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="1.068842477834897" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="1.1424242424242423" WEIGHT="21.356501822265436"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.862550818305001" CI_START="0.10139364738623087" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="0.9939892539921364" LOG_CI_START="-0.9939892539921364" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-10 18:16:59 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="17.892002637764598" Z="0.0">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months)</NAME>
<DICH_DATA CI_END="9.862550818305001" CI_START="0.10139364738623087" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9939892539921364" LOG_CI_START="-0.9939892539921364" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-20 10:23:11 +1100" MODIFIED_BY="[Empty name]" ORDER="742" O_E="0.0" SE="1.1677484162422844" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="1.3636363636363638" WEIGHT="17.892002637764598"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:17:04 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 00:02:53 +1100" MODIFIED_BY="[Empty name]" ORDER="769" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="58.20369009613711" CI_START="0.10590549084477896" DF="0" EFFECT_SIZE="2.4827586206896552" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.03.04" LOG_CI_END="1.764950519659977" LOG_CI_START="-0.9750815225953523" LOG_EFFECT_SIZE="0.3949344985323124" MODIFIED="2014-04-10 18:17:10 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.5720745902699301" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="9.418267913994978" Z="0.5649987893853898">
<NAME>CSA+steroids versus steroids at final follow-up (18 months)</NAME>
<DICH_DATA CI_END="58.20369009613711" CI_START="0.10590549084477896" EFFECT_SIZE="2.4827586206896552" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.764950519659977" LOG_CI_START="-0.9750815225953523" LOG_EFFECT_SIZE="0.3949344985323124" MODIFIED="2011-11-22 07:22:15 +1100" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="1.6095083849981369" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="2.5905172413793105" WEIGHT="9.418267913994978"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.689845677553986" CI_START="0.1440248267939006" DF="0" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.03.05" LOG_CI_END="1.1670172333846214" LOG_CI_START="-0.8415626383892221" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2014-04-10 18:17:15 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.7508056289788316" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="20" WEIGHT="17.52685972678981" Z="0.31757725632823375">
<NAME>CSA+steroids versus alkylating agents+steroids at final follow-up (9-60 months)</NAME>
<DICH_DATA CI_END="14.689845677553986" CI_START="0.1440248267939006" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1670172333846214" LOG_CI_START="-0.8415626383892221" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2011-12-20 10:23:14 +1100" MODIFIED_BY="[Empty name]" ORDER="757" O_E="0.0" SE="1.1798497593106736" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="1.3920454545454546" WEIGHT="17.52685972678981"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 00:02:57 +1100" MODIFIED_BY="[Empty name]" ORDER="407" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.432930996661408" CI_START="0.01908013899293761" DF="0" EFFECT_SIZE="0.42424242424242425" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.03.06" LOG_CI_END="0.9746466575195244" LOG_CI_START="-1.719418465918823" LOG_EFFECT_SIZE="-0.37238590419964945" MODIFIED="2014-04-10 18:17:34 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.587935467611872" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="9.742404202067155" Z="0.5418302284023451">
<NAME>CSA+steroids versus azathioprine+steroids at final follow-up (36 months)</NAME>
<DICH_DATA CI_END="9.432930996661408" CI_START="0.01908013899293761" EFFECT_SIZE="0.42424242424242425" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9746466575195244" LOG_CI_START="-1.719418465918823" LOG_EFFECT_SIZE="-0.37238590419964945" MODIFIED="2011-12-20 10:23:16 +1100" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="1.582507189345124" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="2.504329004329004" WEIGHT="9.742404202067155"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5233567767363017" CI_END="1.3439524640129503" CI_START="0.5446681873896062" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8555747498095818" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.1283839078681292" LOG_CI_START="-0.263867989963916" LOG_EFFECT_SIZE="-0.06774204104789344" METHOD="IV" MODIFIED="2014-04-10 18:18:23 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.960632886936276" P_Q="0.9464843062098048" P_Z="0.49842312648470855" Q="1.6822378511575342" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="216" TOTAL_2="150" WEIGHT="700.0" Z="0.676972942269641">
<NAME>100% increase in serum creatinine</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CSA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8411189255787672" CI_END="1.8705015273571095" CI_START="0.39134325302904516" DF="2" EFFECT_SIZE="0.8555747498095818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.27195806715731596" LOG_CI_START="-0.4074421492531027" LOG_EFFECT_SIZE="-0.06774204104789344" MODIFIED="2014-04-10 18:17:45 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.6566793460927156" P_Z="0.6959077376838639" STUDIES="2" TAU2="0.0" TOTAL_1="72" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.3908505104534702">
<NAME>CSA versus other treatments at final follow-up (18-60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.481216514474636" CI_START="0.21317189239597806" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.3946646630786687" LOG_CI_START="-0.6712700594112315" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2011-12-20 10:23:33 +1100" MODIFIED_BY="[Empty name]" ORDER="758" O_E="0.0" SE="0.6261353324525414" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.39204545454545453" WEIGHT="40.62469775230958"/>
<DICH_DATA CI_END="2.4716460442909356" CI_START="0.1798171892253878" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.3929862770892373" LOG_CI_START="-0.7451687952005998" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-12-20 10:23:34 +1100" MODIFIED_BY="[Empty name]" ORDER="743" O_E="0.0" SE="0.6685579234215214" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.4469696969696969" WEIGHT="35.63267980816984"/>
<DICH_DATA CI_END="8.180088527204632" CI_START="0.3299450345629759" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-12-07 09:51:51 +1100" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.8190283593479222" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.6708074534161491" WEIGHT="23.742622439520574"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4716460442909356" CI_START="0.1798171892253878" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="0.3929862770892373" LOG_CI_START="-0.7451687952005998" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-04-10 18:17:53 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5441979504152998" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="99.99999999999999" Z="0.6064771561349387">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.4716460442909356" CI_START="0.1798171892253878" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.3929862770892373" LOG_CI_START="-0.7451687952005998" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-11-22 03:23:25 +1100" MODIFIED_BY="[Empty name]" ORDER="743" O_E="0.0" SE="0.6685579234215214" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.4469696969696969" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4716460442909356" CI_START="0.1798171892253878" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-006.04.03" LOG_CI_END="0.3929862770892373" LOG_CI_START="-0.7451687952005998" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-04-10 18:17:58 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.5441979504152998" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="99.99999999999999" Z="0.6064771561349387">
<NAME>CSA+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="2.4716460442909356" CI_START="0.1798171892253878" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.3929862770892373" LOG_CI_START="-0.7451687952005998" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-11-22 03:23:28 +1100" MODIFIED_BY="[Empty name]" ORDER="747" O_E="0.0" SE="0.6685579234215214" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.4469696969696969" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.180088527204632" CI_START="0.3299450345629759" DF="0" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-006.04.04" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2014-04-10 18:18:04 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.5444290611546851" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.6061290560306536">
<NAME>CSA+steroids versus steroids at final follow-up (18 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="8.180088527204632" CI_START="0.3299450345629759" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-11-22 07:22:35 +1100" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.8190283593479222" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.6708074534161491" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.180088527204632" CI_START="0.3299450345629759" DF="0" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-006.04.05" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2014-04-10 18:18:09 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.5444290611546851" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.6061290560306536">
<NAME>CSA+steroids versus steroids at 18 months</NAME>
<DICH_DATA CI_END="8.180088527204632" CI_START="0.3299450345629759" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-11-22 07:23:40 +1100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="0.8190283593479222" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.6708074534161491" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.481216514474636" CI_START="0.21317189239597806" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-006.04.06" LOG_CI_END="0.3946646630786687" LOG_CI_START="-0.6712700594112315" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2014-04-10 18:18:17 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.6110311741636574" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="16" WEIGHT="100.0" Z="0.5086020778785426">
<NAME>CSA+steroids versus alkylating agents+steroids at final follow-up (60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.481216514474636" CI_START="0.21317189239597806" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.3946646630786687" LOG_CI_START="-0.6712700594112315" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2011-11-22 03:37:08 +1100" MODIFIED_BY="[Empty name]" ORDER="758" O_E="0.0" SE="0.6261353324525414" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.39204545454545453" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.481216514474636" CI_START="0.21317189239597806" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-006.04.07" LOG_CI_END="0.3946646630786687" LOG_CI_START="-0.6712700594112315" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2014-04-10 18:18:23 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.6110311741636574" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="16" WEIGHT="100.0" Z="0.5086020778785426">
<NAME>CSA+steroids versus alkylating agents+steroids at 60 months</NAME>
<DICH_DATA CI_END="2.481216514474636" CI_START="0.21317189239597806" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.3946646630786687" LOG_CI_START="-0.6712700594112315" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2011-11-22 07:23:44 +1100" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="0.6261353324525414" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.39204545454545453" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.073512405706907" CI_END="1.8691379313481329" CI_START="0.5311695939235525" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9964081673597908" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.2716413509310438" LOG_CI_START="-0.2747667935217536" LOG_EFFECT_SIZE="-0.0015627212953548456" METHOD="IV" MODIFIED="2014-04-10 18:18:55 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.8388826083349868" P_Q="0.8472583037996007" P_Z="0.9910551426867634" Q="1.3823416038046048" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="108" WEIGHT="500.0" Z="0.011210950963538965">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CSA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6911708019023023" CI_END="2.9623789471505297" CI_START="0.33514592619431255" DF="1" EFFECT_SIZE="0.9964081673597908" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.47164061263548485" LOG_CI_START="-0.4747660552261945" LOG_EFFECT_SIZE="-0.0015627212953548456" MODIFIED="2014-04-10 18:18:33 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.4057668298601962" P_Z="0.9948356121027212" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="36" WEIGHT="100.0" Z="0.006472645556670937">
<NAME>CSA versus other treatments at final follow-up (18-36 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="8.180088527204632" CI_START="0.3299450345629759" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-12-07 09:53:20 +1100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="0.8190283593479222" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.6708074534161491" WEIGHT="46.07155889300735"/>
<DICH_DATA CI_END="2.8660820789993" CI_START="0.14741378242297823" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4572886235861159" LOG_CI_START="-0.8314619103004048" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2011-12-20 10:23:42 +1100" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.7570184430229709" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.573076923076923" WEIGHT="53.92844110699264"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.180088527204632" CI_START="0.3299450345629759" DF="0" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2014-04-10 18:18:38 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5444290611546851" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.6061290560306536">
<NAME>CSA+steroids versus steroids at final follow-up (18 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="8.180088527204632" CI_START="0.3299450345629759" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-11-22 07:22:49 +1100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="0.8190283593479222" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.6708074534161491" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.180088527204632" CI_START="0.3299450345629759" DF="0" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-006.05.03" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2014-04-10 18:18:44 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.5444290611546851" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.6061290560306536">
<NAME>CSA+steroids versus steroids at 18 months</NAME>
<DICH_DATA CI_END="8.180088527204632" CI_START="0.3299450345629759" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9127580037530378" LOG_CI_START="-0.4815584030743281" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-11-22 07:24:46 +1100" MODIFIED_BY="[Empty name]" ORDER="423" O_E="0.0" SE="0.8190283593479222" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.6708074534161491" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8660820789993" CI_START="0.14741378242297823" DF="0" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-006.05.04" LOG_CI_END="0.4572886235861159" LOG_CI_START="-0.8314619103004048" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2014-04-10 18:18:49 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.5693208030157408" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.5690520753658608">
<NAME>CSA+steroids versus azathioprine+steroids at final follow-up (36 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.8660820789993" CI_START="0.14741378242297823" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4572886235861159" LOG_CI_START="-0.8314619103004048" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2011-12-07 11:16:06 +1100" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.7570184430229709" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.573076923076923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8660820789993" CI_START="0.14741378242297823" DF="0" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-006.05.05" LOG_CI_END="0.4572886235861159" LOG_CI_START="-0.8314619103004048" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2014-04-10 18:18:55 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.5693208030157408" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.5690520753658608">
<NAME>CSA+steroids versus azathioprine+steroids at 36 months</NAME>
<DICH_DATA CI_END="2.8660820789993" CI_START="0.14741378242297823" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4572886235861159" LOG_CI_START="-0.8314619103004048" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2011-12-07 11:16:14 +1100" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.7570184430229709" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.573076923076923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="19.955755593742346" CI_END="34.413470158802426" CI_START="10.403425142479424" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="22.408447650640923" ESTIMABLE="YES" I2="39.86697249507848" I2_Q="44.45308232343801" ID="CMP-006.06" MODIFIED="2014-04-10 18:19:59 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.06792763689608416" P_Q="0.05491647062318106" P_Z="2.5374723037589525E-4" Q="18.00279910800433" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="403.0917390415762" TOTALS="SUB" TOTAL_1="202" TOTAL_2="205" UNITS="&#956;mol/L" WEIGHT="1100.0" Z="3.658447979989124">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9529564857380217" CI_END="51.54967164898453" CI_START="-17.836365593401794" DF="2" EFFECT_SIZE="16.856653027791367" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" MODIFIED="2014-04-10 18:19:05 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.3766352732802781" P_Z="0.34094090619945605" STUDIES="3" TAU2="0.0" TOTAL_1="48" TOTAL_2="47" WEIGHT="100.0" Z="0.9523078171749726">
<NAME>CSA versus other treatments at final follow-up (12-36 months)</NAME>
<CONT_DATA CI_END="69.69507736219896" CI_START="-16.65507736219896" EFFECT_SIZE="26.519999999999996" ESTIMABLE="YES" MEAN_1="141.44" MEAN_2="114.92" MODIFIED="2013-01-27 17:53:23 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="426" SD_1="114.92" SD_2="17.68" SE="22.028505473956898" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" WEIGHT="64.56808850488602"/>
<CONT_DATA CI_END="73.19307644491332" CI_START="-50.193076444913316" EFFECT_SIZE="11.5" ESTIMABLE="YES" MEAN_1="189.2" MEAN_2="177.7" MODIFIED="2013-01-27 17:53:31 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="372" SD_1="65.4" SD_2="78.7" SE="31.476637801276162" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="31.623601086655633"/>
<CONT_DATA CI_END="75.27714171204639" CI_START="-280.2771417120464" EFFECT_SIZE="-102.5" ESTIMABLE="YES" MEAN_1="167.3" MEAN_2="269.8" MODIFIED="2013-01-27 17:52:33 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="449" SD_1="146.3" SD_2="281.3" SE="90.70429003508727" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="3.808310408458342"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="73.19307644491332" CI_START="-50.193076444913316" DF="0" EFFECT_SIZE="11.5" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.02" MODIFIED="2014-04-10 18:19:10 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.7148499141141942" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="0.36535032974626513">
<NAME>CSA versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="73.19307644491332" CI_START="-50.193076444913316" EFFECT_SIZE="11.5" ESTIMABLE="YES" MEAN_1="189.2" MEAN_2="177.7" MODIFIED="2011-11-22 01:48:44 +1100" MODIFIED_BY="[Empty name]" ORDER="372" SD_1="65.4" SD_2="78.7" SE="31.476637801276162" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="53.25516845232414" CI_START="17.46483154767586" DF="0" EFFECT_SIZE="35.36" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.03" MODIFIED="2014-04-10 18:19:15 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="1.0759413652748596E-4" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.00000000000001" Z="3.8727954239701727">
<NAME>CSA+steroids versus steroids at 6 months</NAME>
<CONT_DATA CI_END="53.25516845232414" CI_START="17.46483154767586" EFFECT_SIZE="35.36" ESTIMABLE="YES" MEAN_1="132.6" MEAN_2="97.24" MODIFIED="2011-11-22 07:26:24 +1100" MODIFIED_BY="[Empty name]" ORDER="424" SD_1="44.2" SD_2="17.68" SE="9.130355758309307" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="62.532838711896375" CI_START="8.187161288103624" DF="0" EFFECT_SIZE="35.36" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.04" MODIFIED="2014-04-10 18:19:21 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.010756850863014245" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="99.99999999999999" Z="2.5505000500000983">
<NAME>CSA+steroids versus steroids at 12 months</NAME>
<CONT_DATA CI_END="62.532838711896375" CI_START="8.187161288103624" EFFECT_SIZE="35.36" ESTIMABLE="YES" MEAN_1="141.44" MEAN_2="106.08" MODIFIED="2011-11-22 07:27:34 +1100" MODIFIED_BY="[Empty name]" ORDER="425" SD_1="70.72" SD_2="17.68" SE="13.86394797365271" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="69.69507736219896" CI_START="-16.65507736219896" DF="0" EFFECT_SIZE="26.519999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.05" MODIFIED="2014-04-10 18:19:26 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.22863031992096172" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="1.2038946551028233">
<NAME>CSA+steroids versus steroids at 18 months</NAME>
<CONT_DATA CI_END="69.69507736219896" CI_START="-16.65507736219896" EFFECT_SIZE="26.519999999999996" ESTIMABLE="YES" MEAN_1="141.44" MEAN_2="114.92" MODIFIED="2011-11-22 07:27:59 +1100" MODIFIED_BY="[Empty name]" ORDER="426" SD_1="114.92" SD_2="17.68" SE="22.028505473956898" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="34.482814358656206" CI_START="-69.6828143586562" DF="0" EFFECT_SIZE="-17.599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.06" MODIFIED="2014-04-10 18:19:31 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.507767685164177" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.6623176291964682">
<NAME>CSA+steroids versus azathioprine+steroids at 6 months</NAME>
<CONT_DATA CI_END="34.482814358656206" CI_START="-69.6828143586562" EFFECT_SIZE="-17.599999999999994" ESTIMABLE="YES" MEAN_1="119.4" MEAN_2="137.0" MODIFIED="2011-11-22 10:12:39 +1100" MODIFIED_BY="[Empty name]" ORDER="444" SD_1="57.0" SD_2="70.4" SE="26.57335276029498" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="39.147326260103455" CI_START="-135.74732626010345" DF="0" EFFECT_SIZE="-48.3" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.07" MODIFIED="2014-04-10 18:19:37 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.27900742798995626" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.08255180005972">
<NAME>CSA+steroids versus azathioprine+steroids at 12 months</NAME>
<CONT_DATA CI_END="39.147326260103455" CI_START="-135.74732626010345" EFFECT_SIZE="-48.3" ESTIMABLE="YES" MEAN_1="122.8" MEAN_2="171.1" MODIFIED="2011-12-07 11:19:53 +1100" MODIFIED_BY="[Empty name]" ORDER="445" SD_1="49.6" SD_2="150.6" SE="44.61680262998545" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.585807201801534E-32" CI_END="24.243590218748558" CI_START="-122.84359021874855" DF="0" EFFECT_SIZE="-49.29999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-006.06.08" MODIFIED="2014-04-10 18:19:43 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Z="0.18889220966380418" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.3138633040679544">
<NAME>CSA+steroids versus azathioprine+steroids at 18 months</NAME>
<CONT_DATA CI_END="24.24359021874855" CI_START="-122.84359021874855" EFFECT_SIZE="-49.3" ESTIMABLE="YES" MEAN_1="121.8" MEAN_2="171.1" MODIFIED="2011-11-22 10:13:19 +1100" MODIFIED_BY="[Empty name]" ORDER="446" SD_1="44.1" SD_2="125.6" SE="37.52292940015786" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="64.66691326304205" CI_START="-186.66691326304203" DF="0" EFFECT_SIZE="-61.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.09" MODIFIED="2014-04-10 18:19:48 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.3414082294836095" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.9513864863274605">
<NAME>CSA+steroids versus azathioprine+steroids at 24 months</NAME>
<CONT_DATA CI_END="64.66691326304205" CI_START="-186.66691326304203" EFFECT_SIZE="-61.0" ESTIMABLE="YES" MEAN_1="145.5" MEAN_2="206.5" MODIFIED="2011-11-22 10:13:54 +1100" MODIFIED_BY="[Empty name]" ORDER="447" SD_1="126.9" SD_2="180.3" SE="64.11695023698732" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.0572351928830193E-32" CI_END="41.67803472353201" CI_START="-234.8780347235321" DF="0" EFFECT_SIZE="-96.60000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-006.06.10" MODIFIED="2014-04-10 18:19:54 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Z="0.17093171337752022" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.3692161686063422">
<NAME>CSA+steroids versus azathioprine+steroids at 30 months</NAME>
<CONT_DATA CI_END="41.67803472353202" CI_START="-234.87803472353207" EFFECT_SIZE="-96.60000000000002" ESTIMABLE="YES" MEAN_1="149.2" MEAN_2="245.8" MODIFIED="2011-11-22 10:14:15 +1100" MODIFIED_BY="[Empty name]" ORDER="448" SD_1="122.1" SD_2="212.9" SE="70.55131411304062" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="75.27714171204639" CI_START="-280.2771417120464" DF="0" EFFECT_SIZE="-102.5" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.11" MODIFIED="2014-04-10 18:19:59 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.2584569540807896" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.130045777992968">
<NAME>CSA+steroids versus azathioprine+steroids at 36 months</NAME>
<CONT_DATA CI_END="75.27714171204639" CI_START="-280.2771417120464" EFFECT_SIZE="-102.5" ESTIMABLE="YES" MEAN_1="167.3" MEAN_2="269.8" MODIFIED="2011-11-22 10:14:38 +1100" MODIFIED_BY="[Empty name]" ORDER="449" SD_1="146.3" SD_2="281.3" SE="90.70429003508727" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.308659718889142" CI_END="19.65728942780536" CI_START="7.566898167896844" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="MD" EFFECT_SIZE="13.612093797851102" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.07" MODIFIED="2014-04-10 18:21:11 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.9668429690477239" P_Q="0.9652553253709036" P_Z="1.0181052415739658E-5" Q="4.15207463323529" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="136" TOTAL_2="152" UNITS="" WEIGHT="1200.0" Z="4.413292014202537">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CSA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.129223373796439" CI_END="21.21112806998629" CI_START="-2.953925281333966" DF="4" EFFECT_SIZE="9.128601394326163" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.01" MODIFIED="2014-04-10 18:20:14 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.7120057817830058" P_Z="0.13866154303186135" STUDIES="4" TAU2="0.0" TOTAL_1="35" TOTAL_2="36" WEIGHT="99.99999999999999" Z="1.4807937480612998">
<NAME>CSA versus other treatments at final follow-up (9-36 months)</NAME>
<CONT_DATA CI_END="42.97818890947444" CI_START="-27.358188909474435" EFFECT_SIZE="7.810000000000002" ESTIMABLE="YES" MEAN_1="43.24" MEAN_2="35.43" MODIFIED="2013-01-27 17:55:59 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="364" SD_1="16.12" SD_2="28.46" SE="17.943283237282227" STUDY_ID="STD-Cattran-1995" TOTAL_1="5" TOTAL_2="3" WEIGHT="11.803628112456243"/>
<CONT_DATA CI_END="20.789462395231432" CI_START="-24.989462395231435" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="44.1" MEAN_2="46.2" MODIFIED="2013-01-27 17:55:59 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="733" SD_1="27.2" SD_2="26.2" SE="11.678511735817898" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="27.864056382758147"/>
<CONT_DATA CI_END="37.41395216598052" CI_START="-19.013952165980523" EFFECT_SIZE="9.199999999999996" ESTIMABLE="YES" MEAN_1="71.3" MEAN_2="62.1" MODIFIED="2013-01-27 17:55:44 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="770" SD_1="25.3" SD_2="19.9" SE="14.395138068111747" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" WEIGHT="18.339507719078657"/>
<CONT_DATA CI_END="37.036641381082376" CI_START="-18.436641381082378" EFFECT_SIZE="9.299999999999997" ESTIMABLE="YES" MEAN_1="71.3" MEAN_2="62.0" MODIFIED="2013-01-27 17:55:32 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="403" SD_1="25.3" SD_2="17.0" SE="14.151607682521446" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" WEIGHT="18.97613592559709"/>
<CONT_DATA CI_END="48.38468362578648" CI_START="-1.9846836257864737" EFFECT_SIZE="23.200000000000003" ESTIMABLE="YES" MEAN_1="77.9" MEAN_2="54.7" MODIFIED="2013-01-27 17:54:46 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="455" SD_1="29.3" SD_2="32.1" SE="12.849564494266245" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="23.016671860109852"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="32.395491846770085" CI_START="-7.875491846770082" DF="0" EFFECT_SIZE="12.260000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.02" MODIFIED="2014-04-10 18:20:19 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.23272322652287547" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.1933733048748727">
<NAME>CSA versus placebo/no treatment at 6 months</NAME>
<CONT_DATA CI_END="32.395491846770085" CI_START="-7.875491846770082" EFFECT_SIZE="12.260000000000002" ESTIMABLE="YES" MEAN_1="42.96" MEAN_2="30.7" MODIFIED="2011-11-22 01:22:35 +1100" MODIFIED_BY="[Empty name]" ORDER="363" SD_1="16.57" SD_2="23.87" SE="10.273398902018748" STUDY_ID="STD-Cattran-1995" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0161026564342568" CI_END="22.327547064785957" CI_START="-9.483855046803942" DF="1" EFFECT_SIZE="6.421846008991007" ESTIMABLE="YES" I2="1.5847470068393286" ID="CMP-006.07.03" MODIFIED="2014-04-10 18:20:24 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.313445540981221" P_Z="0.42875407681401156" STUDIES="2" TAU2="2.092361282467551" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.7913255032099933">
<NAME>CSA versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="35.93031890693066" CI_START="-7.630318906930661" EFFECT_SIZE="14.149999999999999" ESTIMABLE="YES" MEAN_1="44.19" MEAN_2="30.04" MODIFIED="2011-11-22 01:23:05 +1100" MODIFIED_BY="[Empty name]" ORDER="365" SD_1="18.41" SD_2="23.83" SE="11.11261180242649" STUDY_ID="STD-Cattran-1995" TOTAL_1="8" TOTAL_2="7" WEIGHT="52.44212928609851"/>
<CONT_DATA CI_END="20.789462395231432" CI_START="-24.989462395231435" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="44.1" MEAN_2="46.2" MODIFIED="2011-11-22 01:51:11 +1100" MODIFIED_BY="[Empty name]" ORDER="733" SD_1="27.2" SD_2="26.2" SE="11.678511735817898" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="47.55787071390149"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="42.97818890947444" CI_START="-27.358188909474435" DF="0" EFFECT_SIZE="7.810000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.04" MODIFIED="2014-04-10 18:20:29 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.6633734523819986" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0" Z="0.43526036437816057">
<NAME>CSA versus placebo/no treatment at 24 months</NAME>
<CONT_DATA CI_END="42.97818890947444" CI_START="-27.358188909474435" EFFECT_SIZE="7.810000000000002" ESTIMABLE="YES" MEAN_1="43.24" MEAN_2="35.43" MODIFIED="2011-11-22 01:23:39 +1100" MODIFIED_BY="[Empty name]" ORDER="364" SD_1="16.12" SD_2="28.46" SE="17.943283237282227" STUDY_ID="STD-Cattran-1995" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="37.41395216598051" CI_START="-19.01395216598052" DF="0" EFFECT_SIZE="9.199999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.05" MODIFIED="2014-04-10 18:20:34 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.5227548442998184" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.6391046724574271">
<NAME>CSA+steroids versus ACEi/ARB at 9 months</NAME>
<CONT_DATA CI_END="37.41395216598052" CI_START="-19.013952165980523" EFFECT_SIZE="9.199999999999996" ESTIMABLE="YES" MEAN_1="71.3" MEAN_2="62.1" MODIFIED="2011-11-22 04:03:24 +1100" MODIFIED_BY="[Empty name]" ORDER="770" SD_1="25.3" SD_2="19.9" SE="14.395138068111747" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="37.036641381082376" CI_START="-18.436641381082378" DF="0" EFFECT_SIZE="9.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.06" MODIFIED="2014-04-10 18:20:39 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.5110721633770245" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.00000000000001" Z="0.6571691505754759">
<NAME>CSA+steroids versus alkylating agents+steroids at 9 months</NAME>
<CONT_DATA CI_END="37.036641381082376" CI_START="-18.436641381082378" EFFECT_SIZE="9.299999999999997" ESTIMABLE="YES" MEAN_1="71.3" MEAN_2="62.0" MODIFIED="2011-11-22 04:16:44 +1100" MODIFIED_BY="[Empty name]" ORDER="403" SD_1="25.3" SD_2="17.0" SE="14.151607682521446" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="38.34321095554304" CI_START="-3.343210955543043" DF="0" EFFECT_SIZE="17.5" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.07" MODIFIED="2014-04-10 18:20:44 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.09984829608689831" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.6455895304523307">
<NAME>CSA+steroids versus azathioprine+steroids at 6 months</NAME>
<CONT_DATA CI_END="38.34321095554304" CI_START="-3.343210955543043" EFFECT_SIZE="17.5" ESTIMABLE="YES" MEAN_1="85.1" MEAN_2="67.6" MODIFIED="2011-11-22 10:16:31 +1100" MODIFIED_BY="[Empty name]" ORDER="450" SD_1="22.0" SD_2="29.0" SE="10.634486715037434" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="41.470841051584415" CI_START="-6.070841051584406" DF="0" EFFECT_SIZE="17.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.08" MODIFIED="2014-04-10 18:20:50 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.1444527652563068" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.459408291489403">
<NAME>CSA+steroids versus azathioprine+steroids at 12 months</NAME>
<CONT_DATA CI_END="41.470841051584415" CI_START="-6.070841051584406" EFFECT_SIZE="17.700000000000003" ESTIMABLE="YES" MEAN_1="85.5" MEAN_2="67.8" MODIFIED="2011-11-22 10:16:47 +1100" MODIFIED_BY="[Empty name]" ORDER="451" SD_1="23.9" SD_2="34.2" SE="12.128202986935356" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="45.60311190967775" CI_START="-2.4031119096777616" DF="0" EFFECT_SIZE="21.599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.09" MODIFIED="2014-04-10 18:20:55 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.0777759495276378" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.7637388945804202">
<NAME>CSA+steroids versus azathioprine+steroids at 18 months</NAME>
<CONT_DATA CI_END="45.60311190967775" CI_START="-2.4031119096777616" EFFECT_SIZE="21.599999999999994" ESTIMABLE="YES" MEAN_1="83.6" MEAN_2="62.0" MODIFIED="2011-11-22 10:17:02 +1100" MODIFIED_BY="[Empty name]" ORDER="452" SD_1="26.5" SD_2="32.2" SE="12.246710704386018" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="45.459286367272156" CI_START="-1.6592863672721414" DF="0" EFFECT_SIZE="21.900000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.10" MODIFIED="2014-04-10 18:21:01 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.06846663405887549" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.8219232362256454">
<NAME>CSA+steroids versus azathioprine+steroids at 24 months</NAME>
<CONT_DATA CI_END="45.459286367272156" CI_START="-1.6592863672721414" EFFECT_SIZE="21.900000000000006" ESTIMABLE="YES" MEAN_1="78.4" MEAN_2="56.5" MODIFIED="2011-11-22 10:17:40 +1100" MODIFIED_BY="[Empty name]" ORDER="453" SD_1="27.6" SD_2="29.8" SE="12.020264940123793" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.489956136827475E-32" CI_END="50.84302015540001" CI_START="-0.04302015540002202" DF="0" EFFECT_SIZE="25.399999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-006.07.11" MODIFIED="2014-04-10 18:21:06 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Z="0.05038863301153014" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.9566499929353485">
<NAME>CSA+steroids versus azathioprine+steroids at 30 months</NAME>
<CONT_DATA CI_END="50.84302015540001" CI_START="-0.04302015540001847" EFFECT_SIZE="25.4" ESTIMABLE="YES" MEAN_1="81.5" MEAN_2="56.1" MODIFIED="2011-11-22 10:17:56 +1100" MODIFIED_BY="[Empty name]" ORDER="454" SD_1="30.6" SD_2="31.2" SE="12.981371268090287" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="48.38468362578648" CI_START="-1.9846836257864737" DF="0" EFFECT_SIZE="23.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.12" MODIFIED="2014-04-10 18:21:11 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="1.0" P_Z="0.0709951212565566" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.8055086622081509">
<NAME>CSA+steroids versus azathioprine+steroids at 36 months</NAME>
<CONT_DATA CI_END="48.38468362578648" CI_START="-1.9846836257864737" EFFECT_SIZE="23.200000000000003" ESTIMABLE="YES" MEAN_1="77.9" MEAN_2="54.7" MODIFIED="2011-11-22 10:18:15 +1100" MODIFIED_BY="[Empty name]" ORDER="455" SD_1="29.3" SD_2="32.1" SE="12.849564494266245" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="50.64704728496349" CI_END="1.1242171959043703" CI_START="0.8740496889063697" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9912727628374574" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="180" I2="46.689883325111474" I2_Q="47.46196531248709" ID="CMP-006.08" LOG_CI_END="0.05085022392904452" LOG_CI_START="-0.058463877429159886" LOG_EFFECT_SIZE="-0.0038068267500577175" METHOD="IV" MODIFIED="2014-04-10 18:23:20 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.003828274824397737" P_Q="0.008688536333902097" P_Z="0.8914179846865354" Q="38.06765920909779" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08898104196512671" TOTALS="SUB" TOTAL_1="412" TOTAL_2="360" WEIGHT="2100.0" Z="0.1365101708341816">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CSA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.443067511888795" CI_END="1.44146188593662" CI_START="0.7314992189692758" DF="6" EFFECT_SIZE="1.0268535648945358" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="39" I2="36.46132475018296" ID="CMP-006.08.01" LOG_CI_END="0.1588031635842721" LOG_CI_START="-0.13578613323998928" LOG_EFFECT_SIZE="0.011508515172141388" MODIFIED="2014-04-10 18:21:22 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.15015067388510928" P_Z="0.8782901596599687" STUDIES="5" TAU2="0.07258436278225718" TOTAL_1="102" TOTAL_2="83" WEIGHT="100.00000000000001" Z="0.1531370996576701">
<NAME>CSA versus other treatments at final follow-up (9-60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.528124807277152" CI_START="0.8368663102584334" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.4027985101854303" LOG_CI_START="-0.07734391519003078" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2011-12-20 10:24:13 +1100" MODIFIED_BY="[Empty name]" ORDER="759" O_E="0.0" SE="0.28203803740888306" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.07954545454545453" WEIGHT="19.683158414770823"/>
<DICH_DATA CI_END="1.4864315243170512" CI_START="0.5912860670819117" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.17214490728718904" LOG_CI_START="-0.22820235448767603" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2011-12-20 10:24:12 +1100" MODIFIED_BY="[Empty name]" ORDER="749" O_E="0.0" SE="0.2351659633174628" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.05530303030303027" WEIGHT="23.414311777194094"/>
<DICH_DATA CI_END="9.524563395988094" CI_START="0.9524394891009575" EFFECT_SIZE="3.011904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9788450768348977" LOG_CI_START="-0.02116260660702521" LOG_EFFECT_SIZE="0.4788412351139363" MODIFIED="2011-12-09 00:04:25 +1100" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.587409463371653" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.3450498776585733" WEIGHT="7.1698989309659735"/>
<DICH_DATA CI_END="2.381367147137342" CI_START="0.12702787151642592" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37682635789272834" LOG_CI_START="-0.8961009789042407" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2011-12-20 10:24:15 +1100" MODIFIED_BY="[Empty name]" ORDER="734" O_E="0.0" SE="0.7477238187264794" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.5590909090909091" WEIGHT="4.74040290542312"/>
<DICH_DATA CI_END="1.3047512408616342" CI_START="0.31037232615967697" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2011-12-20 10:24:14 +1100" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="14.480823362518938"/>
<DICH_DATA CI_END="1.3539601407751651" CI_START="0.3102720747062478" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.13160587934454637" LOG_CI_START="-0.5082573102899322" LOG_EFFECT_SIZE="-0.1883257154726929" MODIFIED="2011-12-20 10:24:14 +1100" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.0" SE="0.3758588049651641" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.14126984126984127" WEIGHT="14.002040817219624"/>
<DICH_DATA CI_END="2.481415659234841" CI_START="0.6810628415721054" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3946995185615963" LOG_CI_START="-0.16681281394792277" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2011-12-20 10:24:14 +1100" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.3298351236469651" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.10879120879120877" WEIGHT="16.509363791907447"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.381367147137342" CI_START="0.12702787151642592" DF="0" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-006.08.02" LOG_CI_END="0.37682635789272834" LOG_CI_START="-0.8961009789042407" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2014-04-10 18:21:27 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.4239758978383188" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="0.7995425393480902">
<NAME>CSA versus placebo/no treatment at final follow-up (21 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.381367147137342" CI_START="0.12702787151642592" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37682635789272834" LOG_CI_START="-0.8961009789042407" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2011-11-22 01:52:39 +1100" MODIFIED_BY="[Empty name]" ORDER="734" O_E="0.0" SE="0.7477238187264794" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.5590909090909091" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.381367147137342" CI_START="0.12702787151642592" DF="0" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-006.08.03" LOG_CI_END="0.37682635789272834" LOG_CI_START="-0.8961009789042407" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2014-04-10 18:21:32 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.4239758978383188" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="0.7995425393480902">
<NAME>CSA versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="2.381367147137342" CI_START="0.12702787151642592" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37682635789272834" LOG_CI_START="-0.8961009789042407" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2011-11-22 01:52:45 +1100" MODIFIED_BY="[Empty name]" ORDER="735" O_E="0.0" SE="0.7477238187264794" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.5590909090909091" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4864315243170512" CI_START="0.5912860670819117" DF="0" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-006.08.04" LOG_CI_END="0.17214490728718904" LOG_CI_START="-0.22820235448767603" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2014-04-10 18:21:37 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.783747898715015" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="100.0" Z="0.27443818921383306">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.4864315243170512" CI_START="0.5912860670819117" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.17214490728718904" LOG_CI_START="-0.22820235448767603" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2011-11-22 03:30:42 +1100" MODIFIED_BY="[Empty name]" ORDER="749" O_E="0.0" SE="0.2351659633174628" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.05530303030303027" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4864315243170512" CI_START="0.5912860670819117" DF="0" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-006.08.05" LOG_CI_END="0.17214490728718904" LOG_CI_START="-0.22820235448767603" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2014-04-10 18:21:43 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.783747898715015" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="100.0" Z="0.27443818921383306">
<NAME>CSA+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="1.4864315243170512" CI_START="0.5912860670819117" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.17214490728718904" LOG_CI_START="-0.22820235448767603" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2011-11-22 03:30:50 +1100" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.2351659633174628" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.05530303030303027" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3047512408616342" CI_START="0.31037232615967697" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-006.08.06" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2014-04-10 18:21:48 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.2172726787339797" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.2338128358563585">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.3047512408616342" CI_START="0.31037232615967697" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2011-12-20 03:32:57 +1100" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3047512408616342" CI_START="0.31037232615967697" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-006.08.07" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2014-04-10 18:21:54 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.2172726787339797" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.2338128358563585">
<NAME>CSA+steroids versus ACEi/ARB at 9 months</NAME>
<DICH_DATA CI_END="1.3047512408616342" CI_START="0.31037232615967697" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2011-12-20 03:33:00 +1100" MODIFIED_BY="[Empty name]" ORDER="396" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.524563395988094" CI_START="0.9524394891009575" DF="0" EFFECT_SIZE="3.011904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-006.08.08" LOG_CI_END="0.9788450768348977" LOG_CI_START="-0.02116260660702521" LOG_EFFECT_SIZE="0.4788412351139363" MODIFIED="2014-04-10 18:21:59 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.060516897585457106" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="1.8770087283844294">
<NAME>CSA+steroids versus steroids at final follow-up (18 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="9.524563395988094" CI_START="0.9524394891009575" EFFECT_SIZE="3.011904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9788450768348977" LOG_CI_START="-0.02116260660702521" LOG_EFFECT_SIZE="0.4788412351139363" MODIFIED="2011-11-22 07:34:21 +1100" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.587409463371653" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.3450498776585733" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.711706421991934" CI_START="1.5434327175703844" DF="0" EFFECT_SIZE="3.45" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" I2="0.0" ID="CMP-006.08.09" LOG_CI_END="0.8871504879933513" LOG_CI_START="0.1884877021531968" LOG_EFFECT_SIZE="0.5378190950732742" MODIFIED="2014-04-10 18:22:05 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.002548724631619106" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="99.99999999999999" Z="3.0174959305266533">
<NAME>CSA+steroids versus steroids at 6 months</NAME>
<DICH_DATA CI_END="7.711706421991934" CI_START="1.5434327175703844" EFFECT_SIZE="3.45" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.8871504879933513" LOG_CI_START="0.1884877021531968" LOG_EFFECT_SIZE="0.5378190950732742" MODIFIED="2011-11-22 07:34:29 +1100" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="0.41039797883907364" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.1684265010351967" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.994045193999117" CI_START="1.1524611302746577" DF="0" EFFECT_SIZE="3.5595238095238098" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="0.0" ID="CMP-006.08.10" LOG_CI_END="1.041157517918423" LOG_CI_START="0.061626286606673054" LOG_EFFECT_SIZE="0.551391902262548" MODIFIED="2014-04-10 18:22:10 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.02734323594150315" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.00000000000001" Z="2.2065825677745496">
<NAME>CSA+steroids versus steroids at 12 months</NAME>
<DICH_DATA CI_END="10.994045193999117" CI_START="1.1524611302746577" EFFECT_SIZE="3.5595238095238093" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.041157517918423" LOG_CI_START="0.061626286606673054" LOG_EFFECT_SIZE="0.551391902262548" MODIFIED="2011-11-22 07:34:40 +1100" MODIFIED_BY="[Empty name]" ORDER="432" O_E="0.0" SE="0.5753814940303167" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.33106386367255936" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.524563395988094" CI_START="0.9524394891009575" DF="0" EFFECT_SIZE="3.011904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-006.08.11" LOG_CI_END="0.9788450768348977" LOG_CI_START="-0.02116260660702521" LOG_EFFECT_SIZE="0.4788412351139363" MODIFIED="2014-04-10 18:22:15 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.060516897585457106" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="1.8770087283844294">
<NAME>CSA+steroids versus steroids at 18 months</NAME>
<DICH_DATA CI_END="9.524563395988094" CI_START="0.9524394891009575" EFFECT_SIZE="3.011904761904762" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9788450768348977" LOG_CI_START="-0.02116260660702521" LOG_EFFECT_SIZE="0.4788412351139363" MODIFIED="2011-11-22 07:34:47 +1100" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.587409463371653" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.3450498776585733" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9590181798453767" CI_END="2.219572808611553" CI_START="0.4584532982832371" DF="1" EFFECT_SIZE="1.008746982591648" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" I2="66.20500655213093" ID="CMP-006.08.12" LOG_CI_END="0.346269395750034" LOG_CI_START="-0.3387048984474147" LOG_EFFECT_SIZE="0.003782248651309619" MODIFIED="2014-04-10 18:22:20 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.08539995343530582" P_Z="0.9827312842301728" STUDIES="2" TAU2="0.21629058944504967" TOTAL_1="27" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.021644815579036154">
<NAME>CSA+steroids versus alkylating agents+steroids at final follow-up (9-60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.528124807277152" CI_START="0.8368663102584334" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.4027985101854303" LOG_CI_START="-0.07734391519003078" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2011-11-22 03:38:39 +1100" MODIFIED_BY="[Empty name]" ORDER="759" O_E="0.0" SE="0.28203803740888306" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.07954545454545453" WEIGHT="54.72334861863291"/>
<DICH_DATA CI_END="1.3539601407751651" CI_START="0.3102720747062478" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.13160587934454637" LOG_CI_START="-0.5082573102899322" LOG_EFFECT_SIZE="-0.1883257154726929" MODIFIED="2011-12-20 03:38:24 +1100" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.0" SE="0.3758588049651641" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.14126984126984127" WEIGHT="45.2766513813671"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3539601407751651" CI_START="0.3102720747062478" DF="0" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-006.08.13" LOG_CI_END="0.13160587934454637" LOG_CI_START="-0.5082573102899322" LOG_EFFECT_SIZE="-0.1883257154726929" MODIFIED="2014-04-10 18:22:26 +1000" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="1.0" P_Z="0.24861482165908655" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0" Z="1.1537204379582158">
<NAME>CSA+steroids versus alkylating agents+steroids at 9 months</NAME>
<DICH_DATA CI_END="1.3539601407751651" CI_START="0.3102720747062478" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.13160587934454637" LOG_CI_START="-0.5082573102899322" LOG_EFFECT_SIZE="-0.1883257154726929" MODIFIED="2011-12-20 03:38:33 +1100" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.3758588049651641" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.14126984126984127" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.528124807277152" CI_START="0.8368663102584334" DF="0" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" I2="0.0" ID="CMP-006.08.14" LOG_CI_END="0.4027985101854303" LOG_CI_START="-0.07734391519003078" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2014-04-10 18:22:32 +1000" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="1.0" P_Z="0.18400605788549573" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="16" WEIGHT="100.0" Z="1.328520978530995">
<NAME>CSA+steroids versus alkylating agents+steroids at 60 months</NAME>
<DICH_DATA CI_END="2.528124807277152" CI_START="0.8368663102584334" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.4027985101854303" LOG_CI_START="-0.07734391519003078" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2011-11-22 04:21:05 +1100" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.28203803740888306" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.07954545454545453" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.481415659234841" CI_START="0.6810628415721054" DF="0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-006.08.15" LOG_CI_END="0.3946995185615963" LOG_CI_START="-0.16681281394792277" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2014-04-10 18:22:37 +1000" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="1.0" P_Z="0.4263572301208953" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="99.99999999999999" Z="0.7954406479411494">
<NAME>CSA+steroids versus azathioprine+steroids at final follow-up (36 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.481415659234841" CI_START="0.6810628415721054" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3946995185615963" LOG_CI_START="-0.16681281394792277" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2011-11-22 10:28:01 +1100" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.3298351236469651" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.10879120879120877" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.145253849528928" CI_START="0.3048874743906186" DF="0" EFFECT_SIZE="0.5909090909090909" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-006.08.16" LOG_CI_END="0.05890176023974889" LOG_CI_START="-0.5158604172704877" LOG_EFFECT_SIZE="-0.22847932851536945" MODIFIED="2014-04-10 18:22:43 +1000" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="1.0" P_Z="0.11917426569191436" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.5582488640496668">
<NAME>CSA+steroids versus azathioprine+steroids at 6 months</NAME>
<DICH_DATA CI_END="1.145253849528928" CI_START="0.3048874743906186" EFFECT_SIZE="0.5909090909090909" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.05890176023974889" LOG_CI_START="-0.5158604172704877" LOG_EFFECT_SIZE="-0.22847932851536945" MODIFIED="2011-11-22 10:28:01 +1100" MODIFIED_BY="[Empty name]" ORDER="484" O_E="0.0" SE="0.33761814818817715" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.11398601398601396" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0265947366591266" CI_START="0.2858019501761775" DF="0" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" ID="CMP-006.08.17" LOG_CI_END="0.011399033307017994" LOG_CI_START="-0.5439348121165566" LOG_EFFECT_SIZE="-0.2662678894047693" MODIFIED="2014-04-10 18:22:48 +1000" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="1.0" P_Z="0.0601760116943417" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.8795017727572054">
<NAME>CSA+steroids versus azathioprine+steroids at 12 months</NAME>
<DICH_DATA CI_END="1.0265947366591266" CI_START="0.2858019501761775" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.011399033307017994" LOG_CI_START="-0.5439348121165566" LOG_EFFECT_SIZE="-0.2662678894047693" MODIFIED="2011-11-22 10:28:01 +1100" MODIFIED_BY="[Empty name]" ORDER="485" O_E="0.0" SE="0.32620584974867695" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.10641025641025639" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.226619947206592" CI_START="0.6123421625595056" DF="0" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-006.08.18" LOG_CI_END="0.08871002287496484" LOG_CI_START="-0.2130058363726538" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2014-04-10 18:22:53 +1000" MODIFIED_BY="Narelle S Willis" NO="18" P_CHI2="1.0" P_Z="0.4194171131828949" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.807432922127711">
<NAME>CSA+steroids versus azathioprine+steroids at 18 months</NAME>
<DICH_DATA CI_END="1.226619947206592" CI_START="0.6123421625595056" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.08871002287496484" LOG_CI_START="-0.2130058363726538" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2011-11-22 10:28:01 +1100" MODIFIED_BY="[Empty name]" ORDER="486" O_E="0.0" SE="0.17722938923964157" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.03141025641025638" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.226619947206592" CI_START="0.6123421625595056" DF="0" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-006.08.19" LOG_CI_END="0.08871002287496484" LOG_CI_START="-0.2130058363726538" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2014-04-10 18:23:11 +1000" MODIFIED_BY="Narelle S Willis" NO="19" P_CHI2="1.0" P_Z="0.4194171131828949" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.807432922127711">
<NAME>CSA+steroids versus azathioprine+steroids at 24 months</NAME>
<DICH_DATA CI_END="1.226619947206592" CI_START="0.6123421625595056" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.08871002287496484" LOG_CI_START="-0.2130058363726538" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2011-11-22 10:28:01 +1100" MODIFIED_BY="[Empty name]" ORDER="487" O_E="0.0" SE="0.17722938923964157" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.03141025641025638" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2082410741597984" CI_START="0.7653149919978818" DF="0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-006.08.20" LOG_CI_END="0.34404648366867174" LOG_CI_START="-0.11615977905499822" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2014-04-10 18:23:15 +1000" MODIFIED_BY="Narelle S Willis" NO="20" P_CHI2="1.0" P_Z="0.33177616702234214" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.9705424931744311">
<NAME>CSA+steroids versus azathioprine+steroids at 30 months</NAME>
<DICH_DATA CI_END="2.2082410741597984" CI_START="0.7653149919978818" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.34404648366867174" LOG_CI_START="-0.11615977905499822" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2011-11-22 10:28:01 +1100" MODIFIED_BY="[Empty name]" ORDER="488" O_E="0.0" SE="0.2703274367816243" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.07307692307692307" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.481415659234841" CI_START="0.6810628415721054" DF="0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-006.08.21" LOG_CI_END="0.3946995185615963" LOG_CI_START="-0.16681281394792277" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2014-04-10 18:23:20 +1000" MODIFIED_BY="Narelle S Willis" NO="21" P_CHI2="1.0" P_Z="0.4263572301208953" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="99.99999999999999" Z="0.7954406479411494">
<NAME>CSA+steroids versus azathioprine+steroids at 36 months</NAME>
<DICH_DATA CI_END="2.481415659234841" CI_START="0.6810628415721054" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3946995185615963" LOG_CI_START="-0.16681281394792277" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2011-11-22 10:28:01 +1100" MODIFIED_BY="[Empty name]" ORDER="489" O_E="0.0" SE="0.3298351236469651" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.10879120879120877" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.339712753728406" CI_END="1.658887126406349" CI_START="0.8438085272379002" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1831242973529257" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="0.21981683687031986" LOG_CI_START="-0.07375609010173963" LOG_EFFECT_SIZE="0.07303037338429016" METHOD="IV" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.992997426112782" P_Q="0.9829958423478138" P_Z="0.3294923537798895" Q="7.682636962384889" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="412" TOTAL_2="360" WEIGHT="1900.0" Z="0.9751369316445457">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CSA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.172889686158492" CI_END="2.0259048123915884" CI_START="0.5187337528342795" DF="5" EFFECT_SIZE="1.0251366768470025" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="0.30661903607646523" LOG_CI_START="-0.28505549252547696" LOG_EFFECT_SIZE="0.010781771775494161" MODIFIED="2014-04-10 18:23:30 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8247421764047905" P_Z="0.9430549191165376" STUDIES="5" TAU2="0.0" TOTAL_1="102" TOTAL_2="83" WEIGHT="100.0" Z="0.07143077265614664">
<NAME>CSA versus other treatments at final follow-up (9-60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="5.444471073244248" CI_START="0.2869883922569798" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.7359556947200622" LOG_CI_START="-0.5421356687039494" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2011-12-20 10:24:33 +1100" MODIFIED_BY="[Empty name]" ORDER="751" O_E="0.0" SE="0.7507571935295483" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.5636363636363636" WEIGHT="21.430975833965174"/>
<DICH_DATA CI_END="2.860418492619916" CI_START="0.2889249538569359" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.45642957709391396" LOG_CI_START="-0.5392149474103641" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-12-20 10:24:32 +1100" MODIFIED_BY="[Empty name]" ORDER="761" O_E="0.0" SE="0.5848465222136954" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.34204545454545454" WEIGHT="35.31483061012201"/>
<DICH_DATA CI_END="16.990722616248398" CI_START="0.1588501944735225" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-12-07 10:01:30 +1100" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="1.1919762805593697" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="1.420807453416149" WEIGHT="8.501698987566431"/>
<DICH_DATA CI_END="8.025911702882953" CI_START="0.01647556188677972" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2011-12-20 10:24:34 +1100" MODIFIED_BY="[Empty name]" ORDER="736" O_E="0.0" SE="1.5787413475374117" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="2.492424242424242" WEIGHT="4.846396966708234"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-20 10:24:33 +1100" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.980451244520187" CI_START="0.05368314623303219" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.47428202185110857" LOG_CI_START="-1.2701620391951838" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2011-12-20 10:24:33 +1100" MODIFIED_BY="[Empty name]" ORDER="412" O_E="0.0" SE="1.02469507659596" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="1.05" WEIGHT="11.504073607842775"/>
<DICH_DATA CI_END="9.54269099606334" CI_START="0.39847250650457505" EFFECT_SIZE="1.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9796708610713606" LOG_CI_START="-0.3996016383463247" LOG_EFFECT_SIZE="0.290034611362518" MODIFIED="2011-12-20 10:24:34 +1100" MODIFIED_BY="[Empty name]" ORDER="469" O_E="0.0" SE="0.8101914936669332" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.6564102564102563" WEIGHT="18.402023993795382"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.025911702882953" CI_START="0.01647556188677972" DF="0" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.09.02" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2014-04-10 18:23:36 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.5216759098125796" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="0.6407641842385507">
<NAME>CSA versus placebo/no treatment at final follow-up (21 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="8.025911702882953" CI_START="0.01647556188677972" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2011-11-22 01:52:58 +1100" MODIFIED_BY="[Empty name]" ORDER="736" O_E="0.0" SE="1.5787413475374117" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="2.492424242424242" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.025911702882953" CI_START="0.01647556188677972" DF="0" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.09.03" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2014-04-10 18:23:42 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.5216759098125796" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="0.6407641842385507">
<NAME>CSA versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="8.025911702882953" CI_START="0.01647556188677972" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9044943775306834" LOG_CI_START="-1.7831597651912088" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2011-11-22 01:53:02 +1100" MODIFIED_BY="[Empty name]" ORDER="737" O_E="0.0" SE="1.5787413475374117" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="2.492424242424242" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.444471073244248" CI_START="0.2869883922569798" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-006.09.04" LOG_CI_END="0.7359556947200622" LOG_CI_START="-0.5421356687039494" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2014-04-10 18:23:47 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.766294996840361" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="100.0" Z="0.29722465963348416">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="5.444471073244248" CI_START="0.2869883922569798" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.7359556947200622" LOG_CI_START="-0.5421356687039494" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2011-11-22 03:31:18 +1100" MODIFIED_BY="[Empty name]" ORDER="751" O_E="0.0" SE="0.7507571935295483" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.5636363636363636" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.444471073244248" CI_START="0.2869883922569798" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-006.09.05" LOG_CI_END="0.7359556947200622" LOG_CI_START="-0.5421356687039494" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2014-04-10 18:23:53 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.766294996840361" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="100.0" Z="0.29722465963348416">
<NAME>CSA+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="5.444471073244248" CI_START="0.2869883922569798" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.7359556947200622" LOG_CI_START="-0.5421356687039494" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2011-11-22 03:31:22 +1100" MODIFIED_BY="[Empty name]" ORDER="752" O_E="0.0" SE="0.7507571935295483" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.5636363636363636" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.09.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:23:58 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 04:08:07 +1100" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.09.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:24:04 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB at 9 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 04:08:11 +1100" MODIFIED_BY="[Empty name]" ORDER="398" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.990722616248398" CI_START="0.1588501944735225" DF="0" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.09.08" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2014-04-10 18:24:09 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.6770572015743272" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="0.4164821854348675">
<NAME>CSA+steroids versus steroids at final follow-up (18 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="16.990722616248398" CI_START="0.1588501944735225" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-11-22 07:35:16 +1100" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="1.1919762805593697" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="1.420807453416149" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.990722616248398" CI_START="0.1588501944735225" DF="0" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.09.09" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2014-04-10 18:24:15 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.6770572015743272" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="0.4164821854348675">
<NAME>CSA+steroids versus steroids at 6 months</NAME>
<DICH_DATA CI_END="16.990722616248398" CI_START="0.1588501944735225" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-11-22 07:35:23 +1100" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="1.1919762805593697" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="1.420807453416149" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.990722616248398" CI_START="0.1588501944735225" DF="0" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.09.10" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2014-04-10 18:24:19 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.6770572015743272" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="0.4164821854348675">
<NAME>CSA+steroids versus steroids at 12 months</NAME>
<DICH_DATA CI_END="16.990722616248398" CI_START="0.1588501944735225" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-11-22 07:35:28 +1100" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="1.1919762805593697" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="1.420807453416149" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.990722616248398" CI_START="0.1588501944735225" DF="0" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.09.11" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2014-04-10 18:24:24 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.6770572015743272" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="0.4164821854348675">
<NAME>CSA+steroids versus steroids at 18 months</NAME>
<DICH_DATA CI_END="16.990722616248398" CI_START="0.1588501944735225" EFFECT_SIZE="1.6428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2302118498269945" LOG_CI_START="-0.7990122491482848" LOG_EFFECT_SIZE="0.21559980033935483" MODIFIED="2011-11-22 07:35:31 +1100" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="1.1919762805593697" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="1.420807453416149" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4841861051850262" CI_END="2.0107371667285943" CI_START="0.2745628550952533" DF="1" EFFECT_SIZE="0.7430166467469913" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-006.09.12" LOG_CI_END="0.3033553055547402" LOG_CI_START="-0.561358217712264" LOG_EFFECT_SIZE="-0.12900145607876184" MODIFIED="2014-04-10 18:24:29 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.4865323194449227" P_Z="0.5586884697853165" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="20" WEIGHT="100.0" Z="0.5847906874691681">
<NAME>CSA+steroids versus alkylating agents+steroids at final follow-up (9-60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.860418492619916" CI_START="0.2889249538569359" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.45642957709391396" LOG_CI_START="-0.5392149474103641" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-11-22 03:39:12 +1100" MODIFIED_BY="[Empty name]" ORDER="761" O_E="0.0" SE="0.5848465222136954" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.34204545454545454" WEIGHT="75.42857142857143"/>
<DICH_DATA CI_END="2.980451244520187" CI_START="0.05368314623303219" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.47428202185110857" LOG_CI_START="-1.2701620391951838" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2011-11-22 04:24:09 +1100" MODIFIED_BY="[Empty name]" ORDER="412" O_E="0.0" SE="1.02469507659596" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="1.05" WEIGHT="24.57142857142857"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.980451244520187" CI_START="0.05368314623303219" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-006.09.13" LOG_CI_END="0.47428202185110857" LOG_CI_START="-1.2701620391951838" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="1.0" P_Z="0.37121051979598385" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0" Z="0.8942081920780527">
<NAME>CSA+steroids versus alkylating agents+steroids at 9 months</NAME>
<DICH_DATA CI_END="2.980451244520187" CI_START="0.05368314623303219" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.47428202185110857" LOG_CI_START="-1.2701620391951838" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2011-11-22 04:24:11 +1100" MODIFIED_BY="[Empty name]" ORDER="411" O_E="0.0" SE="1.02469507659596" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="1.05" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.860418492619916" CI_START="0.2889249538569359" DF="0" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-006.09.14" LOG_CI_END="0.45642957709391396" LOG_CI_START="-0.5392149474103641" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="1.0" P_Z="0.8705450952054241" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="16" WEIGHT="100.0" Z="0.16296613929337822">
<NAME>CSA+steroids versus alkylating agents+steroids at 60 months</NAME>
<DICH_DATA CI_END="2.860418492619916" CI_START="0.2889249538569359" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.45642957709391396" LOG_CI_START="-0.5392149474103641" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-11-22 03:39:15 +1100" MODIFIED_BY="[Empty name]" ORDER="762" O_E="0.0" SE="0.5848465222136954" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.34204545454545454" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.54269099606334" CI_START="0.39847250650457505" DF="0" EFFECT_SIZE="1.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-006.09.15" LOG_CI_END="0.9796708610713606" LOG_CI_START="-0.3996016383463247" LOG_EFFECT_SIZE="0.290034611362518" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="1.0" P_Z="0.40977717259401625" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.8242858358744972">
<NAME>CSA+steroids versus azathioprine+steroids at final follow-up (36 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="9.54269099606334" CI_START="0.39847250650457505" EFFECT_SIZE="1.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9796708610713606" LOG_CI_START="-0.3996016383463247" LOG_EFFECT_SIZE="0.290034611362518" MODIFIED="2011-11-22 10:28:17 +1100" MODIFIED_BY="[Empty name]" ORDER="469" O_E="0.0" SE="0.8101914936669332" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.6564102564102563" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.432930996661408" CI_START="0.01908013899293761" DF="0" EFFECT_SIZE="0.42424242424242425" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.09.16" LOG_CI_END="0.9746466575195244" LOG_CI_START="-1.719418465918823" LOG_EFFECT_SIZE="-0.37238590419964945" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="1.0" P_Z="0.587935467611872" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.5418302284023451">
<NAME>CSA+steroids versus azathioprine+steroids at 6 months</NAME>
<DICH_DATA CI_END="9.432930996661408" CI_START="0.01908013899293761" EFFECT_SIZE="0.42424242424242425" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9746466575195244" LOG_CI_START="-1.719418465918823" LOG_EFFECT_SIZE="-0.37238590419964945" MODIFIED="2011-11-22 10:28:25 +1100" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="1.582507189345124" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="2.504329004329004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="84.89637896995265" CI_START="0.17172125093643845" DF="0" EFFECT_SIZE="3.818181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.09.17" LOG_CI_END="1.928889166958849" LOG_CI_START="-0.7651759564794982" LOG_EFFECT_SIZE="0.5818566052396754" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="1.0" P_Z="0.3972097512805576" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.8466150135086752">
<NAME>CSA+steroids versus azathioprine+steroids at 12 months</NAME>
<DICH_DATA CI_END="84.89637896995265" CI_START="0.17172125093643845" EFFECT_SIZE="3.8181818181818183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.928889166958849" LOG_CI_START="-0.7651759564794982" LOG_EFFECT_SIZE="0.5818566052396754" MODIFIED="2011-11-22 10:28:29 +1100" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="1.582507189345124" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="2.504329004329004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.150837199637826E-32" CI_END="11.464328315997202" CI_START="0.589655129691913" DF="0" EFFECT_SIZE="2.6000000000000005" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="100.0" ID="CMP-006.09.18" LOG_CI_END="1.0593486149140783" LOG_CI_START="-0.22940191897244236" LOG_EFFECT_SIZE="0.41497334797081803" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="18" P_CHI2="0.0" P_Z="0.2068755390692718" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.2622036541300519">
<NAME>CSA+steroids versus azathioprine+steroids at 18 months</NAME>
<DICH_DATA CI_END="11.464328315997202" CI_START="0.589655129691913" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0593486149140783" LOG_CI_START="-0.22940191897244236" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2011-11-22 10:28:33 +1100" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="0.7570184430229709" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.573076923076923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.960637396583685" CI_START="0.426698995837826" DF="0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-006.09.19" LOG_CI_END="0.5977650837899936" LOG_CI_START="-0.3698783791763201" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="19" P_CHI2="1.0" P_Z="0.6443789357894749" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.4615850266058864">
<NAME>CSA+steroids versus azathioprine+steroids at 24 months</NAME>
<DICH_DATA CI_END="3.960637396583685" CI_START="0.426698995837826" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5977650837899936" LOG_CI_START="-0.3698783791763201" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2011-11-22 10:28:41 +1100" MODIFIED_BY="[Empty name]" ORDER="473" O_E="0.0" SE="0.5683985600588051" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.3230769230769231" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.150837199637826E-32" CI_END="11.464328315997202" CI_START="0.589655129691913" DF="0" EFFECT_SIZE="2.6000000000000005" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="100.0" ID="CMP-006.09.20" LOG_CI_END="1.0593486149140783" LOG_CI_START="-0.22940191897244236" LOG_EFFECT_SIZE="0.41497334797081803" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="20" P_CHI2="0.0" P_Z="0.2068755390692718" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.2622036541300519">
<NAME>CSA+steroids versus azathioprine+steroids at 30 months</NAME>
<DICH_DATA CI_END="11.464328315997202" CI_START="0.589655129691913" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0593486149140783" LOG_CI_START="-0.22940191897244236" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2011-11-22 10:28:47 +1100" MODIFIED_BY="[Empty name]" ORDER="474" O_E="0.0" SE="0.7570184430229709" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.573076923076923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.54269099606334" CI_START="0.39847250650457505" DF="0" EFFECT_SIZE="1.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-006.09.21" LOG_CI_END="0.9796708610713606" LOG_CI_START="-0.3996016383463247" LOG_EFFECT_SIZE="0.290034611362518" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="21" P_CHI2="1.0" P_Z="0.40977717259401625" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.8242858358744972">
<NAME>CSA+steroids versus azathioprine+steroids at 36 months</NAME>
<DICH_DATA CI_END="9.54269099606334" CI_START="0.39847250650457505" EFFECT_SIZE="1.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9796708610713606" LOG_CI_START="-0.3996016383463247" LOG_EFFECT_SIZE="0.290034611362518" MODIFIED="2011-11-22 10:28:50 +1100" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.8101914936669332" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.6564102564102563" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="41.942812461676134" CI_END="1.015901321252791" CI_START="0.6927976789664305" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8389362773315168" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="133" I2="35.62663442116486" I2_Q="40.516335841161485" ID="CMP-006.10" LOG_CI_END="0.006851525155872663" LOG_CI_START="-0.1593935759759293" LOG_EFFECT_SIZE="-0.07627102541002834" METHOD="IV" MODIFIED="2014-04-10 18:25:28 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.033345085061402435" P_Q="0.02879337528514969" P_Z="0.07211198931269253" Q="33.62267654963931" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.14218427904597428" TOTALS="SUB" TOTAL_1="412" TOTAL_2="360" WEIGHT="2100.0" Z="1.7984104415693778">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CSA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.951585429072328" CI_END="1.3107678530822353" CI_START="0.5433002752743894" DF="6" EFFECT_SIZE="0.843884195491537" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" I2="13.68875400844084" ID="CMP-006.10.01" LOG_CI_END="0.11752578165739697" LOG_CI_START="-0.2649600749218874" LOG_EFFECT_SIZE="-0.07371714663224527" MODIFIED="2014-04-10 18:25:17 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.32534795666784366" P_Z="0.44995242524136114" STUDIES="5" TAU2="0.04908669068346828" TOTAL_1="102" TOTAL_2="83" WEIGHT="100.0" Z="0.7554943533568766">
<NAME>CSA versus other treatments at final follow-up (9-60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.4766815053770737" CI_START="0.02238658175056376" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.1692868356146957" LOG_CI_START="-1.6500122146031835" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2011-12-09 00:05:15 +1100" MODIFIED_BY="[Empty name]" ORDER="763" O_E="0.0" SE="1.0686652677735224" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="1.1420454545454546" WEIGHT="4.237854287876261"/>
<DICH_DATA CI_END="1.6907575092527263" CI_START="0.4107297709127858" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.22808132495722366" LOG_CI_START="-0.3864438170524732" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2011-12-09 00:05:16 +1100" MODIFIED_BY="[Empty name]" ORDER="753" O_E="0.0" SE="0.3609751103650088" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.13030303030303028" WEIGHT="28.138983891198297"/>
<DICH_DATA CI_END="15.437856153115133" CI_START="0.8850700542974264" EFFECT_SIZE="3.6964285714285716" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.1885869899429093" LOG_CI_START="-0.05302235304147472" LOG_EFFECT_SIZE="0.5677823184507174" MODIFIED="2011-12-07 10:04:16 +1100" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="0.7293274741343975" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.5319185645272603" WEIGHT="8.688121878096963"/>
<DICH_DATA CI_END="3.52818330812873" CI_START="0.15242342327814115" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786977" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2011-12-09 00:05:18 +1100" MODIFIED_BY="[Empty name]" ORDER="738" O_E="0.0" SE="0.8015137194235931" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.6424242424242423" WEIGHT="7.299731974446428"/>
<DICH_DATA CI_END="1.3047512408616342" CI_START="0.31037232615967697" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2011-12-20 03:34:29 +1100" MODIFIED_BY="[Empty name]" ORDER="399" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="27.540833953301444"/>
<DICH_DATA CI_END="3.422614190866144" CI_START="0.18699156969194897" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5343579466922945" LOG_CI_START="-0.7281779727084072" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-12-20 03:39:36 +1100" MODIFIED_BY="[Empty name]" ORDER="414" O_E="0.0" SE="0.7416198487095663" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.55" WEIGHT="8.425899869894964"/>
<DICH_DATA CI_END="2.8963010948935803" CI_START="0.373441836522781" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4618437084413986" LOG_CI_START="-0.42777702984383786" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2011-12-09 00:05:18 +1100" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="0.5225676253624243" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.27307692307692305" WEIGHT="15.668574145185639"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.52818330812873" CI_START="0.15242342327814115" DF="0" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-006.10.02" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786977" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2014-04-10 18:25:22 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.6987847323689892" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="0.3869614715102904">
<NAME>CSA versus placebo/no treatment at final follow-up (21 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="3.52818330812873" CI_START="0.15242342327814115" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786977" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2011-11-22 01:53:14 +1100" MODIFIED_BY="[Empty name]" ORDER="738" O_E="0.0" SE="0.8015137194235931" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.6424242424242423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.52818330812873" CI_START="0.15242342327814115" DF="0" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-006.10.03" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786977" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2014-04-10 18:25:28 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.6987847323689892" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="0.3869614715102904">
<NAME>CSA versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="3.52818330812873" CI_START="0.15242342327814115" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5475511409837852" LOG_CI_START="-0.8169482887786977" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2011-11-22 01:53:18 +1100" MODIFIED_BY="[Empty name]" ORDER="739" O_E="0.0" SE="0.8015137194235931" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="0.6424242424242423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6907575092527263" CI_START="0.4107297709127858" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-006.10.04" LOG_CI_END="0.22808132495722366" LOG_CI_START="-0.3864438170524732" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.6135021673106729" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="100.0" Z="0.5050806871686963">
<NAME>CSA+steroids versus placebo/no treatment at final follow-up (60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.6907575092527263" CI_START="0.4107297709127858" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.22808132495722366" LOG_CI_START="-0.3864438170524732" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2011-11-22 03:31:42 +1100" MODIFIED_BY="[Empty name]" ORDER="753" O_E="0.0" SE="0.3609751103650088" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.13030303030303028" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6907575092527263" CI_START="0.4107297709127858" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-006.10.05" LOG_CI_END="0.22808132495722366" LOG_CI_START="-0.3864438170524732" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.6135021673106729" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="100.0" Z="0.5050806871686963">
<NAME>CSA+steroids versus placebo/no treatment at 60 months</NAME>
<DICH_DATA CI_END="1.6907575092527263" CI_START="0.4107297709127858" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.22808132495722366" LOG_CI_START="-0.3864438170524732" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2011-11-22 03:31:48 +1100" MODIFIED_BY="[Empty name]" ORDER="754" O_E="0.0" SE="0.3609751103650088" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.13030303030303028" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3047512408616342" CI_START="0.31037232615967697" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-006.10.06" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.2172726787339797" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.2338128358563585">
<NAME>CSA+steroids versus ACEi/ARB at final follow-up (9 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.3047512408616342" CI_START="0.31037232615967697" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2011-12-20 03:34:39 +1100" MODIFIED_BY="[Empty name]" ORDER="399" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3047512408616342" CI_START="0.31037232615967697" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-006.10.07" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.2172726787339797" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.2338128358563585">
<NAME>CSA+steroids versus ACEi/ARB at 9 months</NAME>
<DICH_DATA CI_END="1.3047512408616342" CI_START="0.31037232615967697" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.11552771855612748" LOG_CI_START="-0.508117008844064" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2011-12-20 03:34:35 +1100" MODIFIED_BY="[Empty name]" ORDER="400" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.437856153115133" CI_START="0.8850700542974264" DF="0" EFFECT_SIZE="3.696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-006.10.08" LOG_CI_END="1.1885869899429093" LOG_CI_START="-0.05302235304147472" LOG_EFFECT_SIZE="0.5677823184507174" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.07304246343206497" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="1.7925652726600885">
<NAME>CSA+steroids versus steroids at final follow-up (18 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="15.437856153115133" CI_START="0.8850700542974264" EFFECT_SIZE="3.6964285714285716" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.1885869899429093" LOG_CI_START="-0.05302235304147472" LOG_EFFECT_SIZE="0.5677823184507174" MODIFIED="2011-11-22 07:36:04 +1100" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="0.7293274741343975" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.5319185645272603" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.854185867980936" CI_START="1.5449202972384537" DF="0" EFFECT_SIZE="3.901785714285714" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" I2="0.0" ID="CMP-006.10.09" LOG_CI_END="0.9936207496049346" LOG_CI_START="0.18890607899554568" LOG_EFFECT_SIZE="0.5912634143002402" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.003974687191440783" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="2.8801637144929533">
<NAME>CSA+steroids versus steroids at 6 months</NAME>
<DICH_DATA CI_END="9.854185867980936" CI_START="1.5449202972384537" EFFECT_SIZE="3.9017857142857144" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" LOG_CI_END="0.9936207496049346" LOG_CI_START="0.18890607899554568" LOG_EFFECT_SIZE="0.5912634143002402" MODIFIED="2011-11-22 07:36:11 +1100" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.47269338091781815" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.2234390323635175" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.634983883768357E-32" CI_END="18.358369935501095" CI_START="1.1118107563457924" DF="0" EFFECT_SIZE="4.517857142857144" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="100.0" ID="CMP-006.10.10" LOG_CI_END="1.2638341169825966" LOG_CI_START="0.04603087135663896" LOG_EFFECT_SIZE="0.6549324941696176" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Z="0.03501970027426025" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="2.1081305300966573">
<NAME>CSA+steroids versus steroids at 12 months</NAME>
<DICH_DATA CI_END="18.358369935501084" CI_START="1.1118107563457922" EFFECT_SIZE="4.517857142857143" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.2638341169825962" LOG_CI_START="0.04603087135663888" LOG_EFFECT_SIZE="0.6549324941696175" MODIFIED="2011-11-22 07:36:18 +1100" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.7153436547039752" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.51171654432524" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.437856153115133" CI_START="0.8850700542974264" DF="0" EFFECT_SIZE="3.696428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-006.10.11" LOG_CI_END="1.1885869899429093" LOG_CI_START="-0.05302235304147472" LOG_EFFECT_SIZE="0.5677823184507174" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.07304246343206497" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="1.7925652726600885">
<NAME>CSA+steroids versus steroids at 18 months</NAME>
<DICH_DATA CI_END="15.437856153115133" CI_START="0.8850700542974264" EFFECT_SIZE="3.6964285714285716" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.1885869899429093" LOG_CI_START="-0.05302235304147472" LOG_EFFECT_SIZE="0.5677823184507174" MODIFIED="2011-11-22 07:36:22 +1100" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.7293274741343975" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.5319185645272603" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2973363155169808" CI_END="1.88512393194835" CI_START="0.11506159106840526" DF="1" EFFECT_SIZE="0.4657309942135108" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="22.918984997232123" ID="CMP-006.10.12" LOG_CI_END="0.27533990689833404" LOG_CI_START="-0.9390696248572673" LOG_EFFECT_SIZE="-0.33186485897946666" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.254700468697025" P_Z="0.284075510567494" STUDIES="2" TAU2="0.2515532805709003" TOTAL_1="27" TOTAL_2="20" WEIGHT="100.0" Z="1.0712089362373676">
<NAME>CSA+steroids versus alkylating agents+steroids at final follow-up (9-60 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.4766815053770737" CI_START="0.02238658175056376" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.1692868356146957" LOG_CI_START="-1.6500122146031835" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2011-11-22 03:39:40 +1100" MODIFIED_BY="[Empty name]" ORDER="763" O_E="0.0" SE="1.0686652677735224" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="1.1420454545454546" WEIGHT="36.514704897098035"/>
<DICH_DATA CI_END="3.422614190866144" CI_START="0.18699156969194897" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5343579466922945" LOG_CI_START="-0.7281779727084072" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-12-20 03:40:00 +1100" MODIFIED_BY="[Empty name]" ORDER="414" O_E="0.0" SE="0.7416198487095663" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.55" WEIGHT="63.48529510290196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.422614190866144" CI_START="0.18699156969194897" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-006.10.13" LOG_CI_END="0.5343579466922945" LOG_CI_START="-0.7281779727084072" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="1.0" P_Z="0.7635008904758627" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0" Z="0.30088670321119915">
<NAME>CSA+steroids versus alkylating agents+steroids at 9 months</NAME>
<DICH_DATA CI_END="3.422614190866144" CI_START="0.18699156969194897" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5343579466922945" LOG_CI_START="-0.7281779727084072" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-12-20 03:40:04 +1100" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.7416198487095663" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.55" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4766815053770737" CI_START="0.02238658175056376" DF="0" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-006.10.14" LOG_CI_END="0.1692868356146957" LOG_CI_START="-1.6500122146031835" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="1.0" P_Z="0.11066474560454599" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="16" WEIGHT="100.0" Z="1.5952124052746">
<NAME>CSA+steroids versus alkylating agents+steroids at 60 months</NAME>
<DICH_DATA CI_END="1.4766815053770737" CI_START="0.02238658175056376" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.1692868356146957" LOG_CI_START="-1.6500122146031835" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2011-11-22 03:39:42 +1100" MODIFIED_BY="[Empty name]" ORDER="764" O_E="0.0" SE="1.0686652677735224" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="1.1420454545454546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8963010948935803" CI_START="0.373441836522781" DF="0" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-006.10.15" LOG_CI_END="0.4618437084413986" LOG_CI_START="-0.42777702984383786" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="1.0" P_Z="0.940171865071394" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.07505385188391644">
<NAME>CSA+steroids versus azathioprine+steroids at final follow-up (36 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.8963010948935803" CI_START="0.373441836522781" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4618437084413986" LOG_CI_START="-0.42777702984383786" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2011-11-22 10:29:12 +1100" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="0.5225676253624243" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.27307692307692305" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2928097312012719" CI_START="0.3268075647971921" DF="0" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-006.10.16" LOG_CI_END="0.1115346124520989" LOG_CI_START="-0.4857078991663876" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="1.0" P_Z="0.21947693534392188" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.2279202362029005">
<NAME>CSA+steroids versus azathioprine+steroids at 6 months</NAME>
<DICH_DATA CI_END="1.2928097312012719" CI_START="0.3268075647971921" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.1115346124520989" LOG_CI_START="-0.4857078991663876" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2011-11-22 10:29:21 +1100" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="0.3508232077228117" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.12307692307692311" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.880526460968101E-32" CI_END="0.9407225477876044" CI_START="0.19961015946667218" DF="0" EFFECT_SIZE="0.4333333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="100.0" ID="CMP-006.10.17" LOG_CI_END="-0.02653844642645252" LOG_CI_START="-0.6998173583991986" LOG_EFFECT_SIZE="-0.3631779024128256" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="0.0" P_Z="0.03447474443290328" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="2.1144746881326784">
<NAME>CSA+steroids versus azathioprine+steroids at 12 months</NAME>
<DICH_DATA CI_END="0.9407225477876043" CI_START="0.19961015946667213" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.026538446426452568" LOG_CI_START="-0.6998173583991988" LOG_EFFECT_SIZE="-0.36317790241282566" MODIFIED="2011-11-22 10:29:27 +1100" MODIFIED_BY="[Empty name]" ORDER="478" O_E="0.0" SE="0.3954873656771558" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.15641025641025638" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1752346593095415" CI_START="0.23008170994451604" DF="0" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-006.10.18" LOG_CI_END="0.07012459092117296" LOG_CI_START="-0.6381179036515745" LOG_EFFECT_SIZE="-0.28399665636520083" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="18" P_CHI2="1.0" P_Z="0.11598682588055542" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.00000000000001" Z="1.5718436057451721">
<NAME>CSA+steroids versus azathioprine+steroids at 18 months</NAME>
<DICH_DATA CI_END="1.1752346593095415" CI_START="0.23008170994451604" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.07012459092117296" LOG_CI_START="-0.6381179036515745" LOG_EFFECT_SIZE="-0.28399665636520083" MODIFIED="2011-11-22 10:29:33 +1100" MODIFIED_BY="[Empty name]" ORDER="479" O_E="0.0" SE="0.4160251471689218" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.17307692307692304" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5550619668204688" CI_START="0.2716933530718763" DF="0" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-006.10.19" LOG_CI_END="0.191747699672815" LOG_CI_START="-0.5659209863871039" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="19" P_CHI2="1.0" P_Z="0.333082035781191" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.967924607984906">
<NAME>CSA+steroids versus azathioprine+steroids at 24 months</NAME>
<DICH_DATA CI_END="1.5550619668204688" CI_START="0.2716933530718763" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.191747699672815" LOG_CI_START="-0.5659209863871039" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2011-11-22 10:29:40 +1100" MODIFIED_BY="[Empty name]" ORDER="480" O_E="0.0" SE="0.4450583367120799" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.1980769230769231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.26272182649541" CI_START="0.33195026552356227" DF="0" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-006.10.20" LOG_CI_END="0.35463116613159723" LOG_CI_START="-0.47892697962928615" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="20" P_CHI2="1.0" P_Z="0.7700881938980932" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.29225953717026226">
<NAME>CSA+steroids versus azathioprine+steroids at 30 months</NAME>
<DICH_DATA CI_END="2.26272182649541" CI_START="0.33195026552356227" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.35463116613159723" LOG_CI_START="-0.47892697962928615" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2011-11-22 10:29:45 +1100" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.48963618099931067" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.23974358974358972" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8963010948935803" CI_START="0.373441836522781" DF="0" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-006.10.21" LOG_CI_END="0.4618437084413986" LOG_CI_START="-0.42777702984383786" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="21" P_CHI2="1.0" P_Z="0.940171865071394" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.07505385188391644">
<NAME>CSA+steroids versus azathioprine+steroids at 36 months</NAME>
<DICH_DATA CI_END="2.8963010948935803" CI_START="0.373441836522781" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4618437084413986" LOG_CI_START="-0.42777702984383786" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2011-11-22 10:29:50 +1100" MODIFIED_BY="[Empty name]" ORDER="482" O_E="0.0" SE="0.5225676253624243" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="0.27307692307692305" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="31.438279667544926" CI_END="1.5378918702759612" CI_START="0.18239853604372558" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8601452031598433" ESTIMABLE="YES" I2="39.564123097948936" I2_Q="27.69407681110418" ID="CMP-006.11" MODIFIED="2014-04-10 18:25:53 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.036117540357725186" P_Q="0.15831227394837333" P_Z="0.012866644867706724" Q="17.979163292111092" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.2463526391871853" TOTALS="SUB" TOTAL_1="249" TOTAL_2="247" UNITS="g/24 h" WEIGHT="1400.0" Z="2.487439188512225">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.278775664669487" CI_END="2.0946991422020282" CI_START="-0.8651304505820805" DF="5" EFFECT_SIZE="0.6147843458099738" ESTIMABLE="YES" I2="46.11358027505344" ID="CMP-006.11.01" MODIFIED="2014-04-10 18:25:42 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.09844823486336651" P_Z="0.41552708436033614" STUDIES="5" TAU2="1.4357601709948322" TOTAL_1="67" TOTAL_2="64" WEIGHT="100.0" Z="0.814205776565095">
<NAME>CSA versus other treatments at final follow-up (9-36 months)</NAME>
<CONT_DATA CI_END="-0.3602051960550483" CI_START="-9.03979480394495" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="9.2" MODIFIED="2013-01-27 17:58:49 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="844" SD_1="4.0" SD_2="5.0" SE="2.214221709264404" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" WEIGHT="8.99473034049563"/>
<CONT_DATA CI_END="3.4936586643636716" CI_START="-2.4936586643636716" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="5.7" MODIFIED="2013-01-27 17:58:49 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="429" SD_1="7.1" SD_2="3.5" SE="1.527404935997431" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" WEIGHT="15.12804047267665"/>
<CONT_DATA CI_END="9.636690511419754" CI_START="-0.23669051141975483" EFFECT_SIZE="4.7" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="2.8" MODIFIED="2013-01-27 19:08:21 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="740" SD_1="7.6" SD_2="2.5" SE="2.518765931598611" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="7.328260246866139"/>
<CONT_DATA CI_END="3.1688607094554864" CI_START="-0.36886070945548655" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="1.0" MODIFIED="2013-01-27 17:58:49 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="402" SD_1="1.6" SD_2="1.1" SE="0.9024965373894795" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" WEIGHT="25.336376805266244"/>
<CONT_DATA CI_END="1.8978023739083103" CI_START="-1.0978023739083105" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.0" MODIFIED="2013-01-27 17:58:49 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="393" SD_1="1.6" SD_2="0.6" SE="0.7641989269817121" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" WEIGHT="28.227826462250704"/>
<CONT_DATA CI_END="4.016689567427245" CI_START="-2.016689567427246" EFFECT_SIZE="0.9999999999999996" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="3.1" MODIFIED="2013-01-27 17:57:05 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="461" SD_1="4.3" SD_2="2.6" SE="1.5391556126655939" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="14.984765672444633"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.079490724027718" CI_END="8.581389974133302" CI_START="-6.696099893843221" DF="1" EFFECT_SIZE="0.94264504014504" ESTIMABLE="YES" I2="75.48713632046966" ID="CMP-006.11.02" MODIFIED="2014-04-10 18:25:48 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.04340683871246065" P_Z="0.8088842350430354" STUDIES="2" TAU2="22.96318686868687" TOTAL_1="19" TOTAL_2="19" WEIGHT="99.99999999999999" Z="0.24186569192394392">
<NAME>CSA versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="2.637522806016495" CI_START="-8.837522806016494" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="11.0" MODIFIED="2011-12-07 10:52:34 +1100" MODIFIED_BY="[Empty name]" ORDER="843" SD_1="7.0" SD_2="5.0" SE="2.927361345041716" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" WEIGHT="48.17121743403794"/>
<CONT_DATA CI_END="9.636690511419754" CI_START="-0.23669051141975483" EFFECT_SIZE="4.7" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="2.8" MODIFIED="2011-11-22 01:53:54 +1100" MODIFIED_BY="[Empty name]" ORDER="740" SD_1="7.6" SD_2="2.5" SE="2.518765931598611" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" WEIGHT="51.828782565962044"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3602051960550483" CI_START="-9.03979480394495" DF="0" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.03" MODIFIED="2014-04-10 18:25:53 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.03378386255484397" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0" Z="2.1226420011758473">
<NAME>CSA versus placebo/no treatment at 21 months</NAME>
<CONT_DATA CI_END="-0.3602051960550483" CI_START="-9.03979480394495" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="9.2" MODIFIED="2011-12-07 10:53:03 +1100" MODIFIED_BY="[Empty name]" ORDER="844" SD_1="4.0" SD_2="5.0" SE="2.214221709264404" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8978023739083103" CI_START="-1.0978023739083105" DF="0" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.04" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.6006792822874161" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.5234239225902135">
<NAME>CSA+steroids versus ACEi/ARB at 9 months</NAME>
<CONT_DATA CI_END="1.8978023739083103" CI_START="-1.0978023739083105" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.0" MODIFIED="2011-11-22 04:05:12 +1100" MODIFIED_BY="[Empty name]" ORDER="393" SD_1="1.6" SD_2="0.6" SE="0.7641989269817121" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9401624905227997" CI_START="-6.5401624905228" DF="0" EFFECT_SIZE="-2.8" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.05" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.14229746378732724" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="1.467288966887921">
<NAME>CSA+steroids versus steroids at 6 months</NAME>
<CONT_DATA CI_END="0.9401624905227997" CI_START="-6.5401624905228" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="7.3" MODIFIED="2011-11-22 07:31:46 +1100" MODIFIED_BY="[Empty name]" ORDER="427" SD_1="4.7" SD_2="8.1" SE="1.9082812337495605" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.883495209686647" CI_START="-2.0834952096866464" DF="0" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.06" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.7522466849987525" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="0.3156783193131028">
<NAME>CSA+steroids versus steroids at 12 months</NAME>
<CONT_DATA CI_END="2.883495209686647" CI_START="-2.0834952096866464" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="6.0" MODIFIED="2011-11-22 07:31:57 +1100" MODIFIED_BY="[Empty name]" ORDER="428" SD_1="5.7" SD_2="3.2" SE="1.2671126761900422" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.4936586643636716" CI_START="-2.4936586643636716" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.07" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.7434012020378119" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0" Z="0.3273526150244423">
<NAME>CSA+steroids versus steroids at 18 months</NAME>
<CONT_DATA CI_END="3.4936586643636716" CI_START="-2.4936586643636716" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="5.7" MODIFIED="2011-11-22 07:32:10 +1100" MODIFIED_BY="[Empty name]" ORDER="429" SD_1="7.1" SD_2="3.5" SE="1.527404935997431" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.168860709455486" CI_START="-0.3688607094554863" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.08" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.12084118777192583" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0" Z="1.551252489067245">
<NAME>CSA+steroids versus alkylating agents+steroids at 9 months</NAME>
<CONT_DATA CI_END="3.1688607094554864" CI_START="-0.36886070945548655" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="1.0" MODIFIED="2011-11-22 04:14:42 +1100" MODIFIED_BY="[Empty name]" ORDER="402" SD_1="1.6" SD_2="1.1" SE="0.9024965373894795" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.050387475253954" CI_START="-0.050387475253954594" DF="0" EFFECT_SIZE="2.4999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.09" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.05470128314488029" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.9212413834733983">
<NAME>CSA+steroids versus azathioprine+steroids at 6 months</NAME>
<CONT_DATA CI_END="5.050387475253954" CI_START="-0.050387475253954594" EFFECT_SIZE="2.4999999999999996" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="2.6" MODIFIED="2011-11-22 10:20:09 +1100" MODIFIED_BY="[Empty name]" ORDER="456" SD_1="3.8" SD_2="1.8" SE="1.3012420102466602" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.26586696023816" CI_START="0.3341330397618414" DF="0" EFFECT_SIZE="4.800000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.10" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Z="0.035151649249869264" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="99.99999999999999" Z="2.1066071178462855">
<NAME>CSA+steroids versus azathioprine+steroids at 12 months</NAME>
<CONT_DATA CI_END="9.26586696023816" CI_START="0.3341330397618414" EFFECT_SIZE="4.800000000000001" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="1.9" MODIFIED="2011-11-22 10:20:22 +1100" MODIFIED_BY="[Empty name]" ORDER="457" SD_1="7.1" SD_2="1.4" SE="2.278545419948707" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.795740878178723" CI_START="-0.995740878178724" DF="0" EFFECT_SIZE="3.3999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.11" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="1.0" P_Z="0.12952312738388716" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.5159850710302132">
<NAME>CSA+steroids versus azathioprine+steroids at 18 months</NAME>
<CONT_DATA CI_END="7.795740878178723" CI_START="-0.995740878178724" EFFECT_SIZE="3.3999999999999995" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="1.7" MODIFIED="2011-11-22 10:20:34 +1100" MODIFIED_BY="[Empty name]" ORDER="458" SD_1="7.0" SD_2="1.3" SE="2.2427661492005804" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.711567369476974" CI_START="-0.9115673694769746" DF="0" EFFECT_SIZE="2.4" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.12" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="1.0" P_Z="0.15547691788182078" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.420449303327645">
<NAME>CSA+steroids versus azathioprine+steroids at 24 months</NAME>
<CONT_DATA CI_END="5.711567369476974" CI_START="-0.9115673694769746" EFFECT_SIZE="2.4" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="1.5" MODIFIED="2011-11-22 10:20:46 +1100" MODIFIED_BY="[Empty name]" ORDER="459" SD_1="5.2" SD_2="1.4" SE="1.6896062354197297" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5710316326586403E-32" CI_END="5.272128996259731" CI_START="-1.672128996259732" DF="0" EFFECT_SIZE="1.7999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-006.11.13" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="0.0" P_Z="0.30959482491025114" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="1.016072610197513">
<NAME>CSA+steroids versus azathioprine+steroids at 30 months</NAME>
<CONT_DATA CI_END="5.272128996259731" CI_START="-1.6721289962597319" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="2.5" MODIFIED="2011-11-22 10:20:58 +1100" MODIFIED_BY="[Empty name]" ORDER="460" SD_1="5.4" SD_2="1.7" SE="1.7715269380700065" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.016689567427245" CI_START="-2.016689567427246" DF="0" EFFECT_SIZE="0.9999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-006.11.14" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="1.0" P_Z="0.515881579141434" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.6497068858867004">
<NAME>CSA+steroids versus azathioprine+steroids at 36 months</NAME>
<CONT_DATA CI_END="4.016689567427245" CI_START="-2.016689567427246" EFFECT_SIZE="0.9999999999999996" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="3.1" MODIFIED="2011-11-22 10:21:09 +1100" MODIFIED_BY="[Empty name]" ORDER="461" SD_1="4.3" SD_2="2.6" SE="1.5391556126655939" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.1043371219468288" CI_END="23.7932512915493" CI_START="0.05858104489730079" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1806072683847957" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="52.47909711943638" I2_Q="52.47909711943638" ID="CMP-006.12" LOG_CI_END="1.376453791406752" LOG_CI_START="-1.2322428861695318" LOG_EFFECT_SIZE="0.07210545261861" METHOD="IV" MODIFIED="2014-04-10 18:26:03 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.14688203809696" P_Q="0.14688203809696" P_Z="0.9137193098408907" Q="2.1043371219468288" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.4645601506131554" TOTALS="YES" TOTAL_1="111" TOTAL_2="91" WEIGHT="100.0" Z="0.10834842658115232">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.54624195667168" CI_START="0.29299032187126384" DF="0" EFFECT_SIZE="5.454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-006.12.01" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254185" MODIFIED="2014-04-10 18:26:03 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.2554928994991701" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="50.06337349445786" Z="1.137108620704471">
<NAME>CSA versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 01:26:13 +1100" MODIFIED_BY="[Empty name]" ORDER="368" O_E="0.0" SE="0.0" STUDY_ID="STD-Cattran-1995" TOTAL_1="9" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2011-12-09 00:05:33 +1100" MODIFIED_BY="[Empty name]" ORDER="741" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-CYCLOMEN-Study-1994" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="50.06337349445786"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 00:05:34 +1100" MODIFIED_BY="[Empty name]" ORDER="755" O_E="0.0" SE="0.0" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.12.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus ACEi/ARB</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 00:05:35 +1100" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.12.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus steroids</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 07:37:02 +1100" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.0" STUDY_ID="STD-Cattran-2001" TOTAL_1="28" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.12.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>CSA+steroids versus alkylating agents+steroids</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 03:40:24 +1100" MODIFIED_BY="[Empty name]" ORDER="765" O_E="0.0" SE="0.0" STUDY_ID="STD-Braun-1995" TOTAL_1="22" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 04:11:03 +1100" MODIFIED_BY="[Empty name]" ORDER="401" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosmadakis-2010" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.775977109013901" CI_START="0.013566519887095944" DF="0" EFFECT_SIZE="0.2545454545454545" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.12.06" LOG_CI_END="0.6790622365775999" LOG_CI_START="-1.8675315442096114" LOG_EFFECT_SIZE="-0.5942346538160058" MODIFIED="2014-04-10 18:25:03 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.3603516894469949" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="49.936626505542144" Z="0.9146951733189024">
<NAME>CSA+steroids versus azathioprine+steroids</NAME>
<DICH_DATA CI_END="4.775977109013901" CI_START="0.013566519887095944" EFFECT_SIZE="0.2545454545454545" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6790622365775999" LOG_CI_START="-1.8675315442096114" LOG_EFFECT_SIZE="-0.5942346538160058" MODIFIED="2011-11-22 10:31:07 +1100" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.4958817926769272" STUDY_ID="STD-Naumovic-2011" TOTAL_1="10" TOTAL_2="13" VAR="2.2376623376623375" WEIGHT="49.936626505542144"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-04-02 18:38:53 +1100" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Cyclosporine (CSA) (1.5 mg/kg, twice/d) versus CSA (3.0 mg/kg, once/d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:38:53 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Complete remission at 12 months</NAME>
<GROUP_LABEL_1>1.5 mg/kg, twice/d</GROUP_LABEL_1>
<GROUP_LABEL_2>[3.0 mg/kg, once/d</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once/d</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours twice/d</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7206303613057088" CI_START="0.6561003893615617" EFFECT_SIZE="1.0625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.2356875819560659" LOG_CI_START="-0.18302970451136757" LOG_EFFECT_SIZE="0.02632893872234915" MODIFIED="2013-02-14 00:28:50 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2414" O_E="0.0" SE="0.24595660675496628" STUDY_ID="STD-Saito-2009" TOTAL_1="16" TOTAL_2="17" VAR="0.06049465240641712" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2014-04-02 17:44:15 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="17" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Final proteinuria at 12 months</NAME>
<GROUP_LABEL_1>1.5 mg/kg, twice/d</GROUP_LABEL_1>
<GROUP_LABEL_2>[3.0 mg/kg, once/d</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once/d</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours twice/d</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4429091823255229" CI_START="-0.9570908176744772" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.1" MODIFIED="2013-02-14 00:22:52 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2415" SD_1="0.2" SD_2="0.5" SE="0.1311711948292809" STUDY_ID="STD-Saito-2009" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-04-10 17:53:36 +1000" MODIFIED_BY="Narelle S Willis" NO="8">
<NAME>Tacrolimus (TAC) versus other treatments</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.195817676132171" CI_START="0.01315688646851685" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" METHOD="IV" MODIFIED="2014-04-10 17:48:22 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4636374323790845" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="0.7328704842081468">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.195817676132171" CI_START="0.01315688646851685" DF="0" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2014-04-10 17:48:15 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.4636374323790845" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.7328704842081468">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="7.195817676132171" CI_START="0.01315688646851685" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2011-11-22 21:26:22 +1100" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="2.5865384615384617" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:48:22 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>TAC+steroids versus alkylating agents+steroids at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 01:03:30 +1100" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.195817676132171" CI_START="0.01315688646851685" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" METHOD="IV" MODIFIED="2014-04-10 17:48:40 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4636374323790845" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="0.7328704842081468">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.195817676132171" CI_START="0.01315688646851685" DF="0" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2014-04-10 17:48:35 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.4636374323790845" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.7328704842081468">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="7.195817676132171" CI_START="0.01315688646851685" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2011-11-22 21:26:30 +1100" MODIFIED_BY="[Empty name]" ORDER="484" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="2.5865384615384617" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:48:40 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>TAC+steroids versus alkylating agents+steroids at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 01:03:36 +1100" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-10 17:49:12 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="64" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:49:07 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 21:26:11 +1100" MODIFIED_BY="[Empty name]" ORDER="485" O_E="0.0" SE="0.0" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:49:12 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>TAC+steroids versus alkylating agents+steroids at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 01:03:37 +1100" MODIFIED_BY="[Empty name]" ORDER="522" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06855611697989863" CI_END="0.35249335599756754" CI_START="0.061950152866550756" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14777353378901378" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="-0.4528490644336814" LOG_CI_START="-1.2079576176330744" LOG_EFFECT_SIZE="-0.8304033410333779" METHOD="IV" MODIFIED="2014-04-10 17:50:01 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.9999361233233457" P_Q="0.9999361233233457" P_Z="1.6266563157343976E-5" Q="0.06855611697989863" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="300" TOTAL_2="267" WEIGHT="600.0" Z="4.310799114037796">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TAC</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.179060171309071" CI_START="0.01994055238504708" DF="0" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2014-04-10 17:49:19 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.07159296555727772" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="1.8016977927592697">
<NAME>TAC versus other treatments at final follow-up (12-30 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 05:53:15 +1100" MODIFIED_BY="[Empty name]" ORDER="826" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.179060171309071" CI_START="0.01994055238504708" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2011-12-09 05:53:11 +1100" MODIFIED_BY="[Empty name]" ORDER="825" O_E="0.0" SE="1.0407633764680142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="1.0831884057971015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.179060171309071" CI_START="0.01994055238504708" DF="0" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2014-04-10 17:49:24 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.07159296555727772" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.8016977927592697">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.179060171309071" CI_START="0.01994055238504708" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2011-11-22 21:29:23 +1100" MODIFIED_BY="[Empty name]" ORDER="494" O_E="0.0" SE="1.0407633764680142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="1.0831884057971015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8063627340767032" CI_START="0.005823523114340923" DF="0" EFFECT_SIZE="0.10256410256410255" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-008.04.03" LOG_CI_END="0.2568049650194475" LOG_CI_START="-2.2348141964165213" LOG_EFFECT_SIZE="-0.9890046156985369" MODIFIED="2014-04-10 17:49:29 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.11972074402922876" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.5559467974197663">
<NAME>TAC versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="1.8063627340767032" CI_START="0.005823523114340923" EFFECT_SIZE="0.10256410256410256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2568049650194475" LOG_CI_START="-2.2348141964165213" LOG_EFFECT_SIZE="-0.9890046156985368" MODIFIED="2011-11-22 21:29:30 +1100" MODIFIED_BY="[Empty name]" ORDER="495" O_E="0.0" SE="1.4635894291412526" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="2.1420940170940175" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.179060171309071" CI_START="0.01994055238504708" DF="0" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-008.04.04" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2014-04-10 17:49:35 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.07159296555727772" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.8016977927592697">
<NAME>TAC versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="1.179060171309071" CI_START="0.01994055238504708" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2011-11-22 21:29:36 +1100" MODIFIED_BY="[Empty name]" ORDER="496" O_E="0.0" SE="1.0407633764680142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="1.0831884057971015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.179060171309071" CI_START="0.01994055238504708" DF="0" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-008.04.05" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2014-04-10 17:49:40 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.07159296555727772" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.8016977927592697">
<NAME>TAC versus placebo/no treatment at 18 months</NAME>
<DICH_DATA CI_END="1.179060171309071" CI_START="0.01994055238504708" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2011-11-22 21:29:38 +1100" MODIFIED_BY="[Empty name]" ORDER="497" O_E="0.0" SE="1.0407633764680142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="1.0831884057971015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.179060171309071" CI_START="0.01994055238504708" DF="0" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-008.04.06" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2014-04-10 17:49:45 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.07159296555727772" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.8016977927592697">
<NAME>TAC versus placebo/no treatment at 30 months</NAME>
<DICH_DATA CI_END="1.179060171309071" CI_START="0.01994055238504708" EFFECT_SIZE="0.15333333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07153596913298946" LOG_CI_START="-1.7002628152091661" LOG_EFFECT_SIZE="-0.8143634230380884" MODIFIED="2011-11-22 21:29:43 +1100" MODIFIED_BY="[Empty name]" ORDER="498" O_E="0.0" SE="1.0407633764680142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="1.0831884057971015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.04.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:49:50 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>TAC+steroids versus alkylating agents+steroids at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 01:03:39 +1100" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.04.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:49:55 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>TAC+steroids versus alkylating agents+steroids at 6 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 01:04:48 +1100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.04.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:50:01 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>TAC+steroids versus alkylating agents+steroids at 12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 01:11:24 +1100" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-2010a" TOTAL_1="33" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.05" MODIFIED="2014-04-10 17:50:12 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="66" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TAC</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.05.01" MODIFIED="2014-04-10 17:50:06 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>TAC versus other treatments at final follow-up (12 months)</NAME>
<CONT_DATA CI_END="17.269257316057512" CI_START="-8.869257316057505" EFFECT_SIZE="4.200000000000003" ESTIMABLE="YES" MEAN_1="108.5" MEAN_2="104.3" MODIFIED="2011-11-23 01:10:47 +1100" MODIFIED_BY="[Empty name]" ORDER="529" SD_1="30.8" SD_2="20.6" SE="6.668110954663525" STUDY_ID="STD-Chen-2010a" TOTAL_1="33" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.05.02" MODIFIED="2014-04-10 17:50:12 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>TAC+steroids versus alkylating agents+steroids at 12 months</NAME>
<CONT_DATA CI_END="17.269257316057512" CI_START="-8.869257316057505" EFFECT_SIZE="4.200000000000003" ESTIMABLE="YES" MEAN_1="108.5" MEAN_2="104.3" MODIFIED="2013-01-27 01:38:17 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="529" SD_1="30.8" SD_2="20.6" SE="6.668110954663525" STUDY_ID="STD-Chen-2010a" TOTAL_1="33" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="17.900273791364818" CI_END="1.3904123386042686" CI_START="1.1084716720135828" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2414639301087202" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="126" I2="49.721439432163066" I2_Q="55.13332835326433" ID="CMP-008.06" LOG_CI_END="0.14314361307752851" LOG_CI_START="0.044724598807849146" LOG_EFFECT_SIZE="0.09393410594268883" METHOD="IV" MODIFIED="2014-04-10 17:51:02 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.03634837245360545" P_Q="0.0225329503602969" P_Z="1.830717877215298E-4" Q="17.830607233336085" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03909592792377141" TOTALS="SUB" TOTAL_1="300" TOTAL_2="267" WEIGHT="900.0" Z="3.741298689766683">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TAC</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.06966655802873215" CI_END="1.5517009473329388" CI_START="0.9129838792979013" DF="1" EFFECT_SIZE="1.1902428115331154" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="30" I2="0.0" ID="CMP-008.06.01" LOG_CI_END="0.19080802527422486" LOG_CI_START="-0.03953689080499523" LOG_EFFECT_SIZE="0.07563556723461487" MODIFIED="2014-04-10 17:50:17 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.7918228960740502" P_Z="0.19804576769252868" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="57" WEIGHT="99.99999999999999" Z="1.2871392193359217">
<NAME>TAC versus other treatments at final follow-up (12-30 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.5576361880828198" CI_START="0.8864011426020284" EFFECT_SIZE="1.1750278706800446" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" LOG_CI_END="0.1924660284594021" LOG_CI_START="-0.052369692794530714" LOG_EFFECT_SIZE="0.0700481678324357" MODIFIED="2011-12-09 05:55:06 +1100" MODIFIED_BY="[Empty name]" ORDER="828" O_E="0.0" SE="0.1438177146209265" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.020683535038786255" WEIGHT="88.51313040202172"/>
<DICH_DATA CI_END="2.874146434896417" CI_START="0.6009947571922385" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" MODIFIED="2011-12-09 05:55:03 +1100" MODIFIED_BY="[Empty name]" ORDER="827" O_E="0.0" SE="0.3992228475270142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.15937888198757763" WEIGHT="11.486869597978275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.874146434896417" CI_START="0.6009947571922385" DF="0" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-008.06.02" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" MODIFIED="2014-04-10 17:50:22 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.49361949744298717" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.6845633627749433">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.874146434896417" CI_START="0.6009947571922385" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" MODIFIED="2011-11-22 21:31:16 +1100" MODIFIED_BY="[Empty name]" ORDER="499" O_E="0.0" SE="0.3992228475270142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.15937888198757763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.03982354503659" CI_START="1.4135705937621554" DF="0" EFFECT_SIZE="4.293333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" ID="CMP-008.06.03" LOG_CI_END="1.1152717145603637" LOG_CI_START="0.15031750204789804" LOG_EFFECT_SIZE="0.6327946083041308" MODIFIED="2014-04-10 17:50:28 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.010152312377707497" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="99.99999999999999" Z="2.570597911911194">
<NAME>TAC versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="13.03982354503659" CI_START="1.4135705937621554" EFFECT_SIZE="4.293333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="1.1152717145603637" LOG_CI_START="0.15031750204789804" LOG_EFFECT_SIZE="0.6327946083041308" MODIFIED="2011-11-22 21:31:25 +1100" MODIFIED_BY="[Empty name]" ORDER="500" O_E="0.0" SE="0.5668188810302102" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.32128364389233954" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.4677102317657695" CI_START="1.4689032728317648" DF="0" EFFECT_SIZE="3.3119999999999994" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" I2="0.0" ID="CMP-008.06.04" LOG_CI_END="0.8731874577523097" LOG_CI_START="0.1669931984733752" LOG_EFFECT_SIZE="0.5200903281128425" MODIFIED="2014-04-10 17:50:34 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.0038905012948833775" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.88690625395232">
<NAME>TAC versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="7.4677102317657695" CI_START="1.4689032728317648" EFFECT_SIZE="3.312" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="0.8731874577523097" LOG_CI_START="0.1669931984733752" LOG_EFFECT_SIZE="0.5200903281128425" MODIFIED="2011-11-22 21:31:32 +1100" MODIFIED_BY="[Empty name]" ORDER="501" O_E="0.0" SE="0.41482200361840776" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.1720772946859903" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.9991535411219115" CI_START="1.4147847780411782" DF="0" EFFECT_SIZE="2.913333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="0.0" ID="CMP-008.06.05" LOG_CI_END="0.7780899773247963" LOG_CI_START="0.15069037850468492" LOG_EFFECT_SIZE="0.4643901779147406" MODIFIED="2014-04-10 17:50:40 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.003714259150810032" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.9014619237842694">
<NAME>TAC versus placebo/no treatment at 18 months</NAME>
<DICH_DATA CI_END="5.9991535411219115" CI_START="1.4147847780411782" EFFECT_SIZE="2.9133333333333336" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.7780899773247963" LOG_CI_START="0.15069037850468492" LOG_EFFECT_SIZE="0.46439017791474063" MODIFIED="2011-11-22 21:31:39 +1100" MODIFIED_BY="[Empty name]" ORDER="502" O_E="0.0" SE="0.36853763002503537" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.13581998474446985" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.874146434896417" CI_START="0.6009947571922385" DF="0" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-008.06.06" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" MODIFIED="2014-04-10 17:50:45 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.49361949744298717" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.6845633627749433">
<NAME>TAC versus placebo/no treatment at 30 months</NAME>
<DICH_DATA CI_END="2.874146434896417" CI_START="0.6009947571922385" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.45850889123292204" LOG_CI_START="-0.2211293165703252" LOG_EFFECT_SIZE="0.11868978733129844" MODIFIED="2011-11-22 21:31:45 +1100" MODIFIED_BY="[Empty name]" ORDER="503" O_E="0.0" SE="0.3992228475270142" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.15937888198757763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5576361880828198" CI_START="0.8864011426020284" DF="0" EFFECT_SIZE="1.1750278706800446" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" I2="0.0" ID="CMP-008.06.07" LOG_CI_END="0.1924660284594021" LOG_CI_START="-0.052369692794530714" LOG_EFFECT_SIZE="0.0700481678324357" MODIFIED="2014-04-10 17:50:52 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.26207422207011766" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.00000000000001" Z="1.1215020866354553">
<NAME>TAC+steroids versus alkylating agents+steroids at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.5576361880828198" CI_START="0.8864011426020284" EFFECT_SIZE="1.1750278706800446" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" LOG_CI_END="0.1924660284594021" LOG_CI_START="-0.052369692794530714" LOG_EFFECT_SIZE="0.0700481678324357" MODIFIED="2011-11-23 01:15:25 +1100" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="0.1438177146209265" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.020683535038786255" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.733749304764602" CI_START="0.9863358946406698" DF="0" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="0.0" ID="CMP-008.06.08" LOG_CI_END="0.2389862999288063" LOG_CI_START="-0.005975161785932001" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2014-04-10 17:50:57 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.06227283444255471" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="1.8643481123922592">
<NAME>TAC+steroids versus alkylating agents+steroids at 6 months</NAME>
<DICH_DATA CI_END="1.733749304764602" CI_START="0.9863358946406698" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="0.2389862999288063" LOG_CI_START="-0.005975161785932001" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2011-11-23 01:15:33 +1100" MODIFIED_BY="[Empty name]" ORDER="534" O_E="0.0" SE="0.143891575190029" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.020704785410667767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.319715184811999" CI_START="0.9214826241985464" DF="0" EFFECT_SIZE="1.1027667984189724" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" I2="0.0" ID="CMP-008.06.09" LOG_CI_END="0.12048021377322475" LOG_CI_START="-0.035512849577665415" LOG_EFFECT_SIZE="0.04248368209777966" MODIFIED="2014-04-10 17:51:02 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.2857161031292196" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="1.067566532173266">
<NAME>TAC+steroids versus alkylating agents+steroids at 12 months</NAME>
<DICH_DATA CI_END="1.319715184811999" CI_START="0.9214826241985464" EFFECT_SIZE="1.1027667984189724" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" LOG_CI_END="0.12048021377322475" LOG_CI_START="-0.035512849577665415" LOG_EFFECT_SIZE="0.04248368209777966" MODIFIED="2011-11-23 01:15:43 +1100" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.09163109759043" STUDY_ID="STD-Chen-2010a" TOTAL_1="33" TOTAL_2="27" VAR="0.008396258045626909" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.9981424237887175" CI_END="1.4458121526795782" CI_START="0.7387756157651416" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0335041187032494" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.16011187086018266" LOG_CI_START="-0.13148744744052623" LOG_EFFECT_SIZE="0.01431221170982821" METHOD="IV" MODIFIED="2014-04-10 17:51:47 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.757774724056191" P_Q="0.747802858316938" P_Z="0.8474312289985916" Q="4.273406353170299" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="267" TOTAL_2="240" WEIGHT="800.0" Z="0.1923970169329954">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TAC</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7247360706184194" CI_END="1.7399463612468418" CI_START="0.47197904542404673" DF="1" EFFECT_SIZE="0.9062109151132135" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-008.07.01" LOG_CI_END="0.24053586013686618" LOG_CI_START="-0.3260772824225262" LOG_EFFECT_SIZE="-0.04277071114283005" MODIFIED="2014-04-10 17:51:08 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.39459479812997955" P_Z="0.7673101203275123" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="0.2958951959866547">
<NAME>TAC versus other treatments at final follow-up (12-30 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.2588318840588415" CI_START="0.5026261296306122" EFFECT_SIZE="1.0655270655270654" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3538839092990754" LOG_CI_START="-0.2987549378297633" LOG_EFFECT_SIZE="0.027564485734656047" MODIFIED="2011-12-09 05:56:06 +1100" MODIFIED_BY="[Empty name]" ORDER="832" O_E="0.0" SE="0.38336328941787584" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.14696741167329402" WEIGHT="75.37502095186774"/>
<DICH_DATA CI_END="2.0551828882219874" CI_START="0.14826125779181165" EFFECT_SIZE="0.552" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3128504752687488" LOG_CI_START="-0.8289723198103509" LOG_EFFECT_SIZE="-0.2580609222708011" MODIFIED="2011-12-09 05:56:01 +1100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.670712361943455" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.4498550724637681" WEIGHT="24.62497904813226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0551828882219874" CI_START="0.14826125779181165" DF="0" EFFECT_SIZE="0.552" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-008.07.02" LOG_CI_END="0.3128504752687488" LOG_CI_START="-0.8289723198103509" LOG_EFFECT_SIZE="-0.2580609222708011" MODIFIED="2014-04-10 17:51:14 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.37565282413187306" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.8859345174185664">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.0551828882219874" CI_START="0.14826125779181165" EFFECT_SIZE="0.552" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3128504752687488" LOG_CI_START="-0.8289723198103509" LOG_EFFECT_SIZE="-0.2580609222708011" MODIFIED="2011-11-22 21:32:11 +1100" MODIFIED_BY="[Empty name]" ORDER="504" O_E="0.0" SE="0.670712361943455" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.4498550724637681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.533035597908136" CI_START="0.25280645169509575" DF="0" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-008.07.03" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" MODIFIED="2014-04-10 17:51:19 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.7099331091968111" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.37194592843457325">
<NAME>TAC versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" MODIFIED="2011-11-22 21:32:17 +1100" MODIFIED_BY="[Empty name]" ORDER="505" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.277733056601674" CI_START="0.4451890697249111" DF="0" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-008.07.04" LOG_CI_END="0.6312136798002469" LOG_CI_START="-0.3514555069977739" LOG_EFFECT_SIZE="0.13987908640123647" MODIFIED="2014-04-10 17:51:25 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.576853742289344" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.5579862993977052">
<NAME>TAC versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="4.277733056601674" CI_START="0.4451890697249111" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6312136798002469" LOG_CI_START="-0.3514555069977739" LOG_EFFECT_SIZE="0.13987908640123647" MODIFIED="2011-11-22 21:32:22 +1100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.5772247446160823" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.3331884057971014" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.28819123696657E-32" CI_END="8.14532067980357" CI_START="0.7389327788368418" DF="0" EFFECT_SIZE="2.453333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="100.0" ID="CMP-008.07.05" LOG_CI_END="0.9109081870764012" LOG_CI_START="-0.13139506784072824" LOG_EFFECT_SIZE="0.3897565596178364" MODIFIED="2014-04-10 17:51:30 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.14270028995707315" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.4658091414094918">
<NAME>TAC versus placebo/no treatment at 18 months</NAME>
<DICH_DATA CI_END="8.14532067980357" CI_START="0.7389327788368418" EFFECT_SIZE="2.453333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9109081870764012" LOG_CI_START="-0.13139506784072824" LOG_EFFECT_SIZE="0.3897565596178364" MODIFIED="2011-11-22 21:32:28 +1100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.6122540914226446" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.37485507246376815" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0551828882219874" CI_START="0.14826125779181165" DF="0" EFFECT_SIZE="0.552" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-008.07.06" LOG_CI_END="0.3128504752687488" LOG_CI_START="-0.8289723198103509" LOG_EFFECT_SIZE="-0.2580609222708011" MODIFIED="2014-04-10 17:51:36 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.37565282413187306" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.8859345174185664">
<NAME>TAC versus placebo/no treatment at 30 months</NAME>
<DICH_DATA CI_END="2.0551828882219874" CI_START="0.14826125779181165" EFFECT_SIZE="0.552" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3128504752687488" LOG_CI_START="-0.8289723198103509" LOG_EFFECT_SIZE="-0.2580609222708011" MODIFIED="2011-11-22 21:32:34 +1100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.670712361943455" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.4498550724637681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2588318840588415" CI_START="0.5026261296306122" DF="0" EFFECT_SIZE="1.0655270655270654" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-008.07.07" LOG_CI_END="0.3538839092990754" LOG_CI_START="-0.2987549378297633" LOG_EFFECT_SIZE="0.027564485734656047" MODIFIED="2014-04-10 17:51:41 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.8685033354751718" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="0.16555986371319603">
<NAME>TAC+steroids versus alkylating agents+steroids at final follow-up (6 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.2588318840588415" CI_START="0.5026261296306122" EFFECT_SIZE="1.0655270655270654" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3538839092990754" LOG_CI_START="-0.2987549378297633" LOG_EFFECT_SIZE="0.027564485734656047" MODIFIED="2011-11-23 01:17:22 +1100" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="0.38336328941787584" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.14696741167329402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2588318840588415" CI_START="0.5026261296306122" DF="0" EFFECT_SIZE="1.0655270655270654" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-008.07.08" LOG_CI_END="0.3538839092990754" LOG_CI_START="-0.2987549378297633" LOG_EFFECT_SIZE="0.027564485734656047" MODIFIED="2014-04-10 17:51:47 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.8685033354751718" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="0.16555986371319603">
<NAME>TAC+steroids versus alkylating agents+steroids at 6 months</NAME>
<DICH_DATA CI_END="2.2588318840588415" CI_START="0.5026261296306122" EFFECT_SIZE="1.0655270655270654" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3538839092990754" LOG_CI_START="-0.2987549378297633" LOG_EFFECT_SIZE="0.027564485734656047" MODIFIED="2011-11-23 01:17:29 +1100" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.38336328941787584" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.14696741167329402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.98179927582864" CI_END="2.3294662184285437" CI_START="1.3721192560733098" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7878214269546273" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="50" I2="27.15219246805662" I2_Q="30.068442271811215" ID="CMP-008.08" LOG_CI_END="0.36725641675614257" LOG_CI_START="0.1373918591868964" LOG_EFFECT_SIZE="0.2523241379715195" METHOD="IV" MODIFIED="2014-04-10 17:52:35 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.20273270123858467" P_Q="0.18801969393663476" P_Z="1.6854966274390144E-5" Q="10.009787036644777" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07029928429131119" TOTALS="SUB" TOTAL_1="267" TOTAL_2="240" WEIGHT="800.0" Z="4.302935851302894">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TAC</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9720122391838629" CI_END="2.5939918841521528" CI_START="0.9923068339829226" DF="1" EFFECT_SIZE="1.6043802148930966" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="15" I2="0.0" ID="CMP-008.08.01" LOG_CI_END="0.41396861296878223" LOG_CI_START="-0.0033540176631180994" LOG_EFFECT_SIZE="0.20530729765283204" MODIFIED="2014-04-10 17:51:53 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.3241790519763573" P_Z="0.05379798917775938" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="1.9284595640236357">
<NAME>TAC versus other treatments at final follow-up (12-30 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.453325375170903" CI_START="0.8872216403684392" EFFECT_SIZE="1.47534516765286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.3897551508440721" LOG_CI_START="-0.051967873781821376" LOG_EFFECT_SIZE="0.16889363853112538" MODIFIED="2011-12-09 05:56:48 +1100" MODIFIED_BY="[Empty name]" ORDER="836" O_E="0.0" SE="0.25947029122948617" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.06732483203071438" WEIGHT="89.25731082730597"/>
<DICH_DATA CI_END="13.947084488308839" CI_START="0.7434098509040599" EFFECT_SIZE="3.22" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1444834317692567" LOG_CI_START="-0.12877168837759487" LOG_EFFECT_SIZE="0.5078558716958309" MODIFIED="2011-12-09 05:56:44 +1100" MODIFIED_BY="[Empty name]" ORDER="835" O_E="0.0" SE="0.7479163602887542" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.5593788819875776" WEIGHT="10.742689172694025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.947084488308839" CI_START="0.7434098509040599" DF="0" EFFECT_SIZE="3.22" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-008.08.02" LOG_CI_END="1.1444834317692567" LOG_CI_START="-0.12877168837759487" LOG_EFFECT_SIZE="0.5078558716958309" MODIFIED="2014-04-10 17:51:58 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.11793059543891246" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.5635188928142236">
<NAME>TAC versus placebo/no treatment at final follow-up (30 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="13.947084488308839" CI_START="0.7434098509040599" EFFECT_SIZE="3.22" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1444834317692567" LOG_CI_START="-0.12877168837759487" LOG_EFFECT_SIZE="0.5078558716958309" MODIFIED="2011-11-22 21:32:46 +1100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="0.7479163602887542" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.5593788819875776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.36670009033361" CI_START="1.415214454606311" DF="0" EFFECT_SIZE="10.119999999999997" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" ID="CMP-008.08.03" LOG_CI_END="1.859538769320351" LOG_CI_START="0.15082225568720956" LOG_EFFECT_SIZE="1.0051805125037803" MODIFIED="2014-04-10 17:52:03 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.021112760457954096" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.3059619155666495">
<NAME>TAC versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="72.36670009033361" CI_START="1.415214454606311" EFFECT_SIZE="10.12" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.859538769320351" LOG_CI_START="0.15082225568720956" LOG_EFFECT_SIZE="1.0051805125037803" MODIFIED="2011-11-22 21:32:53 +1100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="1.0037085383912632" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="1.0074308300395256" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="78.36261732967066" CI_START="1.5553538683789156" DF="0" EFFECT_SIZE="11.039999999999997" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" I2="0.0" ID="CMP-008.08.04" LOG_CI_END="1.8941089331017977" LOG_CI_START="0.1918292136845622" LOG_EFFECT_SIZE="1.04296907339318" MODIFIED="2014-04-10 17:52:09 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.01631912648974141" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.4016990833205223">
<NAME>TAC versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="78.36261732967066" CI_START="1.5553538683789156" EFFECT_SIZE="11.04" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.8941089331017977" LOG_CI_START="0.1918292136845622" LOG_EFFECT_SIZE="1.04296907339318" MODIFIED="2011-11-22 21:32:57 +1100" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.9999275336061949" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.999855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.591274698593411" CI_START="1.0744105975543277" DF="0" EFFECT_SIZE="3.373333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-008.08.05" LOG_CI_END="1.0249482321802241" LOG_CI_START="0.0311702833880116" LOG_EFFECT_SIZE="0.5280592577841179" MODIFIED="2014-04-10 17:52:14 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.037259040192852644" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.0829142530636386">
<NAME>TAC versus placebo/no treatment at 18 months</NAME>
<DICH_DATA CI_END="10.591274698593411" CI_START="1.0744105975543277" EFFECT_SIZE="3.3733333333333335" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.0249482321802241" LOG_CI_START="0.0311702833880116" LOG_EFFECT_SIZE="0.5280592577841179" MODIFIED="2011-11-22 21:33:00 +1100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="0.5837500864007293" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.340764163372859" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.947084488308839" CI_START="0.7434098509040599" DF="0" EFFECT_SIZE="3.22" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-008.08.06" LOG_CI_END="1.1444834317692567" LOG_CI_START="-0.12877168837759487" LOG_EFFECT_SIZE="0.5078558716958309" MODIFIED="2014-04-10 17:52:20 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.11793059543891246" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.5635188928142236">
<NAME>TAC versus placebo/no treatment at 30 months</NAME>
<DICH_DATA CI_END="13.947084488308839" CI_START="0.7434098509040599" EFFECT_SIZE="3.22" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1444834317692567" LOG_CI_START="-0.12877168837759487" LOG_EFFECT_SIZE="0.5078558716958309" MODIFIED="2011-11-22 21:33:05 +1100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.7479163602887542" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.5593788819875776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.5770450784248026E-32" CI_END="2.453325375170903" CI_START="0.8872216403684392" DF="0" EFFECT_SIZE="1.47534516765286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="100.0" ID="CMP-008.08.07" LOG_CI_END="0.3897551508440721" LOG_CI_START="-0.051967873781821376" LOG_EFFECT_SIZE="0.16889363853112538" MODIFIED="2014-04-10 17:52:28 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Z="0.1339276229928993" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="1.498791913866324">
<NAME>TAC+steroids versus alkylating agents+steroids at final follow-up (6 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.453325375170903" CI_START="0.8872216403684392" EFFECT_SIZE="1.47534516765286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.3897551508440721" LOG_CI_START="-0.051967873781821376" LOG_EFFECT_SIZE="0.16889363853112538" MODIFIED="2011-11-23 01:18:00 +1100" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="0.25947029122948617" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.06732483203071438" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.5770450784248026E-32" CI_END="2.453325375170903" CI_START="0.8872216403684392" DF="0" EFFECT_SIZE="1.47534516765286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="100.0" ID="CMP-008.08.08" LOG_CI_END="0.3897551508440721" LOG_CI_START="-0.051967873781821376" LOG_EFFECT_SIZE="0.16889363853112538" MODIFIED="2014-04-10 17:52:35 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Z="0.1339276229928993" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="1.498791913866324">
<NAME>TAC+steroids versus alkylating agents+steroids at 6 months</NAME>
<DICH_DATA CI_END="2.453325375170903" CI_START="0.8872216403684392" EFFECT_SIZE="1.47534516765286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.3897551508440721" LOG_CI_START="-0.051967873781821376" LOG_EFFECT_SIZE="0.16889363853112538" MODIFIED="2011-11-23 01:18:04 +1100" MODIFIED_BY="[Empty name]" ORDER="540" O_E="0.0" SE="0.25947029122948617" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.06732483203071438" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.000965861272054" CI_END="-0.7858265457266572" CI_START="-1.4382898386926293" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1120581922096433" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.09" MODIFIED="2014-04-10 17:53:20 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.8911135584462312" P_Q="0.8993893670372907" P_Z="2.3711686484091975E-11" Q="2.8401042785772384" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="265" TOTAL_2="239" UNITS="g/24 h" WEIGHT="800.0" Z="6.6811237626429785">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1076466845508677" CI_END="-0.47099354915045377" CI_START="-1.656636395189995" DF="2" EFFECT_SIZE="-1.0638149721702244" ESTIMABLE="YES" I2="0.0" ID="CMP-008.09.01" MODIFIED="2014-04-10 17:52:40 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.5747482796988839" P_Z="4.36215063794671E-4" STUDIES="3" TAU2="0.0" TOTAL_1="69" TOTAL_2="63" WEIGHT="100.00000000000001" Z="3.51714521558136">
<NAME>TAC versus other treatment at final follow-up (9-18 months)</NAME>
<CONT_DATA CI_END="1.0817486730658565" CI_START="-1.8017486730658563" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="2.32" MODIFIED="2013-01-27 01:37:13 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="531" SD_1="2.98" SD_2="2.71" SE="0.7355995745014633" STUDY_ID="STD-Chen-2010a" TOTAL_1="33" TOTAL_2="27" WEIGHT="16.907081972479215"/>
<CONT_DATA CI_END="1.1542767241751446" CI_START="-3.754276724175145" EFFECT_SIZE="-1.3000000000000003" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="3.2" MODIFIED="2013-01-27 01:37:13 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="517" SD_1="4.0" SD_2="4.62" SE="1.2522050116911159" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" WEIGHT="5.834460739049707"/>
<CONT_DATA CI_END="-0.5255482690349019" CI_START="-1.8744517309650979" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.5" MODIFIED="2013-02-14 01:31:03 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="966" SD_1="0.29" SD_2="1.2" SE="0.34411434918451933" STUDY_ID="STD-Xu-2010" TOTAL_1="11" TOTAL_2="13" WEIGHT="77.25845728847109"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1542767241751446" CI_START="-3.754276724175145" DF="0" EFFECT_SIZE="-1.3000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-008.09.02" MODIFIED="2014-04-10 17:52:45 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.29919155500890793" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.0381686607725173">
<NAME>TAC versus placebo/no treatment at final follow-up (18 months)</NAME>
<CONT_DATA CI_END="1.1542767241751446" CI_START="-3.754276724175145" EFFECT_SIZE="-1.3000000000000003" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="3.2" MODIFIED="2013-02-14 17:21:20 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="517" SD_1="4.0" SD_2="4.62" SE="1.2522050116911159" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.29819337100953636" CI_START="-4.701806628990463" DF="0" EFFECT_SIZE="-2.4999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-008.09.03" MODIFIED="2014-04-10 17:52:51 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.026054108486846375" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.2254043097312146">
<NAME>TAC versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="-0.29819337100953636" CI_START="-4.701806628990463" EFFECT_SIZE="-2.4999999999999996" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="4.1" MODIFIED="2011-11-22 21:58:38 +1100" MODIFIED_BY="[Empty name]" ORDER="516" SD_1="2.67" SD_2="4.74" SE="1.123391371656843" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1542767241751446" CI_START="-3.754276724175145" DF="0" EFFECT_SIZE="-1.3000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-008.09.04" MODIFIED="2014-04-10 17:52:57 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.29919155500890793" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.0381686607725173">
<NAME>TAC versus placebo/no treatment at 18 months</NAME>
<CONT_DATA CI_END="1.1542767241751446" CI_START="-3.754276724175145" EFFECT_SIZE="-1.3000000000000003" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="3.2" MODIFIED="2011-11-22 21:58:56 +1100" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="4.0" SD_2="4.62" SE="1.2522050116911159" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0698666932242946" CI_END="-0.37247078423066815" CI_START="-1.6907340356408178" DF="1" EFFECT_SIZE="-1.031602409935743" ESTIMABLE="YES" I2="6.530411093903197" ID="CMP-008.09.05" MODIFIED="2014-04-10 17:53:03 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.3009759666798242" P_Z="0.00215838496329279" STUDIES="2" TAU2="0.023039290339290475" TOTAL_1="44" TOTAL_2="40" WEIGHT="100.0" Z="3.067526258774104">
<NAME>TAC+steroids versus alkylating agents+steroids at final follow-up (9-12 months)</NAME>
<CONT_DATA CI_END="1.0817486730658565" CI_START="-1.8017486730658563" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="2.32" MODIFIED="2013-02-14 17:21:50 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="531" SD_1="2.98" SD_2="2.71" SE="0.7355995745014633" STUDY_ID="STD-Chen-2010a" TOTAL_1="33" TOTAL_2="27" WEIGHT="20.047332150506765"/>
<CONT_DATA CI_END="-0.5255482690349019" CI_START="-1.8744517309650979" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.5" MODIFIED="2013-02-14 17:22:19 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="966" SD_1="0.29" SD_2="1.2" SE="0.34411434918451933" STUDY_ID="STD-Xu-2010" TOTAL_1="11" TOTAL_2="13" WEIGHT="79.95266784949324"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.26522550487134045" CI_START="-2.23477449512866" DF="0" EFFECT_SIZE="-1.2500000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-008.09.06" MODIFIED="2014-04-10 17:53:08 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.012852388736621373" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="2.487833501775434">
<NAME>TAC+steroids versus alkylating agents+steroids at 6 months</NAME>
<CONT_DATA CI_END="-0.26522550487134045" CI_START="-2.23477449512866" EFFECT_SIZE="-1.2500000000000002" ESTIMABLE="YES" MEAN_1="1.16" MEAN_2="2.41" MODIFIED="2011-11-23 01:12:45 +1100" MODIFIED_BY="[Empty name]" ORDER="530" SD_1="1.11" SD_2="2.41" SE="0.5024451994508242" STUDY_ID="STD-Chen-2010a" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5255482690349019" CI_START="-1.8744517309650979" DF="0" EFFECT_SIZE="-1.2" ESTIMABLE="YES" I2="0.0" ID="CMP-008.09.07" MODIFIED="2014-04-10 17:53:14 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="4.880826355437159E-4" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.0" Z="3.487212907115773">
<NAME>TAC+steroids versus alkylating agents+steroids at 9 months</NAME>
<CONT_DATA CI_END="-0.5255482690349019" CI_START="-1.8744517309650979" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.5" MODIFIED="2013-02-14 01:31:06 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="966" SD_1="0.29" SD_2="1.2" SE="0.34411434918451933" STUDY_ID="STD-Xu-2010" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0817486730658565" CI_START="-1.8017486730658563" DF="0" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-008.09.08" MODIFIED="2014-04-10 17:53:20 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.6245608777949898" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="0.4893966941783267">
<NAME>TAC+steroids versus alkylating agents+steroids at 12 months</NAME>
<CONT_DATA CI_END="1.0817486730658565" CI_START="-1.8017486730658563" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="2.32" MODIFIED="2011-11-23 01:13:00 +1100" MODIFIED_BY="[Empty name]" ORDER="531" SD_1="2.98" SD_2="2.71" SE="0.7355995745014633" STUDY_ID="STD-Chen-2010a" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.445147730128891" CI_START="0.4716889854579875" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7435897435897436" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.10" LOG_CI_END="0.8092328763278223" LOG_CI_START="-0.3263442649683481" LOG_EFFECT_SIZE="0.24144430567973713" METHOD="IV" MODIFIED="2014-04-10 17:53:36 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.4045922258025473" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="0.8334478146758383">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>TAC</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-10 17:53:28 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>TAC versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-22 21:33:47 +1100" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="0.0" STUDY_ID="STD-Praga-2007" TOTAL_1="25" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.445147730128891" CI_START="0.4716889854579875" DF="0" EFFECT_SIZE="1.7435897435897436" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-008.10.02" LOG_CI_END="0.8092328763278223" LOG_CI_START="-0.3263442649683481" LOG_EFFECT_SIZE="0.24144430567973713" MODIFIED="2014-04-10 17:53:36 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.4045922258025473" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="0.8334478146758383">
<NAME>TAC+steroids versus alkylating agents+steroids</NAME>
<DICH_DATA CI_END="6.445147730128891" CI_START="0.4716889854579875" EFFECT_SIZE="1.7435897435897436" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8092328763278223" LOG_CI_START="-0.3263442649683481" LOG_EFFECT_SIZE="0.24144430567973713" MODIFIED="2011-12-09 07:16:52 +1100" MODIFIED_BY="[Empty name]" ORDER="532" O_E="0.0" SE="0.6670436339948774" STUDY_ID="STD-Chen-2010a" TOTAL_1="39" TOTAL_2="34" VAR="0.444947209653092" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2014-04-22 16:00:00 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Mycophenolate mofetil (MMF) versus other treatments</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 17:52:01 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="41" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MMF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 03:37:12 +1100" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>MMF+steroids versus alkylating agents+steroids at final follow-up (15-17 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 21:50:13 +1100" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.0" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 22:53:27 +1100" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.0" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 17:52:18 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="41" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MMF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 03:35:35 +1100" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>MMF+steroids versus alkylating agents+steroids at final follow-up (15-17 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 21:50:20 +1100" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="0.0" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 22:53:36 +1100" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.0" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 17:52:31 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="41" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MMF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 03:37:11 +1100" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>MMF+steroids versus alkylating agents+steroids at final follow-up (15-17 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 21:50:21 +1100" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="0.0" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 22:53:39 +1100" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.0" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 17:52:58 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="57" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>100% increase in serum creatinine</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MMF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus other treatments at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 03:38:37 +1100" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 07:51:58 +1100" MODIFIED_BY="[Empty name]" ORDER="2495" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 09:13:12 +1100" MODIFIED_BY="[Empty name]" ORDER="616" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 17:53:19 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="57" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MMF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus other treatments at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-12-09 07:52:16 +1100" MODIFIED_BY="[Empty name]" ORDER="2496" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-23 03:38:38 +1100" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 09:13:07 +1100" MODIFIED_BY="[Empty name]" ORDER="615" O_E="0.0" SE="0.0" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.310521837960868" CI_END="13.918080710265865" CI_START="1.7410302795580934" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="7.829555494911979" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.06" MODIFIED="2014-04-02 17:53:50 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.8595878679217956" P_Q="0.8460485576422894" P_Z="0.011721454795458965" Q="0.8142799436178645" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="71" UNITS="" WEIGHT="400.0" Z="2.5204209955946153">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MMF</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.49624189434300353" CI_END="16.40784507306267" CI_START="-2.1629082666940294" DF="1" EFFECT_SIZE="7.12246840318432" ESTIMABLE="YES" I2="0.0" ID="CMP-009.06.01" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.48115612204789115" P_Z="0.13273186703174022" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="1.5034157522711105">
<NAME>MMF versus other treatments+steroids at final follow-up (12-17 months)</NAME>
<CONT_DATA CI_END="29.672651201550224" CI_START="-4.932651201550243" EFFECT_SIZE="12.36999999999999" ESTIMABLE="YES" MEAN_1="86.6" MEAN_2="74.23" MODIFIED="2013-01-27 01:30:27 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="558" SD_1="27.84" SD_2="21.13" SE="8.82804548350446" STUDY_ID="STD-Dussol-2008" TOTAL_1="15" TOTAL_2="17" WEIGHT="28.798757166680087"/>
<CONT_DATA CI_END="16.00413066873881" CI_START="-6.004130668738812" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="81.0" MEAN_2="76.0" MODIFIED="2013-01-27 01:30:27 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="566" SD_1="12.5" SD_2="11.9" SE="5.6144555489478325" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="9" TOTAL_2="10" WEIGHT="71.20124283331991"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="28.437288824250714" CI_START="-4.097288824250711" DF="0" EFFECT_SIZE="12.170000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-009.06.02" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.1425659713628124" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="1.4663022184922168">
<NAME>MMF versus placebo/no treatment at 6 months</NAME>
<CONT_DATA CI_END="28.437288824250714" CI_START="-4.097288824250711" EFFECT_SIZE="12.170000000000002" ESTIMABLE="YES" MEAN_1="82.27" MEAN_2="70.1" MODIFIED="2011-11-23 03:40:25 +1100" MODIFIED_BY="[Empty name]" ORDER="557" SD_1="20.62" SD_2="27.74" SE="8.299789665812744" STUDY_ID="STD-Dussol-2008" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="29.672651201550224" CI_START="-4.932651201550243" DF="0" EFFECT_SIZE="12.36999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-009.06.03" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.16114944306368015" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="1.4012161608267433">
<NAME>MMF versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="29.672651201550224" CI_START="-4.932651201550243" EFFECT_SIZE="12.36999999999999" ESTIMABLE="YES" MEAN_1="86.6" MEAN_2="74.23" MODIFIED="2011-11-23 03:40:47 +1100" MODIFIED_BY="[Empty name]" ORDER="558" SD_1="27.84" SD_2="21.13" SE="8.82804548350446" STUDY_ID="STD-Dussol-2008" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.00413066873881" CI_START="-6.004130668738812" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-009.06.04" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.37316618738927265" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="0.8905583019420319">
<NAME>MMF+steroids versus alkylating agents+steroids at 17 months</NAME>
<CONT_DATA CI_END="16.00413066873881" CI_START="-6.004130668738812" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="81.0" MEAN_2="76.0" MODIFIED="2011-11-23 22:56:22 +1100" MODIFIED_BY="[Empty name]" ORDER="566" SD_1="12.5" SD_2="11.9" SE="5.6144555489478325" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.1800497928725138" CI_END="1.164986741809163" CI_START="0.7421460218108558" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9298334667541608" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-009.07" LOG_CI_END="0.06632098287973327" LOG_CI_START="-0.12951063619335523" LOG_EFFECT_SIZE="-0.03159482665681095" METHOD="IV" MODIFIED="2014-04-02 17:54:15 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.9947646171645196" P_Q="0.9653391348746074" P_Z="0.5271070942875935" Q="1.408502876038835" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="132" WEIGHT="700.0" Z="0.6324282323583705">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MMF</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03930439043751282" CI_END="1.3495501615044252" CI_START="0.5776227940131515" DF="2" EFFECT_SIZE="0.8829104909044212" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="0.0" ID="CMP-009.07.01" LOG_CI_END="0.1301890315081037" LOG_CI_START="-0.2383556770748311" LOG_EFFECT_SIZE="-0.05408332278336368" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.9805396565031627" P_Z="0.5651270306460298" STUDIES="3" TAU2="0.0" TOTAL_1="41" TOTAL_2="36" WEIGHT="100.0" Z="0.5752429073108972">
<NAME>MMF versus other treatments at final follow-up (12-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.9570020340484504" CI_START="0.34206478887427294" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.29159127705072413" LOG_CI_START="-0.4658916284885244" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2011-12-09 07:58:43 +1100" MODIFIED_BY="[Empty name]" ORDER="2499" O_E="0.0" SE="0.44494920831460977" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.19797979797979798" WEIGHT="23.671985579053235"/>
<DICH_DATA CI_END="2.0277946620172553" CI_START="0.3947904744083435" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3070239754799399" LOG_CI_START="-0.40363333462904993" LOG_EFFECT_SIZE="-0.04830467957455503" MODIFIED="2011-12-09 07:58:38 +1100" MODIFIED_BY="[Empty name]" ORDER="2498" O_E="0.0" SE="0.4174436217684402" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.17425917735515256" WEIGHT="26.8942789347047"/>
<DICH_DATA CI_END="1.6622491491422666" CI_START="0.4971855641605762" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.2206961193205779" LOG_CI_START="-0.3034814896370279" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-12-09 07:58:43 +1100" MODIFIED_BY="[Empty name]" ORDER="2500" O_E="0.0" SE="0.30790452222270914" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.09480519480519478" WEIGHT="49.43373548624208"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0277946620172553" CI_START="0.3947904744083435" DF="0" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-009.07.02" LOG_CI_END="0.3070239754799399" LOG_CI_START="-0.40363333462904993" LOG_EFFECT_SIZE="-0.04830467957455503" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.789896753727007" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="0.26644468692330925">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.0277946620172553" CI_START="0.3947904744083435" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3070239754799399" LOG_CI_START="-0.40363333462904993" LOG_EFFECT_SIZE="-0.04830467957455503" MODIFIED="2011-11-23 03:43:16 +1100" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.4174436217684402" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.17425917735515256" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.597313398856956" CI_START="0.442660436197504" DF="0" EFFECT_SIZE="1.5740740740740742" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-009.07.03" LOG_CI_END="0.7479796241452057" LOG_CI_START="-0.35392929236255716" LOG_EFFECT_SIZE="0.19702516589132427" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.4833674124578339" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.7008968226137493">
<NAME>MMF versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="5.597313398856956" CI_START="0.442660436197504" EFFECT_SIZE="1.5740740740740742" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7479796241452057" LOG_CI_START="-0.35392929236255716" LOG_EFFECT_SIZE="0.19702516589132427" MODIFIED="2011-11-23 03:43:24 +1100" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.6472667520937663" STUDY_ID="STD-Dussol-2008" TOTAL_1="18" TOTAL_2="17" VAR="0.418954248366013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4835712740666382" CI_START="0.5171763974952388" DF="0" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-009.07.04" LOG_CI_END="0.395076627987243" LOG_CI_START="-0.28636130334205767" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.7545169812470985" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.3126889641386492">
<NAME>MMF versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="2.4835712740666382" CI_START="0.5171763974952388" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.395076627987243" LOG_CI_START="-0.28636130334205767" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2011-11-23 03:43:32 +1100" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="0.4002800140349932" STUDY_ID="STD-Dussol-2008" TOTAL_1="15" TOTAL_2="17" VAR="0.16022408963585433" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.037914642257074166" CI_END="1.443142749324741" CI_START="0.534899688603269" DF="1" EFFECT_SIZE="0.8785992301521037" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-009.07.05" LOG_CI_END="0.15930929171565714" LOG_CI_START="-0.27172765493340195" LOG_EFFECT_SIZE="-0.056209181608872456" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.845614718398932" P_Z="0.6092274982097438" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="0.5111764660098036">
<NAME>MMF+steroids versus alkylating agents+steroids at final follow-up (17-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.9570020340484504" CI_START="0.34206478887427294" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.29159127705072413" LOG_CI_START="-0.4658916284885244" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2011-11-23 21:58:38 +1100" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.44494920831460977" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.19797979797979798" WEIGHT="32.38048299655002"/>
<DICH_DATA CI_END="1.6622491491422666" CI_START="0.4971855641605762" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.2206961193205779" LOG_CI_START="-0.3034814896370279" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-11-23 22:57:43 +1100" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.30790452222270914" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.09480519480519478" WEIGHT="67.61951700344999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6943278841390914" CI_END="1.5445535917996143" CI_START="0.6259678927505727" DF="1" EFFECT_SIZE="0.9832807112412676" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-009.07.06" LOG_CI_END="0.18880298173365595" LOG_CI_START="-0.2034479421232097" LOG_EFFECT_SIZE="-0.007322480194776823" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.4046966047654168" P_Z="0.9416655748524672" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.07317661520413643">
<NAME>MMF+steroids versus alkylating agents+steroids at 15-17 months</NAME>
<DICH_DATA CI_END="1.6862123824232746" CI_START="0.3136767499445034" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.22691227414728482" LOG_CI_START="-0.5035176704798476" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2011-11-23 21:58:43 +1100" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.42905816516051654" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="8" VAR="0.18409090909090908" WEIGHT="28.83837679542602"/>
<DICH_DATA CI_END="1.8978029597675818" CI_START="0.6505248054759919" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.2782511196150616" LOG_CI_START="-0.18673613849371135" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2011-11-23 22:57:52 +1100" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="0.2731358171371426" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="9" TOTAL_2="10" VAR="0.07460317460317459" WEIGHT="71.16162320457398"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6862123824232746" CI_START="0.3136767499445034" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-009.07.07" LOG_CI_END="0.22691227414728482" LOG_CI_START="-0.5035176704798476" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.4579566286626189" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="100.00000000000001" Z="0.7422157576220387">
<NAME>MMF+steroids versus alkylating agents+steroids at 24 months</NAME>
<DICH_DATA CI_END="1.6862123824232746" CI_START="0.3136767499445034" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.22691227414728482" LOG_CI_START="-0.5035176704798476" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2011-11-23 21:58:48 +1100" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.42905816516051654" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="8" VAR="0.18409090909090908" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.236596290969837" CI_END="1.6309311247604303" CI_START="0.47904043850324507" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8839015562684723" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-009.08" LOG_CI_END="0.21243562090043516" LOG_CI_START="-0.31962782379309446" LOG_EFFECT_SIZE="-0.05359610144632962" METHOD="IV" MODIFIED="2014-04-22 16:00:00 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5098068200048449" P_Q="0.9277464770118251" P_Z="0.6929430424914036" Q="1.9104606232590777" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="132" WEIGHT="700.0" Z="0.39486429520475064">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MMF</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3706192966042323" CI_END="2.815678161438908" CI_START="0.3457201870654788" DF="2" EFFECT_SIZE="0.9866289985039172" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="15.63385977390473" ID="CMP-009.08.01" LOG_CI_END="0.4495830124377541" LOG_CI_START="-0.46127526067982055" LOG_EFFECT_SIZE="-0.005846124121033248" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.30565157545032784" P_Z="0.9799280503935341" STUDIES="3" TAU2="0.13958208897496033" TOTAL_1="41" TOTAL_2="36" WEIGHT="100.0" Z="0.025159112157280783">
<NAME>MMF versus other treatments at final follow-up (12-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.5887051519560655" CI_START="0.1149303005528511" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.41308258802831893" LOG_CI_START="-0.9395654575774819" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2011-12-09 08:02:08 +1100" MODIFIED_BY="[Empty name]" ORDER="2505" O_E="0.0" SE="0.7945521577046603" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.6313131313131313" WEIGHT="37.13483218312392"/>
<DICH_DATA CI_END="4.5049681702325906" CI_START="0.0444261749678004" EFFECT_SIZE="0.4473684210526316" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6536917268264734" LOG_CI_START="-1.3523610773035457" LOG_EFFECT_SIZE="-0.34933467523853623" MODIFIED="2011-12-09 08:02:02 +1100" MODIFIED_BY="[Empty name]" ORDER="2504" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="1.388544891640867" WEIGHT="18.73343315006065"/>
<DICH_DATA CI_END="9.202054258760844" CI_START="0.5613191479805413" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9638847896993661" LOG_CI_START="-0.2507901426717408" LOG_EFFECT_SIZE="0.35654732351381263" MODIFIED="2011-12-09 08:02:08 +1100" MODIFIED_BY="[Empty name]" ORDER="2506" O_E="0.0" SE="0.7135060680126757" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.509090909090909" WEIGHT="44.13173466681543"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.876883792725292E-33" CI_END="4.504968170232591" CI_START="0.0444261749678004" DF="0" EFFECT_SIZE="0.44736842105263164" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="99.99999999999999" ID="CMP-009.08.02" LOG_CI_END="0.6536917268264735" LOG_CI_START="-1.3523610773035457" LOG_EFFECT_SIZE="-0.3493346752385362" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.4948485731953328" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.00000000000001" Z="0.6826175069857738">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.5049681702325906" CI_START="0.0444261749678004" EFFECT_SIZE="0.4473684210526316" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6536917268264734" LOG_CI_START="-1.3523610773035457" LOG_EFFECT_SIZE="-0.34933467523853623" MODIFIED="2011-11-23 03:44:10 +1100" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="1.388544891640867" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="65.33683949785127" CI_START="0.12362952338910503" DF="0" EFFECT_SIZE="2.8421052631578947" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.08.03" LOG_CI_END="1.8151581227650624" LOG_CI_START="-0.9078778050247834" LOG_EFFECT_SIZE="0.45364015887013953" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.513733960482249" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.6530346252523781">
<NAME>MMF versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="65.33683949785127" CI_START="0.12362952338910503" EFFECT_SIZE="2.8421052631578947" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8151581227650624" LOG_CI_START="-0.9078778050247834" LOG_EFFECT_SIZE="0.45364015887013953" MODIFIED="2011-11-23 03:43:54 +1100" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="1.5995247832289885" STUDY_ID="STD-Dussol-2008" TOTAL_1="18" TOTAL_2="17" VAR="2.5584795321637426" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.6399079476503475" CI_START="0.05693552343259251" DF="0" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-009.08.04" LOG_CI_END="0.7512720156582093" LOG_CI_START="-1.2446166823409863" LOG_EFFECT_SIZE="-0.24667233334138852" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.6280560557963987" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.48446477984091985">
<NAME>MMF versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="5.6399079476503475" CI_START="0.05693552343259251" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7512720156582093" LOG_CI_START="-1.2446166823409863" LOG_EFFECT_SIZE="-0.24667233334138852" MODIFIED="2011-11-23 03:44:05 +1100" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="1.1723949010131223" STUDY_ID="STD-Dussol-2008" TOTAL_1="15" TOTAL_2="17" VAR="1.3745098039215686" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7859118526220155" CI_END="4.6939362179916095" CI_START="0.2877152584822005" DF="1" EFFECT_SIZE="1.162117495031556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="44.00619501282587" ID="CMP-009.08.05" LOG_CI_END="0.6715371840349459" LOG_CI_START="-0.5410371054405685" LOG_EFFECT_SIZE="0.06525003929718876" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.181425192051077" P_Z="0.8329372871199183" STUDIES="2" TAU2="0.44812852606578557" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="0.21093590408820156">
<NAME>MMF+steroids versus alkylating agents+steroids at final follow-up (17-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.5887051519560655" CI_START="0.1149303005528511" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.41308258802831893" LOG_CI_START="-0.9395654575774819" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2011-11-23 21:59:14 +1100" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.7945521577046603" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.6313131313131313" WEIGHT="46.99944623407969"/>
<DICH_DATA CI_END="9.202054258760844" CI_START="0.5613191479805413" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9638847896993661" LOG_CI_START="-0.2507901426717408" LOG_EFFECT_SIZE="0.35654732351381263" MODIFIED="2011-11-23 22:58:52 +1100" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.7135060680126757" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.509090909090909" WEIGHT="53.00055376592031"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7542065998711163" CI_END="6.651140475131257" CI_START="0.21796500432442736" DF="1" EFFECT_SIZE="1.204041470392261" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="63.69190314020759" ID="CMP-009.08.06" LOG_CI_END="0.8228961204292627" LOG_CI_START="-0.6616132295551606" LOG_EFFECT_SIZE="0.08064144543705108" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0969990066389178" P_Z="0.8313752144846474" STUDIES="2" TAU2="0.9703508982367877" TOTAL_1="20" TOTAL_2="18" WEIGHT="99.99999999999997" Z="0.2129381384085327">
<NAME>MMF+steroids versus alkylating agents+steroids at 15-17 months</NAME>
<DICH_DATA CI_END="2.2617735832344636" CI_START="0.10393527230240995" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.35444912734739387" LOG_CI_START="-0.9832370417913192" LOG_EFFECT_SIZE="-0.31439395722196267" MODIFIED="2011-11-23 21:59:20 +1100" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.7857634774054101" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="8" VAR="0.6174242424242423" WEIGHT="47.89079875580524"/>
<DICH_DATA CI_END="10.936104193206706" CI_START="0.7055574129870769" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.038862639299265" LOG_CI_START="-0.15146764083383965" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2011-11-23 22:59:01 +1100" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.699205898780101" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="9" TOTAL_2="10" VAR="0.4888888888888888" WEIGHT="52.109201244194736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2617735832344636" CI_START="0.10393527230240995" DF="0" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-009.08.07" LOG_CI_END="0.35444912734739387" LOG_CI_START="-0.9832370417913192" LOG_EFFECT_SIZE="-0.31439395722196267" MODIFIED="2014-04-22 16:00:00 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.35689718798848846" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="100.0" Z="0.9212935699392366">
<NAME>MMF+steroids versus alkylating agents+steroids at 24 months</NAME>
<DICH_DATA CI_END="2.2617735832344636" CI_START="0.10393527230240995" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.35444912734739387" LOG_CI_START="-0.9832370417913192" LOG_EFFECT_SIZE="-0.31439395722196267" MODIFIED="2011-11-23 21:59:26 +1100" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="0.7857634774054101" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="8" VAR="0.6174242424242423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.854182550466444" CI_END="1.364585347389566" CI_START="0.6294991922375048" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.926825427964116" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-009.09" LOG_CI_END="0.13500070361249208" LOG_CI_START="-0.20100482283494214" LOG_EFFECT_SIZE="-0.03300205961122498" METHOD="IV" MODIFIED="2014-04-02 17:55:04 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.8273618243593568" P_Q="0.9342759704769584" P_Z="0.7002295471840093" Q="1.8344636474826024" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="132" WEIGHT="700.0" Z="0.3850106213283615">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MMF</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.839790441267855" CI_END="1.702170112795497" CI_START="0.40549414834880787" DF="2" EFFECT_SIZE="0.8307948123530888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-009.09.01" LOG_CI_END="0.23100296077593196" LOG_CI_START="-0.3920154086739339" LOG_EFFECT_SIZE="-0.08050622394900103" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.39856085181436596" P_Z="0.6124833929093199" STUDIES="3" TAU2="0.0" TOTAL_1="41" TOTAL_2="36" WEIGHT="100.0" Z="0.5065317724441677">
<NAME>MMF versus other treatments at final follow-up (12-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="5.824586591901149" CI_START="0.25859317624391503" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7652651061396815" LOG_CI_START="-0.5873829394661193" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2011-12-09 08:04:15 +1100" MODIFIED_BY="[Empty name]" ORDER="2510" O_E="0.0" SE="0.7945521577046603" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.6313131313131313" WEIGHT="21.214465051681735"/>
<DICH_DATA CI_END="2.889951427770075" CI_START="0.39889867104895677" EFFECT_SIZE="1.0736842105263158" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.46089054350786235" LOG_CI_START="-0.39913741056172275" LOG_EFFECT_SIZE="0.030876566473069796" MODIFIED="2011-12-09 08:04:18 +1100" MODIFIED_BY="[Empty name]" ORDER="2512" O_E="0.0" SE="0.5051846774275063" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.25521155830753356" WEIGHT="52.477914596530404"/>
<DICH_DATA CI_END="1.472328681401735" CI_START="0.0898110636768866" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.16800477235529082" LOG_CI_START="-1.0466701600158161" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2011-12-09 08:04:15 +1100" MODIFIED_BY="[Empty name]" ORDER="2511" O_E="0.0" SE="0.7135060680126757" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.509090909090909" WEIGHT="26.307620351787865"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.889951427770075" CI_START="0.39889867104895677" DF="0" EFFECT_SIZE="1.0736842105263158" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-009.09.02" LOG_CI_END="0.46089054350786235" LOG_CI_START="-0.39913741056172275" LOG_EFFECT_SIZE="0.030876566473069796" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.8880812395306014" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="0.1407325377439471">
<NAME>MMF versus placebo/no treatment at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.889951427770075" CI_START="0.39889867104895677" EFFECT_SIZE="1.0736842105263158" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.46089054350786235" LOG_CI_START="-0.39913741056172275" LOG_EFFECT_SIZE="0.030876566473069796" MODIFIED="2011-11-23 03:44:50 +1100" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.5051846774275063" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="0.25521155830753356" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.819699523248335" CI_START="0.32901094235879685" DF="0" EFFECT_SIZE="1.2592592592592593" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-009.09.03" LOG_CI_END="0.6830199636614904" LOG_CI_START="-0.4827896578949547" LOG_EFFECT_SIZE="0.10011515288326783" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.7363973293140653" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.33662802284296606">
<NAME>MMF versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="4.819699523248335" CI_START="0.32901094235879685" EFFECT_SIZE="1.2592592592592593" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6830199636614904" LOG_CI_START="-0.4827896578949547" LOG_EFFECT_SIZE="0.10011515288326783" MODIFIED="2011-11-23 03:44:33 +1100" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Dussol-2008" TOTAL_1="18" TOTAL_2="17" VAR="0.46895424836601296" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.560915041939022" CI_START="0.5194170538235697" DF="0" EFFECT_SIZE="1.36" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-009.09.04" LOG_CI_END="0.5515616121866873" LOG_CI_START="-0.2844837954462523" LOG_EFFECT_SIZE="0.13353890837021754" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.5312376887865555" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.6261177887010949">
<NAME>MMF versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="3.560915041939022" CI_START="0.5194170538235697" EFFECT_SIZE="1.36" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5515616121866873" LOG_CI_START="-0.2844837954462523" LOG_EFFECT_SIZE="0.13353890837021754" MODIFIED="2011-11-23 03:44:40 +1100" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.4910972109351012" STUDY_ID="STD-Dussol-2008" TOTAL_1="15" TOTAL_2="17" VAR="0.24117647058823533" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2974503181471249" CI_END="2.084082854776072" CI_START="0.19366713168922467" DF="1" EFFECT_SIZE="0.6353096478782396" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="22.925757848817714" ID="CMP-009.09.05" LOG_CI_END="0.31891498077756397" LOG_CI_START="-0.7129440795247443" LOG_EFFECT_SIZE="-0.19701454937359014" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.25467959679584895" P_Z="0.4541958331875955" STUDIES="2" TAU2="0.16960677231722424" TOTAL_1="22" TOTAL_2="19" WEIGHT="99.99999999999999" Z="0.7484383014275137">
<NAME>MMF+steroids versus alkylating agents+steroids at final follow-up (17-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="5.824586591901149" CI_START="0.25859317624391503" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7652651061396815" LOG_CI_START="-0.5873829394661193" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2011-11-23 21:59:39 +1100" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.7945521577046603" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="0.6313131313131313" WEIGHT="45.86980367568952"/>
<DICH_DATA CI_END="1.472328681401735" CI_START="0.0898110636768866" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.16800477235529082" LOG_CI_START="-1.0466701600158161" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2011-11-23 22:59:16 +1100" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.7135060680126757" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="0.509090909090909" WEIGHT="54.13019632431047"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7288163558650195" CI_END="1.8397984243795944" CI_START="0.23742562375211612" DF="1" EFFECT_SIZE="0.6609200318393185" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-009.09.06" LOG_CI_END="0.2647702425882091" LOG_CI_START="-0.6244724123669826" LOG_EFFECT_SIZE="-0.17985108488938673" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.3932671494894735" P_Z="0.4278866828435922" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.7928131809678345">
<NAME>MMF+steroids versus alkylating agents+steroids at 15-17 months</NAME>
<DICH_DATA CI_END="5.088990562277543" CI_START="0.23385436268042234" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7066316454587563" LOG_CI_START="-0.6310545236799568" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2011-11-23 21:59:54 +1100" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.7857634774054101" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="8" VAR="0.6174242424242423" WEIGHT="44.190824012782464"/>
<DICH_DATA CI_END="1.7497766709130733" CI_START="0.11288918607793229" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24298262195518985" LOG_CI_START="-0.9473476581779149" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2011-11-23 22:59:25 +1100" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.699205898780101" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="9" TOTAL_2="10" VAR="0.4888888888888888" WEIGHT="55.80917598721753"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.088990562277543" CI_START="0.23385436268042234" DF="0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-009.09.07" LOG_CI_END="0.7066316454587563" LOG_CI_START="-0.6310545236799568" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.9118266336618578" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="100.0" Z="0.11073481969019627">
<NAME>MMF+steroids versus alkylating agents+steroids at 24 months</NAME>
<DICH_DATA CI_END="5.088990562277543" CI_START="0.23385436268042234" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7066316454587563" LOG_CI_START="-0.6310545236799568" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2011-11-23 21:59:59 +1100" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="0.7857634774054101" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="8" VAR="0.6174242424242423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.10" MODIFIED="2014-04-02 17:55:49 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="22" TOTAL_2="16" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MMF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.10.01" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>MMF versus other treatments+steroids at final follow-up (15 months)</NAME>
<CONT_DATA CI_END="1.6481882614505563" CI_START="-0.6481882614505563" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.0" MODIFIED="2011-11-23 22:06:13 +1100" MODIFIED_BY="[Empty name]" ORDER="562" SD_1="1.41" SD_2="1.14" SE="0.5858211020749966" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.10.02" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>MMF+steroids versus alkylating agents+steroids at 15 months</NAME>
<CONT_DATA CI_END="1.6481882614505563" CI_START="-0.6481882614505563" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.0" MODIFIED="2013-01-27 01:31:41 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="562" SD_1="1.41" SD_2="1.14" SE="0.5858211020749966" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.7602229929621" CI_END="5.293799493484685" CI_START="0.12475182687501969" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8126568512738132" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="46.81166505966955" I2_Q="72.62746440795678" ID="CMP-009.11" LOG_CI_END="0.7237674880567057" LOG_CI_START="-0.9039530858173513" LOG_EFFECT_SIZE="-0.0900927988803228" METHOD="IV" MODIFIED="2014-04-02 17:56:12 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.15257319708965644" P_Q="0.05595854029853242" P_Z="0.828236153816746" Q="3.653296921059387" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.283647638017924" TOTALS="YES" TOTAL_1="41" TOTAL_2="36" WEIGHT="100.00000000000001" Z="0.21696431673352534">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>MMF</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MMF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="140.24211218898935" CI_START="0.46783379810755" DF="0" EFFECT_SIZE="8.100000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-009.11.01" LOG_CI_END="2.146878444052046" LOG_CI_START="-0.32990840629474627" LOG_EFFECT_SIZE="0.9084850188786499" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.15048259320620055" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="26.885359451615603" Z="1.437828949428596">
<NAME>MMF versus placebo/no treatment</NAME>
<DICH_DATA CI_END="140.24211218898935" CI_START="0.46783379810755" EFFECT_SIZE="8.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.146878444052046" LOG_CI_START="-0.32990840629474627" LOG_EFFECT_SIZE="0.9084850188786497" MODIFIED="2011-11-23 21:52:14 +1100" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="1.4548768561863465" STUDY_ID="STD-Dussol-2008" TOTAL_1="19" TOTAL_2="17" VAR="2.116666666666667" WEIGHT="26.885359451615603"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10692607190271289" CI_END="1.5910014138009672" CI_START="0.07507133792934662" DF="1" EFFECT_SIZE="0.345598907378945" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-009.11.02" LOG_CI_END="0.20167056557095975" LOG_CI_START="-1.124525844022324" LOG_EFFECT_SIZE="-0.46142763922568225" MODIFIED="2014-04-01 16:34:46 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.7436713061092655" P_Z="0.17260762699890445" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="73.11464054838441" Z="1.3638727232432084">
<NAME>MMF+steroids versus alkylating agents+steroids</NAME>
<DICH_DATA CI_END="2.1932786411390572" CI_START="0.03391277510030719" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3410938093436892" LOG_CI_START="-1.4696366702208143" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2011-11-23 21:52:52 +1100" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="1.063632046956621" STUDY_ID="STD-Chan-2007" TOTAL_1="11" TOTAL_2="9" VAR="1.1313131313131313" WEIGHT="37.85513764483992"/>
<DICH_DATA CI_END="4.280395630134262" CI_START="0.04826926950242054" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6314839120139702" LOG_CI_START="-1.3163292736583827" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2011-11-23 23:00:18 +1100" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="1.1441551070947107" STUDY_ID="STD-Senthil-Nayagam-2008" TOTAL_1="11" TOTAL_2="10" VAR="1.309090909090909" WEIGHT="35.25950290354449"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2014-04-02 18:02:27 +1100" MODIFIED_BY="Narelle S Willis" NO="10">
<NAME>Mycophenolate mofetil (MMF)+cyclosporine (CSA) versus CSA</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 17:57:31 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>MMF+CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>CSA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MMF+CSA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:41:48 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.8616125994960204" CI_START="0.8618573192289324" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.269889309617457" LOG_CI_START="-0.06456462582316162" LOG_EFFECT_SIZE="0.1026623418971477" MODIFIED="2013-02-14 00:29:51 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.19645989725150056" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.03859649122807016" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-010.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:41:57 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="2.081852540666224" CI_START="0.6537980402183219" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.31844996482728344" LOG_CI_START="-0.18455638556605694" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2013-02-14 00:30:07 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.29546842014263947" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.08730158730158732" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-010.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:42:03 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="1.8616125994960204" CI_START="0.8618573192289324" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.269889309617457" LOG_CI_START="-0.06456462582316162" LOG_EFFECT_SIZE="0.1026623418971477" MODIFIED="2013-02-14 00:30:11 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.19645989725150056" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.03859649122807016" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:02:06 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>MMF+CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>CSA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MMF+CSA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:42:13 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.329594317451765" CI_START="0.41061070562936947" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6364472049108398" LOG_CI_START="-0.38656973169424" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-02-14 00:30:51 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:42:19 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="6.942343759903583" CI_START="0.324098039194655" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8415061145691785" LOG_CI_START="-0.489323596457816" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-02-14 00:30:59 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.7817359599705714" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.6111111111111109" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-010.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:42:26 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="4.329594317451765" CI_START="0.41061070562936947" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6364472049108398" LOG_CI_START="-0.38656973169424" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-02-14 00:31:04 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.6009252125773314" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.36111111111111105" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:02:27 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>MMF+CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>CSA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MMF+CSA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:42:37 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="3.185334600743034" CI_START="0.4905293150790251" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5031550591592232" LOG_CI_START="-0.3093350331431103" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-02-14 00:31:33 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.4772607021092118" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.2277777777777778" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-010.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:42:44 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="2.809458388628025" CI_START="0.3559404916078296" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.44862260406819815" LOG_CI_START="-0.44862260406819815" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-14 00:31:35 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.5270462766947299" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.2777777777777778" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-010.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:42:50 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="3.185334600743034" CI_START="0.4905293150790251" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5031550591592232" LOG_CI_START="-0.3093350331431103" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-02-14 00:31:40 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="2417" O_E="0.0" SE="0.4772607021092118" STUDY_ID="STD-Jurubita-2012" TOTAL_1="9" TOTAL_2="9" VAR="0.2277777777777778" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2014-04-20 15:18:49 +1000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Adrenocorticotropic hormone (ACTH) versus other treatments</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:15:50 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACTH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids at final follow-up (22 months)</NAME>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-24 09:18:29 +1100" MODIFIED_BY="[Empty name]" ORDER="621" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:16:05 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACTH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids at final follow-up (22 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 09:18:43 +1100" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.0" SE="0.0" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:17:20 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACTH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids at final follow-up (22 months)</NAME>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-24 09:18:39 +1100" MODIFIED_BY="[Empty name]" ORDER="623" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:13:38 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>100% increase in serum creatinine</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACTH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-20 15:13:38 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids at 22 months</NAME>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-24 09:19:17 +1100" MODIFIED_BY="[Empty name]" ORDER="625" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:15:56 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACTH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-20 15:15:56 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids at 22 months</NAME>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-24 09:19:19 +1100" MODIFIED_BY="[Empty name]" ORDER="627" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.06" MODIFIED="2014-04-20 15:16:53 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="16" UNITS="&#956;mol/L" WEIGHT="0.0" Z="0.0">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACTH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.06.01" MODIFIED="2014-04-20 15:16:53 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids at 22 months</NAME>
<CONT_DATA CI_END="17.068021832872862" CI_START="-19.068021832872862" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="80.0" MODIFIED="2013-01-27 01:22:25 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="628" SD_1="33.3" SD_2="13.3" SE="9.218547879140184" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="28.497522236924933" CI_END="1.5027258574072235" CI_START="1.0980578478640266" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2845543666634744" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="67" I2="68.41830694902141" I2_Q="63.99643489168265" ID="CMP-011.07" LOG_CI_END="0.17687975937960196" LOG_CI_START="0.04062522021094021" LOG_EFFECT_SIZE="0.10875248979527109" METHOD="IV" MODIFIED="2014-04-02 18:18:15 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="7.873337896465715E-4" P_Q="0.004524183935526671" P_Z="0.001755711700413315" Q="22.220021755989613" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12344858408602753" TOTALS="SUB" TOTAL_1="144" TOTAL_2="144" WEIGHT="900.0" Z="3.1287172453600776">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACTH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.861927929459178" CI_END="14.551789538206961" CI_START="0.44684284561238574" DF="1" EFFECT_SIZE="2.549973146134081" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="14" I2="85.42683615625187" ID="CMP-011.07.01" LOG_CI_END="1.162916404921814" LOG_CI_START="-0.349845191149743" LOG_EFFECT_SIZE="0.40653560688603546" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.008805211477503572" P_Z="0.2921434166006621" STUDIES="2" TAU2="1.3712724263556297" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="1.0534312214151067">
<NAME>ACTH versus other treatments at final follow-up (21-22 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="25.615203722900386" CI_START="1.912926421748239" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4084978142580222" LOG_CI_START="0.28169826577049145" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-12-09 10:51:31 +1100" MODIFIED_BY="[Empty name]" ORDER="3355" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.4380952380952381" WEIGHT="43.64046412416589"/>
<DICH_DATA CI_END="1.636036569045252" CI_START="0.8319564103053148" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.21379300688852187" LOG_CI_START="-0.07989942762729547" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2011-12-09 10:51:36 +1100" MODIFIED_BY="[Empty name]" ORDER="3356" O_E="0.0" SE="0.17251638983558856" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.029761904761904767" WEIGHT="56.359535875834105"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1254129761984543E-31" CI_END="25.615203722900386" CI_START="1.9129264217482393" DF="0" EFFECT_SIZE="7.000000000000001" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="100.0" ID="CMP-011.07.02" LOG_CI_END="1.4084978142580222" LOG_CI_START="0.2816982657704915" LOG_EFFECT_SIZE="0.8450980400142569" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.003282754521303212" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.939940336427394">
<NAME>ACTH versus placebo/no treatment at final follow-up (21 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="25.615203722900386" CI_START="1.912926421748239" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4084978142580222" LOG_CI_START="0.28169826577049145" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-11-13 06:06:53 +1100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.4380952380952381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="47.52988229188597" CI_START="2.2465399161320097" DF="0" EFFECT_SIZE="10.333333333333336" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" I2="0.0" ID="CMP-011.07.03" LOG_CI_END="1.6769667387625116" LOG_CI_START="0.351514139466709" LOG_EFFECT_SIZE="1.0142404391146103" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.0027038669707898197" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.999541037355633">
<NAME>ACTH versus placebo/no treatment at 9 months</NAME>
<DICH_DATA CI_END="47.52988229188597" CI_START="2.2465399161320097" EFFECT_SIZE="10.333333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" LOG_CI_END="1.6769667387625116" LOG_CI_START="0.351514139466709" LOG_EFFECT_SIZE="1.0142404391146103" MODIFIED="2011-11-13 06:06:33 +1100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.778577417922537" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.6061827956989247" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1254129761984543E-31" CI_END="25.615203722900386" CI_START="1.9129264217482393" DF="0" EFFECT_SIZE="7.000000000000001" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="100.0" ID="CMP-011.07.04" LOG_CI_END="1.4084978142580222" LOG_CI_START="0.2816982657704915" LOG_EFFECT_SIZE="0.8450980400142569" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.003282754521303212" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.939940336427394">
<NAME>ACTH versus placebo/no treatment at 21 months</NAME>
<DICH_DATA CI_END="25.615203722900386" CI_START="1.912926421748239" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4084978142580222" LOG_CI_START="0.28169826577049145" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-11-24 09:23:49 +1100" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.4380952380952381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.636036569045252" CI_START="0.8319564103053148" DF="0" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-011.07.05" LOG_CI_END="0.21379300688852187" LOG_CI_START="-0.07989942762729547" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.3715668770081192" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.89354223082321">
<NAME>ACTH versus alkylating agents+steroids at final follow-up (22 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.636036569045252" CI_START="0.8319564103053148" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.21379300688852187" LOG_CI_START="-0.07989942762729547" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2011-11-24 09:26:38 +1100" MODIFIED_BY="[Empty name]" ORDER="632" O_E="0.0" SE="0.17251638983558856" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.029761904761904767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.105620019898895" CI_START="0.7094476431533719" DF="0" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-011.07.06" LOG_CI_END="0.32338000115607135" LOG_CI_START="-0.149079649718271" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.4696355693906292" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.7230721410358545">
<NAME>ACTH versus alkylating agents+steroids at 6 months</NAME>
<DICH_DATA CI_END="2.105620019898895" CI_START="0.7094476431533719" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.32338000115607135" LOG_CI_START="-0.149079649718271" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2011-11-24 09:26:45 +1100" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="0.2775251376365788" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.07702020202020202" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.031905694880925" CI_START="0.8317315140450151" DF="0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" ID="CMP-011.07.07" LOG_CI_END="0.30790354753744886" LOG_CI_START="-0.08001684292377528" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.24956964570288598" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.1513953496161073">
<NAME>ACTH versus alkylating agents+steroids at 12 months</NAME>
<DICH_DATA CI_END="2.031905694880925" CI_START="0.8317315140450151" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.30790354753744886" LOG_CI_START="-0.08001684292377528" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2011-11-24 09:26:54 +1100" MODIFIED_BY="[Empty name]" ORDER="634" O_E="0.0" SE="0.227866357593825" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.05192307692307693" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6559279587150857" CI_START="0.8849261548527091" DF="0" EFFECT_SIZE="1.2105263157894737" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-011.07.08" LOG_CI_END="0.2190414388419336" LOG_CI_START="-0.05309296871240584" LOG_EFFECT_SIZE="0.08297423506476391" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.23201181840220553" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="1.1951925802636676">
<NAME>ACTH versus alkylating agents+steroids at 18 months</NAME>
<DICH_DATA CI_END="1.6559279587150857" CI_START="0.8849261548527091" EFFECT_SIZE="1.2105263157894737" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2190414388419336" LOG_CI_START="-0.05309296871240584" LOG_EFFECT_SIZE="0.08297423506476391" MODIFIED="2011-11-24 09:27:10 +1100" MODIFIED_BY="[Empty name]" ORDER="635" O_E="0.0" SE="0.15985309808446194" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="11" TOTAL_2="11" VAR="0.02555301296720061" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.406423946446995E-33" CI_END="1.5036389858523296" CI_START="0.8307412615993195" DF="0" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="99.99999999999999" ID="CMP-011.07.09" LOG_CI_END="0.17714357743086903" LOG_CI_START="-0.08053421828175905" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Z="0.4624395179376801" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.00000000000001" Z="0.7348357819426633">
<NAME>ACTH versus alkylating agents+steroids at 24 months</NAME>
<DICH_DATA CI_END="1.5036389858523298" CI_START="0.8307412615993196" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.1771435774308691" LOG_CI_START="-0.08053421828175898" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2011-11-24 09:27:17 +1100" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="0.15136121272725794" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="9" TOTAL_2="9" VAR="0.022910216718266235" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.255776323417491" CI_END="5.428799382314286" CI_START="2.077623575630041" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="3.358422484450395" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="19" I2="2.76342377430153" I2_Q="0.0" ID="CMP-011.08" LOG_CI_END="0.7347037928872655" LOG_CI_START="0.31756686476330553" LOG_EFFECT_SIZE="0.5261353288252855" METHOD="IV" MODIFIED="2014-04-02 18:18:38 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.41400701099508164" P_Q="0.5598941161473732" P_Z="7.645323780412847E-7" Q="6.785945226844871" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01471922555348215" TOTALS="SUB" TOTAL_1="144" TOTAL_2="144" WEIGHT="900.0" Z="4.94421004694773">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACTH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4066117920624386" CI_END="19.26595327153685" CI_START="0.7540031194494359" DF="1" EFFECT_SIZE="3.8113762430263756" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" I2="58.44780602761812" ID="CMP-011.08.01" LOG_CI_END="1.2847905025951007" LOG_CI_START="-0.12262685737044593" LOG_EFFECT_SIZE="0.5810818226123274" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.12082381928496233" P_Z="0.10557112236119905" STUDIES="2" TAU2="0.8492951502073967" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.00000000000001" Z="1.6184246077779434">
<NAME>ACTH versus other treatments at final follow-up (21-22 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="74.87602215221686" CI_START="1.6160046503808239" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.8743427641057142" LOG_CI_START="0.20844260621073604" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2011-12-09 10:52:51 +1100" MODIFIED_BY="[Empty name]" ORDER="3359" O_E="0.0" SE="0.9785579990862869" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.9575757575757575" WEIGHT="37.82630201687432"/>
<DICH_DATA CI_END="5.328816523105796" CI_START="0.7506357148263529" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7266307672714092" LOG_CI_START="-0.12457077594344677" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-12-09 10:52:55 +1100" MODIFIED_BY="[Empty name]" ORDER="3360" O_E="0.0" SE="0.5" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.25" WEIGHT="62.17369798312569"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="74.87602215221686" CI_START="1.6160046503808239" DF="0" EFFECT_SIZE="11.000000000000002" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" ID="CMP-011.08.02" LOG_CI_END="1.8743427641057142" LOG_CI_START="0.20844260621073604" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.01426827082034153" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.45043755713751">
<NAME>ACTH versus placebo/no treatment at final follow-up (22 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="74.87602215221686" CI_START="1.6160046503808239" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.8743427641057142" LOG_CI_START="0.20844260621073604" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2011-11-24 09:27:57 +1100" MODIFIED_BY="[Empty name]" ORDER="637" O_E="0.0" SE="0.9785579990862869" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.9575757575757575" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="328.8590425264282" CI_START="1.3410000728946343" DF="0" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-011.08.03" LOG_CI_END="2.5170097880086804" LOG_CI_START="0.1274288014591579" LOG_EFFECT_SIZE="1.3222192947339193" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.030082581131902233" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.1690013537348047">
<NAME>ACTH versus placebo/no treatment at 9 months</NAME>
<DICH_DATA CI_END="328.8590425264282" CI_START="1.3410000728946343" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5170097880086804" LOG_CI_START="0.1274288014591579" LOG_EFFECT_SIZE="1.3222192947339193" MODIFIED="2011-11-24 09:29:26 +1100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="1.4036517001158426" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="1.9702380952380953" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="74.87602215221686" CI_START="1.6160046503808239" DF="0" EFFECT_SIZE="11.000000000000002" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" ID="CMP-011.08.04" LOG_CI_END="1.8743427641057142" LOG_CI_START="0.20844260621073604" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.01426827082034153" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.45043755713751">
<NAME>ACTH versus placebo/no treatment at 21 months</NAME>
<DICH_DATA CI_END="74.87602215221686" CI_START="1.6160046503808239" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.8743427641057142" LOG_CI_START="0.20844260621073604" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2011-11-13 06:07:59 +1100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.9785579990862869" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.9575757575757575" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.328816523105796" CI_START="0.7506357148263529" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-011.08.05" LOG_CI_END="0.7266307672714092" LOG_CI_START="-0.12457077594344677" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.16565703800830708" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.3862943611198906">
<NAME>ACTH versus alkylating agents+steroids at final follow-up (22 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="5.328816523105796" CI_START="0.7506357148263529" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7266307672714092" LOG_CI_START="-0.12457077594344677" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-11-24 09:29:48 +1100" MODIFIED_BY="[Empty name]" ORDER="639" O_E="0.0" SE="0.5" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.25" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.870086473447536" CI_START="0.3478921498479488" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-011.08.06" LOG_CI_END="1.4127978803933245" LOG_CI_START="-0.4585553709539996" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="0.31758790299628126" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.9994269920292427">
<NAME>ACTH versus alkylating agents+steroids at 6 months</NAME>
<DICH_DATA CI_END="25.870086473447536" CI_START="0.3478921498479488" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4127978803933245" LOG_CI_START="-0.4585553709539996" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-24 09:29:57 +1100" MODIFIED_BY="[Empty name]" ORDER="640" O_E="0.0" SE="1.0992421631894098" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="1.2083333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.993752631669524" CI_START="1.0003906130396254" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-011.08.07" LOG_CI_END="1.2039503746916411" LOG_CI_START="1.6960796428365355E-4" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.04993547623045178" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.9605162869370942">
<NAME>ACTH versus alkylating agents+steroids at 12 months</NAME>
<DICH_DATA CI_END="15.993752631669524" CI_START="1.0003906130396254" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2039503746916411" LOG_CI_START="1.6960796428365355E-4" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-11-24 09:30:05 +1100" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.5" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.24440992845388" CI_START="0.9249185177878316" DF="0" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-011.08.08" LOG_CI_END="1.1220326141602455" LOG_CI_START="-0.033896525459694106" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.06503523801708956" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="1.8450158154439988">
<NAME>ACTH versus alkylating agents+steroids at 18 months</NAME>
<DICH_DATA CI_END="13.24440992845388" CI_START="0.9249185177878316" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1220326141602455" LOG_CI_START="-0.033896525459694106" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2011-11-24 09:30:08 +1100" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="0.6789984985542759" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="11" TOTAL_2="11" VAR="0.4610389610389609" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.437342591868191E-32" CI_END="5.61891677725605" CI_START="0.7118809832156593" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="100.0" ID="CMP-011.08.09" LOG_CI_END="0.7496525997321793" LOG_CI_START="-0.14759260840421687" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Z="0.18845804827380766" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="1.3151543065760478">
<NAME>ACTH versus alkylating agents+steroids at 24 months</NAME>
<DICH_DATA CI_END="5.61891677725605" CI_START="0.7118809832156592" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.7496525997321793" LOG_CI_START="-0.14759260840421695" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-11-24 09:30:14 +1100" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.5270462766947299" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="9" TOTAL_2="9" VAR="0.2777777777777778" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.928733626996433" CI_END="1.2116653844777747" CI_START="0.60910379508897" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8590867151011872" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-011.09" LOG_CI_END="0.08338270090357426" LOG_CI_START="-0.21530869457005572" LOG_EFFECT_SIZE="-0.06596299683324076" METHOD="IV" MODIFIED="2014-04-02 18:18:56 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.4438787204865515" P_Q="0.47169673943505275" P_Z="0.3866674630365825" Q="7.617497383071663" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="144" WEIGHT="900.0" Z="0.8656767490772629">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ACTH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.406203943175224" CI_END="3.248578197764944" CI_START="0.32867704233151573" DF="1" EFFECT_SIZE="1.0333117021615634" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="28.886559815641753" ID="CMP-011.09.01" LOG_CI_END="0.5116933252953437" LOG_CI_START="-0.48323062976973363" LOG_EFFECT_SIZE="0.014231347762805007" MODIFIED="2014-04-01 16:36:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.23568780812814605" P_Z="0.9552856649518681" STUDIES="2" TAU2="0.2775726945030698" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.056070474380603336">
<NAME>ACTH versus other treatments at final follow-up (21-22 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="25.6782739076548" CI_START="0.3504908481140964" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-12-09 10:54:13 +1100" MODIFIED_BY="[Empty name]" ORDER="3363" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="23.115650662010907"/>
<DICH_DATA CI_END="1.6694093372690153" CI_START="0.3369455216539001" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.22256283824936693" LOG_CI_START="-0.4724403114659668" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-12-09 10:54:18 +1100" MODIFIED_BY="[Empty name]" ORDER="3364" O_E="0.0" SE="0.40824829046386296" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.16666666666666663" WEIGHT="76.8843493379891"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.6782739076548" CI_START="0.3504908481140964" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-011.09.02" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.3159133624715845" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.0028912207598348">
<NAME>ACTH versus placebo/no treatment at final follow-up (22 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="25.6782739076548" CI_START="0.3504908481140964" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-24 09:28:27 +1100" MODIFIED_BY="[Empty name]" ORDER="638" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="37.85185589009337" CI_START="0.6604695968564918" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-011.09.03" LOG_CI_END="1.5780871779726027" LOG_CI_START="-0.18014716930056512" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.11915467176373172" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5583315579030255">
<NAME>ACTH versus placebo/no treatment at 9 months</NAME>
<DICH_DATA CI_END="37.85185589009337" CI_START="0.6604695968564918" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5780871779726027" LOG_CI_START="-0.18014716930056512" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-11-24 09:30:49 +1100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="1.0666666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.6782739076548" CI_START="0.3504908481140964" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-011.09.04" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.3159133624715845" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.0028912207598348">
<NAME>ACTH versus placebo/no treatment at 21 months</NAME>
<DICH_DATA CI_END="25.6782739076548" CI_START="0.3504908481140964" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-13 06:09:11 +1100" MODIFIED_BY="[Empty name]" ORDER="307" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Arnadottir-2006" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6694093372690153" CI_START="0.3369455216539001" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-011.09.05" LOG_CI_END="0.22256283824936693" LOG_CI_START="-0.4724403114659668" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.4810129624049533" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.7046742856532445">
<NAME>ACTH versus alkylating agents+steroids at final follow-up (22 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="1.6694093372690153" CI_START="0.3369455216539001" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.22256283824936693" LOG_CI_START="-0.4724403114659668" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-11-24 09:31:05 +1100" MODIFIED_BY="[Empty name]" ORDER="644" O_E="0.0" SE="0.40824829046386296" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.16666666666666663" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9996095013570478" CI_START="0.5000976437256092" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-011.09.06" LOG_CI_END="0.30094519168183936" LOG_CI_START="-0.3009451916818394" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids at 6 months</NAME>
<DICH_DATA CI_END="1.9996095013570478" CI_START="0.5000976437256092" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.30094519168183936" LOG_CI_START="-0.3009451916818394" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 09:31:10 +1100" MODIFIED_BY="[Empty name]" ORDER="645" O_E="0.0" SE="0.3535533905932738" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.125" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.501581538002586" CI_START="0.2601423832898292" DF="0" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-011.09.07" LOG_CI_END="0.17654891998030375" LOG_CI_START="-0.5847888852921533" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="1.0" P_Z="0.29327694711812236" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.050960064665073">
<NAME>ACTH versus alkylating agents+steroids at 12 months</NAME>
<DICH_DATA CI_END="1.501581538002586" CI_START="0.2601423832898292" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.17654891998030375" LOG_CI_START="-0.5847888852921533" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2011-11-24 09:31:16 +1100" MODIFIED_BY="[Empty name]" ORDER="646" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="0.2" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4060320899165386" CI_START="0.2322355333044217" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-011.09.08" LOG_CI_END="0.14799523271413229" LOG_CI_START="-0.6340713300867211" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="1.0" P_Z="0.22315861324767494" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0" Z="1.2181720711650645">
<NAME>ACTH versus alkylating agents+steroids at 18 months</NAME>
<DICH_DATA CI_END="1.4060320899165388" CI_START="0.23223553330442165" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.14799523271413234" LOG_CI_START="-0.6340713300867212" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2011-11-24 09:31:24 +1100" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="0.4593897702811427" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="11" TOTAL_2="11" VAR="0.21103896103896105" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7903122675350842" CI_START="0.20108223941047487" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-011.09.09" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.0" P_Z="0.3597560241441482" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0" Z="0.9158300998592989">
<NAME>ACTH versus alkylating agents+steroids at 24 months</NAME>
<DICH_DATA CI_END="1.7903122675350842" CI_START="0.20108223941047487" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2529287875383019" LOG_CI_START="-0.6966262867710147" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2011-11-24 09:31:29 +1100" MODIFIED_BY="[Empty name]" ORDER="648" O_E="0.0" SE="0.5577733510227171" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="9" TOTAL_2="9" VAR="0.3111111111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.10" MODIFIED="2014-04-20 15:18:49 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="16" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACTH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.10.01" MODIFIED="2014-04-20 15:18:49 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids at 22 months</NAME>
<CONT_DATA CI_END="-0.4103039873714234" CI_START="-3.189696012628577" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="2.1" MODIFIED="2013-01-27 01:24:13 +1100" MODIFIED_BY="Yi-Zhi Chen" ORDER="629" SD_1="1.26" SD_2="2.52" SE="0.7090416066776336" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-011.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:20:04 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>ACTH</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ACTH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-011.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:34:11 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ACTH versus alkylating agents+steroids</NAME>
<DICH_DATA CI_END="4.978428653813436" CI_START="0.050216648140272525" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6970922876062648" LOG_CI_START="-1.2991522789342274" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-11-24 09:21:59 +1100" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="1.1726039399558574" STUDY_ID="STD-Ponticelli-2006" TOTAL_1="16" TOTAL_2="16" VAR="1.375" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2014-04-20 15:31:46 +1000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Azathioprine versus other treatments</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:27:23 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 02:27:51 +1100" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:27:44 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-012.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 02:28:00 +1100" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:28:07 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-012.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 02:28:03 +1100" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:28:27 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>100% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-012.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="9.179676193816485" CI_START="0.06971923480602833" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.962827362059746" LOG_CI_START="-1.1566473880758588" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-11-24 02:31:03 +1100" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="1.2449899597988732" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="1.55" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-012.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="9.179676193816485" CI_START="0.06971923480602833" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.962827362059746" LOG_CI_START="-1.1566473880758588" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-11-24 02:31:08 +1100" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="1.2449899597988732" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="1.55" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:28:47 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-012.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="68.16470792875079" CI_START="0.25469354507112146" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8335595781915652" LOG_CI_START="-0.5939820616147772" LOG_EFFECT_SIZE="0.619788758288394" MODIFIED="2011-12-11 01:32:10 +1100" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="1.4259499757471625" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="2.033333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-012.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="68.16470792875079" CI_START="0.25469354507112146" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8335595781915652" LOG_CI_START="-0.5939820616147772" LOG_EFFECT_SIZE="0.619788758288394" MODIFIED="2011-12-11 01:32:12 +1100" MODIFIED_BY="[Empty name]" ORDER="847" O_E="0.0" SE="1.4259499757471625" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="2.033333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.06" MODIFIED="2014-04-02 18:41:17 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" UNITS="&#956;mol/L" WEIGHT="0.0" Z="0.0">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.06.01" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="113.78413714560355" CI_START="-219.98413714560354" EFFECT_SIZE="-53.099999999999994" ESTIMABLE="YES" MEAN_1="159.1" MEAN_2="212.2" MODIFIED="2011-11-24 02:33:13 +1100" MODIFIED_BY="[Empty name]" ORDER="598" SD_1="106.1" SD_2="141.4" SE="85.14653251894643" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.07" MODIFIED="2014-04-02 18:24:38 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azathioprine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.07.01" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="85.01110748227539" CI_START="-19.011107482275392" EFFECT_SIZE="33.0" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="54.0" MODIFIED="2011-11-24 02:33:41 +1100" MODIFIED_BY="[Empty name]" ORDER="599" SD_1="54.0" SD_2="22.0" SE="26.53676694701146" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-012.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:30:10 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azathioprine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-012.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-20 15:30:10 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="5.427609016158132" CI_START="0.014216295535925991" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7346085552292558" LOG_CI_START="-1.8472135567638301" LOG_EFFECT_SIZE="-0.5563025007672873" MODIFIED="2011-11-24 02:37:07 +1100" MODIFIED_BY="[Empty name]" ORDER="601" O_E="0.0" SE="1.51657508881031" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="2.3" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-012.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:31:10 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azathioprine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-012.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-20 15:31:10 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="5.427609016158132" CI_START="0.014216295535925991" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7346085552292558" LOG_CI_START="-1.8472135567638301" LOG_EFFECT_SIZE="-0.5563025007672873" MODIFIED="2011-11-24 02:37:36 +1100" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="1.51657508881031" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="2.3" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:31:46 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azathioprine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-012.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-20 15:31:46 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 02:37:50 +1100" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.11" MODIFIED="2014-04-02 18:26:38 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.11.01" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment at 12 months</NAME>
<CONT_DATA CI_END="4.98646575733909" CI_START="-2.786465757339089" EFFECT_SIZE="1.1000000000000005" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="4.1" MODIFIED="2011-11-24 02:38:30 +1100" MODIFIED_BY="[Empty name]" ORDER="606" SD_1="2.9" SD_2="3.0" SE="1.98292712927127" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:26:56 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-012.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Azathioprine versus placebo/no treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 02:38:54 +1100" MODIFIED_BY="[Empty name]" ORDER="607" O_E="0.0" SE="0.0" STUDY_ID="STD-Silverberg-1976" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2014-04-02 18:30:02 +1100" MODIFIED_BY="Narelle S Willis" NO="13">
<NAME>Mizoribine versus other treatments</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:28:15 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="94" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Mizoribine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mizoribine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-013.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Mizoribine versus placebo/no treatment at final follow-up (6 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.1625103052817094" CI_START="0.23429583095269915" EFFECT_SIZE="0.7118055555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.33495818573977293" LOG_CI_START="-0.630235439146726" LOG_EFFECT_SIZE="-0.14763862670347655" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1896" O_E="0.0" SE="0.5669595130438277" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="0.32144308943089434" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-013.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>MIzoribine versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="2.2529998094781516" CI_START="0.24486595269055406" EFFECT_SIZE="0.7427536231884058" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.35276115499831334" LOG_CI_START="-0.6110715970172401" LOG_EFFECT_SIZE="-0.12915522100946342" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1897" O_E="0.0" SE="0.566160129583005" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="46" TOTAL_2="41" VAR="0.32053729232944506" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1851056457694362" CI_END="3.344772231072071" CI_START="1.3217767580675188" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1026274506104747" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.5243665489628828" LOG_CI_START="0.12115811102981966" LOG_EFFECT_SIZE="0.3227623299963513" METHOD="IV" MODIFIED="2014-04-02 18:28:48 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.785281369765778" P_Q="0.8477524829699746" P_Z="0.0017019556591196289" Q="1.3794863788126839" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="122" WEIGHT="500.0" Z="3.1378437693513694">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>Mizoribine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mizoribine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6255052895046023" CI_END="4.3752179969095835" CI_START="1.1447892370836827" DF="1" EFFECT_SIZE="2.238013063580488" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" I2="0.0" ID="CMP-013.02.01" LOG_CI_END="0.6409996967860485" LOG_CI_START="0.05872553768294053" LOG_EFFECT_SIZE="0.3498626172344946" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.42900902594939216" P_Z="0.018507249551544317" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="100.00000000000001" Z="2.355310187121342">
<NAME>Mizoribine versus placebo/no treatment at final follow-up (6-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.139431378393984" CI_START="0.9941954681460111" EFFECT_SIZE="2.0286458333333335" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6169406874526974" LOG_CI_START="-0.002528220842630064" LOG_EFFECT_SIZE="0.30720623330503366" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1905" O_E="0.0" SE="0.36387910315322597" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="0.13240800171159606" WEIGHT="88.35192300347555"/>
<DICH_DATA CI_END="33.60917724158162" CI_START="0.6612625366033063" EFFECT_SIZE="4.714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5264578809962663" LOG_CI_START="-0.17962608126900487" LOG_EFFECT_SIZE="0.6734158998636307" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1904" O_E="0.0" SE="1.0021621646864367" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="14" TOTAL_2="11" VAR="1.0043290043290045" WEIGHT="11.64807699652446"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2466670363073966" CI_END="3.975496995333746" CI_START="0.7132982338655276" DF="1" EFFECT_SIZE="1.68395813056895" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" I2="19.786120040361343" ID="CMP-013.02.02" LOG_CI_END="0.5993914295556814" LOG_CI_START="-0.14672885129602117" LOG_EFFECT_SIZE="0.2263312891298301" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.2641900978390589" P_Z="0.23440523107338151" STUDIES="2" TAU2="0.1129233199100504" TOTAL_1="57" TOTAL_2="49" WEIGHT="100.0" Z="1.1890875684617888">
<NAME>Mizoribine versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="4.30886448272306" CI_START="1.0399595384761793" EFFECT_SIZE="2.1168478260869565" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.634362835390044" LOG_CI_START="0.0170164426080497" LOG_EFFECT_SIZE="0.3256896389990468" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1907" O_E="0.0" SE="0.3626323270340729" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="46" TOTAL_2="41" VAR="0.1315022046101468" WEIGHT="78.58620888520974"/>
<DICH_DATA CI_END="4.12502868001892" CI_START="0.12822350118358078" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6154269724085276" LOG_CI_START="-0.8920323687410906" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1906" O_E="0.0" SE="0.8854890790353708" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="8" VAR="0.7840909090909091" WEIGHT="21.413791114790254"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.092539508355522" CI_START="0.34726118335995926" DF="0" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-013.02.03" LOG_CI_END="0.7847983541399229" LOG_CI_START="-0.4593437591445235" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.6081569049018443" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="100.0" Z="0.5127061273652227">
<NAME>Mizoribine versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="6.092539508355522" CI_START="0.34726118335995926" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7847983541399229" LOG_CI_START="-0.4593437591445235" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1908" O_E="0.0" SE="0.7308152359460693" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="8" VAR="0.5340909090909091" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="28.866373207882734" CI_START="0.6874079768771546" DF="0" EFFECT_SIZE="4.454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-013.02.04" LOG_CI_END="1.460392222233769" LOG_CI_START="-0.16278543249319188" LOG_EFFECT_SIZE="0.6488033948702886" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.11715167772821207" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="7" WEIGHT="100.0" Z="1.5668417850503116">
<NAME>Mizoribine versus placebo/no treatment at 18 months</NAME>
<DICH_DATA CI_END="28.866373207882734" CI_START="0.6874079768771546" EFFECT_SIZE="4.454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.460392222233769" LOG_CI_START="-0.16278543249319188" LOG_EFFECT_SIZE="0.6488033948702886" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1909" O_E="0.0" SE="0.9534625892455924" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="7" VAR="0.9090909090909092" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.207947662934256" CI_START="0.5050344319913789" DF="0" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-013.02.05" LOG_CI_END="1.3264986429725427" LOG_CI_START="-0.2966790117544183" LOG_EFFECT_SIZE="0.5149098156090622" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.21368639337709805" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="6" WEIGHT="100.0" Z="1.2434925911417665">
<NAME>Mizoribine versus placebo/no treatment at 24 months</NAME>
<DICH_DATA CI_END="21.207947662934256" CI_START="0.5050344319913788" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3264986429725427" LOG_CI_START="-0.2966790117544184" LOG_EFFECT_SIZE="0.5149098156090622" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1910" O_E="0.0" SE="0.9534625892455925" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="6" VAR="0.9090909090909093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.24182961851305096" CI_END="11.035168674410547" CI_START="1.157063246102153" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="3.573288133875893" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="1.042778975812661" LOG_CI_START="0.0633570985217203" LOG_EFFECT_SIZE="0.5530680371671907" METHOD="IV" MODIFIED="2014-04-02 18:29:17 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.9932532030998577" P_Q="0.982469728752632" P_Z="0.026860623920617076" Q="0.16874575204013564" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="122" WEIGHT="400.0" Z="2.213537310083895">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>Mizoribine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mizoribine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07308386647291532" CI_END="22.8059834363604" CI_START="0.7310389762848056" DF="1" EFFECT_SIZE="4.083143737916306" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-013.03.01" LOG_CI_END="1.3580488045653718" LOG_CI_START="-0.13605946745505226" LOG_EFFECT_SIZE="0.6109946685551598" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.7868984866702163" P_Z="0.1089347235126229" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="100.0" Z="1.60299968555121">
<NAME>Mizoribine versus placebo/no treatment at final follow-up (6-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="29.369805407980195" CI_START="0.397469814625984" EFFECT_SIZE="3.4166666666666665" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.467901069079137" LOG_CI_START="-0.40069584773491573" LOG_EFFECT_SIZE="0.5336026106721107" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1916" O_E="0.0" SE="1.0976230786404901" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="1.2047764227642277" WEIGHT="63.93414836609544"/>
<DICH_DATA CI_END="98.20668387837253" CI_START="0.31932653421877966" EFFECT_SIZE="5.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9921410465722078" LOG_CI_START="-0.49576499255980705" LOG_EFFECT_SIZE="0.7481880270062004" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1917" O_E="0.0" SE="1.4614083227196584" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="14" TOTAL_2="11" VAR="2.1357142857142852" WEIGHT="36.06585163390456"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.621974325848246" CI_START="0.41508672536929514" DF="0" EFFECT_SIZE="3.565217391304348" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-013.03.02" LOG_CI_END="1.486033188033681" LOG_CI_START="-0.3818611553014335" LOG_EFFECT_SIZE="0.5520860163661239" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.24662037370671785" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="49" WEIGHT="100.0" Z="1.1585973396265725">
<NAME>Mizoribine versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="30.621974325848246" CI_START="0.41508672536929514" EFFECT_SIZE="3.5652173913043477" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.486033188033681" LOG_CI_START="-0.3818611553014335" LOG_EFFECT_SIZE="0.5520860163661238" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1919" O_E="0.0" SE="1.097210383501167" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="46" TOTAL_2="41" VAR="1.2038706256627782" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1918" O_E="0.0" SE="0.0" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Mizoribine versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1920" O_E="0.0" SE="0.0" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="43.21505974115402" CI_START="0.09256032558924757" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-013.03.04" LOG_CI_END="1.6356351177117878" LOG_CI_START="-1.0335751263838253" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.6584282178491678" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="7" WEIGHT="100.0" Z="0.44208428397333643">
<NAME>Mizoribine versus placebo/no treatment at 18 months</NAME>
<DICH_DATA CI_END="43.21505974115402" CI_START="0.09256032558924757" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6356351177117878" LOG_CI_START="-1.0335751263838253" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1921" O_E="0.0" SE="1.5679073101855647" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="7" VAR="2.458333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.01076626202222" CI_START="0.24516134764418604" DF="0" EFFECT_SIZE="4.083333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-013.03.05" LOG_CI_END="1.8325776679720913" LOG_CI_START="-0.6105480000103136" LOG_EFFECT_SIZE="0.6110148339808888" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.3269101852409607" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="6" WEIGHT="100.0" Z="0.9803565034059373">
<NAME>Mizoribine versus placebo/no treatment at 24 months</NAME>
<DICH_DATA CI_END="68.01076626202222" CI_START="0.24516134764418604" EFFECT_SIZE="4.083333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8325776679720913" LOG_CI_START="-0.6105480000103136" LOG_EFFECT_SIZE="0.6110148339808888" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1922" O_E="0.0" SE="1.4351041110399654" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="6" VAR="2.0595238095238093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.831240901143925" CI_END="2.827143970633039" CI_START="1.1282502076865966" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.785980339204952" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="0.45134792524205475" LOG_CI_START="0.05240542213646402" LOG_EFFECT_SIZE="0.2518766736892594" METHOD="IV" MODIFIED="2014-04-02 18:29:40 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.9345465911105597" P_Q="0.9385257131336611" P_Z="0.013327758603277349" Q="0.7994207675925113" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="122" WEIGHT="500.0" Z="2.474889013497934">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>Mizoribine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mizoribine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0479131256948779" CI_END="3.973331320996746" CI_START="0.8973248452458816" DF="1" EFFECT_SIZE="1.8882184494183982" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="0.0" ID="CMP-013.04.01" LOG_CI_END="0.5991547807314771" LOG_CI_START="-0.04705030728099648" LOG_EFFECT_SIZE="0.2760522367252403" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8267352149572635" P_Z="0.09402190207406458" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="100.0" Z="1.6745533325876645">
<NAME>Mizoribine versus placebo/no treatment at final follow-up (6-24 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.050993762107117" CI_START="0.8270087457911954" EFFECT_SIZE="1.8303571428571428" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6075615744389465" LOG_CI_START="-0.08248989766780115" LOG_EFFECT_SIZE="0.26253583838557265" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1928" O_E="0.0" SE="0.40533965052537996" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="0.16430023228803714" WEIGHT="87.69559377183766"/>
<DICH_DATA CI_END="19.655895228225052" CI_START="0.28266951896453085" EFFECT_SIZE="2.357142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2934928285592757" LOG_CI_START="-0.5487210201599768" LOG_EFFECT_SIZE="0.37238590419964945" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1929" O_E="0.0" SE="1.0821255338433111" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="14" TOTAL_2="11" VAR="1.170995670995671" WEIGHT="12.304406228162339"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.983907007856536" CI_END="3.3243714874715393" CI_START="0.7865100590974481" DF="1" EFFECT_SIZE="1.6169884399936543" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" ID="CMP-013.04.02" LOG_CI_END="0.5217095487896688" LOG_CI_START="-0.10429571858096355" LOG_EFFECT_SIZE="0.2087069151043526" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.32123635477230994" P_Z="0.19125221612713483" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="49" WEIGHT="100.0" Z="1.3068836901233392">
<NAME>Mizoribine versus placebo/no treatment at 6 months</NAME>
<DICH_DATA CI_END="4.217864189345108" CI_START="0.8648601692752751" EFFECT_SIZE="1.9099378881987579" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.625092591817036" LOG_CI_START="-0.06305410365786429" LOG_EFFECT_SIZE="0.28101924407958584" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1930" O_E="0.0" SE="0.40422077530303646" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="46" TOTAL_2="41" VAR="0.1633944351865879" WEIGHT="82.75493798680506"/>
<DICH_DATA CI_END="4.12502868001892" CI_START="0.12822350118358078" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6154269724085276" LOG_CI_START="-0.8920323687410906" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1931" O_E="0.0" SE="0.8854890790353708" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="8" VAR="0.7840909090909091" WEIGHT="17.245062013194936"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.092539508355522" CI_START="0.34726118335995926" DF="0" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-013.04.03" LOG_CI_END="0.7847983541399229" LOG_CI_START="-0.4593437591445235" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.6081569049018443" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="100.0" Z="0.5127061273652227">
<NAME>Mizoribine versus placebo/no treatment at 12 months</NAME>
<DICH_DATA CI_END="6.092539508355522" CI_START="0.34726118335995926" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7847983541399229" LOG_CI_START="-0.4593437591445235" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1932" O_E="0.0" SE="0.7308152359460693" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="8" VAR="0.5340909090909091" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.351560101025147" CI_START="0.5750538561965934" DF="0" EFFECT_SIZE="3.818181818181818" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-013.04.04" LOG_CI_END="1.4040046903919763" LOG_CI_START="-0.24029147991262548" LOG_EFFECT_SIZE="0.5818566052396754" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.16540519717021981" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="7" WEIGHT="100.0" Z="1.387119925268991">
<NAME>Mizoribine versus placebo/no treatment at 18 months</NAME>
<DICH_DATA CI_END="25.351560101025157" CI_START="0.5750538561965933" EFFECT_SIZE="3.8181818181818183" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.4040046903919763" LOG_CI_START="-0.24029147991262556" LOG_EFFECT_SIZE="0.5818566052396754" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1933" O_E="0.0" SE="0.9658677098342366" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="7" VAR="0.9329004329004331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.49497188716743" CI_START="0.2143010784332582" DF="0" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-013.04.05" LOG_CI_END="1.096735283330673" LOG_CI_START="-0.6689756434405106" LOG_EFFECT_SIZE="0.21387981994508107" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="1.0" P_Z="0.6349158327268072" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="6" WEIGHT="100.0" Z="0.47481922182904823">
<NAME>Mizoribine versus placebo/no treatment at 24 months</NAME>
<DICH_DATA CI_END="12.49497188716743" CI_START="0.2143010784332582" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.096735283330673" LOG_CI_START="-0.6689756434405106" LOG_EFFECT_SIZE="0.21387981994508107" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1934" O_E="0.0" SE="1.0371873387954442" STUDY_ID="STD-Shibasaki-2004" TOTAL_1="11" TOTAL_2="6" VAR="1.0757575757575757" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-013.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:30:02 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>Mizoribine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mizoribine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-013.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 15:50:51 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Mizoribine versus placebo/no treatment</NAME>
<DICH_DATA CI_END="86.795025768913" CI_START="0.21161750660317297" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9384948364320844" LOG_CI_START="-0.6744484070212731" LOG_EFFECT_SIZE="0.6320232147054056" MODIFIED="2012-02-21 02:33:18 +1100" MODIFIED_BY="[Empty name]" ORDER="1940" O_E="0.0" SE="1.5348557954821587" STUDY_ID="STD-Koshisawa-1993" TOTAL_1="48" TOTAL_2="41" VAR="2.3557823129251703" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2014-04-20 15:43:40 +1000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Tripterygium wilfordii versus other treatments</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:30:57 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Death or ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Tripterygium wilfordii</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1943" O_E="0.0" SE="0.0" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:31:13 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Death (ITT analysis)</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Tripterygium wilfordii</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1945" O_E="0.0" SE="0.0" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:31:31 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>ESKD (dialysis/transplantation) (ITT analysis)</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Tripterygium wilfordii</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1947" O_E="0.0" SE="0.0" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:31:45 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>100% increase in serum creatinine (ITT analysis)</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Tripterygium wilfordii</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at final follow-up (12 months)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1950" O_E="0.0" SE="0.0" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-20 15:43:40 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="83" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>50% increase in serum creatinine</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Tripterygium wilfordii</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-014.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="4.456794229078568" CI_START="0.2039896905683631" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.649022583101504" LOG_CI_START="-0.6903917808212061" LOG_EFFECT_SIZE="-0.02068459885985102" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1955" O_E="0.0" SE="0.786778627576232" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.6190206088107392" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-014.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-20 15:43:37 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at 12 months</NAME>
<DICH_DATA CI_END="3.9396369726788314" CI_START="0.1833925321065109" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5954562045600524" LOG_CI_START="-0.736618353131467" LOG_EFFECT_SIZE="-0.07058107428570728" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1956" O_E="0.0" SE="0.7824671890634036" STUDY_ID="STD-Liu-2009b" TOTAL_1="40" TOTAL_2="34" VAR="0.6122549019607842" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="98" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-014.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:32:32 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="126" TOTAL_2="116" WEIGHT="0.0" Z="0.0">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Tripterygium wilfordii</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="15" I2="0.0" ID="CMP-014.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="3.1566246129854147" CI_START="1.310766406347269" EFFECT_SIZE="2.034108527131783" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="15" LOG_CI_END="0.49922293849584903" LOG_CI_START="0.11752530231289833" LOG_EFFECT_SIZE="0.3083741204043737" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1968" O_E="0.0" SE="0.22421108092763672" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.05027060881073927" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="21" I2="0.0" ID="CMP-014.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at 6 months</NAME>
<DICH_DATA CI_END="2.1601695415693856" CI_START="1.103220208853038" EFFECT_SIZE="1.5437430786267996" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="21" LOG_CI_END="0.3344878382243046" LOG_CI_START="0.04266220867266504" LOG_EFFECT_SIZE="0.18857502344848484" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1969" O_E="0.0" SE="0.17141981935879697" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.02938475446900258" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="15" I2="0.0" ID="CMP-014.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at 12 months</NAME>
<DICH_DATA CI_END="2.7291022348099694" CI_START="1.2048569437365682" EFFECT_SIZE="1.8133333333333332" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="15" LOG_CI_END="0.43601980506607974" LOG_CI_START="0.08093548489095517" LOG_EFFECT_SIZE="0.25847764497851744" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1970" O_E="0.0" SE="0.2085782873666008" STUDY_ID="STD-Liu-2009b" TOTAL_1="40" TOTAL_2="34" VAR="0.043504901960784305" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-014.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:33:00 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="126" TOTAL_2="116" WEIGHT="0.0" Z="0.0">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Tripterygium wilfordii</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="2" I2="0.0" ID="CMP-014.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="31.129402463158314" CI_START="1.8691320822725266" EFFECT_SIZE="7.627906976744186" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.493170784368872" LOG_CI_START="0.27163999189531296" LOG_EFFECT_SIZE="0.8824053881320926" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1980" O_E="0.0" SE="0.7175332341739109" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.5148539421440725" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="0" I2="0.0" ID="CMP-014.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at 6 months</NAME>
<DICH_DATA CI_END="419.95235871077205" CI_START="1.5816876778916915" EFFECT_SIZE="25.772727272727273" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.623200024867945" LOG_CI_START="0.19912073127345545" LOG_EFFECT_SIZE="1.4111603780707003" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1981" O_E="0.0" SE="1.42391617644343" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="2.0275372775372773" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="2" I2="0.0" ID="CMP-014.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at 12 months</NAME>
<DICH_DATA CI_END="27.494637431080218" CI_START="1.6817824972563495" EFFECT_SIZE="6.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.4392479970595644" LOG_CI_START="0.22576982835290824" LOG_EFFECT_SIZE="0.8325089127062363" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1982" O_E="0.0" SE="0.7128030831121016" STUDY_ID="STD-Liu-2009b" TOTAL_1="40" TOTAL_2="34" VAR="0.5080882352941176" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="53" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-014.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:33:15 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="126" TOTAL_2="116" WEIGHT="0.0" Z="0.0">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Tripterygium wilfordii</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-014.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at final follow-up (12 months) (ITT analysis)</NAME>
<DICH_DATA CI_END="2.125010958524" CI_START="0.6480714491089373" EFFECT_SIZE="1.1735241502683362" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.3273611740165569" LOG_CI_START="-0.18837711103808302" LOG_EFFECT_SIZE="0.06949203148923695" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1992" O_E="0.0" SE="0.3029472215867799" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.09177701906714952" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="21" I2="0.0" ID="CMP-014.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at 6 months</NAME>
<DICH_DATA CI_END="1.4622112441799655" CI_START="0.6217569994316832" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.16501011923909467" LOG_CI_START="-0.20637931695879674" LOG_EFFECT_SIZE="-0.02068459885985102" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1993" O_E="0.0" SE="0.21815599323000007" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.047592037382167836" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-014.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii at 12 months</NAME>
<DICH_DATA CI_END="1.8525836703778944" CI_START="0.5907629908015108" EFFECT_SIZE="1.0461538461538462" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.26777783163804747" LOG_CI_START="-0.22858671951128595" LOG_EFFECT_SIZE="0.01959555606338077" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1994" O_E="0.0" SE="0.29156699438927336" STUDY_ID="STD-Liu-2009b" TOTAL_1="40" TOTAL_2="34" VAR="0.08501131221719457" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-014.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:33:36 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>Tripterygium wilfordii</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Tripterygium wilfordii</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-014.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-01 16:53:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Tripterygium wilfordii+steroids versus Tripterygium wilfordii</NAME>
<DICH_DATA CI_END="3.0017650343235185" CI_START="0.1703635317032192" EFFECT_SIZE="0.7151162790697675" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4773766944727313" LOG_CI_START="-0.7686233654090332" LOG_EFFECT_SIZE="-0.14562333546815096" MODIFIED="2012-02-21 02:33:20 +1100" MODIFIED_BY="[Empty name]" ORDER="1998" O_E="0.0" SE="0.7319066029743179" STUDY_ID="STD-Liu-2009b" TOTAL_1="43" TOTAL_2="41" VAR="0.5356872754774058" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2014-04-10 17:47:09 +1000" MODIFIED_BY="Narelle S Willis" NO="15">
<NAME>Early versus late immunosuppressive treatments</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:34:20 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Death or ESKD (dialysis/transplantation)</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours early</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours late</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.283481648287168" CI_START="0.059811533780690526" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0893214813270087" LOG_CI_START="-1.2232150605882353" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2011-11-24 10:38:59 +1100" MODIFIED_BY="[Empty name]" ORDER="651" O_E="0.0" SE="1.3583954119615156" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" VAR="1.8452380952380953" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:34:43 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours early</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours late</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.498244971946492" CI_START="0.012842973831203235" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8127960794249695" LOG_CI_START="-1.8913344023619834" LOG_EFFECT_SIZE="-0.5392691614685069" MODIFIED="2011-11-24 10:38:18 +1100" MODIFIED_BY="[Empty name]" ORDER="649" O_E="0.0" SE="1.5884196306634222" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" VAR="2.5230769230769226" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:35:02 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>ESKD (dialysis/transplantation)</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours early</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours late</GRAPH_LABEL_2>
<DICH_DATA CI_END="58.48420474751842" CI_START="0.11558676448082908" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7670385888642943" LOG_CI_START="-0.9370918929226586" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2011-11-24 10:38:35 +1100" MODIFIED_BY="[Empty name]" ORDER="650" O_E="0.0" SE="1.5884196306634222" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" VAR="2.5230769230769226" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.04" MODIFIED="2014-04-02 18:35:38 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" UNITS="&#956;mol/L" WEIGHT="0.0" Z="0.0">
<NAME>Final serum creatinine</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours early</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours late</GRAPH_LABEL_2>
<CONT_DATA CI_END="49.26401570044036" CI_START="-73.26401570044035" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="93.0" MEAN_2="105.0" MODIFIED="2011-11-24 10:43:24 +1100" MODIFIED_BY="[Empty name]" ORDER="656" SD_1="105.75" SD_2="46.25" SE="31.257725235607946" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.05" MODIFIED="2014-04-02 18:36:20 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Final GFR [mL/min/1.73 m²]</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours late</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours early</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.589547477588344" CI_START="-8.589547477588344" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="76.0" MEAN_2="68.0" MODIFIED="2011-11-24 10:43:42 +1100" MODIFIED_BY="[Empty name]" ORDER="657" SD_1="25.0" SD_2="18.0" SE="8.46421036735602" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-015.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:36:42 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Complete or partial remission</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours late</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours early</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6887110808350743" CI_START="0.7734434053300041" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.22755535310435035" LOG_CI_START="-0.11157145914897688" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2011-12-11 02:29:28 +1100" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="0.1992047682223989" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" VAR="0.039682539682539666" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-015.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:37:06 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours late</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours early</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.449830525494349" CI_START="0.3879763807622993" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.1613172393768946" LOG_CI_START="-0.4111947125934945" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-12-11 02:29:22 +1100" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="0.33629635456727464" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" VAR="0.1130952380952381" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:37:28 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Partial remission</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours late</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours early</GRAPH_LABEL_2>
<DICH_DATA CI_END="31.7881438727287" CI_START="0.5778049518183099" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5022651699605212" LOG_CI_START="-0.23821874054971004" LOG_EFFECT_SIZE="0.6320232147054056" MODIFIED="2011-12-11 02:28:55 +1100" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="1.0223688645680165" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" VAR="1.0452380952380953" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.09" MODIFIED="2014-04-02 18:37:53 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" UNITS="g/24 h" WEIGHT="0.0" Z="0.0">
<NAME>Final proteinuria</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours early</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours late</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8153439954405097" CI_START="-0.6353439954405096" EFFECT_SIZE="0.5900000000000001" ESTIMABLE="YES" MEAN_1="0.77" MEAN_2="0.18" MODIFIED="2011-11-24 10:44:06 +1100" MODIFIED_BY="[Empty name]" ORDER="658" SD_1="1.3325" SD_2="1.78" SE="0.6251869958355698" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-015.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2014-04-02 18:38:18 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Temporary or permanent discontinuation or hospitalisation due to adverse events</NAME>
<GROUP_LABEL_1>Early</GROUP_LABEL_1>
<GROUP_LABEL_2>Late</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours early</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours late</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1613030056684033" CI_START="0.07029401686103424" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.06494555007505319" LOG_CI_START="-1.1530816387756044" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2011-12-11 02:23:00 +1100" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="0.7154752000627009" STUDY_ID="STD-Hofstra-2010" TOTAL_1="14" TOTAL_2="12" VAR="0.5119047619047619" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-11-19 16:52:34 +1100" MODIFIED_BY="Narelle Willis">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-11-19 16:52:34 +1100" MODIFIED_BY="Narelle Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study selection flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAooAAANGCAYAAAB6Ka/3AACAAElEQVR42uy9D6QV2///f8l1JUkk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-04-22 16:10:32 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAk4AAAHhCAMAAACvJcFhAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-04-22 16:10:32 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAnwAAAXXCAIAAABd8zSiAACAAElEQVR42uzdv24Ty9/HcUtIiCIF
ha+Aa0iFLCqouCdO6SISKX0XiEt4RB7KkIoO8ZwEgYsU5vw6CJGfNf4J+dgzu+s/u96ZfX20OspZ
7Hc2M9/dz3xnZmcGAyIiImpNcyIiImpYTJeIiIjpEhERMV0iIiJiukREREyXiIiI6TJdIiIipktE
RMR0iYiIiOkSERExXSKizj8Kfz8MPRKJ6RIRNfgcjP1AxHSJiJguMV0iIqZLxHSJiKofhTZeI6ZL
RETEdImIiIjpEhFt+ShcfSYqEGK6RESNO+7aD0RMl4iI6RLTJSJiukRMl4io8lHIcYnpEhERMV0i
IiJiukREuzwKLUpFTJeIqOnn4OoPHonEdImIWjJdvktMl4iI6RLTJSLKy3c9EonpEhERMV0iIiJi
ukRE2z0KzV4mpktE1PRzMPYDEdMlImK6xHSJiJguEdMlIqp+FFoDkpguERER0yUiyuQ5qBCI6RIR
8V1iukRE+T0HDesS0yVK8amtQIiI6RI1dQvVOUlExHSJ9rp/dv5X6mxVqjhiukRE7TWePBWJ6RIl
8NR2QzFdIqZL1JLjemSn/Sg0FY6YLhHTJSKmS0RMl4iYLtExbiSOm/yjUA8zMV0ioqafgwqBmC4R
EdMlpktEwRtJ5yTfJWK6RO08r5c/uKEyaDOpRGK6RGmYLt8lIqarCa+imS5RL27DLt+AnsWZ222d
k9SfG56CFad7WcOX6dJhQnCHfyUiYrpMl4iIWjSGdPJ+pktdjEUV3VDx6pykLB8aadl5KqvCeUD0
xXG7H4tElLfpermO6TJdIqKWfLe5J1JCOyIzXaZLh7uR9C2nX4MHv02aI7cTzAcM6SaeSIO4mC4d
rYI5bstpgaLWPNXwrSyQww7oJta8c9cRMV01yHSJ6RIl5rtuKKabuummOFySyj3IdPvRqjLc2Fbx
Kuc8qrLPBtZEz03TL9eZSEVdbL+raCLKycCYLnXadPkuER3RwNpcdqPLxct0mS6Rm6XZlZKS62Fu
rrNdpDHdvviuiiZq2QncdOXtjx6WD9MlImbAdPNx9LnZy0Q9bMIrE76bnO+mu4GHXYbIzeN5TQm3
mQ44dcg92E45M10ipktEbdw4TJfI44Mo+Xhu2iCamyXe9XRfkGV88+jXarmQFXVy7tJEDRofbcd0
k7vXPCD6lX6payI6luk20f5Ibrk9pst0ZedEdJxMtyEvt58udcJ3k+jXCjYUUrlyDYWk7xQrUgVv
uu47rkyXutv06/j8gp3/VY8CNRd73SRr3DBdIo9sj1qmKxLaLg3dy0SHuTP7vP8o8d387kGFzHSp
03d7QreTMd3Uo86KVO3cg+4OzwhiukTUxj3YaBPEhgdETJfIPeiamW7P7h+vK8RK41C3uhWp2om6
5hbKtyJVa/cg0/WA6EWLldJ9A1jUxbDqLrmosMsQ0/X4Uw6NrP7a8+3bWmMe/JGdEJnCZmbDA+K7
e948Cdw/upcbjrrmTLe5Gkx3gRrxzHTpkLd9Ks/rJmYhJvf2YQbxdsDx0TYzXbHRdJD0tnCYLnXa
dJt4sJoXnU3qrAbd3UyXqI+mm9bGEi0bZBJdtTY8aOGamS7T7U0FJzUw03QncHN23nPfTXeEu7lB
jUaHS1ruV2C6TJeYwS7h3mia2wQ8uSSpNWb3M7CGyMF46P4Id6PxbEUqYrp6FA7WRCg/KZh7Zbqb
YxlNGFii4eE9Xcr5OWV1p2Pli93fV7zREcF5k28lNWdgh71TGm2EtVCDqfRVMF2SgXXuUUIlj78m
DMwoSaPNr3Zc3IpURJlnYE2bQUPjSenuLtzcAtruweRMt4W6syIVUbdunhRfRrLfS/upWPcbZC28
n8YUmC7tcs80/V5jExlYiqM+TLfp2Ei3c7KhiVRNl0Zrby0zXaKuPKSaaHSn+wawVbRSj2c1OE92
4RSmSzlnjfM0V3dq+u1Dz2um64mUx3OD6Wbdg5FUd5wde/ILv8O611pHRUMjr90nt3BHNDTCbQtF
ptu7dmU/M7DWNtBOLkFPJWuMJTHe4W509nJD/ViNTjFhukR6FA78K5huC3lSlxu+SZtuazdj16/T
01OjmLr8yE5xufy0Mt2EfDdd0/UIYrq9MwMbliW6eUDPc44WMt2EXr9pv38liRYq06WcTTePDcua
eEjNE1mIP9VHVWrrc1ELTZB5Umu2M91+RXkSZpDuzMlGX6ByqxLJdKnvOXRa7zU2PRwoH52nueRQ
c6OkTZOb61huonlKTJc6l4Elumwe0220O6HRMd0UXx5tKOQa3am3uXZY0+9wM13aMdBNHUoovUtx
d+HYtXV59nI715xiaTT3Hm07fQnGdImBHc3AiOnmarrtlDPTZbp0NNNNMQMjpst0mS7TJZluDiWc
7huTTDcGSWhMt7miYLpMlzJ/ZKd157RzzWmt6txcE6TlHWSTuAFbW8qj+zWY1jvcTJe69TRJegmL
hFIlImK6lFLcJGczba4o2/PdhYmI6fY6DU1rM7ukV9E6eI9ZuhPW0tq6BxmZ6VIyj1RvAJNHNjLT
ZbqUXg7d5sU3fYf3/M7yyEZmuky3vx45T2omcFrvyQQ7291WRMR0e5pqJNShmmg0JvpqlvdkkJGZ
LjHdNuA2AmoiO0dGzonMdCl/023uIhN957WhTb+bKHxk5JzITJcO8MhO0WP6vNCEe5Moz2eygqCj
Z2CaIC2bbnPL5iEj50RmuiQD63ppNLrG5MGfUIf9RcjIOZGZLnWi9dd0BpbYRMS2FuJvorPdgxUZ
menSvPuB2E4G1uhLBc2NFvc5NpCRmS7TZbqHD/F0MzDa7PxoonGDjJwHmelShq2/1E3XJvZExHQp
mdZfzHcbmt/Y0AW3QHa3EjFd6nHoeAM4WdNtLTtHRk6azHRpXxtoYlUjO+qkZbrNTVhDRs6JzHRp
u6qtc7I/GVhyOXRzPQpmqCIjM11q3A8SysDacUepuQcrMjLTJXbeuM0Ie0v9ISMzXaL0Fj5cbYIc
CvsHJTsnyjBdURDU2Rxa1xYRMV3qdRqa4us38+ZXom5hQY9DzTxvogaRkXMiM13qkaknes0HNN2m
t1IgIqZLjVVwUhvCJ+q7aU0rIyKmSwlkjeluZjf3ylArDQVk5MzITJeOnycl3Qmc0NW2OXaOjIzM
dKl37phoQyHFVbQ8WJGRmS416wQNDTcmsRfQPItdhhqCN1eDyMipk5kuZZ4nJTem25o1NlfCh3p5
Axk5GzLTpV6YbkLu1U4ObfIXUWYPT7dxDyq4x3MFWzNd1khETFc+mlg+2nRDIS07t28xEdMlppvk
Nae1dKUVqYiYLjHdgCvMG16Oqs991+5NIqZLCVZwY+8LJbHEf9MGlugSFg1dNjJyTmSmS91K7Brd
mzaVMd3WjLyFN60PuBkwMnIeZKZLeZpu03GY4vho+1O0mqhHZOR0yUyXtgjBNheaOOA1p94KSXQQ
2iMbGZnpUu/aCknnoy10tjfdbGpigA0ZOWky06V9W39pXXNzpt59010DulWJMkktFERPUsbur3Sa
4kITrZku3yViutTTrDG5y27hreUmsM2ZbnIbSyAjH4XMdKl3OXr3TbeFJkhz7wul0tRDRs4gwWC6
vfOwg5MTinjrKXqwIiMzXWojSZqn0+2Z4g158Hy0HNLCr0BGRma61BVrbGes8bDu0sLd3sQrEHVO
HqQLJImNJZCRWyYzXcrcdBs1sKZHi9NaFJOImC416LtJbGLf5lYK3b9mImK6RGln583dSEk4bnNL
hCIj50RmutQtm2k8KPu9yxARyXSJ74ZT0lReeE1uVec2AyPFHZGRkZsmM13qhM0YxYwV9TyF7uXk
lghFRm6fzHSpi3mS+brzNBdr9CImMjLTJabbxgrJCS0V0sLyJh6syMhMlw5dwQ10eza9xP/Bbydv
LXu2IiMzXUoyH23nsufJ7tiTRA5t1SFkZKZLXTfdptcEbnTCRdJNELcqUR6PZXcy090laOqc7Gi4
W1KRiJgupWUzBye3sK9OcvloO9PKUlkiFBk5gyY106XOhWNyOXRD3fjtbNJwcDtHRs6JzHRJdt45
ctKbNHiwIiMzXWrKZix82OgNn9AULQ9WZGSmS40/WJVGQ+XT3C5DzTWbjNshIzNdSsN0E2pXxi4y
xQUm3apEGTyWmS7f3SvxSqXjOsUrt7EEEdOl1Go3qeXyU2/cpDJFa64LERmZ6RI1YWAtrKLVqDU2
aucHb0ghI+dEZrrU3TS6y7ldo28Am72MjMx0mS79yxrnqW1QY1uCNn334B19yMjZkJkuHd8MEjXd
pm+kg6fmLe/KcqiNJZCRsyEzXepQ1piKgeVRiUqDKI87muky3cO0KxV4o47Ld4mYLiVSwen4YrrL
bqS1LcG8sfF+ZOTMyEyXetE+SGvZjdUfbNKAjJwNmelS5zxy3vmh4ta2yUvxlSEPVmRkpkvNmk0/
bSZFA2O6yMhMl5L0g/mht1hvLsRTnKLV0LpRbbbJkJGRmS4dzHFXz3TZdBuNxlSmWhBRxo9lpst0
O9SutOzGsWIDGRmZ6VIj1tjxGm/o8pJe66qhedGercjITJe0EswxbvyaW15gEhk5UTLTpe66Y6J5
fz9Nl4iYLqUUNwohaOfzxjbTPVTJN7e7MDJyTmSmS30x3dRXpJp3fjvC5nYXRkbOicx0KX/fbXNJ
xT6PFs+9i4mMzHSpuQcrA/MyEhExXWojGWVg83a7xLvfuCEipksMbP1qU3kztemiICKmS/013UQN
LN0pWkTEdCk9p+mzgbXs6HyXiJgu9behkGg+2uYKPk0syo2MnDSZ6VL+jtucpTU94zo5O9/8+bDb
LSMjZ0BmurRvIDbRomzOwNKa/JWK6baw7SMycgZkpktdyRoTaii0Y7ppjel6sCIjM11ius1m0inm
o43aeUPbPiIj50RmurRvIHY8t0vOwNxBRMR0qY0curN9OEfvVCAiYrrUiOnODzcqk+gSFi13Ajd0
2cjIyEyXuhiI9tU5VgLd59eckJHbJzNd6kogNrdCcnIGxnSRkZku06VUBxpbe2Wo+53ATV+zZysy
MtOlXvtum7ld98nzBFfPRkbOicx0qSuBuAqUj+bRx0BETJc6nY82tGmg6U5ExHSJ2jDdDDoVGnL0
Ay7L1UQvCDJyTmSmS3uZwbyZTuDkXhlaLRY5NBExXUojH21oYeQWFmtMqKFgWhkycmbNU6bLdJXG
ge/5RteNOjjwsB19yMjZkJkuye06Whp5LLuBjIzMdKlzeVJzuV0LLdaG9vzKozvOIxsZmelSf/PR
njdu2mmCeLYiIzNdYrp9bwu3UxpWHUJGZrqUxoN13lbHdRIe5sUeImK6lGSql1ZbuOlO4BR3FyYi
pksysBxKteMvIyEjZ0lmutSJp7YMLOkatAACMjLTpWZqN6mJr01fdkOLYrbWBPFgRUZmuiTfOjw5
3fWik+hO8GBFRma6xHfbWDeqhfW5UpyzhoyMzHTpwHlSo7N2mW5apktETJcafPontGLLanR2vy3c
6ICu2WpETJfSc1wZmBpszc6RkXMiM13K/JFNLdQgMjIy06XGKjidua9a2R5/yMhMl8htmWETpKEn
FDJyTmSmS0xXK/vAXp7EetTIyO2TmS7tGIvzpFbuTastbMIaETFdavXN1D5nYHPTyoiI6VKKpkvt
t2/mjfWCICNnQGa61AnTTXHZDWohNpCRcyIzXdqx9ZfQK0PUQvvdgxUZmelSennSAU03xZWQm753
PP6QkZkuUSM5dHODMSmSW3iUWIQEGZnpUoNP7XSnLveTPDcVjijXdEVBZO+4qTyydTK3035XzsjI
R0ldmC7Tpb6HBzIycmtPUabLdLt42caTYvV1wI7r5rrEkZFzIjNd2rqC03Lc5mwmIXJCa8kSSV2Y
LrWdj9rwoB0yESWdujBd6pYZMF0iyj9dURDUnQzMmG6QzMuJmC7xXWqjkM0/JzqyTR6oVc106TBR
KIqSM107ySAjb3sPGtOlVttolI3pIiMjH4XsQdyLRzZl02xi58jITJf6aLoSaDk0MnL25LllIKkL
vtvySkl93vMgxWYTMnJO5EbuO+aUsemmtYTFGuqw7daEyFakIsr5mawgpLndyXSDZw7Sq5Mcuek7
HxkZufy+PnjDl+ky3cOkYk3bOdNttBKRkZFlutR1323TzpsYfE2XLLlBRj4KmenSFs9rdZ1Bm6m5
9QRkM8jILTR8PYhpFxtg56mbrvQFGfko96DHJSWQoPec3FCaS0RMl5o1sCQysNZuniTIB39xqLm+
CmTknMgNNXyZrjba8W2A6RJRxzMWrwxRnvko380vNpCR0yU35eX8iel2uXXZW/K8gdHi5voqkJFz
IjNdOkBENuqOSltqjoycGZnpUrfMIJWll5guETFdysR054dbTNHMyaMkBwfvBUFGzoPc1FIbXCTP
xlTzc4yb2L2SyquyoUcJMjJyC77LdPuSkjbXrhRC7VRf02SPbGTkmgkM06UjtP4Sys7TnTmZ4j5R
yMiZkRu57/gT0+1Vdp4omYgyeCwz3R5UcDPtyiaMQddWZSYtqomO8hSdWwaS8suhkRN9lCAjZ0k+
+KRRpkudsxnjSW3W4MHnnyMjIzNdHSONL0+oqNupQaaLjMx0KZl8lPQoePwhIx+x4ct0mW5/s/Pu
k3XjIyMfndzI840/8d2OhLjF1lszXSJiutRsypjiTOA+m+7c2DlR9x6kTJeOn0BLdpNuitmNFRm5
nVub6VLnMl2b2BNRZ591TJfa6xgpISvqFu555UyUuu96YvYiVmw1r0ehpNk0t54RMnKNjMWYLm1n
uvPO7zI0t4l9W6brXUxk5GM96Jgu0z1+649qFnj3G2TIyFmSD9Xw9bjske+qaPJgRUY+boLBdKmj
KZ3XFRLNoZGRcyKbvUzZWiPVLHBlQpT8Ha0gMn5YN9pqo6YrUSEQdafVy3Sp+mG9OsO20bg8bEOh
ofUrEiI3Z7qrF9lEaSAjZ0M++C3JdHthuo0+u5uI78OuCJEiuTnfVc7IyPvceiZS0RaB2ERuxwya
K/Pm3i1WzsjITJcSMN3mBond8MeNDQ9WZGSmSzJdpst0kZGPcw8a06WtfbHRF05a2KvHhmVN1OAa
qqFpZcjIqZPnZi9Tlz1eORARMV0iIiKmS0RExHSJiIiI6RIRETFdIiIiYro51xwREXVPTDdD00VG
RkZGTovMdJkuMjIyMjLTJSGOjIyMzHSJ6SIjIyMjM12mi4yMjIzMdEkgIiMjIzNdppur6d7fz75/
H0+no5ubx3//Pbi+Pvn27XQ2++v+/raz5LvZ7Ho8vhqN/vfx4/8ZDC5OTi5PT//vr79+3vaRPLub
ja/Ho6vR4/99PPifwcnFyenl6V//99ftT+S+k0VdO+QmnnVMN0/T/c9/Jjc3wyJKNo8iev7557yD
5K+TyfvhsHiCbB7Fk+XLeb/Ik6+T4fvhIIQuniznX5D7SxZ17ZAbetYx3QxNt2iIBQNl9Sg+0yly
0UgPPkRWj+IzPSEXjfRBFbr4DHIPyaKuHXJzzzqmm5vpFq2zylhZHrGWWvvkouVe+RxZHrFWfE7k
ouU+qIeOteKRcyWLunbIzT3remG6a39dQ39sDLt5PrhIWMnKYfXJyxGI1f6Qd+8Gz54NHj1aHC9f
Dj58WO8h+fVrenTy3WwW6ysL9p79mOZMnt3NYn1lwd6z6Q/kvpBFXTvk5p51vTDd5Z+2+ge2abpB
c938ueTySmoneP779/FqQDx5svj627eDN28WPzx9Wqt7pGXy9Xhc8zlS0nWWDXl8PR5sgw52nSFn
SRZ17ZCbe9b12nTX/urNkzWT0T9nghlteZ7dhOlOp6NgH8inTwvOw4fr5799Oz06+Wo02upRcnma
M3l0NQp8f6kQ+vQSuS9kUdcOublnXX9Nd9PtYnZb7oslDl2nc7vSdGN2XlKpy3nta8fHj4PnzxdX
+Pr1+j9dX58cnbx856H+cXGSM3n5zkP9R8nJBXJfyKKuHXJzz7r8Tbe+w5Xb3g4ZaqXpVnr/bqYb
bKC9eLHAvnoVnghwdPLmDTL89w5Zmx/ImBx+iJSikXtCFnXtkJt71vXCdDd3N9zZdGuiKos+2CO9
eTL4W3Zroz14sIB//hyIlT0z3YOQZbpyDmRR1/FM9yDPOpnujplu+Se3KvqSk5X7IW81GhE79h/T
3Z9sTNfoGrKo6/6Y7v7PusxNt87MpkN1Lzc0pruDna/Nu1seS9V/ubtlstnLqzKPFFnUHZfc3LOO
6W5huvPtZy+Xdy+3855uebjs857uAcne012VNyaRRd1xyc096/LvXs5bVqTKlWxtIGRRd1yyFalo
u0q19nLqZKvgIou645KtvUxbVOr8v/tjPI7vj3HWQXLRio/NzyzO35z1i1y04sPzM3/3lZ3dIPeX
LOraITf0rGO6eZruPL4TZHAEoiPk2C6hwdGp7MmxXUKDo1PIvSKLunbITTzrmG62pouMjIyM3DUy
02W6yMjIyMhMl4Q4MjIyMtMlpouMjIyMzHSZLjIyMjIy0yWBiIyMjMx0mW66pktERN0U05XpIiMj
IyPLdEkgIiMjIzNdYrrIyMjIyEyXhDgyMjIy0yWmi4yMjIzMdJkuMjIyMjLTpUbCJbY/xv39bWfJ
sb1Tft72kayckZHzIzPdPE33906Qw/hOkOcdJH+dTN4Ph7FdQr+c94usnJGRsyQz3QxNt0iGgg/r
1aP4TKfIReMxGNyrR/GZnpCVMzJyrmSmm5vpFhlS5fN6ecSypfbJRYuyMr6XR6x1mRNZOSMj50pO
23QPftnlwD//uvlDReH++2N7niy/2vv72Wqf5Lt3g2fPBo8eLY6XLwcfPqz3Uv76NT06+W42i/Xh
BHt1fkxzJitnZORcyWmb7vKaD3vl25pufVrwuzucrLza79/Hqw/lJ08Wlfv27eDNm8UPT5/W6qJs
mXw9HteM75IunWzIyhkZOVdybqa7eubPf+snlJu01U8GF7NeM8jyUt7HdOs3EabTUbAf8tOnxTU/
fLh+/tu306OTr0ajrUL88jRnsnJGRs6VnKHprnnkVt4W/Ep5r3Lwu4c13W27l5fvlqwdHz8Onj9f
cF6/Xv+n6+uTo5OXc/HrHxcnOZOVMzJyruSETXer/tjyvtkdUs9tB3crLyx2spwfPBlMkl68WKBe
vQpPxjk6eTOIh//uVNj8QMZk5YyMnCs5bdPd3LawjunW/FZHTHeHMd1gnvTgweLv/fw58LzeM9M9
CFlbWDkjI8t0M8x0D3VyK9PdHD9u1HRjI4KxY/8x3f3JRn2UMzKyMd00HLdkfHfb4ds9x3S3utTm
THdt7uvyWKr+Agstk81vVM7IyGYvZ2i689KJyvPS2ctrHwvOXq7TBz5v9z3d8kf2Pu/pHpDsTT7l
jIzsPV1Kr/GxlBWpUicrZ2TkXMlMN0PTnVt7OX2yckZGzpXMdDM03fl/96h5HN+j5qyD5KJ1GZs3
WJy/OesXWTkjI2dJZrp5mu48vhtrcBSwI+TY7pXBUZPsycoZGTk/MtPN1nSRkZGRkbtGZrpMFxkZ
GRmZ6ZIQR0ZGRma6xHSRkZGRkZku00VGRkZGZrokEJGRkZGZLtNN13SJiKibYroyXWRkZGRkmS4J
RGRkZGSmS0wXGRkZGZnpkhBHRkZGZrrEdJGRkZGRmS7TRUZGRkZmutRIuMT2qLm/v0XuOTm2d8rP
W2Rk5GbvQaabp+n+3o11GN+N9Ry5t+Svk8n74TC2S+iXc2Rk5AbvQaaboekWDbFgoKwexWeQe0gu
mv/Bx9PqUXwGGbnn5ObuQaabm+kWrbPKWFkesZYacq7kIieofEItj1h+gIzcB3Jz92Dmprvz3/Xn
i1sRNj8cXA+s/skd/rr7+9lqf8i7d4NnzwaPHi2Oly8HHz6s95D8+jVF7gn5bjaL9cIF++V+TJGR
+0hu7h7M3HSXf9Ruf9oO3wr6aLmLl5/c7SK/fx+vBsSTJ4urevt28ObN4oenT2t1jyBnSb4ej2s+
oUo65ZCRsyc3dw/2znRLfl4thNX/XfPFWFkFDX43062f/gbPT6ejYB/Ip08LzsOH6+e/fTtF7gn5
ajTa6iF1eYqM3Edyc/cg060+uebElR65j+muVURl+hs8uZzXvnZ8/Dh4/nwBf/16/Z+ur0+Qe0Je
vk1R/7g4QUbuI7m5ezBn090zyyxx3x1MN2jYm7n1tv4aPBlsoL14seC/ehWeCIDcE/LmY2j4753I
Nj+AjNxDcnP3YOamu7mvYc3u5UOZ7qqbbv66OvDyrRnrt9EePFgQPn8OxMqeGRhyQmTZDDLyce9B
me4WCe5uprvtr9vtauuMRsSO/ccakVMhG7dDRj7uPZit6QYzzjoDtIc13T1nLwevtrJS1+bdLY+l
6r/cjZwl2QxVZOTj3oO9M93y/t7deoDrdC/v/J5u8GrLL2PtDbPycNnn/VHk5MjexURGPu49mHP3
ch9kDSZkK1IhI1uRio5sunOrDSNbXxcZ2drL1Jrpzv+7P8bj+P4YZ8i9JRf5QWzmZ3H+5gwZGbnB
e5Dp5mm68/hOkMERCORekWP7jwbHvZCRe0tu4h5kutmaLjIyMjJy18hMl+kiIyMjIzNdEuLIyMjI
TJeYLjIyMjIy02W6yMjIyMhMlwQiMjIyMtNluumaLhERdVNMV6aLjIyMjCzTJYGIjIyMzHSJ6SIj
IyMjM10S4sjIyMhMl5guMjIyMjLTZbrIyMjIyEyXGgmX2P4Y9/e3nSXHdgv5edtH8uxuNr4ej65G
j//38eB/BicXJ6eXp3/931+3P5H7ThZ16ZYz083TdH/vBDmM7wR53kHy18nk/XAY2xfzy3m/yJOv
k+H7YXBX7uLJcv4Fub9kUZd0OTPdDE23SDqDprh6FJ/pFLloPAaDe/UoPtMTctFIH1Shi88g95As
6lIvZ6abm+kWmWilLy6PWFbaPrloUVbG9/KItS5zIhct90E9dKwVj5wrWdSlXs4Zmm7NhbgO0oW7
GyF4bfVPll/b/f1ste/33bvBs2eDR48Wx8uXgw8f1nuDf/2aHp18N5vF+nCCvTo/pjmTZ3ezWF9Z
sPds+gO5L2RRl3o5Z2u6B3TN/b9ecj1/fq5/svLavn8fr5rfkyeLC3j7dvDmzeKHp09rdQW3TL4e
j2vGd0mXTjbk8fV4sA062HWGnCVZ1KVezv0y3eUPq/+79of/+UDsM3W+svmrWzbd6XQU7O/99Glx
kQ8frp//9u306OSr0WirEL88zZk8uhoFvr9UCH16idwXsqhLvZx7Z7qVJrf5gR2+Uj/zbsJ0l+/w
rB0fPw6eP19c6uvX6/90fX1ydPJyLn794+IkZ/LynYf6j5KTC+S+kEVd6uXcrzHdSlMsd77dfHHb
RsDmNW87phtMRl+8WEBevQpPejo6eTOIh/+uxM0PZEwOP0RK0cg9IYu61Mu5j93LQW+uabo1v1JZ
9H8Im/7aUKb74MEC/vlzwBf3zHQPQpbpyjmQRZ1MN2fT3aGPt9L2tspH6zAPO6YbO/Yf092fbEzX
6BqyqDOm2wvT3SrTPWz38ryV2cvLY6n6C1m0TDZ7eVXmkSKLulzLuddjujW7c+vMXt6te7md93TL
rXGf93QPSPae7qq8MYks6nIt5zxNtz+yIlWuZGsDIYu6XMuZ6WZounNrL6dPtgousqjLtZyZboam
O//vXkCP43sBnXWQXLQuY/MGi/M3Z/0iF6348PzM331lZzfI/SWLuqTLmenmabrz+K63wdHWjpBj
u1cGR02yJ8d2CQ2OTiH3iizq0i1npput6SIjIyMjd43MdJkuMjIyMjLTJSGOjIyMzHSJ6SIjIyMj
M12mi4yMjIzMdEkgIiMjIzNdppuu6RIRUTfFdGW6yMjIyMgyXRKIyMjIyEyXmC4yMjIyMtMlIY6M
jIzMdInpIiMjIyMzXaaLjIyMjMx0qZFwie0FdH9/21lybE+Pn7fIhyTHdmW5/Yl8SLLYcM1Mty+m
+3vX22F819vzDpK/Tibvh8PY7pVfzpEPQ558nQzfD2P7j55/QT4MWWy4ZqbbF9Mtks6gKa4exWc6
RS4aj8HgXj2KzyDvSS6a/4MqdPEZ5D3JYsM1M92+mG6RiVb64vKIZaXtk4sWZWV8L49Y6xK5DrnI
CQb10LH8AFlsdKc0Urzm3pluzWW6GrXG4G8vPxm81ODJ+/vZat/vu3eDZ88Gjx4tjpcvBx8+rPcG
//o1PTr5bjaL9eEEe3V+TJF3Ic/uZrFeuGC/3PQH8i5kseGamW60IJr+w4M+uvlz8GTl5QX/9fv3
8ar5PXmyuIC3bwdv3ix+ePq0Vldwy+Tr8bhmfJd06SBXksfX48E26GCnHLLY6EhppHjNTHfd9lb/
d61YSsyyPBPd2XQrKyX4gel0FOzv/fRpcZEPH66f//bt9Ojkq9FoqxC/PEXehTy6GgW+v1QIfXqJ
vAtZbLhmplvLdOtbYOW3aubWdeAltRM8v3yHZ+34+HHw/PmC8/r1+j9dX58cnbyci1//uDhB3oW8
fJui/kPq5AJ5F7LYcM1Mt3pMt9LYtuoW3tnmK72/slKDyeiLFwvsq1fhSU9HJ28G8fDf1bT5AeQd
yOHHUykaeQey2HDNTLdu93LQmw9ruqvOuvb1YHf0tqYbzEcfPFjAP38O+OKeme5ByPJRma5MV9Yo
0+2v6e427LpVJ/C2Vlr/ZGzkNXbsP6a7P9nIqzFdY7rGR43pMt0D9ADPDzSRqr7prs0xXh5L1V/I
omWyOcbtkM0xbocsNlwz0916TLdmD/A+3ctbvadbP1Fee5u23Br3eU/3gGRv07ZD9jZtO2Sx4ZqZ
bi+y9j+yIhWydaOOSxYbrpnp9sh059ZeRrZC8rHJYsM1M90eme78v3sBPY7vBXTWQXLRuozNGyzO
35whH4Zc5AfhmZ+/e+HObpAPQxYbrpnp9sh05/Fdb4OjrR0hx3avDI6aIO9Mju0/Ghz3QhYbHS+N
tK6Z6WZrusjIyMjIXSMzXaaLjIyMjMx0SYgjIyMjM11iusjIyMjITJfpIiMjIyMzXRKIyMjIyEyX
6aZrukRE1E0xXZkuMjIyMrJMlwQiMjIyMtMlpouMjIyMzHRJiCMjIyMzXWK6yMjIyMhMl+kiIyMj
IzNdaiRcYjtv3P68RUZGRkY+Cpnp5mm6k6+T4fthbI/J8y/nyMjIyMjtk5luhqZbNMSCgbJ6FJ9B
RkZGRm6ZzHRzM92idVYZK8sj1lJDRkZGRm6CnLbpVq621U1rDF52/ZPllTq7m8X6Q4I9JNMfU2Rk
ZGTkFshpm+7qNXf2+oM+uvlz/ZOVlTq+HteMlZLuEWRkZGTkg5MTNt1g+liSIC5/Xj1ZJ6388636
2M1Latl0R1ejQFgsFQqX08tTZGRkZOQWyFmZbqWrxX6u/636Hyi51KZNdzmvvX64nFycICMjIyO3
QM7TdIMfixnYbrZX3xdLTDfm/XuabjhQVrURMcjIyMjILZCzNd3NHQ3r2Odu39rWdFeddbNLXKaL
jIyMLNNNaUx3/5y1/JP7m25NKzWmi4yMjGxMt4u+u9uI7HG7l+dmLyMjIyObvZyW7wYvvn5XbZ05
zzU/sG33svd0kZGRkb2nS8kPbFv/BRkZGdmKVNSS6c6tdIqMjIxs7WVqzXSXLbXwHLzf/SFnN2fI
yMjIyO2TmW6epjuP7wQZHIFARkZGRm6BzHSzNV1kZGRk5K6RmS7TRUZGRkZmuiTEkZGRkZkuMV1k
ZGRkZKbLdJGRkZGRmS4JRGRkZGSmy3TTNV0iIuqmmK5MFxkZGRlZpksCERkZGZnpEtNFRkZGRma6
JMSRkZGRmS4xXWRkZGRkpst0kZGRkZGZLjUSLrH9MW5/3naWfDebXY/HV6PR/z5+/D+DwcXJyeXp
6f/99dfP2z6SU6xBUSfqXDPT7aPpTr5Ohu+HsZ0gz7+cd5D8dTJ5PxwGt4suIv7Leb/IKdagqBN1
rpnp9tF0iyZeMARXj+IznSIXjccq8KD4TE/IKdagqBN1rpnp9tF0i3ZfZRQuj1gbsH1y0aKsBx7E
Wpc5kVOsQVEn6lwz013582r8gX8+c9jS2KQFL6n+yfJKnd3NYj0twb6X6Y/p0cl3s1msDyfYq/Nj
mjM5xRoUdaLONTPd9T+78m9swnSDPlr+G8tPVlbq+HpcMwpLOl5aJl+Px9uAw1062ZBTrEFRJ+pc
M9MNp5ixJDK4VvXqf4N5558PlJhiy6Y7uhoFgmKpULycXp4enXw1Gm0V4penOZNTrEFRJ+pcM9Ot
+JtLTG7NZcu/Upkft2y6yxnz9QPx5OLk6OTlXPz6x8VJzuQUa1DUiTrXzHTr9hKXm279juhtTXcz
aQ6m0ZWZ9PrJYAiuaiNkjk7eDOJhBThncoo1KOpEnWtmuhWmu7nrYaXplnylvumummglZ/OTcg45
h0xX1MkaZbqJjenW717eoVt4h17u3XqSja4ZXTOmK+qM6RrT7ajv1h+U3W0ctyNjuuaRpk42x1jU
zc0EzvSa8zfdefxV12Af79ps5GD38v6Zrvd01+SNydRrUNSJOtfMdPOXtYFyJVs3StRZ3SnXa2a6
GZru3Cq46ZOtkCzqcoo618x0MzfdZRswPLvvd0/L2c1ZB8lF6zI2b7A4f3PWL3KKNSjqRJ1rZro9
Nd15fI/J4NhGR8ix3SuDoybZk1OsQVEn6lwz0+2p6SIjIyMjd43MdJkuMjIyMjLTJSGOjIyMzHSJ
6SIjIyMjM12mi4yMjIzMdEkgIiMjIzNdppuu6RIRUTfFdGW6yMjIyMgyXRKIyMjIyEyXmC4yMjIy
MtMlIY6MjIzMdInpIiMjIyMzXaaLjIyMjMx0qZFwie28cfvzdk/y/f3s+/fxdDq6uXn899+D6+uT
b99OZ7O/7u9vO3vNsd1Cft52l9xcaSCLDfF8LDLTzdN0J18nw/fD2B6T51/Odyb/5z+Tm5th4bWb
R+HB//xz3sFr/jqZvB8OY/tifjnvIrm50kAWG+L5iGSmm6HpFg2xYKCsHsVndiAX6WzQbleP4jOd
uuaikV4FHhSf6RS5udJAFhvi+bhkppub6Rats8pYWR6xllqMXOS4lY67PGL5bvvXXLTc64EHsVZ8
++TmSgNZbIjn45LzN93KFbk2y+iwpbFJC15S+cngJQVPzu5msf6QYA/J9Me0Jvn+frbaq/zu3eDZ
s8GjR4vj5cvBhw/r/cy/fk2Pfs13s1msryzYe/Zjenxyc6WBLDbE83HJ+Zvu6t9V+Tc2YbpBHy3/
jfWvOfiv4+txzVgp6R4Jkr9/H6/a6pMniz/t7dvBmzeLH54+rdXJ3PI1X4/H24DDXWctk5srDWSx
IZ6PS87cdIMpZiyzDK5VvfrfYDL65wMlmejOplu/lbCq0dUoEBZLhcLl9PK0Jnk6HQV7kj99WrAf
Plw//+3b6dGv+Wo02upRcnl6fHJzpYEsNsTzccm9M92azrfmsuVfqfTIfUy3vG88eH45r71+uJxc
nNQkL98OWjs+fhw8f75gv369/k/X1ydHv+blOw/1j4uT45ObKw1ksSGej0vur+mW9yrX99E6XcEx
0w0adqXNV/6B4UBZ1UbE1CQH09wXLxbIV6/C06mOfs2bN8iwAnx8cnOlgSw2xPNxyb023c08stJ0
S75S33RXnXWzu3s7f+1ApvvgwQL8+XPAcWW6MgOZrkxX1BnT3a57eYdu4d16uQ91sv0x3dhhTNcY
mDFdY7qirkemW9M1tzXdPTPd3SZS1Tfd1mYvL4+l6i+RYYbqEUsDWWyI5+OS8zfdefw93c3u3NUz
sYnHm1/ZuXt5q/d06yfKrb2nW2663tP1XqP3dL2nK+r6aLoZy4pUdchWHUIWG+LZilTUoOnOrb38
b1lfF1lsiOfukJluhqa7bKmF5+D97g85uznbmfx7l6HH8V2Gzjp4zUUrPjY/szh/c9ZFcnOlgSw2
xPMRyUw3T9Odx3eCDI5AbEWO7acbHMftyDXHdgkNjk51hNxcaSCLDfF8LDLTzdZ0kZGRkZG7Rma6
TBcZGRkZmemSEEdGRkZmusR0kZGRkZGZLtNFRkZGRma6JBCRkZGRmS7TTdd0iYiom2K6Ml1kZGRk
ZJkuCURkZGRkpktMFxkZGRmZ6ZIQR0ZGRma6xHSRkZGRkZku00VGRkZGZrrUSLjE9se4/XnbQ3Js
75Sft90lq0FkUZcfmenmabqTr5Ph+2FsJ8jzL+e9In+dTN4Ph7FdQr+cd5GsBpFFXZZkppuh6RYN
sWCgrB7FZ3pCLpr/VeBB8ZlOkdUgsqjLlcx0czPdonVWGSvLI9ZSy4lc5AT1wINYftA+WQ0ii7pc
yfmbbuWKXJtldMDSCP72+icray44AhHrDwn2kEx/TDMm381msV64YL/cj+nxyWoQWdTlSs7fdFf/
rsq/8eCmG/zt9U/+qZutTHd8Pa4ZKyXdI9mQr8fjbcDhTrmWyWoQWdTlSs7cdMuzxrXMMrhW9ep/
g8nonw/s5uh1Tm5ruqOrUSAslgqFy+nlacbkq9Foq4fU5enxyWoQWdTlSu6d6dbMQddctvwrNfPj
3TLdHUx3Oa+9fricXJxkTF6+TVH/uDg5PlkNIou6XMn9Nd1yO6z00TpmWaeXuwnTDQfKqjYiJmPy
5g0yrAAfn6wGkUVdruRem+7mroeVplvyle6YrnalTBdZPIs6mW63xnTrdy/vbJZ1TLQJ0zWCYkwX
WTyLOmO6x/fd+oOyu43jDur15DRtuuYKrsrsZWTxrJzNXm7bd2PvvwYnJwf/qeQr5f662SM9955u
i2Tv6SKLZ+XsPV1qdtDa+i+rsiIVsnhWzlakogZNd26l03/L2svI4lk5d4fMdDM03WVLLTwH73d/
yNnNWa/IRX4Qm/lZnL856yJZDSKLuizJTDdP053Hd4IMjkBkT47tPxoc9+oIWQ0ii7r8yEw3W9NF
RkZGRu4amekyXWRkZGRkpktCHBkZGZnpEtNFRkZGRma6TBcZGRkZmemSQERGRkZmukw3XdMlIqJu
iunKdJGRkZGRZbokEJGRkZGZLjFdZGRkZGSmS0IcGRkZmekS00VGRkZGZrpMFxkZGRmZ6VIj4RLb
H+P25+2e5Pv72ffv4+l0dHPz+O+/B9fXJ9++nc5mf93f70uO7Z3y87aP5OZqEFlsIB/rWcd08zTd
ydfJ8P0wthPk+Zfzncn/+c/k5mZYxN/mUcTlP//sTv46mbwfDmO7hH457xe5uRpEFhvIR3zWMd0M
Tbdo4gVDcPUoPrMDuWjiBUNw9Sg+swO5aP5XXfKg+ExPyM3VILLYQD7us47p5ma6RbuvMgqXR6wN
GCMX7b7KKFwesTZgjFzkBPUueRDLD3IiN1eDyGID+bjPur6bbnC9rgOWRoxf52TlimLBk7O7Wayn
Jdj3Mv0xrUm+v5+t9rS8ezd49mzw6NHiePly8OHDet/Lr191yXezWawXLtgv92OaM7m5GkQWG8jH
fdb13XTXHO7gphtk1j9ZWX/Bk+Prcc0oLOl4CZK/fx+vhtqTJ4uweft28ObN4oenT2t1vATJ1+Px
Npcc7pTLhtxcDSKLDeTjPut6bbqbf/KaBdZMRoOfLPl1O5huDB48P7oaBQJuqVAgnl6e1iRPp6Ng
78qnTwv2w4fr5799q0u+Go22ekhdnuZMbq4GkcUG8nGfdUy3rERqmmXwAwc03fLr3Dy5nDFfPxBP
Lk5qkpcz5teOjx8Hz58v2K9fr//T9XVd8vJtivrHxUnO5OZqEFlsIB/3Wcd0t+t23qFbuGY/9gFN
NxyCq9qIxZrkYNPvxYsF8tWr8BSDmuTNG2RYcck5k5urQWSxgXzcZx3T3doj13qYO2i6Lbf+HjxY
gD9/DkShTFc2I9MVG9lkugd51jHdfXuA65huiYlWcmp2WR93nCN2GNM1bmdMV2zkNKa7/7Ou16Zb
0+qCg7v7zDpu2nRbm9G3PJaq/9q42ctHrEFksYF83Gdd3013XuM93c3u5fk2s46DL9pu9fLutqbb
2rtr5YHoPV3vYnpPV2zMs3hP94DPOqab57C0FalSJ1sbqB2y2EC2IhUdwHTn1l5On2wV3HbIYgO5
/Wcd083QdJdtwPDsvt89LWc3ZzuTf++88Ti+88bu5CI/iM38LM7fnPWL3FwNIosN5CM+65hunqY7
j+8xGRzb2Ioc22MyOLaxFTm2/2hw3Ct7cnM1iCw2kI/1rGO62ZouMjIyMnLXyEyX6SIjIyMjM10S
4sjIyMhMl5guMjIyMjLTZbrIyMjIyEyXBCIyMjIy02W66ZouERF1U0xXpouMjIyMLNMlgYiMjIzM
dInpIiMjIyMzXRLiyMjIyEyXmC4yMjIyMtNlusjIyMjITJcaCZfYzhu3P287S47tyvLzto/kFGsQ
WWzkRI7tMnR/vzuZ6eZpupOvk+H7YWyPyfMv5x0kf51M3g+Hsf1Hv5z3i5xiDSKLjZzIv/fTHcb3
092RzHQzNN2iiRcMwdWj+EynyEXzvwo8KD7TE3KKNYgsNnIiF+ls0G5Xj+IzTJfpLtp9lVG4PGJt
wPbJRU5QDzyI5Qc5kVOsQWSxkRO5yHErHXd5xPJdpjsPLs11wD88xg8Wb/DMthUR/PDsbhbraQn2
vUx/TI9OvpvNYr1wwX65H9OcySnWILLYyIl8fz9b7VV+927w7Nng0aPF8fLl4MOH9X7mX7+mTLfs
74/9fHB+yS8t8f76lxT85Ph6XDMKSzpeWiZfj8fbgMOdctmQU6xBZLGRE/n79/GqrT55snhiv307
ePNm8cPTp7U6mXttuiWJ5vKHOhlq7JMlv67EiWuabnn6Gzw/uhoFAm6pUCCeXp4enXw1Gm31kLo8
zZmcYg0ii42cyNPpKNiT/OnTgv3w4fr5b99Ome52f3xNswx+YFvTrfzfOl8vObmcMV8/EE8uTo5O
Xr5NUf+4OMmZnGINIouNnMjLt4PWjo8fB8+fL9ivX6//0/X1CdPd4o/fKkPdDbib6Vb+CeGTwRBc
1UYsHp28eYMMK8A5k1OsQWSxkRM5mOa+eLFAvnoVnk7FdPc13c09EY9iuuVbM8oMZLqyGZmuGmwn
033wYAH+/DnguDLdrcd0S07WT0a3yl+b6142BmZMF9mYrhpsYkw3dhjT3TEB3bN7ufy9oH1Md6tM
12zP1MnmkYpn5Xxc8trs5eWxVP0lMrynW/2ebvm04XLTDfZIz/d+T/fPmfqm673G1MnemBTPyvm4
5LX3dMtN13u6PZIVfHIlWxtIPCvn45KtSEXbVaq1alMnWwVXPCvn45KtvUxbVOqyDRie3fe7p+Xs
5qyD5CI/iM38LM7fnPWLnGINIouNnMi/dxl6HN9laEcy083TdOfxPSaDYxsdIcf2Hw2Oe2VPTrEG
kcVGTuTYfrrBcVym23fTRUZGRkbuGpnpMl1kZGRkZKZLQhwZGRmZ6RLTRUZGRkZmukwXGRkZGZnp
kkBERkZGZrpMN13TJSKiborpynSRkZGRkWW6JBCRkZGRmS4xXWRkZGRkpktCHBkZGZnpEtNFRkZG
Rma6TBcZGRkZmelSI+ES23nj9uftnuTYzhv397edvWZk5PbJsV2Gft52l5xiaaQVG0w3T9OdfJ0M
3w9je0yefznfmfx7j8lhfI/J8w5eMzJy++Svk8n74TC2n+6X8y6SUyyN5GKD6WZoukVDLBgoq0fx
mR3IRTobtNvVo/hMp64ZGbl9cpHAVYEHxWc6RU6xNFKMDaabm+kWrbPKWFkesZZajFzkuJWOuzxi
+W7714yM3D65yOrqgQexDK99coqlkWJsZGW6lYtvHbwLdzfC5nXGFg8r/4uC52d3s1h/SLCHZPpj
WpN8fz9b7VV+927w7Nng0aPF8fLl4MOH9X7mX7+mR79mZOT2yXezWawfNdiz+mN6fHKKpZFibGRl
umte1al2wFbX+edk/U+uanw9rhkrJd0jQfL37+NVW33yZPGnvX07ePNm8cPTp7U6mVu+ZmTk9snX
4/E24HC3asvkFEsjxdjIx3SD2WR5vvjnzOYng87353yQU2KKW5lu7F/rm+7oahQIi6VC4XJ6eVqT
PJ2Ogj3Jnz4t2A8frp//9u306NeMjNw++Wo02spmLk+PT06xNFKMjZxNt9y6Vn/Y82TlNdQ33Z1z
4lUt57XXD5eTi5Oa5OXbQWvHx4+D588X7Nev1//p+vrk6NeMjNw+efk+TP3j4uT45BRLI8XYYLpb
nKz8Ss1rC7r4tp8sc+JgoKxqI2JqkoNp7osXC+SrV+HpVEe/ZmTk9smbj+VhBfj45BRLI8XYYLr7
mu68xuyt2ESqyky35JPdyXQfPFiAP38OOK5MF1mmK9OV6fZuTLdp0922e3mrDuQkxnRjhzFdZGO6
xnSN6eZpuvN6U5AOPnx7wDHd+pOqyk+2Nnt5eSxVf4kMc1+RzV42e9ns5czf0z3g7OUDdi9X9i3P
u/2ebrnpek8X2Xu63tOde083b9M94HhwEgViRSpkZCtSWZHKilQp5cSxZaHSbS4sZe1lZOTjkq29
nPo1W3uZtkvHi5ZaeA7e7/6Qs5uzncm/dxl6HN9l6KyD14yM3D65yPBic3eL8zdnXSSnWBrJxQbT
zdN05/GdIIMjEFuRY/vpBsdxO3LNyMjtk2M7yAZHLjtCTrE00ooNpput6SIjIyMjd43MdJkuMjIy
MjLTJSGOjIyMzHSJ6SIjIyMjM12mi4yMjIzMdEkgIiMjIzNdppuu6RIRUTfFdGW6yMjIyMgyXRKI
yMjIyEyXmC4yMjIyMtMlIY6MjIzMdInpIiMjIyMzXaaLjIyMjMx0qZFwie2PcfvztrPk2D4kP2/7
SE6xBkWdchYbTLePpjv5Ohm+H8Z2gjz/ct5B8tfJ5P1wGNtx88t5v8gp1qCoU85ig+n20XSLJl4w
BFeP4jOdIheNxyrwoPhMT8gp1qCoU85ig+n20XSLdl9lFC6PWBuwfXLRoqwHHsRalzmRU6xBUaec
xcbhTXdzdavNL6796ya8+lKqPv/nTGzZrfKr2vx15X/RzoMBJRcT/DNjFRH7RcHzs7tZrKcl2Pcy
/TE9OvluNov14QR7dX5McyanWIOiTjmLjcObbsyZ9vm5Jj/2vyWo+s69aeQHNN3yKwn+0qAZ17+A
8fW4ZhSWdLy0TL4ej7cBh7t0siGnWIOiTjmLjQObbnm6Wce6yl2tMp3d1nQrnT7ohavpZmUjoPK3
bH6gBdMdXY0CQbFUKF5OL0+PTr4ajbYK8cvTnMkp1qCoU85io3HT3dbkKnt6y0066HMHNN1tGxOV
3lyZUtcx3aBtl/+65Yz5+oF4cnFydPJyLn794+IkZ3KKNSjqlLPYaNV0y62lUdMtH9OtTK9LxnS3
PVnTGoMZfElav63phkNwVRshc3TyZhAPK8A5k1OsQVGnnMVGX0y35vBw/etv2nRLsuTYXyfTlenK
ZmS6yH3PdMtd9rBjuk2YbuVEquZMt2b7o3I/ZCMoxnSN2xnTRc5zTHeHIdIDzl7eqtO45lyk+qZb
vx942z6AOhOptrVzcwVTJ5tHmnrUKWexMW/uPd3KpK3khdTgeGrJOzYx5zv4e7qVs6X2nDjmPd01
eU839RoUdcpZbDRiurTzmHebv9T6L6mTrQ2UetQpZ7HBdHNz3LmVTrMmWwU39ahTzmKD6fbL7Is2
YHh23++elrObsw6Si9ZlbN5gcf7mrF/kFGtQ1ClnscF0+5thx/aYDI5tdIQc270yOGqSPTnFGhR1
yllsMF3d2sjIyMjInSAzXaaLjIyMjMx0SYgjIyMjM11iusjIyMjITJfpIiMjIyMzXRKIyMjIyEyX
6aZrukRE1E0xXZkuMjIyMrJMlwQiMjIyMtMlpouMjIyMzHRJiCMjIyMzXWK6yMjIyMhMl+kiIyMj
IzNdaiRcYjtv3P687Sw5tqfHz9s+klOsQWSxgcx0+2i6k6+T4fthbI/J8y/nHSR/nUzeD4ex3Su/
nPeLnGINIosNZKbbR9MtGmLBQFk9is90ilw0/6vAg+IzPSGnWIPIYgOZ6fbRdIvWWWWsLI9YS619
cpET1AMPYvlBTuQUaxBZbCDnabo119k6lJ9t9Ss2P7x5neXXv+evW45AxPpDgj0k0x/To5PvZrNY
L1ywX+7HNGdyijWILDaQczbdnV3qID235eUYgwSBm5/f33TH1+OasVLSPdIy+Xo83gYc7pTLhpxi
DSKLDeS+mO6mt21mljFHjJ2MZbol6fXat+qYbiwtrrzI8kodXY0CYbFUKFxOL0+PTr4ajbZ6SF2e
5kxOsQaRxQZyH003aHKrf13lJ7f9Sv0svDJB37TtbRPlpZbz2uuHy8nFydHJy7cp6h8XJzmTU6xB
ZLGBzHQH21pXpRPvbLrlPc8lufIOphsOlFVtRMzRyZthPKwA50xOsQaRxQYy060wy83ZTAc33WB/
daU9B7uXZboyXTmHeFbOMt1UTXeHk7uZbv3x3ZqNAGNgxnSNrhnTVc7GdI9mupWDoLsN3zY6prut
N2+V6ZrtmTrZbE/xrJxzJadquuXvuQZnL8e6lytP1py9XJnC7pAQl/ROl3C815g62XuN4lk550pO
0nSpslKt4JM62Qo+4lk550pmuhma7txatemTrVUrnpVzrmSmm6HpLltq4Tl4v/tDzm7OOkgu8oPY
zM/i/M1Zv8gp1iCy2EBmuj013Xl8J8jgCERHyLH9R4PjXtmTU6xBZLGBzHR7arrIyMjIyF0jM12m
i4yMjIzMdEmIIyMjIzNdYrrIyMjIyEyX6SIjIyMjM10SiMjIyMhMl+mma7pERNRNMV2ZLjIyMjKy
TJcEIjIyMjLTJaaLjIyMjMx0SYgjIyMjM11iusjIyMjITJfpIiMjIyMzXWokXGL7Y9z+vO0sObYr
y8/bPpJTrEFksaE0mG4fTXfydTJ8P4ztBHn+5byD5K+TyfvhMLb/6JfzfpFTrEFksaE0mG4fTbdo
iAUDZfUoPtMpctHgrQIPis/0hJxiDSKLDaXBdPtoukXrrDJWlkespdY+uWgF1wMPYi3inMgp1iCy
2FAafTfdmityNWqBwd++58ny3zi7m8X6Q4I9JNMf06OT72azWL9TsCfqxzRncoo1iCw2lAbTnW8a
WMumu3rmz897nqz8i8bX45qxUtI90jL5ejzeBhzuhsqGnGINIosNpcF0y1ww5mf75KDlZdia6Y6u
RoGwWCoULqeXp0cnX41GW92Wl6c5k1OsQWSxoTSY7tame8CTRzTd5bz2+uFycnFydPLy/YH6x8VJ
zuQUaxBZbCgNpruX6dZ3uzqmW5JY75B5V1xbMFBWtRExRydvhvGwApwzOcUaRBYbSoPpNti93I7p
ynRlurJG8aw0ZLo5m27Nk1uZbsl8LmO6xnSNj4pnY7rGdPM03ZixNTqme/ApzZWVan5j6mQzgcWz
0si1NPI33ZL3dP+cbG72cuwCvKe7Ju/ppl6DyGJDaTDd/GXNmlzJVncSz0oj19Jguhma7tzqrOmT
rWMsnpVGrqXBdDM03WVLLTwH73d/yNnNWQfJRYs4NtexOH9z1i9yijWILDaUBtPtqenO4ztBBkcg
OkKO7bgZHOnJnpxiDSKLDaXBdHtqusjIyMjIXSMzXaaLjIyMjMx0SYgjIyMjM11iusjIyMjITJfp
IiMjIyMzXRKIyMjIyEyX6aZrukRE1E0xXZkuMjIyMrJMlwQiMjIyMtMlpouMjIyMzHRJiCMjIyMz
XWK6yMjIyMhMl+kiIyMjIzNdaiRc7u9n37+Pp9PRzc3jv/8eXF+ffPt2Opv9dX9/i9xzcmy/l5+3
yMjIzd6DTDdP0/3PfyY3N8MiSjaPInr++eccubfkr5PJ++EwtrPpl3NkZOQG70Gmm6HpFg2xYKCs
HsVnkHtILpr/wcfT6lF8Bhm55+Tm7kGmm5vpFq2zylhZHrGWGnKu5CInqHxCLY9YfoCM3Adyc/dg
5qZbc1GufRyuHBv81fVPVtZccARitT/k3bvBs2eDR48Wx8uXgw8f1ntIfv2aIveEfDebxXrhgv1y
P6bIyH0kN3cP9sJ06xvkwU139Z/+/Fz/5J+62eqSvn8frwbEkycLwtu3gzdvFj88fVqrewQ5S/L1
eFzzCVXSKYeMnD25uXuwd6b750zM+WIJaMkXY34Zu5JtnXhb051OR8E+kE+fFn/Iw4fr5799O0Xu
CflqNNrqIXV5iozcR3Jz9yDTrbbhoPUGv1jZz7xDpruD6S7nta8dHz8Onj9f/AmvX6//0/X1CXJP
yMu3KeofFyfIyH0kN3cP9td0y/PIrRLQyny0vPf44KYbbKC9eLGo4levwhMBkHtC3nwMDf896WHz
A8jIPSQ3dw8y3cAA6mpp1DTdygJs03SDbbQHDxZX+PlzIFb2zMCQEyLLZpCRj3sPMt0DDLVWdi+X
mGgTphsbjYgd+481IqdCNm6HjHzce7B3plvT/0rGdGsaZx3Xb8h01+bdLY+l6r/cjZwl2QxVZOTj
3oO9MN2S93TLJyqXn6z8ueS3t/mebnm47PP+KHJyZO9iIiMf9x7M33S37Xxu+ovtXL81mJCtOoSM
bEUqjtven2C1YeTYP1lfFxn5uPegtZfzbDf83h/jcXx/jDPk3pKL/CA287M4f3OGjIzc4D3IdLNN
1mM7QQZHIJB7RY7tPxoc90JG7i25iXuQ6fauhxwZGRkZ+Vhkpst0kZGRkZGZLglxZGRkZKZLTBcZ
GRkZmekyXWRkZGRkpksCERkZGZnpMt10TZeIiLoppivTRUZGRkaW6ZJAREZGRma6xHSRkZGRkZku
CXFkZGRkpktMFxkZGRmZ6TJdZGRkZGSmS42Ey+xuNr4ej65Gj//38eB/BicXJ6eXp3/931+3P287
S47tFvLzto/kFGsQ2Z2iBpluH0138nUyfD8M7ulcRM/5l/MOkr9OJu+Hw9i+mF/O+0VOsQaR3Slq
kOn20XSLhlgwUFaP4jOdIhdN6SrwoPhMT8gp1iCyO0UNMt0+mm7ROquMleURa6m1Ty7a1/XAg1hb
OydyijWI7E5Rg0x3Fxurs4jXaoFWFt3mB4L8+ifLK3V2N4v1hwR7SKY/pkcn381msR6tYB/Xj2nO
5BRrENmdogaZ7oE7bHcz3aCPlkPKT1Ze7fh6XDNWSrpHWiZfj8fbgMMdXNmQU6xBZHeKGmS6hzTd
zYyzjjUu/3dn0628sODJ0dUoEBZLhcLl9PL06OSr0WirG/7yNGdyijWI7E5Rg0z3YKZbbpOVKW/L
pruc114/XE4uTo5OXr6ZUP+4OMmZnGINIrtT1CDT3XdMt2avcjCdrWO6q78leLJO/h04GQyUVW1E
zNHJm2E8rADnTE6xBpHdKWqQ6TbSvRyzyfqmu+qsawluzL+3Ml3td5kBsjtFPMt0dS/v8ut2+LqR
KmNgyO4U8WxMNwfTjWW6zY3p1nxtaVXmZKZONtsTWTznSma623UvV3ptzelONV/JrXxp2NuHWZK9
14gsnnMlM908mwjW2UmdbAUfZPGcK5npZmi6cyvKpk+2Vi2yeM6VzHQzNN1lSy08B+93f8jZzVkH
yUVbOzaLsjh/c9Yvcoo1iOxOUYNMt6emO4/vBBkcgegIObaXZ3AMKXtyijWI7E5Rg0y3p6aLjIyM
jNw1MtNlusjIyMjITJeEODIyMjLTJaaLjIyMjMx0mS4yMjIyMtMlgYiMjIzMdJluuqZLRETdFNOV
6SIjIyMjy3RJICIjIyMzXWK6yMjIyMhMl4Q4MjIyMtMlpouMjIyMzHSZLjIyMjIy06VGwiW2P8bt
z9s9yff3s+/fx9Pp6Obm8d9/D66vT759O53N/rq/35cc2+Hk520fyc3VILIaRD7Ws47p5mm6k6+T
4fthbCfI8y/nO5P/85/Jzc2wiL/No4jLf/7Znfx1Mnk/HMb28vxy3i9yczWIrAaRj/isY7oZmm7R
xAuG4OpRfGYHctHEC4bg6lF8ZgdykVhUXfKg+ExPyM3VILIaRD7us47p5ma6RbuvMgqXR6wNGCMX
7b7KKFwesTZgjFxkG/UueRDLPHIiN1eDyGoQ+bjPupxNd/OPqvwzS4pityIKrgcWWyQseGbbS5rd
zWI9LcG+l+mPaU3y/f1stafl3bvBs2eDR48Wx8uXgw8f1vtefv2qS76bzWL9e8Eevx/TnMnN1SCy
GkQ+7rOO6R7sXyu/8ufn4Mmg38c+WX5yfD2uGYUlHS9B8vfv49VQe/JkccFv3w7evFn88PRprY6X
IPl6PN7mksPdfdmQm6tBZDWIfNxnXa9Ndy2JrP+/q/+tTEZrmu4acx/THV2NAgG3VCgQTy9Pa5Kn
01Gwd+XTpwX74cP189++1SVfjUZbPf4uT3MmN1eDyGoQ+bjPuv6abnkOWvmvlWnrtqZb+b/1TXc5
Y75+IJ5cnNQkL2fMrx0fPw6eP1+wX79e/6fr67rk5Xsa9Y+Lk5zJzdUgshpEPu6zLn/Tje21VN90
y12zfhHXsdKDmG44BFe1EYs1ycGm34sXC+SrV+EpBjXJmzfIsOKScyY3V4PIahD5uM86mW7ZybVi
iZluzd0TWzPdllt/Dx4swJ8/B6JQpitPkukq52wy3YM865juLgluTQfdwUoTHdONHcZ0jQga01XO
OY3p7v+sY7o7jukG/7WmLzZtuq3N6FseS9V/bdzs5SPWILIaRD7us66/plvegRz719gc4+D5zUHl
EnjJBXf2Pd3yQPSerrc8vaernOdZvKd7wGdd5qabvaxIlSvZ2kDtkNUgshWp6ACmO7f2cvpkq+C2
Q1aDyO0/65huhqa7bAOGZ/f97mk5uznbmfx7543H8Z03dicXmUdsTmlx/uasX+TmahBZDSIf8VnH
dPM03Xl8j8ng2MZW5Ngek8Gxja3IsZ1NgyNq2ZObq0FkNYh8rGcd083WdJGRkZGRu0ZmukwXGRkZ
GZnpkhBHRkZGZrrEdJGRkZGRmS7TRUZGRkZmuiQQkZGRkZku003XdImIqJtiujJdZGRkZGSZLglE
ZGRkZKZLTBcZGRkZmemSEEdGRkZmusR0kZGRkZGZLtNFRkZGRma61Ei4xHbeuP1521lybL+Xn7d9
JKdYg8ip3ynKuWky083TdCdfJ8P3w9gek+dfzjtI/jqZvB8OYzubfjnvFznFGkRO/U5Rzi2QmW6G
pls0xIKBsnoUn+kUuWikV4EHxWd6Qk6xBpFTv1OUcztkppub6Rats8pYWR6xllr75KLlXg88iLXi
cyKnWIPIqd8pyrkdcjKmW/8KD/63lAP//GvsY5vng4uE1T9ZfmGzu1msPyTYQzL9MT06+W42i/WV
BXvPfkxzJqdYg8ip3ynKuR0y023Dkjd9tNywy09W/urx9bhmrJR0j7RMvh6PtwGHu86yIadYg8ip
3ynKuR1ykqa7/GH1mteuf/MDu+WXMZvc/NV/fmPwmls23dHVKBAWS4XC5fTy9Ojkq9Foq0fJ5WnO
5BRrEDn1O0U5t0NO1XRjP5ef3NbqtoXU7ARu2nSX89rrh8vJxcnRyct3HuofFyc5k1OsQeTU7xTl
3A454Uz3IF5V08lqQrY13c18ujzDrlmp4UBZ1UbEHJ28GcbDCnDO5BRrEDn1O0U5t0Pul+kGtzks
t7o6kJ0nUsl0ZboyA2SZrkw3T9PdJ/09bPfyDmRjusZ0ja4hizpjut013fJx2f3HdPfJdM1e3jxp
9nLqNYic+p2inNsh55zplsxJLu9enteYvRw0YO/pek/XG5PIc+/pIudhulS/Uq2zkzrZCj7Ioi5X
MtPN0HTnVpRNn2ytWmRRlyuZ6WZousuWWngO3u/+kLObsw6Si1Z8bH5mcf7mrF/kFGsQOfU7RTm3
QGa6eZruPL4TZHAEoiPk2C6hwdGp7Mkp1iBy6neKcm6azHSzNV1kZGRk5K6RmS7TRUZGRkZmuiTE
kZGRkZkuMV1kZGRkZKbLdJGRkZGRmS4JRGRkZGSmy3TTNV0iIuqmmK5MFxkZGRlZpksCERkZGZnp
EtNFRkZGRma6JMSRkZGRmS4xXWRkZGRkpst0kZGRkZGZLjUSLrH9MW5/3u5Jvr+fff8+nk5HNzeP
//57cH198u3b6Wz21/39vuTY3ik/b/tIbq4Gkdshiw1kptsX0518nQzfD2M7QZ5/Od+Z/J//TG5u
hoXXbh6FB//zz+7kr5PJ++Ewtkvol/N+kZurQeR2yGIDmen2xXSLhlgwUFaP4jM7kIt0Nmi3q0fx
mR3IRfO/6pIHxWd6Qm6uBpHbIYsNZKbbF9MtWmeVsbI8Yi21GLnIcSsdd3nE8t0YucgJ6l3yIJYf
5ERurgaR2yGLDWSmu6+x7VZEwfXAap6sXFEseHJ2N4v1hwR7SKY/pjXJ9/ez1V7ld+8Gz54NHj1a
HC9fDj58WO9n/vWrLvluNov1wgX75X5McyY3V4PI7ZDFBjLTPY7prjnoticr6y94cnw9rhkrJd0j
QfL37+NVW33yZBE2b98O3rxZ/PD0aa1O5iD5ejze5pLDnXLZkJurQeR2yGIDmekezHRrpq01zbum
6cbgwfOjq1EgLJYKhcvp5WlN8nQ6CvYkf/q0YD98uH7+27e65KvRaKuH1OVpzuTmahC5HbLYQGa6
hzHdTY+szFD3N93ymts8uZzXXj9cTi5OapKXbwetHR8/Dp4/X7Bfv17/p+vruuTl2xT1j4uTnMnN
1SByO2Sxgcx0D9y9XL+zt/y7TZhuOFBWtRExNcnBNPfFiwXy1avwdKqa5M0wHlZccs7k5moQuR2y
2EBmug2abs3dE1sz3ZYz3QcPFuDPnwOOK9OVzch0xQYy093CaOd7T4AqN9E6jl7zOo84phs7jOka
tzOmKzaQmW4jplv/rZ6mTbe12cvLY6n6S2SYvXzEGkRuhyw2kJnuLr67+dZsSfdyzF+Dnc9bvby7
rem29p5uuel6T9e7mN7TFRvITDfbjHxVVqRKnWwFn9TJYgOZ6fbIdOfWXk6fbK3a1MliA5np9sh0
ly218By83/0hZzdnO5N/7zL0OL7L0O7kIj+Izfwszt+c9YvcXA0it0MWG8hMt0emO4/vBBkcgdiK
HNtPNziOuxU5tv9ocNwre3JzNYjcDllsIDPdHpkuMjIyMnLXyEyX6SIjIyMjM10S4sjIyMhMl5gu
MjIyMjLTZbrIyMjIyEyXBCIyMjIy02W66ZouERF1U0xXpouMjIyMLNMlgYiMjIzMdInpIiMjIyMz
XRLiyMjIyEyXmC4yMjIyMtNlusjIyMjITJcaCZfYXkD397edJcd2Zfl520dybIeT25/KGVnUpfqs
Y7p5mu7vXW+H8V1vzztI/jqZvB8OY/uPfjnvF3nydTJ8P4zt5Xn+RTkji7okn3VMN0PTLRpiwUBZ
PYrPdIpcNHiDN+TqUXymJ+QisRhUoYvPKGfknkddis86ppub6Rats8pYWR6xllr75KIVXHlPLo9Y
izgncpFtDOqhY5mHckbuQ9Sl+KzL1nT3/IuCX/9zsj48uB5YbJGw4JmS2gmev7+frfaHvHs3ePZs
8OjR4nj5cvDhw3oPya9f06OT72azWL9TsCfqxzRn8uxuFuvfC/b4TX8oZ+Q+Rl2Kzzqmu+PXa8JX
PxY07LWfN725ZiNgVd+/j1cD4smTBfbt28GbN4sfnj6t1T3SMvl6PK55T5Z0Q2VDHl+PB9ugg919
yhk5+6hL8VnXC9Mtcb7V/8Y+sPmva9ln5drW217PDpn3qqbTUbAP5NOnxUU+fLh+/tu306OTr0aj
rW7Ly9OcyaOrUeD7S4XQp5fKGbmPUZfis67XprvDB0p+qJ8cl3zlIKa7nNe+dnz8OHj+fPEXvX69
/k/X1ydHJy/fH6h/XJzkTF6+p1H/8XdyoZyR+xh1KT7r+p7pbvuB8jHdmpa5g+ludT7YQHvxYlHF
r16FJwIcnbx54w3/vUPW5gcyJocffKVo5Yzcw6hL8VnHdA9gujV3T2zNdINttAcPFpf3+XMgVvZs
/R2ELOeQ6SKLuoNkuh1/1uVmujvY556mW6d7uf70qH0S6MrRiNix/zjH/mSja8Z0kUXdocZ0u/ys
65fpbjuOu9WYbqwMy98LqjTdHSZRr827Wx5L1X+5u2WyeaSrMnsZWdTl+qzLsHu55L3YkkHZ2AeC
s5dj9lzylu0mp857urGvl1fq2htm5eGyz7trByR7Y3JV3tNFFnW5PutyHtPtg6xIlSvZilTIoi7X
Zx3TzdB059ZeTp9s7WVkUZfrs47pZmi68//uj/E4vj/GWQfJRYs4NtexOH9z1i9ykXmE55T+7t87
u1HOyKIuyWcd083TdOfxnSCDIxAdIcd23AyO9GRPju1sGhxRU87IvY26tJ51TDdb00VGRkZG7hqZ
6TJdZGRkZGSmS0IcGRkZmekS00VGRkZGZrpMFxkZGRmZ6ZJAREZGRma6TDdd0yUiom6K6cp0kZGR
kZFluiQQkZGRkZkuMV1kZGRkZKZLQhwZGRmZ6RLTRUZGRkZmukwXGRkZGZnpUiPhEtsf4/7+trPk
2A4ntz+RD0mO7ffy87aPZOWcemmkdc1MN0/T/b0T5DC+E+R5B8mTr5Ph+2FsL8/zL8iHIX+dTN4P
h7GdTb+c94usnFMvjeSumelmaLpF0hk0xdWj+EynyEWzNHjbrB7FZ5D3JBeN9CrwoPhMT8jKOfXS
SPGamW5upltkopW+uDxiWWn75KKtWnnnLI9YuxW5DrloudcDD2Kt+JzIyjn10kjxmrtrupuXtO1F
Bj/f/l8a/EM2y7z+yfK/5f5+ttr3++7d4NmzwaNHi+Ply8GHD+u9wb9+TY9Ont3NYr1Dwf6i6Q/k
Xch3s1msryzYe/ZjmjNZOadeGilec0qmu8MVduGPCvro5s/1T1b+gd+/j1fN78mTxQW8fTt482bx
w9OntbqCWyaPr8c175ySziLkSvL1eLwNONx1lg1ZOadeGileczKmu1tSuPw5eLI+p+S7lcnonwvY
zXR3y9qn01Gwv/fTp8VFPny4fv7bt9Ojk0dXo0AgLxWK8dNL5F3IV6PRVo+Sy9Ocyco59dJI8ZrT
MN19MsXND2ybXJabbqVZtm+6y3d41o6PHwfPny9K4/Xr9X+6vj45Onk5y7/+zXNygbwLefnOQ/3j
4iRnsnJOvTRSvOYETLd8ZDdmzHU+Wfknr31y8781izhmurE2QTDzrt9/HkxGX7xYQF69Ck96Ojo5
fNusaiPMkXcgbz4shhXgnMnKOfXSSPGau2669btnS7qXy3PKku7lmqZbuXtibCJVkNNQpvvgwQL+
+XPAF/fMdA9Clo/KwORJSkOm29Ex3fo9sTvkxCVfCZruDt3Lu1np/mO6sWP/Md39yUZejTUaEVQa
xnQ7ZLrznSb61u9eruzmrTmd6rBjugeZvbw8lqq/kEXLZHOM2yGbvayc52YvH/WaUzLdedWE4cN2
L9dPr8u7hefHfk+33Br3eU/3gGRv07ZD9p6ucp57T/eo19xp06Ud2iVLWZEK2YpUytmKVFakopZM
d27tZWRrLyvnfpSGtZepE6Y7/+9eQI/jewGddZBctFvDMxJ/9w6d3SAfhly04mPzM4vzN2f9Iivn
1EsjuWtmunma7jy+621wtLUj5Ni+mMHxGOSdybFdQoOjU9mTlXPqpZHWNTPdbE0XGRkZGblrZKbL
dJGRkZGRmS4JcWRkZGSmS0wXGRkZGZnpMl1kZGRkZKZLAhEZGRmZ6TLddE2XiIi6KaYr00VGRkZG
lumSQERGRkZmusR0kZGRkZGZLglxZGRkZKZLTBcZGRkZmekyXWRkZGRkpkuNhEtsL6D7+9vOkmN7
evy87SM5tnfK7U/kQ5LFBnKbNch08zTd37veDuO73p53kPx1Mnk/HMZ2r/xy3i/y5Otk+H4Y2yX0
/AvyYchiA7nlGmS6GZpukXQGTXH1KD7TKXLReAwG9+pRfKYn5KKRPqhCF59B3pMsNpDbr0Gmm5vp
FplopS8uj1hW2j65aFFWxvfyiLUucyIXLfdBPXSsFY8sNsRGN2Pj+Ka7+avbv5jy37jPFQbXA4st
EhY8U1I7wfP397PVvt937wbPng0ePVocL18OPnxY7w3+9Wt6dPLdbBbrwwn26vyY5kye3c1ifWXB
3rPpD+RdyGIDuf0a7KLpHuVKtjXdHbB/fg6e/FMNlV+vvLDv38er5vfkyQL79u3gzZvFD0+f1uoK
bpl8PR7XjO+SLp1syOPr8WAbdLDrDFlsiI0OxkbnTLdORrh5cvnz6smayeWfM5vmV2KNlZ8v/zNL
nPggpjudjoL9vZ8+LS7y4cP189++nR6dfDUabRXil6c5k0dXo8D3lwqhTy+RdyGLDeT2a7BbplvH
cmInYz/XQQW/EvtkzbR1W9OtXwKVlbp8h2ft+Phx8Pz54s98/Xr9n66vT45OXs7Fr39cnORMXr7z
UP9RcnKBvAtZbCC3X4MdMt3yAc6YMVd22O5mfpVpaPn17HyFBzHdYDL64sWiil+9Ck96Ojp5M4iH
/94ha/MDGZPDD5FSNPIOZLGB3H4NdsV0t+pcrdP9W/KtmmOrm9lz/es5rukG89EHDxZX+PlzwBf3
zHQPQpbpyjlkumpQpnvkMd39c9aancZbdURva4FbWWmjY7qxY/8x3f3JxnSNrhnTVYPGdI9gugd0
yvrDt1ud3LmPujXTXZtjvDyWqr+QRctks5dXZR5pO2SxgTw3eznofDVnL9fpNN7t5M6zl9fGFyq/
0sR7uuXWuM97ugcke093Vd6YbIcsNpDn/XxPlw7YXlnKilSpk60N1A5ZbCD3cUUqOrjpzq29nD7Z
KrjtkMUGcvs1yHQzNN35f/cCehzfC+isg+SidRmbN1icvznrF7loxYfnZ/7uKzu7QT4MWWwgt1yD
TDdP053Hd70NjrZ2hBzbvTI4apI9ObZLaHB0CllsiI0kYoPpZmu6yMjIyMhdIzNdpouMjIyMzHRJ
iCMjIyMzXWK6yMjIyMhMl+kiIyMjIzNdEojIyMjITJfppmu6RETUTTFdmS4yMjIyskyXBCIyMjIy
0yWmi4yMjIzMdEmIIyMjIzNdYrrIyMjIyEyX6SIjIyMjM11qJFxiewHd3992lhzb0+PnbR/Jsb1T
bn8ip0EWda6Z6fbFdH/vejuM73p73kHy18nk/XAY273yy3m/yJOvk+H7YWyX0PMvyF0nizrXzHT7
YrpF0hk0xdWj+EynyEXjMRjcq0fxmZ6Qi0b6oApdfAa5s2RR55qZbl9Mt8hEK31xecSy0vbJRYuy
Mr6XR6x1mRO5aLkP6qFjrXjk45JFnWtmujt6WP2SCS79tc/Jyl8d/MD9/Wy17/fdu8GzZ4NHjxbH
y5eDDx/We4N//ZoenXw3m8X6cIK9Oj+mOZNnd7NYX1mw92z6A7lbZFHnmpnuvr21W333z88HPFn/
gr9/H6+a35Mni8p9+3bw5s3ih6dPa3UFt0y+Ho9rxndJl0425PH1eLANOth1hnxEsqhzzUz3AJlu
/Rz0sKZbUjvB89PpKNjf++nTgvPw4fr5b99Oj06+Go22CvHL05zJo6tR4PtLhdCnl8jdIos618x0
UzXd8qw3eHL5Ds/a8fHj4PnzBe316/V/ur4+OTp5ORe//nFxkjN5+c5D/UfJyQVyt8iizjUz3fZM
N/axmqYbM9r6phtMRl+8WGBfvQpPejo6eTOIh//eIWvzAxmTww+RUjRyp8iizjUz3a6b7qrd7mm6
wXz0wYMF/PPngC/umekehCzTlTXKdGWNMl2mu7Xpbk5I3oGzp+nGRl5jx/5juvuTjekaHzWma3zU
mC7Tre4BLv/6UcZ01+YYL4+l6i9k0TLZ7OVVmQmcOlnUuWamW9d011TZAxz77ub54IfLT+42e3nt
bdpya9znPd0Dkr2nuyrvvKZOFnWumen2KDWfW5EqfbLVnVInizrXzHR7ZLpzay+nT7aOcepkUeea
mW6PTHf+372AHsf3AjrrILloXcbmDRbnb876RS5a8eH5mb/7ys5ukLtOFnWumen2yHTn8V1vg6Ot
HSHHdq8MjppkT47tEhocnULuIFnUuWam2yPTRUZGRkbuGpnpMl1kZGRkZKZLQhwZGRmZ6RLTRUZG
RkZmukwXGRkZGZnpkkBERkZGZrpMN13TJSKiborpynSRkZGRkWW6JBCRkZGRmS4xXWRkZGRkpktC
HBkZGZnpEtNFRkZGRma6TBcZGRkZmelSI+ES23nj9udtZ8mxPT1+3vaRnGINIqd+p7jmpq+Z6eZp
upOvk+H7YWyPyfMv5x0kf51M3g+Hsd0rv5z3i5xiDSKnfqe45haumelmaLpFEy8YgqtH8ZlOkYvG
YxV4UHymJ+QUaxA59TvFNbdzzUw3N9Mt2n2VUbg8Ym3A9slFi7IeeBBrXeZETrEGkVO/U1xzO9ec
uelu/l17/qU7fD14DZtlXv9k+cXM7maxnpZg38v0x/To5LvZLNaHE+zV+THNmZxiDSKnfqe45nau
uRemu/qn7f+Xbvv1oI9u/lz/ZOXFjK/HNaOwpOOlZfL1eLwNONylkw05xRpETv1Occ3tXHOvTbfE
59b+u/nJSs4mbQfTray/4MnR1SgQFEuF4uX08vTo5KvRaKsQvzzNmZxiDSKnfqe45nauuS/dy5v/
LTG/2M+xk9v6ZdOmu5wxXz8QTy5Ojk5ezsWvf1yc5ExOsQaRU79TXHM718x065pf/fy4vulWmnpl
5YWdOBiCq9oImaOTN4N4WAHOmZxiDSKnfqe45naumekewXRXnTXY9b2n6Wq/y3SR3SkyXZku062d
qsa7o41UGdM1PmpM1/ioMd2um27lDzFPLflWnYHY/cd0y+vFnMwsyebrIs/NBM70mnttusEe3fKJ
ygcx3XntV3LXhidqVqq3D1MnezMVee6d10yvOX/TPYhhH/zDTV+hdXZSJ1uDCdnqTrleM9M9gI8e
q/SsKJsx2WrDyDlFnWtmuvk3C4o2YHh23++elrObsw6Si9ZlbN5gcf7mrF/kFGsQOfU7xTW3cM1M
N9tcPLbHZHBsoyPk2O6VwVGT7Mkp1iBy6neKa276mplu/h3gyMjIyMgdITNdpouMjIyMzHRJiCMj
IyMzXWK6yMjIyMhMl+kiIyMjIzNdEojIyMjITJfppmu6RETUTTFdmS4yMjIyskyXBCIyMjIy0yWm
i4yMjIzMdEmIIyMjIzNdYrrIyMjIyEyX6SIjIyMjM11qJFzu72ffv4+n09HNzeO//x5cX598+3Y6
m/11f3/bWXJsT4+ft30kx/ZOuf2JjIzcBrmJu5vp5mm6//nP5OZmWDji5lE45T//nHeQ/HUyeT8c
xnav/HLeL/Lk62T4fhjbJfT8CzIycrPkhu5uppuh6RZJZ9AUV4/iM50iF43HYHCvHsVnekIuGumD
KnTxGWRk5IbIzd3dTDc30y0y0UpfXB6xrLR9ctGirIzv5RFrXeZELlrug3roWCseGRl5H3Jzd3di
prt5nce68pq/N7geWGyRsCCzvOY2T97fz1b7ft+9Gzx7Nnj0aHG8fDn48GG9N/jXr+nRyXezWawP
J9ir82OaM3l2N4v1lQV7z6Y/kJGRD0lu7u5O0nQ3DSyJJsKfn4Mng39a7GT53/79+3jV/J48WRDe
vh28ebP44enTWl3BLZOvx+Oa8V3SpZMNeXw9HmyDDnadISMj70xu7u5ONdMt962Sf12DrJ4pT0Y3
OZV+GauA8ksq/2PrVOp0Ogr29376tLjIhw/Xz3/7dnp08tVotFWIX57mTB5djQLfXyqEPr1ERkY+
JLm5uzsr093qZOznmhYb/HB5GVZmuofqXl6+w7N2fPw4eP588Ze+fr3+T9fXJ0cnL+fi1z8uTnIm
L995qP8oOblARkY+JLm5uzvhMd1yq9vBibdNRmt6bc3feEDTDSajL14sqvjVq/Ckp6OTN4N4+O8d
sjY/kDE5/BApRSMjIx+Q3NzdnbDplnTzlncLZ2+6wXz0wYNFmXz+HPDFPTPdg5BlunIOZGSZbmKm
u2efc3OmW+KsTZhubOQ1duw/prs/2Ziu0TVkZGO6XTfdkhHZmid3duUdOrpbM921OcbLY6n6C1m0
TDZ7eVXmkSIjH5ds9vIWHlYytXhbTy1/PanO7OW18YVy+LyZ93TLrXGf93QPSPae7qq8MYmMfFyy
93RpC9OdW5EqfbK1gZCRj0u2IhVtV6nWXk6dbBVcZOTjkq29TFtU6vy/ewE9ju8FdNZBctG6jM0b
LM7fnPWLXLTiw/Mzf/eVnd0gIyM3S27o7ma6eZruPL7rbXC0tSPk2O6VwVGT7MmxXUKDo1PIyMgH
JzdxdzPdbE0XGRkZGblrZKbLdJGRkZGRmS4JcWRkZGSmS0wXGRkZGZnpMl1kZGRkZKZLAhEZGRmZ
6TLddE2XiIi6KaYr00VGRkZGlumSQERGRkZmusR0kZGRkZGZLglxZGRkZKZLTBcZGRkZmekyXWRk
ZGRkpkuNhEtsL6D7+9vOkmN7evy8RT4kObYry+1P5EOSxYZrZrp9Md3fu94O47venneQ/HUyeT8c
xnav/HKOfBjy5Otk+H4Y23/0/AvyYchiwzUz3b6YbpF0Bk1x9Sg+0yly0XgMBvfqUXwGeU9y0fwf
VKGLzyDvSRYbrpnp9sV0i0y00heXRywrbZ9ctCgr43t5xFqXyHXIRU4wqIeO5QfIYqM7pZHiNffF
dGuuzlWzl3+rb22eD15G/ZPlv/H+frba9/vu3eDZs8GjR4vj5cvBhw/rvcG/fk2PTr6bzWJ9OMFe
nR9T5F3Is7tZrBcu2C83/YG8C1lsuGamO980s4ObbknhxuB/fq5/svI6v38fr5rfkyeLC3j7dvDm
zeKHp09rdQW3TL4ej2vGd0mXDnIleXw9HmyDDnbKIYuNjpRGitfMdMPZ5PLnOnnnn0/GMtrKX72P
vwZPTqejYH/vp0+LK3/4cP38t2+nRydfjUZbhfjlKfIu5NHVKPD9pULo00vkXchiwzUz3ajzxSxw
8wP1P7mV3x/cdJfv8KwdHz8Onj9fXOrr1+v/dH19cnTyci5+/ePiBHkX8vJtivoPqZML5F3IYsM1
M91aY7o7WGDlJ8v9PmjtwfS6fjd4MBl98WIBefUqPOnp6OTNIB7+u742P4C8Azn8eCpFI+9AFhuu
menW+PsjOWuwI3of01310U14Q5nugwcL+OfPAV/cM9M9CFk+KtOV6coaZbq9MN09pzXtZrqH6kne
auQ1duw/prs/2cirMV1jusZHjen2y3Qr89f6nzzUmO5BZi8vj6XqL2TRMtkc43bI5hi3QxYbrpnp
Vv/9ddyu/ifrdC+3855uuTXu857uAcnepm2H7G3adshiwzUz3X61JKxIhWzdqOOSxYZrZrr9St+t
vYwc+ycrJLdDFhuumen2yHTn/90L6HF8L6CzDpKL1mVs3mBx/uYM+TDkIj8Iz/z83Qt3doN8GLLY
cM1Mt0emO4/vehscbe0IObZ7ZXDUBHlncmz/0eC4F7LY6HhppHXNTDdb00VGRkZG7hqZ6TJdZGRk
ZGSmS0IcGRkZmekS00VGRkZGZrpMFxkZGRmZ6ZJAREZGRma6TDdd0yUiom6K6cp0kZGRkZFluiQQ
kZGRkZkuMV1kZGRkZKZLQhwZGRmZ6RLTRUZGRkZmukwXGRkZGZnpUiPhEtt54/bnbWfJsT09ft72
kZxiDSKnfqco56bJTDdP0518nQzfD2N7TJ5/Oe8g+etk8n44jO1e+eW8X+QUaxA59TtFObdAZroZ
mm7REAsGyupRfKZT5KKRXgUeFJ/pCTnFGkRO/U5Rzu2QmW5uplu0zipjZXnEWmrtk4uWez3wINaK
z4mcYg0ip36nKOd2yGmbbs01t+r41rZf3/xijLB5PnjB9U+WV+rsbhbrDwn2kEx/TI9OvpvNYn1l
wd6zH9OcySnWIHLqd4pyboecg+nW753foUN/f7cO+mg5pPxk5cWPr8c1Y6Wke6Rl8vV4vA043HWW
DTnFGkRO/U5Rzu2QczbdzRxx+fPqydXPbH63POOsk+lukg/rr8GTo6tRICyWCoXL6eXp0clXo9FW
j5LL05zJKdYgcup3inJuh5yt6caMrcQp6/xQ/2P1WwYHN93lvPb64XJycXJ08vKdh/rHxUnO5BRr
EDn1O0U5t0POdkx3hy7cyoT14KYbawSUX0C1EwcDZVUbEXN08mYYDyvAOZNTrEHk1O8U5dwOObdM
tznT3bT2/SdSxfq09zRd7XeZLrI7RdTJdNM23ZJfsYPpbtVpvO3XjVQZ00V2p4g6Y7rpmW4XxnQr
p0ZvnjQnM3Wy2Z7Ioi5XcramOy+dbxwcQ21i9nJlf3Xlryh/C9nbh1mSvdeILOpyJSdvuj2XdXZy
JVvBB1nU5Upmuhma7tyKsumTrVWLLOpyJTPdDE132VILz8H73R9ydnPWQXLRio/NzyzO35z1i5xi
DSKnfqco5xbITDdP053Hd4IMjkB0hBzbJTQ4OpU9OcUaRE79TlHOTZOZbrami4yMjIzcNTLTZbrI
yMjIyEyXhDgyMjIy0yWmi4yMjIzMdJkuMjIyMjLTJYGIjIyMzHSZbrqmS0RE3RTTlekiIyMjI8t0
SSAiIyMjM11iusjIyMjITJeEODIyMjLTJaaLjIyMjMx0mS4yMjIyMtOlRsIltj/G7c/bzpJje6f8
vO0jOcUaRE79TlHOTZOZbp6mO/k6Gb4fxnaCPP9y3kHy18nk/9s7f53mmW0PW0JCFCnewlfANaRC
ERVU3BO7dBGJlLkLxCUcwaEEKjrE2QFBihRm744/Uc4Yb73yjteMx3/jGT9Lo0/5HOd5zcyyf7PW
jGduw1C3S+jrbFhkF1sQsut3CvXcARnR9VB0VUdMdJRsUef0iqw66UXgQJ0zELKLLQjZ9TuFeu6G
jOj6Jrqqd1boK2nR9dS6J6ueux040PXifSK72IKQXb9TqOduyG6LruWaWza6Vfbn+R/qCPnj4gXb
HzQ3avwd6/IhYoZk+bncOfk7jnW5MjF79rn0mexiC0J2/U6hnrsh+yC69tn5Cgn9+mot6qgZYj5Y
ePHRIrL0FUN6pGPyIorKgOXUmTdkF1sQsut3CvXcDdln0c3HiOnn7MHsOfnfmiNOm0g3T+5AdCcP
E8EtUpPcZXw33jn5YTIp9Si5G/tMdrEFIbt+p1DP3ZC9FV2dhhmU0uaD/Wn2PYPGRTed127vLqOb
0c7J6TsP9uVm5DPZxRaE7PqdQj13Q/Z2TLeCsBUGrI2Lrq4TYI7XCxtVdpSs5Txm5+S8G4cFYJ/J
LrYgZNfvFOq5G7JvkW57opuX9voTqXQ5bSJdIl0iA8h4HZHuoEXX8E9UEN2yZMZ0GdNldA0yXseY
ruei6+iYLnMyXScz2xMyXucr2VvR3RjnG4tjqG3MXi7MV1c7aP7zefvQdTLvNULG63wlOy+6AzfW
2fGVzAo+kPE6X8mIroeiu2FFWffJrFULGa/zlYzoeii6aU9NnoP3mw+Zvkx7SFa9eN38THX8ZTos
sostCNn1O4V67oCM6Popuhv9TpDiCERPyLpdQsXRKe/JLrYgZNfvFOq5bTKi663oQoYMGTLkvpER
XUQXMmTIkCEjuhguDhkyZMiILoboQoYMGTJkRBfRhQwZMmTIiC6GI0KGDBkyoovouiu6GIZhWD8N
0SXShQwZMmTIRLoYjggZMmTIiC6G6EKGDBkyZEQXw8UhQ4YMGdHFEF3IkCFDhozoIrqQIUOGDBnR
xVpxF93+GKuvVW/Jur1TvlZDJLvYgpBdv1Oo57bJiK6fojt/m4e3oW4nyNnrrIfkt/n8Ngx1u4S+
zoZFdrEFIbt+p1DPHZARXQ9FV3XEREfJFnVOr8iqk14EDtQ5AyG72IKQXb9TqOduyIiub6KremeF
vpIWXU+te7LquduBA10v3ieyiy0I2fU7hXruhuy26FquuWWjW2V/nv+hSBCvreZBc6PG37EuHyJm
SJafy52Tv+NYlysTs2efS5/JLrYgZNfvFOq5G7IPomufna+Q0K+p1tmvxPMrHCy8+GgRWfqKIT3S
MXkRRWXAcurMG7KLLQjZ9TuFeu6G7LPo5mPE9HP2YPac/G/NEadlpNuU6Nr3GCYPE8EtUpPcZXw3
3jn5YTIp9Si5G/tMdrEFIbt+p1DP3ZC9FV2dhhmU0uaD/WkNim7Z9HI6r93eXUY3o52T03ce7MvN
yGeyiy0I2fU7hXruhuztmG6FaNKgnfVFt/K1FQ4YCwdFR8lazmN2Ts67cVgA9pnsYgtCdv1OoZ67
IfsW6bYnunlp70Z0K4zp0n8n0oXMnYLXEem6Lbo26WLLJHDbostIFWO6kLlT8DrGdN0T3UbGdMsm
qzfMXmb2MrM9IeN1npK9Fd2Ncb6xOG7axuxlw5Az7+lmjfd0XW9ByK7fKdRzN2TnRXfgxjo7vpJZ
wQcyXucrGdH1UHQ3rCjrPpm1aiHjdb6SEV0PRTftqclz8H7zIdOXaQ/Jqhevm5+pjr9Mh0V2sQUh
u36nUM8dkBFdP0V3o98JUhyB6AlZt0uoODrlPdnFFoTs+p1CPbdNRnS9FV3IkCFDhtw3MqKL6EKG
DBkyZEQXw8UhQ4YMGdHFEF3IkCFDhozoIrqQIUOGDBnRxXBEyJAhQ0Z0EV13RRfDMAzrpyG6RLqQ
IUOGDJlIF8MRIUOGDBnRxRBdyJAhQ4aM6GK4OGTIkCEjuhiiCxkyZMiQEV1EFzJkyJAhI7pYK+6i
2x9j9bXqLVm3d8rXaohkF1sQMl4HGdEdoujO3+bhbajbCXL2Oush+W0+vw1D3S6hr7NhkV1sQch4
HWREd4iiqzpioqNkizqnV2TVSS8CB+qcgZBdbEHIeB1kRHeIoqt6Z4W+khZdT617suq524EDXS/e
J7KLLQgZr4OM6Or/2qCjv1r8hywPFl6qeDD+jnX5EDFDsvxc7pz8Hce6XJmYPftc+kx2sQUh43WQ
EV2r6LDVP3xLQcseLLxO8WC0iCx9xZAe6Zi8iKIyYDl15g3ZxRaEjNdBRnTLiW76Ifu/umA0r5E2
FVhHdHVw8fjkYSK4RWqSu4zvxjsnP0wmpR4ld2OfyS62IGS8DjKiW1p0LXWx8MxmRdfccvmD6bx2
e3cZ3Yx2Tk7febAvNyOfyS62IGS8DjKiW25MtzCarJYBNv+2DdGVHSVrOY/ZOTnvxmEB2Geyiy0I
Ga+DjOiWECpR6raE2SCcNrsndia6RAbEHJDxZ7yOSNcl0W1wApRZRG0UvezfwhgYo2uQ8We8jjFd
J0VXjHQLD5r/ubZFl9merpOZ7Yk/43W+khHdgvSymEm2OVg4fmz/8m7Zv4X3Gl0n814j/ozX+Uoe
oui2qtw9uQxW8HGdzAo++DNe5ysZ0S2hcJ2tY1Vf+1mr1nUya9Xiz3idr2RE18+AW/XU5Dl4v/mQ
6cu0h2TVi9fNz1THX6bDIrvYgpDxOsiI7nCz3LqdIMURiJ6QdbuEiqNT3pNdbEHIeB1kRHegogsZ
MmTIkPtGRnQRXciQIUOGjOhiuDhkyJAhI7oYogsZMmTIkBFdRBcyZMiQISO6GI4IGTJkyIguouuu
6GIYhmH9NESXSBcyZMiQIRPpYjgiZMiQISO6GKILGTJkyJARXQwXhwwZMmREF0N0IUOGDBkyoovo
QoYMGTJkRBdrxV10+2OsvlY1yet1/PERLZeTl5c///xnsFiM3t/HcfyP9bouWbd3ytdqiOT2WhCy
62QXvc7Fa27jWYfo+im687d5eBvqdoKcvc4qk//97/nLS6j8L1+UX/7rX9XJb/P5bRjqdgl9nQ2L
3F4LQnad7KLXuXjNLT3rEF0PRVd18UQXzBZ1TgWy6uKJLpgt6pwKZNXhLbrkQJ0zEHJ7LQjZdbKL
XufiNbf3rEN0fRNd1e8r9MK06PqAOrLq9xV6YVp0fUAdWfWC7S450PWIfSK314KQXSe76HUuXnN7
zzp/RNd+CS6bGmlQAvPHxSs0XLY9OR3b0GVaxNzL8nNpSV6v42ym5fo6OD4ODg6ScnYW3N9v515+
fmzJ33GsyzuJmajPpc/k9loQsutkF73OxWtu71nnm+g2op3Niq4orvnP4kEdwfwvRovI0gsNiReR
/PERZV3t8DC5sKur4PIy+XB0ZJV4EcmLKCpzyXIayhtyey0I2XWyi17n4jW396wbkOjm48j8t1tf
2QSj2TN1+tqx6E4eJoLDpSY54vhubEleLididuXpKWHv728ff3+3JT9MJqVuy7uxz+T2WhCy62QX
vc7Fa27vWTcU0TXrnPjB8G3hmeYLKyW6omybGzWdMW/viKObkSU5nTG/VR4fg5OThH1xsf3VYmFL
Tt8fsC83I5/J7bUgZNfJLnqdi9fc3rNuKGO6lqJbQRcNEWqh6Oqkvaboyi6YtZwvWpLFrt/paYI8
P5enGFiS8zdIWHDJPpPba0HIrpNd9DoXr7m9Z523ka4uLVwYwhYGtTrIpvxEKl2K2+YK+9P729tL
wM/PghcS6RLpQiZq9CbSbeRZ53N6uVAO60S69v/Kpvw0abPM93CcQ1cY02VMFzLjoz6N6dZ/1g1R
dC3HdDtIL9tz+jl7OS2p2b82zuzlHbYgZNfJzF52/Vnns+huas9ergkpTC+7/p6u2RF5T5f3dCHz
zuvGi/d0G3zWeSW6AzRWpPKVzBpMkFmRytdnHaLroehuWHvZfTKrDUP2yetYexnR9Vx00z6gPLvv
N9MyfZlWJv/uvPFHv/NGdbLqEevmOqrjL9NhkdtrQciuk130OhevuaVnHaLrp+hu9HtMimMbpci6
PSbFsY1SZN2Om+JIj/fk9loQsutkF73OxWtu41mH6HorupAhQ4YMuW9kRBfRhQwZMmTIiC6Gi0OG
DBkyooshupAhQ4YMGdFFdCFDhgwZMqKL4YiQIUOGjOgiuu6KLoZhGNZPQ3SJdCFDhgwZMpEuhiNC
hgwZMqKLIbqQIUOGDBnRxXBxyJAhQ0Z0MUQXMmTIkCEjuoguZMiQIUNGdLFW3EW3P8Z6veotWbcP
yddqiGTd3imrL+oZsntehz8juj6L7u9OkKF+J8hZD8lv8/ltGOp23HydDYs8f5uHt6Ful9DZK/UM
2SWvw58RXZ9FVwWdoihmizqnV2TVeRSdO1vUOQMhq+5/UIRW51DPkJ3wOvwZ0fVZdFUkWqiLadFF
pd2TVY+y0L/Toutd+kRWMUFgh9bFB9Qz5P54Hf6M6Ep/v0Ul/D3BvrpEcs2D5kZdr+Ns7vf6Ojg+
Dg4OknJ2Ftzfb2eDf36WOyd/x7EuhyNmdT6XPpPj71iXhRPzcstP6hlyf70Of0Z0TfViWQ8VThMF
u8LBwsv4+Iiy4nd4mDTu1VVweZl8ODqySgV3TF5EkaV/G1I63pCjRRSUQYtJOeoZck+8Dn9GdG1F
Nx9lpp+3jteJktsQ3eVyIuZ7n56Si9zf3z7+/j7eOflhMinl4ndjn8mTh4nw+9Qk9PiOeobcX6/D
nxFdq3oxq6C9LnYvuuk7PFvl8TE4OUla+eJi+6vFYrRzcjoX377cjHwmp29T2D+kRjfUM+T+eh3+
jOiWHtOtL7q60yxFV3dt4kExGD09TQjn5/Kkp52T804c/vcOWfkTPCbLjycjmnqG3Fuvw58R3RKj
sPlMcpeim5XbmpHu3l7CeX4WdLFmpNsImZiDyAAykS6R7qDHdBtML5uHjetkkkuNvOpK/THd+mRG
1xgDg8yYLmO6iO52areC6OYPdjx7OS2p2S9k0TGZeaRZY7Yn5A2zlz2tZ0TXNKabT+3qlNgw5irC
u3xP1yyNdd7TbZDMG5NZ471GyBve0/W0nhFdr8L0v8aKVGDvuUwAABW9SURBVK6TWcEHMitS+VrP
iK6Horth7WX3yaxVC9knr8OfEV3PRXfzn72A/uj3Apr2kKx6l7p5g+r4y3RYZBUfyDM/f7Nw0xfq
GbJLXoc/I7qei+5Gv+utONraE7Ju90px1MR7sm7/UXHci3qG3HOvw58RXc9FFzJkyJAh942M6CK6
kCFDhgwZ0cVwcciQIUNGdDFEFzJkyJAhI7qILmTIkCFDRnQxHBEyZMiQEV1E113RxTAMw/ppiC6R
LmTIkCFDJtLFcETIkCFDRnQxRBcyZMiQISO6GC4OGTJkyIguhuhChgwZMmREF9GFDBkyZMiILtaK
u+j29Fh9rWqSdbsMrdd1ybo9Pb5WQyS314KQ8Q2f6tmt2kB0/RTd+ds8vA11u1fOXmeVyb/76Yb6
/XSrk9/m89sw1O1e+TobFrm9FoSMb/hUz87VBqLroeiqjpjoKNmizqlAVuGsKLfZos6pQFYd3qJL
DtQ5AyG314KQ8Q2f6tnF2kB0fRNd1Tsr9JW06HpqOrKKcQsVNy26eFdHVr1gu0sOdD1in8jttSBk
fMOnenaxNmqJrs16VzaaIf7c8K3Nkf7oYr5+ah40/9Xxd6zLh4gZkuXn0pK8XsfZrPL1dXB8HBwc
JOXsLLi/384z//zYkr/jWJd3EjNRn0ufye21IGR8w6d6drE2aoluXh6aFV2zxNb/1zuORMU/tsLB
wr86WkSWvmJIj4jkj48oK6uHh0krXF0Fl5fJh6MjqySzSF5EUZlLltNQ3pDba0HI+IZP9exibbQl
uvn4LP2cPZg9J/+tTaSr06Stf13H1IWVlf+WCj2MNkR38jAR3CI1yV3Gd2NL8nI5ETPJT08Je39/
+/j7uy35YTIpdVvejX0mt9eCkPENn+rZxdpoUnQLw7u8lth/ay+6ojqW+qGlYJtP3qHopvPa7d1l
dDOyJKdvB22Vx8fg5CRhX1xsf7VY2JLT9wfsy83IZ3J7LQgZ3/Cpnl2sjVbGdCuIiv239ufkv7Uf
Oa52prmKK9RPtTFd2VGylvMYS7IY5p6eJsjzc3k6lSU578ZhwSX7TG6vBSHjGz7Vs4u1UVd0dZqU
F+OWRFcXvIr/us05BtnrXnSdiHT39hLw87OguES6RLpEuvgGtdH6mG6hPLQqugZUUwnesqJrHvz2
YExXVxjTZUyXMV18g9roVHQ7iHQNQ8I28aX9AHM10bXpMWzcnL2cltTsl8hg9vIOWxAyvrFh9vJO
ya2M6W70M351SlZTdMWEsFm0DBOVCw/ai66Yad/48p6uWXR5T5f3dHlPF9+gNloc0+25lfoDXakN
VqTylcy6Ud2Q8Q3X63lwK1L5pLg1V9fq29/F2suuk1khuRsyvuF6PbP2MtaXzoTqqclz8H7zIdOX
aWXy7y5Df/S7DFUnqx6xbq6jOv4yHRa5vRaEjG/4VM/O1Qai620Er9sJUhyBKEXW7acrjuOWIut2
3BRHerwnt9eCkPENn+rZrdpAdH1Om0OGDBky5F6REV1EFzJkyJAhI7oYLg4ZMmTIiC6G6EKGDBky
ZEQX0YUMGTJkyIguhiNChgwZMqKL6LoruhiGYVg/DdEl0oUMGTJkyES6GI4IGTJkyIguhuhChgwZ
MmREF8PFIUOGDBnRxRBdyJAhQ4aM6CK6kCFDhgwZ0cVacRfdXkDr9aq3ZN0+JF8ryJAhd0HW7auz
+qKemyEjun6K7u+ut6F+19tZD8lv8/ltGOp23HydQYYMuV3y/G0e3oa6HWRnr9RzA2RE10PRVUGn
KIrZos7pFVl1HkXnzhZ1DmTIkFsiq3A2KEKrc6jnmmRE1zfRVZFooS6mRReVdk9WPcpC/06LrncJ
GTLkOmQV4wZ2aF28Sz37KbriIlvi9f892MZfl2fqriFfvfYHzdcvHl+v42zu9/o6OD4ODg6ScnYW
3N9vZ4N/fpY7J3/HsS6HI2Z1PpeQIUNukhx/x7qssphnXn5Sz1XI7oluXqhsZLUb0TWfI16q+WC2
eeyv4eMjyorf4WHy86ur4PIy+XB0ZJUK7pi8iCJL/zakdCBDhlyZHC2ioAxaTDJTz4MTXV34K35b
MwzNf7YU/rZFd7mciPnep6eEs7+/ffz9fbxz8sNkUsrF78aQIUNukjx5mAi/T01Cj++o5ypk50VX
VCbxg+HbmgfLRtulRNcs5+Lx9B2erfL4GJycJJVwcbH91WIx2jk5nYtvX25GkCFDbpKcvh1kL7qj
G+q5CtnPMV1Lfa02+puPni2ruELOuZroisHo6WlSXefn8qSnnZPzThz+9w5Z+RMgQ4bcIFmWWyOa
eq5AdlJ0K4SPBkkT9duQXt6KnlsV3cKugH08ureXXOrzs6CLNSPdRsj0hSFDJtIl0nVvTLeU6FYL
fyukl3XXbPNPmPdDLjXyqiv1x3Trkxn1gQyZMV3GdL0S3bIjvtU4NvVeoQdQZ/ZyWlKzX8iiYzLz
GyFD3i2Z2cvdkIc1pqtLGutyzuYzbUZedaFql+/pmqWxznu6DZJ5kw8y5N2SeU+3G7LzY7oDN1ak
ggwZMitSsSIVtmPR3bD2MmTIkMuTWXu5GzKi66Hobv6zF9Af/V5A0x6SVe9SN29QHX+ZQoYMuV2y
inflmcy/WeXpC/XcABnR9VN0N/pdb8XR1p6QdbtXiqMmkCFDbpys209XHMelnhFdRBcyZMiQIfeX
jOgiupAhQ4YMGdHFcHHIkCFDRnQxRBcyZMiQISO6iC5kyJAhQ0Z0MRwRMmTIkBFdRNdd0cUwDMP6
aYgukS5kyJAhQybSxXBEyJAhQ0Z0MUQXMmTIkCEjuhguDhkyZMiILoboQoYMGTJkRBfRhQwZMmTI
iC7WirvodgtZfa0gQ4YMGXLlHdXW6+pkRNdP0Z2/zcPbULcv5ux1BhkyZMiQDd/+7h0e6vcOr0hG
dD0UXdXFE10wW9Q5kCFDhgxZjp7jf4hymy3qHEQX0U36fYVemBZdHxAyZMiQh0xWMW6h4qZFF+/6
I7riIlt/P1f+Q7ocThevX/d3GVpHPB5/x7pMi5h7WX4uIUOGDBnyX1uv42xW+fo6OD4ODg6ScnYW
3N9v55l/fpbeiu7WdYp61ivRzdet2FcQT7A/M2vRIrL0QkPiBTJkyJAHS/74iLKyeniYPMavroLL
y+TD0ZFVktlz0d36oAuCxfh467/5f8Lwq+xPdD2AUqJbKLSFjTp5mAgOl5rkiOO7MWTIkCFD/mvL
5UTMJD89Jez9/e3j7+/joYiuTn0NGinqZf6zQQJ1Z1omgQ2yKv5v2fRyOmPe3hFHNyPIkCFDhvzX
0reDtsrjY3BykrAvLra/WixG3oqu/ZhuPh61z9/W/JV9dF4ouuaxavmg6IJZy/kiZMiQIUP+a2KY
e3qaIM/P5elUPouuTXpZlwTeUmsb0a3wq8Kq12WkK4/+0mOFDBky5FYj3b29BPz8LCiuz5Gu5Ziu
OdItVLWavypV9XXGdxmbgQwZMuTOxnR1ZUBjupajsJaJYvsxXZtccdn4tSnRZRYiZMiQITc4ezkt
qdkvkTHE93Qt5yFvRcalfrUxzl42p5cLX3/a8J4uZMiQIe/6PV2z6Hr+nq5DUfgO/0VWloEMGTJk
VqTyU2jNweiuZJ41VCFDhgyZtZex7mJr1QeUZ/f9ZlqmL1PIkCFDhmz49neXoT/6XYYqkhFdbxPa
uj0mxbENyJAhQ4a8Zbr9dMVxXER36KILGTJkyJD7RkZ0EV3IkCFDhozoYrg4ZMiQISO6GKILGTJk
yJARXUQXMmTIkCEjuhiOCBkyZMiILqLrruhiGIZh/TREl0gXMmTIkCET6WI4ImTIkCEjuhiiCxky
ZMiQEV0MF4cMGTJkRBdDdCFDhgwZMqKL6EKGDBkyZEQXa8VddPtjrNermmTdnh6rr1Vvr9lF8ncc
L6LoYTL53z9//icIbkaju/H4//7xj68VZMiQXSUjun6K7u9OkKF+J8hZZfL8bR7ehrrdK2evsx5e
s4vkt/n8NgzFbbnV/f86gwwZspNkRNdD0VVhligD2aLOqUBW4awot9mizunVNbtIVl3pomoO1DmQ
IUN2jozo+ia6KvYqVIK06OIwHVnFuIWKmxZdvNv9NbtIVv1ru2oOdH1tyJAh95PskuiKy2v1/8rz
VyguEmZYOUz3N4rH1+s4m+28vg6Oj4ODg6ScnQX399v5z5+fpSU5/o51WWUxz7z8XO78ml0kf8ex
LqMl5rg+l5AhQ3aD7JLo5iXKCdEVxdX8V4hibC+6Hx9R9nF/eJj8/OoquLxMPhwdWSU/RXK0iCwV
15Bk7viaXSQvoqhMNcsJLsiQIfeQ7LzobkWHhggyL2xixJynmYPR/K/Ei+xSdJfLiZjhfHpKOPv7
28ff38eW5MnDRHC31CRPHN+Nd37NLpIfJpNSN/zdGDJkyG6QHRZdS90SFVR3pvlkm1+VitFtRFeU
bXOdpG+tbJXHx+DkJLnUi4vtrxaLkSU5fTvIXnRHN6OdX7OL5PTNBPtyM4IMGbIbZK/GdNs4qKs4
mwjVJjFu7hxUE10x/Do9TbDn5/I0H0uyLLdZyznjzq/ZRXL+lg4LqhkyZMhukB0TXbPsiRsZGsJT
mzN1Sek6omvOeOv+tJqR7t5eAn9+FpSgt5FuI9fsIpnIADJkIt2ejukWKlNhUGsjtNXGYi2r3tyf
MO+HXGqsUVf6PKZb/5pdJDMGBhkyY7qOiW61MV1L0a0Z6VYQ7zqzl9OSmv3SDbudvdzgNbtIZrYn
ZMi+kj0Z021w9rJNerl+pNvle7pmMejne7oNXrOLZN5rhAzZV7LDY7r1Y2WP/yJWpHKdzAo+kCH7
SvZcdM1joh53I1h72XUya9VChuwrmbWX/Yzdf3e/+aPf/WZamaziXXkm829Wefoy7eE1u0hWfW3d
LEp1/GUKGTJkJ8mIrrcJc90+r+L4Yimybj9dcRy3J9fsIlm3l6c4hgQZMmQnyIiut6ILGTJkyJD7
RkZ0EV3IkCFDhozoYrg4ZMiQISO6GKILGTJkyJARXUQXMmTIkCEjuhiOCBkyZMiILqLrruhiGIZh
/TREl0gXMmTIkCET6WI4ImTIkCEjuhiiCxkyZMiQEV0MF4cMGTJkRBdDdCFDhgwZMqKL6EKGDBky
ZEQXa8VddLvfrNer3pJ1e3p8rSA3SdbtE7X6GiIZ38Cfu3zWIbp+iu7vPq+hfp/XWQ/Jb/P5bRjq
dq98nUFuhjx/m4e3oW5H5NnrsMj4Bv7c8bMO0fVQdFVHTHSUbFHn9IqsOrziDZkt6hzINcmq+x8U
odU5AyHjG/hz9886RNc30VW9s0JfSYuup9Y9WfWCC+/JtOh6xJBtyComCOzQuvjAJzK+gT93/6wb
uujq1u76WyH5D/WlUVwkTLdymLnlxBGIbD7k+jo4Pg4ODpJydhbc329nSH5+ljsnf8exLu8kZqI+
l5CrkOPvWJeFE/Nyy0+fyfgG/tz9sw7RLa6gmqIriqsZvvW5rOh+fERZhzg8TAhXV8HlZfLh6Mgq
PdIxeRFFlvekIQ0FuZAcLaKgDFpMynlDxjfw5+6fdYiutoLMkW4+Kt2KjwsP2oiu+PPCRl0uJ2IO
5OkpueD9/e3j7+/jnZMfJpNSt+XdGHIV8uRhIvw+NQk9vvOZjG/gz90/6xDdKqKrE8jCWLlCpFtB
dNN57Vvl8TE4OUmu8OJi+6vFYrRzcvr+gH25GUGuQk7fprB/SI1ufCbjG/hz9886RLdJ0a1ANkfP
1URX7KCdnibk83N5IsDOyfkbJPzvUfb8CZArkOXHkxHtMRnfwJ+7f9YhuhVFN79jYilpNEzXainS
3dtL/sXnZ8FXaka6jZDpvxPpEulC7nmk28izDtGtG+lWlsb20su60QhdqT+mW5/MSBVjuozpQu7/
mG79Zx2iu8v0ckuiuzXvLi2p2b/c3TGZOZndkJm9jG/gz7t91iG6VUR3o5+9XCq93M17umZ3qfOe
boNk3j7shsx7uvgG/rzbZx2i61VH4a+xIhVkVqTCN/BnVqTCOhLdDWsvQ2btZXwDf2btZawz0d38
Z3+MP/r9MaY9JKsesW6uozr+MoXcDFnFB/LMz98s3PRlWGR8A3/u+FmH6Popuhv9TpDiCERPyLod
N8WRHsiVybr9R8VxL+/J+Ab+3OWzDtH1VnQhQ4YMGXLfyIguogsZMmTIkBFdDBeHDBkyZEQXQ3Qh
Q4YMGTKii+hChgwZMmREF8MRIUOGDBnRRXTdFV0MwzCsn4boEulChgwZMmQiXQxHhAwZMmREF0N0
IUOGDBkyoovh4pAhQ4aM6GKILmTIkCFDRnQRXciQIUOGjOhirbiLbn+M9XrVW7Jut5DVF+Qmybr9
Xr5WkCG3RcafEV2fRfd3J8hQvxPkrIfk+ds8vA11+2LOXiE3Q36bz2/DULez6esMMuTmyfgzouuz
6KqgUxTFbFHn9IqsOrziDZkt6hzINcmqk14EDtQ5kCE3SMafEV2fRVdFooW6mBZdVNo9WfWCC+/J
tOh6xJBtyKrnbgcOdL14yJDLkvFnRLcBebOsMXE9MN0iYeIRQ+uIx9frOJv7vb4Ojo+Dg4OknJ0F
9/fb2eCfn+XOyfF3rMs7iZmo5SfkKuTvONblysTs2ecSMuS6ZPwZ0W1Ad+0VN/9ZxxG12fwvigc/
PqKs+B0eJtirq+DyMvlwdGSVCu6YHC0iy3vSkIaCXEheRFEZsJw6gwy5FBl/RnTriq5BNSv/PP3Q
iOgulxMx3/v0lLTy/v728ff38c7Jk4eJ4MipST4+voNchfwwmZR6lNyNIUOuS8afEd26utuG6Bb+
r73opu/wbJXHx+DkJGnli4vtrxaL0c7J6fsD9rfl6AZyFXL6zoN9uRlBhlyXjD8juk0O7lqKrqVO
NyK6YjB6epo08fm5POlp52T5hsxazs0hVyDnHxZhARgy5Lpk/BnR3UGk26XoivHo3l7SxM/Pgi7W
jHQbIROPEhlAJtIl0sWaGdO1l9JWx3R1pf6Ybn0yI6+MgUFmTJcxXaw4Ws1+sNTFtkV3a45xWlKz
X8iiYzJzjLshM6sW8obZyzslI7oVh3JFuTW8ZbtVw12+p2uWxjrv6TZI5m3absi8Pwp5w3u6OyUj
ur51BVJjRSrIrJQEmRWpWJEK60h0N6y9DJk1gSH3iYw/I7qei+7mP3sB/dHvBTTtIVn1iOW5jr95
p+kL5GbIqhevm5+pjr9MIUNunow/I7qei+5Gv+utONraE7Jux01xpAdyZbJul1BxdAoy5EbI+DOi
67noQoYMGTLkvpERXUQXMmTIkCEjuhguDhkyZMiILoboQoYMGTJkRBfRhQwZMmTIiC6GI0KGDBky
oovouiu6GIZhWD8N0cUwDMOwfsRLVASGYRiGIboYhmEYhuhiGIZhGIboYhiGYRiii2EYhmGILoZh
GIZhiC6GYRiGeSW6GIZhGIZ1YP8PXhXEXTry5EkAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Supplement Figure 6 publication bias.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-04-15 20:35:31 +1000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Publication bias of comparison: 1 Immunosuppressive treatments versus placebo/no treatment/non-immunosuppressive treatments, outcome: 1.1 all-cause mortality or risk of ESKD (Harbord test) (A); 1.6 complete or partial remission (Harbord test) (B); 1.1 all-cause mortality or risk of ESKD (funnel plot) (C); and 1.6 complete or partial remission (funnel plots) (D).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA+gAAAL/CAIAAAB6ZXokAACAAElEQVR42uydBXQc1923N8nb9oV8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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2011-12-22 08:30:21 +1100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2014-10-09 11:06:11 +1100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-10-09 11:06:11 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-04-10 17:41:56 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-10 17:44:34 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Databases</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>MeSH descriptor Glomerulonephritis, Membranous, this term only in MeSH products</LI>
<LI>(membranous NEAR/2 glomerulo*):ti,ab,kw</LI>
<LI>(membranous NEAR/2 nephropathy):ti,ab,kw</LI>
<LI>(extramembranous next glomerulo*):ti,ab,kw</LI>
<LI>mgn:ti,ab,kw 14</LI>
<LI>imn:ti,ab,kw 56</LI>
<LI>(#1 OR #2 OR #3 OR #4 OR #5 OR #6</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>Glomerulonephritis, Membranous/</LI>
<LI>(membranous adj2 glomerulo$).tw.</LI>
<LI>(membranous adj2 nephropathy).tw.</LI>
<LI>extramembranous glomerulopathy.tw.</LI>
<LI>mgn.tw.</LI>
<LI>imn.tw.</LI>
<LI>or/1-6</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>Membranous Glomerulonephritis/</LI>
<LI>(membranous adj2 glomerulo$).tw.</LI>
<LI>(membranous adj2 nephropathy).tw.</LI>
<LI>extramembranous glomerulopathy.tw.</LI>
<LI>mgn.tw.</LI>
<LI>imn.tw.</LI>
<LI>or/1-6</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
<P>NOTE: Search strategies used in the original review can be found in <LINK REF="REF-Schieppati-2004" TYPE="REFERENCE">Schieppati 2004</LINK>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-02-13 14:07:18 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2012-11-19 11:53:42 +1100" MODIFIED_BY="Narelle S Willis">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-19 11:54:33 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2011-12-22 08:30:21 +1100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="AFF_399ECB6682E26AA2017F61BBC29478EB_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="399ECB6682E26AA2017F61BBC29478EB">
<ADDRESS>
<DEPARTMENT>Department of Renal Medicine, Laboratory of Biostatistics, Clinical Research Center for Rare Diseases "Aldo e Cele Daccò"</DEPARTMENT>
<ORGANISATION>Mario Negri Institute for Pharmacological Research</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ranica (Bergamo)</CITY>
<ZIP>24020</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_5863_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="5863">
<ADDRESS>
<DEPARTMENT>Renal Services</DEPARTMENT>
<ORGANISATION>Mueritz-Klinik</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Klink</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16160_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16160">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>CIBER Epidemiologia y Salud Publica (CIBERESP)</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Madrid</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Efficacy&lt;/p&gt;&lt;p&gt;- All-cause mortality: 30 studies&lt;/p&gt;&lt;p&gt;- 50% or 100% serum creatinine increase: 30 studies&lt;/p&gt;&lt;p&gt;- Final serum creatinine: 15 studies&lt;/p&gt;&lt;p&gt;- Final GRR: 13 studies&lt;/p&gt;&lt;p&gt;- Complete or partial remission: 32 studies&lt;/p&gt;&lt;p&gt;- Final proteinuria: 22 studies&lt;/p&gt;&lt;p&gt;Safety&lt;/p&gt;&lt;p&gt;- Severe adverse events: 31 studies&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;2014 update&lt;/p&gt;&lt;p&gt;Total included studies: 39 (77 reports)&lt;/p&gt;&lt;p&gt;- studies excluded from meta-analyses: 3&lt;/p&gt;&lt;p&gt;Total excluded studies: 23 (35 reports)&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 18 (19 reports)&lt;/p&gt;&lt;p&gt;Excluded studies: 10 (10 reports)&lt;/p&gt;&lt;p&gt;Studies awaiting assessment: 4 (4 reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 3 (3 reports)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records excluded after screening titles and abstracts: 907&lt;/p&gt;&lt;p&gt;(not RCT, wrong population or intervention)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;MEDLINE, EMBASE, CENTRAL, Renal Register&lt;/p&gt;&lt;p&gt;2004 review: 943 records&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;New included studies: 21 (33 reports)&lt;/p&gt;&lt;p&gt;Existing included studies: 12 (25 new reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 14 (14 reports)&lt;/p&gt;&lt;p&gt;Studies awaiting assessment: 8 (9 reports)&lt;/p&gt;&lt;p&gt;New excluded studies: 15 (19 reports) (not RCT, wrong population or intervention)&lt;/p&gt;&lt;p&gt;Existing excluded studies: 2 (8 new reports)&lt;/p&gt;&lt;p&gt;Reclassified studies: 3 (3 excluded studies were reports of an existing included study)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;2014 review update&lt;/p&gt;&lt;p&gt;Renal Register and other sources: 244 reports&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>